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Abstract 
 
The majority of modern targeted cancer therapeutics are directed against components 
of cell signalling pathways. In this thesis inhibitors of two enzymes involved in cell 
signalling are investigated.  
Sulfatase-2 is a heparan sulfate processing enzyme which has been implicated as a 
tumour promoter in multiple cancer cell lines, with high Sulf-2 expression being an 
indicator of a poor clinical prognosis. A monosaccharide sulfamate inhibitor 25, based 
on the structure of the endogenous substrate and having an IC50 of 130 M against 
Sulf-2, has been published. Multiple strategies were pursued in parallel in order to 
attempt to identify compounds with an IC50 against Sulf-2 of < 100 M for use as 
chemical tools in target validation studies. These strategies included the preparation of 
25, and of a set of analogues of the generic structure A, with variation of substituents 
at R
1
, R
2
, R
3
 and R
4
.  
                                         
                    25       A                                             64 
      Sulf-2; IC50 130 M 
Access to these targets was facilitated by the development of a procedure for 
regioselective sulfamoylation of the O
6
-position of the template. Analysis of this 
reaction on a model substrate resulted in an increased understanding of the factors 
which affect the success of sulfamate formation, enabling the reaction to be used with 
greater efficiency on complex intermediates, and longer reaction sequences to be 
undertaken to provide the desired test compounds.  
Sets of phenolic, benzylic, and cyclic aliphatic sulfamates such as 64 were also 
designed in an attempt to identify a non-saccharide scaffold which could mimic the 
spatial arrangements of groups believed to be important for binding of the endogenous 
substrate to Sulf-2.  
Preliminary sulfatase inhibition data has been generated, indicating that analogues of 
25 with superior inhibition of Sulf-2 have been identified. 
iv 
 
ERK5 is a soluble serine/threonine protein kinase component of a non-classical MAP 
kinase pathway, which has been implicated in tumour development. Breast cancer 
patients with high ERK5 levels have decreased disease-free survival, and ERK5 has 
been shown to have a role in cellular invasion and metastatic spread through affecting 
cell migration and attachment to the extracellular matrix. A pyrrole carboxamide series 
of ERK5 inhibitors was optimised from lead compounds including 212, which 
suffered from high clearance and low membrane permeability in vitro, and translated 
to poor oral bioavailability in vivo.  
 
      212   ERK5; IC50 199 nM                                  305   ERK5; IC50 7 nM  
 
The focus of optimisation studies was to improve ERK5 inhibitory activity and 
pharmacokinetic parameters to deliver compounds suitable for in vivo target validation 
studies. Analysis of medicinal chemistry design tactics and physicochemical 
properties, which had previously led to the development of successfully approved 
kinase drugs was used to guide compound design. The amide substituent was explored 
and developed into three sub-series. The first analogues prepared suffered from 
instability in human and mouse liver microsomes and activity against the hERG 
cardiac ion channel. These flaws were successfully overcome leading to compounds 
such as 305, which achieved an ERK5 inhibition improvement of over 20-fold, with 
good microsomal stability and low hERG activity. Docking of compounds into a 
recently published co-crystal structure of a small molecule inhibitor bound to ERK5 
has provided information on the possible binding mode of the pyrrole carboxamide 
series. 
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Chapter 1: Introduction 
  
1.1 The Genetic Basis of Cancer  
 
 
According to the clonal evolution model, cancer is believed to arise through a 
Darwinian evolution process on a cellular level in multi-cellular organisms.
1
 Random 
introduction of genetic variation may confer an advantage in proliferation or cell 
survival, which is passed on to subsequent generations of cells through a process 
analogous to natural selection. The causes of genetic variance range from 
substitutions, deletions or insertions of single or multiple nucleotide bases, through 
chromosomal rearrangements, to an increase or decrease in copy number of whole 
chromosomes.
1 The human genome contains 22,000 protein-coding genes, and 
mutations have been reported which link over 1.6% of these to cancer development.
2
 
Mutations found in cancer can be broadly classified as either driver or passenger 
mutations.
3
 Driver mutations affect key pathways associated with cancer development, 
whereas passenger mutations confer little phenotypic advantage, but may be carried 
through to later cell generations by being present in cells bearing driver mutations.
1
  
 
In cancer, tumours develop due to abnormal cell proliferation and such malignancies 
acquire the ability to invade other tissues, forming secondary tumours or metastases.  
In a seminal paper,
4
 six hallmarks of cancer were identified (Figure 1.1). 
 
Figure 1.1: The six hallmarks of cancer.
5
 
2 
In a recent update, two further emerging hallmarks were suggested; the avoidance of 
immune destruction, and reprogramming of energy metabolism.
5
 For a cell to become 
cancerous, it must accumulate mutations that confer most or all of these 
characteristics, and it is thought that between five and seven driver mutations may be 
required in epithelial cancers such as breast, colorectal and prostate.
1 Under normal 
conditions it has been estimated that each cell experiences over ten thousand DNA 
replication errors every day.
6
 Genetic defects may be further accumulated with age, 
through an inherent genetic susceptibility, or following exposure to mutagens such as 
tobacco smoke or ultra-violet radiation. Viral infections which introduce foreign DNA 
into a cell, such as the Epstein Barr or hepatitis B viruses, can also disrupt the genetic 
material of a host cell, contributing to the development of a cancer phenotype.
7
  
 
Genetic alternations may confer gain of function (GOF) or loss of function (LOF) on 
proteins coded by the affected genes. GOF mutations in oncogenes lead to constitutive 
activation of pathways, whereas transformations of tumour suppressor genes imparting 
LOF result in a decrease in regulatory signals. Diverse mechanisms have been 
identified which underlie each of the functional hallmark capabilities required for a 
cell to become cancerous, leading to complex heterogeneity in the genetic make-up of 
tumours between patients, organs, tissues, and even between regions in a single 
tumour.
8
 Cataloguing of DNA mutations present in cancer has revealed that hundreds 
of genes may be transformed in each cancer subtype.
6
  
 
Genome instability leading to an increased mutation rate has been identified as an 
additional enabling characteristic, with the development of a ‘hyper-mutatable’ 
phenotype facilitating the acquisition of the set of mutations required for a cell to 
become malignant.
5
 In addition to the progressive accumulation of mutations as a 
tumour matures, it may enter a phase where much more fundamental chromosomal 
changes are acquired. This phenomenon has been described as genome chaos, and 
often leads to rapid development of drug resistance and a resultant poor prognosis.
9
  
 
An alternative to the clonal evolution model of cancer development is the cancer stem 
cell (CSC) model, in which normal cells acquire the properties of stem cells. It is 
proposed that these cells sustain the tumour and generate heterogeneity through 
differentiation.
10
 It is likely that aspects of both the clonal evolution model, the cancer 
stem cell model, and genome chaos are active in the replicative cycle of most cancers, 
3 
and that effective therapeutic strategies will be required that target pathways involved 
in each of these models.  
 
1.2 Early Cancer Chemotherapy – Cytotoxic Agents 
 
The advent of cancer chemotherapy can be traced to the observation that nitrogen 
mustards used on the battlefields of World War I depleted bone marrow and lymph, 
leading scientists at Yale to find that they could cause regression in lymphoma 
patients.
11
 Chlorambucil (1) and cyclophosphamide (2) were subsequently introduced 
as orally available alkylating agents, often providing short-lived beneficial effects in 
cancer patients.  
            
    1                                         2 
These agents act by cross-linking DNA, leading to cytotoxicity and cell death. Even at 
this early stage in the development of cancer chemotherapeutics, the issue of 
selectivity for malignant tissue over healthy cells was apparent. In the case of 
cyclophosphamide, elevated levels of phosphoramidase in certain tumour types were 
expected to generate the active nitrogen mustard, imparting a degree of selectivity.
12
 
However, it was subsequently found that hepatic oxidation by cytochrome P450s could 
generate the active species, and that the moderate therapeutic index achieved may be 
attributable to the action of aldehyde dehydrogenase in healthy tissues which converts 
cyclophosphamide into an inactive metabolite.
12
 Resistance to cyclophosphamide 
treatment occurs through several mechanisms including the development of elevated 
aldehyde dehydrogenase expression, and increased glutathione production in resistant 
tumours.
12
 
In the 1940s the anti-metabolite class of chemotherapeutics was discovered. Treatment 
with antifolates such as aminopterin and methotrexate (3) led to remission in 
leukaemia patients,
11
 and, subsequently, 5-fluorouracil (5-FU, 4) was found to be 
active against solid tumours.
13
 Dihydrofolate reductase, an enzyme that converts 
dihydrofolate to tetrahydrofolate, is inhibited by methotrexate. Tetrahydrofolate is a 
4 
co-enzyme required for C1-metabolism in the synthesis of nucleic acid bases required 
for DNA replication.
14,15
 5-FU is an inhibitor of thymidylate synthase, another enzyme 
required for nucleotide synthesis.
16
 A second mechanism of 5-FU mediated 
cytotoxicity is through incorporation of fluoronucleotides during DNA and RNA 
synthesis.
16
 Selectivity for tumour cells was anticipated due to their requirement for a 
higher DNA synthesis rate to support rapid proliferation. In practice, these treatments 
are accompanied by significant side-effects related to their effects on healthy cells. For 
example, expression of thymidylate synthase is often higher in tumour cells than in 
healthy tissue, and healthy cells with lower levels are consequently more sensitive to 
5-FU treatment.  
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Cisplatin, a platinum complex, was discovered in 1965 and proved to have efficacy in 
testicular cancer.
17
 Carboplatin (5) was subsequently developed, providing broader 
anti-tumour activity and reduced nephrotoxicity as compared to cisplatin.
18
 The 
platinum drugs act by complexing to DNA bases, in particular guanidine, and cross 
linking DNA strands, resulting in an anti-mitotic effect. A further class of anti-mitotic 
agents acting through disrupting mitotic spindle formation have also proved effective, 
such as the vinca alkaloids,
19
 and paclitaxel (Taxol).
18
  
In order to achieve their effects, most cytotoxic anti-cancer drugs require high doses. 
Throughout their development, toxicity caused by non-specific cytotoxic or anti-
mitotic effects has limited the utility and dose that can be administered due to 
concomitant adverse reactions. Multi-agent approaches are often used to improve 
outcomes; for example the response rate was improved from 24-26% to 48-92% by the 
dual use of carboplatin and 5-FU compared to single agent carboplatin therapy in 
squamous cell carcinomas of the head and neck.
20
 However the use of multiple drugs 
at high concentrations also often leads to significant adverse effects.
21
 Cytotoxic drugs 
can also increase the risk of developing secondary tumours later in life, an issue of 
particular concern when used in the treatment of childhood cancer.
22
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1.2.1 Resistance to Cytotoxic Chemotherapy 
 
There are many mechanisms whereby tumours may develop resistance to cytotoxic 
agents. For example, sub-populations of tumour cells often over-express membrane 
associated efflux pumps, which reduce the access of a drug to its intracellular site of 
action.
23
 In the presence of cytotoxic agents these cellular sub-types gain a survival 
advantage, and may rapidly become the predominant tumour cell type. Over-
expression of promiscuous efflux pumps such as P-glycoprotein (P-gp) often results in 
such tumours becoming resistance to multiple drugs.
23
 Tumour cells may develop 
other mechanisms to reduce a drug’s access to its site of action. Resistant cell types 
have been found to have altered pH gradients across the membrane of certain 
intracellular organelles, resulting in sequestration of weakly basic drug molecules in 
the acidic environment of these organelles prior to secretion.
23
 The action of many 
cytotoxic agents relies on their ability to impede DNA synthesis in a rapidly dividing 
malignant cell population. Alterations in the DNA damage repair machinery of a 
tumour cell may allow it to overcome the action of the drug. For example, 
temozolomide is a DNA alkylating agent that methylates guanine residues, leading to 
DNA replication errors and cell death. Resistance to temozolomide can develop 
through the over-expression of the DNA repair enzyme, O
6
-methylguanine-DNA 
methyltransferase (MGMT), which allows the cell to repair the damage caused by 
temozolomide, thus reducing its cytotoxic efficacy.
23
 
 
1.3 Targeted Therapies 
 
The concept of oncogenes, tumour suppressor genes, and signalling pathways emerged 
in the 1960s, leading to the idea of cancer therapies targeted at altering the function of 
specific proteins responsible for driving tumour progression.
11
 If the activity of a 
protein is specific to tumour cells, its selective modulation should result in reduced 
effects in healthy tissue, leading to fewer dose-limiting adverse events. An early 
example of a targeted therapy was tamoxifen (6), a selective oestrogen receptor 
modulator (SERM) for the treatment of oestrogen-dependent breast cancer. Tamoxifen 
was initially developed as an anti-oestrogenic compound primarily for use in the 
control of fertility and the menstrual cycle.
24
 Oestrogens were known to enhance 
breast cancer tumourigenesis, with increases in oestrogen sensitivity correlating with 
susceptibility.
24
 Tamoxifen subsequently became the agent of choice for endocrine 
6 
treatment of breast cancer, and it is estimated that its use has contributed to the 
survival of over 400,000 female cancer patients.
24
 Further generations of SERMs have 
been developed with reduced side-effect profiles, such a raloxifene (7).
25
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New cell biology techniques have identified signalling networks responsible for the 
regulation of cellular processes including cell survival and proliferation, which have 
expanded the scope for possible targeted therapies. Specific components of these 
signalling networks were recognised as promising biological targets for drug 
discovery, including targeting growth factors and their receptors, cell cycle 
modulators, and proteins involved in the regulation of apoptosis.
18
 These discoveries 
have led to a concerted effort to rationally design drugs against a specific protein 
target for the treatment of cancer.  
  
1.3.1 Cell Signalling Pathways and Targeted Cancer Chemotherapy 
 
Over two hundred cell signalling pathways have been identified which transmit signals 
from the extracellular environment, transduce them through the cell membrane and 
cytosol, and cause an intracellular response.
26
 Extracellular signals take a variety of 
forms including hormones, growth factors, cytokines, or extracellular stress signals 
such as osmotic stress. Intracellular effects may occur in the nucleus, such as the 
activation of transcription of certain genes, or may be due to activation of enzymes, for 
example by phosphorylation. Aberrant signalling through these pathways is often a 
feature of cancer. This can occur through increased production of extracellular growth 
factors, constitutive activation or amplification of expression of a component protein, 
or loss of function or expression of a regulatory protein affecting a pathway, resulting 
in uncontrolled cell growth, proliferation and survival.
27
 In a substantial proportion of 
cancers, mutations are found in genes associated with cell signalling.
26
 For example, in 
7 
pancreatic cancer between 67% and 100% of cancers have been found to have 
mutations in genes coding for members of 12 signalling pathways, comprising a total 
of 63 genetic alterations.
28
 Mutational analysis has found that the majority of glioma 
cases have at least one mutation of a gene encoding for a component of a signalling 
pathway.
26
 The mutation frequency for most somatic genes in tumours is 
approximately 2%, whereas certain genes have much higher frequencies. For example, 
mutations in the gene coding for the tumour suppressor protein p53 are present in 41% 
of cancers, and components of key signalling pathways such as Ras and 
phosphatidylinositol-3-kinase (PI3K) have 15% and 10% mutation frequency, 
respectively.
26
 The cell signalling cascades are often depicted as independent linear 
sequences. In reality they comprise a vast, complex, interconnected signalling network 
(Figure 1.2), often involving regulatory feedback effects between apparently 
independent pathways, making the effect of blocking one pathway difficult to model.
29 
However, certain key pathways have been identified as having potential for 
intervention, and many of the approved targeted anti-cancer therapeutics modulate 
these.  
 
Figure 1.2: Representation of some of the complex interactions which form a cellular 
signalling network (adapted from reference 30). 
 
The decision as to which pathway component to target for intervention with a small-
molecule drug is complex, and will influence the efficacy, side effects, development of 
resistance, and the patient population that may respond to the drug. For example, 
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targeting a protein early in a pathway, such as a growth factor receptor, is likely to 
affect multiple downstream signalling outcomes.
31
 This may lead to enhanced 
efficacy, but may also cause unwanted adverse effects, such as cardiotoxicity.
32
 In 
patients where constitutive activation of an enzyme later in the sequence is driving 
tumourigenesis, blocking a component upstream of this target is unlikely to be 
effective.
33
 In these cases blocking the aberrant protein itself, or inhibition downstream 
in the signalling cascade is preferable.
33
 However, inhibition of a single downstream 
element may have limited efficacy if there are multiple parallel downstream pathways. 
There are also likely to be opportunities for the cell to develop alternative mechanisms 
to bypass the inhibition of a downstream target, via diversion of signal transduction 
through other pathways.
34
 The options for effective combination with other targeted 
therapies also differ depending on the position in the pathway that is blocked.
34
 Thus, 
the advantages of drugs targeting upstream or downstream pathway components will 
largely depend on the driver mutations present in a specific tumour.  
 
The classical mitogen-activated protein kinase (MAPK) pathway is an important cell 
signalling pathway in which gain of function or loss of function of constituent proteins 
has been implicated in tumour development, and will be discussed in the following 
sections.  
 
1.3.1.1 The MAP Kinase Signalling Pathways 
 
The MAP kinases are a family of serine/threonine kinases involved in a signalling 
sequence that transduces extracellular stimuli, leading to intracellular responses such 
as activation of the transcription of genes.
35
 The MAP kinase pathway involves three 
sequentially activated protein kinases (Figure 1.3).
28
  
 
Figure 1.3: General representation of a MAP kinase signalling pathway. 
 
The MAP kinase is activated by phosphorylation by a MAP kinase kinase (MAPKK), 
which in turn is activated by a MAP kinase kinase kinase (MAPKKK). The MAPKKK 
is itself activated in response to an extracellular signal such as an increase in growth 
9 
factor levels, cytokines, or as a stress response. The MAP kinases phosphorylate 
transcription factors, protein kinases, structural proteins, cytoplasmic enzymes and 
phospholipids, leading to diverse downstream events including inflammation, 
apoptosis, cell differentiation and growth.
36
 There are 14 MAP kinases in eukaryotes 
that are categorised as conventional MAP kinases or atypical MAP kinases. 
Extracellular signal-related kinase (ERK) 1, 2, and 5, c-Jun amino (N)-terminal kinase 
(JNK), and p38 are classed as conventional MAP kinases, whereas ERK3/4, ERK7 
and Nemo-like kinase (NLK) are classed as atypical.
37
 The conventional MAP kinases 
are characterised by having a conserved T-X-Y phosphorylation motif, which is not 
conserved in the atypical MAP kinases.
28
 
 
1.3.2 The Classical MAPK Pathway 
 
The pathway involving Raf, MEK1/2 and ERK1/2 is referred to as the classical 
MAPK pathway, and is involved in the control of a number of cellular processes 
including cell proliferation, differentiation, survival, and motility.
38
 Of the MAP 
kinase pathways, the classical pathway has received the most attention as a target for 
modulation in cancer chemotherapy. 
 
Figure 1.4: The classical MAP kinase pathway (adapted from reference 39). 
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In response to a growth factor binding to a receptor tyrosine kinase such as the 
fibroblast growth factor (FGF) receptor, a member of the Ras family of proteins (H-
Ras, K-Ras or N-Ras) is activated (Figure 1.4). The Ras protein then activates a 
MAPKKK of the Raf kinase family (A-Raf, B-Raf or C-Raf), which in turn 
phosphorylates one of the MAPKK proteins, MEK1 or MEK2, which themselves 
phosphorylate the MAP kinase ERK1/2 proteins. ERK1/2 is phosphorylated by 
MEK1/2 on threonine and tyrosine in a Thr-Glu-Tyr (TEY) triad of amino acids. This 
results in activation of ERK1/2, leading to phosphorylation of downstream targets 
such as protein kinases, and transcription factors including Elk-1 and c-Myc.
40
   
Unregulated activation of this pathway can occur through several mechanisms, 
including abnormally increased external growth factor availability or mutations 
conferring increased constitutive activity of a member of the pathway, allowing 
signalling to occur in the absence of growth factors.
41
 Mutations in tyrosine kinase 
receptors upstream of the classical MAPK pathway such as Epidermal Growth Factor 
Receptor (EGFR), Fibroblast Growth Factor Receptor (FGFR) 1-3, Platelet Derived 
Growth Factor Receptor (PDGFR) A & B, and ERBB2, are found in many cancers,
35
 
as are mutations in the cytoplasmic components including H-Ras, K-Ras, N-Ras, B-
Raf, and MEK1 (Table 1.1).
41
  
Gene Tumour type Frequency  
K-Ras Pancreas 
Lung 
Colon 
Breast 
69% 
16% 
35% 
3% 
N-Ras Melanoma 
Colon 
Breast 
19% 
2% 
2% 
H-Ras Breast 1% 
B-Raf Melanoma 
Thyroid Cancer 
Colon 
41% 
45% 
14% 
MEK1 Melanoma 
Colon 
3% 
2.2% 
 
Table 1.1: Frequency of mutations of components of the MAP kinase signalling 
pathway across cancer types.
41
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1.3.3 Inhibitors of the Classical MAPK Pathway  
 
1.3.3.1 Inhibitors of the Raf protein family 
 
There are three functional Raf proteins in humans, termed A-Raf, B-Raf and C-Raf. B-
Raf has significantly higher basal kinase activity than A-Raf or C-Raf, and elevated 
levels have been reported in 60% of malignant melanoma cases, with moderate to high 
frequency in ovarian, papillary thyroid and colorectal cancers.
42
 In melanoma, 80% of 
cases where Raf is mutated contain a specific substitution of a glutamate residue for a 
valine (V600E).
43
 The resulting sustained signalling through the classical MAPK 
pathway, in the absence of growth factor signals from the extrinsic environment, leads 
to a cellular phenotype characterised by uncontrolled proliferation, resistance to 
apoptosis and increased potential for invasion of other tissues.
43
 The marketed kinase 
inhibitors sorafenib (8) and vemurafenib (9) include inhibition of B-Raf in their 
pharmacologic profile. Vemurafenib, which targets the B-Raf V600E mutation, has 
proven effective in drug-resistant metastatic melanoma patients.
43
 Sorafenib is a multi-
kinase inhibitor marketed for renal and liver cancer, with potent inhibitory activity 
against Vascular Endothelial Growth Factor Receptor (VEGFR) 2, PDGFR, and c-kit, 
in addition to C-Raf (IC50 = 6 nM) and B-Raf (IC50 = 22 nM).
44
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1.3.3.2 Inhibitors of MEK1/2  
 
The first MEK inhibitor to enter the clinic, CI-1040 (10) suffered from poor 
bioavailability, resulting in insufficient plasma levels being achieved to validate the 
target.
45
 This was followed by PD-325901 (11), which is currently undergoing Phase 
II trials for melanoma and breast, colon and non-small cell lung cancer (NSCLC).
46
 
Selumetinib (12) from AstraZeneca is a dual MEK1/2 inhibitor with an IC50 against 
MEK1 of 14 nM.
47
 In preclinical studies the drug demonstrated potent anti-melanoma 
12 
activity in in vitro and in vivo models. Clinical studies are currently on-going but 
efficacy outcomes have been modest thus far.
47
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1.3.3.3 ERK1/2 inhibitors 
 
To date no inhibitors of ERK1 or ERK2 have entered clinical trials. However, several 
chemotypes have been identified which provide potent inhibition of these kinases. 
 
13 
 
Compound 13 is a potent inhibitor of ERK2 (IC50 < 2 nM) based on a pyrrole 
carboxamide scaffold, with over 200-fold selectivity against a panel of kinases.
38
 The 
compound exhibits good oral bioavailability in rat (F = 65%) and mouse (F = 67%), 
and was shown to be active in a cell proliferation assay in the HT29 human colorectal 
cancer cell-line with a GI50 of 48 nM. 
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FR180204 (14) is an ATP-competitive inhibitor of ERK1 (IC50 = 0.51 μM) and ERK2 
(IC50 = 0.33 μM).
48
 The benzoxacyclotetradecine derivative FR148083 (15) is an 
ERK2 inhibitor (IC50 = 80 nM) which acts via an irreversible mechanism, whereby a 
cysteine residue in the active site of ERK2 covalently binds to the enone Michael 
acceptor functionality.
49
 The covalent mechanism confers selectivity over other MAP 
13 
kinases such as JNK and p38, in which the ATP-binding site cysteine residue is not 
conserved.
48
 
 
1.3.4 Other Cancer Chemotherapeutics Targeting Signalling Pathways 
 
Imatinib (Glivec) (16), the first molecularly targeted cancer therapy to reach the 
market, was designed to block sustained proliferative signalling in chronic myeloid 
leukaemia (CML) caused by a t(9:22) gene translocation. This genetic defect, also 
known as the Philadelphia chromosome, produces a fusion of the Bcr and Abl gene 
products,
50,51
 lacking the regulatory control elements of Abl kinase resulting in 
constitutive signalling, which affects multiple downstream signalling pathways.
52
 
Phenotypic effects of this activity include increased proliferation, resistance to 
apoptosis, and altered adhesion properties.
53
 Inhibition by imatinib of the Bcr-Abl 
kinase is largely responsible for its efficacy in the treatment of Philadelphia 
chromosome positive CML.
52
 Since this fusion protein is present only in tumour cells, 
selectivity over healthy tissue can be achieved. Imatinib is also used for the treatment 
of gastrointestinal stromal tumours (GIST), where it acts through a different 
mechanism. GIST, a form of soft tissue sarcoma, is often driven by mutations resulting 
in constitutive activation of the c-Kit kinase, or of the platelet derived growth factor 
receptor (PDGFR) kinase. Imatinib potently inhibits both c-Kit and PDGFR,
50
 and 
GIST patients dosed with imatinib show a response rate of 38% compared with 0-5% 
on previous chemotherapy regimes.
54
   
     
                                                                  16 
Clinical responses in both CML and GIST correlate with the presence of Bcr-Abl, and 
mutations in c-Kit or PDGFR, respectively. In the treatment of chronic phase CML, 
imatinib results in 90% remission rates.
26
 However, there is a high incidence of 
resistance arising during treatment. The principal mechanisms for acquisition of 
resistance to imatinib is the development of sub-clones of tumour cells bearing single 
amino acid changes in the drug-binding site, which reduce its binding affinity. Drug 
treatment results in selective growth advantage of the resistant sub-clones.
50
 
14 
Nevertheless, the advent of imatinib treatment has greatly improved the prognosis and 
survival of CML and GIST patients, and provided a positive proof of concept for 
targeted cancer therapies. The second generation agents, dasatinib (Sprycel) and 
nilotinib (Tasigna), have been designed to have broad spectrum Bcr-Abl activity 
against a wide range of known imatinib resistant mutant cell lines and ponatinib 
(Iclusig), a third generation Bcr-Abl inhibitor which is active against dasatinib and 
nilotinib resistant mutants, has also recently been approved.
55
   
The binding of growth factors to their receptors is one of the common methods by 
which cell signalling pathways are activated, and therapies which directly target 
growth factor receptors have been developed. Activation of a single class of receptor 
can initiate signal transduction through multiple pathways, leading to diverse 
intracellular responses. Increased growth factor availability, or mutations leading to 
constitutive activation of growth factor receptors are common drivers of tumour 
development, and some of the most successful marketed targeted anti-cancer agents 
act on these receptors. 
Gefitinib (17) and erlotinib (18) are examples of agents that directly target the EGFR 
growth factor receptor tyrosine kinase, and which have proven effective in the 
treatment of non-small cell lung cancer (NSCLC) in cases where mutations in EGFR 
are present.
56
 These account for around 10% of NSCLC cases, and in these cases the 
response rate to gefitinib is 75%, compared to 30% using cytotoxic drugs, with a 
doubling of progression-free survival from five to eleven months.
56
 However, 
resistance to gefitinib treatment usually arises within two years of the commencement 
of treatment.  
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In addition to targeted small molecule inhibitors, antibody therapies have also emerged 
as injectable biologic treatments. Examples of these therapies are trastuzumab 
(Herceptin) an antibody targeted at the Human Epidermal Growth Factor Receptor 
(Her-2), and bevacizumab (Avastin) targeted at the VEGF Receptor.
57
 These bind to 
15 
their respective receptors, preventing interaction with the endogenous growth factor 
ligands, or promoting receptor internalisation, thereby reducing downstream 
signalling.
57
  
The majority of small-molecule targeted therapies which have been approved for use 
in human cancers are directed towards the inhibition of kinase enzymes in signalling 
pathways. Analysing the design and discovery of those kinase inhibitors which have 
reached the market can provide useful insights into the challenges and successful 
tactics that have been used. This will be explored further in chapter 6 in the 
formulation of strategies for the optimisation of inhibitors of ERK5.    
 
1.3.5 Alternative Approaches to Targeted Therapy  
 
In addition to drugs affecting cell signalling pathways, targeted cancer therapeutics 
which act on components of other cellular processes have also been developed. For 
example, the 26S proteasome has been targeted, which is involved in the degradation 
of poly-ubiquitin tagged proteins, including many involved in the cell cycle such as 
the tumour suppressor p53, and the endogenous cyclin-dependent kinase inhibitors 
p21 and p27.
58
 In tumour cells the level of the 26S proteasome is often up-regulated, 
and its inhibition was found to induce apoptosis, arrest growth, and increase sensitivity 
to cytotoxic agents and radiotherapy, with little effect on healthy cells. Bortezomib 
(Velcade, 19) is a boronic acid based inhibitor of the 26S proteasome which is 
approved for the treatment of multiple myeloma.
58
 The exact mechanism of action of 
19 is likely to be complex due to the number of proteasomal substrates affected by the 
activity of the drug.59 In addition to stabilising the tumour suppressor p53, effects on 
the NF-B pathway and an increase of pro-apoptotic factors derived from the B-cell 
leukaemia/lymphoma 2 (Bcl-2) family of proteins, have been implicated in its 
functional response.59 
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A reduction of susceptibility to apoptosis is a common mechanism of tumour 
resistance to both cytotoxic and targeted agents. The Bcl-2 protein family has pro-
apoptotic functions, and new targeted therapies that affect this apoptotic pathway are 
under investigation, such as ABT-263.
60
 Epigenetic changes which allow tumour cells 
to transiently tolerate drug treatment have also been proposed, with a change in the 
methylation state of the promoter region of many genes which affects their 
transcription being observed in cancer. Histone deacetylase inhibitors have shown 
activity against drug-tolerant cancer cells,
61
 and two DNA-methyltransferase 
inhibitors, decitabine (Dacogen, 20) and azacitidine (Vidaza, 21) have been approved 
for myelodysplastic syndrome,
62,63
 and are undergoing clinical trials for acute myeloid 
leukaemia.
8,64,65
 
 
1.4 Resistance to Targeted Therapies 
 
The benefits of targeted agents have often proven to be short lived due to rapid 
emergence of drug resistance. In addition to the mechanisms discussed in section 
1.2.1, such as the action of efflux pumps reducing a drug’s access to its site of action, 
resistance to targeted therapies may arise through mutations in the drug target itself, 
reducing the binding affinity of the drug. These may be single point changes affecting 
a single amino acid in the protein sequence, or may be through changes in the splicing 
pattern, as is the case for some resistance to vemurafenib.
66
 These resistance mutations 
may arise during drug treatment (acquired), or may be present in a small number of 
tumour cells prior to drug treatment (intrinsic).
8
 Resistance may also develop through 
mutations that lead to a switching of pathway dependency in a sub-population of 
tumour cells. The approach of employing combinations of targeted agents against 
components of different signalling pathways, or single agents having activity against 
multiple targets may provide an approach to reducing the rate of development of 
resistance through such mechanisms.
67
 While the development of new agents as stand-
alone therapies is important, there is also likely to be significant benefit in developing 
agents which expand the options for combination therapy, affecting parallel pathways 
that may confer resistance to existing therapies. 
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1.5 Stratified Medicine 
 
Targeted therapies, by their nature, only produce a response in patients having the 
underlying genetic defect for which the targeted drug aims to compensate. This led to 
the emergence of the paradigm of personalised or stratified medicine, whereby genetic 
testing or biomarker assessment is used to identify patient populations harbouring 
specific driver mutations that are therefore likely to be responsive to a specific drug.
68
 
Those with non-responsive genotypes can be directed to a more appropriate 
therapeutic strategy (Figure 1.5).  
 
Figure 1.5: Personalised medicine allows only patients who will benefit, and 
experience low toxicity to be selected for treatment with a targeted agent.
69
 
Personalised medicine requires the development of methods for screening for the 
presence of the genetic defect which is susceptible to inhibition by the targeted agent, 
to allow selection of patients who will be responsive to the drug. For example, tests 
have been developed to identify CML patients with the Bcr-Abl fusion protein who 
may respond to imatinib treatment, melanoma patients having the V600E mutation 
responsive to treatment with vemurafenib, and EGFR mutations for erlotinib and 
gefitinib in non-small-cell lung cancer.
70
 However, there is still a need to improve the 
sophistication of the screening used to identify responsive patient populations, as the 
genetic instability and associated heterogeneity in the tumour cell genome often leads 
to the development of redundancy in reliance on a particular driver mutation or 
pathway.
8
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1.6 The Drug Discovery Process 
 
The current prevalent drug discovery paradigm involves identification of a biological 
target, the modulation of which is hypothesised to affect the progression of a disease. 
A process of validation of the target follows, with biological studies designed to 
examine the effects of altering the activity of the target on the phenotype of cells, 
tissues or whole organisms.
71
  
 
 
Figure 1.6: Factors involved in validation of a biological target (adapted from ref. 72). 
 
This may be achieved through multiple diverse experiments, including examination of 
organisms genetically engineered to lack the gene coding for the target of interest 
(knock-out animals), the application of tools such as short interfering RNA (si-RNA) 
to block transcription of the gene of interest, or the use of small molecules that interact 
with the target to modulate its activity (Figure 1.6). One role of the medicinal chemist 
in this target validation phase is to identify ‘tool’ compounds that selectively modulate 
the target, initially for use in in vitro studies. The key criteria for an in vitro tool are 
potency and selectivity, with sufficient compound solubility to achieve a concentration 
to effectively modulate the target in the biological studies.   
Once evidence for the role of a target in a disease has been established in vitro, tool 
reagents suitable for in vivo evaluation are required. In addition to potency and 
selectivity, the design of these compounds requires a consideration of ADMET 
(Absorption, Distribution, Metabolism, Excretion, Toxicology) parameters to ensure 
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sufficient free compound levels are maintained for the duration of the experiment.
73
 
Depending on the disease under investigation, sub-optimal pharmacokinetics may be 
overcome by the use of non-oral routes of administration such as intravenous bolus 
injection or infusion, or intraperitoneal injection.
74
  
When the potential benefit of modulation of the target in the treatment of the disease 
has been established, a full drug discovery project is initiated (Figure 1.7). A hit-to-
lead (H2L) program ensues, which may take the chemical tool as a starting point, or 
may require the identification of alternative chemical hits. New hit matter is often 
generated using high-throughput screening (HTS) techniques, where large libraries of 
chemically diverse templates are screened against the target. Alternatively, fragment-
based approaches may be employed,
75
 or compounds may be designed based on 
known inhibitors of the target or close family members. De novo design based on the 
endogenous ligand is a further possible approach. In practice, the drug discovery 
process is often initiated in parallel with the target validation and tool identification 
studies.
76
  
 
Figure 1.7: Phases in the pre-clinical drug discovery process (adapted from ref. 77). 
 
 
In the H2L phase the structure-activity relationships (SARs) of initial hits are explored 
to ascertain functional groups required for activity, and those that may be varied to 
improve potency. The potential for oral absorption (assuming the intended route of 
delivery is oral), and pharmacokinetic parameters are also assessed in in vitro assays. 
Attempts are made to replace structural alerts which have been implicated in toxic 
outcomes in the clinic.
78
 Lead criteria are defined that reflect the progression of a hit 
structure into a lead, which has clear potential to be developed into a drug. 
The lead optimisation (LO) process involves combining all of the desired properties 
into a single agent suitable for progression into clinical trials. Thus, in addition to good 
potency against the primary target and selectivity over relevant secondary targets, the 
candidate molecule must demonstrate in vivo pharmacokinetics, safety, and 
pharmaceutical properties suitable for entering clinical evaluation studies.
79
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1.7 The Sulfatase-2 and ERK5 Projects 
 
The global incidence of new cancer cases is predicted to rise from 12.7 million in 2008 
to 20.3 million by 2030.
80
 Despite the advent of new targeted agents and antibody 
therapies, cancer related deaths are expected to increase from 7.6 million in 2008 to 
13.2 million by 2030.
80
 Thus, the need for new cancer treatments is clear. Inhibition of 
components of cell signalling pathways has provided targeted therapies which are 
efficacious in the treatment of cancer, and further opportunities exist for modulators of 
components of signalling cascades. This approach is a current area of focus for anti-
cancer drug discovery efforts, and the two projects described in this thesis centre on 
attempts to develop small molecules that modulate key signalling pathways. However, 
the approaches taken in the two projects differ significantly. In the sulfatase-2 (Sulf-2) 
project the aim is to affect both the availability of growth factors, and the activation of 
certain growth factor receptors, and can be thought of as an “upstream” approach i.e. 
modulating a pathway early in the signalling sequence. This approach is likely to 
affect multiple signalling pathways. In contrast, the ERK5 project aims to identify 
selective inhibitors of a non-classical MAP kinase pathway, where targeting the ERK5 
MAP kinase directly affects its transcriptional activation and phosphorylation roles. 
This approach can therefore be considered as a “downstream” approach, affecting a 
signalling pathway at a late point in its signalling cascade.  
The two projects described in this thesis cover different stages of the drug discovery 
process. The Sulf-2 project is at the target validation stage. Hence the focus of 
medicinal chemistry design efforts are on identifying chemical tools for use in in vitro 
and in vivo models to assess the effect of inhibition of Sulf-2 on cellular phenotypes 
and tumour growth. The initial aim of this project was improving potency and 
achieving selectivity to provide a fit-for-purpose tool molecule. 
The ERK5 project is at a more mature stage, entering the lead optimisation phase. In 
addition to primary potency and selectivity, compound design was required to 
incorporate multiple parameters including parallel optimisation of ADMET properties 
and pharmacology. 
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Chapter 2: Introduction to the Sulf-2 Project 
 
Sulf-2 is an extracellular enzyme that affects multiple signalling pathways, and has 
been implicated in the progression of several cancers including hepatocellular 
carcinoma.
81
 Literature reports and earlier work at the Northern Institute for Cancer 
Research suggest that modulation of Sulf-2 activity by small molecules may be 
beneficial in the treatment of cancer.  
 
2.1 The Human Sulfatase Family  
 
Seventeen human sulfatases have been identified and are categorised into two classes 
(Tables 2.1 and 2.2).
82
 The first category comprises arylsulfatases, which catalyse the 
removal of a sulfate from a phenol in a substrate. The most widely explored of these is 
arylsulfatase C (ARSC), which removes sulfate from steroids such as oestrone sulfate, 
22 (Scheme 2.1). 
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Scheme 2.1: The action of arylsulfatase C on its endogenous substrate, oestrone 
sulfate. 
 
The second category catalyse removal of sulfate groups from alcohols in saccharides 
(Table 2.2). In the endogenous substrates, the saccharide to be de-sulfated is usually 
contained within a polysaccharide, which may be part of a larger proteoglycan such as 
a heparan sulfate proteoglycan (HSPG). The members of the sugar sulfatase family 
have different specificities for sulfate removal, either from distinct sites on a single 
sugar, or from different sugar residues.
83
 Sulfatase-1 (Sulf-1) and sulfatase-2 (Sulf-2) 
are the only family members reported to have the ability to function as endosulfatases, 
removing sulfates from the O
6
-position of glucosamine residues internal to the heparan 
sulfate structure.
82
 This is in contrast to lysosomal sulfatases such as glucosamine-6-
sulfatase, which remove sulfates exclusively from the O
6
-position of glucosamine 
residues at the non-reducing end of heparin during its degradation in the lysosome.
83
 
22 
Sulf-1 and Sulf-2, were first cloned in 2002,
84
 with the genes coding for them being 
located on human chromosomes 8 and 20, respectively.
85
  
 
Sulfatase Synonyms Endogenous 
Substrate 
Removes 
Sulfate from 
Site of 
Action 
Arylsulfatase A ARSA Sulfatide (a sulfated 
galactosylceramide) 
Phenol, 
saccharide 
Lysosome 
Arylsulfatase B ARSB Dermatan sulfate, 
Chondroitin sulfate 
Phenol, 
saccharide 
Lysosome 
Arylsulfatase C ARSC 
Steroid 
sulfatase, 
STS 
Oestrone 
sulfatase 
Steroid sulfates Phenol  ER
a 
Arylsulfatase D ARSD Unknown Phenol  ER
a
 
Arylsulfatase E ARSE Unknown Phenol  Golgi 
apparatus 
Arylsulfatase F ARSF Unknown Phenol  ER
a
 
Arylsulfatase G ARSG Unknown Phenol  ER
a
 
a 
Endoplasmic reticulum 
Table 2.1: The arylsulfatase family.  
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Sulfatase Endogenous 
substrate 
Removes 
sulfate from  
Site of Action 
Galactosamine-6-
sulfatase 
Chondroitin 
sulfate,  
Keratan sulfate 
Terminal O
6-
galactosamine 
Lysosome 
Glucosamine-3-
sulfatase 
Heparan sulfate Terminal N
2-
glucosamine-
 
Lysosome 
Glucosamine-6-
sulfatase 
Heparan sulfate, 
Keratan sulfate 
Terminal O
6-
glucosamine- 
Lysosome 
Glucuronate-2-
sulfatase 
Heparan sulfate Terminal O
2-
glucuronic acid 
Lysosome 
Heparan-N-sulfatase Heparan sulfate Terminal N
2-
glucosamine 
 
Lysosome 
Iduronate-2-sulfatase Heparan sulfate, 
Dermatan sulfate 
Terminal O
2-
iduronic acid 
Lysosome 
Sulfatase-1 Heparan sulfate Non-terminal or 
terminal  O
6-
glucosamine  
Extracellular 
Sulfatase-2 Heparan sulfate Non-terminal or 
terminal  O
6-
glucosamine 
Extracellular 
 
Table 2.2: The sugar sulfatase family. 
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2.2 Heparan Sulfate Proteoglycans: Endogenous Substrates of Sulf-2 
 
Heparan sulfate proteoglycans (HSPGs) consist of a protein core conjugated to 
multiple heparan sulfate polysaccharide chains. HSPGs comprise five protein classes, 
the syndecans, glypicans, perlecans, agrins, and type XVIII collagens.
86
 The 
polysaccharide chains are composed to a large extent of repeating disaccharide units of 
hexuronic acids (glucuronic acid or iduronic acid) and glucosamine (Figure 2.1).
87
 
Heparin is a closely related polysaccharide with no protein component, and consists 
predominantly of the same repeating disaccharide unit. 
 
Figure 2.1: The basic repeating disaccharide unit of heparan sulfate chains. R’ and R” 
denote points of attachment to further disaccharide motifs. X & Y may be 
independently H or sulfate, and Z may be H, sulfate or acetate. 
 
Mature heparan sulfate oligosaccharide chains are typically between 50 and 200 
residues long. Both HSPGs and heparin contain considerable heterogeneity driven by 
C
5
-epimerisation, sulfation of the O
6
- or N
2
-position of the glucosamine subunit, 
acetylation of the glucosamine N
2
-position, and the sulfation state of the O
2
-position of 
iduronic acid.
82
 Through compositional analysis, at least twelve disaccharide units 
having different sulfation and acetylation patterns have been identified.
88
 Heparin and 
heparan sulfates differ in the density of sulfation, with heparin being much more 
highly sulfated. In heparin the trisulfated disaccharide unit (Figure 2.1, X, Y, Z = 
SO3
-
) is predominant, whereas the polysaccharide chains of HSPGs contain much 
greater heterogeneity in their sulfation pattern, with regions of high sulfation
89
 
comprising 2-8 highly sulfated disaccharide units
90,91
 separated by more flexible 
regions of lower sulfation (Figure 2.2).
90
 In bovine kidney HSPGs the trisulfated 
disaccharides have been show to account for 6.4% of the total disaccharide content of 
the proteoglycan.
88
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Figure 2.2: Schematic representation of the structure of an HSPG. 
 
Sulf-1 and Sulf-2 preferentially recognise the highly sulfated sub-domains of HSPGs. 
They have highest enzymatic activity against the trisulfated disaccharide units, 
hydrolysing O
6
-sulfate groups from glucosamine residues, resulting in an increase in 
the disulfated disaccharide motif.
88
  
 
2.3 Rationale for Sulf-2 Inhibitors as Potential Cancer Therapeutics 
 
Sulf-1 and Sulf-2 mRNA levels have each been shown to be up-regulated in human 
breast cancer cell lines.
92,93
 In hepatocellular carcinoma (HCC) patients, high Sulf-2 
mRNA expression correlates with a poor prognosis.
94
 In a separate study, eleven 
hepatic cancer cell lines were examined for Sulf-2 levels, with eight showing increased 
Sulf-2 expression.
81
 The Sulf-2 protein has also been shown to be over-expressed in 
non-small-cell lung carcinomas.
95
 Gastric cancer tissue samples have significantly 
higher expression of both Sulf-1 and Sulf-2 compared to healthy tissue, which 
correlates with hypo-methylation of the gene promoter sequences.
85
 Sulf-2 levels have 
been found to be elevated in 50% of glioblastoma tumours, whereas Sulf-1 levels were 
not.
96
 Furthermore, a correlation was found between overall survival and the number 
of cells staining for Sulf-2 expression in a study of 100 oesophageal cancer patients.
97
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Overexpression of Sulf-2 mRNA and protein has been shown to increase proliferation 
and migration in a lung cancer cell-line.
95,98
 Conversely, in pancreatic cancer, shRNA 
knockdown of Sulf-2 resulted in decreased proliferation.
98
 
Stable transfection of Sulf-2 into HCC cell-lines has been shown to promote the 
growth of tumours in vivo. Pancreatic carcinoma cells transfected with Sulf-2 shRNA 
exhibited inhibition of tumour growth,
98
 and this has also been demonstrated in lung 
cancer cell lines.
98
 In the AGS gastric cancer cell line, transfection with Sulf-1 or Sulf-
2 resulted in increased tumour growth relative to control (Figure 2.3).
85
 However, 
forced expression of Sulf-1 and Sulf-2 has also been reported to reduce tumour growth 
in vivo suggesting that both may have tumour suppressor functions under certain 
circumstances.
99
 
 
Figure 2.3: Nude mouse xenograft tumour growth model for AGS clones stably 
expressing (A) Sulf1 or (B) Sulf2. Tumour volumes represented as means ± SD. 
AGS: parental cell line; AGS_V: AGS cell line transfected with empty vector; AGS + 
Sulf1: AGS cell line transfected with SULF1 expression vector; AGS + Sulf2: AGS 
cell line transfected with SULF2 expression vector.
85
 
 
In gastric cancer, overall survival and higher recurrence correlated significantly with 
high Sulf-1 expression.
85
 However, this was not the case for in vitro assessments,
99
 
and contrasting reports provide evidence that Sulf-1 may have a tumour suppressor 
function.
100
 In these studies Sulf-2 continued to appear to act as a tumour promoter.
95
 
Another study suggests that, in HCC, a wide spectrum of splice variants are present, 
27 
particularly of Sulf-1 and to a lesser extent of Sulf-2, that may confer the potential to 
regulate growth.
101
  
 
2.4 The Signalling Pathways Influenced By Sulf-2 
 
The activity of Sulf-2 is believed to affect signalling through multiple pathways that 
have been implicated in cell proliferation. The mechanisms whereby Sulf-2 is thought 
to affect three key pathways, the classical MAP kinase pathway, the wnt pathway, and 
the hedgehog signalling pathway, are outlined in the following sections. 
 
2.4.1 Sulf-2 and the Classical MAP Kinase Pathway 
 
Sulf-2 interacts with HSPGs resulting in their partial desulfation. Desulfated HSPGs 
exhibit decreased affinity for HSPG-binding proteins, resulting in their release into the 
extracellular matrix. This increases the availability of HSPGs to interact with growth 
factor receptors such as the FGF receptor. The interaction between the FGF receptor 
and an HSPG facilitates dimerization of the receptor into its active form. Various 
models have been proposed for the mechanism whereby HSPGs assist in this 
dimerization, and all invoke formation of a ternary complex between HSPGs, two FGF 
receptors, and one or two FGF ligands (Figure 2.4).
102
  
 
Figure 2.4: The FGF:FGFR:HS ternary complex (adapted from reference 103). 
 
Formation of these complexes increase the affinity of the receptor for its agonist, 
FGF.
104
 A disaccharide digestion analysis of the product of Sulf-2 activity on heparan 
28 
sulfate suggested that the enzyme has greater activity against the non-reducing end 
residues than internal residues, and this residue has been implicated as important for 
formation of the ternary complex. Thus, Sulf-2 exosulfatase activity may be of highest 
relevance for its effect on FGF signalling.
105
 Activation of the FGF receptor increases 
signalling through the classical MAP kinase pathway, which is known to promote cell 
proliferation, invasion, migration and angiogenesis.
41,103
 Inhibitors of Sulf-2 would be 
expected to affect this pathway, enabling HSPG binding proteins to sequester HSPGs, 
thus reducing the availability of free HSPGs to promote FGF receptor dimerisation. 
 
2.4.2 Sulf-2 and the Wnt Signalling Pathway 
 
Wnt (wingless/int) family proteins are involved in embryogenesis and development, 
affecting mitogenic stimulation and cell differentiation.
106
 The primary wnt signalling 
pathway is referred to as the canonical pathway, and involves signalling through the 
cell surface frizzled receptor, a seven transmembrane domain protein with an 
extracellular N-terminal cysteine-rich domain (CRD).  
 
Figure 2.5: The canonical wnt signalling pathway.
106
 
 
In the absence of wnt ligand bound to the frizzled receptor, β-catenin is 
phosphorylated through the action of a destruction complex comprising the structural 
proteins axin, adenomatous polyposis coli (APC), casein kinase 1 (CK1) and GSK3. 
The phosphorylation of β-catenin leads to its ubiquitinylation and subsequent 
proteasomal degradation.
107
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Signalling cells secrete wnt peptides, which bind to HSPGs for transport to their site of 
action. On binding of wnt ligands to the CRD of the frizzled receptor, a signal is 
transduced through dishevelled, and a complex series of further interactions results in 
inactivation of the destruction complex, thereby suppressing phosphorylation of 
β-catenin. This leads to reduced proteasomal degradation of β-catenin,28 increasing its 
availability for translocation to the nucleus,
82
 where it forms a complex with TCF-LEF 
(T-cell factor/lymphocyte enhancer factor) that activates transcription of genes 
associated with cell proliferation and apoptosis, including cyclin D1 and c-myc. 
Cyclin D1 is a regulator of cell-cycle progression through activation of cyclin-
dependent kinases (CDKs), while c-myc is an oncogene that regulates cell-cycle 
progression and apoptosis. Other genes affected by the β-catenin/TCF-LEF complex 
include those coding the c-jun and fra-1 transcription factors. Accumulation of β-
catenin and activation of TCF-LEF1 have been found in several human tumour types 
linked to mutations in β-catenin, axin, or APC.28 Thus, activation of the wnt/β-catenin 
pathway is implicated in cell growth and proliferation.
108
 Dysregulation of wnt/β-
catenin signalling has been linked to colon cancer.
109,110
 Si-RNA silencing of the wnt 
pathway,
111
 and antibody approaches have shown efficacy in HCC and sarcoma 
cells.
112
 Conversely, wnt signalling has been suggested to have anti-oncogenic effects 
in melanoma.
28
  
The wnt signalling pathway differs from the previously discussed pathways in that it 
has few enzymic components that could be targeted for modulation by drugs. 
Mutations in APC are prevalent in the majority of colorectal cancers, and it has been 
suggested that inhibitors acting downstream of APC would be required to influence 
the disease state in this patient population.
33
 However, approaches to identifying drugs 
to affect this pathway have explored targeting components both upstream and 
downstream of APC. Downstream approaches include developing compounds which 
bind to and stabilise axin, thus stabilising the β-catenin destruction complex, while 
upstream approaches include identifying compounds which reduce secretion of, or 
sequester, the wnt ligand. No inhibitors of the wnt signalling pathway have yet 
progressed to the clinic.
33
 
Glypican 3 is an HSPG which binds to the wnt signalling peptide in the extracellular 
matrix. The action of Sulf-2 in desulfating sugar residues in glypican 3 reduces the 
affinity of glypican 3 for the wnt peptide. This results in the release of wnt from 
glypican 3, increasing its availability for interaction with the cell surface frizzled 
30 
receptor, leading to increased signalling through frizzled and dishevelled and 
ultimately to increased β-catenin levels in the nucleus.82 Inhibitors of Sulf-2 should 
allow HSPGs to remain tightly bound to wnt, reducing signalling through this 
pathway. A schematic representation of the effects of Sulf-2 on both the classical 
MAPK and wnt signalling pathways is presented in Figure 2.6. 
 
Figure 2.6: Summary of the role of Sulf-2 in the classical MAP kinase and wnt-
signalling pathways (adapted from reference 17). 
 
2.4.3 The Role of Sulf-2 in Other Signalling Pathways 
 
HSPGs bind to and regulate the activity of other growth factors including platelet 
derived growth factor (PDGF), vascular endothelial growth factor (VEGF), glial cell-
line-derived neurotrophic factor (GDNF), sonic hedgehog (Shh) and noggin.
96
 In the 
U251 glioblastoma cell line the activity of platelet derived growth factor α (PDGFRα), 
and insulin-like growth factor receptor β (IGF1Rβ) were reduced by over 50% when 
Sulf-2 expression was knocked down with shRNA, whereas other receptor tyrosine 
kinase activities such as PDGFRβ were unaffected.96 The reduction of PDGFRα 
signalling in the presence of PDGF was confirmed.  
31 
Hedgehog (Hh) proteins are signalling molecules which have a function in embryonic 
development.
113
 Three homologues have been identified in vertebrates, designated 
Sonic (Shh), Indian (Ihh) and Desert (Dhh). During development, accumulation of Shh 
protein at the cell surface has been shown to be attributable to the action of Sulf-1. In 
several human cancers, aberrant signalling through the Shh-mediated pathway has 
been implicated. In this pathway, Shh protein interacts with the 12-transmembrane cell 
surface patched (Ptc) protein. In the absence of Shh, Ptc inhibits smoothened (Smo), a 
7-transmembrane domain protein. Shh binding to Ptc reduces the Ptc-driven inhibition 
of Smo, leading to pathway activation. A membrane bound HSPG (Dally-like protein, 
Dlp) modulates Hh signalling. Although the mechanism for this modulation has not 
been elucidated, the participation of Sulf-1 and Sulf-2 is possible.
114
 Inhibition of 
hedgehog signalling as an anti-cancer approach has been strengthened by the recent 
approval of vismodegib (Erivedge, 24), a competitive inhibitor of the smoothened 
receptor, for the treatment of basal cell carcinoma.
115
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At present, the greatest body of evidence for the potential of Sulf-2 inhibitors in cancer 
therapy involves their effects on modulating signalling through the classical MAP 
kinase and wnt signalling pathways. It is not clear at present which of these pathways 
is affected to the greatest extent by Sulf-2 over-expression.  
 
 
2.4.4 The Roles of Sulf-1 and Sulf-2 in Cancer 
 
A recent report suggests that Sulf-1 may be anti-proliferative and anti-angiogenic, 
acting by negatively regulating VEGFR2 signalling.
116
 A microarray analysis of genes 
associated with expression of Sulf-1 and Sulf-2 suggested that some gene associations 
were common to both. The common genes were associated with cell adhesion, 
cytoskeletal remodelling, blood coagulation, wnt/β-catenin, and epithelial-
mesenchymal transition signalling pathways. However, Sulf-2 had a higher association 
with neoplastic processes than Sulf-1. The association of Sulf-1 to prognosis was 
found to be complex, with those patients having very high or very low expression of 
Sulf-1 having a poorer prognosis than those with moderate Sulf-1 expression.
117
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Reports suggest that Sulf-1 may have a similar effect to Sulf-2 on the wnt pathway, 
but an inhibitory role on MAP kinase signalling.
98
 This might explain the conflicting 
evidence on the effect of Sulf-1 on cell proliferation. It may be that, in cancers where 
over-activity of the wnt signalling pathway is driving proliferation, inhibitors of both 
Sulf-1 and Sulf-2 could prove beneficial. However, in cancers where over-activity of 
the MAPK pathway is a significant contributory factor, inhibition of Sulf-1 may be 
detrimental, and a selective Sulf-2 inhibitor would be preferable.  
An added complication is the recent identification of splice variants of Sulf-1 and 
Sulf-2.
101
 It has been suggested that full length Sulf-1 and Sulf-2 may promote wnt 
signalling, while shorter variants might be associated with growth factor signalling via 
the FGF, VEGF and EGF receptor pathways.
101
 A further layer of complexity arises 
from potential cross-talk between the wnt and MAPK pathways, which differ between 
tumour types. For example, in colorectal cancer, activation of the wnt pathway results 
in stabilisation of Ras, leading to activation of the MAPK pathway,
28
 whereas, in 
melanoma, activation of the MAPK pathway leads to down-regulation of the wnt 
pathway.
28
  
It is therefore unclear whether a Sulf-2 inhibitor with selectivity over Sulf-1 will have 
the widest utility, or if a dual Sulf-1/Sulf-2 inhibitor may be beneficial. Sulf-1 and 
Sulf-2 have 64% sequence identity, with the amino acid residues in the active-site 
being highly conserved.
84
 This suggests that it may be a considerable challenge to 
identify a compound with selectivity for Sulf-2 over Sulf-1. The overall aim of this 
project was to develop both dual Sulf-1/Sulf-2 inhibitors and selective Sulf-2 inhibitor 
tool compounds, to allow further study of the implications of inhibiting these 
endosulfatases.  
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2.5 The Mechanism of Desulfation by Sulfatase Enzymes 
 
Sulf-2 is translated as a pre-proenzyme, requiring two major post-translational 
modifications for its correct localization and activation. The first modification requires 
the translated 125 kDa pre-proenzyme to be cleaved into 75 kDa and 50 kDa 
domains,
84
 which are subsequently linked by a disulfide bridge. If this does not occur 
the enzyme retains catalytic activity, but is no longer targeted to the lipid rafts of the 
cell membrane, resulting in a much higher proportion of secreted enzyme and a 
reduction in membrane associated sulfatase. Membrane localisation appears to be 
important for functional activity.
123
  
The second post-translational modification conserved across the entire sulfatase family 
involves conversion of a cysteine residue into a formylglycine (FG), and is essential 
for catalytic activity (Figure 2.7). This modification is governed by formylglycine 
generating enzyme (FGE),
124
 and occurs before the protein adopts its folded tertiary 
structure.
125
  
 
Figure 2.7: The post-translational modification mediated by FGE. 
 
A highly conserved twelve amino acid signature sequence (C/S-X-P-S/X-R-X-X-L/X-
T/X-G/X-R/X) is present in all hydrolytically active sulfatases, and is a key 
recognition element for FGE.
82
 A second twelve amino acid signature sequence (G-
Y/V-X-S/T-X-X-X-G-K-X-X-H) contains residues essential for catalytic activity, 
including key lysine and histidine amino acids. 
Two mechanisms were originally proposed for the desulfation of substrates by 
sulfatases, each of which utilise the key active-site formylglycine in the desulfation 
step, with the mechanism outlined in figure 2.8 now generally accepted.
126
 In this 
mechanism, the formylglycine is hydrated to hydroxyformylglycine which acts as a 
nucleophile, attacking the sulfate sulfur atom to liberate the alcohol or phenol. The 
sulfate is then released through a geminal elimination mechanism.  
34 
 
Figure 2.8: A proposed mechanism for sulfatase-mediated desulfation; FGly denotes 
the backbone atoms of the formylglycine residue.(adapted from reference 82).  
 
Amino acid residues in the active-site, and co-ordination to a metal ion, facilitate the 
desulfation. For example, it has been proposed that an interaction between an aspartic 
acid residue and the hydrated aldehyde renders one of the hydroxyformylglycine 
oxygen atoms more nucleophilic, thereby facilitating attack on the sulfate group.  
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2.6 Structural Biology of the Sulfatases 
 
The tertiary structure of all sulfatase family members contains four domains (A-D), 
with domain A being found at the N-terminus, and domain D at the C terminus.
127
 
Domain B contains the active-site, and is highly conserved with over 90% sequence 
similarity across the human sulfatase family.
128
 The D domain is the major site of 
sequence variation between sulfatase family members. At the outset of this project 
four sulfatase crystal structures (ARSC (PDB accession code 1p49), ARSA (PDB 
accession code 1auk), ARSB (PDB accession code 1fsu) and PARS (PDB accession 
code 1hdh)) had been deposited.
124,129
 Figure 2.9 shows a published overlay of these 
structures.  
 
Figure 2.9: Superposition of the crystal structures of members of the sulfatase family. 
Human placental ARSC (green), ARSA (cyan), ARSB (magenta) & PARS (yellow). 
The Ca
2+
 ion is shown as a sphere.
124
 
 
All four sulfatases have a similar active-site which can be closely overlaid. In three of 
the structures the active-site metal was found to be a calcium ion, with the fourth 
crystal structure (ARSA) containing magnesium. It is not certain whether this is the 
metal ion that is bound under physiological conditions, or an artefact arising from the 
high magnesium concentration used during the enzyme purification.
82
 In the ARSC 
structure, a sulfate ion was present and covalently linked to the hydroxyformyl glycine 
residue, which led to a proposal that the resting state of the enzyme may retain the 
sulfate after cleavage from the substrate.
124
 However, there is no evidence that this is 
36 
the case under physiological conditions. Across all four crystal structures, nine of the 
ten residues believed to be involved in catalysis are conserved.
124
 There are significant 
differences in other residues in the substrate binding cavity, which may be responsible 
for substrate recognition. The ARSC structure contains two hydrophobic α helices 
which constitute a membrane anchoring domain. In the other three crystal structures 
no such domain exists, and the sequence of Sulf-2 suggests that it also lacks these 
hydrophobic α helices. In contrast to ARSC, Sulf-2 contains a hydrophilic domain of 
300-320 amino acid residues, which has been implicated in both membrane anchoring, 
and in the binding of heparan sulfate to the enzyme.
84
 Mutant forms of Sulf-2 lacking 
regions of the hydrophilic domain have higher extracellular secretion and lower 
membrane localization.
123
 The membrane anchoring of Sulf-2 may involve a region of 
positively charged amino acids in the hydrophilic domain, which interact with the 
negatively charged head groups of membrane phospholipids.
130
  
No crystal structures of a sulfatase with its substrate bound have been published to 
date. However, construction of an homology model has been reported for bacterial 
heparan sulfate 6-O-sulfatase from F. heparinium based on the known sulfatase crystal 
structures, into which a disulfated monosaccharide has been docked (Figure 2.10).
131
  
 
Figure 2.10: Schematic diagram of the proposed active-site interactions of F. 
heparinium sulfatase and a sulfated monosaccharide substrate.
131
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Many of the polar residues lining the active-site in this model are not conserved in 
arylsulfatases. It has been proposed that the calcium ion in the active-site co-ordinates 
to both the sulfate to be hydrolysed and the hydrated formyl glycine residue, and that 
an aspartate residue interacts with the NH from the glucosamine N-sulfate motif.
131
 
This implies that the role of the N-sulfate may be to increase the hydrogen bond donor 
ability of the glucosamine NH to facilitate this interaction. The authors state that the 
catalytic site residues proposed in this model would not allow for endosulfatase 
activity, which would require space for adjacent sugar chains to occupy or exit the 
active-site. Therefore, caution should be adopted in the use of this model to inform 
design for inhibitors of an endosulfatase.  
 
2.7 Precedent for Small-Molecule Sulfatase Inhibitors 
2.7.1 Inhibitors of Sulf-1 and Sulf-2 
 
At the start of this project no small molecule inhibitors of either Sulf-1 or Sulf-2 had 
been reported in the literature. A study in 2005 had investigated the compositional 
profile of heparan sulfate and the ability of different fragments of heparin to interact 
with Sulf-2.
88
 The investigators determined, through enzymatic digestion and mass 
spectrometry analysis, that the major component disaccharide present in bovine kidney 
heparan sulfate was the unsulfated disaccharide UA-GlcNAc. However, it was 
determined that the trisulfated disaccharide motif of heparan sulfate (Figure 2.11) is 
the primary motif for desulfation by human Sulf-2.  
 
Figure 2.11: The trisulfated disaccharide unit, IdoA2S-GlcNS6S. 
 
The length of sulfated polysaccharide required for recognition and Sulf-2 mediated 
desulfation was also investigated, with a decasaccharide containing trisulfated 
disaccharide units suffering a 47% decrease in O
6
-sulfation by the action of Sulf-2. A 
tetrasaccharide had a 14% decrease, whereas no desulfation was observed for a single 
trisulfated disaccharide.
88
 This may suggest that recognition elements distal to the 
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enzyme active-site are required for substrate recognition, and that high molecular 
weight inhibitors may therefore be necessary. 
However, the first small molecule Sulf-2 inhibitors were reported soon after the 
commencement of this project.
132
 These compounds were derived from the 
monosaccharide of the substrate glucosamine residue, bearing a primary, or a 
methylated tertiary sulfamate at the O
6
-position, and an acetate or sulfate group at the 
N
2
-position. The most potent analogue from this series was 25 with an IC50 against 
Sulf-2 of 130 M (Table 2.4). 
 
Cmpd R’ R” Sulf-2 IC50 M  
(or % inhibition) 
Sulf-1 IC50 M  
(or % inhibition) 
25 SO3Na H 130 95 
26 SO3Na Me 240 180 
27 Ac H (30% @ 5 mM) (40% @ 5 mM) 
28 Ac Me (45% @ 5 mM) (50% @ 5 mM) 
 
Table 2.4: Reported Sulf-2 inhibitory activity of monosaccharide sulfamates.
132
 
 
Compounds 27 and 28 bearing an N-acetyl group were an order of magnitude less 
potent than 25 and 26, suggesting that the N-sulfonyl substituent plays an important 
role in substrate binding. All compounds tested had no selectivity for Sulf-2 over Sulf-
1. Although these compounds were not sufficiently potent for use in biological target 
validation studies, the results provided encouragement that viable Sulf-2 inhibition 
was possible with low molecular weight compounds. In the same paper two simple 
arylsulfamates (29 and 30) were also tested against Sulf-1 and Sulf-2 (Table 2.5), and 
found to be markedly weaker inhibitors than 25 and 26. Both 25 and 26 were shown to 
be reversible inhibitors, whereas phenol sulfamate 29 was reportedly an irreversible 
inhibitor of Sulf-2.
132
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 Compound Structure Sulf-2  
% inhibition 
29 
 
30% @ 5 mM 
30 
 
50% @ 5 mM 
 
Table 2.5: Reported Sulf-2 inhibitory activity of non-saccharide sulfamates 29 and 30. 
 
The alkyl nitrone OKN-007 (31) has also been suggested to be an inhibitor of Sulf-
2.
133
 Compound 31 (also known as disufenton sodium, NXY-059, and Cerovive) has 
previously been investigated in Phase II clinical trials for ischaemia due to stroke, with 
a proposed mechanism of action arising through its ability to scavenge free radicals.
134
 
No inhibition data against isolated active Sulf-2 have been published. 
 
31 
In a HuH-7 HCC cell-line expressing high levels of Sulf-2, 31 showed a dose-
dependent increase in apoptosis, with some effects on cell migration but little 
influence on proliferation and cell viability.
133
 In Sulf-2 shRNA-silenced Huh-7 cells, 
31 had a reduced effect on apoptosis. In a low Sulf-2 expressing cell line (Hep3B) 
with Sulf-2 expressed to high levels, treatment with 31 resulted in a 60% increase in 
apoptosis compared with a 22% increase in the untransfected control cells.
133
 In Huh-7 
cells 31 inactivated TGFB1/SMAD2 and hedgehog/GLI1 signalling pathways, 
suggesting that Sulf-2 may play a role in the regulation of these pathways. However, 
while there is circumstantial evidence that 31 is an inhibitor of Sulf-2, the absence of 
isolated enzyme inhibition data offers the potential for other pharmacological effects, 
which may be responsible for at least some of the observed anti-tumour activity.  
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2.7.2 Inhibitors of Arylsulfatase C 
 
ARSC inhibitors are believed to interact with its membrane anchoring domain, which 
is not present in Sulf-2. Therefore, SARs for inhibitors of ARSC are unlikely to 
transfer between the two targets. However, the conserved catalytic mechanism would 
suggest that SARs for sulfate isosteres may have relevance for the design of Sulf-2 
inhibitors.
129
 A brief review of ARSC inhibitors follows, with an emphasis on SARs 
around the sulfate warhead and the A ring of the steroid, which may inform Sulf-2 
inhibitor design. 
 
2.7.2.1 Steroid-Based ARSC Inhibitors 
 
In 1994 the Potter group disclosed inhibitors of oestrone sulfatase based on a steroid 
template.
135
 They explored oestrones substituted on the phenol and prepared oestrone 
sulfamate (EMATE, 32), oestrone N-methylsulfamate (33), and oestrone 
N,N-dimethylsulfamate (34) (Table 2.6). Irreversible inhibition was observed for 32, 
whereas the secondary and tertiary methylated sulfamates were reversible inhibitors. 
Increasing the size of the N-substituents resulted in a further loss of potency.
136
 
 
Cmpd R
1
 R
2
 ARSC inhibition Modality 
32 H H IC50 = 65 pM Irreversible 
33 Me H 87% inh @ 1 M Reversible 
34 Me Me 87% inh @ 1 M Reversible 
 
Table 2.6: ARSC inhibitory activity for simple primary, secondary, and tertiary 
sulfamate derivatives of oestrone.
135
 
 
ARSC inhibition data have also been reported for a wide range of sulfamate isosteres, 
including sulfonates,
137
 alkylsulfones and sulfonamides,
138
 sulfonylureas,
139
 
41 
carbamates, and esters,
140
 which universally led to significant potency loss. By 
contrast, cyclic sulfamate isosteres gave potent ARSC inhibition (Table 2.7).
138
 
Cmpd Structure ARSC IC50 nM 
35 
 
9  
 
36 
 
360 
 
Table 2.7: ARSC inhibitory activity data for analogues of EMATE (32) containing 
cyclic sulfamate isosteres.
138
 
 
2.7.2.1.1  A-Ring Substituted Steroid Sulfamates 
 
Substitution on the A ring of 32 ortho to the sulfamate exhibited remarkable SARs 
with small structural changes resulting in potency differences of over one hundred 
thousand fold (Table 2.8).
141
 These SARs are unlikely to be due solely to electronic 
effects on the leaving group ability of the steroid phenol, and may suggest that A-ring 
substituents participate in binding interactions within the sulfatase active-site. This is 
further supported by the difference in potency between the 2- and 4-nitro analogues, 
40 and 41, which would have broadly similar electronic properties. 
 
 
Cmpd R1 R2 ARSC IC50 nM 
37 Cl H 3.4  
38 Me H 11,000 
39 CF2H H 0.1  
40 NO2 H 70  
41 H NO2 0.8  
 
Table 2.8: ARSC inhibitory activity of primary sulfamate analogues of oestrone 
bearing substituents on the steroid A-ring. 
42 
2.7.2.2 Non-Steroidal ARSC Inhibitors 
 
The most advanced ARSC inhibitor in development is 667-coumate (STX-64, 42), 
which is reported to bind irreversibly to the enzyme,
142
 and completed phase I trials 
with few adverse events, prior to entering Phase II clinical trials for breast cancer.
143
 
Four patients with hormone-independent breast cancer exhibited stabilisation of 
disease for 2.75 to 7 months during treatment with 42.
143
 The lack of significant 
adverse events in the phase I study provides encouragement that compounds 
containing a phenolic primary sulfamate have no inherent toxicological liability. 
 
42 
While the vast majority of ARSC inhibitors contain a sulfamate group or an obvious 
sulfamate isostere, there are a limited number of non-sulfamate inhibitors, for example 
43, 44 (Naringenin),
144
 and 45.
145
 These compounds indicate that a sulfamate, or a 
sulfamate isostere, is not an absolute requirement for inhibition of a sulfatase.  
 
        43    44    45 
   ARSC; IC50 = 48 nM               ARSC; 50% inh @ 10 M          ARSC; IC50 = 76 nM 
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2.8 Further considerations for the Design of Sulfatase Inhibitors 
 
In this section, a wider consideration of the literature that may provide information 
relevant to the synthesis of inhibitors for Sulf-2 is examined, including a discussion of 
known saccharide sulfate and sulfamate drugs and alternative approaches to heparin 
mimetics. Potential issues that may arise in the development of saccharide-based 
sulfatase inhibitors will also be discussed. 
 
2.8.1 Saccharides as Drugs 
The primary aim of the project at the present time is the identification of probe 
molecules to support in vitro target validation studies. However, the potential of a tool 
series for development into suitable in vivo tools, and ultimately compounds amenable 
for clinical development, should be considered. The physicochemical properties of 
saccharides have limited their application as oral therapies, as the high polar surface 
area and hydrogen bonding potential render them unlikely to diffuse passively through 
membranes. Exploiting active uptake via saccharide transporters is a potential 
approach for obtaining oral bioavailability. Advances in formulating low molecular 
weight heparin to improve bioavailability have also been made through co-
administration with additives, which improve absorption by mechanisms such as 
targeting for active transport, or enlarging the pores in the gut epithelium to allow 
absorption by the paracellular route. An alternative prodrug strategy has also had some 
success, masking the saccharide hydroxyl groups as acyl esters which have sufficient 
stability in the stomach, and are absorbed in the lower intestine. The active component 
is then liberated in the plasma by the action of esterase enzymes.
146
 This prodrug 
approach may have limited utility for intracellular targets, as, once liberated, the polar 
active species would be unlikely to cross plasma membranes to reach the site of 
action. However, this approach may be viable for Sulf-2, with its proposed 
extracellular site of action. Topiramate (46) is a monosaccharide derived primary 
sulfamate which has been employed as an anticonvulsive treatment for epilepsy,
147
 the 
mode of action of which is yet to be established. However, it is known to have 
pharmacological activity against voltage-dependent sodium channels, GABA-A 
receptors, the AMPA/kainate subtype of the glutamate receptor, and carbonic 
anhydrase enzymes. Topiramate has high oral bioavailability (80%) and a long 
duration of action (t1/2 18-23 h).
148
 The clinical precedence and widespread use of 
44 
topiramate lend further support to the safety of primary alkyl sulfamates, and the 
potential for developing saccharide-based inhibitors as oral drugs.  
 
46     
PI-88 (47) is a phosphosulfomannan oligosaccharide inhibitor of tumour growth and 
metastases currently in Phase III clinical trials. The compound was developed as an 
inhibitor of heparanase, but may act through multiple mechanisms including 
preventing the formation of the FGFR ternary complex. 
  
47 
PI-88 has reported inhibitory activity against Sulf-1 and Sulf-2, with IC50 values of 2.6 
g/mL against Sulf-1, and 1.2 g/mL against Sulf-2,149 and it has been proposed that 
some of the antitumour activity exhibited by 47 may be attributable to inhibition of 
sulfatases. Owing to poor oral bioavailability, 47 is administered intravenously. 
 
2.8.2 Carbonic Anhydrase Inhibition 
 
Small molecule sugar sulfamates including 46 have been shown to potently inhibit 
carbonic anhydrase.
146
 Inhibitors of this enzyme class have been approved for human 
use, for example acetazolamide for the treatment of glaucoma.
150
 However, carbonic 
anhydrase inhibition can result in acidosis leading to the formation of kidney stones.
151
 
Carbonic anhydrase inhibitors also often partition into red blood cells, complicating 
the analysis of a compound’s pharmacokinetics.152 Thus, a sulfamate-based Sulf-2 
inhibitor which also inhibits carbonic anhydrase may be viable for progression to 
clinical studies, but monitoring of the carbonic anhydrase inhibition during later stages 
of the development process would be advisable.  
45 
Chapter 3: Design of Potential Sulf-2 Inhibitors 
3.1 Considerations in the Design of Chemical Tools for Target 
Validation 
 
With the advent of the discipline of chemical biology, it has become widely accepted 
that the design of chemical tools for use in validating a novel target in a disease area 
will usually differ from the methods used for the design of potential drugs for clinical 
development.
76,153
 Validation of a novel target is a high risk endeavour, with a good 
chance that the outcome will be a negative result, i.e. that the target of interest is 
unsuitable for a small-molecule drug discovery program.
154,155
 This may be for a 
variety of reasons, including unsuitability of the target for efficient binding by a small 
molecule,
156
 evidence that selectivity against key safety targets may not be achievable, 
or failure of modulation of the target to have the desired efficacy in disease models.
157
  
 
Figure 3.1: Criteria for consideration in the design of a chemical tool.
157
 
 
Several recent commentary articles provide interesting discussions on how design 
criteria for tool compounds may differ from those for designing potential drug 
candidates. Kodadek
153
 suggests that achieving potency against the target of interest is 
the unifying criterion in both cases. Drugs require optimization of oral bioavailability, 
pharmacokinetic half-life and cost of goods. While selectivity for the target of interest 
is often advantageous to a drug for reasons of safety, it is not a prerequisite. In 
46 
contrast, for a high quality tool compound to evaluate a mechanism, selectivity is 
important to ensure off-target pharmacology is not responsible for any effects 
observed, or, conversely, that off-target activity does not interfere with the ability to 
detect the effect of the primary pharmacology. Ensuring complete selectivity is usually 
not possible, as it is not practical to screen against all other biological targets that may 
affect the functional outcome. Indeed, often it is not practically or technically possible 
to screen against all of the close family members of the target of interest. One strategy 
to mitigate the risk of unknown selectivity is to identify more than one structural class 
of probe molecule, which are less likely to have similar off-target pharmacology 
profiles. Use of a control compound of similar structure to the probe molecule but with 
low activity against the target of interest, such as an inactive enantiomer, can also 
provide useful information about off-target effects.
157
 For intracellular targets, cell 
permeability is important to enable the probe molecule to access the biological 
target.
157
 Frye outlines several principles to be considered for a high quality tool, 
including sufficient potency and selectivity to allow a confident link between in vitro 
and in vivo activity, evidence for the mechanism of action, dose-dependent cellular 
activity, and chemical stability.
76
 However, the nature of each target will dictate 
specific requirements for a chemical probe, and defining the rules can often only be 
achieved in hindsight once a probe molecule has been developed.
76
 A set of ‘fitness 
factors’ for chemical tools has been described which summarize the aspects of the 
chemistry, potency, selectivity and biological context of the target which should be 
considered in the design and selection of a tool compound.
158
  
  
3.2 The Design of Potential Chemical Tools for Sulf-2 Inhibition  
 
As discussed in section 2.8, the first small-molecule Sulf-2 inhibitors were reported 
soon after the commencement of this project.
132
 These compounds were derived from 
the glucosamine monosaccharide unit of HSPGs, bearing a primary or tertiary 
methylated sulfamate at the O
6
-position, and an acetate or sulfate group on the N
2
-
position. The most potent analogue from this series was 25 with an IC50 of 130 M. 
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The initial aim of the Newcastle Sulf-2 project was to identify a tool compound for use 
in in vitro experiments to address the following questions:- 
1. Is an IC50 of < 100 M against Sulf-2 achievable with a small-molecule (MW 
< 500) inhibitor? 
2. Is selectivity over Sulf-1, and over other human sulfatases, achievable? 
3. Does inhibition of Sulf-2 alone, or dual Sulf-1/Sulf-2 inhibition, by a small-
molecule inhibit the growth of cancer cell lines in vitro? 
In order to answer these questions as rapidly as possible, the project’s initial focus was 
on identifying probe compounds that aim solely to modulate the target in vitro, with 
improved potency, and sufficient solubility to allow the compounds to be tested in the 
relevant assays. Active compounds would subsequently be assessed for selectivity 
over other sulfatases. Inhibitors selective for Sulf-2, and dual Sulf-1/Sulf-2 inhibitors, 
were sought. In this phase of the project, in vivo properties that would be considered 
for a lead development or drug discovery program, such as pharmacokinetic and 
toxicological liabilities, were not high priority considerations for compound design.   
Literature evidence suggests that the active-site of Sulf-2 is extracellular.
90
 It follows 
that there is no requirement to achieve high cell permeability for a tool compound to 
effectively modulate this target. Indeed, lack of cell penetration may provide an 
alternative method to confer selectivity over off-target intracellular sulfatases.  
There are no published crystal structures of Sulf-1 or Sulf-2, and attempts to build 
homology models based on the known sulfatase crystal structures resulted in structures 
with low confidence levels in key regions around the active-site, rendering them 
unsuitable for use in compound design. Ligand based approaches were thus pursued 
for the identification of improved tool compounds. The approaches taken are 
summarised below: 
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1. Synthesize compound 25 for use in assay development. 
2. Prepare analogues of 25 to generate Sulf-1 and Sulf-2 SARs. 
3. Prepare non-saccharide templates based on: 
a. Inhibitors of other sulfatase family members. 
b. De novo design based on the structure of the endogenous substrates of 
Sulf-2. 
 
Generation of an assay for Sulf-2 inhibition was complicated by issues in the isolation 
of catalytically active Sulf-2 protein, due in part to the requirements for post-
translational modification of the cysteine into a formylglycine residue. Consequently, 
a viable Sulf-2 biological assay has only recently become available. In the absence of a 
biological assay to allow a high-throughput screening campaign, and with no crystal 
structure of Sulf-2 on which to investigate structure-based design approaches, the 
structures of the endogenous HSPG substrates were considered as a potential starting 
point for analogue design. No crystal structures of HSPGs were available, so attention 
focussed on understanding the features of the related biomolecule, heparin, and its low 
molecular weight fragments. Heparin is highly sulfated, and may therefore reflect the 
structure of the oligosaccharide regions of HSPGs which are de-sulfated by Sulf-2. 
Gaining an understanding of the conformations, surface features and interactions made 
between heparin and its protein binding partners allowed analogue and de novo ligand-
based design by overlaying prospective designs with key features of the substrate 
which were likely to contribute to binding. 
  
3.3 Structural Characteristics of Heparan Sulfate Oligosaccharides 
 
The primary structure of heparan sulfate oligosaccharides consists largely of the 
repeating disaccharide unit [-4IduAβ(1,4)-GlcNS1-]n.
87
 The lowest energy 
conformation of glucosamine is the 
4
C1 chair form, with all substituents occupying 
equatorial positions, and it would be expected that this form would predominate in the 
oligosaccharide structure. However, iduronic acid can adopt two low energy 
conformations of similar energy, the 
1
C4 chair and the 
2
S0 skew boat conformations 
(Figure 3.2).
159
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Figure 3.2: The most abundant forms of O
2
-sulfated iduronic acid in heparin (adapted 
from reference 160). 
 
 
The oligosaccharides also have considerable flexibility in the linkage between the 
monosaccharide sub-units, with the carbon-oxygen bonds in the ether linkers having 
low energy barriers to rotation. Consequently, heparan sulfate oligosaccharides could 
adopt a large number of secondary structures. However, two published modelled 
structures of heparin based on NMR and molecular modelling studies on a heparin 
dodecasaccharide consisting of the repeating trisulfated disaccharide unit suggest a 
helical rod-like secondary structure is likely to predominate in aqueous solution.
161
 
The first model assumes that the iduronic acids all adopt the 
1
C4 form, whereas in the 
second all iduronic acids are modelled in the 
2
S0 skew boat conformation. While it is 
likely that, in reality, the iduronic acid conformations may be heterogeneous along the 
length of an oligosaccharide, it is notable that remarkably similar helical structures 
appear favoured, regardless of the iduronate conformation.  
 
The computed solution structure models were found to be closely related to the 
reported solid state X-ray crystal structure.
161
 The proposed helical structures suggest 
that clusters of sulfate groups are presented at regular intervals of approximately 17 Å 
on either side of the helix.
161
 A comparison of space-filling representations based on 
van der Waals atomic radii of the two modelled structures (Figure 3.3), clearly 
indicates a large number of negatively charged sulfate and carboxylate groups that 
dominate the accessible surface. These are likely to be important in the binding of 
heparin and heparan sulfate to biological targets.  
50 
 
Figure 3.3: Space filling representations of the models of the heparan sulfate 
oligosaccharides (PDB accession code 1hpn).
162
 Green: All iduronate residues in 
1
C4 
conformation; White: All iduronate residues in 
2
S0 conformation. 
 
3.4 General Observations on the Interactions between 
Oligosaccharides and Proteins 
 
A review of carbohydrate mimetic strategies concluded that polysaccharide-protein 
interactions often involve a mixture of hydrogen bonding, hydrophobic, and ionic 
interactions.
163
 Hydrogen bonding interactions between NH and carbonyl groups on 
the peptide backbone, and the saccharide hydroxyl groups dominated the hydrogen 
bonding contributions in the interactions surveyed. Far fewer hydrogen bond 
interactions were observed between serine and threonine side chains and the sugar 
hydroxyl groups.
163
  
Hydrophobic interactions between the faces of the pyran rings of the saccharide core 
and lipophilic amino acid side chains were also found to play a significant role in 
protein-saccharide interactions. An example can be seen in the binding of a 
disaccharide to the maltose binding protein, where both saccharide rings are 
sandwiched between tryptophan and tyrosine aromatic side chains of the protein 
partner.
164
 Thus while saccharide-binding sites are likely to contain more hydrophilic 
amino acids than in other binding site classes, the potential for hydrophobic 
interactions should also be considered in inhibitor design.   
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3.5 Interactions between Heparin Oligosaccharides and Proteins 
 
Heparin oligosaccharides differ from the majority of other oligosaccharides in that 
they are highly sulfated. The presence of such polar groups would be expected to 
affect the interactions observed on the binding of a heparan sulfate derived saccharide 
to a protein. The first study to investigate heparin-protein interactions concentrated on 
the features of protein partners that confer heparin binding ability.
165
 This study 
compared four proteins which interact with heparin (apolipoprotein B, apolipoprotein 
E, vitronectin, and platelet factor 4) and found certain primary sequence motifs rich in 
basic amino acid residues which are conserved across the heparin binding domains of 
these proteins. These conserved sequences were XBBXBX and XBBBXXBX where B 
are basic and X are hydropathic i.e. neutral or hydrophobic amino acid residues. 
Molecular modelling suggested that if these sequences formed an  helix, the basic 
residues would be aligned on one face of the helix and the hydrophobic residues on 
another face (Figure 3.4).  
 
Figure 3.4: Helical wheel diagram of residues 161-177 of apolipopotein B.
166
  
 
 The face displaying the basic residues is likely to interact with the acidic sulfate and 
carboxylate groups on the surface of heparin. It has also been noted that basic residues 
distant from each other in the primary sequence could, on protein folding, form 
regions dense in positively charged residues that could bind to the negatively charged 
heparin surface.
166
 
 
The structure of a heparin tetrasaccharide bound to the enzyme 3-O-sulfotransferase 
(Figure 3.5) is the closest protein in function to Sulf-2 with a published crystal 
structure bound to a heparin derived oligosaccharide.
168
 Analysis of this structure 
52 
shows that the heparin oligosaccharide binds in a clear pocket in the protein, and that 
the major polar interactions between the protein and the oligosaccharide involve 
sulfate and carboxylate groups of the saccharide, and basic amino acids and backbone 
amide groups of the protein. Only a limited number of saccharide hydroxyl groups 
appear to make interactions with the protein, and none of the tetrahydropyran core 
oxygen atoms, or the linking ether oxygen atoms appear to contribute to binding. 
Several water molecules also occupy the pocket in the bound structure, and 
interactions between the ligand, the water molecules and the protein may also 
contribute to binding. 
 
 
 
Figure 3.5: The binding surface of 3-O-sulfotransferase with a heparin-derived 
tetrasaccharide bound (PDB accession code 1t8u).
168
 
From these analyses it can be concluded that interactions of the charged sulfate and 
carboxylate groups on the heparin oligosaccharide with basic residues on the protein 
are often the critical interactions responsible for binding. Attempting to mimic some of 
these interactions was a key consideration when designing potential inhibitors of 
Sulf-2. Interactions between the tetrahydropyran ring oxygen atoms or the linking 
ether atoms and the protein partner, either directly or through bridging water 
molecules, appear to be relatively uncommon. The saccharide scaffold may act 
principally as a template to display the charged and polar groups in the correct 
orientations for interaction with the protein. Mimicking of the spatial orientation of the 
pyran oxygen atoms may not therefore be necessary in inhibitor design. 
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It has been reported for heparin oligosaccharides bound to FGF that the helical 
parameters and glycosidic bond conformations of the bound oligosaccharide closely 
mimic those of heparin in the unbound solution state.
165,166
 Similarly, in a crystal 
structure of heparin bound to angiotensin II, the bound structure in the crystal was 
found to closely resemble the solution structure. Comparison of the solution structure 
of heparin, and the conformation of four crystal structures of heparin oligosaccharides 
bound to proteins, revealed that the secondary structure was similar in all cases. This 
increased confidence that the solution structure could be used as a template for ligand-
based design by superposition, in order to select templates which may mimic the 
heparin-protein binding interactions. The results of this analysis were used to inform 
both the design of analogues of monosaccharide Sulf-2 inhibitor (25), and the 
attempted de novo design of non-saccharide based Sulf-2 inhibitors. 
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3.6 Monosaccharide Sulfamate Inhibitors of Sulf-2 
 
The reported Sulf-1/Sulf-2 dual inhibitors, 25 and 27,
132
 were successfully prepared 
for use in the development of a Sulf-2 primary pharmacology assay, using the novel 
synthetic route described in Section 4.1.  
                  
3.6.1 Design of Analogues of Compound 25 
 
Analogues of 25 were targeted to develop SARs in order to build an understanding of 
features required for binding, and structural changes affecting selectivity. A program 
of work was thus undertaken to systematically vary the substituents around the 
monosaccharide core (Figure 3.6). The key design questions and rationale that guided 
the selection of analogues for synthesis are presented in the following sections. 
 
Figure 3.6: Exploration of monosaccharide SARs by variation of R
1
 to R
4
 
 
3.6.1.1 Variation of the 2-Substituent of Compound 25 
 
The N-sulfate is a highly polar group, contributing to the overall hydrophilic nature of 
25 (clogP -2.7). Due to its acidic nature, the sulfate is likely to be deprotonated in the 
active-site, bearing a net negative charge on oxygen that may participate in a charge-
charge interaction with basic residues in the binding site of Sulf-2. A report on an 
homology model of F. heparinium sulfatase suggested that the N
2-
sulfate may instead 
influence binding by enhancing the hydrogen bond donor ability of the N
2
-H.
131
 
Analogues were designed to explore the possible N
2
-sulfate/protein interactions. The 
first targets (25, 27, 48, and 49) explored the effect of variation of the N-H pKa on 
Sulf-2 inhibition (Table 3.1), as a potential surrogate for the hydrogen bonding ability 
of the N-H hydrogen atom. 
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                    27           48             49 
 
Compound 25 27 48 49 
Calculated N-H pKa 14.1 16.2 11.0 6.9 
Table 3.1: N-H pKa values for potential novel N-substituted analogues (calculated 
using ACD labs software).169  
 
Methanesulfonamide 48 resulted in an increase in N-H acidity of three pKa units 
relative to 25. Trifluoromethylsulfonamide (49) further acidifies the N-H, and would 
be expected to be significantly ionised at physiological pH.  
Glucose- and mannose-based analogues, 50 and 51, were prepared to assess whether 
the N-sulfate could be replaced with a hydroxyl group. Mannopyranoside 51 positions 
the 2-hydroxyl group in the axial position, which may enable it to participate in 
alternative hydrogen bonding interactions in the active-site.  
       
                            50                       51                               52 
The final N
2
-sulfate replacement prepared, 52, incorporates an N-succinamide, 
providing a flexible link to a carboxylic acid which might be able to interact with basic 
residues in the active site. The amide carbonyl of 52 may also be able to mimic the 
sulfonyl group in the N
2
-sulfate of compound 25.  
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3.6.1.2 Variation of the O1 Substituent of Compound 25 
 
The O
1
-position of glucosamine residues in HSPGs is linked to a hexuronic acid 
residue. Analogues were prepared to explore whether substitution at this position with 
polar or lipophilic residues would improve potency by mimicking possible interactions 
between the O
1
-hexuronate and the Sulf-2 active site. Analogues were selected for 
synthesis based on overlay analyses with a heparin disaccharide template derived from 
the modelled solution structure.  
 
53 R = (CH2)2OH 
54 R = (CH2)3OH 
55 R = CH2CO2H 
56 R = i-Pr 
57 R = n-Pr 
58 R = (CH2)3OBn 
Figure 3.7 demonstrates this superposition for 53, confirming the potential for O
1
 
substituents to mimic polar functionality of the O
1
-iduronate residue, and suggesting 
that these substituents may occupy similar regions of space to hydrogen bonding 
groups in the endogenous substrate.  
 
 
Figure 3.7: Superposition of 53 (orange) with a template disaccharide derived from 
the modelled solution structure of heparin (green). 
 
The pyran ring of saccharides may also engage in hydrophobic interactions with 
lipophilic amino acid side chains, which can contribute to binding of saccharides to 
proteins. Identification of regions of the template where lipophilicity can be 
productively incorporated would also be useful to improve drug-like properties, for 
any future programs to identify an orally bioavailable Sulf-2 inhibitor based on this 
template. A set of analogues with lipophilic anomeric substituents was prepared (56-
58) to investigate whether increased lipophilicity at this position might improve the 
binding affinity. Figure 3.8 shows the superposition of analogue 56 with the 
57 
disaccharide template, demonstrating the overlay of the isopropyl substituent with the 
pyran core of the neighbouring iduronic acid residue. 
 
Figure 3.8: Superposition of 56 (orange) with a template disaccharide derived from 
the modelled solution structure of heparin (green). 
 
To provide further information on the role of the O
1
-substituent on the inhibition of 
Sulf-2 by 25, β-anomer 59, and analogue 60, lacking an O1-substituent, were also 
prepared. 
       
59                                                60 
 
3.6.1.3 Variation of the Substituents at the 3- and 4- Positions of 
Compound 25 
 
In the endogenous HSPG substrates, the O
4
-position of glucosamine residues is 
substituted with a hexuronic acid residue. The carbohydrate substrates for exosulfatase 
family members, such as glucosamine-6-sulfatase and galactosamine-6-sulfatase, are 
unsubstituted at this position. Substitution at O
4
 may therefore introduce selectivity for 
Sulf-1 and Sulf-2 over exosulfatases. The synthesis of analogues incorporating O
4
-
substituents proved challenging, with the O
4
-benzyl ether 61, being the only analogue 
prepared. An investigation of a wider range of polar and lipophilic groups at this 
position would be of interest for future studies.  
58 
To explore whether the 3- and 4-hydroxy groups participate in interactions with the 
active site of Sulf-2, 62 and 63 were prepared, whereby each of these groups was 
deleted.                        
 
                             61                                     62                                           63 
Thus, analogues varying each of the O
1
-, N
2
-, O
3
- and O
4
-positions of the template 
have been designed and prepared.  
 
3.6.2 Sulfatase Inhibition Data for Monosaccharide Sulfamates 
 
Preliminary sulfatase activity against Sulf-2 has recently been generated by Dr Gary 
Beale and Sari Alhasan on a subset of the compounds prepared. Inhibition of aryl 
sulfatases A (ARSA) and B (ARSB) was also assessed to determine if the compounds 
were non-selective inhibitors of the sulfatase enzyme class. Compounds were assayed 
for their ability to inhibit the desulfation of 4-methylumbelliferyl sulfate (4-MUS) to 
the fluorescent phenol, 4-methylumbelliferone (4-MU), at a single concentration of 1 
mM. In this assay format, lead monosaccharide sulfamate 25 exhibited 38% inhibition 
of Sulf-2 activity, with no inhibition of ARSA or ARSB. The measured Sulf-2 
inhibition of 25 was considerably reduced relative to the reported literature value (IC50 
= 130 M), which may reflect differences in the assay procedures. Data for derivatives 
are therefore considered relative to the activity of compound 25. 
 
                               4-MUS                                                          4-MU 
Scheme 3.1: The action of sulfatases in converting 4-MUS to 4-MU. 
 
At the anomeric position, removal of the anomeric alkoxy substituent (60) led to a 
moderate improvement in Sulf-2 inhibition (Table 3.2). The -methoxy anomer (59), 
and analogues incorporating larger polar or lipophilic α-alkoxy substituents (53-57) 
59 
exhibited low Sulf-2 inhibition. However, compound 59 was one of the most potent 
inhibitors of ARSA and ARSB in the monosaccharide-based set.  
 
Substitution on the N
2
-position was not tolerated (48, 52 and 104), but the N
2
-primary 
amine (105) retained encouraging Sulf-2 inhibitory activity, indicating that an N
2
-
sulfate is not essential. This compound was the most potent inhibitor of ARSA tested, 
but exhibited selectivity over ARSB. Replacement of the amine with an equatorial 
(50) or axial (51) hydroxyl group abolished Sulf-2 activity. This may indicate that a 
similar interaction between the amino substituent and an active site aspartate residue to 
that proposed in the homology model of F. Heparinium sulfatase
131
 (see section 2.6) 
may be conserved in Sulf-2. Investigation of alternative basic groups at this position 
may therefore be of merit. 
 
Cmpd 
Sulf-2 
% inh @  
1 mM 
ARSA 
% inh @ 
1 mM 
ARSB 
% inh @ 
1 mM 
R
1
 R
2
 R
3
 R
4
 
25 38 0 0 α-OMe NHSO3Na OH OH 
60 58 0 32 H NHSO3NH4 OH OH 
59 13 70 67 -OMe NHSO3Na OH OH 
53 0 0 0 α-O(CH2)2OH NHSO3Na OH OH 
54 0 0 0 α-O(CH2)3OH NHSO3NH4 OH OH 
55 0 0 0 α-CH2CO2H NHSO3Na OH OH 
56 9 0 19 α-O
i
Pr NHSO3NH4 OH OH 
57 3 0 0 α-O
n
Pr NHSO3NH4 OH OH 
48 0 0 12 α-OMe NHSO2Me OH OH 
52 9 0 33 α-OMe NHCO(CH2)2CO2H OH OH 
104 5 0 44 α-OMe NHCbz OH OH 
105 53 86 3 α-OMe NH2 OH OH 
50 0 0 11 α-OMe OH
eq
 OH OH 
51 0 0 14 α-OMe OH
ax 
OH OH 
63 0 0 12 α-OMe NHSO3Na H OH 
62 65 0 21 α-OMe NHSO3Na OH H 
61 59 0 0 α-OMe NHSO3Na OH OBn 
Sulfatase inhibition data are reported as the mean of two determinations 
Table 3.2: Preliminary sulfatase inhibition data for monosaccharide sulfamates. 
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Compound 63, lacking the 3-hydroxyl group did not inhibit Sulf-2 activity. In contrast, 
removal of the 4-hydroxyl group (62), gave the most potent compound in this set of 
analogues. The O
4
-benzyl ether (61) also displayed encouraging levels of Sulf-2 
inhibition.  
 
Thus, it appears that substitution at C
1
 is not tolerated for Sulf-2 inhibition and a 
sulfate on the N
2
 position is not essential. Variation at the 4-position appears to be 
tolerated, and this may be a productive area for future investigation. 
 
3.7 Simplified Cyclic Aliphatic Scaffolds  
 
To further explore the structural requirements for inhibition of Sulf-2, simplified 
aliphatic scaffolds were designed, aiming to mimic the position of the sulfamate and 
N-sulfate groups in 25, while minimizing other functional groups present. Three cyclic 
aminoalcohol scaffolds were selected for synthesis based on cyclohexane and 
piperidine templates (64-66). The primary sulfamate of pyran-2-methanol (67) was 
also prepared to explore the role of the N-sulfate in Sulf-2 inhibitor binding. 
 
                               64   65         66            67 
These compounds investigate the contribution of the sulfamate and sulfate moieties to 
inhibitor binding, and the effect of varying the spatial separation of these groups. 
Superposition of compounds 64 and 66 with monosaccharide 25 (Figure 3.9) indicated 
that the sulfamate and sulfate groups can be overlaid in each template. 
          
Figure 3.9: Superposition of cyclohexane 64 and piperidine 66 (purple) with 
monosaccharide 25 (green). 
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3.7.1 Sulfatase Inhibition Data for Inhibitors Based on Cyclic Aliphatic 
Sulfamate Scaffolds 
 
Preliminary sulfatase inhibition data have been generated on cyclic aliphatic 
sulfamates 64-66 (Table 3.3). The cyclohexane (64) and piperidine methanol (65) 
scaffolds demonstrated weak Sulf-2 inhibition at 1 mM concentration, with no 
inhibitory activity against ARSA or ARSB. However, the 4-piperidinol template (66) 
displayed no Sulf-2 inhibition, possibly indicating that there is an optimal distance and 
orientation of the sulfamate and sulfate moieties.   
 
Structure Cmpd Sulf-2 
% inh @ 1 mM 
ARSA 
% inh @ 1 mM 
ARSB 
% inh @ 1 mM 
 
64 19 0 0 
 
65 23 0 0 
 
66 0 39 0 
    Sulfatase inhibition data are reported as the mean of two determinations 
Table 3.3: Preliminary sulfatase inhibition data for cyclic aliphatic sulfamates. 
 
3.8 Non-Saccharide Aromatic Heparan Sulfate Mimics 
 
As discussed in chapter 2, aryl sulfamates have been extensively explored as inhibitors 
of ARSC. A report identified 3-nitrophenylsulfamate as the most potent of the 
monocyclic aryl sulfamate ARSC inhibitors prepared (ARSC; IC50 = 120 M).
170
 In 
general, ARSC inhibitory activity was found to increase with the electron-withdrawing 
nature of the aromatic substituent. The parent phenyl sulfamate 29 has also been 
reported to have weak Sulf-2 inhibitory activity,
132
 but other simple aryl sulfamates 
have been examined for their inhibitory activity against Sulf-2. 
62 
Thus, in parallel with the synthesis of monosaccharide-based inhibitors, a set of 16 
phenol-derived primary sulfamates (29, and 68-82) was designed and prepared to 
explore the electronic and steric effects of substituents on the aryl ring on Sulf-2 
inhibition. This compound set has yet to be profiled for Sulf-2 inhibition. 
 
 
From the analysis of heparin-protein interactions presented in chapter 2, it was clear 
that the sulfate and carboxylate groups often provide important binding contributions. 
A second generation of phenol-based templates was designed to position the sulfamate 
and a second polar group in similar regions of space to those adopted in the heparin 
solution structure. Literature examples where similar non-saccharide heparin mimetic 
strategies have been successful include suramin (83) and its analogues.
171
 These high 
molecular weight compounds are believed to interact with the heparin-binding domain 
of FGF, with significant contributions to binding arising via interactions between the 
naphthalenesulfonic acid functionalities and basic amino acid residues in the heparin 
binding domain. 
 
83 
An investigation of lower molecular weight non-saccharide heparin mimics as 
inhibitors of hepatocyte growth factor/scatter factor activity has also been described, 
with the sulfate and carboxylic acid being appended to a benzoic acid scaffold.
172
 Two 
compounds obtained through this strategy (84 and 85) were able to completely inhibit 
hepatocyte growth factor/scatter factor activity at concentrations of 100 g/mL. 
 
R H CF3 CN NO2 OMe Ph 
Ortho - 
29 
- 
68 71 74 77 80 
Meta 69 72 75 78 81 
Para 70 73 76 79 82 
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The first template explored for the design of potential Sulf-2 inhibitors using this 
strategy was based on a biphenyl sulfamate scaffold, with polar groups incorporated 
on the B-ring (Figure 3.10).  
 
Figure 3.10: General structures for analogues designed in the biphenyl template. 
The aim was to mimic the spatial orientation of hydrogen bonding groups of the 
neighbouring iduronate residues in the endogenous substrate. The designs were 
minimised in the gas phase, and overlaid onto a heparin-derived truncated 
trisaccharide template, in order to identify compounds that may allow the correct three 
dimensional orientations of polar functionalities. Representative overlay diagrams are 
shown in figure 3.11. The trisaccharide template was taken from the reducing end of 
the modelled heparin structure incorporating iduronic acid residues in the 
1
C4 
conformation. In addition to specific rationally designed analogues, this template was 
used to probe the active-site for polar interactions through incorporation of polar 
functional groups with diverse hydrogen bonding and charge characteristics into the 
2’, 3’ and 4’ positions of the B ring. This strategy could provide lead compounds with 
improved physicochemical properties relative to the saccharide based series, and 
amenable to more rapid analogue synthesis. The biaryl analogues described in this 
section were prepared by other colleagues working on the project. Sulf-2 inhibition 
data has not yet been generated on this compound set. 
    
                      86                                       87                                      88 
 
Figure 3.11: Representative overlays of biaryl targets 86, 87, and 88 (cyan) with a 
heparin trisaccharide template (green).  
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3.9 Benzylic Sulfamates 
 
Benzylic sulfamates 89-92 were also investigated, incorporating the sulfamate 
functionality on an sp
3
 hybridised carbon atom, which mimics the hybridisation-state 
of the linking-atom in the endogenous substrate of Sulf-2.  
 
Superposition of benzylic sulfamate 90 with monosaccharide 25 demonstrates the 
overlap of both the sulfamate and sulfate groups in these templates (Figure 3.12). 
However, due to synthetic chemistry issues, only nitro intermediates 89 and 91 were 
successfully prepared, with evidence of potential chemical instability being observed 
for compound 90 (See section 4.6). Sulf-2 inhibition data has not yet been generated 
on compounds 89 and 91. 
 
Figure 3.12: Overlay of benzylic sulfamate 90 (cyan) with monosaccharide 25 
(green). 
  
65 
3.10 Sulf-2 Design and Biological Data Summary 
 
In order to attempt to identify tool compounds for use in biological target validation 
studies, two approaches were investigated. Analogues of the literature monosaccharide 
inhibitor, 25, were designed and prepared, incorporating structural changes in the 
substituents around the pyran core to build knowledge of the SARs. The aim was to 
identify features that improve Sulf-2 inhibitory potency, and explore how these 
changes affect selectivity over other sulfatase family members. Preliminary sulfatase 
inhibition data indicated that larger substituents at C
1
 and N
2
 were not tolerated. The 
C
1
-methylene (60) and N
2
-primary amine (105) derivatives exhibited improved Sulf-2 
inhibition relative to 25, indicating that simplification of the template is possible. 
Variation at the C
4
-position (compounds 61 and 62) was also tolerated, and would 
merit further investigation. 
The second approach employed a de novo design strategy, based on an analysis of 
functional groups in the endogenous substrate HSPGs, which may be important for 
binding in the active site of Sulf-2. Non-saccharide aryl sulfamate scaffolds were 
selected that allowed superposition of sulfamate and other polar groups with those 
present in the HSPG template. Sulfatase inhibition data has not yet been generated on 
these compounds. 
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Chapter 4: Synthesis of Potential Sulf-2 Inhibitors 
 
4.1 Synthesis of Monosaccharides 25 and 27 
 
The literature monosaccharide-based inhibitors of Sulf-2, 25 and 27 were the first two 
compounds targeted. The published synthesis of 27 comprises nine steps starting from 
glucosamine (93) with an overall 8.5% yield (Scheme 4.1).
132
  
 
Scheme 4.1: Reagents and conditions a) TfN3; NaOMe, DMAP/MeOH, CH2Cl2/20 
C; b) HCl/MeOH; c) PhCH(OMe)2, TsOH, DMF, 51% over 3 steps; d) BnBr, NaH, 
THF, 85%; e) BF3, Bu2OTf, 0 C, 2 h, 69%; f) NaH, ClSO2NH2, THF, r.t. 24 h, 88%; 
g) H2/10% Pd/C, MeOH, r.t. 4 h, 65%; h) Py.SO3, pyridine, r.t. 2 h, 65%; i) H2/10% 
Pd/C, EtOH, r.t. 36 h, 77%. 
 
Six of the nine steps of the published synthetic route involve protecting group 
manipulations to enable regioselective introduction of the O
6
-sulfamate. In the first 
step, the N
2
-position of glucosamine (93) is protected as an azide (94), introduced 
using triflic azide, a reagent with a well-documented explosion hazard.
173
 This reaction 
is performed in dichloromethane, leading to a combination of reagents which can 
readily form diazidomethane, another high energy compound that has been implicated 
in several laboratory explosion incidents.
174
 After introduction of the anomeric 
methoxy substituent, selective protection of the 3- and 4-positions is achieved using a 
3-step procedure which starts with protection of the 4- and 6-positions as a 
benzylidene acetal, 96. The remaining alcohol group at the 3-position is protected as 
67 
benzyl ether 97, and regioselective reductive cleavage of the acetal provides 98 as the 
substrate for sulfamate formation. Chemoselective reduction of azide 99 gives amine 
100, which is sulfated before a final double debenzylation reaction to provide 25. The 
length of the synthesis and low overall yield would require the potentially hazardous 
first step to be performed on a large scale to enable sufficient quantities of 
intermediate 94 to be prepared to allow analogue synthesis. The number of synthetic 
steps required for each analogue was also considered sub-optimal. For example, 
introduction of alternative groups at the anomeric position would be achieved in step 
two, with seven further steps required to progress each analogue to the target 
compound. Thus an alternative route was sought. 
 
4.1.1 Development of a Novel Route to Monosaccharides 25 and 27 
 
A more efficient synthesis was envisioned through minimising the number of 
protecting group manipulations. A route was designed seeking to investigate whether 
the reactivity difference of primary and secondary alcohols with electrophiles could be 
exploited to develop a regioselective sulfamoylation process, which would allow 
access to 25 in just five steps (Scheme 4.2). A similar approach for the regioselective 
mono-methylsulfonylation of the O
6
-position of N-acetylglucosamine had been 
reported to proceed in over 70% yield.
176
 
 
Scheme 4.2: Proposed route employing a regioselective sulfamoylation for the 
preparation of 25. Reagents: a) CbzCl, NaHCO3, H2O; b) HCl/MeOH; c) ClSO2NH2, 
DMA/Tol; d) H2/Pd/C, MeOH; e) PySO3, pyridine. 
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For an initial investigation of the key regioselective sulfamoylation reaction, a readily 
available pyranoside monosaccharide template was required. The commercial 
availability of N-acetyl glucosamine (106) led to the selection of 107 as the first 
template in which to explore this concept. This would also lead to the preparation of 
27, an analogue of 25 with reportedly weak inhibitory activity against Sulf-2.
132
  
 
                             106                                      107                        108 
Scheme 4.3: Synthesis of 107 as a substrate for regioselective sulfamoylation studies. 
Reagents and conditions: a) Amberlite IR120 H
+
, MeOH, 69 C, 18 h, (107: 44%.)
  
 
Treatment of N-acetylglucosamine (106) with Amberlite IR120 H
+
 ion exchange resin 
in methanol at reflux allowed introduction of the anomeric methoxy group. A 4:1 
mixture of anomers was obtained, favouring the desired α anomer (107), and 
consistent with the stabilisation of the axial-isomer by the anomeric effect (Scheme 
4.3). The major isomer had a coupling constant of 3.6 Hz between H
1
 and H
2
,
 
in 
keeping with the α anomer; the minor anomer (108) had a larger coupling constant (J 
= 7.9 Hz) consistent with the vicinal diaxial arrangement of the β anomer.177  
Separation of 107 and 108 was not possible by normal or reversed phase 
chromatography, but isolation was achieved using a quaternary ammonium ion 
exchange column converted to the hydroxide form.
178
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4.1.1.1 Studies on the Formation of Sulfamoyl Chloride (H2NSO2Cl) 
 
Literature procedures for the preparation of primary sulfamates generally involve 
reaction of a phenol or alcohol with sulfamoyl chloride (112, R = SO2Cl), prepared in 
situ by the reaction of formic acid with chlorosulfonyl isocyanate 109 (R = SO2Cl).
179
 
The proposed mechanism for the formation of sulfamoyl chloride in this reaction is 
shown in scheme 4.4.
180,181,182
 
 
                    109    110           111              112 
Scheme 4.4: Probable mechanism for the formation of sulfamoyl chloride from the 
reaction of chlorosulfonyl isocyanate with formic acid. 
 
In support of this mechanism, gas evolution studies when R is aryl have confirmed 
that two mole equivalents of gas are liberated,
181
 with radio-tracer studies establishing 
that the first is released as CO2.
180
 In the same study the carbon of the CO2 was found 
to derive from the isocyanate (C1), and formamide intermediate 111 contained the 
carbon from formic acid (C2).
180
 The second step of the mechanism can be considered 
as an intramolecular transacylation,
182
 with subsequent loss of carbon monoxide to 
give 112. Dichloromethane is the most commonly used solvent for the formation of 
sulfamoyl chloride.
159
 However, in the current work the reagent formed as a 
suspension in this solvent, complicating its addition to the alcohol substrate. Reaction 
of formic acid with chlorosulfonyl isocyanate under solvent-free conditions, with 
subsequent addition of toluene to prepare a stock homogeneous sulfamoyl chloride 
solution
170
 proved superior, and this method was used in the synthesis of the first 
analogues prepared. Dissolution of sulfamoyl isocyanate in toluene prior to the 
addition of formic acid led to inferior conversion when used in sulfamate formation 
reactions. An improved process was subsequently developed later in the project, 
employing MeCN as solvent for the sulfamoyl chloride formation, and was used for 
the synthesis of further analogues. This method gave a homogeneous solution, and 
provided superior control of gas evolution, which would be of particular value for 
future scale-up. The shelf-life of the acetonitrile sulfamoyl chloride solution was 
assessed by investigating its effectiveness in the sulfamate formation reaction on 2-(4-
nitrophenyl)ethanol (113) over a 28 day period (Table 4.1).  
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113      114 
Time days
a 
113 %
b 
114 %
b 
0
c 
0 100 
1 0 100 
4 4  96  
7 8  87  
14 12  82  
28 19  72  
a 
Number of days of storage
 
of the sulfamoyl chloride solution at r.t. under nitrogen prior to being used 
in the sulfamate formation reaction; 
b 
Percentages of 113 and 114 were estimated from LC-MS UV 
traces; 
c
 Solution used immediately after preparation.  
Table 4.1: Investigation of the stability of a solution of sulfamoyl chloride in 
acetonitrile. Reagents and conditions: a) ClSO2NH2 (1 M in MeCN, 3 eq.), DMA, r.t., 
30 min.  
 
On storage for 24 h, the sulfamoyl chloride solution retained the ability to effect rapid 
sulfamoylation of 113. A steady fall in conversion of 113 into 114 was seen when the 
reagent was stored for longer periods. Between days 4 and 7, material was observed to 
precipitate from the solution, and this could not be redissolved using sonication. Thus, 
freshly prepared sulfamoyl chloride solution was used in the preparation of sulfamate 
target compounds. 
 
4.1.1.2 Regioselective Sulfamate Formation 
 
Amide solvents such as DMA, NMP, or DMF have been reported as optimal for 
sulfamoylation of alcohols and phenols.
183
 DMF has been found to form adducts with 
the sulfamate products, reducing the yield,
184
 leading to the selection of DMA as 
solvent for our initial studies. The effect of sulfamoyl chloride stoichiometry on the 
sulfamate formation was studied for the conversion of 107 into 27 (Table 4.2).  
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                                             107                                      27 
Expt ClSO2NH2  
       Eq. 
Temp  
C 
Time  
h 
27
a 
%  
107
a 
% 
1 1 8 72 12 70 
  2 1.5 8 2 20 80 
3 1.8 8 18 40 60 
      4 3 8 3 40 0 
                           a 
Percentages of 107 and 27 were estimated from LC-MS UV traces.  
Table 4.2: Reagents and conditions: a) ClSO2NH2 (1 M in MeCN), DMA, 8 C.  
 
Reactions were performed at an internal reaction temperature of 8 C. Low conversion 
was obtained with one equivalent of sulfamoyl chloride, even on extended reaction 
times. Increasing the number of equivalents of sulfamoyl chloride improved 
conversion, with 1.8 equivalents proving optimal. Use of 3 equivalents led to a similar 
isolated yield, with complete consumption of starting material. In addition to 
formation of 27, two derivatives, the O
3
,O
6
-bis(sulfamate) (115) and O
4
,O
6
-
bis(sulfamate) (116) were also isolated.  
 
      115                                           116 
The regiochemistry of sulfamoylation of 27, 115 and 116 was determined from the 
chemical shifts of the CHOSO2NH2 protons which could be unambiguously assigned 
from 2-dimensional homonuclear COSY NMR experiments. These protons 
experienced a downfield shift of between 0.3 and 0.6 ppm on sulfamate formation of 
the respective alcohols. This study provided proof of principle that regioselective 
sulfamoylation of glucosamine monosaccharide templates was achievable, and 
attention was turned to the synthesis of substrate 103, required for the synthesis of 25.  
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4.1.1.3 The Synthesis of 103 
 
 
                          93                                      102                                    103 
Scheme 4.5: Reagents and conditions: a) CbzCl, NaHCO3, H2O, r.t., 18 h, 92%; b) 
1.25 M HCl in MeOH, 65 C, 18 h, 73%;  
 
A literature procedure was successfully employed for the preparation of benzyl 
carbamate 102 from D-glucosamine (93, Scheme 4.5).
185
 Precipitation of 102 from the 
reaction mixture allowed its isolation by simple filtration as a white solid in 92% 
yield. Introduction of the anomeric methoxy group using Amberlite IR-120 resin 
resulted in formation of multiple minor by-products, complicating isolation of 103. 
Heating at reflux for 18 h resulted in a 1:1 mixture of α:β anomers, which equilibrated 
to 5α:1β on prolonged heating (72 h), and remained constant on further extension of 
the reaction time. A cleaner profile was obtained by heating at reflux in a 1.25 M 
solution of HCl in methanol, with a stable product ratio of 5α:1β being achieved after 
18 h. In this case, the anomers were readily separable by chromatography on silica to 
give 103 in a 73% yield. As described previously for 107, the anomeric 
stereochemistry was assigned from the coupling constant of the H
1
 proton.  
 
4.1.1.4 Regioselective Sulfamoylation of 103 
 
 
                                                103                                    104                 
Scheme 4.6: Reagents and conditions: a) ClSO2NH2 (2.25-3 eq.), DMA, -15 C, 18 h, 
37-43%; b) H2/10% Pd/C, MeOH/CH2Cl2, 40 C, 1 h, 100%.  
 
The key regioselective sulfamoylation was performed at room temperature in DMA, 
giving a 15% yield of 104, with LC-MS analysis indicating significant formation of 
bis-sulfamate by-products. When the reaction was performed at -15 C, bis-
sulfamoylation was reduced, leading to an improved yield of 104. The freezing point 
of DMA (-20 C) prevented further reduction of the reaction temperature. To achieve 
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complete consumption of 103, 2.25-3 equivalents of sulfamoyl chloride were required, 
with variability observed between batches of sulfamoyl chloride. Careful reaction 
monitoring and titration of sulfamoyl chloride was required to achieve optimal 
conversion leading to isolated yields of 104 of 37-43%. This method is referred to as 
sulfamoylation method 1. The regiochemistry was ascertained from 2D 
1
H NMR, with 
coupling of the C
3
-H and C
4
-H protons to the O
3
-H
 
and O
4
-H protons, respectively, 
confirming that these hydroxyl groups remained unsubstituted. No coupling was 
observed between the C
6
- and O
6
-protons, indicating that this position had
 
been 
sulfamoylated. The proton NMR signals for the C
6
-protons of 104 also experienced a 
downfield shift of between 0.5 and 0.6 ppm, consistent with the addition of the 
electron-withdrawing sulfamate group to the O
6
-oxygen atom. The C
3
- and C
4
-protons 
experienced no such downfield shift.  
 
                           104                                    105                                       25 
Scheme 4.7: Reagents and conditions a) H2/10% Pd/C, MeOH/CH2Cl2, 40 C, 1 h, 
100%; b). SO3.Py, H2O, pH 9-10, r.t. 2.5 h, 43%. 
 
The Cbz protecting group was removed in quantitative yield using flow hydrogenation 
over 10% palladium on carbon to give 105 (Scheme 4.7). Sulfation of the amino group 
of 105, in the presence of the unprotected secondary alcohol groups, proved to be non-
selective using sulfur trioxide-pyridine complex in anhydrous pyridine, affording a 
mixture of 2,3- and 2,4-bis sulfated products. A literature procedure for selective 
sulfation of an amino group in the presence of unprotected alcohols under pH 
controlled conditions was successfully applied.
186,187
 Maintaining a pH of 9-10 during 
the addition of sulfur trioxide-pyridine complex, resulted in chemoselective sulfation 
on the amino group. Buffering was achieved by adjusting the pH of the reaction with 2 
M aqueous NaOH after each portionwise addition of the sulfating reagent, resulting in 
isolation of 25 in a 43% yield after column chromatography.  
No explanation as to the origin of the observed chemoselectivity of the sulfation 
reaction under the buffered conditions is given in the literature. It is possible that 
sulfate esters formed on the alcohol groups may be unstable at the basic reaction pH. 
At higher basicities, sulfur trioxide-pyridine complex is known to be unstable, 
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degrading to a “red complex”,188 dictating the narrow optimum pH range for the 
reaction. This step was the lowest yielding in the synthesis of 25, and was later found 
to be substrate-dependent, with optimal yields of 40-45% being obtained. An 
alternative N-sulfation process via a trichloroethyl protected sulfate (117) provided 25 
in a superior yield of 56% over two steps (Scheme 4.8). Incorporation of this sulfation 
protocol into the synthesis of 25 improved the overall yield for the preparation of this 
key Sulf-2 inhibitor to 16% over six steps.  
 
                             105                                   117                                   25 
Scheme 4.8: Reagents and conditions: a) 1,1,1-trichloroethylsulfonyl imidazolium 
tetrafluoroborate (1 eq.), THF, 60 C, 18 h, 61%; b) i) Zn (15 eq.), MeOH, H2O, 60 
C. 1 h; ii) Ion exchange chromatography on Dowex 50W8x200 Na form, H2O, 93%.  
 
4.1.2 Optimisation of the Sulfamoylation Reaction 
 
Sulfamoylation method 1 was used for the synthesis of a number of analogues of 
compound 25, which will be described later. However, during the course of these 
syntheses it became apparent that the yields for this reaction were substrate-dependent, 
varying from 15-43%. Thus, in parallel with preparing analogues of 25 using this 
procedure, attempts were also made to further improve the overall regioselectivity, 
yield, and cross-substrate reliability of this reaction.  
 
4.1.2.1 Studies with Alternative Sulfamate Transfer Reagents 
 
Increased steric bulk around the electrophilic sulfur centre of sulfamoyl chloride was 
investigated in the hope of improving the regioselectivity for sulfamate formation on 
the less hindered O
6
-primary alcohol. A small program of work was undertaken to 
investigate additives that might exchange with the chloride leaving group of sulfamoyl 
chloride, resulting in a more sterically constrained sulfamoyl transfer reagent (Scheme 
4.9).  
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Scheme 4.9: Introduction of a bulky leaving group (Y) to form an alternative 
sulfamoyl transfer reagent. Reagents and conditions: a) HCO2H (1 eq.), MeCN; b) 
Additive (1 eq.); c) ROH (0.5 eq.), DMA, -15 C. 
 
In situ generation of potential sulfamate transfer reagents 118a-d was explored by 
addition of imidazole, pyridine, DMAP and sodium iodide, respectively, as additives 
to the stock solution of sulfamoyl chloride.  
 
                                118a         118b         118c    118d 
 
These reagents were first investigated for the sulfamoylation of model substrate 113, 
with the high UV activity of 114 allowing facile reaction monitoring and purification. 
Only adduct 118d, prepared by addition of one equivalent of sodium iodide to the 
sulfamoyl chloride solution, resulted in successful conversion to 114, but with an 
inferior isolated yield to that obtained in the absence of additives. The iodide adduct 
was subsequently reacted with 103, giving an isolated yield of 36% of 104 as 
compared to 43% using sulfamoylation method 1.  
A modified Burgess reagent (119) was subsequently reported to provide successful 
sulfamoylation of alcohols and phenols.
189,190
 This reagent was prepared in two steps 
from chlorosulfonyl isocyanate (Scheme 4.10). 
                                                                                                                           119 
Scheme 4.10: The synthesis of 119. Reagents and conditions: a) 
t
BuOH, toluene; b) 
DABCO 
 
Reaction of 119 with alcohols and phenols was reported to proceed in high yield, and 
give selectivity for primary alcohols over secondary alcohols. On preparation, 119 was 
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found to be moisture sensitive, hydrolysing in less than ten minutes in CD3CN 
containing trace water during NMR studies. Reaction of 119 with 103 under 
anhydrous conditions gave multiple products with low regioselectivity. As these 
reagents require an extra acidic deprotection step to liberate the free primary 
sulfamate, which may not be compatible with the anomeric acetal in 103, this 
approach was not investigated further.      
 
4.1.2.2 Model Studies on the Sulfamate Formation Reaction 
 
The identification of 4-nitrophenethyl alcohol (113) as a substrate that undergoes rapid 
conversion into sulfamate 114, and can easily be monitored by LC-MS, provided a 
useful model system to enable detailed investigation of factors affecting the sulfamate 
transfer reaction. All reactions in the following section were performed by adding 2 
equivalents of sulfamoyl chloride (1 M in MeCN) to 1 equivalent of 113 in DMA at 
the specified temperature. Conversions were monitored by analysis of the LC-MS UV 
trace. The extinction coefficients of 113 ( = 3,499 M-1cm-1) and 114 ( = 10,546 
M
1
cm
-1
) at 254 nm were determined using the Beer-Lambert law from a 3-point 
concentration-absorbance curve measured in ethanol, and indicated that the 
absorbance of product 114 was approximately 3-fold greater than that of substrate 113 
at this wavelength. The percentages %113 and %114 in the following tables are 
corrected from the integral of the UV trace for this difference in extinction coefficients 
using equations 1 and 2. Where %113 and %114 do not sum to 100%, the remaining 
percentage was accounted for by one or more by-product peaks in the UV trace. 
 
Equation 1:  
%113corr = ((%113meas× 3.014)/((%113meas× 3.014) + %114meas))×(%113meas+ %114meas)     
Equation 2: 
%114corr = ((%114meas/3.014)/((%114meas/3.014) + %113meas))×(%113meas+ %114meas)     
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4.1.2.3 Investigation of the Effect of Solvent on Sulfamate Formation 
 
The use of DMA as solvent in the sulfamoylation reaction has several disadvantages. 
The high freezing point precludes the use of temperatures below -15 C, and its high 
boiling point complicates reaction work-up. TLC analysis was also complicated by the 
presence of DMA, owing to a large solvent spot having similar Rf to 103 and 104. 
Substitution of DMA for alternative solvents at -15 C was therefore investigated 
(Table 4.3). 
 
                                113                                                             114 
Entry Solvent 5 min 3 h 24 h 
%113 %114 %113 %114 %113 %114 
1 DMA 11 89 9 91 6 94 
2 DMF 8 76 11 60 11 60 
3 Dioxane 80 0 75 4 75 4 
4 MeCN 85 0 75 4 74 4 
5 THF 87 1 75 13 75 13 
6 CH2Cl2 87 0 78 2 78 2 
7 EtOAc 82 0 70 4 70 4 
 
Table 4.3: Investigation of the effect of solvent on the conversion of 113 into 114. 
 
Reaction in DMF (entry 2) gave a similar initial conversion to DMA (entry 1), but 
extended reaction times resulted in by-product formation, consistent with reports of 
the formation of DMF adduct 120 with primary sulfamates.
184
 
 
 
120 
 
All other solvents investigated resulted in a slow reaction, coupled to the formation of 
multiple side products. The poor reactivity in ethyl acetate suggests that amide 
containing solvents have a unique effect on the reaction, which cannot be mimicked by 
an ester group. The cyclic ethers, THF and dioxane, were the next most successful 
solvents, with no starting material remaining after 24 h, and moderate conversion to 
product. The use of THF as a co-solvent allowed the amount of DMA to be reduced, 
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conversion in 10% DMA in THF proving similar to the reaction in 100% DMA (Table 
4.4), with only a small retardation of the reaction. Further reduction of the DMA 
concentration led to a significantly slower reaction and by-product formation. Other 
amide or urea additives gave inferior results. 
 
 
                               113                                                             114 
Solvent 5 min 30 min 3 h 
%113 %114 %113 %114 %113 %114 
100% DMA 11 89 n.d. n.d. 9 91 
10% DMA/THF 16 77 0 100 n.d. n.d. 
5% DMA/THF 43 41 20 65 n.d. n.d. 
1% DMA/THF 33 53 0 45 n.d. n.d. 
10% DMF/THF 20 65 n.d. n.d. 34 58 
10% NMP/THF 58 42 n.d. n.d. 40 55 
10% DMI†/THF 46 16 n.d. n.d. 15 53 
† DMI = 1,3-dimethylimidazolidinone; n.d. = not determined 
 
Table 4.4: Investigation of the effect of solvent mixtures on the conversion of 113 into 
114.  
 
4.1.2.4 Investigation of Sulfamate Formation at Reduced 
Temperature  
 
DMF and 10% DMA in THF were selected as solvents for an investigation of the 
effect of reducing the reaction temperature. The freezing point of DMF (-61 C) 
enables studies at lower temperatures than in DMA. At -40 C in 100% DMF, the 
reaction proceeded cleanly, and with significant conversion after 24 hours (Table 4.5). 
Furthermore, at this temperature, formation of undesired DMF adduct 120 was 
completely suppressed. 
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Entry Time h %113   %114 
1 0.08 95 5 
2 0.5  92 8 
3 1.5 86 14 
4 4  75 23 
5 18  62 38 
6 24  69 31 
Table 4.5: Investigation of conversion of 113 into 114 at -40 C in DMF 
 
The reaction progressed more slowly in 10% DMA in THF at -40 C, with only 19% 
of 114 being obtained after 24 h, and multiple by-products being observed (Table 4.6).  
Entry Time h %113 %114  
1 0.08 63 1 
2 1 63 1 
3 4  60 2 
4 24  32 19 
 
Table 4.6: Investigation of conversion of 113 into 114 at -40 C in 10% DMA/THF 
 
Other solvent mixtures were re-investigated for the low temperature reaction, to ensure 
that the optimal solvent systems for application to the monosaccharide synthesis were 
selected (Table 4.7). 
 Solvent 5 min 3 h 18 h 
%113 %114 %113 %114 %113 %114 
DMA 97 3 75 25 33 67 
10% DMA/THF 100 0 89 11 54 46 
10% DMA/MeCN 91 9 61 39 25 75 
DMF 93 7 47 53 0 95 
10% DMF/THF 100 0 96 4 78 18 
Table 4.7: Investigation of solvent systems for conversion of 113 into 114 at -40 C.  
 
In contrast to the results in MeCN at room temperature (Table 4.3), the use of 10% 
DMA in MeCN at low temperature gave high conversion and a similar reaction profile 
to that in neat DMF. These two solvent systems were therefore selected as the solvents 
of choice for an investigation of the regioselectivity of the sulfamoylation reaction 
with primary and secondary alcohols at low temperature. The reaction in DMF will be 
referred to as sulfamoylation method 2, and in 10% DMA/MeCN as method 3.  
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4.1.3 Application of Low Temperature Conditions to the Formation of 
Monosaccharide 25 
 
The optimised low temperature conditions were applied directly to monosaccharide 
103. After 24 hours at -40 C, TLC analysis suggested that starting material (103) was 
the major component present in both reactions. A further equivalent of sulfamoyl 
chloride was added to each reaction, with stirring at -40 C for a further 72 hours. 
Isolated yields after chromatography are presented in Table 4.8.  
 
103          104 
 104  
% 
Mixed by-products
a 
% 
Method 2 55 15 
Method 3 19 42 
                                                   a 
Isolated yield of mixed bis-sulfamoylated by-products.  
 
Table 4.8: Isolated yields from the low temperature sulfamoylation of 103 to give 
104. Reagents and conditions: a) Method 2: ClSO2NH2 (1 eq., 1 M in MeCN), DMF,  
-40 C, 24 h; Method 3: ClSO2NH2 (1 eq., 1 M in MeCN), 10% DMA/MeCN, -40 C, 
24 h.  
 
Sulfamoylation method 2 proved superior to method 3, giving the highest isolated 
yield (55%) yet achieved for this reaction. The relatively poor results obtained with 
method 3 may have arisen from the reaction becoming viscous due to the temperature 
approaching the freezing point of MeCN (mp -46 C). Reduced efficiency of mixing 
could result in high local concentrations of sulfamoyl chloride, which may lead to an 
increase in bis-sulfamoylation. The reaction using method 2 remained as a free 
flowing homogeneous solution throughout. The yield obtained for the sulfamoylation 
of 103 resulted in an improvement in the overall yield of the six step synthesis of 25 to 
21%, which compares favourably with the 9% yield obtained in the literature 9 step 
synthesis of 25. Analogues of 25 requiring regioselective sulfamoylation were 
subsequently prepared using method 2.  
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4.2 Preparation of Analogues of 25 
 
4.2.1 Variation of the 2-Amino Substituent of 25 
 
From the homology model of F. heparinium sulfatase, it was proposed that the sulfate 
on N
2
 of the glucosamine residue in heparan sulfate may affect binding solely by 
enhancing the hydrogen bond donor ability of the N
2
-hydrogen atom.
131
 In order to 
explore this hypothesis for Sulf-2, sulfonamide derivatives 48 and 49 that would 
further acidify the NH were synthesised. The reaction of amine 105 with the respective 
sulfonyl chlorides provided 48 and 49, as described in Scheme 4.11. Optimisation of 
these conditions was not investigated.   
 
        105                                      48 R = MeSO2 
                                                                                        49 R = CF3SO2 
Scheme 4.11: Reagents and conditions: a) R = MeSO2: MeSO2Cl, Et2iPrNH, CH2Cl2, 
0 C-r.t., 1 h, 28%; b) R = CF3SO2: (CF3SO2)2O, Et3N, CH2Cl2/dioxane, 0 C, 1 h, 
33%.  
 
Slow evaporation of a dilute methanolic solution of 48 provided a crystal suitable for 
small molecule X-ray crystallography. The structure generated (Figure 4.3) 
unequivocally confirmed the assignment of the O
6
-sulfamate regiochemistry.  
 
48 
 
Figure 4.3: Small molecule X-ray crystal structure of 48. 
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4.2.1.1 Glucose- and Mannose-Based Analogues of 25 
 
To assess whether the N-sulfate could be replaced by a hydroxyl group, analogue 50 
was prepared in a single step from commercially available methyl-α-D-
glucopyranoside (122) using sulfamoylation method 2 (Scheme 4.12). The reaction did 
not proceed cleanly and an isolated yield of only 25% of 50 was obtained. 
Sulfamoylation of the 2-position is a likely confounding factor in this reaction, 
consistent with the empirically observed order of reactivity of the hydroxyl groups of 
glucopyranosides (6 > 2 > 3 > 4) in reactions with benzoyl chloride.
191
   
 
       122    50 
Scheme 4.12: Reagents and conditions: a) ClSO2NH2, DMF, -40 C 18 h, 25%. 
 
Target 51 was also prepared in low yield in a single step from commercially available 
methyl-α-D-mannopyranoside 123 using sulfamoylation method 2 (Scheme 4.13). The 
low yield is again likely to reflect the nucleophilicity of the axial hydroxy group at the 
2-position.
191
 
 
      123          51 
Scheme 4.13: Reagents and conditions: a) ClSO2NH2, DMF, -40 C 18 h, 9%. 
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4.2.1.2 Preparation of the N2-Succinate Analogue of 25 
 
Succinamide derivative 52 was prepared by reaction of 105 with succinic anhydride 
(Scheme 4.14). Separation of 52 from an unidentified impurity could not be achieved 
using column chromatography, but trituration in ethyl acetate allowed 52 to be isolated 
in high purity.  
 
                                           105          52 
Scheme 4.14: Reagents and conditions: a) Succinic anhydride, H2O/dioxane, r.t., 18 h, 
18%. 
 
4.2.2 Variation of the C1-Substituent of 25 
 
4.2.2.1 Preparation of the β-Anomer of 25 
 
The importance of the anomeric stereochemistry of the monosaccharide template was 
investigated by preparing β anomer, 59 (Scheme 4.15). Significant quantities of 124 
were obtained from reaction of 102 with a 1.25 M methanolic HCl solution at short 
reaction times. After 1 hour, a ratio of α to β anomers of approximately 3:2 was 
obtained, allowing isolation of a 37% yield of 103 and 22% of 124. Sulfamoylation of 
124 using method 1 gave a 19% yield of 125, which was converted into target 59 with 
no evidence of epimerisation of the anomeric centre by proton NMR spectroscopy.  
   
  
Scheme 4.15: Preparation of the β-anomer 59. Reagents and conditions: a) 
HCl/MeOH, 70 C, 1 h, 124 21% (+ 103 37%); b) ClSO2NH2, Tol/DMA, -15 C, 2.5 
h, 19%; c) H2/10% Pd/C, MeOH/CH2Cl2, 40 C, 1 h, 95%; d) SO3.Py, H2O, pH 9-10, 
r.t. 2.5 h, 29%. 
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4.2.2.2 Preparation of the C1-Methylene Analogue of 25 
 
Removal of the anomeric substituent of compound 25 was also investigated to 
determine whether a substituent at this position was required for activity (Scheme 
4.15). Treatment of 102 with acetyl chloride in the absence of solvent at room 
temperature
192
 introduced the α-chloro substituent at the anomeric position, with 
simultaneous protection of the 3-, 4-, and 6-hydroxy groups as their acetate esters to 
give 127. Radical hydrodechlorination
192
 with tributyltin hydride and AIBN gave a 
47% isolated yield of 128, with successful removal of contaminating tin residues 
achieved by purification through a SiO2 column containing 10% K2CO3.
193
 Tributyltin 
hydride was replaced by the less toxic tris(trimethylsilyl)silane,
194
 resulting in a 
cleaner reaction profile and a more straightforward purification on a standard silica 
solid phase, leading to an improved isolated yield of 90% for 128. 
 
Scheme 4.16: Reagents and conditions: a) AcCl, r.t., 48 h, 55%; b) i) Bu3SnH/AIBN, 
110 C, 1.5 h, 47%, or ii) (TMS)3SiH/AIBN, 110 C, 1.5 h, 92%; c) NaOMe (cat.), 
MeOH, r.t., 2 h, 85%; d) ClSO2NH2, Tol/DMA, -15 C, 2 h, 34%; e) H2/10% Pd/C, 
MeOH/CH2Cl2, 40 C, 2 h, 98%; f) SO3.Py, H2O, pH 9-10, r.t., 2 h, 24%. 
 
Deprotection of the alcohol groups of 128 under Zemplen conditions
195
 proceeded in 
high yield giving triol 129. The use of sulfamoylation method 1, gave a 34% yield of 
130, which was progressed using the standard conditions described for the previous 
analogues, to provide 60. 
From consideration of the structure of heparan sulfate, it was concluded that the 
binding site of Sulf-2 should be sufficiently large to accommodate further saccharide 
units at the reducing end of the monosaccharide template. In an effort to develop 
SARs for this region, alternative anomeric substituents were investigated.  
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4.2.2.3 Preparation of C1-Isopropoxy Derivative 56 
 
Reaction of protected glucosamine 102 with 4 M HCl/dioxane in isopropyl alcohol 
gave predominantly α-anomer 132 in 73% isolated yield. Sulfamoylation using 
method 1 resulted in a 37% isolated yield of 133, which was progressed through the 
deprotection/sulfation steps as described previously (Scheme 4.17) to provide target 
56.  
 
 
Scheme 4.17: Reagents and conditions: a) HCl/Dioxane, IPA, 60 C, 4 h, 73%; b) 
ClSO2NH2, Tol/DMA, -15 C, 2 h, 37%; c) H2/10% Pd/C, MeOH/CH2Cl2, 40 C, 1 h, 
100%; d) SO3.Py, H2O, pH 9-10, r.t., 90 min, 27%. 
 
4.2.2.4 A Divergent Approach to Further Diversification at the C1-
Position 
 
Further elaboration of the anomeric C
1
-substituent was desirable, particularly to allow 
investigation of the tolerance of polarity at this position. The anomeric position of 
glucosamine in HSPGs is linked to an iduronic acid residue, and it was hypothesised 
that polar groups at this position may be able to mimic interactions of the polar 
functionality of the iduronate residue with the Sulf-2 protein.  
A divergent approach was adopted to probe for polar interactions in this region of 
space, with the versatility of the allyl group being exploited to enable late stage 
diversification, enabling the introduction of both polar and lipophilic functionality 
from a common intermediate. The allyloxy group was introduced into the anomeric 
position using allyl alcohol and 4 M HCl/dioxane at 70 C for 18 h, to give a 52% 
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yield of the α anomer 135, together with 20% of β anomer 136, which were readily 
separable (Scheme 4.18).  
 
     
Scheme 4.18: Reagents and conditions: a) Allyl alcohol, HCl/Dioxane, 60 C, 4 h, 
52% (135) and 20% (136). 
 
The first analogue prepared from intermediate 135 was n-propyl target 57. Sulfamate 
formation using method 1 resulted in a 40% yield of 137. Reduction of the alkene was 
achieved concurrently with hydrogenolysis of the Cbz-protected amine to give 138, 
which was sulfated to provide target compound 57 (Scheme 4.19). 
 
          
Scheme 4.19: Reagents and conditions: a) ClSO2NH2, Tol/DMA, -15 C, 2.5 h, 40%; 
b) H2/10% Pd/C, MeOH/CH2Cl2, 40 C, 2 h, 100%; c) SO3.Py, H2O, pH 9-10, r.t. 90 
min, 39%. 
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The hydroxyethyl derivative 53 was also obtained from allyl intermediate 137. 
Ozonolysis of 137, followed by reductive work-up, led to isolation of 139 (Scheme 
4.20), which was carried through the standard deprotection/sulfation methodology to 
provide target 53.  
 
                                         137     139 
 
140      53 
Scheme 4.20: Reagents and conditions: a) i) O3/MeOH, -78 C, 30 min; ii) NaBH4, 1 
h, 69%; b) H2/10% Pd/C, MeOH/CH2Cl2, 40 C, 3 h, 78%; c) SO3.Py, H2O, pH 9-10, 
r.t., 1 h, 30%. 
 
 
4.2.2.1 Preparation of Carboxylic Acid 55 
 
Subjecting C
1
-allyloxy triacetate 141 to conditions reported for the ozonolysis of 
alkenes to methyl esters in the presence of sodium methoxide,
196
 resulted in none of 
the desired methyl ester being obtained. An alternative method for oxidative cleavage 
of allyl groups to carboxylic acids has been documented using NaIO4 with catalytic 
RuCl3.
197
 Dihydroxylation of the alkene is followed by cleavage of the resultant diol 
by ruthenium tetraoxide, generated in situ from RuCl3, and the aldehyde product is 
further oxidised to the carboxylic acid under the reaction conditions. This approach 
was successful in converting 141 into 142 in good yield (Scheme 4.21). 
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Scheme 4.21: Reagents and conditions: a) Pyridine, Ac2O, r.t. 8 h, 96%; b) RuCl3, 
NaIO4, MeCN, CH2Cl2, H2O, r.t. 30 min, 56-62%. c) MeI/Cs2CO3/CH3CN, r.t., 18 h, 
77-95%; d) NaOMe (cat), MeOH, r.t., 1 h, 100%. 
 
Four sets of conditions were investigated for the transformation of 142 into methyl 
ester 143 (Table 4.9). The use of N,N’-diisopropyl-O-methylisourea resulted in low 
isolated yields of 143, primarily due to issues with isolation of the product from the 
urea by-product. TMS-diazomethane also gave a disappointing conversion. Alkylation 
of the carboxylic acid with methyl iodide in the presence of cesium carbonate in 
acetonitrile proved optimal for this transformation. 
 
Reagents Solvent Temp Time Yield 
i
PrNHC(OMe)NH
i
Pr MeCN 135Ca 5 min < 20% 
TMSCHN2 (1.5 eq.) MeOH/toluene 1:1 r.t. 2 h 50% 
MeI (1.5 eq.), NaHCO3 (3 eq.) DMF r.t. 18 h 57-75% 
MeI (2 eq.), Cs2CO3 (2 eq.) MeCN r.t. 18 h 77-95% 
   a 
With microwave heating. 
Table 4.9: Studies on the formation of methyl ester 143.  
 
Deprotection of the alcohol groups using Zemplen conditions proceeded smoothly in 
high yield to furnish 144, which was sulfamoylated in 67% yield using method 2 
(Scheme 4.22). Hydrogenation of 145 was unsuccessful in methanol over 10% Pd/C, 
requiring addition of acetic acid to achieve quantitative conversion to acetate salt 146.  
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   144               145         146 
Scheme 4.22: Reagents and conditions: a) ClSO2NH2, DMF, -40 C, 18 h, 67%; b) 
H2/10% Pd/C, AcOH, 40 C, 2 h, 100%. 
 
Attempted sulfation of 146 under the pH buffered conditions led to a complex mixture 
of products. In addition to desired N
2
-sulfate, there was evidence of partial hydrolysis 
of the methyl ester. In the mass spectrum, formation of a by-product with a mass 
consistent with -lactam 147 was evident, which could conceivably form through 
intramolecular nucleophilic attack of the liberated amine on the methyl ester.  
 
147 
Hydrolysis of ester 145 to the corresponding carboxylic acid 148 prior to deprotection 
of the amino functionality avoided formation of these by-products, allowing the 
successful preparation of acid 55 (Scheme 4.23).  
               
Scheme 4.23: Reagents and conditions: a) 2 M NaOH(aq), THF, r.t., 2 h, 82%; b) 
H2/10% Pd/C, MeOH, 40 C, 3 h, 100%; c) SO3.Py, H2O, pH 9-10, r.t., 24 h, 38%. 
 
The synthesis of C
1
-hydroxypropyl target 54 was investigated from allyl intermediate 
141 employing hydroboration to introduce the hydroxypropyl functionality (Scheme 
4.24). Hydroboration of 3,4,6 tris(acetate) ester 141 proved slow and low yielding 
with 9-BBN. The use of BH3.THF resulted in a slightly improved yield of 35% of 150. 
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However, a significant by-product was also formed, having a mass ion identical to the 
desired product, and this was proposed to be regioisomeric alcohol 151, derived from 
Markovnikov addition of borane to the alkene. The expected ratios of anti-
Markovnikov to Markovnikov product using borane are >95:5.
198
 However, the ratio 
of 150 to 151 obtained was approximately 3:1 for this substrate. Co-ordination of the 
borane to the neighbouring carbamate may facilitate addition of boron to the more 
substituted end of the alkene, although this was not explored further.  
 
                                         141                             150 R
1
 = H, R
2
 = OH 
                                                                            151 R
1
 = OH, R
2
 = H 
Scheme 4.24: Reagents and conditions: a) i). BH3.THF, THF, 0 C-r.t., 18 h; ii) H2O2, 
35% 150. 
 
An alternative synthetic strategy to access 54 was also investigated, employing direct 
introduction of commercially available 3-benzyloxypropanol at the C
1
-position of 102 
to give a 31% yield of α anomer 152 (Scheme 4.25). Regioselective sulfamoylation 
using method 2 gave 153 in 57% yield. Palladium catalysed hydrogenation allowed 
deprotection of both O-benzyl and N-Cbz groups to give acetate salt 154, which was 
subjected to the pH controlled N-sulfation conditions to give target 54. 
 
102                  152                                              153          
 
                                                  154              54 
Scheme 4.25: Reagents and conditions: a) 3-(Benzyloxy)propan-1-ol, HCl/Dioxan, 75 
C, 5 h, 31%; b) ClSO2NH2, DMF, -40 C, 18 h, 57%; c) H2/5% Pd/C, AcOH, 20 C, 
1 h, 83%; d) SO3.Py, H2O, pH 9-10, r.t., 1 h, 41%. 
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Chemoselective methods for the removal of a Cbz group from an amine in the 
presence of a benzyl ether have previously been reported, using mild hydrogenation 
conditions on specific substrates.
199
 Other systems appear to require the use of 
attenuated catalysts to achieve chemoselectivity, with amines such as triethylamine or 
pyridine being employed to partially poison the catalyst and impart selectivity.
200
 
Chemoselective removal of the carbamate from 153 was achieved by flow 
hydrogenation over 5% palladium on carbon at room temperature and 20 bar hydrogen 
pressure, providing 155, which was sulfated using the pH-controlled sulfation 
conditions to give benzyloxypropyl derivative 58 in 62% yield (Scheme 4.26). 
 
    153         155      58 
Scheme 4.26: Reagents and conditions: a) H2/5% Pd/C, EtOH, 20 C, 1 h, 75%; b) 
SO3.Py, H2O, pH 9-10, r.t., 18 h, 62%. 
 
4.2.3 Preparation of C3- and C4-Methylene Derivatives of Compound 25 
 
An approach employing Barton-McCombie radical deoxygenation to allow 
preparation of C
3
- and C
4
-methylene targets 63 and 62 was inspired by a similar 
strategy described for the synthesis of a series of activators of the glmS-riboswitch of 
Staphylococcus aureus.
201
  
 
4.2.3.1 Preparation of C3-Methylene Derivative 63 
 
 
                   103                                              156                     157 
Scheme 4.27: Reagents and conditions: a) PhCH(OMe)2, p-TsOH, DMF, 75 C, 3 h, 
79%; b) i) CS(Im)2, toluene, 110 C, 3 h; ii) TMS3SiH, AIBN, 110 C, 1 h, 83%. 
The 4- and 6-positions of 103 were selectively protected as benzylidene acetal 156 
(Scheme 4.27). Performing the benzylidene acetal formation in dioxane at room 
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temperature resulted in an isolated yield of only 35% of 156, along with a significant 
by-product which was tentatively assigned as 3,4-benzylidene acetal 158.  
 
158 
Following a literature procedure,
202
 the reaction was repeated in DMF at 75 C for 3 h, 
to give 4,6-benzylidine acetal 156 under thermodynamic control, in an isolated yield 
of 78%. Radical deoxygenation of 156 under modified Barton-McCombie 
conditions
203,204
 using tris(trimethylsilyl)silane
194
 gave 157 in 83% isolated yield. 
Regio- and chemo-selective cleavage of 4,6-benzylidene acetals to give 4-benzyl 
protected species has been reported for a range of differentially protected 
monosaccharides, using borane tetrahydrofuran complex in the presence of 
trimethylsilyl triflate.
205
 A remarkable influence of the choice of borane complex is 
described; thus, borane.THF complex gave almost exclusive regioselectivity for the 
O
4
-benzyl ether product, whereas both borane dimethysulfide and borane 
trimethylamine complexes resulted in predominant formation of the O
6
-benzyl ether. 
Variation of the Lewis acid had little effect on the reaction outcome, with good yields 
being obtained with TMSOTf, Sc(OTf)3, ZnI2, AlCl3, and BF3·OEt2. However, 
TMSOTf was reported to give the fastest reaction rates, with complete reaction in one 
hour, other Lewis acids requiring between 6 and 240 hours to achieve complete 
conversion. No rationale was offered for the observed regioselectivity, or for 
chemoselectivity over the anomeric acetal. An alternative procedure utilising 
Bu2BOTf and BH3.THF has also been published.
206
 This method was employed in the 
literature synthesis of 25, in this instance providing a 69% yield of 4-benzyloxy 
intermediate 98.
132
 
Subjecting 157 to TMSOTf/BH3.THF resulted in a disappointing 22% yield of 159. In 
contrast, with Bu2BOTf and BH3.THF a yield of 40% was achieved (Scheme 4.28). 
The regiochemistry of 159 was confirmed by 
1
H NMR, with coupling observed 
between the hydrogen of the 6-hydroxy group to both protons on the C
6
-carbon atom. 
The C
6
-protons were readily identifiable by 2D COSY NMR.  
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                             157                                       159                                     160 
Scheme 4.28: Reagents and conditions: a) BH3.THF (1 M), Bu2BOTf, 0 C, 1 h, 40%; 
b) ClSO2NH2, 10% DMA/CH3CN, r.t., 15 min, 73%. 
Sulfamoylation of 159 had no regioselectivity issues, and was therefore performed at 
room temperature in 10% DMA in MeCN to avoid the potential for DMF adduct 
formation at this temperature. Complete consumption of 159 was observed in 15 
minutes and a yield of 73% of 160 was obtained. However, the benzyl ether of 
compound 160 proved resistant to catalytic hydrogenation at elevated temperature and 
pressure. An alternative route from intermediate 157 was therefore investigated.  
Complete removal of the benzylidene acetal from 157 gave diol 161 (Scheme 4.29). 
Initial low yields for this transformation were found to be caused by para-
toluenesulfonic acid catalysing the reverse reaction on evaporation of the reaction 
mixture prior to work-up. Direct basic aqueous work-up of the reaction with potassium 
carbonate was critical in preventing this reverse reaction, allowing isolation of 161 in 
high yield.  
 
157           161 
Scheme 4.29: Reagents and conditions: a) i) p-TSA (cat), MeOH/CH2Cl2, W, 80 C, 
20 min; ii) 10% K2CO3 (aq), 72%. 
 
Regioselective sulfamate formation using method 2 gave a 36% yield of 162 (Scheme 
4.30). The relatively low yield obtained may be due to reduced steric crowding around 
the 4-hydroxyl group arising from removal of the 3-hydroxyl substituent. 
Hydrogenation of 162 to 163, followed by N-sulfation, gave 63.  
94 
 
                 161       162                               163                            63 
Scheme 4.30: Reagents and conditions: a) ClSO2NH2, Tol/DMA, -40 C, 24 h, 36%; 
b) H2/10% Pd/C, AcOH, 40 C, 2 h, 97%; c) SO3.Py, H2O, pH 9-10, r.t., 2 h, 21%. 
 
The synthesis of C
4
-methylene derivative 62 required selective protection of the 3- and 
6-hydroxyl groups. As discussed for the synthesis of 50, the observed order of 
reactivity of the hydroxyl groups of methyl-D-glucopyranoside toward benzoyl 
chloride is 6 > 2 > 3 > 4.
191
 This trend is conserved in D-glucosamine systems which 
is reported to enable selective protection at the 3- and 6-positions.
201
 Using the 
literature conditions at room temperature resulted in no selectivity, with only 7% of 
164 being obtained along with 69% of tris(benzoyl) product. Reducing the reaction 
temperature to -40 C allowed 164 to be isolated in a 72% yield (Scheme 4.31).  
 
                              103                                 164                    165 
 
                  166      167                168                               62 
Scheme 4.31: Reagents and conditions: a) BzCl (2.2 eq.), CH2Cl2/pyridine, -40 C, 3 
h, 72%; b) i) CS(Im)2, toluene, 110 C, 3 h; ii) TMS3SiH, AIBN, 110 C, 1 h, 79%; c) 
NaOMe (cat), MeOH, r.t., 18 h, 68%; d) ClSO2NH2, Tol/DMA, -40 C, 36 h, 51%; e) 
H2/10% Pd/C, AcOH, 40 C, 2 h, 70%; f) SO3.Py, H2O, pH 9-10, r.t., 2 h, 8%. 
 
Radical deoxygenation of 164 provided 165, which was deprotected under Zemplen 
conditions to give a 68% yield of diol 166. Sulfamoylation using method 2 gave 167 in 
51% yield, with subsequent N-deprotection and sulfate formation providing target 62. 
The low isolated yield obtained for the final step reflected the presence of close-
running impurities which hindered purification.  
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4.2.4 Substitution on the 4-Hydroxy Position of Monosaccharide 25 
 
Introduction of alkoxy substituents at the 4-position of 25 was investigated starting 
from 3,6-dibenzoyl protected intermediate 164. Benzylation of the 4-position of a 
similar substrate containing adjacent acyl protected alcohols has been reported to 
proceed with no acyl migration under basic conditions.
207
 However, when applied to 
164 a complex mixture formed.  
 
                                                  169                                  174 
Benzyl ether formation under mildly acidic conditions using Bundle’s reagent (benzyl-
2,2,2-trichloroacetimidate, 169) with catalytic triflic acid
208
 has been successfully used 
on monosaccharide alcohol substrates bearing vicinal benzoyl protected alcohols with 
no acyl migration,
209
 and successfully provided O
4
-benzyl ether 170 in 75% yield. 
However, 6 equivalents of 169 were required for complete consumption of starting 
material, and on scale-up a yield of only 17% was achieved after addition of 12 
equivalents of 169. Conversion was improved by performing the reaction at 60 C in 
dioxane, giving a 78% yield of 170 on a 500 mg scale (Scheme 4.32).  
 
                        164                170                        171 
 
                                    172                                   173                                 61 
Scheme 4.32: Reagents and conditions: a) Benzyl-2,2,2-trichloroacetimidate (8 eq.) 
(182), TfOH, dioxane, 60C, 4 h, 78%; b) 3 eq. LiAlH4, 0 C, 2 h, 69%; c) ClSO2NH2, 
Tol/DMA, -40 C, 22 h, 52% d) 10 bar H2/5% Pd/C, MeOH, r.t. 35 min, 100% e) 
SO3.Py, H2O, pH 9-10, r.t., 2 h, 25%. 
 
Benzyl ether formation under neutral conditions was also investigated using 1-methyl 
2-benzyloxypyridinium triflate (174), at room temperature in the presence of 
magnesium oxide, to give a 43% yield of 170. Under microwave heating at 150 C, the 
96 
reaction achieved high conversion in 30 minutes, with an improved isolated yield of 
170 of 73%.  
Removal of the benzoyl protecting groups from 170 under Zemplen conditions 
required more than one equivalent of sodium methoxide to achieve a 25% isolated 
yield of 171. Attempts to cleave the benzoyl groups reductively with DIBAL in DCM 
gave exclusively starting material at -78 C, and at room temperature only the 6-
benzoyl group was removed. Access to the carbonyl group of the 3-benzoyl ester is 
hindered by the neighbouring benzyl ether, which may explain the low reactivity 
towards nucleophiles. Reaction of 170 with lithium aluminium hydride allowed 
isolation of 171 in 69% yield, the small size of the hydride reducing species, and non-
coordinating mechanism, presumably aiding reaction with this sterically hindered 
substrate. Sulfamoylation using method 2 gave 172 in 52% yield, which was 
deprotected selectively in the presence of the benzyl ether under mild palladium-
catalysed flow hydrogenation conditions, to give 173 which was successfully sulfated 
to provide 61.  
 
4.3 Synthesis of Cyclic Aliphatic Sulfamates 
 
Sulfamoylation of racemic tetrahydropyran-2-methanol (175) was achieved at room 
temperature in DMA to yield 67 (Scheme 4.33).   
 
                                    175                                                67 
Scheme 4.33: Reagents and conditions: a) ClSO2NH2, DMA, r.t., 48%. 
 
Sulfamoylation of Cbz protected trans-4-aminocyclohexanol (177) proceeded in high 
yield (Scheme 4.34). However, Cbz deprotection of 178 using palladium-catalysed 
hydrogenation resulted in none of the desired amine being isolated. A proposed 
pathway for decomposition involves intramolecular transannular SN2 displacement of 
the sulfamate by the liberated amine, to give 180. The hydrogenation was repeated in 
acetic acid, resulting in successful isolation of acetate salt 179. However, attempts to 
prepare the N-sulfate from 179 were unsuccessful, which may be due to rapid 
97 
formation of 180 on liberation of the free amine under the basic conditions used for N-
sulfate formation.    
 
         176                       177                         178                              179               180 
Scheme 4.34: Reagents and conditions: a) CbzCl (1.1 eq.), NaHCO3 (7 eq.), H2O, r.t., 
18 h, 79% ; b) ClSO2NH2, DMF, - 40 C, 18 h, 76%; c) H2, 10% Pd/C, MeOH, 40 C, 
2 h, AcOH (2 eq.), 100%. 
 
An alternative three-step route which avoided the possibility of formation of 180 was 
designed, employing a trichloroethyl protected sulfate, and successfully applied to the 
synthesis of 64 (Scheme 4.35). Protection of 176 was followed by sulfamate 
formation, and zinc-mediated deprotection of the sulfate provided 64, which was 
isolated as the sodium salt after ion exchange chromatography. 
 
                176                            181                              182                              64 
Scheme 4.35: Reagents and conditions: a) 1,1,1-trichloroethylsulfonyl imidazolium 
tetrafluoroborate (1 eq.), THF, r.t., 18 h, 73%; b) ClSO2NH2, DMF, - 40 C, 18 h, 
76%; c) i) Zn (15 eq.), MeOH, H2O, r.t. 1 h; ii) Ion exchange chromatography on 
Dowex 50W8X200 Na form, H2O, 95%. 
 
Derivative 66 was prepared from piperidinol 183 using a similar reaction sequence 
(Scheme 4.36).  
 
             183                              184                             185                              66 
Scheme 4.36: Reagents and conditions: a) 1,1,1-trichloroethylsulfonyl imidazolium 
tetrafluoroborate (1 eq.), THF, r.t., 18 h, 83%; b) ClSO2NH2, K2CO3 (5 eq.), DMF, - 
40 C, 18 h, 92%; c) i) Zn (15 eq.), MeOH, H2O, r.t. 1 h; ii) Ion exchange 
chromatography on Dowex 50W8X200 Na form, H2O 99% . 
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Attempted sulfamate formation at room temperature resulted in degradation of 184, 
and the low temperature sulfamoylation method 2 yielded 185 in only 19% yield with 
significant evidence of trichloroethanol as a by-product. A potential pathway for 
degradation was nucleophilic attack of the liberated chloride ion at the sulfur centre of 
the protected N-sulfate of 185, to release trichloroethanol, thereby forming chloride 
186 (Scheme 4.37).  
 
       184                                                        185                                   186 
Scheme 4.37: Proposed pathway for liberation of trichloroethanol in the sulfamate 
formation reaction with 184. 
 
Addition of potassium carbonate to the reaction as an acid scavenger completely 
suppressed this side reaction, resulting in a 92% isolated yield of 185. Sulfate 
deprotection was performed in the absence of ammonium chloride to avoid issues with 
purification. The zinc salt thus obtained was converted into the sodium salt of 66 by 
ion exchange chromatography, giving 66 in 99% isolated yield.  
A similar route was applied to the synthesis of 65 from 4-piperidine methanol (187) as 
shown in scheme 4.38, again employing potassium carbonate in the sulfamate 
formation step to suppress degradation of the trichloroethyl protected N-sulfate. 
 
             187                            188                               189                               65 
Scheme 4.38: Reagents and conditions: a) 1,1,1-trichloroethylsulfonyl imidazolium 
tetrafluoroborate (1 eq.), THF, r.t., 18 h, 94%; b) ClSO2NH2, K2CO3 (5 eq.), DMF, - 
40 C, 18 h, 75%; c) i) Zn (15 eq.), MeOH, H2O, r.t. 1 h; ii) Ion exchange 
chromatography on Dowex 50W8X200 Na form, H2O 90%.  
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4.4 Synthesis of Aryl Sulfamates 
 
Prior to the preparation of the aryl sulfamate compound set, a study was undertaken to 
confirm the effect of base and solvent on sulfamate formation for this class of 
substrates, using 3-trifluoromethylphenol (190) as a representative example. The 
results from these experiments are summarised in Table 4.10. 
 
                                           190                                          69 
Entry Base Solvent Outcome 
1 None MeCN No product formation 
2 None NMP Trace conversion 
3 None DMA 93% isolated yield 
4 NaH (2 eq) NMP No conversion 
5 NaH (3 eq) DMF New TLC component, not consistent with 
desired product 
6 Cs2CO3 (1.2 eq) MeCN Trace product, mainly starting material 
 
Table 4.10: Summary of conditions explored for reaction of phenols with sulfamoyl 
chloride. Conditions: 2 eq. of a freshly prepared sulfamoyl chloride (2 M in toluene) 
added to 3-trifluoromethyl phenol at 0C, in the presence of the base stated above. The 
reaction was allowed to warm to room temperature over 18 h. 
 
The presence of base resulted in either no significant conversion to product (Entries 4 
and 6), or formation of unidentified compounds which were inconsistent with the 
formation of 69 (Entry 5). Primary aryl sulfamates have been reported to degrade 
under basic conditions via an E1cB mechanism, to regenerate the phenol (Scheme 
4.39). 
 
Scheme 4.39: Proposed E1Cb pathway for decomposition of primary arylsulfamates 
under basic conditions. 
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In the absence of base, the choice of solvent had a dramatic effect on the outcome of 
the reaction, with DMA again being confirmed as the optimal solvent for room 
temperature sulfamoylation.
183
 This study led to the selection of DMA as solvent in 
the absence of a base for the synthesis of primary arylsulfamates. Isolated yields for 
the synthesis of a matrix of substituted phenyl sulfamates, are summarised in Table 
4.11.  
 
 
Table 4.11: Isolated yields (%) for the synthesis of substituted phenyl sulfamates. 
 
4.4.1 X-ray Crystal Structures of Representative Phenyl Sulfamates 
 
Sepctroscopic data for 4-nitrophenyl sulfamate (76) and 4-methoxphenyl sulfamate 
(79) were inconsistent with literature NMR data.
210
 Crystals of these products were 
grown by slow evaporation from water (76), and from acetonitrile (79). X-ray crystal 
structures were obtained, providing definitive structural confirmation (Figure 4.3). 
 
                                        76                                                               79 
Figure 4.3: X-ray crystal structures of 76 and 79. 
 
In both crystal structures the C-O-S torsion angle is close to 90, suggesting that it is 
unfavourable for the sulfur-oxygen bond to reside in the plane of the aromatic ring, 
presumably due to steric interactions between the sulfamate amino or sulfonyl 
functionalities and ortho-hydrogen atoms.  
R H CF3 CN NO2 OMe Ph 
Ortho 
29 (76%)  
68 (31%) 71 (26%) 74 (52%) 77 (29%) 80 (67%) 
Meta 69 (80%) 72 (58%) 75 (87%) 78 (56%) 81 (43%) 
Para 70 (60%) 73 (21%) 76 (48%) 79 (53%) 82 (67%) 
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4.5 Stability of Primary Aryl and Aliphatic Sulfamates  
 
Nitro-substituted phenyl sulfamates 74-76 were found to suffer from chemical 
instability in neat DMSO-d6 during overnight acquisition of 
13
C NMR spectra, with 
signals corresponding to both the expected product and phenolic starting material 
being present. No such degradation was observed with spectra obtained in CD3OD. 
1
H 
NMR stability studies were performed over 24 h at room temperature to explore the 
stability profile for a set of phenolic and aliphatic sulfamates in DMSO-d6 (Table 4.12) 
and CD3OD (Table 4.13). In DMSO-d6, analogues 74 and 75, bearing the strongly 
electron withdrawing nitro group at either the 2- or the 3-position, suffered significant 
degradation after 24 h. Over the same time period, between 10% and 20% degradation 
was seen with the moderately electron withdrawing groups, cyano and trifluoromethyl. 
The representative alkyl sulfamate tested (67) showed no evidence of degradation. 
Compound 
Time h 
0 1.5 3 6 24 
3-nitrophenyl sulfamate (75) >99%
a 
>99% 97% n.d. 55% 
2-nitrophenyl sulfamate (74) >99% 97% 91% n.d. 53% 
3-cyanophenyl sulfamate (72) >99% n.d. 97% 95% 80% 
3-trifluoromethylphenyl sulfamate (69) >99% n.d. 98% 96.5% 86% 
2-tetrahydropyranylmethyl sulfamate (67) >99% n.d. >99% >99% >99% 
a 
Percentages of sulfamate remaining were calculated by 
1
H NMR from integrals of characteristic 
aromatic protons, which were identified from 
1
H NMR of pure samples of the sulfamate and phenol;  
n.d. indicates value not determined.. 
Table 4.12: Stability studies on sulfamate compounds in DMSO-d6.  
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In CD3OD, 74 showed greater stability than in DMSO-d6. The less electron-
withdrawing 69 and the alkyl sulfamate 67 were stable in CD3OD over 24 hours 
(Table 4.13). 
  
Compound 
Time h 
0 1.5 3 6 24 
2-nitrophenyl sulfamate (74) >99%
a 
>99% 97% 95% 86% 
3-trifluoromethylphenyl sulfamate (69) >99% >99% >99% >99% >99% 
2-tetrahydropyranylmethyl sulfamate (67) >99% n.d. >99% >99% >99% 
a 
Percentages of sulfamate remaining were calculated by 
1
H NMR from integrals of characteristic 
aromatic protons, which were identified from 
1
H NMR of pure samples of the sulfamate and phenol;  
n.d. indicates value not determined.. 
Table 4.13: Stability studies on sulfamate compounds in CD3OD.  
 
In contrast to the solution instability, all phenolic and aliphatic sulfamates proved 
stable for one year when stored at room temperature as solid samples, with no signs of 
degradation by 
1
H NMR spectroscopy.  
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4.6 Synthesis of Benzylic Sulfamates 
 
The sulfamoylation conditions were applied to the synthesis of 4-nitrobenzyl 
sulfamate (89), giving a 50% isolated yield. Diversification of 89 was anticipated to 
enable synthesis of the N-sulfate (90), acetamide (192) and methanesulfonamide (193) 
via aniline 191 (Scheme 4.40). 
Scheme 4.40: Proposed synthetic route to substituted 4-aminobenzylsulfamate targets. 
Reagents and conditions: a) HCO2NH4, 10% Pd/C. 
 
Catalytic transfer hydrogenation of 89 resulted in multiple products with no evidence 
of formation of 191. Degradation of 191 is possible via a highly reactive aza quinone 
methide intermediate (194, Scheme 4.41), which may account for the observed 
reaction profile.  
 
 
                                              191                                            194 
Scheme 4.41: Proposed mechanism for the degradation of 191 via a reactive aza 
quinone methide intermediate 194. 
 
In an attempt to decrease formation of 194, the electron-withdrawing nitrogen 
substituents were introduced prior to sulfamate formation. Acetylation of 195 gave 
196, which, under the sulfamoylation conditions, formed a significant amount of 
benzylic chloride 197, with no 192 being obtained (Scheme 4.42). Chloride 197 may 
arise either via an SN1 mechanism, through an aza quinone methide intermediate, or by 
direct SN2 displacement of the benzylic sulfamate formed by chloride.  
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Scheme 4.42: Unexpected formation of 4-acetamidobenzyl chloride 197. Reagents 
and conditions: a) Ac2O (4.6 eq), MeOH, r.t., 5 h, 65%; b) ClSO2NH2, DMA, r.t. 
 
No chloride by-product was formed in the preparation of 89, where the aza quinone 
methide degradation pathway is not available. The electron-withdrawing nitro group 
of 89 would be expected to accelerate chloride displacement via an SN2 mechanism. 
The SN1 degradation pathway is therefore the more likely. 
Methanesulfonamide formation employing 4-aminobenzyl alcohol was also attempted, 
resulting in a complex reaction mixture. Thus, 4-amino substituted benzyl sulfamates 
may suffer from inherent chemical instability and these targets were not pursued 
further. Future work investigating a similar synthetic strategy on substrates with 
nitrogen substituents meta to the benzylic sulfamate would be of interest. These 
substrates would be unable to participate in the proposed aza quinone methide 
degradation pathway, and would therefore provide further mechanistic insights.  
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4.7 Summary 
 
A series of analogues of the literature monosaccharide Sulf-2 inhibitor 25 has been 
prepared, varied with respect to R
1
-R
4 
(Figure 4.4).  
 
Figure 4.4: Generic structure of analogues of monosaccharide sulfamate 25 prepared. 
 
Access to these targets was facilitated by the development of a procedure for the 
regioselective sulfamoylation of the O
6
-position of the monosaccharide template. 
Analysis of a model substrate resulted in an increased understanding of the factors that 
influence the success of this reaction. The information gained from these model 
experiments allowed further improvements in the regioselectivity, reproducibility and 
hence in the isolated product yields. This enabled the reaction to be used with greater 
efficiency on more complex intermediates, and longer reaction sequences to be 
undertaken to provide more complex final compounds.  
Variations of R
1
 and R
2
 were achieved using a diverse range of chemical 
transformations. The use of an allyl group as a versatile synthetic handle allowed the 
introduction of both lipophilic and hydrophilic functionality at the anomeric position. 
The R
3
 and R
4
 hydroxy groups were independently removed, and synthetic 
methodology for substitution at the R
4
 position was developed.  
Focussed libraries of phenolic, benzylic, and cyclic aliphatic sulfamates were also 
prepared in an attempt to identify non-saccharide based templates with inhibitory 
activity against Sulf-2.   
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Chapter 5: Introduction to the ERK5 Project 
 
 
5.1 Protein Kinases 
 
Protein kinases are a class of enzymes which catalyse the transfer of the -phosphate 
from adenosine triphosphate (ATP) to a substrate protein on a serine, threonine or 
tyrosine side chain.
211
 The introduction of the charged phosphate group often induces 
a conformational change in the secondary, tertiary or quaternary structure of the 
substrate, affecting its biological activity.
211
 Signal transduction in eukaryotic cells is 
mediated primarily by protein kinases.
212
 Many other cellular processes, including 
metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell 
movement, apoptosis, and differentiation are also mediated by protein kinases, and 
tumour formation has been linked to the loss of regulation of protein kinase activity.
27
 
This can occur through several mechanisms, including mutation or formation of fusion 
proteins leading to constitutive kinase activity, or the loss of negative regulators,
211
 
resulting in oncogenic signalling leading to increased tumour cell survival, 
proliferation, migration and angiogenesis.
213
 Over five hundred protein kinases have 
been identified, representing approximately 1.7% of the human genome, and genes 
coding for 164 of the 518 human protein kinases are located in chromosomal regions 
implicated in cancer.
214
  
Kinases can be classified by the residues that they phosphorylate. Typical kinases are 
divided into serine/threonine kinases and tyrosine kinases.
214
 A third class encompass 
atypical kinases, which exhibit kinase activity but are structurally dissimilar to the 
typical kinase families. In the human kinome, 388 kinases are classed as 
serine/threonine kinases, 90 as tyrosine kinases, and 40 as atypical kinases.
214
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Figure 5.1: Ribbon diagram representing the main features of a prototypical kinase 
catalytic domain based on the structure of IRK. The N-lobe is shown in green, the C-
lobe is shown in purple and the activation loop is colored yellow. The ATP binding 
site is coded in red. The substrate peptide, docked onto the activation loop, is shown in 
black, and an ATP analog is shown in blue and orange.
215
 
 
Protein kinases may be integrated into the plasma membrane of a cell, or may be 
intracellular. Membrane-associated kinases can transduce an extracellular signal across 
the plasma membrane, allowing downstream intracellular signalling, which manifests 
in a variety of ways. For example, the enzymic activity of the substrate protein may be 
activated by kinase-mediated phosphorylation, allowing it to catalyse transformations 
of further downstream substrates. Phosphorylation may also influence the substrate’s 
affinity for other proteins, resulting in their release or sequestration, and in so doing 
affecting their biological activity.  
The catalytic domain of typical protein kinases consists of approximately 290 amino 
acid residues arranged into two distinct lobes connected by a linker (Figure 5.1). The 
vast majority of protein kinases utilise ATP as the phosphate source, and have highly 
conserved ATP binding pockets (Figure 5.2). ATP binds in a cleft at the hinge 
between the N-terminal and C-terminal lobes.
211
 Selectivity is principally achieved 
through protein-protein interactions between the kinase and its substrate. 
Consequently, the mode of ATP binding is largely consistent across kinase families, 
with the N
1
 and N
6
 positions of the adenine ring system forming hydrogen bonds with 
the peptide backbone in the kinase hinge region.
216
 This binding mode positions the -
108 
phosphate group towards the substrate binding site.
211
 Secondary interactions such as 
Van der Waals contacts contribute further to ATP binding. 
 
 
Figure 5.2: Simplified illustration of the molecular contacts between the substrates 
and conserved active site residues and cofactors involved in catalysis of phosphate 
transfer by kinases.
216
 
 
Kinases exist in active and inactive forms, which may differ in their phosphorylation 
state.
213
 In the inactive form of many kinases an activation loop blocks the ATP site, 
preventing ATP from binding. A change of conformation on phosphorylation of 
activation loop residues enables ATP to access the binding site, and the enzyme to 
become catalytically active.
213
 Kinase inhibitors can be classified by their binding 
mode, and the kinase state that they inhibit.
217
  
 
5.2 Classes of Kinase Inhibitor 
 
Four main classes of kinase inhibitors have been defined (Types I-IV).217 The majority 
of small-molecule kinase inhibitors that have been developed are Type I inhibitors, 
which directly compete with ATP for the active conformation of the kinase. These 
inhibitors usually utilise hydrogen bond donor and acceptor motifs which mimic the 
hydrogen bonding interactions of ATP to the kinase hinge residues. Further potency 
and selectivity are achieved through incorporation of groups occupying adjacent 
hydrophobic pockets. 
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a. Type I Inhibitor binding   b. Type II inhibitor binding 
 
Figure 5.3: Ribbon diagram showing differences in the conformation of the activation 
loop on binding to Abl kinase of a). a type I inhibitor (PD173955) and b). a type II 
inhibitor (imatinib). The position of the activation loop is highlighted in red and blue, 
respectively.
218
 
 
Type II inhibitors target the inactive form of the kinase which has reduced affinity for 
ATP, and usually utilise a pocket formed by a change in conformation of the 
activation loop. These inhibitors are often referred to as ‘DFG-out’, a reference to the 
movement of a conserved triad of amino acid residues (aspartate (D), phenylalanine 
(F) and glycine (G)) at the start of the activation loop.
219
 In contrast, type I inhibitors 
are often referred to as ‘DFG-in’.219 Type II inhibitors are not directly ATP 
competitive, and thus their affinity is less susceptible to changes in intracellular ATP 
concentration.
219
 Their use of the pocket formed by movement of the activation loop 
also allows the inhibitor to interact with the kinase protein in a region of lower 
sequence conservation, increasing options for achieving selectivity. Access to this 
pocket is controlled by a “gatekeeper” residue, which may vary in size and 
hydrophobicity, providing another mechanism of introducing selectivity into inhibitor 
design. Mutations of this residue can also significantly affect the binding affinity of 
Type II inhibitors, which can confer drug resistance.
213
 Type III inhibitors bind to a 
site adjacent to, but distinct from the ATP-binding site, and thus may be considered 
allosteric binders.
220
 While this may be advantageous, the identification of leads for 
Type III inhibitors requires alternative biological assay procedures from those which 
110 
have been historically used for the identification of kinase inhibitors.
217
 Type IV 
inhibitors bind to distant sites distinct from the ATP-binding site, acting as true 
allosteric inhibitors,
220
 which may impart higher selectivity. There are currently no 
marketed Type IV kinase inhibitors.  
 
Figure 5.4: Examples of type III and IV kinase inhibitor binding sites. The cMET 
crystal structure in DFG-in, α-C-helix-out conformation (pdb id: 3eqg) is to used 
highlight these pockets. The protein kinase is shown in grey, with the hinge region 
connecting the N- and the C-loops in green. Type III inhibitor (PD-325089) binding at 
the allosteric pocket, adjacent to the ATP pocket, is represented by magenta van der 
Waals surface. The region where the Type IV inhibitor GNF-2 binds, the myristoyl 
pocket in cAbl, is shown in this cartoon representation using a russet surface. The 
activation loop between the DFG and PE sequences are colored in red, and the α-C-
helix is represented in blue.
220
 
 
Research has also been undertaken into the design of selective covalent kinase 
inhibitors, incorporating electrophilic functional groups which irreversibly interact 
with nucleophilic residues in the ATP-binding site (usually cysteines).
220
 No covalent 
kinase inhibitors are currently on the market.
213
 The purpose of this project is to 
develop an inhibitor of the ERK5 protein kinase, with the ultimate aim of identifying a 
drug that may be approved for human use as an anti-cancer therapy.  
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5.3  The MAP Kinase Pathways and the Role of ERK5 
 
In addition to the classical MAP kinase pathway discussed in chapter 1, three other 
MAP kinase pathways have been identified.
35
 Each of these has a similar composition, 
with the MAP kinase (MAPK) being activated by a MAP kinase kinase (MAPKK), 
which in turn is activated by a MAP kinase kinase kinase (MAPKKK). A distinct set 
of growth factor signals and stimuli, such as cellular stress and the release of 
cytokines, initiate signalling in these pathways. A schematic representation of the four 
pathways is shown in Figure 5.5.  
 
Figure 5.5: Schematic representation of the classical and non-classical MAP kinase 
pathways. 
 
5.3.1 The Jnk and p38 MAP Kinase Pathways 
 
The p38 and c-jun N-terminal kinase (Jnk) pathways are activated by pro-
inflammatory cytokines such as interleukin 1-β (IL-1β) and tumour necrosis factor-α 
(TNF-α) in response to cellular stress.35 These pathways have been the target of 
investigations into the treatment of inflammatory diseases such as rheumatoid arthritis, 
psoriasis and inflammatory bowel disease.
35
 Neuronal apoptosis in neurodegenerative 
diseases such as Alzheimer’s disease and Parkinson’s disease have been linked to 
persistent activation of these pathways.
40
 Inflammation has also been identified as a 
risk factor for tumour development, which may be in some part mediated by the p38 
and Jnk MAP kinase pathways.
40
 Elevated Jnk activity promotes proliferation in 
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mouse fibroblasts, and Jnk 1 has been shown to be over-activated in over a half of 
hepatocellular carcinoma (HCC) cases.
221
 Increases in Jnk activity accelerated the 
development of chronic colitis-induced colorectal cancer, and has also been implicated 
in human prostate cancer.
40
 p38α is an important regulator of differentiation of various 
cell types, and mouse embryonic fibroblasts deficient in p38α proliferate faster and 
exhibit increased G1/S and G2/M transitions as compared to control cells.
222
 These 
observations lend further evidence to the critical roles of MAP kinase signalling 
pathways in cancer. 
 
5.3.2 The ERK5 MAP Kinase Pathway  
 
The ERK5 (extracellular signal-regulated kinase 5) pathway has been shown to be 
activated by a wide range of stimuli, including vascular endothelial growth factor 
(VEGF), epidermal growth factor (EGF), fibroblast growth factor (FGF2), platelet 
derived growth factor (PDGF), brain derived neurotrophic factor (BDNF), nerve 
growth factor (NGF), inflammatory cytokines such as interleukin 6 (IL-6) and osmotic 
and hypoxic stress.
36
 MEK5 uniquely activates ERK5 by phosphorylation first of 
Thr
218 
and subsequently of Tyr
220
. ERK5 does not interact with MEK1/2, indicating 
that the MEK5-ERK5 pathway is independent of the classical MAPK pathway.
223
 
MEK5 is activated by the closely related MAPKKKs, MEKK2 and MEKK3, which 
share 94% sequence identity.
36
 The PB1 domain of MEK5 mediates the interactions 
between MEK5 and MEKK2 and 3, and between MEK5 and ERK5. It has been 
proposed that the PB1 domain of MEK5 has a role as a scaffold for a MEKK2-MEK5-
ERK5 ternary complex.
224
  
ERK5 double knock-out mice exhibit defects in development of the vasculature and 
cardiac systems, resulting in embryonic lethality at around day ten.
225
 ERK5 is 
expressed in many tissues, with high levels evident in the brain during early 
embryonic development, and has been shown to facilitate neurone survival.
36
 The role 
of ERK5 in cancer, and the effect of its inhibition on cancer progression, has still to be 
fully elucidated. The key data which support the inhibition of ERK5 as a potential 
cancer therapeutic strategy are outlined below. 
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5.3.3 The Role of ERK5 in Cancer  
 
The ERK5 Pathway and Prognosis 
 
In breast cancer, patients with high ERK5 levels have a decreased median  disease-free 
survival time of 14 months compared with 34 months for patients with low ERK5 
levels (Figure 5.6a).
226
 In prostate cancer, MEK5 over-expression also correlates with 
poor survival (Figure 5.6b).
227
  
 
a.                                                              b. 
Figure 5.6: a) Kaplan-Meier plot of disease-free survival (DFS) with respect to ERK5 
levels in 84 early stage breast cancer patients. Patients with high levels of ERK5 (n = 
17) had a worse disease-free survival time (14.13 months; 95% CI: 3.78-24.48) 
compared with patients (n = 67) with low levels (34.33 months; 95% CI: 18.52-
50.14).
226
 b) Kaplan-Meier plot of DFS with respect to MEK5 levels in prostate 
cancer. Patients with moderate/strong MEK5 expression had a shorter mean disease-
specific survival of 52 months compared to those exhibiting weak MEK5 expression 
(58 months).
227
 
 
ERK5 Amplification and Overepression 
ERK5 gene amplification is observed in approximately 50% of HCC tumours,
228
 and 
overexpression of ERK5 has been detected in 20% of breast cancer patients.
226
 ERK5 
expression was also found to be significantly upregulated in high grade prostate cancer 
when compared to benign prostatic hyperplasia.
229
  
 
ERK5 and In Vitro Cell Proliferation 
Proliferation of the HeLa cervical cancer cell line has been shown to be ERK5-
dependent.
230
 Proliferation of MCF-7 and BT474 breast cancer cell lines is affected by 
ERK5 activity, and ERK5 also affects the expression of the p21 proliferation 
114 
modulator through suppression of promyelocytic leukaemia protein (PML) activity.
36
 
The MDA-MB-231 human breast cancer cell line has also been shown to be dependent 
on ERK5 for proliferation.
231
 
 
The ERK5 Pathway and Metastatic Potential 
 
ERK5 has been shown to play a role in cellular invasion and metastatic spread, 
affecting cell migration, and attachment to the extracellular matrix, through 
interactions with the avβ3 integrin and focal adhesion kinase (FAK).36 Lymph node 
metastases in oral squamous carcinoma are associated with high ERK5 expression.
232
 
In a prostate cancer cell line, reduction of expression or inhibition of the MEK5/ERK5 
signalling cascade resulted in reduced invasive capability, and ERK5 signalling 
promoted metastatic formation in vivo.233 Hepatocyte growth factor (HGF) induced cell 
migration of MDA-MB-231 breast cancer cells has also been found to be dependent 
on ERK5 expression.
234
 In prostate cancer, over-expression of constitutively active 
MEK5 leads to increased expression of matrix metalloproteases-2 and -9 through 
induction of expression of activator protein (AP)-1.
36
 ERK5 expression correlates with 
prognosis in prostate cancer, having a significant link to bone metastases.
36
 Figure 5.7 
shows the results from another study of prostate cancer patients, which found that 
MEK5 over expression also correlates with higher metastatic potential.
227
 
 
Figure 5.7: MEK5 expression level and presence of metastases.
227
 White bars – 
high/moderate MEK5 expression, Black bars - low MEK5 expression. 
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ERK5 and Apoptosis 
Multiple myeloma cells are protected from induced apoptosis by over-expression of 
ERK5, whereas over-expression of a catalytically inactive mutant of ERK5 leads to 
increased sensitivity to induced apoptosis.
235
 Double MEK5 knockout in mouse 
embryonic fibroblasts resulted in sensitisation to osmotic stress induced apoptosis, 
suggesting that the MEK5/ERK5 pathway may have a role in protecting against 
apoptosis.
236
  
The ERK5 Pathway and Angiogenesis 
 
In human xenograft models, deletion of ERK5 reduced tumour growth in mice and 
inhibited development of tumour blood vessels.
36
 VEGF-stimulated tubular 
morphogenesis in endothelial cells is mediated by ERK5,
237
 and VEGF and FGF pro-
angiogenic factors have been shown to stimulate ERK5 activation in HUVEC cells.
36
  
 
Constitutive Activation of ERK5 
 
Out of 900 samples sequenced, only one somatic mutation of ERK5 has been reported, 
suggesting that mutation of ERK5 into a constitutively active form is rare in cancer.
232
 
De-regulation of this pathway is therefore likely to occur through altered protein 
levels, as seen in HCC, with the 17p11 amplification being present in 50% of cases.
232
 
Sustained activation of upstream signalling may also result in dysregulation of ERK5 
signalling.
232
 
 
ERK5 Interactions with other Pathways Implicated in Tumour Development 
 
ERK5 also regulates cyclin D1 expression, and regulates NF-B activity, affecting cell 
cycle progression.
36
 Ras is mutated in 20-30% of cancers, and Ras activity resulted in 
activation of ERK5 in PC12, C2C12 and COS7 cells.
36
 Constitutive activation of 
signal transducer and activator of transcription (STAT) is often apparent in advanced 
breast cancer patients, and elevated STAT has been shown to result in up-regulation of 
MEK5.
232,238
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5.3.4 The Structure of ERK5 
 
Two research groups independently discovered ERK5 in 1995.223,239 The ERK5 MAP 
kinase consists of 816 amino acids and has a molecular weight of approximately 102 
kDa, which is more than double that of other MAP kinases. ERK5 is consequently also 
known as Big Map Kinase-1 (BMK-1). The kinase domain resides towards the 
N-terminus, and has high similarity with ERK1/2 and the same TEY phosphorylation 
triad (Figure 5.8).
36
 
 
Figure 5.8: Schematic representation of the domain structure of ERK5.
36
 
 
Amino acids 1-77 at the N-terminus are involved in targeting the protein to the 
cytoplasm, with residues 78-406 comprising the kinase domain, which shares 66% 
sequence identity with ERK2.
36
 ERK5 has a unique 410 amino acid C-terminal tail, 
which may have an auto-inhibitory function, as truncation leads to increased kinase 
activity. The C-terminal amino acids also contain a nuclear localisation signal (NLS) 
domain (505-539), two proline rich domains (PR1, 434-465 and PR2, 578-701) and a 
transcriptional activation domain (664-789). The proline rich domains are believed to 
be involved in binding to proteins containing a Src-homology 3 (SH3) domain.
36
 
 
5.3.5 Downstream Effects of ERK5 
 
ERK5 and ERK1/2 require translocation to the nucleus in order to potentiate their 
signals, but the mechanism by which this translocation is controlled is different.
240
 It 
has been proposed that in the inactive state of ERK5 the C- and N-termini interact, 
resulting in a folded conformation which is exported from the nucleus (Figure 5.9). 
Phosphorylation of the kinase domain disrupts this interaction leading to an extended 
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active conformation that can autophosphorylate multiple C-terminal residues, resulting 
in nuclear translocation.  
 
Figure 5.9: Schematic representation of the process of activation of ERK5 for nuclear 
localisation.
36
 
 
ERK1/2 has a shorter C-terminal domain, with no nuclear import or export signalling 
role. Instead, MEK1/2 contains a nuclear export signal, and in its unphosphorylated 
form associates with ERK1/2, localising it to the cytoplasm.
240
 The phosphorylation of 
ERK1/2 results in dissociation of the ERK1/2-MEK1/2 complex, enabling ERK1/2 to 
translocate to the nucleus by both passive diffusion and active transport.  
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The mechanism of control of transcription by ERK1/2 also differs from that of 
ERK5.
240
 In addition to the activation of transcriptional factors, ERK5 itself has a C-
terminal transcriptional activation region which is activated by autophosphorylation. 
ERK1/2, lacking the C-terminal domain, only acts by phosphorylation of other 
transcription factors.  
There are some common downstream targets of phosphorylation by ERK5 and 
ERK1/2, including Sap1a, c-Myc, RSK, c-Fos and c-Jun. ERK5 also activates 
members of the MEF family of transcription factors which are involved in the 
modulation of apoptosis.
241
 MEF2A and MEF2C are activated by both ERK5 and p38 
MAP kinases, whereas MEF2D appears to be a specific substrate of ERK5. An ERK5 
construct containing only the kinase domain (AAs 1-400) was unable to activate the 
lklf (lung kruppel-like factor) reporter gene, whereas a construct devoid of kinase 
activity, comprising only the C-terminal residues (400-806), constitutively activated 
lklf transcription. This suggests that the kinase domain may have a regulatory 
function,
242
 and that activation of MEF transcription factors may be independent of the 
kinase activity of ERK5. Autophosphorylation of the C-terminal domain has been 
shown to increase the transcriptional activating activity of ERK5.
243
 c-Fos is a 
transcription factor which has been implicated in proliferation, differentiation and 
apoptosis.
244
 ERK5 and ERK1/2 both phosphorylate c-Fos.
240
 However, only ERK5 
subsequently phosphorylates further sites on c-Fos, allowing full c-Fos transcriptional 
activity. ERK5 also affects the transcription factors c-Myc, CREB and Sap1a, and 
indirectly affects AKT phosphorylation, all of which have been implicated in tumour 
development.
36
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5.3.6 Literature Inhibitors of ERK5  
There are two classes of inhibitor of the MEK5/ERK5 pathway described in the 
literature; a diazepinone series,
245
 and an oxindole series.
246
 Both classes are selective 
for the MEK5/ERK5 pathway over the classical MAP kinase pathway. 
5.3.6.1 The Diazepinone Series 
 
A series of diazepinone ERK5 inhibitors has been described.
245
 SARs around the polar 
aliphatic heterocycle have been published, showing little effect on potency through 
variation at this position (Table 5.1). 
 
Cmpd R1 R2 ERK5 IC50 nM 
198 
 
Me 190 
199 
 
Me 230 
200 
 
Me 260 
201 
 
Me 240 
202 
 
Me 200 
203 
 
Me 130 
204 
 
c-Pent 200 
205 
 
c-Pent n.d. 
                 n.d. = not disclosed 
Table 5.1: Selected ERK5 inhibition data for the diazepinone class of ERK5 
inhibitors.
245
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A co-crystal structure of 205 bound to ERK5 was recently published, using a kinase 
domain construct (residues 1-397), determined at a resolution of 2.8Å (Figure 5.10).
247
 
This construct was not phosphorylated on the activation loop. The structure confirms 
the key binding interaction between the aminopyrimidine of 205 and the hinge region 
of ERK5. The cyclopentyl group projects towards the glycine-rich loop, and the 
carbonyl of the diazepinone central ring forms a hydrogen bond through a water 
molecule to the backbone nitrogen of Asp200 in the DFG motif. 
 
 
205 
 
Figure 5.10: The X-ray co-crystal structure of 205 bound to ERK5.
247
 The N-terminal 
lobe is colored blue. The C-terminal lobe is colored green. The activation loop and αC 
helix are colored red, and compound 205 is colored yellow. The surface of the ERK5 
ATP-binding site around the inhibitor is shown in purple. (PDB accession code 4b99). 
 
The piperidylpiperazine ring system points out of the ATP-binding site towards 
solvent and appears to lie close to the glycine-rich loop. The position of this group 
towards the solvent-exposed surface of the protein is consistent with the flat SAR 
published for analogues having diversity at this position.
245
 Diazepinone 203 has 
shown anti-proliferative activity in HeLa cells,
248
 and in in vivo tumour xenograft 
models this compound also exhibited growth inhibitory activity,
248
 lending further 
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support to the hypothesis that inhibition of ERK5 may have a role in cancer therapy. 
Compound 203 has been profiled in an in vivo rat pharmacokinetic study, 
demonstrating good bioavailability and moderate clearance (Table 5.2).
248
 
 t1/2 
 h 
Cl 
ml/min/kg 
Vd  
L/kg 
F  
% 
203 2.6 18 5.4 87 
 
Table 5.2: Rat in vivo pharmacokinetic parameters for 203.
248
 
 
5.3.6.2 Oxindole inhibitors 
 
The oxindole compounds 206 and 207 inhibit both ERK5 and MEK5, with 50- to 200-
fold greater activity against MEK5 than ERK5 (Table 5.3).
246
 IC50 values against 
MEK1, MEK2 and ERK1 were all greater than 6 M, and both compounds were over 
100-fold selective for MEK5 against a panel of 87 kinases.
246
  
 
Table 5.3: Published MEK5 and ERK5 inhibitory data for 206 and 207.
246
  
 
Neither 206 nor 207 affected phosphorylation of ERK1/2, p38 or Jnk1/2 MAP kinases 
in HeLa cells, but inhibited transcriptional activation of MEF2C, a downstream target 
of the MEK5/ERK5 pathway, supporting the hypothesis that their effects are due to 
inhibition of this pathway.
246
 
 
 
 
 
 
Cmpd R MEK5 IC50 
nM 
ERK5 IC50 
nM 
206 H 4.3 810 
207 Me 1.5 59 
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5.4 The Pyrrole Carboxamide Series of ERK5 Inhibitors  
 
The Newcastle pyrrole carboxamide series was identified from a high-throughput 
screen against ERK5, with the most potent hit in the series, 208, having an IC50 of 0.7 
M. Seventeen members of this series demonstrated ERK5 inhibition (IC50 < 33 M), 
with seven compounds having an IC50 of less than 10 M. Four compounds had been 
re-synthesised and re-tested against ERK5 to validate the hits, with two of the 
resynthesised compounds failing to inhibit ERK5, and 208 showing only a 5-fold 
reduction in potency, the resynthesised sample having an IC50 of 3.7 M. 
 
208 
 
5.5 In Silico and In Vitro Tools for Assessing ADMET Properties 
 
The in vitro assays used in the program to optimise the pyrrole carboxamide series 
were outsourced to Cyprotex, and are summarised in Table 5.3. An assessment of 
kinetic solubility was also performed at Cyprotex, using a turbidimetric method, which 
entails diluting a test compound solution prepared in DMSO with aqueous buffer, and 
determining precipitation as the end-point by measuring absorbance at 620 nm. An 
estimated precipitation range in M is reported, and when this value is less than 1 µM, 
a compound is considered highly insoluble. In cases where the lower solubility limit is 
between 1 and 100 µM, a compound can be considered to be moderately soluble, and 
above 100 µM denotes high solubility. 
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Assay Explanation 
HLM (Human 
liver microsomes) 
MLM (Mouse 
liver microsomes). 
A measure of the vulnerability of a compound to metabolism by 
cytochrome P450 in human or mouse. Figures are quoted as 
intrinsic clearance (Clint) in units of μL/min/mg protein, with 
lower figures representing low liability to cyp-mediated 
metabolism. A Clint of < 48 L/ml/mg protein was targeted. 
 
Caco-2 
 
A measure of the rate of permeation of a compound across a 
monolayer of a Caco-2 cancer cell line, which contain efflux 
pumps. Intrinsic flux is measured by the B2A measurement, with 
recognition by efflux transporters being implied from the ratio of 
B2A over A2B. Two figures are quoted: Apparent permeability 
(Papp) is quoted as a rate in units of 10
-6
 cm/s; efflux ratio (ER) is 
a ratio with no units. A high B2A figure and low ER reflect that a 
compound is highly permeable with low propensity for efflux. 
An ER of below 2 was targeted. 
 
Ppb 
 
Ppb represents the extent of binding to plasma proteins in blood. 
It is reported as fraction unbound (Fu), and is a value between 0 
and 1. An Fu of 0.1 indicates that, in blood, 90% of the compound 
is bound to proteins, with 10% free. A figure of > 0.005 was 
targeted. 
 
Cyp inhibition 
 
Inhibition of cytochrome P450s can lead to drug-drug interactions, 
or a compound inhibiting its own metabolism leading to 
unpredictable accumulation. Inhibition of four isoforms of 
cytochrome P450 (2D6, 3A4, 2C9 and 2C19) were assessed, 
initially at a single concentration with results presented as per 
cent inhibition (% inh.). Ki values are generated on compounds 
showing evidence of Cyp inhibition. 
 
hERG 
 
The hERG (human ether-a-go-go-related gene product) ion 
channel is linked to cardiac arrhythmias leading to life-
threatening Torsades de Pointes. A significant therapeutic 
window over hERG inhibition is required.  
Table 5.3: Summary of the Cyprotex in vitro ADMET assays used in the ERK5 
inhibitor optimisation program. 
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5.6 The Screening Sequence for the ERK5 Discovery Program 
 
The initial screening sequence (Figure 5.11) started with generation of cell free IC50 
data for ERK5 using an IMAP® format assay.
249
 In this screening platform, the 
isolated kinase acts on a fluorescently labelled substrate, with subsequent addition of 
the IMAP binding system, which stops the enzymic reaction and binds to the 
phosphorylated substrate, relying on a specific, high affinity interaction between 
phospho-groups and metal-containing nanoparticles within the IMAP® binding 
system. This binding is detected by fluorescence polarisation to determine the extent 
of phosphorylation.  
  
Figure 5.11: The initial screening sequence for the evaluation of ERK5 inhibitors. 
 
In the early stages of SAR development, selectivity over the closely related p38α 
MAPK, was a significant issue for the pyrrole carboxamide series, and IC50 values 
against this counter-target were obtained in parallel with the primary pharmacology 
determination. Compounds with encouraging primary potency and selectivity data 
were progressed to a panel of in vitro pharmacokinetic screens. In the third tier of the 
cascade, the ERK5 cellular activity was measured in a MEF2D reporter gene assay in 
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HEK293 cells, and membrane permeability and transporter-mediated efflux were 
assessed in Caco-2 cells. Promising compounds were progressed to an in vivo 
pharmacokinetic study in mice, before profiling against a panel of kinases to assess the 
wider selectivity profile, and in vivo efficacy assessment in a tumour xenograft model 
in mouse. 
As the project matured, structural features which conferred selectivity over p38α were 
identified, and p38α activity became less of a concern. Counter-screening against this 
target was moved to the second tier of the screening cascade. It became apparent that 
further mouse in vivo studies to support target validation would be required, and the 
screen sequence was adjusted to reflect this (Figure 5.12).  
  
Figure 5.12: The second screening sequence for the evaluation of ERK5 inhibitors. 
In vitro pharmacokinetic assays that would inform the selection of compounds for 
studies in mouse (mouse liver microsomes, Caco-2 permeability, and solubility) were 
prioritised in the second tier, with a further round of in vitro assays forming a third 
assay tier. Human liver microsomal (HLM) intrinsic clearance and inhibition of the 
hERG ion channel were determined, but were not considered to be on the critical path 
for selection of a compound for in vivo studies. Inhibition of cytochrome P450 (Cyp) 
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enzyme isoforms was assessed on an ad hoc basis when substituents with a known 
liability, such as potential haem-binding groups, were present.
250,251
 In parallel, 
determination of ERK5 inhibition in an EGF-stimulated HeLa cell-line was assessed, 
using Western blotting to monitor ERK5 autophosphorylation, with quantification by 
densitometry enabling IC50 determination. Details of the protocols for the ERK5 
isolated enzyme and cell-based assays, and for the p38α selectivity assay are included 
in Chapter 10. 
 
5.7 Early SARs in the Pyrrole Carboxamide Series 
 
Extensive structure-activity relationship studies
252,253
 led to the identification of 
functionality in the template which was important for activity, and areas that may be 
amenable to further optimisation. The key SARs that had been generated prior to the 
start of this thesis are summarised in Figure 5.13. 
 
Figure 5.13: Summary of the key pyrrole carboxamide series SARs for ERK5 
inhibition. 
The pyrrole NH and amide carbonyl were essential for activity. Based on this 
observation it was hypothesised that these may be involved in binding to the key hinge 
region of the kinase. Both the aryl ketone and amide substituent were required for 
ERK5 inhibition, and fragments lacking each of these features resulted in an ERK5 
IC50 of over 120 M. Replacement of the 2,3-dichlorobenzoyl ring with a saturated 
cyclohexyl ketone resulted in inactive compounds. Substituents on this aryl ring are 
numbered with a prime suffix. An unsubstituted aryl ring gave a loss of potency 
(ERK5; IC50 = 40 M), as did introduction of substituents at the 4’-position, including 
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Me, F, Cl, OMe, O
i
Pr, OCF3, and NO2. Halogens at the 2’- and 6’-positions were 
optimal, with disubstituted benzoyl groups such as 2’-bromo-6’-fluoro- and 2’-chloro-
6’-fluorobenzoyl being found to provide potent ERK5 inhibitors. Substitution at the 
3’- and 5’- positions was tolerated, but had not been extensively studied  
 
Figure 5.14: Summary of key SARs in the pyrrole carboxamide series. 
Incorporation of a heteroatom into the benzylic amide, to give pyridylmethyl amide 
(209) was tolerated, and aliphatic heterocyclic amides also retained good ERK5 
inhibitory activity (Figure 5.14). Replacing the benzylic amide with a heteroaryl amide 
(210) led to a significant and consistent improvement in selectivity over p38. 
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Exploitation of SAR knowledge for this template led to the identification of two key 
classes of lead compound with sub-micromolar potency against ERK5.  
 
5.8 Lead Compounds in the Pyrrole Carboxamide Series 
 
The most promising compounds in this series at the commencement of the work 
described in this thesis can be classified according to their amide substituent. The 
following section summarises the pharmacological, physicochemical, and 
pharmacokinetic properties of the lead compounds in each class. 
 
5.8.1 Class 1: Aliphatic Heterocyclic Amides 
 
The class 1 aminopiperidyl amide 212 was the most potent analogue at the start of my 
involvement in this project (ERK5; IC50 = 199  68 nM, L.E. 0.38). This amide 
substituent introduces a basic centre into the template, with an estimated pKa of 9.5, 
which would be expected to be protonated under physiological conditions.  
 
212 
Compound 212 had low metabolic turnover in human and mouse liver microsomes 
(Table 5.4). However, 212 exhibited low flux and a high efflux ratio (ER) in the Caco-
2 assay, suggesting it is slow to cross membranes, and is recognised by an efflux 
transporter.  
 
MW clogP clogD HLM Clint
a 
MLM Clint
a 
Caco-2 AB
b
 (ER) 
363 2.6 1.3 <5 8 3.8 (9) 
                a L/min/mg protein. b Papp 10
-6
 cm s
-1
. 
Table 5.4: Physicochemical and in vitro ADME parameters of 212.  
 
Compound 212 was progressed into a mouse in vivo pharmacokinetic study (Table 
5.5). This compound had low plasma protein binding, and was cleared at 
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approximately liver blood flow in mouse (mouse liver blood flow ~90-110 
ml/min/kg).
254
 The unbound clearance was moderate, consistent with low in vitro 
mouse microsomal clearance. The translation to high total plasma clearance was likely 
to be due to the high unbound fraction in plasma available to be metabolised. An 
alternative explanation is that the compound is cleared by non-cytochrome P450-based 
mechanisms for which microsomal data would not be relevant. The volume of 
distribution was consistent with expectations for a basic compound. The 
bioavailability was low, which reflected the high total plasma clearance. The high 
efflux in the Caco-2 assay indicated that absorption may also be impaired.  
 
Fu Cl 
ml/min/kg 
Clu 
ml/min/kg 
Vd 
L/kg 
t1/2 
min 
F 
% 
0.32 91 284 3.4 61 <10 
 
Table 5.5: In vivo pharmacokinetic parameters for 212. Dose 10 mg/kg i.v. and p.o. 
 
In this series the target for the optimisation program was to further improve potency 
against ERK5 (target IC50 < 20 nM), decrease in vivo plasma clearance, and reduce 
transporter-mediated efflux in the Caco-2 assay. 
 
5.8.2 Class 2: Heteroaromatic Amides 
 
The structures of the key heteroaromatic amide lead compounds are shown in Table 
5.6. The matched compound pair of 213 and 214 demonstrate that the postion of the 
pyridyl nitrogen has little effect on ERK5-inhibitory potency. However, unflanked 
pyridine nitrogen atoms are known to carry a risk of inhibition of cytochrome P450 
enzymes,
255
 and 4-pyridyl analogue 214 was found to be a potent cyp inhibitor, with 
an IC50 of 74 nM for the 2C19 isoform. The 5-aminopyrimidyl amide (215) was 
identified as an alternative to the pyridyl substituent that retained similar potency but 
exhibited no inhibition of cytochrome P450s, although some evidence of efflux in the 
Caco-2 assay (efflux ratio = 3.3) suggested that this compound may be a transporter 
substrate. Substitution of the 2-position of the pyrimidyl ring with a methyl group 
(217) led to a small loss in potency. 
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Compound R
1
 R
2
 ERK5 IC50
a
 nM
 
Cyp Inhibition 
211 Br 
 
821  73a No cyp inhibition 
213 Cl 
 
583  242 Weak (IC50 > 6 M) 
214 Cl 
 
602  266  Strong (IC50 <1.5 M) 
216 Cl 
 
400  166 n.d. 
215 Cl 
 
404  91 Weak (IC50 > 11 M) 
217 Cl 
 
1185  615 n.d. 
    a
 Determination  standard deviation; n.d. = not determined. 
Table 5.6: Primary pharmacology and Cyp inhibition profiles for key leads in the 
class 2 amide series.  
 
In in vitro ADME studies, compound 211 had low turnover in mouse and human 
microsomes, with high flux and no evidence of efflux in the Caco-2 assay (Table 5.7).  
 
MW clogP HLM Clint
a 
MLM Clint
a 
Caco-2 AB
b
 (ER) 
388 3.1 <5 20 34 (0.82) 
                             aL/min/mg protein. bPapp 10
-6
 cm s
-1
. 
Table 5.7: Physicochemical and in vitro ADMET parameters for 211.  
 
An in vivo pharmacokinetic study in mouse had been undertaken with 211 in order to 
benchmark the series, and provide information for use in in vivo target validation 
studies. The key in vivo pharmacokinetic parameters are shown in Table 5.8. 
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Fu Cl 
ml/min/kg 
Clu 
ml/min/kg 
Vd 
L/kg 
t1/2 
min 
F 
% 
0.06 27 459 1.2 65 68 
 
Table 5.8: In vivo pharmacokinetic parameters for 211 in mouse. Dose 10 mg/kg i.v. 
and p.o. 
Compound 211 was moderately protein bound in plasma, and after intravenous dosing 
it was cleared at approximately one third of liver blood flow in mouse. The compound 
had a moderate volume of distribution consistent with the presence of a weakly basic 
centre. The bioavailability after oral dosing is consistent with the clearance determined 
from the intravenous leg of the study, suggesting that the compound is well absorbed. 
Profiling of 211 against a panel of 130 kinases showed it to be a selective kinase 
inhibitor, with CDK2 being the only kinase with over 50% inhibition at 1 M. 
Independently, 211 was found to inhibit MEK5, the upstream activator of ERK5, with 
an IC50 of 3.4 M. Inhibition of two components of the pathway may provide an 
improved resistance profile, as single point mutations which reduce the binding 
affinity of the inhibitor would be required to occur simultaneously in both ERK5 and 
MEK5 in order for the efficacy of the drug to be reduced.  
Compound 211 was assessed in an in vivo tumour xenograft model in CD1 mice 
subcutaneously inoculated with A2780 human ovarian carcinoma cells. Before 
compound treatment, tumours were allowed to develop for 7 days to an average 
volume of 72 mm
3
. Mice were randomised to receive either vehicle, 100 mg/kg 211 
p.o. or 50 mg/kg of the literature diazepinone ERK5 inhibitor, 203, i.p. twice daily for 
11 days. Tumour volumes were measured at days 0, 2, 4, 7, 9 and 11, and body weight 
was also assessed as a surrogate for toxicity. No weight loss was observed in animals 
dosed with 211. However, one mouse in the 203-dosed group showed weight loss 
(78% of original body weight) at day 10 of the study. Treatment with either 203 or 211 
led to similar significant decreases in tumour growth compared with the vehicle 
control group (Figure 5.15).  
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Figure 5.15: B.i.d. Treatment of CD1 mice bearing A2780 xenograft with 203 (50 
mg/kg i.p.) or 211 (100 mg/kg p.o.) 
 
In the heteroaromatic amide series the target for the optimisation program was to 
improve primary ERK5 inhibitory potency, while maintaining the attractive 
pharmacokinetic profile. To guide design, Susan Boyd at Cancer Research Technology 
modelled compound 213 in the ATP-binding site of ERK5 from the published protein 
co-crystal structure (PDB code 4b99) using the GOLD docking program.
256
 The 
pyrrole amide was proposed to interact with the hinge region of the enzyme, through a 
hydrogen bond donor-acceptor motif as shown in figure 5.16. 
 
213 
 
 
Figure 5.16: Docking of 213 into the published ERK5 crystal structure (PDB code 
4b99)
247
 to show the likely interaction between the inhibitor and the hinge region.  
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In the model of the bound inhibitor, the ketone and amide carbonyl groups are co-
planar with the pyrrole ring, with the 2,6-disubstituted phenyl ring orthogonal to this 
plane, occupying a hydrophobic pocket (Figure 5.17). The pyridyl amide projects into 
the mouth of the binding pocket. The orientation of the phenyl and pyridyl rings was 
difficult to predict accurately.  
 
Figure 5.17: Possible binding pose of 213 modelled in the active site of ERK5 (PDB 
code 4b99).
247
  
 
Further optimisation of the lead structures was directed towards two parallel aims: 
1) Identification of in vivo tool compounds with improved potency relative to 211, and 
2) Identification of compounds with the potential for pre-clinical development, having 
sub-20 nanomolar potency against ERK5, selectivity over p38α, and a suitable 
ADMET profile. 
In order to guide the optimisation program, and to gain general insights into the 
challenges, physicochemical properties and successful strategies that have been used 
in the development of kinase inhibitor drugs, the following chapter analyses marketed 
kinase inhibitors and compares their properties with those of the ERK5 lead 
compounds.  
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Chapter 6: Kinase Inhibitors in Clinical Use 
 
 
The first kinase inhibitor to become a marketed drug, imatinib (Glivec, 16), was 
approved in 2001, and in the ensuing years through to 2012 a further 14 kinase 
inhibitors have reached the market. Fourteen of the fifteen approved kinase inhibitors 
are indicated as cancer therapeutic agents, with the first kinase inhibitor developed for 
a non-cancer indication, tofacitinib (Xeljanz) being approved by the FDA for the 
treatment of rheumatoid arthritis in November 2012. 
Understanding the molecular properties and medicinal chemistry design tactics that 
were used in the development of successfully marketed kinase inhibitors provided 
useful information to guide the optimisation of the pyrrole carboxamide series of 
ERK5 inhibitors. The following section briefly analyses the key medicinal chemistry 
decisions and breakthroughs that led to the identification of some of the approved 
first-in-class kinase inhibitor drugs. The profiles of these agents are discussed, with 
emphasis on the pharmacokinetic and safety parameters. A comparison of the 
molecular properties of lead compounds in the pyrrole carboxamide series with the 
properties of marketed kinase inhibitors is also presented, and its impact on the 
optimisation of the current series is discussed. 
 
6.1 Inhibitors of the Bcr-Abl Fusion Gene Product 
 
6.1.1 Imatinib 
 
16 
As discussed in Chapter 1, imatinib (16) is a Type II inhibitor of the Bcr-Abl fusion 
protein kinase with efficacy in the treatment of Philadelphia chromosome-positive 
CML.
52
 Imatinib is also licensed for the treatment of GIST, acting in this indication 
through inhibition of c-Kit, and PDGFR kinases, and affecting downstream signalling 
through the classical MAPK pathway.
54
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6.1.1.1 Medicinal Chemistry Leading to the Discovery of Imatinib.53 
 
The initial lead compound from which imatinib was developed was identified from a 
screen for protein kinase C inhibitors (PKC).
53
 From the hits, phenylaminopyrimidine 
218 was selected for follow-up due to its lead-like properties and synthetic tractability, 
having the potential for rapid SAR generation using simple chemistry. Substitution of 
the 3-position of the pyrimidine ring with a 3-pyridyl group (219) gave improved PKC 
potency, and adding an amide group to the phenyl ring (220) imparted increased 
potency against Bcr-Abl and receptor tyrosine kinases. Introduction of a methyl group 
at the 6-position of the central phenyl ring (221) significantly reduced PKC activity, 
while retaining activity against Bcr-Abl. The first members of this structural class of 
inhibitor had poor oral bioavailability and solubility. Addition of a polar 
N-methylpiperazine group improved these properties, resulting in the discovery of 
imatinib (16).
53
 
 
Figure 6.1: Key stages in the discovery of imatinib (16). 
Table 6.1 outlines the molecular properties of imatinib, showing it to have sub-
nanomolar potency against the isolated Bcr-Abl kinase, moderate lipophilicity, and a 
molecular weight close to 500. This results in good ligand efficiency (LE) and 
excellent lipophilic efficiency (LipE). 
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Bcr-Abl IC50  
nM 
MW clogP clogD tPSA 
Å
2
 
HBD HBA LE LipE 
0.2 494 3.6 3.3 85 2 8 0.37 7.2 
 
Table 6.1: The molecular properties of imatinib (16). 
6.1.2 Resistance and Second Generation Bcr-Abl Inhibitors  
 
Although imatinib demonstrated impressive results in the clinic and validated the 
targeted therapy paradigm for cancer drug discovery, development of resistance to this 
kinase inhibitor has emerged as a significant issue. Between 15-25% of imatinib-
treated CML patients show intrinsic resistance, and a further 7-15% lose their initial 
response to the drug through acquired insensitivity.
213
 The principal resistance 
mechanism is the development of point mutations in the Bcr-Abl gene, with over thirty 
such resistance-inducing mutations having been observed in the clinic.
213
 Other 
mechanisms such as gene amplification or over-expression, and up-regulation of 
downstream effectors also decrease the drug’s effectiveness. For example, some 
imatinib-resistant CML cells show up-regulation of members of the MAPK and PI3K 
signalling pathways. Second generation Bcr-Abl inhibitors that have reached the 
market include dasatinib (Sprycel, 222) and nilotinib (Tasigna, 223). Dasatinib is 325-
fold more potent against Bcr-Abl than imatinib, and has activity against 21 imatinib-
resistant mutants.
257
 Nilotinib and dasatinib both also inhibit c-kit and the PDGF 
receptor, with dasatinib having additional activity against Src.  
               
                           222                           223 
Bosutinib (Bosulif, 224) is another second generation Bcr-Abl inhibitor that was 
approved for use in CML in September 2012,
258
 with activity also against the c-Src 
137 
kinase. Its negligible inhibitory activity against c-kit or platelet-derived growth factor 
receptor kinase has been proposed to be advantageous in reducing haematological 
side-effects which can arise during treatment with imatinib and other second 
generation agents.
258
 The first and second generation drugs are ineffective against the 
common T315I mutation of the gatekeeper residue of Bcr-Abl.
259
 These agents all 
exploit a hydrogen bond with the native threonine gatekeeper residue as a key 
interaction, which contributes to their binding affinity.
260
 
   
                         224                                                                    225          
 
Ponatinib (Iclusig, 225), a third generation Bcr-Abl inhibitor, was approved by the 
FDA in December 2012. This compound was developed to include inhibition of the 
T315I mutant kinase in its profile, utilising an acetylene linker to bypass interaction 
with the gatekeeper threonine residue.
260
 Ponatinib potently inhibits the native enzyme 
and all other mutants tested.
260
  
                                           
6.2 EGFR Inhibitors 
 
A second group of marketed kinase inhibitors target EGF receptor kinases. Gefitinib 
(Iressa, 17) was approved in May 2003 for patients with NSCLC, followed in 2004 by 
erlotinib (Tarceva, 18). These agents are Type I kinase inhibitors with selectivity for 
the EGFR receptor (ErbB1) kinase over Her-2, despite high sequence identity between 
these two sub-types.
261
 The use of these agents has given an improvement of 25% in 
progression-free survival.
56
 However, resistance is common, with treatment often 
providing benefit for only a matter of months.
262
  
 
         
         17             18 
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6.2.1 Medicinal Chemistry Leading to the Discovery of Gefitinib (17) 
 
Gefitinib (17) was the first-in-class EGFR kinase inhibitor. The aminoquinazoline core 
was identified from a 3D computational search for structures that could satisfy a 
pharmacophore proposed for EGFR activity.
263
 This was developed from a 
computational model of the enzyme active-site, with features from both the tyrosine 
and ATP substrates being incorporated.
264
 Three features were selected based on their 
likely importance in the interaction between enzyme and substrate, and the confidence 
in their position in the model. Thus, the desired features were mimics of any of the 
non-bridging oxygen atoms of the ATP γ-phosphate, tyrosyl hydroxyl and tyrosyl 
aromatic ring. Once virtual hits had been identified, these were used to query a larger 
database using 2-dimensional molecular descriptors, which resulted in the discovery of 
4-(3-chloroanilino)quinazoline (226) as a 16 nM inhibitor of EGFR (Figure 6.2). Key 
SARs for activity were identified as the presence of electron-donating substituents at 
the 6- and 7-positions of the quinazoline, a free NH at the 4-position, and a small 
lipophilic group at the 3-position of the aniline. Substitution at the 2-, 5-, and 8-
positions of the quinazoline was detrimental. Replacement of the aniline chloro 
substituent by a methyl group and addition of two methoxy groups to the quinazoline 
core led to 227, a 5 nM inhibitor with a cellular growth inhibition IC50 of 50 nM in KB 
oral carcinoma cells.
264
 However, this compound was rapidly metabolised, resulting in 
a short pharmacokinetic half-life of one hour. Identification of the metabolites as 
arising from oxidation of the phenyl 4-position, and oxidation of the 3-methyl group 
on the phenyl ring led to the synthesis of analogues to block these metabolic routes, 
including 228. Compound 228 had an isolated enzyme IC50 of 9 nM, an IC50 of 80 nM 
in the cell growth assay, and a pharmacokinetic half-life in mouse of three hours.
264
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Figure 6.2: Key stages in the discovery of gefitinib (17). 
In an attempt to improve the in vivo activity of 228, modification of the alkoxy groups 
was investigated to tune the pharmacokinetic properties.
263
 A range of alkoxy 
replacements were introduced, with focus on incorporation of pendant basic centres 
that varied the basicity, lipophilicity and solubility. In vivo pharmacodynamic 
experiments indicated that a 24 hour duration of action may be necessary for optimal 
efficacy. Compounds were thus assessed both for potency and plasma concentration at 
a 6 hour time-point after dosing. Alkoxymorpholine derivatives provided potent 
compounds which achieved high plasma levels after 6 hours. Gefitinib (17), while not 
the most potent analogue, allowed a compound concentration of 70-fold the IC50 value 
to be maintained for 24 hours after a single 200 mg/kg dose. Table 6.2 outlines the 
molecular properties of gefitinib, showing it to be a moderately lipophilic compound 
with good ligand and lipophilic efficiency. 
 
EGFR IC50 
nM 
MW clogP clogD tPSA 
Å
2
 
HBD HBA LE LipE 
23 446 4.1 3.5 67 1 7 0.35 5.0 
Table 6.2: Molecular properties of gefitinib (17). 
140 
 
229 
Lapatinib (Tykerb, 229) is another 4-aminoquinazoline-derived kinase inhibitor, with 
dual activity against EGFR and Her-2 kinases, which is marketed for the treatment of 
breast cancer.
265
 This dual inhibition results in reduced signalling through both the 
PI3K and classical MAPK pathways. Lapatinib exhibits slow offset binding kinetics 
from the target, with a binding half-life of five hours, in contrast to gefitinib and 
erlotinib which have dissociative half-lives of under 10 minutes.
266
  
 
6.3 Inhibitors of VEGF, PDGF and Raf Kinases 
 
Tumours require angiogenesis to grow beyond 1-2 mm, and a third major group of 
marketed kinase inhibitors target the pro-angiogenic growth factor receptors VEGFR 
and PDGFR. Over-expression of VEGF is associated with many cancers including 
pancreatic, lung, prostate, and breast cancers, renal cell carcinoma, and melanoma.
267
  
           
                       230                                                          8     R = H 
                     231 R = F 
Sunitinib (Sutent, 230) was designed as a multi-kinase inhibitor, with the hypothesis 
being that inhibiting the VEGF and PDGF receptor kinase sub-types could provide a 
greater benefit than inhibition of either VEGFR or PDGFR alone.
268
 It is a Type II 
kinase inhibitor with an IC50 of less than 20 nM against VEGFR 1-3, PDGFR-β, c-Kit 
and Flt-3 kinases.
268
 Sunitinib and erlotinib have been used in combination in NSCLC 
to provide triple inhibition of signalling through the VEGF, PDGF and EGF 
receptors.
268
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Sorafenib (Nexavar, 8) is also a type II inhibitor of VEGFR-2 and 3 and PDGFR-β 
kinases, in addition to B-Raf, C-Raf, and c-Kit.
268
 This drug was originally designed 
as an inhibitor of the raf enzyme isoforms, as aberrant signalling through the classical 
MAPK pathway, of which raf is a key component, is observed in approximately 30% 
of human cancers.
269
 The inhibition of raf and VEGF family members by sorafenib 
results in its affecting the classical MAPK pathway at two distinct points in the 
signalling cascade. Regorafenib (Stivarga, 231), a close analogue of sorafenib 
differing by a single fluorine atom, was approved by the FDA in September 2012. 
Despite the small structural difference, the spectrum of kinase activity differs 
markedly, with regorafenib being significantly more potent against VEGFR-2, c-Kit, 
ret and p38 kinases than sorafenib.
270,271
 This leads to regorafenib having broader anti-
angiogenic properties than sorafenib while having similar activity against the classical 
MAPK pathway.
270
   
       
                         232                                                                233 
Axitinib (Inlyta, 232) is a type I ATP-competitive inhibitor of VEGFR kinases 1-3, 
that also has activity against c-Kit and PDGFR-β kinases.271 The inhibition of VEGFR 
2 and 3 reduces Akt phosphorylation and signalling through the classical MAPK 
pathway.
271
 Pazopanib (Votrient, 233) inhibits VEGFR kinases 1-3, PDGFR-α & β 
and c-Kit kinases, and is approved for renal cell carcinoma, while vandetanib 
(Zactima, 234) is an inhibitor of VEGFR-2 and ErbB1 kinases.
268
 
  
                               234                                                              235 
Carbozantinib (Cometriq, 235) is an inhibitor of VEGFR2 and c-Met that also inhibits 
Ret, Kit, Axl, and Flt3 kinases, all of which have been implicated in tumour 
development. It was approved for the treatment of medullary thyroid cancer in 
142 
November 2012.
272
 The simultaneous inhibition of multiple kinases from key tumour 
survival, metastasis, and angiogenesis pathways is thought to result in a greater 
reduction in invasiveness and metastases than single activity agents.
273
 
 
6.3.1 Medicinal Chemistry Leading to the Discovery of Sorafenib (8) 
 
An HTS of 200,000 compounds led to the identification of hit compound 236, which 
inhibited Raf-1 with an IC50 of 17 μM (Figure 6.3).
269
 Addition of a methyl group to 
the 4-position of the phenyl ring (237) resulted in a 10-fold potency improvement, but 
an analogue synthesis campaign failed to identify compound with an IC50 of below 1 
μM. A one-thousand compound bis-arylurea library was screened, from which the 
isoxazole urea (238) emerged as an alternative template. Introduction of a nitrogen 
atom into the distal phenyl ring resulted in 4-pyridyl analogue 239, which improved 
potency (IC50 = 230 nM). This compound was orally available in mice, and 
demonstrated in vivo inhibition of tumour growth in a tumour xenograft model using 
the HCT116 human colorectal carcinoma cell-line.
269
 
Figure 6.3: Key stages in the discovery of sorafenib (8). 
Further SAR studies established that the urea was essential, but that the isoxazole 
heterocycle could be replaced. A disubstituted phenyl ring provided improved 
potency, and addition of a polar group to the pyridyl ring resulted in the discovery of 
sorafenib (8), having an IC50 against Raf-1 kinase of 6 nM. Sorafenib also inhibited 
wild type and V600E mutant B-raf kinase (IC50 = 38 nM). The VEGF1 (IC50 = 26 nM) 
and VEGF2 (IC50 = 90 nM) kinases were also inhibited along with p38 (IC50 = 38 
nM), c-Kit (IC50 = 68 nM) and Flt-3 (IC50 = 33 nM).
269
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When sorafenib was co-crystallised with Raf, the pyridyl carboxamide was found to 
undergo a bidentate interaction with the hinge region of the kinase. The urea forms 
hydrogen bonds with the backbone of an aspartate residue in the DFG loop, and 
another with a glutamate side-chain. The terminal di-substituted phenyl group is 
buried in a hydrophobic pocket formed by two helices and regions of the DFG and 
catalytic loops.
269
 Table 6.3 outlines the molecular properties of sorafenib, showing it 
to have relatively high lipophilicity, good ligand efficiency and moderate lipophilic 
efficiency. 
 
Raf-1 IC50  
nM 
MW clogP clogD tPSA 
Å
2
 
HBD HBA LE LipE 
6 464 3.9 3.9 92 3 7 0.36 3.4 
 
Table 6.3: Molecular properties of sorafenib (8). 
 
6.4 Other Classes of Marketed Kinase Inhibitors 
 
The scope of the kinases targeted by marketed inhibitors has been expanded by the 
recent approval of four further drugs. Vemurafenib (Zelboraf, 9) is an inhibitor of the 
V600E B-Raf mutant, and approved for non-resectable or metastatic melanoma.
274
 The 
therapeutic effect is a result of direct inhibition of the classical MAPK pathway.  
 
              
                        9                                                                       240 
Crizotinib (Xalkori, 240) is an inhibitor of the Alk and c-Met kinases approved for 
non-small cell lung carcinoma (NSCLC).
275
 Over-expression of c-Met, also known as 
the hepatocyte growth factor receptor (HGFR), correlates with metastatic progression 
or poor prognosis in several cancers, and has also been found to affect cell survival, 
angiogenesis, and invasion.
275
 Anaplastic lymphoma kinase (Alk) is a member of the 
insulin receptor family of receptor tyrosine kinases. Chromosomal rearrangements 
144 
forming several Alk fusion proteins have been observed in many cancers; for example 
a translocation forming an Alk-Npm (nucleophosmin) hybrid results in oncogenic 
signalling.
276
  
 
Ruxolitinib (Jakafi, 241) is an inhibitor of janus kinase 2 (Jak-2) approved in 2012 for 
myelofibrosis, and may be also used as a treatment for other myeloproliferative 
diseases where a V617F mutation in Jak-2 causes constitutive activation.
277
 The 
structurally related Jak-3 inhibitor tofacitinib (Xeljanz, 242) became the first kinase to 
be approved for a non-cancer indication in 2012.
278
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6.4.1 Medicinal Chemistry Leading to the Discovery of Crizotinib (240)  
 
Crizotinib (240) was designed as an inhibitor of c-Met kinase. The starting point for 
the discovery program was a high molecular weight c-Met inhibitor based on an 
oxindole scaffold (Figure 6.4, 243). This lead was a potent Met inhibitor (IC50 = 9 
nM), but suffered from sub-optimal physicochemical properties, having a molecular 
weight of 641, poor solubility, high metabolic turnover and low membrane 
permeability.
276
 Crizotinib was designed using a structure-based approach aiming to 
reduce lipophilicity and identify a lower molecular weight hinge binding motif to 
increase binding efficiency. Examination of co-crystal structures of leads bound to a 
Met kinase domain construct guided compound design. Lipophilic efficiency (LipE or 
LLE)
279,280
 was also a key parameter which guided optimisation. An ambitious 
template re-design was undertaken based on the binding mode observed in the crystal 
structure, leading to an aminopyridine replacing the oxindole scaffold, that enabled 
positioning of the distal portions of the lead to be replicated by substitution from this 
simplified core.
276
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Figure 6.4: Key stages in the discovery of crizotinib (240). 
From the first set of compounds prepared in this scaffold, 244, a compound with 460 
nM potency against Met was discovered. The substituents from this core were re-
investigated, with an optimal tri-halogenated substitution pattern on the benzyl ring 
initially being identified. Structure-based design guided the incorporation of a small 
lipophilic methyl group on the benzyl linker, which provided a potency benefit (245). 
The pyridyl 5-substituent projected into the solvent exposed surface of the kinase, and 
a range of polar groups were introduced at this position, with pyrazolopiperidine 240, 
(crizotinib), giving the best overall balance of properties.
276
 Table 6.4 shows the 
molecular properties of crizotinib, confirming it as a potent, moderately lipophilic 
compound with excellent ligand efficiency and LipE. 
 
Met IC50  
nM 
MW clogP clogD tPSA  
Å
2
 
HBD HBA LE LipE 
2 450 4.7 2.3 75 3 6 0.41 6.4 
 
Table 6.4: Molecular properties of crizotinib (240). 
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6.5 Summary 
 
It is notable that high selectivity for the target for which the drug was initially 
designed is rarely achieved. Secondary off-target pharmacology in many agents has 
proven to be advantageous, providing wider scope for their use in other cancer types 
than those originally targeted. This is clearly dependent on the nature of the secondary 
targets inhibited, but indicates that during optimisation of a kinase inhibitor, activity 
against other kinase targets should be investigated further, and that the advantages and 
disadvantages of any observed polypharmacology should be carefully considered 
during compound selection. Second- and third-generation agents in each class have 
primarily attempted to address resistance developed to the first-in-class agent, often 
arising through point mutations in the drug’s binding site in the kinase.  
 
6.6 In Vitro ADMET Data and Human Pharmacokinetics of Approved 
Kinase Drugs 
 
Examination of the new drug application (NDA) reports for the kinase inhibitors in 
clinical use (Table 6.5), in conjunction with the above analyses, reveals some 
interesting trends. A large proportion of these drugs contain a basic centre. This was 
often introduced to improve pharmaceutical properties including solubility, but also 
leads to high volumes of distribution which contribute to the long human 
pharmacokinetic half-lives often achieved.  
Common metabolic pathways involve dealkylation of amines and phenols, or 
formation of N-oxide metabolites. Inhibition of cytochrome P450 enzyme isoforms is 
also common in the approved kinase drugs dataset. A significant number of the drugs 
are substrates for efflux transporters but this does not appear to substantially limit their 
oral bioavailability. However, this is a potential mechanism for the development of 
resistance through over-expression of the relevant transporter proteins. Many of the 
marketed agents also inhibit the hERG ion channel, and adversely affect the cardiac 
QTc interval.   
   
 Table 6.5: Summary of ADMET properties of Approved Kinase Drugs.  
 
Kinase 
Inhibitor 
Human 
PK T1/2 h 
Human 
F % 
hERG IC50  
M 
QTc
a 
Transporter 
Effects 
Major metabolic 
route 
Cyp inhibition 
Imatinib
281
 18 98 n.a. N Caco-2 
ER = 54 
N-demethylation - 
Dasatinib
282
 3-6 14-34 14.3 Y Caco-2 
ER = 2 
N-oxidation, 
N-dealkylation 
Cyp 3A4 inhibitor 
Nilotinib
283
 17 30 0.13 Y P-gp substrate Hydroxylation Multiple Cyp inhibitor 
Bosutinib
284
 19-30 n.a. 0.3 N P-gp substrate Oxydechlorination, 
N-demethylation and 
N-oxidation 
- 
Ponatinib
285
 24 n.a. 2.3 Y P-gp and BCRP 
inhibitor 
N-demethylation - 
Gefitinib
286
 25-85 60 ca. 1 M Y Caco-2 
ER = 12 
O-demethylation Cyp 2D6 inhibitor 
Erlotinib
287
 36 59 IC20 = 3 M N P-gp substrate O-demethylation Cyp 1A1, 3A4 and 2C8 
inhibitor 
Lapatinib
288
 6-24 <25 n.a. Y P-gp and BCRP 
substrate 
Multiple oxidised  
metabolites 
Cyp 3A4 and 2C8 inhibitor 
Sunitinib
289
 40-60 n.a. 0.27 Y n.a. N-deethylation - 
Sorafenib
290
 25-48 n.a. >10 N n.a. N-oxidation Multiple Cyp inhibitor 
Regorafenib
291
 14-58 n.a. >10 N Caco-2 
ER = 0.8 
N-oxidation Multiple Cyp inhibitor 
Axitinib
292
 2-5 58 >10 N Caco-2 
ER = 10 
BCRP and P-gp 
substrate 
N-glucuronide 
and sulfur oxidation 
Cyp 1A2 and 2C8 inhibitor 
Pazopanib
293
 18-53 14-39 >10 N Caco-2 
ER = 5 
BCRP and P-gp 
substrate 
Biliary clearance of 
parent 
Multiple Cyp inhibitor 
 
 
1
4
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 Table 6.5: Summary of ADMET properties of Approved Kinase Drugs (continued). 
Kinase 
Inhibitor 
Human 
PK T1/2 h 
Human 
F % 
hERG IC50 
M 
QTc
a 
Transporter
Effects 
Major metabolic route Cyp inhibition 
Vandetanib
294
 19 d n.a. Metabolites 
inhibit hERG 
Y Caco-2       
ER = 0.8 
Demethylation and N-
oxidation 
Cyp 2D6 inhibitor, 1A2, 2C9, 
3A4 inducer 
Vemurafenib
295
 57 “Low” 1.25 Y Caco-2 
ER = 1.3  
Biliary clearance of 
parent 
Inhibitor and inducer of 
multiple Cyps 
Crizotinib
296
 42 43 n.a. Y Caco-2 
ER >20 
Oxidation to lactam and 
O-dealkylation 
Inhibitor and inducer of Cyp 
3A isoforms 
a
 Prolongation of cardiac QTc interval observed in pre-clinical or clinical setting; n.a. = Data not available from FDA new drug approval 
reports; FDA reports not available for carbozantinib, ruxolitinib and tofacitinib. 
 
1
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6.7 Comparison of the Molecular Properties of ERK5 Lead Compounds 
with Approved Kinase Inhibitors 
 
Examining the physicochemical properties of kinase inhibitors that have reached the 
market may help define the chemical property space occupied by successful inhibitors of 
this target class. Comparison with the physicochemical properties of the pyrrole 
carboxamide lead compounds can inform the lead optimisation process, allowing potential 
targets to be assessed as to whether they fall inside or outside of precedented kinase drug 
space. While compounds outside of this chemical space are not destined to fail per se, and 
those that lie inside are not guaranteed to succeed, confidence in the likelihood of 
developing a successful kinase drug is increased if the optimised compounds have 
physicochemical properties in a similar range to those that have previously been 
successfully developed.   
To this end, the physicochemical and structural properties of the kinase drugs marketed for 
cancer treatment from 2001-2012 were determined using the Stardrop
TM
 program. 
Properties selected were molecular weight (MW), clogP, clogD, number of hydrogen bond 
acceptors (HBA), number of hydrogen bond donors (HBD), topological polar surface area 
(tPSA), number of rings present, (ring count), and the rotatable bond count.  
The value of a property for each drug was assigned to a bin, allowing a histogram of the 
distribution of each property across all of the drugs to be generated. For non-continuous 
parameters (HBA, HBD, ring count), the bins reflect the absolute values of the property.  
The same physicochemical properties were then generated for the benchmark pyrrole 
carboxamide lead, 212 (Table 6.6).  
 Property Value 
 
212 
MW 363 
clogP 2.6 
clogD 1.3 
tPSA (Å
2
) 65 
HBA 5 
HBD 2 
Rotatable bonds 5 
Ring count 3 
Table 6.6: The molecular properties of benchmark pyrrole carboxamide 212 
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The value of each property for compound 212 is overlaid onto each histogram as a red line. 
Thus, it can quickly be determined where the lead compound lies relative to precedented 
kinase drug chemical space, as defined by this process. For parameters where the property 
of the lead is towards the lower end of the range, confidence was gained that there was 
scope to design analogues where the value of this property was increased. The conclusions 
drawn from analysis of each of the properties follow: 
 
6.7.1 Molecular Weight 
 
Figure 6.5: Histogram of molecular weights of marketed kinase inhibitor drugs. The red 
line indicates the molecular weight of pyrrole carboxamide lead 212.  
 
It is clear from figure 6.5 that the molecular weight of 212 is towards the lower end of the 
range for kinase drugs. The only two marketed kinase inhibitors having lower molecular 
weight are the recently approved Jak inhibitors, ruxolitinib (241, MW = 306) and 
tofacitinib (242, MW = 311). Minimising the molecular weight of a compound offers 
advantages for compound absorption,
297
 and often correlates with an increased chance of 
progressing through the drug development pipeline.
298
 However, it was clear that there was 
scope to increase the molecular weight of 212 during the optimisation process. Subsequent 
compound design was thus aimed at preparing 90% of future compounds having a 
molecular weight below 500, and attempting to reduce the molecular weight to a minimum 
where possible.  
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6.7.2 Lipophilicity 
 
Two calculated measures of lipophilicity were examined, namely clogP and clogD. clogP 
is an estimate of the inherent lipophilicity of the unionised compound, whereas clogD 
incorporates the effect of the ionisation state of the compound at pH 7.4. Calculated values 
may not accurately reflect the experimentally measured logD values, but are useful in 
compound design as they can be determined computationally prior to compound synthesis.  
 
Figure 6.6: Histogram of the clogP values of marketed kinase inhibitor drugs. The red line 
indicates the clogP of pyrrole carboxamide 212.  
 
The marketed kinase drugs spanned a wide range of clogP values (figure 6.6), with no 
clear clustering of marketed drugs in any clogP bin. The clogP of 2.6 for 212 is at the 
lower end of the range covered by marketed inhibitors. However, the distribution of clogD 
values in the drug dataset (figure 6.7) showed that the majority of kinase drugs have a 
clogD between 2 and 4, with only 3 compounds lying outside of this range. Thus it appears 
that the clogD of a compound may be the more important lipophilicity measure to consider 
during compound optimisation; hence analogues with a clogD in the range 2 to 4 were 
targeted. 
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Figure 6.7: Histogram of the clogD values of marketed kinase inhibitor drugs. The red line 
indicates the clogD of pyrrole carboxamide 212.  
 
6.7.3 Hydrogen Bonding Groups 
 
Three measures of hydrogen bond interactions were included in this analysis; tPSA, HBD 
and HBA. Relationships between the presence of hydrogen bonding groups and the ability 
to cross cell membranes have been observed in several studies.
299,300
 With kinase targets 
having intracellular drug binding sites, attaining good cell penetration is essential for a 
successful drug. The tPSA is a simplified polar surface area calculation based on the 2 
dimensional structure of a compound, which does not take into account 3-dimensional 
conformational effects.
299
 However, it has been shown to correlate with the more time 
consuming calculation of polar surface area based on the 3-dimensional structure of a 
compound. tPSA is calculated computationally by adding together tabulated contributions 
of the polar fragments contained in a molecule. It is essentially an estimate of the total 
surface area of a molecule which is available to participate in hydrogen bonding with a 
polar solvent such as water.    
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Figure 6.8: Histogram of the tPSA values of marketed kinase inhibitor drugs. The red line 
indicates the tPSA of pyrrole carboxamide 212.  
 
The majority of members of the kinase drug dataset have a tPSA between 60 and 100 Å
2 
(figure 6.8), with only two examples having a tPSA above 120 Å
2
. Compound 212 has a 
tPSA of 65 Å
2
, which is towards the lower end of the range, suggesting that there is scope 
to introduce further heteroatoms and moderately increase the tPSA during compound 
optimisation.    
 
a.                                                                b. 
Figure 6.9: Histogram of the a) HBD and b) HBA parameters of marketed kinase inhibitor 
drugs. The red line indicates the respective values of pyrrole carboxamide 212.  
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The majority of the marketed kinase inhibitor drugs have less than three hydrogen bond 
donors (Figure 6.9a). A design criterion was thus defined that minimising the hydrogen 
bond donor count was preferable, and the majority of targets would be limited to a 
maximum of three hydrogen bond donors. Lead 212 has two hydrogen bond donors, 
suggesting that no more than one further hydrogen bond donor should be added during 
compound optimisation.  
The range of hydrogen bond acceptors varied more widely across the drug dataset (Figure 
6.9b), with a maximum of nine and a minimum of five being represented. Pyrrole 212 has 
five hydrogen bond acceptors. This analysis suggests that increases in tPSA through 
introduction of hydrogen bond acceptors may be better tolerated than through additional 
hydrogen bond donors. 
6.7.4 Ring Count and Rotatable Bond Count 
 
Ring count and rotatable bond count are intended as surrogates for the flexibility of a 
molecule. A flexible molecule can access more conformations than a more rigid molecule 
of a similar molecular weight. The ability to readily achieve alternative conformations may 
increase the chance of a molecule being able to adopt a conformation whereby it can bind 
to secondary targets, increasing the probability of off-target effects. Flexibility may also be 
detrimental to the binding affinity of a compound, due to an entropic loss on binding.  
 
Figure 6.10: Histogram of the rotatable bond count of marketed kinase inhibitor drugs. 
The red line indicates the rotatable bond count of pyrrole carboxamide 212.  
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The number of rotatable bonds in the drug dataset varied between 5 and 11 (Figure 6.10), 
with 212 again occupying the lower end of this range, indicating that it is relatively rigid 
for a kinase inhibitor, and that increased flexibility may be tolerated.  
 
Figure 6.11: Histogram of the ring count of marketed kinase inhibitor drugs. The red line 
indicates the ring count of pyrrole carboxamide 212.  
 
The number of rings present in kinase drugs ranges from three to five (Figure 6.11), and 
this analysis indicates that addition of a further ring during optimisation may be possible. 
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6.8 Summary 
 
The above analyses have been compressed into a spider plot (Figure 6.12), where the green 
area depicts the range of properties currently occupied by successful kinase drugs, with the 
properties of 212 superimposed in red. This clearly indicates scope for increasing the value 
of most of the parameters during the optimisation of the pyrrole carboxamide lead 
compounds. 
 
Figure 6.12: Spider plot of molecular properties of marketed kinase inhibitors (green area) 
in comparison with the properties of pyrrole 212 (red line). 
 
The target physicochemical properties for the majority of analogues designed in the 
optimisation of the pyrrole carboxamide series were thus defined as shown in table 6.7. 
 
MW clogD tPSA Å
2
  HBA HBD Rot bonds Ring count 
<500 2-4 60-100 ≤ 3 ≤ 9 ≤ 11 ≤ 5 
 
Table 6.7: Target molecular properties for analogues during the optimisation of the pyrrole 
carboxamide series.  
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Chapter 7: ERK5 SARs and Biological Results 
 
 
7.1 Class 1: Heterocyclic Aliphatic Amides 
 
Compound 212 was the most potent analogue at the start of my involvement in the ERK5 
project. A summary of the profile of this compound is given in Table 7.1. 
 ERK5 IC50
a
  199  68 nM 
             
212 
HLM Clint  <5 L/min/mg 
MLM Clint 8 L/min/mg 
Caco-2 AB  3.8 × 10
-6
 cm s
-1
 
Caco-2 ER 9 
Cl   91 ml/min/kg 
F <10% 
  a
 Determination  standard deviation 
Table 7.1: ERK5-inhibitory activity, and selected in vitro and in vivo pharmacokinetic 
parameters for 212. 
 
 
 
For the design of analogues of compound 212, three parameters were selected for 
improvement: ERK5 potency, metabolic stability, and absorption. The docking of this 
compound into the ATP-binding site from the published ERK5 co-crystal structure
247
 
suggested that the piperidine N-substituent may project out of the binding pocket towards 
the solvent-exposed surface of the protein. Exploration of this region of the template had 
not previously been extensively undertaken, although two existing compounds, 246 and 
247, retained ERK5 potency, indicating that the binding site of ERK5 may accommodate 
larger substituents at this position. This was therefore investigated as a region where 
variation might allow modulation of pharmacokinetic parameters. 
                    
                            246     247 
               ERK5; IC50 1.5 M                                ERK5; IC50 = 2.9  0.7 M 
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7.1.1 Reducing Metabolic Liability  
 
The in vitro microsomal stability data (MLM Clint = 8 L/min/mg protein), and the mouse 
in vivo unbound clearance (Clu = 284 ml/min/kg) of compound 212, suggested that it was 
not highly susceptible to metabolism. However, in vivo, 212 was cleared with an extraction 
ratio of approximately 100% by the liver (Clp = 91 ml/min/kg; mouse liver blood flow = 
90-110 ml/min/kg). The high free fraction in blood (Fu = 0.32) contributes to the high 
observed total plasma clearance. Thus, in order to improve the bioavailability, a further 
reduction in the unbound clearance would be beneficial. 
Metabolite identification studies were not available to guide compound design. However, 
cytochrome P450 mediated N-dealkylation and N-oxidation are both known mechanisms of 
metabolism of tertiary amines, and were prevalent pathways observed in the metabolism of 
the tertiary amine containing kinase inhibitor drugs including imatinib,
301
 ponatinib,
302
 
sunitinib,
303
 and vandetanib.
294
 Altering the steric character of the environment around the 
nitrogen atom may affect the propensity for metabolism at this position.
304
 Variation of the 
N-substituent was therefore of potential benefit in reducing metabolic turnover of 212. 
Targets were thus designed to investigate the effect of sterically hindering the exocyclic α-
carbon atom, and introducing nitrogen substituents that cannot undergo α-oxidation.  
 
7.1.2 Strategies for Improving Membrane Flux 
 
The Caco-2 cell-line used to assess membrane permeability in vitro is a colon cancer cell-
line that expresses multiple transporters. The transporters vary between cell bank sources, 
but include P-glycoprotein (P-gp, multidrug resistance protein 1 (MDR1)), breast cancer 
resistance protein (BCRP), and peptide transporter 1 (PEPT1).
305
 P-gp is a member of the 
ATP-binding cassette (ABC) family of proteins and is the most studied of these efflux 
transporters. It is localised on the apical membrane of gut epithelial cells and in the blood 
brain barrier (BBB), and has a physiological role to prevent undesirable compounds from 
passing through these membranes.
306
 
Functional groups which contain hydrogen bond donor groups have been found to increase 
P-gp recognition, such as primary and secondary amides, sulfonamides, alcohols, 
carboxylic acids, and ureas.
307
 One strategy to reduce P-gp mediated efflux is to minimise 
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the number of HBDs in the molecule. Another approach is to introduce hydrogen bond 
acceptor groups into positions that can form intramolecular hydrogen bonds with a 
hydrogen bond donor,
308
 masking some of the hydrogen bonding character of the molecule. 
This strategy is limited by the structural topology of the template, and the tolerance of the 
primary pharmacology SARs to such structural modifications.  
 
Topological polar surface area
299
 (tPSA) is a further parameter that has been shown to have 
a relationship with P-gp recognition, and minimising tPSA is another strategy for reducing 
P-gp-mediated efflux.
307
 Compounds with a tPSA below 60 Å
2
 have been shown to have a 
high probability of good membrane penetration, with those having a tPSA of over 140 Å
2
 
having a low probability.
309
 Compounds containing basic centres that are significantly 
protonated at physiological pH are more susceptible to P-gp-mediated efflux, and the tPSA 
threshold for recognition by P-gp may be lower in basic than in neutral compounds.
307
 
Thus, reducing the basicity of the template, or removing the basic centre, may mitigate the 
risk of P-gp-mediated efflux. An example of a successful implementation of this tactic is 
observed by a comparison of desloratidine (248) and loratidine (249) (Table 7.2).
307
  
 
Cmpd R MW clogP pKa PSA Å
2 
Caco-2 ER 
248 H 310 6.8 10.3 25 9.1 
249 CO2Et 382 5.9 4.3 42 1.9 
 
Table 7.2: An example of the effect of a basic amine on drug efflux.
307
 
 
 
Desloratidine (248) has a basic pKa of 10.3, and an efflux ratio of 9.1 in a Madin-Darby 
Canine Kidney (MDCK) cell line. Substitution of the secondary amine with an 
ethoxycarbonyl group in loratidine (249) renders the piperidine nitrogen essentially non-
basic under physiological conditions, with a resultant reduction in efflux ratio to 1.9.
307
 
Pyrrole carboxamide 212 has a low tPSA (65 Å2), and contains two hydrogen bond donors. 
While only the pyrrole NH is essential for ERK5 activity, the amide NH cannot easily be 
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replaced, since methylation of the amide resulted in a 10-fold reduction in the ERK5 IC50 
(212 and 250).  
 
212 R = H   ERK5; IC50 = 0.20  0.07 M 
250 R = Me ERK5; IC50 = 2.47  0.38 M 
 
  
Thus, the first strategy employed in an attempt to reduce efflux in the Caco-2 assay was to 
introduce nitrogen substituents expected to reduce the pKa of the basic centre. 
7.1.3 Variation of the Piperidine N1-Substituent of 212 
 
The compounds in table 7.3 were designed and synthesised with the aim of addressing 
either or both of the issues of metabolic stability and membrane permeability, including 
derivatives increasing the steric bulk of the piperidine N
1
-alkyl chain (252-254), and 
analogues which reduce the pKa of the piperidyl nitrogen (254-258). Analogues 255-258 
increase the number of hydrogen bond acceptors in the molecule, and consequently result 
in increased tPSA. 
 
Cmpd R MW clogP clogD tPSA Å
2
 HBA HBD 
251 H
 
349 2.3 0.9 74 5 3 
212 Me
 
363 2.6 1.4 65 5 2 
252 Et 377 3.0 1.7 65 5 2 
253 i-Pr 391 3.4 1.9 65 5 2 
254  389 3.3 1.8 65 5 2 
255 Ac 391 2.0 2.0 82 6 2 
256 SO2Me 427 1.9 1.9 99 7 2 
257 
 
427 3.4 1.8 86 7 2 
258 Boc 449 4.2 4.2 92 7 2 
Table 7.3: Structures and molecular properties of N
1
-substituted piperidine amides. 
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Diverse substitution of the piperidyl nitrogen was found to have little effect on ERK5 
inhibitory potency (Table 7.4), with the majority of N
1
-substituted derivatives having an 
IC50 within 3-fold of 212. The tert-butyl carbamate (258) was tolerated, resulting in only a 
5-fold reduction in potency, consistent with the hypothesis that this substituent points 
towards the solvent exposed surface of the protein. However, these compounds did not 
achieve the IC50 threshold of 150 nM required to trigger generating Caco-2 and 
microsomal stability data.  
 
Cmpd R ERK5 IC50
b
 nM 
251 H
a 
487  40 
212 Me
a 
198  68 
252 Et 437  109 
253 i-Pr 657  85 
254  360  87 
255 Ac 458  182 
256 SO2Me 297  29 
257 
 
263  57 
258 Boc
a 
1078  422 
                                                                                  a 
Existing compounds previously prepared                  
                                                                by Dr Stephanie Myers. 
                                                                                                    b
 Determination  standard deviation 
Table 7.4: ERK5 inhibitory activity of N
1
-substituted piperidine amides.  
 
However, in parallel with this work, a co-worker identified 2,5-dichloro-6-fluorobenzoyl 
as an alternative substituent at the pyrrole 4-position which conferred improved ERK5 
inhibition relative to the 2-chloro-6-fluorobenzoyl group. Compounds containing a sub-set 
of the piperidine N
1
-substituents in combination with the 2,5-dichloro-6-fluorobenzoyl-
substituted pyrrole scaffold were prepared, resulting in a potency improvement of up to 10-
fold (Table 7.5).  
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Cmpd R ERK5 IC50
a
 nM 
X = Cl 
IC50 Ratio 
X=H/X=Cl 
259 Me 115 1.7 
260 H 82  30 10 
261 Ac 88  53 5.8 
262 SO2Me 143  60 3.5 
263 Boc 1354  683  1.3 
                                                                                                        a
 Determination  standard deviation 
Table 7.5: ERK5 inhibitory activity of N
1
-substituted piperidine amides. 
 
Compounds 259-262 were progressed to in vitro ADME assessment, exhibiting good 
stability in human and mouse liver microsomes, but increased plasma protein binding 
relative to 212 (Table 7.6). Acetamide 261 was assessed in the Caco-2 permeability assay, 
and found to have a high efflux ratio, suggesting that, despite the absence of a basic centre, 
the compound was still a substrate for transporter pumps.  
 
Cmpd R X MLM
Clint
a
 
HLM 
Clint
a
 
Ppb 
Fu 
Sol  
M 
Caco-2      
AB
b
 (ER) 
212 Me H <5 8 0.32 >100 4 (9) 
259 Me Cl <5 <5 0.02 3-20 n.d. 
260 H Cl <5 <5 0.04 >100 n.d. 
261 Ac Cl <5 <5 0.02 >100 3 (16) 
262 SO2Me Cl <5 <5 0.02 30-100 n.d. 
                 a L/min/mg protein; b Papp 10
-6
 cm s
-1
; n.d. = not determined.  
Table 7.6: In vitro ADME data for N-substituted piperidine amides.  
 
A literature review identified an example of replacement of an acetamide (264) with 
fluorinated amides (265-268) which affected Caco-2 efflux. The trifluoroacetamide (265) 
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resulted in a significant reduction in P-gp mediated efflux (Table 7.7).
310
 This observation 
inspired the design and preparation of trifluoroacetyl-substituted piperidine 269.  
 
Cmpd R Caco-2 ER 
264 Me 8.6 
265 CF3 2.3 
266 CF2CF3 1.4 
267 CHF2 3.2 
268 CH2CF3 8.6 
 
 
Table 7.7: Case study of the effect of fluorination of an acetamide substituent on the Caco-
2 efflux ratio.
310
     
            
Introduction of a trifluoroacetamide group into the piperidine N
1
-position of 212 proved 
successful in improving membrane permeability, with the efflux ratio in the Caco-2 assay 
for 269 being reduced to 1.1, and high membrane flux being observed. This observation is 
consistent with the effect reported for the literature series, and suggests that fluorination 
alpha to carbonyl groups may have a more general application for reducing a compound’s 
efflux liability. It is possible that the electronic effect of the trifluoromethyl group on the 
hydrogen bond acceptor ability of the carbonyl group plays a part in reducing the 
recognition of the compound by efflux pumps. Unfortunately, the ERK5 inhibitory potency 
of 269 was significantly reduced relative to acetamide 261. 
 
Compound ERK5 IC50 
nM 
MLM 
Clint
a
 
Sol 
M 
Caco-2 
AB
b
 (ER) 
269 521  224 30 30-100 19 (1.1) 
                                a L/min/mg protein. b Papp 10
-6
 cm s
-1
. 
Table 7.8: ERK5 inhibitory activity and in vitro ADME data for 269. 
  
Due to the lack of success in achieving an acceptable balance of potency and low efflux in 
the Caco-2 assay, focus turned to optimisation of the heteroaromatic amide series.   
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7.2 Class 2: Heteroaromatic Amides 
7.2.1 Pyrimidine Amide-Linked Analogues 
 
In progressing the heteroaromatic amide series the main aim was to improve the potency of 
lead compound 215.  
 
215 ERK5; IC50 = 403  91 nM  
Diversification at the 2-position of the pyrimidine was synthetically amenable (see section 
8.2) and was the first position explored. Previous SARs had shown that substitution of this 
position with a methyl group (217, table 5.6) led to a 3-fold reduction in ERK5 potency. 
Examination of 215 modelled in the ERK5 ATP-binding site from the literature co-crystal 
structure,
247
 suggested that substituents at this position may project towards the solvent 
exposed surface of ERK5. A small library of heteroatom-linked 2-substituted pyrimidyl 
derivatives (271-276) was prepared to explore the effect of elaboration at this position on 
ERK5 inhibition. The molecular properties of these analogues are shown in Table 7.9. 
 
Cmpd R X MW clogP clogD tPSA Å
2
 HBA HBD 
215 
270 
H 
H 
H 
Cl 
344 
379 
3.3 
4.0 
3.3 
4.0 
88 
88 
6 
6 
2 
2 
217 Me H 358 3.6 3.6 88 6 2 
271 OMe H 374 3.2 3.2 97 7 2 
272 NHMe H 373 2.8 1.4 100 7 3 
273 NMe2 H 387 3.2 1.6 91 7 2 
274 
 H 
413 3.6 2.0 91 7 2 
275 
276  
H 
Cl 
442 
477 
2.8 
3.4 
1.9 
2.4 
94 
94 
8 
8 
2 
2 
Table 7.9: Structures and molecular properties of 2-substituted pyrimidine amides. 
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Substitution with methoxy (271) and small alkylamines (272-274) reduced ERK5 binding 
affinity (Table 7.10). Pyrrolidine analogue 274 also exhibited reduced aqueous solubility, 
with evidence of precipitation under the assay conditions. A breakthrough was made with 
N-methylpiperazine 275, which resulted in a 6-fold increase in potency relative to 215. 
Combination with the trihalogenated aromatic ring gave derivative 276, having a further 
two-fold improvement in potency. 
 
Cmpd R X ERK5 
IC50
a
 nM 
L.E. LipE 
215 
270 
H
 
H 
H 
Cl 
403  91 
315  368 
0.37 
0.36 
3.1 
2.5 
217 Me
 H 1185  619 0.33 2.3 
271 OMe H 790  180 0.33 2.9 
272 NHMe H 1748  212 0.31 4.4 
273 NMe2 H 3478  169 0.28 3.9 
274 
 
H 4109  1354 0.26 3.4 
275 
276  
H 
Cl 
72  10 
37  17 
0.32 
0.32 
5.2 
4.9 
                                    a
 Determination  standard deviation 
Table 7.10: ERK5 inhibitory activity of 2-substituted pyrimidine amides.  
 
 
Possible binding interactions between the piperazine and the protein include the basic 
nitrogen interacting with an acidic amino acid side-chain (Asp or Glu) through a charge-
charge interaction. Alternatively, the protonated amine may act as a hydrogen bond donor 
to side-chain or backbone hydrogen bond acceptors, or may interact with aromatic residues 
through –cation interactions. Unprotonated piperazine may also serve as a hydrogen bond 
acceptor, interacting with a hydrogen bond donor in the protein. Analogues 279-282 were 
therefore designed and prepared to investigate the potential role of the basic piperazine 
nitrogen (Table 7.11).  
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Cmpd R X MW clogP clogD tPSA Å
2
 HBA HBD 
275 
276  
H 
Cl 
442 
477 
2.8 
3.4 
1.9 
2.4 
94 
94 
8 
8 
2 
2 
279 
280  
H 
Cl 
429 
464 
3.1 
3.7 
2.0 
2.5 
100 
100 
8 
8 
2 
2 
281 
282  
H 
Cl 
443 
478 
3.1 
3.7 
1.5 
2.0 
111 
111 
8 
8 
3 
3 
283 
284  
H 
Cl 
485 
520 
3.7 
4.3 
1.9 
2.4 
117 
117 
9 
9 
2 
2 
 
Table 7.11: Structures and molecular properties of 2-substituted piperidine amides. 
 
The ERK5 inhibitory activity of morpholine analogues 279 and 280 (Table 7.12) was 
significantly reduced relative to 275 and 276, suggesting that the presence of a hydrogen 
bond acceptor at this position was not able to replicate the interactions of the piperazine. 
The 4-hydroxypiperidine analogues 281 and 282 position a hydrogen bond donor in the 
vicinity of the basic centre of 275, and were also much less potent than the piperazine 
analogues. Acetoxypiperidines 283 and 284, prepared as intermediates en route to 281 and 
282, probed the effect of an alternative hydrogen bonding motif in this region of space, and 
were again less potent than 275 and 276. Thus, the improved potency observed for 275 and 
276 appeared to be due to the basic nature of the piperazine nitrogen.   
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Cmpd R X ERK5 
IC50
a
 nM 
L.E. LipE 
275 
276  
H 
Cl 
72  10 
37  17 
0.32 
0.32 
5.2 
4.9 
279 
280  
H 
Cl 
2081  226 
1508  230 
0.30 
0.29 
4.4 
3.8 
281 
282  
H 
Cl 
2232  427 
536  89 
0.29 
0.28 
4.9 
4.3 
283 
284  
H 
Cl 
5385 
9661  7320 
0.26 
0.25 
4.4 
3.9 
                                              a
 Determination  standard deviation 
Table 7.12: ERK5 inhibitory activity data for 2-substituted pyrimidine amides. 
 
This SAR contrasts with that described for the diazepinone class of literature ERK5 
inhibitors described in chapter 5, where similar potency was achieved by morpholine, 
hydroxypiperidine and piperazine substituents, suggesting that the binding mode of these 
groups in the pyrrole carboxamide series is significantly different from that observed in the 
published co-crystal structure.
247
 Comparison of a modelled pose of 275 with the X-ray 
structure of diazepinone 205 bound to ERK5 (Figure 7.1), suggests that the piperazine 
groups in each series are likely to adopt different exit vectors from the binding-site. The 
pyrrole carboxamide series may bind in a more planar conformation, with the ortho-
substituents twisting the halogenated phenyl ring out of the plane of the remainder of the 
molecule.  
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Figure 7.1: Comparison of the co-crystal structure of 205 (yellow) bound to ERK5 with a 
modelled structure of 275 (cyan) in the ATP-binding site. 
 
In vitro human and mouse liver microsomal data for 275 and 276 indicated that they were 
both subject to rapid metabolism (Table 7.13). In an attempt to improve microsomal 
stability, NH-piperazine analogues 285 and 286 were prepared. Compound 285 was 
equipotent with 275, and compound 286 had superior ERK5 inhibitory activity over 276. 
The improved stability of 286 in both human and mouse liver microsomes relative to 276 
supports the possibility of N-dealkylation as a major route of metabolism. As an alternative 
approach to reducing the potential for metabolic N-dealkylation, N-cyclopropylpiperazine 
derivative 287 was prepared. Cyclopropyl groups have been reported to confer resistance 
to oxidative metabolism,
311
 although this group has also been implicated in covalent 
inactivation of cytochrome P450 enzymes.
312
 Unexpectedly, 296 suffered a 24-fold 
reduction in potency relative to 287, which may be due to a variety of factors including the 
cyclopropyl group reducing the basicity of the piperazine nitrogen, a possible adverse 
steric interaction between the cyclopropyl and the kinase ATP-binding site, or an effect of 
this more sterically demanding nitrogen substituent on the conformation of the piperazine 
ring. 
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Cmpd R X ERK5 IC50
a
 
nM 
MLM 
Clint
b 
HLM 
Clint
b 
Ppb Fu Sol 
M 
275 
276 
Me 
Me 
H 
Cl 
72  10 
37  17 
51 
75 
200 
252 
0.11 
0.028 
> 100 
30-100 
285 
286 
H 
H 
H 
Cl 
89  14 
13  5 
n.d. 
13 
n.d. 
31 
n.d. 
0.066 
n.d. 
> 100 
287  Cl 1747  1703 n.d. n.d. n.d. n.d. 
                a
 Determination  standard deviation; b L/min/mg protein. n.d. = not determined. 
 
Table 7.13: ERK5 inhibitory activity and in vitro ADME data for 2-substituted pyrimidine 
amides. 
 
 
To investigate tolerance to variation of the position of the basic centre, the 4-
aminopiperidines 288-290 were prepared (Table 7.14). 
 
Cmpd R X MW clogP clogD tPSA Å
2
 HBA HBD 
288 
289 
Me 
Me 
H 
Cl 
456 
491 
3.8 
3.5 
2.4 
2.6 
103 
103 
8 
8 
3 
3 
290  Cl 517 4.4 2.6 103 8 3 
 
Table 7.14: Structures and molecular properties of 2-substituted pyrimidine amides. 
 
Analogues 288 and 289 retained similar potency to 275 and 276, respectively (Table 7.15). 
In contrast to 287, in this template N-cyclopropyl analogue 290 exhibited good ERK5 
170 
 
inhibitory activity. The metabolic stability of N-methylpiperidine 289 (Table 7.15) was 
much improved relative to 276, indicating that N-dealkylation is a slower metabolic 
process in this template. Interestingly, the microsomal stability of 290 was species-
dependent, with higher turnover in mouse than in human liver microsomes. The solubility 
was also reduced for 290 relative to 289, which may be due to increased lipophilicity and a 
reduction in the basicity of the piperidine nitrogen. 
 
Cmpd R X ERK5 
IC50
a
 nM 
MLM 
Clint
b
 
HLM 
Clint
b
 
Ppb Fu Sol 
M 
288 
289 
Me 
Me 
H 
Cl 
93  20 
14  3 
n.d. 
19 
n.d. 
6 
n.d. 
0.067 
n.d. 
10-100 
290  Cl 50  28 141 20 n.d. 3-20 
      a
 Determination  standard deviation; b L/min/mg protein; n.d. = not determined.  
Table 7.15: ERK5 inhibitory activity and in vitro ADME data for 288-290.  
 
Further modelling of 276 in the ATP-binding site of ERK5 from the literature co-crystal 
structure suggested that the piperazine could adopt a conformation that would allow the 
protonated basic centre to participate in an ionic interaction with a glutamate residue on the 
exit of the binding-site (Figure 7.2). However, the glutamate residue is in a flexible region 
of the protein, and it is likely that some re-ordering of the protein might occur on binding 
of the basic group, leading to an alternative binding conformation. 
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Figure 7.2: Modelling of 276 in the ATP-binding site of ERK5. The protein structure is 
taken from the ERK5 crystal structure.
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The presence of a basic centre in a molecule increases the probability of undesired activity 
against the hERG cardiac ion channel, and 276 was found to inhibit hERG with an IC50 of 
2.63 M (Table 7.16). In contrast, the hERG IC50 of both 286 and 289 was greater than 25 
M indicating the presence of subtle hERG SAR in this series, which enabled this 
undesirable activity to be avoided. 
 
Cmpd R ERK5 
IC50
a
 nM 
hERG  
IC50 M 
Caco-2 
AB
b
 (ER) 
276 
 37  17 2.63 n.d. 
286 
   13  5 >25 0.6 (35) 
289 
 
14  3 >25 0.3 (99) 
                                a
 Determination  standard deviation; b Papp10
-6
 cms
-1
; n.d. = not determined. 
Table 7.16: Inhibitory activity against ERK5, the hERG ion channel, and Caco-2 
membrane permeability data for 276, 286, and 289.   
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In the Caco-2 membrane permeability assay, both 286 and 289 were found to exhibit high 
efflux, suggesting significant recognition by active transporters (Table 7.16). The focus for 
further optimisation thus turned to reducing efflux liability while maintaining ERK5 
inhibitory potency. 
7.2.2 Pyridine-Amide Linked Analogues 
 
Previous SAR had demonstrated that ERK5 inhibitory potency for pyridyl and pyrimidyl 
amides was broadly similar (Table 7.17). 
 
Cmpd Y R ERK5 IC50 nM 
213 CH H 583  242 
215 N H 403  91 
291 CH Me 1030  65 
217 N Me 1200  619 
                                                                                                                             a
 Determination  standard deviation 
Table 7.17: Comparison of ERK5 inhibitory activity for simple 3-pyridyl and 5-pyrimidyl 
amides. 
Incorporation of a pyridine ring in place of the pyrimidine removes a hydrogen bond 
acceptor, and the resultant reduction in tPSA was considered of potential benefit for 
membrane permeability. This modification was therefore investigated in combination with 
the most potent basic substituents, to give 292 and 293 (Table 7.18).   
 
Cmpd R Y MW clogP clogD tPSA Å
2
 HBA HBD 
286 
292  
N 
CH 
463 
462 
3.1 
2.9 
2.1 
2.3 
103 
90 
8 
7 
3 
3 
289 
293 
 
N 
CH 
491 
490 
3.8 
3.5 
2.4 
2.6 
103 
90 
8 
7 
3 
3 
Table 7.18: Comparison of the molecular properties of 2-substituted 5-pyridyl and 5-
pyrimidyl amides that incorporate a basic centre.  
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ERK5 inhibition was found to be comparable for the pyrimidyl and pyridyl amide 
analogues (Table 7.19; 286 vs. 292, and 289 vs. 293). Good in vitro microsomal stability 
and low hERG activity were also maintained. However, undesirable high efflux ratios in 
the Caco-2 assay were retained in the pyridyl analogues. 
 
Cmpd R Y ERK5  
IC50
a
 nM 
MLM 
Clint
b
 
HLM 
Clint
b
 
hERG IC50 
M 
Caco-2 
AB
c
 (ER) 
286 
292  
N 
CH 
13  5 
13  6 
31 
25 
13 
19 
>25 
>25 
0.6 (36) 
0.3 (105) 
289 
293 
 
N 
CH 
14  3 
24  20 
19 
n.d. 
6 
n.d. 
>25 
n.d. 
0.3 (99) 
n.d. 
 a
 Determination  standard deviation; b L/min/mg protein; c Papp
 
10
-6
 cm s
-1
; n.d. = not determined.  
Table 7.19: Comparison of ERK5 inhibitory activity and in vitro ADME parameters for 2-
substituted 5-pyridyl and 5-pyrimidyl amides.  
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7.2.3 Analogues of 4-Pyridyl Amide Lead 214 
 
The effect of a change in the shape of the molecule was investigated by appending 
substituents to the 2-position of 4-aminopyridine amide 214. Compound 216 was the most 
potent 4-pyridyl amide previously prepared, having an ERK5 IC50 of 400 nM (Table 7.20). 
Introduction of the 2-methyl group on the pyridyl ring resulted in reduced cytochrome P450 
inhibition relative to the unsubstituted analogue. In an attempt to improve the potency of 
this series, basic and neutral substituents were incorporated at the 2-position of the pyridine 
ring (Table 7.20). 
 
Cmpd R ERK5 IC50
a
 nM 
214 H 602  266 
216 Me 400  166 
294 Cl 2322  267b  
295 CF3 n.d.
c 
296 OMe 1827  170 
297 
 
523  260b  
298 
 
137  65 
 a
 Determination  standard deviation; b Evidence of precipitation in assay; c Insufficient solubility for data to 
be generated. 
 
Table 7.20: ERK5 inhibitory activity data for 2-substituted 4-pyridyl amide analogues.  
 
Compounds of this structural class generally suffered from poor solubility, affecting the 
ability to generate reliable IC50 values in the primary assay. Despite this, pyrrolidine 297 
retained encouraging activity. The N-methylpiperazine 298 was more soluble under the 
assay conditions, and gave an ERK5 IC50 value of 137 nM, providing encouragement for 
further work in this area.  
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Incorporation of the trihalogenated phenyl group (299) again improved ERK5 inhibition 
(Table 7.21). The morpholine analogue 300 was also prepared in this series, providing 
further evidence of the importance of the basic centre for potent ERK5 inhibition in this 
regioisomeric series. 
 
Cmpd R ERK5 
IC50
a
 nM 
MLM 
Clint
b 
Caco-2 
AB
c
 (ER) 
Sol 
M 
299 
 
36  4 103 3.6 (3.6) 3-65 
300 
 
588  55 n.d. n.d. n.d. 
                          a
 Determination  standard deviation; b L/ml/mg protein; c Papp
 
10
-6
 cm s
-1
; n.d. = not determined.  
Table 7.21: ERK5 inhibitory activity and in vitro ADME data for 299 and 300.  
In mouse liver microsomes 299 suffered from a high turnover, which may be due to 
N-demethylation. Caco-2 efflux for this compound was moderate (ER = 3.6). Despite the 
presence of the water-solubilising N-methylpiperazine, the turbidimetric solubility assay 
indicated that 299 was considerably less soluble than isomer compound 276. Future work 
in this series should investigate the NH-piperazine 301, which would be anticipated to have 
improved microsomal clearance and solubility.  
 
301 
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7.2.4 Pyrazole-Amide Linked Analogues 
 
Another approach investigated was to replace the pyrimidyl ring of 289 with a pyrazole 
heterocycle. Removal of one heavy atom from the heteroaromatic amide reduces the 
molecular weight, and the pyrazole architecture enables carbon-linked substituents to be 
appended to the ring using facile synthetic chemistry. Such analogues result in a reduction 
in the tPSA compared to pyridyl and pyrimidyl analogues, which is of potential benefit in 
reducing efflux liability. The change from a 6-membered ring to a 5-membered ring also 
results in a subtle variation of the position of the basic centre, which may enable 
improvements in the binding interactions with ERK5, and may also affect recognition by 
the P-gp efflux pump. The set of pyrazole analogues 302-307 were therefore prepared, 
incorporating a basic centre on the pyrazole N
1
-substituent (Table 7.22). 
 
Cmpd R MW clogP clogD tPSA Å
2
 HBA HBD 
302 
 
450 3.3 2.0 92 7 3 
303 
 
464 3.8 2.4 83 7 2 
304 
 
422 2.7 1.8 92 7 3 
305 
 
463 3.6 2.0 92 7 3 
306 
 
478 4.2 2.4 83 7 2 
307 CH2CH2N(Et)2 466 4.1 2.1 83 7 2 
 
Table 7.22: Structures and molecular properties of pyrazole analogues 302-307. 
 
ERK5 inhibitory activity for these pyrazole linked analogues was comparable with the 
most potent pyrimidine and pyridine linked compounds (Table 7.23). Compound 305 was 
the most potent analogue prepared, and the first to achieve a sub-10 nM ERK5 IC50 value. 
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It exhibited good stability in mouse liver microsomes, and the Caco-2 efflux ratio was 
reduced significantly compared to 286. However, the intrinsic flux across the Caco-2 
monolayer was low (Papp = 1.5 × 10
-6
 cm/s). The only analogue prepared with an acyclic 
basic side-chain (307), surprisingly resulted in a 10-fold potency reduction, which may 
reflect the increased conformational flexibility resulting in an entropic penalty for binding. 
Increased steric crowding around the basic centre in 307 may also hinder the proposed 
charge-charge interaction with a glutamate residue in ERK5.  
 
Cmpd R ERK5 
IC50
a
 nM 
MLM 
Clint
b 
HLM 
Clint
b 
hERG 
IC50 M 
Caco-2 
AB
c
 (ER) 
Sol 
M 
302 
 
19  6 8.2 n.d. n.d. 0.3/6 (18) >100 
303 
 
22  6 103 n.d. n.d. 1.3/19 (15) 30 
304 
 
32  12 3.7 n.d. n.d. 0.2/4.0 (19) 10 
305 
 
7  4 0.3 2.4 n.d. 0.2/1.5 (4.5) >100 
306 
 
16  7 5.9 10 >25 0.6/18 (32) >100 
307 CH2CH2N(Et)2 207  19 n.d. n.d. n.d. n.d. n.d. 
     a
 Determination  standard deviation; b L/min/mg protein; c Papp
 
10
-6
 cm s
-1
; n.d. = not determined.  
Table 7.23: ERK5 inhibitory activity and in vitro ADME parameters for pyrazole amides 
incorporating a basic centre.  
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The effect of modulation of the basicity of the basic centre on ERK5 inhibition and 
transporter recognition was next investigated. Fluorination beta to a basic amine has a 
significant effect on its basicity, as shown in table 7.24.
313
  
 
Conjugate acid of amine pKa 
CH3CH2NH3
+
 10.7 
FCH2CH2NH3
+
 9.0 
F2CHCH2NH3
+
 7.3 
F3CCH2NH3
+
 5.7 
CH3CH2N(CH3)2H
+
 10.2 
F3CCH2N(CH3)2H
+
 4.8 
 
Table 7.24: Effect on the measured pKa of successive -fluorination of an amine.
313
 
 
Trifluoroethyl-substituted amine 308 was the first analogue prepared in an attempt to 
moderate the pKa of the basic centre (Table 7.25). Another approach for pKa moderation 
was incorporation of the basic centre within an aromatic heterocycle. Pyridyl analogues 
309-311 and imidazole analogue 312 were selected for synthesis. The pKa of pyridine 
(5.23) suggests that these analogues would be expected to be less than 1% protonated at 
physiological pH, which may be advantageous if the protonated form is recognised by 
efflux pumps. In the ERK5 ATP-binding site, the pyridine would be likely to be protonated 
in proximity to the glutamate residue, and the proposed charge-charge interaction 
contribution to the binding affinity may still be achieved. Imidazole (pKa = 7.0) is of 
intermediate basicity, and 312 explores an alternative heteroaromatic basic group. 
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Cmpd R MW clogP clogD tPSA Å
2
 HBA HBD 
308 
 
532 4.5 3.3 83 7 2 
309 
 
458 4.0 4.0 93 7 2 
310 
 
458 4.0 4.0 93 7 2 
311 
 
458 4.0 4.0 93 7 2 
312 
 
461 3.9 3.9 98 8 2 
 
Table 7.25: Structure and molecular properties of pyrazole analogues containing weakly 
basic centres. 
 
Compound 308 (Table 7.26) was over 100-fold less potent than the equivalent N-methyl 
analogue 303 (ERK5; IC50 = 22  6 nM). The 3-pyridylmethyl (310) and 4-pyridylmethyl 
(311) compounds retained good activity, while 2-pyridyl derivative 309 suffered a 4-fold 
loss of potency. In the Caco-2 assay 309 and 310 had efflux ratios above 5, indicating that 
incorporation of weakly basic heterocycles had not abrogated transporter recognition.  
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Cmpd R ERK5 
IC50
a
 nM 
MLM 
Clint
b 
Caco-2 
AB
c
 (ER) 
Sol 
M 
308 
 
2994  386 n.d. n.d. n.d. 
309 
 
124  10 40 6 (5.6) 10-65 
310 
 
34  2 41 2.7 (15) 30-100 
311 
 
31  1 n.d. n.d. n.d. 
312 
 
23  6 n.d. n.d. n.d. 
                          a
 Determination  standard deviation; b L/min/mg protein. c Papp
 
10
-6
 cm s
-1
. n.d. = not determined.  
Table 7.26: ERK5 inhibitory activity and in vitro ADME data for pyrazole analogues 
containing weakly basic centres.  
 
In order to confirm whether the basic centre was providing a potency advantage in the 
pyrazole series, the parent NH-pyrazole (313) and the N-methylpyrazole (314) were 
prepared. These low molecular weight compounds lacking a basic centre have relatively 
low tPSA, and fewer hydrogen bonding groups than the basic analogues (Table 7.27).  
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Cmpd R MW clogP clogD tPSA Å
2
 HBA HBD 
313 H 367 3.1 3.1 91 6 3 
314 Me 381 3.6 3.6 80 6 2 
315 Et 395 4.0 4.0 80 6 2 
316 CH2CH2OMe 425 3.7 3.7 90 7 2 
Table 7.27: Structures and molecular properties of neutral pyrazole amide analogues.  
Compound 313 retained ERK5 inhibitory potency similar to the unsubstituted 3-pyridyl 
analogue 213, but suffered from higher microsomal turnover, and an efflux ratio of 9.4 in 
the Caco-2 cell assay (Table 7.28). Surprisingly, N-methyl pyrazole 314 was 3-fold more 
potent than 313, having similar ERK5 inhibition to the most potent basic analogues. 
Furthermore, the mouse microsomal clearance of 314 was significantly lower than for 313. 
More importantly, 314 exhibited no efflux in the Caco-2 assay, and thus had the best 
balance of ERK5 inhibitory activity and in vitro pharmacokinetic parameters of the 
compounds prepared. Due to the low molecular weight of 314, this compound also 
achieved an impressive ligand efficiency of 0.43. Increasing the size of the neutral 
pyrazole substituent (315 and 316), did not result in any further improvement in ERK5 
inhibition. 
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Cmpd R ERK5  
IC50
a
 nM 
MLM 
Clint
b 
HLM 
Clint
b 
Caco-2 
AB
c
 (ER) 
Sol 
M 
LE 
313 H 99  40 85 n.d. 5.6 (9.4) >100 0.42 
314 Me 27  10 28 13 27 (0.9) >100 0.43 
315 Et 92  31 n.d. n.d. n.d. n.d. 0.38 
316 CH2CH2OMe 89  36 n.d. n.d. n.d. n.d. 0.35 
   a
 Determination  standard deviation; b L/min/mg protein. c Papp
 
10
-6
 cm s
-1
. n.d. = not determined.  
Table 7.28: ERK5 inhibitory activity and in vitro ADME data for neutral pyrazole amides.
 
 
 
To follow up on the exciting result for 314, a set of 5-membered aromatic heterocyclic 
amides was prepared as mimics of the N-methylpyrazole moiety (Table 7.29). A significant 
reduction in ERK5 inhibitory activity was apparent for compounds 317-320, suggesting 
that the position of heteroatoms in the 5-membered ring is crucial to activity. In contrast to 
314, these analogues all contain a heteroatom in a position adjacent to the amine linker 
atom, which may influence the conformational preference of the heterocyclic ring. 
 
 
Cmpd R ERK5 IC50 nM 
314 
 
27  10 
317 
 
1235  605 
318 
 
2482  921 
319 
 
1038  141 
320 
 
642  154 
                                                                                                                 a
 Determination  standard deviation 
Table 7.29: Structures and ERK5 inhibitory activity data for compounds 317-320.  
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7.3 Investigation of an Alternative Pyrrole 4-Substituent 
 
During the course of the program to optimise the amide substituent, work in the research 
group was also being undertaken to investigate the SARs at the pyrrole 4-position. A 
colleague identified 2-fluoro-3-methoxy-6-chlorobenzoyl as a substituent that conferred 
similar ERK5 inhibitory potency to the 2-fluoro-3,6-dichlorobenzoyl substituent at the 
pyrrole 4-position. A selection of the optimised amide substituents was therefore prepared 
in combination with the 2-fluoro-3-methoxy-6-chlorobenzoyl group (Table 7.30). This 
confirmed that these benzoyl substitution patterns endowed similar ERK5 activity and 
ADMET properties. 
 
R ERK5 IC50
a
 nM 
 X = Cl X = OMe 
 
292 13  6 321 16  2 
 
293 24  20 322 27  4 
 
314 27  10 323 107  26 
 
316 89  36 324 107  37 
 
30617  6 325 20  3 
 
308 2994  386 326 3546  201 
  
309 124  10 327 74  4 
 
310 34  2 328 23  2 
 
311 31  1 329 23  1 
a
 Determination  standard deviation 
Table 7.30: Comparison of ERK5 inhibitory activity for 2-fluoro-3,6-dichlorobenzoyl and 
2-fluoro-3-methoxy-6-chlorobenzoyl pyrrole-4-substituents.  
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An analysis of a matched pair of compounds in mouse liver microsomes revealed that both 
chloro- (292; MLM Clint = 26 L/min/mg protein) and methoxy- (321; MLM Clint = 20 
L/min/mg protein) benzoyl analogues exhibited similar levels of microsomal stability. 
 
7.4 Evaluation of ERK5 Inhibitors in a Cell-Based Assay 
 
Cellular activity was measured in HeLa cells by Lan-Zhen Wang. The cells were incubated 
with the ERK5 inhibitor for 1 hour, followed by stimulation with EGF. Cell lysis was followed 
by western blotting with an ERK5 antibody (Cell signalling #3372S). An IC50 value was 
generated from a seven point concentration response curve, using a densitometry measurement 
of the phospho-ERK5 band. An example western blot with a dose-response for an inhibitor is 
shown in Figure 7.4.  
 
 
330 
ERK5; IMAP IC50 66  33 nM 
 
Figure 7.4: Inhibition of EGF-stimulated phospho-ERK5 formation by 330. Upper figure 
shows the resolution of a phospho-ERK5 band (upper band) from non-phosphorylated 
ERK5 (lower band). The IC50 value for 330 was calculated as 90  10 nM and is the mean 
from three independent experiments, following densitometry and an analysis of the ratio of 
phospho-ERK5 to total ERK5.  
 
Western blotting is a semi-quantitative technique, and as such, the use of densitometry 
resulted in a high degree of variability in the ERK5 IC50 values generated using this assay. 
The IC50 values for the majority of the compounds tested were below one micromolar, 
which provides confirmation that this class of compound is able to affect ERK5 auto-
phosphorylation in a cellular context (Table 7.31).   
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Cmpd R ERK5 IC50
a 
nM 
HeLa IC50
b 
nM 
286 
 
13  5 100  10 
289 
 
14  3 60  40 
302 
 
19  6 790 ± 520 
304 
 
32  12 140c 
305 
 
7  4 830 ± 1020 
306 
 
16  7 2700c 
314 
 
27  10 220 ± 120 
                           a 
ERK5 inhibitory activity in the cell-free IMAP format assay;  
                         
b 
IC50 determined by densitometry in the cell-based assay; 
  
                                            c
 Data from a single determination. 
 
Table 7.31: Comparison of inhibition of ERK5 in the IMAP cell-free assay, with 
inhibition of ERK5 auto-phosphorylation determined by western blot densitometry in 
HeLa cells. 
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7.5 In vivo Pharmacokinetic Evaluation of 306 and 314 
 
Compounds 306 and 314 from the pyrazole amide series were selected for pharmacokinetic 
evaluation in mouse. In vivo pharmacokinetic studies were performed by Dr Huw Thomas. 
Table 7.32 shows a comparison of the in vitro and in vivo pharmacokinetic parameters of 
the two compounds.  
 
Cmpd HLM 
Clint
a 
MLM 
Clint
a 
Caco-2  
AB
b
 (ER) 
Fu Cl  
ml/min/kg 
Clu  
ml/min/kg 
Vd 
L/kg 
t1/2  
min 
F 
% 
306 2 0.3 0.2 (4.5) 0.10 10 100 0.1  132 1 
314 13 28 27 (0.9) 0.08 14 175 0.6 80 42 
a L/min/mg protein. b Papp
 
10
-6
 cm s
-1
. 
Table 7.32: In vitro and in vivo pharmacokinetic parameters for 306 and 314. In vivo 
studies were performed at a dose of 10 mg/kg i.v. and 10 mg/kg p.o. in mouse.  
 
Compound 306 had low plasma clearance, but negligible bioavailability (F ~ 1%) 
suggesting that the oral dose was poorly absorbed. This is consistent with the low 
membrane permeability and moderate efflux observed in the Caco-2 assay. The low 
volume of distribution is surprising for a basic compound. Derivative 314 had low 
clearance, with a hepatic extraction ratio of approximately 15%. Oral bioavailability was 
determined to be 42%, implying that 314 suffered impairment of absorption (Fabs ~ 50%), 
which is not predicted from the Caco-2 and solubility data. However, the bioavailability 
was sufficient for this compound to be progressed into a tumour xenograft in vivo efficacy 
study. Data from this study are awaited. 
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7.6 Summary 
 
Exploration of SAR around the amide substituent in the pyrrole carboxamide series of 
ERK5 inhibitors has resulted in the identification of groups which improve the potency. 
Combination with trisubstituted benzoyl 4-substituents provided a set of potent compounds 
with ERK5 inhibitory-activity below 20 nM. The most potent compounds incorporate a 
basic centre, which is hypothesised to interact with an aspartate residue on the exit to the 
active site. However, all compounds containing a basic centre suffered from efflux in the 
Caco-2 assay, and this translated to poor in vivo bioavailability in the case of compound 
306.   
 
          314 ERK5; IC50 = 27  10 nM 
                 Caco-2 ER 0.9 
                            L.E. 0.43 
                           Mouse F = 42% 
 
The neutral compound, 314 had the best balance of potency and in vitro ADME 
parameters, and inhibited ERK5 auto-phosphorylation in a cell-based assay. This 
compound had good bioavailability in a mouse pharmacokinetic study, and is currently 
being progressed into a tumour xenograft model to examine the effects of ERK5 inhibition 
in vivo. 
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Chapter 8: Discussion of ERK5 Inhibitor Synthesis 
 
 
Knowledge of the SARs around the amide substituent on the pyridyl carboxamide scaffold 
was limited at the start of this program of work. Thus, robust, reliable, and relatively high-
throughput synthetic methods were sought to enable rapid analogue preparation to 
facilitate elaboration of this region.  
The carboxylic acids 336 and 337 were key building blocks for the synthesis of amide 
derivatives. These were prepared in two steps from commercially available materials, 
employing a Friedel-Crafts acylation followed by basic ester hydrolysis, which had been 
previously developed in our research group (Scheme 8.1).  
  
331 X = H          333                               334 X = H                                  336 X = H 
332 X = Cl                                              335 X = Cl                                  337 X = Cl 
Scheme 8.1: Reagents and conditions a) Aryl acid chloride (2 eq.), AlCl3 (2.5 eq.), 
CH2Cl2, 0 C-r.t., 18 h, (X = H, 92%; X = Cl, 89%); b) LiOH (20 eq.), THF:H2O (1:2) 65 
C, 48 h, (X = H, 99%). 
 
 
8.1 Variation of the Piperidine 4-Substituent of 212 
 
 
Two strategies were employed for the synthesis of analogues of 212 which varied the 
piperidine nitrogen substituent (R). Where the desired 4-aminopiperidine was 
commercially available at an acceptable price (R = i-Pr, c-Pr) this reagent was purchased 
and directly coupled to pyrrole carboxylate 336 using carbonyldiimidazole (CDI) as the 
coupling reagent (Scheme 8.2) to give targets 253 and 254.  
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                                  336                                            253 R = i-Pr 
                                                                                    254 R = c-Pr     
Scheme 8.2: Reagents and conditions a) i) CDI (2 eq.), THF, 70 C, 3 h; ii) 1-c-Pr-4-
aminopiperidine (2.2 eq), 50 C, 3 h, 52%, or 1-i-Pr-4-aminopiperidine (2.5 eq.), 50 C, 3 
h, 60%. 
For the second approach, unsubstituted piperidine amides 251 and 260 were prepared in 
two steps from pyrrole carboxylates 336 and 337 (Scheme 8.3).  
 
     336 X = H                                     258 X = H                                    251 X = H 
     337 X = Cl                                    263 X = Cl                                   260 X = Cl 
Scheme 8.3: Reagents and conditions a) i) CDI (2 eq.), THF, 70 C, 3 h; ii) 1-Boc-4-
aminopiperidine (2.2 eq), 50 C, 3 h, (X=H, 75%; X = Cl, 79%); b) Et3SiH, TFA/CH2Cl2, 
r.t., 2 h, (X = H, 99%; X = Cl, 75%). 
 
The versatile secondary amine functionality of compounds 251 and 260 allowed the 
introduction of a diverse set of piperidine N
1
-substituents at the final step of the synthesis. 
An array of synthetic transformations were employed including reductive alkylation, amide 
and sulfonamide formation, and nucleophilic aromatic substitution reactions as 
summarised in scheme 8.4. 
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Scheme 8.4: Reagents and conditions a) i) MeCHO (2 eq.), AcOH (2 eq.), MgSO4, 
MeOH, r.t., 1 h; ii) NaCNBH3 (1.5 eq.), r.t., 18 h, (X = H, 16%); b) AcCl (1.1 eq.), Et3N 
(1.2 eq), CH2Cl2, r.t., 1 h, (X = H, 48%; X = Cl, 52%); c) MeSO2Cl (1.5 eq.), Et3N (1.5 
eq.), CH2Cl2, r.t., 1 h, (X = H, 27%; X = Cl, 35%); d) 2-chloropyrimidine (1 eq.), iPr2EtNH 
(1.2 eq.), MeCN, W, 150 C, 1.5 h, (X = H, 23%); e) (CF3CO)2O (4.5 eq), Et3N (1.2 eq.), 
CH2Cl2/dioxane, r.t., 3 h, (X = Cl, 41%). 
 
8.2 Variation of the Pyrimidyl 2-Substituent of 215 
 
Exploration of the pyrimidyl 2-position of 215 was achieved through preparation of the 
requisite aminopyrimidines from 2-chloro-5-nitropyrimidine (338). The first amine 
prepared was 2-(pyrrolidin-1-yl)pyrimidin-5-amine 340. SNAr displacement of the 2-chloro 
group of 338 proceeded at room temperature to give 339, which was cleanly reduced using 
palladium-catalysed hydrogenation to give 340. 
 
                    338                                             339                                           340 
Scheme 8.5: Reagents and conditions: a) Pyrrolidine, Et3N, THF, r.t. 18 h, 80%; b) H2, 
10% Pd/C, MeOH, CH2Cl2, 100%. 
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A previous investigation of amide coupling conditions of aromatic heterocyclic amines to 
carboxylic acid 336 conducted in our research group led to the identification of conditions 
employing PCl3 under microwave heating at 150 C as optimal. However, when these 
conditions were applied to the coupling of 340 with 336, a complex mixture was formed. 
CDI-mediated coupling resulted in product formation along with several close-running 
impurities, which led to difficulties in purification. However, coupling using cyanuric 
fluoride allowed isolation of 274 in high purity and 42% yield (Table 8.1). 
 
                336                              340                                                         274 
Entry Reagent Amine  
Equiv. 
Solvent Temp 
C 
Time 
h 
Result 
1 PCl3 2.5 MeCN 150 0.5 Complex mixture
a 
2 CDI 2.5 THF 70 2 Product plus impurities
a 
3 Cyanuric 
fluoride 
1.25 MeCN r.t. 18 42% isolated yield 
a 
Observations from TLC and LCMS analyses.  
Table 8.1: Exploration of conditions for the coupling of 336 and 340.  
 
 
This three step scheme was applied to the synthesis of a small library of nitrogen-linked 
derivatives, introducing small cyclic and acyclic alkylamines. The yields for each step are 
summarised in Table 8.2. 
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                              338                                  341-350                        351-360  
 
                                         336-337                        
Entry R Step 1 Step 2 Step 3 
   Yield  Yield X  Yield 
1 NHMe 341 55% 351 100% H 272 26% 
2 NMe2 342 87% 352 100% H 273 34% 
3 
 
343 82% 353 96% 
H 275 50% 
4 Cl 276 41% 
5 
 
344 89% 354 98% Cl 287 18% 
6 
 
345 68% 355 99% 
H 361 49% 
7 Cl 362 69% 
8 
 
346 73% 356 100% 
H 279 50% 
9 Cl 280 40% 
10 
 
347 94% 357 72% H 281 0% 
11 
12  
348 97% 358 78% 
H 
Cl 
283 
284 
47% 
54% 
13 
14 
 
349 83% 359 92% 
H 
Cl 
288 
289 
35% 
35% 
15 
 
350 95% 360 100% Cl 290 15% 
 
Table 8.2: Summary of yields for the three step synthesis of analogues of 215; Reagents 
and conditions: Step 1: Amine, Et3N, THF, r.t. 18 h; Step 2: H2, 10% Pd/C, MeOH, 
CH2Cl2; Step 3: Amine (2.5 eq.), cyanuric fluoride (0.3-0.7 eq.), pyridine (1 eq), MeCN, 
r.t., 18 h. 
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t-Butyl carbamates 361 and 362 were deprotected using TFA/DCM in the presence of 
triethylsilane, which acted as a scavenger for the liberated t-butyl cation, preventing 
alkylation of the pyrrole ring. This provided secondary amine targets 285 and 286 (Scheme 
8.5).  
 
                         361 X = H                                                           285 X = H  
                         362 X = Cl                                                          286 X = Cl        
Scheme 8.5: Reagents and conditions: a) TFA, DCM, Et3SiH (2.5 eq.) (X = H, 52%; X = 
Cl, 69%).  
 
Amine 357 failed to react under the cyanuric fluoride coupling conditions, with evidence 
by LC-MS analysis of the unprotected alcohol participating in undesired side-reactions. 
The scheme was repeated with the alcohol protected as acetate ester 358, allowing good 
yields to be achieved for the amide coupling. The acetate was removed under mild 
conditions to provide alcohols 281 and 282 (Scheme 8.6).  
 
                         283 X = H                                                           281 X = H  
                         284 X = Cl                                                          282 X = Cl        
Scheme 8.6: Reagents and conditions: a) K2CO3 (2 eq.), THF, MeOH, H2O, r.t., 18 h, X = 
H, 93%, X = Cl, 54%.  
 
Methoxy-substituted pyrimidine 271 was prepared in a similar three step sequence from 
338, using freshly prepared sodium methoxide in the nucleophilic aromatic substitution 
reaction (Scheme 8.7). 
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Scheme 8.7: Reagents and conditions: a) Na (1.2 eq.), MeOH, 65 C, 1 h, 59%; b) H2, 
10% Pd/C, MeOH, CH2Cl2, 97%; c) Cyanuric fluoride (0.3-0.7 eq.), 336 (0.33 eq.), 
pyridine (1 eq), MeCN, r.t., 18 h, 43%. 
 
8.3 Synthesis of Pyridyl Analogues of 286 and 289 
 
Compounds incorporating a pyridyl linker in place of the pyrimidine ring were also 
prepared. A similar reaction sequence was employed to that described for the pyrimidyl 
analogues above. The 2-chloro-5-nitropyridine starting material (365) reacted more slowly 
with amines than in the pyrimidine case, with incomplete conversion observed after 4 
hours at room temperature. Increasing the reaction temperature to 80 C enabled complete 
conversion to the desired products within 30 minutes. Hydrogenation and amide coupling 
(Table 8.3) was achieved in a manner analogous with the pyrimidyl targets discussed in the 
previous section. 
Deprotection of 370 using TFA/DCM and triethylsilane gave secondary amine target 292 
in 46% yield. Amine 369 failed to couple under the cyanuric fluoride conditions, but target 
293 was successfully obtained by employing PyBrOP to activate the carboxylic acid. This 
reaction achieved high conversion in 2 hours, and had a further advantage of requiring only 
1.5 equivalents of the amine. However, the overall yield was relatively low due to 
difficulties in isolating the product from close-running impurities.  
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                                    365                                        366-367 
 
                              368-369                                               293, 370 
Entry R Step 1 Step 2 Step 3 
   Yield  Yield X Method  Yield 
1 
 
366 97% 368 100% Cl 1 370 45% 
2 
 
367 56% 369 95% Cl 2 293 19% 
 
Table 8.3: Reagents and conditions: a) Amine (2 eq.), K2CO3 (2 eq.), THF, 80 C, 0.5-3 h; 
b) H2, 10% Pd/C, MeOH; c) Method 1: Amine (2.5 eq.), cyanuric fluoride (0.3-0.7 eq.), 
pyridine (1 eq), MeCN, r.t., 18 h; Method 2: Amine (1.5 eq.), PyBrOP (1.3 eq.), pyridine 
(1 eq.), MeCN, r.t., 2 h. 
 
8.4 Elaboration of the Pyridyl 2-Position of 214 
 
A literature report indicated that elaboration of the 2-position of 2-chloro-4-nitropyridines 
by reacting with nucleophiles is complicated by competing displacement of the 4-nitro 
group, and that selectivity for substitution of the chloro group can be achieved by 
performing the reaction on the equivalent pyridine N-oxides.
314
 Reaction of 2-chloro-4-
nitropyridine N-oxide (371) with pyrrolidine at reflux in IPA resulted in the formation of 
372 (Scheme 8.6). Reduction of both the nitro group and the N-oxide was achieved in a 
single process, using palladium catalysed flow hydrogenation, to give 373. 
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                  371                                            372                                                 373 
Scheme 8.6: Reagents and conditions: a) Pyrrolidine, NaHCO3, IPA, r.t. 2 h, 88%; b) H2, 
20% Pd(OH)2/C, MeOH, 89%. 
 
However, coupling of this amine to carboxylic acid 336 under a range of conditions was 
unsuccessful (Table 8.4). A review of the literature revealed few examples of successful 
amide couplings with 2,4-diaminopyridines. A patent procedure for the coupling of 2,2-
dimethylamino-4-aminopyridine to a carboxylic acid
315
 utilised the Mukaiyama pyridinium 
coupling reagent to activate the acid,
316
 but no yield was given for this reaction. Applying 
these conditions to the coupling of 336 with 373 led to isolation of target 297 in 20% yield.  
    
             336                                373                                                      297 
Entry Amine 
Eq. 
Reagents Solvent Temp 
C 
Time 
h 
Result 
1 2.5 PCl3 (1 eq.)   MeCN 150  0.5 Degraded 
2 2.5 Cyanuric fluoride  
(0.7 eq.), pyridine (1 eq.) 
MeCN r.t. 18 Trace 
conversion
b 
3 2 Mukaiyama reagent
a
   
(1.1 eq.), Et3N (2.5 eq.) 
DCM 50 2 20% isolated 
yield 
a 
2-chloro-1-methylpyridinium iodide; 
b 
Determined by LC-MS. 
Table 8.4: Conditions investigated for the coupling of 336 and 373.
 
 
 
In an attempt to improve both the yield and throughput for analogue synthesis, an 
alternative approach was investigated which would allow late-stage diversification of the 
2-pyridyl substituent in this series (Scheme 8.7). Coupling of commercially available 2-
chloro-4-aminopyridine 374 to carboxylic acid 336 using PCl3 with microwave irradiation 
resulted in a 45% isolated yield of pyridyl 2-chloride 294. 
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                  336                           374                                                   294 
 
Scheme 8.9: Reagents and conditions: a) PCl3, MeCN, 100 C, 0.5 h, 45%. 
 
Palladium-catalysed amination
317-319
 of 294 was investigated using pyrrolidine as a 
representative amine (Table 8.5). No conversion was observed using conditions which had 
previously been successful on another project in the research group for carbon-nitrogen 
cross coupling (entry 1). The conditions recommended by the Buchwald group for 
coupling of aliphatic secondary amines
320
 also gave no conversion (entries 2 and 3). The 
presence of unreacted starting material indicated that oxidative addition of palladium to the 
2-chloropyridine was not occurring under these conditions. 
 
294                                                                                  297 
Entry Conditions Temp 
C 
Time 
h 
Result
a 
1 Pd2(dba)3 (0.1 eq), Xphos (0.1 eq), 
pyrrolidine (1.25 eq.), K2CO3 (2.25 
eq), MeCN 
100  0.75  SM only
 
2 Pd2(dba)3 (0.1 eq), Xphos (0.1 eq), 
pyrrolidine (1.25 eq.), K2CO3 (2.25 
eq), MeCN 
120  2  SM only 
3 Pd2(dba)3 (0.1 eq), Xphos (0.1 eq), 
pyrrolidine (1.25 eq.), K2CO3 (2.25 
eq), MeCN 
150  2   SM only 
         a 
Determined by LC-MS and TLC analyses.  
Table 8.5: Summary of investigation of palladium-catalysed cross-coupling conditions 
employed for the synthesis of 297.  
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Thermal displacement of the 2-chloropyridine with amines in the absence of catalyst was 
also investigated, with NMP as solvent (Table 8.6).  
  
294                                                                                  298 
Expt Pyrrolidine 
Equiv. 
Temp 
C 
Time 
h 
Product
a 
% 
1 4 200  0.5 <5 
2 4 250  0.5 23 
3 4 250  2  65 
4 4 250  3  0 
5 2 250 3 77 
                                         a 
Percentages from LC-MS UV trace.  
Table 8.6: Summary of studies on the SNAr reaction of 2-chloropyridine intermediate 294 
with pyrrolidine. All reactions were performed in NMP.  
 
Under microwave irradiation at 200 C no discernible reaction occurred (entry 1). 
Increasing the temperature to 250 C and extending the reaction time to 2 hours improved 
conversion to 298 (entries 2 and 3). Further extension of the reaction time (entry 4) led to 
product depletion due to competing substitution of the 2-fluoro group on the phenyl ring. 
Reducing the number of equivalents of pyrrolidine decreased this side-reaction. Scaling up 
of the conditions for entry 5 gave an isolated yield of 45% of 298.  
However, when these optimized conditions were applied to other amines, multiple by-
products were formed from which the target compounds could not be isolated in high 
purity. It has been reported that the use of 1,2-ethanediol as solvent facilitates the 
displacement of 2-halopyridines by amines, enabling the use of lower reaction 
temperatures.
321
 However, repeating the reaction in 1,2-ethanediol, using two equivalents 
of N-methylpiperazine at 150 C under microwave irradiation led to a 1:1 mixture of 
starting material and 2-hydroxyethyl ester 375.  
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    375 
Displacement of the 2-chloropyridine of 294 with sodium methoxide
322
 was also explored, 
resulting in methanolysis of the amide bond to form methyl ester 334 (Scheme 8.8). Thus it 
appears that the amide bond of 294 is unstable to nucleophilic reagents at elevated 
temperatures.  
         
               294                                                    305                                           334 
Scheme 8.8: Reagents and conditions: a) NaOMe, MeOH, W, 125 C, 30 min. 
In order to develop a more efficient synthesis of amine analogues, several alternative 
routes were investigated. Oxidative addition of palladium catalysts is often facilitated by 
the use of aryl iodides and bromides in place of chlorides. A procedure for direct 
conversion of 2-pyridyl chlorides to 2-pyridyl iodides has been reported, using transient 
acylation of the pyridyl nitrogen with acetyl chloride to activate the ring to nucleophilic 
displacement.
323
 However, applying these conditions to the synthesis of 376 led to an 
inseparable mixture of chloride 294 and iodide 376 (Scheme 8.9). The chloropyridine also 
proved resistant to SNAr reaction with sodium thiomethoxide in a sealed tube at 110 C. 
 
                                   294                                                                 376 
Scheme 8.9: Reagents and conditions: a) AcCl (1.5 eq.), NaI (10 eq.), MeCN, 80 C, W, 
3 h. 
Methods for the activation of pyridine N-oxides, which enable direct attack of nucleophiles 
at the pyridine 2-position under mild conditions, have also been described, including the 
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use of toluenesulfonic anhydride/t-butylamine,
324
 and PyBrOP.
325,326
 Pyridine N-oxide 378 
was formed in two steps from 337 using the process outlined in scheme 8.10.  
 
Scheme 8.10: Reagents and conditions: a) 4-aminopyridine (2.5 eq.), PCl3, MeCN, 100 
C, 0.5 h, 58%; b) mCPBA (1.5 eq.), MeCN, r.t., 18 h, 72%. 
 
Activation of N-oxide 378 with PyBrOP in the presence of either N-methylpiperazine or 
morpholine led to isolation in low to moderate yields of the desired products 299 and 300, 
respectively, (Table 8.7). 
 
                                    378                                                299-300 
Entry NHR
1
R
2
 Cmpd Isolated 
yield 
1 N-Methylpiperazine 299 35% 
2 Morpholine 300 14% 
 
 
Table 8.7: Yields for the amide coupling step in the synthesis of 299 and 300. Reagents 
and conditions: a) PyBrOP (1.3 eq.), NHR1R2 (1.25 eq.), Hünig base (3.75 eq.), CH2Cl2, 
r.t, 18 h. 
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The final derivatives in this series, 295 and 296, were prepared by coupling of 
commercially available amines using either PCl3 or cyanuric fluoride coupling procedures 
(Table 8.8). 
 
                                             336                                               295-296 
Entry Amine Cmpd Isolated yield 
1 2-trifluoro-4-aminopyridine
a 
295 45% 
2 2-methoxy-4-aminopyridine
b 
296 33% 
 
Table 8.8: Reagents and conditions: a) Amine (2.5 eq.), PCl3, MeCN, 100 C, 0.5 h or b). 
Amine (2.5 eq.), cyanuric fluoride (0.7 eq.), pyridine (1 eq), MeCN, r.t., 18 h 
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8.5 Pyrazole-Linked Amides 
 
Replacement of the pyrimidine linker with a pyrazole ring was achieved using a 3-step 
route. The heterocyclic NH of 4-nitropyrazole has a pKa of 9.64,
327
 enabling participation 
in Mitsunobu reactions with alkyl alcohols.
328
 This allowed access to the desired amine 
coupling partners in two steps from 4-nitropyrazole 379 and commercially available 
alcohols, as shown in Table 8.8. 
 
                   379                                               380-392                                393-405          
 Entry R Step 1 Step 2 
1 
 
380 67% 393 100% 
2 
 
381 63% 394 99% 
3 
 
382 82% 395 95% 
4 
 
383 34% 396 91% 
5 
 
384 54% 397 97% 
6 Me 385 67% 398 98% 
7 Et 386 54% 399 100% 
8 CH2CH2N(Et)2 387 43% 400 28% 
9 CH2-2-pyridyl 388 83% 401 96% 
10 CH2-3-pyridyl 389 40% 402 91% 
11 CH2-4-pyridyl 390 55% 403 99% 
12 CH2CH2OMe 391 85% 404 91% 
13 
 
392 18% 405 96% 
      
Table 8.8: Summary of yields for the synthesis of substituted pyrazole compounds; 
Reagents and conditions: a) PPh3, DEAD, THF, r.t. 18 h; b) H2, 10% Pd/C, MeOH. 
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The increased polarity imparted by the introduction of a basic centre resulted in certain 
products having a similar retention factor on silica to the reaction by-products of 
triphenylphosphine oxide or reduced diazocarboxylate. The use of a catch-and-release 
process on an SCX strong acid ion exchange resin, in conjunction with standard medium 
pressure column chromatography on silica, allowed successful isolation of these products. 
In order to avoid this issue, an alternative synthesis was developed for N-methylated 
aliphatic heterocycles via the N-Boc protected intermediates using an in situ 
deprotection/Eschweiler-Clarke methylation strategy (Scheme 8.11).
329,330
  
 
                                              382                                                    383 
Scheme 8.11: Reagents and conditions: a) HCHO (4 eq.), HCO2H, 95 C, sealed tube, 2 h, 
84%. 
 
Preparation of 308 required the synthesis of 1-trifluoroethyl substituted piperidine (409), 
which was accessed in two steps from 4-hydroxypiperidine (Scheme 8.12), the initially 
formed N,O-bis(trifluoroacetyl) intermediate 407 being cleaved to trifluoracetamide 408 on 
treatment with weak base prior to work-up. 
 
Scheme 8.12: Reagents and conditions: a) TFAA (1.1 eq.), pyridine (2 eq.), DCM, 0 C to 
r.t., 18 h; b) NaHCO3, H2O, MeOH, r.t., 15 min, 47% over 2 steps; c) BH3.THF (2.5 eq.), 
THF, 66 C, 90 min, 67-71%. 
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Amine 410 was obtained in a single step by hydrogenation of 4-nitropyrazole (Scheme 
8.13). 
 
Scheme 8.13: Reagents and conditions: a) H2, 10% Pd/C, MeOH, 40 C, 2 h, 98%. 
 
The Mitsunobu reaction utilised for the synthesis of 392 (Table 8.8, entry 13) was low 
yielding due to competing formation of a significant by-product. This was isolated and 
structure 411 was proposed based on spectroscopic data. The structure was confirmed by 
small molecule X-ray crystallography of a crystal grown by slow evaporation from ethyl 
acetate.  
  
Figure 8.1: The X-ray crystal structure of side-product 411. 
The isolated yield of 411 was 18%. A proposed mechanism for the formation of 411 under 
the reaction conditions is shown in Scheme 8.14.  
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Scheme 8.14: Proposed mechanism for the formation of 411. 
 
A similar reaction has been reported when attempting a nucleophilic displacement of 
substituted 2-chloromethylimidazoles with amines (Scheme 8.15).
331
 In this report the 
nucleophiles explored were aliphatic primary and secondary amines, with optimal yields of 
413 when R
1
 was tert-butyl. No examples have previously been described where R
1
 = H, 
or with heteroaromatic nucleophiles. 
 
                                                                                        413 
Scheme 8.15: Literature reaction of 2-chloromethylimidazoles with amines.
331
 
 
To complete the synthesis of the pyrazole-linked amide targets, the substituted 
aminopyrazole intermediates 393-405 were coupled to the pyrrole carboxylic acid 337 
using either the cyanuric fluoride or Mukaiyama coupling protocols (Table 8.11). During 
the course of this work, a transition was made to using the Mukaiyama coupling protocol 
as the method of choice, principally due to its requirement for a lower number of 
equivalents of the bespoke amine coupling component (1.25 equivalents) as compared to 
the 2.5 equivalents required to achieve high conversion in couplings employing cyanuric 
fluoride.  
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               337                         393-405                                               306-316, 414-416 
Entry R Amide Coupling 
  Method Yield % 
1 
 
1 414 76 
2 
 
1 415 70 
3 
 
1 416 59 
4 
 
1 306 43 
5 CH2CH2N(Et)2 2 307 43 
6 
 
2 308 34 
7 
 
2 309 55 
8 
 
2 310 30 
9 
 
2 311 19 
10 
 
2 312 43 
11 H 1 313 64 
12 Me 1 314 59 
13 Et 2 315 26 
14 CH2CH2OMe 2 316 49 
 
Table 8.11: Methods and yields for amide coupling; Reagents and conditions: Method 1: 
Amine (2.5 eq.), cyanuric fluoride (0.3-0.7 eq.), pyridine (1 eq), MeCN, r.t., 18 h or 
Method 2: Amine (1.25 eq.), 2-chloro-1-methyl pyridinium iodide (1.1 eq.), Et3N (2.5 eq.), 
CH2Cl2, r.t., 18 h.  
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The Boc-protected amines 414-416 were deprotected to give secondary amine targets 302, 
304 and 305 (Table 8.10).  
 
     414-416                         302, 304-305       
 
 
 
 
Table 8.10: Reagents and conditions: a) TFA, DCM, Et3SiH (2.5 eq.).  
 
The Eschweiler-Clarke methylation procedure was also employed to convert 414 directly 
to 303 in a single step in high yield, demonstrating the utility of this process for elaboration 
of Boc-protected intermediates to their N-methylated counterparts in the final synthetic 
step (Scheme 8.15).  
 
Scheme 8.15: Yields for Eschweiler-Clarke deprotection-in situ methylation; Reagents and 
conditions: a) HCHO (4 eq.), HCO2H, 95 C, sealed tube, 2 h, 100%. 
 
 
8.6 Synthesis of Other 5-Membered Heterocyclic Amides 
 
To access the methylated imidazole amide 320, regioselective methylation of 
4-nitroimidazole 417 was required. Alkylation of 4-nitroimidazole using Mitsunobu 
conditions has not previously been reported, and resulted in exclusive formation of the 
undesired 1-methyl-5-nitroimidazole regioisomer (419). This is consistent with the 1:350 
ratio of 418:419 reported for methylation of this substrate using dimethyl sulfate under 
neutral conditions.
332
 In the presence of sodium hydroxide the regioselectivity is reported 
to change, giving a 418:419 ratio of 3:1.
332
 The use of the carcinogenic dimethyl sulfate 
Substrate Product Yield % 
414 302 69 
415 304 85 
416 305 64 
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was undesirable, and, in preference, an alternative procedure employing dimethyl oxalate 
as the methylating reagent under basic conditions was identified.
333
 Under these conditions 
a 4:1 ratio in favour of 418 was achieved (Scheme 8.16).  
 
                           417                                                   418                              419       
Scheme 8.16: Reagents and conditions: a) DEAD (1.5 eq), PPh3 (1.5 eq.), MeOH (1 eq.), 
THF, r.t., 18 h, A (0%), B (50%); b) Dimethyl oxalate (1.5 eq.), KOtBu (1.5 eq.), DMF, 
140 C, 4 h, A (49%), B (12%). 
The complex mechanistic factors governing the regiochemistry of this alkylation reaction 
have been discussed in a series of papers.
332,334,335
 Two mechanistic possibilities for the 
reaction of 417 with electrophilic methylating reagents (R-Me
+
) were proposed, termed 
SE2cB and SE2’:  
SE2cB mechanism 
 
At basic pHs, the SE2cB mechanism predominates, with the position of alkylation 
governed by the most nucleophilic nitrogen in the conjugate base. Nominal deprotonation 
of tautomer 2 leads to a more stable, less nucleophilic anion, leading to formation of 418 as 
the major product.
332
 
SE2’ mechanism 
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In the SE2’ mechanism a more complex situation exists with substitution occurring at the 
non-protonated nitrogen. The reaction outcome is affected by both the tautomeric ratio and 
rate of reaction of each tautomer. Under neutral conditions the tautomer ratio has been 
determined as 400:1 in favour of tautomer 1, and in practice near exclusive formation of 
1-methyl-5-nitroimidazole regioisomer 419 is observed. Between pH 11 and pH 6 there is 
a transition from the SE2cB to the SE2’mechanism, with a subsequent change in the ratio of 
regioisomers formed.
332
 
 
                                             418                                            420     
Scheme 8.17: Reagents and conditions: a) H2/10% Pd/C, MeOH, EtOAc, 40 C, 2 h, 99%,  
Reduction of the nitro group gave aminoimidazole 420 (Scheme 8.17), which degraded on 
storage at room temperature for 48 hours. However, when progressed immediately after 
preparation to the amide coupling step using the PCl3 protocol, desired analogue 320 was 
successfully formed (Table 8.11). A set of commercially available methylated 5-membered 
aromatic heterocyclic amines were also successfully coupled to pyrrole carboxylic acid 
337 using the PCl3 coupling protocol (Table 8.12). 
 
                         337                                                                     317-320      
 
Cmpd R Yield % 
317 
 
34 
318 
 
40 
319 
 
67 
320 
 
24 
Table 8.12: Yields for amide couplings in the synthesis of 317-320; Reagents and 
conditions: a) Amine (3.5 eq.), PCl3, MeCN, W, 150 C, 15 min.  
210 
 
8.7 Analogues Containing an Alternative Pyrrole 4-Substituent 
 
A selection of the amines described above were coupled to a pyrrole carboxylic acid 
incorporating a methoxy substituted benzoyl group at the 4-position of the pyrrole core. 
Pyrrole carboxylic acid 421 was prepared by a colleague (Tristan Reuillon) using a 
procedure analogous to that described in scheme 8.1. The yields for the coupling reactions 
with this monomer are summarised in table 8.13. 
 
421                                                                  330-338, 422     
Entry R Amide Coupling 
  Method Yield % Product 
1 
 
1 50 422 
2 
 
2 35 322 
3 
 
2 60 323 
4 
 
2 45 324 
9 
 
2 43 325 
5 
 
2 49 326 
6 
 
2 45 327 
7 
 
2 30 328 
8 
 
2 26 329 
 
Table 8.13: Yields for coupling of pyrrole carboxylic acid 421 with amines. Reagents and 
conditions: Method 1: Amine (2.5 eq.), cyanuric fluoride (0.3-0.7 eq.), pyridine (1 eq), 
MeCN, r.t., 18 h or Method 2: Amide (1.25 eq.), 2-chloro-1-methyl pyridinium iodide (1.1 
eq.), Et3N (2.5 eq.), CH2Cl2, r.t., 18 h.  
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Compound 422 was deprotected using the TFA/triethylsilane procedure to give 321 
(Scheme 8.18). 
 
                                                  422                                   321      
Scheme 8.18: Reagents and conditions: a) TFA, DCM, Et3SiH (2.5 eq.), 72%.  
 
8.8 Summary 
 
The synthetic component of the ERK5 project has focussed on the synthesis of bespoke 
amine monomers to explore the SARs of the amide substituent of the pyrrole carboxylate 
lead. In order to rapidly build an understanding of the SARs in this position, robust routes 
that allowed facile analogue preparation were developed, which enabled diversification of 
cyclic aliphatic, and 5- and 6-membered heteroaromatic amides substituents. Nucleophilic 
aromatic substitution reactions allowed access to 2-substituted 5-amino-linked pyridyl and 
pyrimidyl amides.  
Diversification of the 2-position in the 4-aminopyridine-linked series proved challenging, 
with the optimal route being through reaction of a pyridine N-oxide with PyBrOP to 
activate it towards nucleophilic aromatic substitution. Yields were moderate for this 
transformation, and further work to optimize this route would be a useful future direction 
to enable the synthesis of a wider range of analogues of this structural class.   
Access to diverse substituted pyrazole amides was achieved through the use of Mitsunobu 
alkylation reaction, employing alcohol monomers.  
A range of different amide coupling protocols was used, with yields often being substrate 
dependent. The Mukaiyama protocol emerged as the most versatile, having the advantage 
of requiring fewer equivalents of amine as compared to the other procedures investigated. 
This was particularly beneficial in cases where the amine coupling partner required a 
multi-step synthesis.     
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Chapter 9: Conclusions and Future Directions 
 
 
The two medicinal chemistry programs described in this thesis encompassed diverse 
chemistry, biology, and stages of the drug discovery process.  
 
9.1 The Sulfatase-2 Project 
 
Sulf-2 has been implicated as a tumour promoter in multiple cancer cell lines, and high 
Sulf-2 expression is an indicator of a poor disease prognosis. The case is less certain for 
Sulf-1, with conflicting reports regarding its tumour promoter and tumour suppressor 
functions. The aim of the project was to identify tool compounds that either selectively 
inhibit Sulf-2, or exhibit dual Sulf-1/Sulf-2 inhibition. The Sulf-2 project was in the early 
target validation phase, with little prior literature on the design of inhibitors. The only 
known series of inhibitors were monosaccharide sulfamate mimics of the endogenous 
substrate, exemplified by compound 25, which has Sulf-2 inhibitory potency above 100 
M.  
Two approaches were employed in the design of potential inhibitors. The first attempted to 
build knowledge of the structural features present in 25 that contribute to binding, and 
identify areas of the template where substitution might improve potency and affect 
selectivity. Novel regioselective sulfamoylation chemistry was developed to allow rapid 
synthesis of compound 25 and a set of novel analogues, exploring variation of the 1-, 2-, 
3-, and 4- positions. Derivatives 60-62, and compound 105 were identified as more potent 
inhibitors of Sulf-2 than the lead monosaccharide 25. A summary of the key SAR 
developed in the monosaccharide series is shown in figure 9.1.  
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Figure 9.1: Summary of Sulf-2 inhibition SARs for analogues of compound 25  
The second approach attempted the de novo design of non-saccharide inhibitors based on a 
superposition of potential scaffolds onto the solution structure of heparin as a surrogate for 
the endogenous HSPG ligands. Compounds based on a biphenyl template were designed, 
and these compounds were synthesised by other colleagues in the group. These compounds 
have yet to be assayed for sulfatase inhibitory activity. 
 
9.1.1 Potential Future Design Options 
 
Combination of structural features present in the monosaccharide sulfamates with highest 
per cent inhibition of Sulf-2 may provide more potent inhibitors, and compounds such as 
423 and 424 should be assessed. Introduction of alternative substituents at the O
4
-position 
(425) should also be investigated. 
                                 
             423                     424         425 
In order to improve the potency of the monosaccharide sulfamate against Sulf-2, it may be 
necessary to expand the template into di-, tri- or tetra-saccharides, to better mimic the key 
binding interactions of the endogenous substrate, for example 426.  
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426 
Alternative sulfamate isosteres could also be explored, with an initial focus on those that 
were active in the literature exploration of SARs for ARSC inhibitors (e.g. 427). 
Incorporation of the most potent substituents from the simple phenyl sulfamate library (68-
82) into the most promising compounds from the biaryl series, would explore whether the 
SAR was additive (428). 
           
                                              427                                    428 
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9.2 The ERK5 Project  
 
The ERK5 program was a more mature project, with extensive existing knowledge of 
ERK5 potency SARs in the lead pyrrole carboxylate series. Two sub-classes of the series 
were the cyclic aliphatic amides, and the heteroaromatic amides. In this thesis, 
optimisation of the amide substituents of each of this class was attempted, with the aim of 
improving both potency and ADMET properties. The molecular properties of the lead 
compounds were assessed relative to the set of marketed kinase inhibitors, to inform the 
optimisation program, and define ideal physicochemical and structural space. 
Combination of optimised amide substituents with a trisubstituted arylketone substitution 
pattern has provided a set of potent compounds with ERK5 inhibitory activity below 20 
nM. In the class 1 aliphatic heterocyclic amides, reduction of efflux in the Caco-2 assay 
was achieved for 269, with the N-methylpiperidine of 212 replaced by an 
N-trifluoroacetylpiperidine. However, this resulted in a 3-fold loss of ERK5 inhibitory 
activity relative to 212, and this series was not pursued further.  
 
212 ERK5; IC50 = 199 nM    269 ERK5; IC50 = 520 nM 
       Caco-2 ER = 9                       Caco-2 ER = 1.1 
 
Further work in the cyclic aliphatic amide series may be warranted, to attempt to vary the 
electronics of the nitrogen subsituent through changes in the fluorination pattern of the 
amide, for example by preparation of analogues 429-432. 
 
429 R = COCHF2 
430 R = COCH2F 
431 R = COCF2CF3 
432 R = CH2CF3 
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Variation of the position of the basic centre through alternative aminopiperidine 
regioisomers (433), and by adjusting the ring size (434 and 435), could also be investigated 
(Table 9.1). 
 
                                                                 
 
 
 
Table 9.1: Possible future analogues of 212 
 
Substitution on the aliphatic ring carbons could also be investigated, to prepare either 
bicylic bridged analogues such as 436, or incorporating substituents α to the ring nitrogen 
which may affect the pKa of the piperidine (e.g. 437). The aim of these targets would be to 
combine improved potency with low efflux in the Caco-2 membrane permeability assay.   
         
436     437 
 
In the heteroaromatic amide series, introduction of a basic centre at the 2-position of the 
pyrimidine led to improved ERK5 potency. hERG inhibition and microsomal instability 
issues were successfully overcome, leading to the identification of piperazine 286 and 4-
aminopiperidine 289 having ERK5 IC50 values below 20 nM. However, these compounds 
suffered from significant efflux (ER = 30-100) in the Caco-2 membrane permeability 
assay. Replacement of the pyrimidine with a pyridine led to compounds with similar 
pharmacological and in vitro ADME profiles. 
 
NHR 
   
              433                434                    435 
R
1
 = H, Me, Ac, CF3CO 
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Substitution of the 2-position of 4-pyridyl amides was synthetically challenging. The 
N-methylpiperazine 299 had encouraging ERK5 inhibition, but suffered from metabolic 
instability and poor solubility. Development of an improved synthetic route to allow rapid 
exploration of this area would be of interest. Targets which may represent potent ERK5 
inhibitors with superior pharmacokinetic and pharmaceutical properties, such as 438 and 
439 would be of interest. 
  
Incorporation of a pyrazole as a replacement for the pyrimidine ring allowed facile 
introduction of carbon linked substituents, minimising the number of hydrogen bond donor 
and acceptor groups in the molecule. Compound 305 proved the most potent analogue, 
having an ERK5 IC50 of 7 nM. Efflux in the Caco-2 cell assay was greatly reduced (ER = 
4.5) but low intrinsic flux. Related analogue 306 had poor oral bioavailability in an in vivo 
mouse PK study. Investigation of neutral pyrazole substituents led to the identification of 
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314 as a potent ERK5 inhibitor with high ligand efficiency. This compound had good 
stability in mouse liver microsomes, high solubility, and a Caco-2 efflux ratio of 0.9, which 
translated in vivo into low clearance and sufficient bioavailability to allow its use as an in 
vivo tool.  
        
           305 ERK5; IC50 = 7 nM     314 ERK5; IC50 = 27 nM 
                  Caco-2 ER = 4.5             Caco-2 ER = 0.9 
                  L.E. = 0.37                        L.E. = 0.43 
                                                Mouse F = 42% 
 
Compound 314 is currently undergoing evaluation in an in vivo tumour xenograft model.  
Future design options in this series include incorporation of alternative non-basic pyrazole 
substituents such as 440-444, with the aim of attaining further improvements in potency, 
whilst maintaining the favourable pharmacokinetic profile. 
 
Cmpd R 
440 
 
441 
 
442 
 
443 
 
444 
 
 
Table 9.2: Possible future pyrazole-linked analogues of 314. 
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The tolerance of the benzoyl substituent at the pyrrole 4-position to alternative substituents 
replacing the 3’-chloro group may also be an area of the template which could be explored 
in more detail (Table 9.3).  
 
Cmpd R 
445 OEt 
446 CH2CH2OH 
447 
 
448 
 
449 
 
 
Table 9.3: Possible future analogues of 314 incorporating diversity on the benzoyl group 
at the pyrrole 4-position. 
Thus, the work presented in this thesis has considerably extended the understanding on 
SARs for ERK5 inhibition in the pyrrole carboxamide series, and has highlighted structural 
features which improve ERK5 inhibition, and which affect ADMET properties. The key 
SAR developments are summarised in Figure 9.2. This has provided insights into areas of 
the template which may benefit from further exploration.  
 
Figure 9.2: Summary of SARs for compound 212 developed or confirmed by the work 
contained in this thesis.  
  
220 
 
Chapter 10: Experimental 
 
10.1 Sulf-2 Project Experimental Procedures 
 
The sulfatase biological assays were performed by Dr Gary Beale and Sari Alhasan. 
 
10.1.1 Sulfatase Biological Assay Protocols 
 
Sulf-2 Assay Protocol 
 
Compounds were screened using 4-MUS as a substrate for Sulf-2 according to a protocol 
described by Morimoto-Tomita et al.
84 
Briefly 293T cells were transiently transfected with 
pcDNA3.1Myc/His (-)-Sulf-2 DNA (Addgene) using Fugene 6 according to the 
manufacturers protocol. Conditioned medium containing Sulf-2 was bound to Ni-NTA 
agarose beads overnight at 4

C. Beads were washed with three times 15 mLs of 50 mM 
Hepes (pH 7.5), 10 mM MgCl2, 0.05% Tween 20, followed by 15 mLs of 50 mM Hepes 
(pH 7.5), 10 mM MgCl2. Beads were suspended in reaction buffer 50 mM Hepes (pH 7.5), 
10 mM MgCl2 prior to inhibition assays. 20 Ls of bead suspension was incubated with 1 
mM compound (in DMSO) plus 10X reaction buffer for 1 h at 37

C. The reaction was 
started by the addition of 20 Ls of 20 mM 4-MUS (Final Concentration 8 mM) and 
incubated at 37

C for 1 h. The reaction was stopped with 140 L 1 M Tris buffer (pH 10.4) 
and read at 460 nm following excitation at 355 nm in FLUOstar Omega plate reader (BMG 
Labtech) using Omega data analysis software. 
ARSA and ARSB  Assay Protocols 
  
Compounds were screened in a 96-well black plate (Sterilin) using 4-MUS as a substrate, 
using 50 µl reaction mixture containing 40 ng of the commercially available enzymes 
(ARSA or ARSB from R & D Systems), 50 mM HEPES (pH = 4.5), 10 mM CaCl2, 1 mM 
test compound (dissolved in DMSO; final concentration of DMSO in reaction = 2%), and 
H2O (45 L). The assay mixture was incubated for 1 h at 37 C, followed by addition of 5 
L of 4-MUS (Km = 1.6 mM for ARSA and 612 M for ARSB), and incubation for a 
further 1 h at 37 C. The reaction was stopped with 100 µL of 1 M Tris (pH = 10.5) and 
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read at 460 nm following excitation at 355 nm in FLUOstar Omega plate reader (BMG 
Labtech) using the Omega data analysis software. 
10.2 Summary of Generic Analytical and Chromatographic Conditions 
 
All commercial reagents were obtained from Aldrich Chemical Company or Apollo 
Scientific Ltd and were of the highest available purity. Unless otherwise stated, chemicals 
were used as supplied without further purification. Anhydrous solvents were obtained from 
Aldrich SureSeal™ bottles and were stored under nitrogen. Petrol refers to the fraction 
with a boiling point between 40 and 60°C. All reactions carried out in a microwave were 
performed in a Biotage Initiator Sixty apparatus.  
The progress of reactions was monitored by thin layer chromatography was conducted on 
plates pre-coated with silica gel (Merck 60F254), NH2F254s or C18-SiO2. Eluent mixture 
ratios are quoted as volume:volume. Visualisation was either by short wave (254 nm) 
ultraviolet light, or by treatment with the visualisation reagent stated. ‘Flash’ medium 
pressure liquid chromatography (MPLC) was carried out either on a Biotage SP4 
automated purification system or a Varian automated purification system, using pre-packed 
Varian or Grace silica, amino-bonded or C18 silica cartridges. Elution gradients are quoted 
as per cent polar component at the start and end of the elution.  
Compounds requiring semi-preparative HPLC were purified on one of the following machines: 
(i) Varian Prostar Modular HPLC system equipped with a binary pumping system, UV 
detector and fraction collector and controlled by Varian Star software. (ii) Agilent 1200 HPLC 
system equipped with a binary pump, autosampler, fraction collector and diode array detector 
and controlled by Agilent ChemStation software.  
Melting points were determined with on either a Stuart Scientific SMP3 or SMP40 
apparatus and are uncorrected. 
1
H, 
13
C and 
19
F nuclear magnetic resonance (NMR) spectra 
were obtained as CD3OD, CDCl3, D2O, or DMSO-d
6
 solutions and recorded at 500 MHz, 
75 MHz, and 125 MHz, respectively, on a Bruker Avance III 500 spectrometer. Where 
13
C 
NMR data are not quoted, insufficient material was available or problems obtaining 
adequate spectra were encountered. Chemical shifts are quoted in parts per million () 
referenced to the appropriate deuterated solvent employed. Multiplicities are indicated by s 
(singlet), d (doublet), t (triplet), q (quartet), quin (quintet), sept (septet), m (multiplet) or 
(br) broad, or combinations thereof. Coupling constant values are given in Hz. 
222 
 
Homonuclear and heteronuclear two dimensional NMR experiments were used where 
appropriate to facilitate assignment of chemical shifts. LC-MS was carried out on a Waters 
Acquity LC platform running either positive ion or negative ion electrospray mode, unless 
otherwise stated. Optical rotations were determined on an Optical Activity PolAAR 3001 
polarimeter with a path length of 0.25 dm. IR spectra were recorded on either a Bio-Rad 
FTS 3000MX diamond ATR or an Agilent Cary 630 FTIR as a neat sample. UV spectra 
were obtained using a U-2001 Hitachi Spectrophotometer and performed in ethanol. High 
resolution mass spectra were performed by the EPSRC National Mass Spectrometry 
Service, University of Wales Swansea, Singleton Park, Swansea, SA2 8PP. Data were 
compared with literature data for compounds which had been previously reported. 
 
10.2.1 Procedures for the Synthesis of Sulfamoyl Chloride  
 
Method 1: Formic acid (460 L, 550 mg, 12 mmol, 1 eq) was added dropwise to 
chlorosulfonyl isocyanate (1.05 mL, 1.7 g, 12 mmol, 1 eq) in anhydrous dichloromethane 
(5 mL) at 0 C. Gentle gas evolution was observed. The mixture was allowed to warm to 
room temperature and stirred at room temperature for 3 h to give a white suspension. 
Method 2: Formic acid (460 L, 550 mg, 12 mmol, 1 eq) was added dropwise to 
chlorosulfonyl isocyanate (1.05 mL, 1.7 g, 12 mmol, 1 eq) at 0 C. Gentle gas evolution 
was observed. The mixture was allowed to warm to room temperature and stirred at room 
temperature for 3 h to give a white solid. The solid was dissolved in anhydrous toluene (6 
mL) to give a clear 2 M solution. Stock solutions were used immediately. 
Method 3: Formic acid (460 L, 550 mg, 12 mmol, 1 eq) was added dropwise to 
chlorosulfonyl isocyanate (1.05 mL, 1.7 g, 12 mmol, 1 eq) in anhydrous MeCN (5 mL) at 0 
C. Gentle gas evolution was observed. The mixture was allowed to warm to room 
temperature and stirred at room temperature for 3 h to give a white suspension. 
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10.2.2 General Procedures for Sulfamoylation of Alcohols and Phenols 
 
Sulfamoylation Method 1: Sulfamoyl chloride (1.5-3 eq.) was added portion-wise over 30 
minutes to the substrate alcohol (1 eq.) in anhydrous DMA (2 mL) at -15 C. The reaction 
mixture was stirred at -15 C for 2 h. 
Sulfamoylation Method 2: Sulfamoyl chloride (1.5 eq.) was added to the substrate 
alcohol (1 eq.) in anhydrous DMF (4 mL/mmol) at -40 C over 15 minutes. The mixture 
was stirred at -40 C for 18 h. The reaction was quenched with water (2 mL) and extracted 
with EtOAc (20 mL). Saturated NaCl(aq) (10 mL) added to aqueous layer and further 
extracted with EtOAc (3 × 20 mL). The organic layers were combined, dried (MgSO4) and 
the solvent was removed in vacuo. 
Sulfamoylation Method 3: Sulfamoyl chloride (1.5 eq.) was added to the substrate 
alcohol (1 eq.) in anhydrous MeCN (5.4 mL) containing 600 L DMA at room 
temperature. The mixture was stirred at room temperature for 15 min, quenched with EtOH 
(1.5 mL) and partitioned between EtOAc (2 × 10 mL) and H2O (10 mL). The aqueous 
layer was extracted with a further 10 mL of CH2Cl2, the organic extracts were combined, 
dried over MgSO4 and solvent removed in vacuo. 
Sulfamoylation Method 4: Sulfamoyl chloride (2 eq.) was added to the substrate alcohol 
(1 eq.) in DMA at 0 C. The mixture was stirred at r.t. overnight, and then quenched with 
water. The mixture was extracted with EtOAc (2 × 20 mL), washed with brine, dried over 
MgSO4, filtered and the solvent removed in vacuo. 
 
10.2.3 Sulf-2 General Synthetic Procedures  
 
General Procedure A: Deprotection of Benzyl Carbamate using Palladium-
Catalysed Flow Hydrogenation  
 
The appropriate benzyl carbamate (1 eq.) was dissolved in MeOH (25 mL/mmol) and 
hydrogenated on a Thales H-cube over 10% Pd/C on full H2 mode at 40 C for 18 h with 
continuous recycling of the reaction mixture. The solvent was removed in vacuo. 
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General Procedure B: Chemoselective N-Sulfation 
 
The substrate amine (1 eq.) was dissolved in de-ionised water (6 mL/mmol) and the pH of 
the solution was adjusted to between pH 9 and 10 with NaOH (2 M aq.). Pyridine-sulfur 
trioxide complex (1.1 eq.) was added portion-wise at 30 minute intervals. After each 
addition the pH of the solution was adjusted to pH 9-10 by the addition of 2 M aqueous 
NaOH. The mixture was stirred at room temperature for 2 h and the solvent removed in 
vacuo. 
General Procedure C: Synthesis of Trichloroethysulfate Protected Amines 
 
2,3-Dimethyl-1-((2,2,2-trichloroethoxy)sulfonyl)-1H-imidazol-3-ium tetrafluoroborate (1 
eq.) was added to the substrate alcohol (1 eq.) in THF (10 mL/mmol) at r.t., and the 
mixture was stirred at room temperature for 18 h. The solvent was removed in vacuo. 
 
10.3 Synthesis of Compounds for the Sulf-2 Project 
 
10.3.1 Synthesis of monosaccharide sulfamates 
 
 Nomenclature 
The monosaccharide sulfamates prepared below have been titled using their IUPAC 
names. However, NMR peaks have been assigned using the common saccharide 
numbering system. This allows direct comparison with NMR assignments from the 
carbohydrate chemistry literature for known compounds. The numbering system used for 
the NMR assignments is outlined on the generic structures below. 
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N-((3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-methoxy tetrahydro-2H-
pyran-3-yl)acetamide (107) 
 
Amberlite IR120 (H
+
) ion exchange resin (1.25 g) was added to N-acetylglucosamine (1 g, 
4.5 mmol) in anhydrous MeOH (30 mL) and heated to reflux for 18 h. The mixture was 
allowed to cool to r.t., filtered, and the solvent removed in vacuo. Dowex 1X8 200-400 
mesh ion exchange resin in the chloride form (400 g) was suspended in 2 volumes of 
water. This suspension was allowed to stand for 2 minutes and the resin decanted away 
from large settled particles. The suspension was then allowed to stand for a further 90 
minutes, and the supernatant decanted away from resin. The remaining resin was re-
suspended in 2 volumes of water and packed into a glass column (50 cm × 4 cm). The 
column was eluted with NaOH (2 M aq.) until the pH of the eluant reached pH 14 to 
convert resin to OH
-
 form. The column was then eluted with water until the pH of eluant 
returned to neutral. The crude compound mixture was dissolved in water (3 mL) and eluted 
under gravity at a rate of 3 mL/min, collecting 15 mL fractions. Fractions were analysed 
for the presence of compound by spotting onto SiO2 TLC plates and staining with 
anisaldehyde visualisation reagent. Six fractions containing compound were individually 
frozen and lyophilised overnight and analysed by 
1
H NMR to determine purity and anomer 
composition. Fractions containing levels of β anomer below the detection limit of 1H NMR 
were combined to give a white solid (466 mg, 44%). Rf 0.3 (40% MeOH/CH2Cl2, 
anisaldehyde); m.p. 190-192 C; max(EtOH)/nm < 210 nm; IR  max/cm
-1 
3288 (br), 2928, 
1645 (amide I), 1550 (amide II); 
1
H NMR(500 MHz; CD3OD) H 1.88 (3H, s, CH3CO), 
3.25 (1H, dd, J = 9.9 and 8.9 Hz, H-4), 3.27 (3H, s, OCH3), 3.53 (1H, dd, J = 10.6 and 8.9 
Hz, H-3), 3.42-3.47 (1H, m, H-5), 3.59 (1H, dd, J = 11.9 and 5.7 Hz, H-6a), 3.73 (1H, dd, J 
= 11.9 and 2.4 Hz, H-6b), 3.80 (1H, dd, J = 10.6 and 3.6 Hz, H-2), 4.55 (1H, d, J = 3.6 Hz, 
H-1); 

C NMR(125 MHz; CD3OD) C 22.6 (CH3CO), 55.4 (CH3O), 55.5 (C-2), 62.8 (C-
6), 72.4 (C-4), 73.0 (C-3), 73.7 (C-5), 99.8 (C-1), 173.7 (CO); MS (ESI+) m/z 236.2 
[M+H]
+
. 
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((2R,3S,4R,5R,6S)-5-Acetamido-3,4-dihydroxy-6-methoxytetrahydro-2H-pyran-
2-yl)methyl sulfamate (27) 
 
Prepared according to sulfamoylation method 1 using sulfamoyl chloride (0.6 mL, 1.0 M in 
toluene, 0.60 mmol, 1.5 eq.), alcohol 107 (100 mg, 0.43 mmol, 1 eq.) and DMA (2 mL) 
at -15 C with stirring at -15 C for 2 h. The reaction was quenched with water (0.3 mL) 
and MeOH (2 mL) and the solvent was removed in vacuo. The residue was azeotroped 
with toluene (2 × 10 mL) and purified by MPLC on SiO2 with gradient elution from 2-10% 
MeOH/EtOAc to give a white solid (44 mg, 35%). Rf 0.2 (5% MeOH/EtOAc; 
anisaldehyde); m.p. 182-184 C dec.; max(EtOH)/nm < 210 nm; IR  max/cm
-1
 3325, 1641 
(amide I), 1542 (amide II), 1365 (SO), 1182 (SO); 
1
H NMR (500 MHz; CD3OD)H 2.02 
(3H, s, CH3CO), 3.39 (1H, dd, J = 10.0 and 8.8 Hz , H-4), 3.42 (s, 3H, OCH3), 3.68 (1H, 
dd, J = 10.7 and 8.8 Hz, H-3), 3.81 (1H, ddd, J = 10.0, 6.0 and 1.9 Hz, H-5), 3.95 (1H, dd, 
J = 10.7 and 3.6 Hz, H-2), 4.30 (1H, dd, J = 10.8 and 6.0 Hz, H-6a), 4.45 (1H, dd, J = 10.8 
and 1.9 Hz, H-6b), 4.69 (1H, d, J = 3.6 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 22.6 
(CH3CO), 55.2 (C-2), 55.7 (OCH3), 70.1 (C-6), 71.3 (C-5), 72.1 (C-4), 72.9 (C-3), 99.9 (C-
1); HRMS calcd for C9H19N2O8S [M+H]
+
 315.0857, found 315.0860.  
Two other bis-sulfamate by-products were also isolated from this reaction, and 
characterised as the following two compounds:- 
((2R,3R,4R,5R,6S)-5-acetamido-3-hydroxy-6-methoxy-3-((aminosulfonyl)oxy) 
tetrahydro-2H-pyran-2-yl) methyl sulfamate (115) 
 
Bis-sulfamate 115 was isolated as a by-product from the synthesis of sulfamate 27 as a 
white solid. Rf 0.4 (5% MeOH/EtOAc, anisaldehyde); m.p. 118-120 C; max(EtOH)/nm 
<210 nm;
 1
H NMR (500 MHz; CD3OD) H 1.88 (3H, s, CH3CO), 3.32 (3H, s, OCH3), 3.51 
(1H, dd, 10.0 and 8.8 Hz, H-4), 3.77 (1H, ddd, J = 10.0, 5.5 and 1.9 Hz, H-5), 4.09 (1H, 
dd, J = 10.6 and 3.5 Hz, H-2), 4.21 (1H, dd, J = 10.9 and 5.5 Hz, H-6a), 4.32 (1H, dd, J = 
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10.9 and 1.9 Hz, H-6b), 4.49 (1H, dd, J = 8.8 and 10.6 Hz, H-3), 4.59 (1H, d, J = 3.5 Hz, 
H-1); 

CR (125 MHz; CD3OD)C 22.7 (CH3CO), 53.2 (C-2), 55.8 (OCH3), 65.6 (C-
6), 70.2 (C-4), 71.3 (C-5), 83.0 (C-3), 100.0 (C-1), 173.8 (CO); HRMS calcd for 
C9H18N3O10S2 [M-H]
- 
392.0439, found 392.0437. 
((2R,3S,4R,5R,6S)-5-Acetamido-4-hydroxy-6-methoxy-4-((amino sulfonyl)oxy) 
tetrahydro-2H-pyran-2-yl) methyl sulfamate (116) 
 
Bis-sulfamate 116 was isolated as a by-product from the synthesis of sulfamate 27 as a 
white solid. Rf 0.3 (5% MeOH/EtOAc, anisaldehyde); m.p. 170-174 C; max(EtOH)/nm 
<210 nm; IR  max/cm
-1
 3288 (br), 1662 (amide I), 1540 (amide II), 1349 (SO), 1172 (SO); 
1
H NMR (500 MHz; CD3OD) H 1.88 (3H, s, CH3CO), 3.30 (3H, s, OCH3), 3.77 (1H, dd, J 
= 10.9 and 8.9 Hz, H-3), 3.87 (1H, ddd, J = 10.1, 6.6 and 2.1 Hz, H-5), 3.94 (1H, dd, J 
=10.9 and 3.6 Hz, H-2), 4.14 (1H, dd, J =11.1 and 6.6 Hz, H-6a), 4.22 (1H, dd, J = 10.1 
and 8.9 Hz, H-4), 4.37 (1H, dd, J = 11.1 and 2.1 Hz, H-6b), 4.59 (1H, d, J = 3.6 Hz, H-
1);

CR (125 MHz; CD3OD) C 22.5 (CH3CO), 55.2 (OCH3), 55.9 (C-2), 69.0 (C-5), 
69.4 (C-6), 71.2 (C-3), 80.3 (C-4), 99.4 (C-1), 173.8 (CO); HRMS calcd for C9H23N4O10S2 
[M+NH4]
+
 411.0850, found 411.0851. 
Benzyl ((3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-
pyran-3-yl)carbamate (102) 336 
 
NaHCO3(s) (9.3 g, 110.7 mmol, 3 eq.) was added to a solution of D-glucosamine 
hydrochloride (7.7 g, 35.7 mmol, 1 eq.) in H2O (230 mL). Benzyl chloroformate (5.60 mL, 
39.3 mmol, 1.1 eq.) was added portion-wise over 30 min and the mixture was stirred at 
room temperature for 18 h. The white precipitate formed was filtered off, azeotroped with 
toluene (2 × 50 mL) and dried in vacuo at 45 C to give the product mixture of anomers as 
a white solid (10.25 g, 92 %). Rf 0.2 (10% MeOH/CH2Cl2; anisaldehyde); mp 180 C 
dec.; max(EtOH)/nm < 210; IR  max/cm
-1
 3297, 1681 (carbamate I), 1543 (carbamate II); 
1
H NMR (500 MHz; CD3OD) H 3.27-3.47 (2H, m), 3.56-3.90 (4H, m), 4.59 (0.3 H, d, J = 
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8.2 Hz, β anomer H-1), 5.11 (2H, s, CH2Ph), 5.14 (0.7 H, d, J = 3.3 Hz, α anomer H-1), 
7.26-7.44 (5H, m, H-Ar); 

C NMR(125 MHz; CD3OD) C 57.7 (C-2), 67.5, 62.8, 72.5, 
72.9, 73.1, 78.0, 93.0, 97.3 (C-1), 128.9 (C-Ar), 129.5 (C-Ar), 138.3 (C-Ar), 158.9 (CO); 
MS (ESI-) m/z 312.2 [M-H]
-
. 
Benzyl((2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-methoxy 
tetrahydro - 2H-pyran-3-yl) carbamate (103) 
 
Carbamate 102 (5 g, 16 mmol) was suspended in a 1.25 M solution of HCl in methanol (40 
mL) and heated to 80 C for 18 h. The resulting solution was evaporated and the residue 
purified by MPLC on SiO2 with a gradient elution from 2-12% MeOH/CH2Cl2. Product 
containing fractions were combined and evaporated to give a white solid (3.8 g, 73%). Rf 
0.3 (10% MeOH/CH2Cl2; anisaldehyde); mp 159-160 C; [α]D
22.8
 +84.8 (c = 1.0, MeOH); 
max(EtOH)/nm 204; IR  max/cm
-1
 3330 br, 1678 (carbamate I), 1539 (carbamate II); 
1
H 
NMR (500 MHz; CD3OD) H 3.36-3.40 (1H, m, H-4), 3.52-3.67 (3H, m, H-2, H-3, H-5), 
3.71 (1H, dd, , J = 11.8 and 5.7 Hz, H-6a), 3.84 (1H, dd, J = 11.8 and 2.1 Hz, H-6b), 4.70 
(1H, d, J = 3.2 Hz, H-1), 5.11 (2H, s, CH2Ph), 7.28-7.41 (5H, m, H-Ar); 

CNMR (125 
MHz; CD3OD)C 55.5 (OMe), 56.1 (C-2), 62.7 (C-6), 67.6 (CH2Ph), 72.3 (C-4), 73.2 (C-
5), 73.7 (C-3), 100.2 (C-1), 128.9 (C-Ar), 129.4 (C-Ar), 138.3 (C-Ar), 158.9 (CO); MS 
(ESI-) m/z 313.1[M-H]
-
; (ESI+) m/z 315.2 [M+H]
+
. 
((2R,3S,4R,5R,6S)-5-(((Benzyloxy)carbonyl)amino)-3,4-dihydroxy-6-methoxy 
tetrahydro-2H-pyran-2-yl)methyl sulfamate (104) 
 
Prepared according to sulfamoylation method 2 using sulfamoyl chloride (1.0 mL, 1.0 M in 
toluene, 1.0 mmol, 1.65 eq.), alcohol 103 (200 mg, 0.61 mmol, 1 eq.) and DMF (4 mL) 
at -40 C. The mixture was stirred at -40 C for 18 h, quenched by cautious addition of 
water (2 mL) and extracted with EtOAc (20 mL). Saturated NaCl(aq) (10 mL) added to 
aqueous layer and further extracted with EtOAc (3 × 20 mL). The organic layers were 
combined, dried (MgSO4) and the solvent was removed in vacuo. The residue was purified 
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by MPLC on SiO2 with a gradient elution from 50% EtOAc/petrol to 100% EtOAc to 10% 
MeOH/EtOAc to give a white solid (136 mg, 55%). Rf 0.5 (5% MeOH/EtOAc; 
anisaldehyde); mp 104-106 C[α]D
22.6 
+40.93 (c = 0.43, MeOH); max(EtOH)/nm 257.5 
(weak), 210; IR  max/cm-
-1 
3377, 3332, 3236, 1685 (carbamate I), 1542 (carbamate II), 
1372 (SO), 1180 (SO); 
1
H NMR(500 MHz; DMSO-d6) H 3.14 (1H, m, H-4), 3.26 (3H, s, 
OCH3), 3.39-3.51 (2H, m, H-2 and H-3), 3.60 (1H, ddd, J = 1.6, 6.6 and 8.0 Hz, H-5), 4.08 
(1H, dd, J = 6.6 and 10.6 Hz, H-6a), 4.28 (1H, dd, J = 1.6 and 10.6 Hz, H-6b), 4.61 (1H, d, 
J = 3.2 Hz, H-1), 4.91 (1H, d, J = 5.6 Hz, OH-3), 5.01 (1H, d, J = 12.5 Hz, CHaHbPh), 5.05 
(1H, d, J = 12.5 Hz, CHaHbPh), 5.31 (1H, d, J = 5.7 Hz, OH-4), 7.18 (1H, d, J = 7.9 Hz, 
NHCO2Bn), 7.29-7.41 (5H, m, H-Ar), 7.49 (2H, br s, OSO2NH2); 
1
H NMRH (500 MHz; 
CD3OD) 3.36-3.44 (4H, m, OCH3 and H-4), 3.58-3.68 (2H, m, H-2 and H-3), 3.79 (1H, 
ddd, J = 9.9, 6.0 and 1.6 Hz, H-5), 4.27 (1H, dd, J = 10.7 and 6.0 Hz, H-6a), 4.42 (1H, dd, J 
= 10.7 and 1.6 Hz, H-6b), 4.70 (1H, d, J = 3.2 Hz, H-1), 5.11 (2H, s, CH2Ph), 7.29-7.41 
(5H, m, H-Ar);

CNMR (125 MHz; CD3OD)C 55.7 (OCH3), 57.1 (C-2), 67.6 (CH2Ph), 
70.1 (C-6), 71.3 (C-5), 72.0 (C-4), 73.1 (C-3), 100.2 (C-1), 128.9 (C-Ar), 129.0 (C-Ar), 
129.5 (C-Ar), 138.3 (C-Ar), 158.9 (CO); HRMS calc. for C15H23N2O9S [M+H]
+
 407.1119, 
found 407.1119. 
((2R,3S,4R,5R,6S)-5-Amino-3,4-dihydroxy-6-methoxytetrahydro-2H-pyran-2-
yl)methyl sulfamate (105) 
 
Prepared according to general procedure A using sulfamate 104 (1.525 g, 3.8 mmol), 
MeOH (90 mL) and CH2Cl2 (30 mL) for 18 h to give a white solid (1.015 g, 99%). Rf 0.05 
(CH2Cl2/MeOH/NH4OH 80:20:3; anisaldehyde); mp 104-112 C; [α]D
17.1
 +59.2 (c = 0.5, 
MeOH); max(EtOH)/nm <220; IR  max/cm
-1
 3297, 1359 (SO), 1176 (SO); 
1
H NMR (500 
MHz; CD3OD) H 3.17 (1H, dd, J = 10.5 and 3.7 Hz, H-2), 3.40 (1H, dd, J = 10.1 and 8.9 
Hz, H-4), 3.5 (3H, s, OCH3), 3.77 (1H, dd, J = 10.5 and 8.9 Hz, H-3), 3.84 (1H, ddd, J = 
10.1, 5.8 and 2.0 Hz, H-5), 4.31 (1H, dd, J = 10.9 and 5.8 Hz, H-6a), 4.45 (1H, dd, J = 10.9 
and 2.0 Hz, H-6b), 4.94 (1H, d, J = 3.7 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 55.8 
(OCH3), 56.2 (C-2), 69.8 (C-6), 71.5 (C-4), 71.6 (C-5), 73.6 (C-3), 99.4 (C-1); HRMS calc. 
for C7H17N2O7S [M+H]
+
 273.0751, found 273.0755. 
230 
 
Ammonium ((2S,3R,4R,5S,6R)-4,5-dihydroxy-2-methoxy-6-((sulfamoyloxy) 
methyl)tetrahydro-2H-pyran-3-yl)sulfamate (25) 
 
Prepared according to general procedure B, using amine 105 (140 mg, 0.52 mmol, 1 eq.), 
de-ionised water (3 mL) and pyridine-sulfur trioxide complex (90 mg, 0.565 mmol, 1.1 
eq.). The crude product was purified by MPLC on SiO2 with a gradient elution from 
70/30/3 to 35/65/3 CH2Cl2/MeOH/NH4OH to give an off-white solid (81 mg, 0.23 mmol, 
43%); (Found: C, 21.4; H, 5.1; N, 10.5; C, 21.6; H, 5.1; N, 11.1; calcd for 
C7H19N3O10S2.H2O: C, 21.7; H, 5.5; N, 10.9); Rf 0.1 (MeOH/NH3 95:5; anisaldehyde); mp 
125-135 C; [α]D
16.9
 +103.13 (c = 0.32, MeOH);max(EtOH)/nm < 220; IR  max/cm
-1 
3218, 3084, 1356 (SO), 1170 (SO); 
1
H NMR (500 MHz; DMSO-d
6
) H 3.01 (1H, ddd, J = 
3.5, 8.0 and 10.7 Hz, H-2), 3.12 (1H, ddd, J = 5.6, 8.5 and 9.9 Hz, H-4), 3.28 (3H, s, 
OCH3), 3.40-3.46 (1H, m, H-3), 3.60 (1H, ddd, J = 1.6, 6.9 and 9.9 Hz, H-5), 4.08 (1H, dd, 
J = 6.9 and 10.1 Hz, H-6a), 4.20 (1H, d, J = 8.0 Hz, NHSO3
-
), 4.31 (1H, dd, J = 1.6 and 
10.1 Hz, H-6b), 4.69 (1H, d, J = 3.5 Hz, H-1), 5.24 (1H, d, J = 5.6 Hz, OH-4), 5.49 (1H, d, 
J = 2.2 Hz, OH-3), 7.09 (4H, br s, NH4
+
), 7.50 (2H, br s, OSO2NH2); 
1
H NMR (500 MHz; 
D2O)H 3.30 (1H, dd, J = 10.0 and 3.6 Hz, H-2), 3.47 (3H, s, OCH3), 3.57 (1H, app t, J = 
10.0 Hz, H-4), 3.64 (1H, app t, J = 10.0 Hz, H-3), 3.95 (1H, ddd, J = 10.0, 4.6, and 2.3 Hz, 
H-5), 4.47 (1H, dd, J = 11.2 and 4.6 Hz, H-6a), 4.51 (1H, dd, J = 11.2 and 2.3 Hz, H-6b), 
5.07 (1H, d, J = 3.6 Hz, H-1); 

CR (125 MHz; D2O) C 55.5 (OCH3), 57.6 (C-2), 68.9 
(C-6), 69.1 (C-5), 69.5 (C-4), 71.3 (C-3), 98.7 (C-1); HRMS calc. for C7H15N2O10S2 
[M-H]
-
 351.074, found 351.074. 
2,2,2-Trichloroethyl ((2S,3R,4R,5S,6R)-4,5-dihydroxy-2-methoxy-6-
(sulfamoyloxy)methyl)tetrahydro-2H-pyran-3-yl)sulfamate (117) 
 
Amine 105 (50 mg, 0.18 mmol, 1 eq.) and 2,3-dimethyl-1-((2,2,2-
trifluoroethoxy)sulfonyl)-1H-imidazol-3-ium tetrafluoroborate (70 mg, 0.18 mmol, 1 eq.) 
were combined in THF and stirred at r.t. for 18 h. The solvent was removed in vacuo and 
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the residue purified by MPLC on SiO2 with gradient elution from 60-80% EtOAc/petrol to 
give a clear gum (54 mg, 61%); Rf 0.55 (EtOAc; anisaldehyde); max(EtOH)/nm <220; 
[α]D
19.5
 +106.7 (c = 0.15, EtOH); IR  max/cm
-1 
3281 (br), 2926, 1358 (SO), 1178 (SO); 
1
H 
NMR(500 MHz; DMSO-d6) H 3.17-3.24 (2H, m, H-4 and H-2), 3.36 (3H, s, OMe), 3.49-
3.55 (1H, ddd, J = 6.0, 8.7, and 10.4 Hz, H-3), 3.65 (1H, ddd, J = 1.7 , 6.5 and 9.9 Hz, H-
5), 4.08-4.15 (1H, m, H-6a), 4.32 (1H, dd, J = 1.7 and 10.4 Hz, H-6b), 4.67 (1H, d, J = 11.2 
Hz, CHaHbCCl3), 4.73 (1H, d, J = 3.6 Hz, H-1), 4.91 (1H, d, J = 11.2 Hz, CHaHbCCl3), 
5.41-5.48 (2H, m, OH
3
 and OH
4
 ), 8.77 (1H, s, CHNH), 7.53 (2H, s, NH2); 

C NMR (125 
MHz; DMSO-d
6
)C 54.7 (OMe), 58.2 (C-2), 68.3 (C-6), 69.5 (C-5), 70.2 (C-3), 70.5 (C-
4), 77.4 (CH2CCl3), 98.1 (C-1); HRMS calcd for C9H16N2O10S2
35
Cl3 [M-H]
-
 
480.9317, found 480.9314. 
((2R,3S,4R,5R,6S)-3,4-Dihydroxy-6-methoxy-5-(methylsulfonamido) 
tetrahydro-2H-pyran-2-yl)methyl sulfamate (48) 
 
Methanesulfonyl chloride (76 L, 0.77 mmol, 1.05 eq.) was added dropwise to amine 105 
(200 mg, 0.74 mmol, 1 eq.) and N,N-diisopropylethylamine (192 L, 1.1 mmol, 1.5 eq.) in 
anhydrous dichloromethane (2 mL) and dioxane (2 mL) at 0 C. The mixture was stirred at 
0 C for 1 h. A further 19 L (0.19 mmol, 0.25 eq.) of methanesulfonyl chloride was added 
and the mixture stirred at 0 C for 1 h. Water was added, and the mixture extracted with 
CH2Cl2 (2 × 10 mL). The organic layer was evaporated in vacuo and purified by MPLC on 
SiO2 with a gradient elution from EtOAc to 8% MeOH/EtOAc to give a clear gum (73 mg, 
0.21 mmol, 28%). Rf 0.2 (CH2Cl2/MeOH 90:10; anisaldehyde); [α]D
22.6 
+41.48 (c = 0.27, 
MeOH); max(EtOH)/nm < 220; IR  max/cm
-1 
3316 br, 2938, 1368 (SO), 1178 (SO);1H 
NMR(500 MHz; CD3OD) H 3.08 (3H, s, CH3SO2), 3.32-3.37 (2H, m, H-2 and H-4), 3.45 
(1H, s, OCH3), 3.64 (1H, dd, J = 10.4 and 8.8 Hz, H-3), 3.80 (1H, ddd, J = 10.1 , 5.9, and 
2.0 Hz, H-5), 4.29 (1H, dd, J = 10.7 and 5.9 Hz, H-6a), 4.44 (1H, dd, J = 10.7 and 2.0 Hz, 
H-6b), 4.72 (1H, d, J = 3.6 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 41.1 (CH3SO2), 
55.5 (OCH3), 57.3 (C-2), 68.8 (C-6), 69.3 (C-5), 69.6 (C-4), 71.4 (C-3), 99.4 (C-1); HRMS 
calc. for C9H17N2O9S2 [M-H]
-
 349.0381, found 349.0383. 
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((2R,3S,4R,5R,6S)-3,4-Dihydroxy-6-methoxy-5-(trifluoromethylsulfonamido) 
tetrahydro-2H-pyran-2-yl)methyl sulfamate (49) 
 
Trifluoromethanesulfonic anhydride (62 L, 0.37 mmol, 1 eq.) was added to amine 105 
(100 mg, 0.37 mmol, 1 eq.) and triethylamine (57 L, 0.44 mmol, 1.2 eq.) in a mixture of 
dioxane (8 mL) and dichloromethane (2 mL) at 0 C. The mixture was stirred at 0 C for 1 
h, and then further trifluoromethanesulfonic anhydride (31 L, 0.18 mmol, 0.5 eq.) was 
added at 0 C. The mixture was stirred at 0 C for a further 1 h, and then quenched by the 
cautious addition of water. The mixture was extracted with CH2Cl2 (2 × 20 mL). The 
aqueous layer was diluted with saturated NaCl(aq) and extracted with further CH2Cl2 (2 × 
20 mL). The organic layers were combined, dried over MgSO4, and the solvent was 
removed in vacuo. The residue was purified by MPLC on SiO2 with a gradient elution 
from 2-15% MeOH/CH2Cl2 to give a clear gum which was dissolved in EtOAc (20 mL) 
and washed with water (4 × 30 mL). The organic layer was dried over MgSO4 and the 
solvent removed in vacuo to give a white solid (55 mg, 0.14 mmol, 37%). Rf 0.6 
(CH2Cl2/MeOH 80:20; anisaldehyde,); mp 55-65 C;[α]D
22.6 
+95.5 (c = 0.18, MeOH); 
max(EtOH)/nm <220; IR  max/cm
-1 
3274 (br), 2923, 2851, 1363 (SO), 1178 (SO); 
1
H 
NMR(500 MHz; CD3OD) H 3.35-3.42 (2H, m, H-2 and H-4), 3.46 (3H, s, OCH3), 3.65 
(1H, dd, J = 10.4 and 8.8 Hz, H-3), 3.81 (1H, ddd, J = 10.0 Hz, 6.0 and 2.0 Hz, H-5), 4.28 
(1H, dd, J = 10.8 and 6.0 Hz, H-6a), 4.44 (1H, dd, J = 10.8 and 2.0 Hz, H-6b), 4.73 (1H, d, 
J = 3.6 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 59.9 (OCH3), 60.3 (C-2), 69.9 (C-6), 
71.2 (C-5), 72.0 (C-4), 72.5 (C-3), 100.7 (C-1), 128.3 (q, JCF = 320.1 Hz, CF3); 
19
FR 
(470 MHz; CD3OD) F -79.51; HRMS calc. for C8H14O9N2F3S2 [M-H]
-
 403.0098, found 
403.0100. 
((2R,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-methoxytetrahydro-2H-pyran-2-
yl)methyl sulfamate (50) 
 
Prepared according to sulfamoylation method 2 using sulfamoyl chloride (1.85 mL, 1 M in 
MeCN, 1.85 mmol, 1.8 eq.), methyl-α-D-glucopyranoside (200 mg, 1.02 mmol, 1 eq.), and 
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DMF (7 mL). The residue was purified by MPLC on SiO2 with a gradient elution from 2-
8% MeOH/EtOAc to give a white solid (70 mg, 25%); Rf 0.25 (15% MeOH/EtOAc; 
anisaldehyde); mp 55-60 C; max(EtOH)/nm < 220; [α]D
18.1
 +105.8 (c = 0.31, MeOH); IR 
 max/cm
-1 
3339, 2919, 1360 (SO), 1177 (SO); 
1
H NMR(500 MHz; CD3OD) H 3.32 (1H, 
dd, J = 9.2 and 10.0 Hz, H-4), 3.43 (1H, dd, 3.7 and 9.2 Hz, H-2), 3.45 (3H, s, OCH3), 3.66 
(1H, app t, J = 9.2 Hz, H-3), 3.80 (1H, ddd, J = 2.0, 5.9 and 10.0 Hz, H-5), 4.28 (1H, dd, J 
= 5.9 and 10.7 Hz, H-6a), 4.43 (1H, dd, J = 2.0 and 10.7 Hz, H-6b), 4.71 (1H, d, J = 3.7 Hz, 
H-1); 

CNMR (125 MHz; CD3OD)C 68.2 (OCH3), 70.1 (C-6), 71.2 (C-5), 71.5 (C-4), 
73.4 (C-2), 75.1 (C-3), 101.3 (C-1); HRMS calc. for C7H14N1O8S1 [M-H]
-
 272.0446, 
found 272.0442. 
((2R,3S,4S,5S,6S)-3,4,5-Trihydroxy-6-methoxytetrahydro-2H-pyran-2-yl)methyl 
sulfamate (51) 
 
Prepared according to sulfamoylation method 2 using sulfamoyl chloride (1.85 mL, 1 M in 
MeCN, 1.85 mmol, 1.8 eq.), methyl-α-D-mannopyranoside (200 mg, 1.02 mmol, 1 eq.), 
and DMF (7 mL). The residue was purified by MPLC on SiO2 with a gradient elution from 
EtOAc to 8% MeOH/EtOAc to give a white solid. This material was re-purified by MPLC 
on SiO2 with a gradient elution from 5-10% MeOH/CH2Cl2 to give a white solid (25 mg, 
9%); Rf 0.2 (5% MeOH/EtOAc; anisaldehyde); m.p. 65-70 C; max(EtOH)/nm < 220; 
[α]D
18.8
 +96.8 (c = 0.28, EtOH); IR  max/cm
-1 
3341, 1356 (SO), 1176 (SO); 
1
H NMR(500 
MHz; CD3OD) H 3.42 (3H, s, OCH3), 3.63-3.72 (2H, m, H-3 and H-4), 3.75 (1H, ddd, J = 
1.8, 6.3 and 9.6 Hz, H-5), 3.83 (1H, dd, J = 1.7 and 3.2 Hz, H-2), 4.30 (1H, dd, J = 6.3 and 
10.8 Hz, H-6a), 4.48 (1H, dd, J = 1.8 and 10.8 Hz, H-6b), 4.67 (1H, d, J = 1.7 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 55.4 (OCH3), 68.3 (C-4), 70.4 (C-6), 71.9 (C-2), 72.2 (C-
5), 72.5 (C-3), 102.8 (C-1); HRMS calcd for C7H14N1O8S1 [M-H]
-
 272.0446, found 
272.0434. 
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4-(((2S,3R,4R,5S,6R)-4,5-Dihydroxy-2-methoxy-6-((sulfamoyloxy) methyl) 
tetrahydro-2H-pyran-3-yl)amino)-4-oxobutanoic acid (52) 
 
Succinic anhydride (38 mg, 0.37 mmol, 1 eq.) was added to a solution of compound 105 
(100 mg, 0.37 mmol, 1 eq.) in a mixture of water (3 mL) and dioxane (3 mL), and the 
mixture was stirred at room temperature for 18 h. The solvent was removed in vacuo and 
purified by MPLC on SiO2 with a gradient elution from EtOAc to 50 % MeOH/EtOAc. 
Product containing fractions were evaporated, and triturated with EtOAc (2 × 3 mL). The 
resultant solid was dried under vacuum to give a white solid (25 mg, 0.067 mmol, 18%); Rf 
0.1 (40% MeOH/EtOAc; anisaldehyde); mp 87-90 C; [α]D
22.6
 +90.0 (c = 0.08, MeOH); 
max(EtOH)/nm < 220; IR  max/cm
-1
 3319, 1716 (carbamate I), 1636 (CO2H), 1542 
(carbamate II), 1361 (SO), 1176 (SO); 
1
H NMR(500 MHz; CD3OD) H 2.55-2.68 (4H, m, 
CH2CH2CO2H), 3.39 (1H, dd, J = 9.0 and 9.9 Hz, H-4), 3.42 (3H, s, OCH3), 3.69 (1H, dd, 
J = 9.0 and 10.6 Hz, H-3), 3.82 (1H, ddd, J = 1.7, 6.0 and 9.9 Hz, H-5), 3.95 (1H, dd, J = 
3.5 and 10.6 Hz, H-2), 4.29 (1H, dd, J = 6.0 and 10.7 Hz, H-6a), 4.44 (1H, dd, J = 1.7 and 
10.7 Hz, H-6b), 4.69 (1H, d, J = 3.5 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 30.4 
(CH2CO2H), 31.5 (CH2CONH), 55.2 (C-2), 55.8 (OCH3), 70.1 (C-6), 71.3 (C-5), 72.0 (C-
4), 72.9 (C-3), 99.9 (C-1), 175.1 (CO), 176.5 (CO); HRMS calcd for C11H19N2O10S [M-H]
- 
371.0766, found 371.0771. 
Benzyl ((2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-methoxy 
tetrahydro-2H-pyran-3-yl)carbamate (124) 

A solution of hydrogen chloride (15 mL, 1.25 M in MeOH) was added to glucosamine 
derivative 102 (2.0 g, 6.4 mmol, 1 eq.) and the mixture was heated to 70 C for 1 h. The 
solvent was removed in vacuo, and the residue purified by MPLC on SiO2 with a gradient 
elution from 2-15% MeOH/CH2Cl2 to give a white solid (430 mg, 1.31 mmol 21%, β 
anomer). The α anomer (103) was also obtained (770 mg, 2.14 mmol, 37%). Data for the β 
anomer 124: Rf 0.25 (5% MeOH/EtOAc; anisaldehyde); mp 174-176 C; max(EtOH)/nm < 
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220; IR  max/cm
-1 
3297 br, 1696 (carbamate I), 1542 (carbamate II); 
1
H NMR(500 MHz; 
CD3OD) H 3.26-3.47 (4H, m, H-2, H-3, H-4, H-5), 3.51 (3H, s, OCH3), 3.72 (1H, dd, J = 
5.8 and 12.0 Hz, H-6a), 3.92 (1H, dd, J = 2.1 and 12.0 Hz, H-6b), 4.31 (1H, d, J = 7.9 Hz, 
H-1), 5.13 (2H, s, CH2Ph), 7.30-7.43 (5H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 
57.2 (C-2), 59.0 (OCH3), 62.8 (C-6), 67.4 (CH2Ph), 72.2 (C-3), 76.1 (C-5), 78.0 (C-4), 
104.2 (C-1), 128.8 (C-Ar), 128.9 (C-Ar), 129.4 (C-Ar), 138.4 (C-Ar), 159.1 (CO); MS 
(ESI-) m/z 326.3 [M-H]
-
. 
((2R,3S,4R,5R,6R)-5-Amino-3,4-dihydroxy-6-methoxytetrahydro-2H-pyran-2-
yl) methyl sulfamate (125) 

Prepared according to sulfamoylation method 1 using sulfamoyl chloride (3.75 mL, 1 M, 
3.75 mmol, 3 eq.), alcohol 124 (410 mg, 1.25 mmol, 1 eq.) and DMA (3 mL) at -20 C. 
The mixture was stirred at -20 C for 1 h, and then allowed to warm to -5 C and stirred at 
-5 C for 90 minutes. The reaction was quenched by the addition of water, and extracted 
with EtOAc (20 mL). Saturated aqueous sodium chloride solution was added to the 
aqueous layer, and further extracted with CH2Cl2 (7 × 20 mL). The organic extracts were 
combined, dried over MgSO4, and the solvent removed in vacuo. The residue was purified 
by MPLC on SiO2 with a gradient elution from 70% EtOAc/petrol to 100% EtOAc to give 
a white solid. (96 mg, 0.24 mmol, 19%); Rf 0.25 (EtOAc; anisaldehyde); mp 155 C dec.; 
max(EtOH)/nm < 220; IR  max/cm
-1 
3464, 3391, 3325, 3231, 1695 (carbamate I), 1534 
(carbamate II), 1369 (SO), 1180 (SO); 
1
H NMR (500 MHz; CD3OD) H 3.36-3.51 (6H, m, 
OCH3, H-2, H-3, H-4), 3.55 (1H, ddd, J = 1.9, 6.0, and 9.7 Hz, H-5), 4.28 (1H, dd, J = 6.0 
and 10.9 Hz, H-6a), 4.34 (1H, d, J = 7.9 Hz, H-1), 4.49 (1H, dd, J = 1.9 and 10.9 Hz, H-
6b), 5.13 (2H, s, CH2Ph), 7.30-7.42 (5H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 54.9 
(OMe), 57.3 (C-2), 67.4 (CH2Ph), 71.8 (C-6), 73.9 (C-5), 75.3 (C-4), 75.9 (C-3), 102.4 (C-
1), 128.8 (C-Ar), 128.9 (C-Ar), 129.4 (C-Ar), 138.4 (C-Ar), 159.1 (CO); HRMS calcd for 
C15H21O9N2S [M-H]
-
 405.0973, found 405.0973. 
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((2R,3S,4R,5R,6R)-5-Amino-3,4-dihydroxy-6-methoxytetrahydro-2H-pyran-2-
yl)methyl sulfamate (126) 

Prepared according to general procedure A using sulfamate 125 (90 mg, 0.22 mmol), 
MeOH (3 mL) and CH2Cl2 (1.5 mL) for 1 h to give a clear gum (57 mg, 0.21 mmol, 95%). 
Rf 0.2 (70:30:3 CH2Cl2/MeOH/NH4OH; anisaldehyde); max(EtOH)/nm < 220; IR  
max/cm
-1 
3321 br, 1358 (SO), 1176 (SO); 
1
H NMR (500 MHz; CD3OD)H 2.62 (1H, dd, J 
= 8.1 and 9.6 Hz, H-2), 3.29-3.38 (2H, m, H-3 and H-4), 3.54-3.59 (4H, m, OCH3 and H-
5), 4.22 (1H, d, J = 8.1 Hz, H-1), 4.29 (1H, dd, J = 5.8 and 10.8 Hz, H-6a), 4.47 (1H, dd, J 
= 1.9 and 10.8 Hz, H-6b); 

CNMR (125 MHz; CD3OD)C 57.4 (OMe), 58.2 (C-2), 69.8 
(C-6), 71.5 (C-4), 75.6 (C-5), 77.1 (C-3), 105.2 (C-1); HRMS calcd for C7H15O7N2S [M-
H]
-
 271.0606, found 271.0606. 
Ammonium ((2R,3R,4R,5S,6R)-4,5-dihydroxy-2-methoxy-6-((sulfamoyloxy) 
methyl)tetrahydro-2H-pyran-3-yl)sulfamate (59) 
 
Prepared according to general procedure B, using amine 126 (50 mg, 0.18 mmol, 1 eq.) 
de-ionised water (2 mL) and pyridine-sulfur trioxide complex (32 mg, 0.20 mmol, 2.1 eq.). 
for 2 h. The crude product was purified by MPLC on SiO2 with a gradient elution from 
70:30:3 to 50:50:5 CH2Cl2/MeOH/NH4OH. Product containing fractions were evaporated, 
dissolved in MeOH (5 mL) and filtered. The solvent was removed in vacuo and the residue 
dissolved in water, frozen and lyophilized to give a white solid (20 mg, 0.054 mmol, 29%); 
Rf 0.25 (70:30:3 CH2Cl2/MeOH/NH4OH; anisaldehyde); mp 130 C dec.; max(EtOH)/nm 
< 220; IR  max/cm
-1 
3372, 3261 br, 1363 (SO), 1177 (SO); 
1
H NMR (500 MHz; CD3OD) 
H 3.05 (1H, dd, J = 8.2 and 9.7 Hz, H-2), 3.39 (1H, dd, J = 8.8 and 9.9 Hz, H-4), 3.54 
(3H, s, OMe), 3.58 (1H, ddd, J = 1.9, 6.1 and 9.9 Hz, H-5), 3.72 (1H, dd, J = 8.8 and 9.7 
Hz, H-3), 4.28 (1H, dd, J = 6.1 and 10.9 Hz, H-6a), 4.41 (1H, d, J = 8.2 Hz, H-1), 4.48 
(1H, dd, J = 1.9 and 10.9 Hz, H-6b); 

CNMR (125 MHz; CD3OD)C 57.1 (OMe), 61.6 
(C-2), 70.0 (C-6), 71.5 (C-4), 75.3 (C-5), 77.3 (C-3), 103.5 (C-1); HRMS calcd for 
C7H15O10N2S2 [M-H]
-
 351.0175, found 351.0174. 
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(2R,3S,4R,5R,6R)-2-(Acetoxymethyl)-5-(((benzyloxy)carbonyl)amino)-6-chloro 
tetrahydro-2H-pyran-3,4-diyl diacetate (127) 
 
Benzyl carbamate protected glucosamine 102 (1.0 g, 3.2 mmol, 1 eq.) was suspended in 
acetyl chloride (3 mL), and stirred at room temperature for 48 h. The mixture was diluted 
with CH2Cl2 (20 mL) and poured onto ice. The organic layer was separated, and treated 
with saturated aqueous NaHCO3 solution until the aqueous layer was pH 7. The organic 
layer was separated, the aqueous layer extracted with CH2Cl2. The organic layers were 
combined, washed with brine, dried over MgSO4, and the solvent removed in vacuo to give 
a white solid (800 mg, 1.74 mmol, 55 %); Rf 0.2 (25% EtOAc/petrol; anisaldehyde); mp 
116-117 C; max(EtOH)/nm < 220; IR  max/cm
-1
 3372, 2940, 1742, 1720, 1517; 
1
H 
NMR(500 MHz; CD3OD) H 1.94 (3H, s, CH3), 2.05 (3H, s, CH3), 2.09 (3H, s, CH3), 4.16 
(1H, dd, J = 3.8 and 13.9 Hz, H-6a), 4.29 (1H, dd, J = 3.7 and 10.6 Hz, H-2), 4.34-4.39 
(2H, m, H-5 and H-6b), 5.10 (1H, d, J = 12.5 Hz, CHaHbPh), 5.15 (1H, app t, J = 9.5 Hz, 
H-4), 5.19 (1H, d, J = 12.5 Hz, CHaHbPh), 5.37 (1H, dd, J = 9.5 and 10.6 Hz, H-3), 6.29 
(1H, d, J = 3.7 Hz, H-1), 7.31-7.41 (5H, m, H-Ar); 

CR (125 MHz; CDCl3)C 20.5 
(CH3CO2), 20.6 (CH3CO2), 20.7 (CH3CO2), 55.3 (C-2), 61.2 (CH2Ph), 67.1 (C-4), 67.4 (C-
6), 70.1 (C-3), 70.9 (C-5), 93.8 (C-1), 128.2 (C-Ar), 128.4 (C-Ar), 128.6 (C-Ar), 138.4 (C-
Ar), 158.6 (CO), 169.2 (CO), 170.5 (CO), 171.0 (CO); MS (ESI-) m/z 456.3 [M-H]
-
; 
(ESI+) m/z 458.4 [M+H]
+
. 
(2R,3S,4R,5S)-2-(Acetoxymethyl)-5-(((benzyloxy)carbonyl)amino) tetrahydro-
2H-pyran-3,4-diyl diacetate (128) 
 
TMS3SiH (1.94 mL, 6.3 mmol, 1.2 eq.) was added to a solution of chloride 127 (2.4 g, 5.2 
mmol, 1 eq.) in anhydrous toluene (30 mL). A solution of AIBN (0.2 M in toluene, 1 mL, 
0.2 mmol, 0.04 eq.) was added and the mixture heated to 110 C for 1.5 h. The reaction 
was allowed to cool to r.t., the solvent removed in vacuo, and the residue purified by 
MPLC on SiO2 with a gradient elution from 20-70% EtOAc/petrol to give a white solid 
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(1.85 g, 84%); Rf 0.65 (50% EtOAc/petrol; anisaldehyde); mp 115-117 C; max(EtOH)/nm 
< 220; [α]D
23.3
 +31.2 (c = 0.50, EtOH); IR  max/cm
-1
 3365, 2953, 1738, 1695, 1531; 
1
H 
NMR (500 MHz; CD3OD) H 1.93 (3H, s, CH3), 2.04 (3H, s, CH3), 2.08 (3H, s, CH3), 3.41 
(1H, app. t, J = 11.0 Hz, H-1a), 3.67 (1H, ddd, J = 2.0, 4.7 and 9.7 Hz, H-5), 3.87 (1H, 
app. td, J = 11.0 and 5.4 Hz, H-2), 3.97 (1H, dd, J = 5.4 and 11.0 Hz, H-1b), 4.12 (1H, dd, 
J = 2.0 and 12.3 Hz, H-6a), 4.25 (1H, dd, J = 4.7 and 12.3 Hz, H-6b), 4.97 (1H, app t, J = 
9.7 Hz, H-4), 5.04-5.17 (3H, m, CHaHbPh, CHaHbPh and H-3), 7.31-7.40 (5H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 20.6 (3 × CH3CO), 52.6 (C-2), 63.7 (C-6), 67.6 (CH2Ph), 
69.1 (C-1), 70.5 (C-4), 75.7 (C-3), 77.6 (C-5), 128.8 (C-Ar), 129.1 (C-Ar), 129.5 (C-Ar), 
138.3 (C-Ar), 158.3 (PhCH2CO), 171.4 (CH3CO), 172.1 (CH3CO), 172.4 (CH3CO); 
HRMS calcd for C20H25O9N1 [M-H]
-
 422.1457, found 422.1450. 
Benzyl ((3S,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-
3-yl)carbamate (129) 
 
Triacetate ester 128 (100 mg, 0.24 mmol) was dissolved in methanol (3 mL) and sodium 
methoxide (10 mg, 0.19 mmol, 0.8 eq.) was added. The mixture was stirred at room 
temperature for 2 h. Three drops of 4 M HCl in dioxane were added, and the solvent was 
removed in vacuo. The material was purified by MPLC on SiO2 with a gradient elution 
from EtOAc to 5% MeOH/EtOAc to give a white solid (50 mg, 0.17 mmol, 71%); Rf 0.15 
(5% MeOH/EtOAc; anisaldehyde); mp 172-175 C; max(EtOH)/nm < 220; [α]D
16.9
 +18.6 
(c = 0.22, EtOH); IR  max/cm
-1
 3372 br, 3301br, 2954, 2894, 2860, 1693 (carbamate I), 
1543 (carbamate II);
 1
H NMR (500 MHz; CD3OD) H 3.15-3.22 (2H, m, H-1a and H-5), 
3.29 (1H, app t, J = 9.3 Hz, H-4), 3.36-3.42 (1H, m, H-3), 3.59 (1H, app td, J = 10.2 and 
5.1 Hz, H-2), 3.66 (1H, dd, J = 6.0 and 12.0 Hz, H-6a), 3.87 (1H, dd, J = 1.9 and 12.0 Hz, 
H-6b), 3.97 (1H, dd, J = 5.1 and 11.0 Hz, H-1b), 5.12 (2H, s, CH2Ph), 7.30-7.42 (5H, m, H-
Ar), ; 

CNMR (125 MHz; CD3OD)C 54.6 (C-2), 63.1 (C-6), 67.6 (CH2Ph), 69.5 (C-1), 
72.5 (C-4), 77.1 (C-3), 82.6 (C-5), 128.9 (C-Ar), 129.0 (C-Ar), 129.5 (C-Ar); HRMS Calc 
for C14H20O6N1 [M+H]
+
 298.1285, found 298.1290. 
Note: Unable to visualise all carbon signals by 
13
C nmr. 
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((2R,3S,4R,5S)-5-(((Benzyloxy)carbonyl)amino)-3,4-dihydroxytetrahydro-2H-
pyran-2-yl)methyl sulfamate (130) 
 
Prepared according to sulfamoylation method 1 using sulfamoyl chloride (10 mL, 1 M in 
toluene, 10 mmol, 1.7 eq.), alcohol 129 (950 mg, 5.9 mmol, 1 eq.), and DMA (15 mL) 
at -20 C. The mixture was stirred at -20 C for 1 h. Further sulfamoyl chloride (7.6 mL, 1 
M in toluene, 7.6 mmol, 1.3 eq.) was added at -20 C and the mixture was stirred at -20 C 
for 1 h. The reaction was quenched by the addition of water, and extracted with EtOAc (50 
mL). Saturated aqueous sodium chloride solution was added to the aqueous layer, and 
further extracted with CH2Cl2 (5 × 30 mL). The organic extracts were combined, dried over 
MgSO4, and the solvent removed in vacuo. The residue was purified by MPLC on SiO2 
with a gradient elution from 50% EtOAc/petrol to 100% EtOAc to 12 % MeOH/EtOAc to 
give a white solid. (200 mg, 0.53 mmol, 17%); Rf 0.25 (EtOAc; anisaldehyde); mp 158-
162 C dec.;max(EtOH)/nm < 220; [α]D
16..9
 -8.7 (c = 0.23, EtOH); IR  max/cm
-1
 3414, 
3388, 3336, 3237, 1685 (carbamate I), 1534 (carbamate II), 1374 (SO), 1182 (SO); 
1
H 
NMR (500 MHz; CD3OD) H 3.21 (1H, app t, J = 11.2 Hz, H-1a), 3.28-3.34 (1H, m, H-4), 
3.38-3.46 (2H, m, H-3 and H-5), 3.60 (1H, app td, J = 11.2 and 5.3 Hz, H-2), 3.96 (1H, dd, 
J = 5.3 and 11.2 Hz, H-1b), 4.24 (1H, dd, J = 6.0 and 10.8 Hz, H-6a), 4.45 (1H, dd, J = 1.3 
and 10.8 Hz, H-6b), 5.12 (2H, s, CH2Ph), 7.31-7.42 (5H, m, H-Ar); HRMS calcd for 
C14H19O8N2S1 [M-H]
-
 375.0868 , found 379.0877. 
((2R,3S,4R,5S)-5-Amino-3,4-dihydroxytetrahydro-2H-pyran-2-yl) methyl 
sulfamate (131) 
 
Prepared according to general procedure A using carbamate 130 (175 mg, 0.47 mmol, 1 
eq.), MeOH (15 mL) and CH2Cl2 (10 mL) for 3 h to give a clear gum (110 mg, 0.45 mmol, 
97%); Rf(CH2ClMeOH:NH4OH 70:30:3; anisaldehyde)max(EtOH)/nm < 220; IR  
max/cm
-1
 3921, 2876, 1355 (SO), 1174 (SO); 
1
H NMR (500 MHz; CD3OD) H 2.79 (1H, 
ddd, J = 5.0, 9.4 and 10.7 Hz, H-2), 3.19-3.26 (2H, m, H-1a and H-3), 3.29 (1H, app t, J = 
9.4 Hz, H-4), 3.45 (1H, ddd, J = 1.8, 6.0 and 9.4 Hz, H-5), 3.95 (1H, dd, J = 5.0 and 11.3 
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Hz, H-1b), 4.25 (1H, dd, J = 6.0 and 10.8 Hz, H-6a), 4.43 (1H, dd, J = 1.8 and 10.8 Hz, H-
6b); 

CNMR (125 MHz; CD3OD)C 54.1 (C-2), 70.4 (C-6), 71.2 (C-1), 71.7 (C-4), 79.9 
(C-5), 80.1 (C-3); HRMS calcd for C6H13O6N2S1 [M-H]
-
 241.0500, found 241.0500. 
Sodium ((3S,4R,5S,6R)-4,5-Dihydroxy-6-((sulfamoyloxy)methyl)tetrahydro-2H-
pyran-3-yl)sulfamate (60) 
 
Prepared according to general procedure B, using amine 131 (130 mg, 0.54 mmol, 1 
eq.), de-ionised water (3 mL) and pyridine-sulfur trioxide complex (165 mg, 1.07 mmol, 
2.0 eq.) for 2 h. The crude product was purified by MPLC on SiO2 with a gradient elution 
from 20% EtOAc/MeOH to 100% MeOH. Product containing fractions were evaporated, 
dissolved in MeOH (5 mL) and filtered. The solvent was removed in vacuo to give a pale 
yellow solid (42 mg, 0.13 mmol, 24%); Rf 0.15 (20% MeOH /EtOAc; anisaldehyde); mp 
120-124 C; [α]D
22.2 
+8.0 (c = 0.20, MeOH); max (EtOH)/nm < 220; IR  max/cm
-1
 3290 
(br), 1358 (SO), 1173 (SO); 
1
H NMR (500 MHz; D2O) H 3.22-3.28 (1H, m, H-2), 3.35 
(app t, J = 11.2 Hz, H-1a), 3.42 (1H, app t, J = 8.5 Hz, H-3), 3.49 (1H, app t, J = 8.5 Hz, H-
4), 3.59 (1H, ddd, J = 2.0, 5.0 and 8.5 Hz, H-5), 4.25 (1H, dd, J = 4.8 and 11.2 Hz, H-1b), 
4.33 (1H, dd, J = 5.0 and 11.2 Hz, H-6a), 4.43 (1H, dd, J = 2.0 and 11.2 Hz, H-6b); 

CNMR (125 MHz; CD3OD)C 58.5 (C-2), 70.4 (C-1 and C-6), 71.9 (C-4), 78.1 (C-3), 
79.7 (C-5); 

CNMR (D2O) C 54.9 (C-2), 68.7 (C-1), 69.0 (C-6), 69.6 (C-4), 75.2 (C-3), 
77.5 (C-5); HRMS calcd for C6H13N2O9S2 [M-H]
-
 321.0068, found 321.0069. 
Benzyl ((2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-isopropoxy 
tetrahydro-2H-pyran-3-yl)carbamate (132) 
 
Benzyl carbamate protected glucosamine 102 (500 mg, 1.6 mmol, 1 eq.) was dissolved in 
isopropyl alcohol (15 mL) and a HCl in dioxane (1.5 mL, 4 M) was added. The mixture 
was heated to 60 C for 4 h, allowed to cool, and the solvent was removed in vacuo. The 
mixture was dissolved in MeOH and purified by MPLC on SiO2, with a gradient elution 
from 2-10% MeOH/CH2Cl2, to give a white solid (414 mg, 1.17 mmol, 73%). Rf 0.5 (10% 
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MeOH/CH2Cl2; anisaldehyde); mp 158-159 C; max (EtOH)/nm < 220; [α]D
22.7
 +114.1 (c 
= 0.27, EtOH); IR  max/cm
-1 
3318 br, 2967, 1689 (carbamate I), 1535 (carbamate II); 
1
H 
NMR (500 MHz; CD3OD) H 1.13 (3H, d, J = 6.2 Hz, CH3), 1.25 (3H, d, J = 6.2 Hz, CH3), 
3.37-3.40 (1H, m, H-3), 3.59-3.75 (4H, m, H-2, H-4, H-5 and H-6a), 3.83 (1H, dd, 11.0 and 
1.1 Hz, H-6b), 3.91 (1H, sept, J = 6.2 Hz, CH(CH3)2), 4.95 (1H, d, J = 2.8 Hz, H-1), 5.10 
(1H, d, J = 12.5 Hz, CHaHbPh), 5.17 (1H, d, J = 12.5 Hz, CHaHbPh), 7.31-7.45 (5H, m, H-
Ar); 

CNMR (125 MHz; CD3OD)C 21.7 (CH3), 23.6 (CH3), 55.8 (C-2), 62.8 (C-6), 67.5 
(CH2Ph), 71.1 (CH(CH3)2), 72.4 (C-4), 73.0 (C-3), 73.8 (C-5), 97.1 (C-1), 128.9 (C-Ar), 
129.0 (C-Ar), 129.4 (C-Ar), 138.4 (C-Ar), 158.8 (CO); HRMS calc. for C17H26O7N1 
[M+H]
+
 356.1704, found 356.1708. 
((2R,3S,4R,5R,6S)-5-(((Benzyloxy)carbonyl)amino)-3,4-dihydroxy-6-
isopropoxy tetrahydro-2H-pyran-2-yl)methyl sulfamate (133) 
 
Prepared according to sulfamoylation method 1 using sulfamoyl chloride (3.3 mL, 1.0 M in 
toluene, 3.3 mmol, 3 eq.), alcohol 132 (390mg, 1.1 mmol, 1 eq.), and DMA (5 mL) at -20 
C. The mixture was allowed to warm to -5 C over 1 h, and stirred at -5 C for a further 1 
h. The reaction was quenched with water, and extracted with EtOAc (20 mL). Saturated 
aqueous NaCl solution was added, and the mixture extracted with CH2Cl2 (2 × 20 mL). 
The organic layers were combined, dried over MgSO4, and the solvent removed in vacuo. 
The residue was purified by MPLC on SiO2 with a gradient elution from 70% 
EtOAc/Petrol to 100% EtOAc to give a white solid (148 mg, 0.32 mmol, 31%). Rf 0.4 
(EtOAc; anisaldehyde); mp 166-168 C;max(EtOH)/nm < 220; IR  max/cm
-1
 3336 br, 
3244, 2973, 1683 (carbamate I), 1537 (carbamate II), 1371 (SO), 1178 (SO);
 1
H NMR 
(500 MHz; CD3OD)H 1.13 (3H, d, J = 6.2 Hz, CH3), 1.25 (3H, d, J = 6.2 Hz, CH3), 3.35-
3.41 (1H, m, H-4), 3.60 - 3.67 (2H, m, H-2 and H-3), 3.87-3.95 (2H, m, H-5 and CHMe2), 
4.29 (1H, dd, J = 5.9 and 10.8 Hz, H-6a), 4.41 (1H, dd, J =1.7 and 10.8 Hz, H-6b), 4.95 
(1H, d, J = 2.4 Hz, H-1), 5.10 (1H, d, J = 12.5 Hz, CHaHbPh), 5.16 (1H, d, J = 12.5 Hz, 
CHaHbPh), 7.30-7.45 (5H, m, H-Ar);

CNMR (125 MHz; CD3OD)C 21.7 (CH3), 23.6 
(CH3), 57.1 (C-2), 67.6 (CH2Ph), 70.2 (C-6), 71.4 (C-5), 71.6 (CH(Me)2), 72.1 (C-4), 72.8 
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(C-3), 96.0 (C-1), 128.9 (C-Ar), 129.0 (C-Ar), 129.5 (C-Ar), 138.4 (C-Ar), 158.8 (CO); 
HRMS calcd for C17H25O9N2S [M-H]
-
 433.1286, found 433.1286.  
(2R,3S,4R,5R,6S)-5-Amino-3,4-dihydroxy-6-isopropoxytetrahydro-2H-pyran-2-
yl)methyl sulfamate (134) 
 
Prepared according to general procedure A using carbamate 133 (108 mg, 0.25 mmol), 
MeOH (4 mL) and CH2Cl2 (4 mL) for 1 h to give a clear oil (75 mg, 0.25 mmol, 100%); Rf 
0.02 (10% MeOH/EtOAc; anisaldehyde);max(EtOH)/nm < 220; IR  max/cm
-1
 1368 (SO), 
1179 (SO); 
1
H NMR (500 MHz; CD3OD) H 1.22 (3H, d, J = 6.2 Hz, CH3), 1.29 (3H, d, J 
= 6.2 Hz, CH3), 2.69 (1H, dd, J = 3.7 and 10.0 Hz, H-2), 3.31 (1H, dd, J = 9.0 and 10.0 
Hz, H-4), 3.52 (1H, dd, J = 9.0 and 10.0 Hz, H-3), 3.92 (1H, ddd, J = 1.9, 5.9 and 10.0 Hz, 
H-5), 3.97 (1H, sept, J = 6.2 Hz, CH(Me)2), 4.28 (1H, dd, J = 5.9 and 10.7 Hz, H-6a), 4.41 
(1H, dd, J = 1.9 and 10.7 Hz, H-6b), 4.97 (1H, d, J = 3.7 Hz, H-1); 

CNMR (125 MHz; 
CD3OD)C 21.9 (CH3), 23.7 (CH3), 56.8 (C-2), 70.1 (C-6), 71.6 (CH(CH3)2), 71.8 (C-5), 
71.8 (C-4), 75.5 (C-3), 98.2 (C-1); HRMS calcd for C9H19O7N2S [M-H]
-
 299.0918, found 
299.0914. 
Ammonium ((2S,3R,4R,5S,6R)-4,5-dihydroxy-2-isopropoxy-6-((sulfamoyloxy) 
methyl)tetrahydro-2H-pyran-3-yl)sulfamate (56) 
 
Prepared according to general procedure B, using amine 134 (70 mg, 0.23 mmol, 1 eq.), 
de-ionised water (2 mL), and pyridine-sulfur trioxide complex (41 mg, 0.26 mmol, 1.1 
eq.). After 30 min further SO3.pyridine complex (15 mg, 0.09 mmol, 0.4 eq.) was added, 
the pH of the mixture re-adjusted to pH 9-10. The mixture was stirred at room temperature 
for 1 h and the solvent removed in vacuo. The residue was purified by MPLC on SiO2 with 
a gradient elution from 70:30:3 to 50:50:5 CH2Cl2/MeOH/NH4OH. Product containing 
fractions were evaporated, dissolved in MeOH (5 mL) and filtered. The solvent was 
removed in vacuo, the residue dissolved in water (1 mL), frozen and lyophilized to give a 
white solid (24 mg, 27%); Rf 0.1 (70:30:3 CH2Cl2/MeOH/NH4OH; anisaldehyde); mp 50-
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70 C;[α]D
22.6 
+97.3 (c = 0.30, MeOH); max(EtOH)/nm < 220; IR  max/cm
-1 
3222 br, 
3069, 2976, 2932, 1360 (SO), 1172 (SO); 
1
H NMR (500 MHz; CD3OD) H 1.24-1.29 (6H, 
2 × d, J = 6.2 Hz, 2 × CH3), 3.25 (1H, dd, J = 3.7 and 10.2 Hz, H-2), 3.38 (1H, app t, J = 
9.6 Hz, H-4), 3.57 (1H, dd, J = 9.6 and 10.2 Hz, H-3), 3.91 (1H, ddd, J = 1.9, 6.0 and 9.6 
Hz, H-5), 3.96 (1H, sept, J = 6.2 Hz, CH(Me)2), 4.28 (1H, dd, J = 6.0 and 10.6 Hz, H-6a), 
4.42 (1H, dd, J = 1.9 and 10.6 Hz, H-6b), 5.23 (1H, d, J = 3.7 Hz, H-1); 

CR (125 
MHz; D2O)C 20.6 (CH3), 22.3 (CH3), 57.5 (C-2), 68.9 (C-6), 69.2 (C-5), 69.6 (C-4), 71.3 
(C-3), 71.5 (CHMe2), 95.8 (C-1); HRMS calcd for C9H19O10N2S2 [M-H]
-
 379.0487, found 
379.0484. 
Benzyl ((2S,3R,4R,5S,6R)-2-(allyloxy)-4,5-dihydroxy-6-(hydroxymethyl) 
tetrahydro-2H-pyran-3-yl)carbamate336 (135) 
 
Benzyl carbamate protected glucosamine 102 (6 g, 19 mmol, 1 eq.) was dissolved in allyl 
alcohol (40 mL) and HCl in dioxane (5 mL, 4 M) was added. The mixture was heated to 60 
C for 4 h, allowed to cool, and the solvent removed in vacuo. The mixture was purified by 
MPLC on SiO2, with a gradient elution from 0-12% MeOH/CH2Cl2, to give a white solid 
(3.53 g, 10 mmol, 52%); Rf 0.5 (10% MeOH/CH2Cl2; anisaldehyde); mp 135-138 C; 
max(EtOH)/nm < 220; [α]D
23.1
 +17.4 (c = 0.46, EtOH); IR max/cm
-1 
3309, 2921, 1686 
(carbamate I), 1536 (carbamate II); 
1
H NMR (500 MHz; CD3OD) H 3.38-3.42 (1H, m, H-
4), 3.62 (1H, ddd, J = 2.0 , 5.9 and 9.6 Hz, H-5), 3.67 (2H, m, H-2 and H-3), 3.72 (1H, dd, 
J = 5.9 and 12.0 Hz, H-6a), 3.85 (1H, dd, J = 2.0 and 12.0 Hz, H-6b), 4.03 (1H, dd, J = 6.0 
and 13.1 Hz, OCHaHbCHCH2), 4.23 (1H, dd, J = 5.0 and 13.1 Hz, OCHaHbCHCH2), 4.88 
(1H, d, J = 2.6 Hz, H-1), 5.09-5.20 (3H, m, CHaHbCHCH2O and CH2Ph), 5.34 (1H, ddd, J 
= 1.7, 2.6 and 17.1 Hz, CHaHbCHCH2O), 5.90-5.99 (1H, m, OCH2CHCH2), 7.31-7.43 
(5H, m, H-Ar);
 
CNMR (125 MHz; CD3OD)C 57.2 (C-2), 62.8 (C-6), 67.6 (CH2Ph), 
69.2 (CH2CHCH2O), 72.3 (C-4), 73.0 (C-3), 74.0 (C-5), 98.1 (C-1), 117.5 (CH2CHCH2O), 
128.9 (C-Ar), 129.0 (C-Ar), 129.4 (C-Ar), 135.4 (C-Ar), 138.4 (CH2CHCH2O), 158.8 
(CO2Bn); HRMS calcd for C17H22O7N1 [M-H]
-
 352.1402, found 352.1409. 
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((2R,3S,4R,5R,6S)-6-(Allyloxy)-5-(((benzyloxy)carbonyl)amino)-3,4-dihydroxy 
tetrahydro-2H-pyran-2-yl)methyl sulfamate (137) 
 
Prepared according to sulfamoylation method 1 using sulfamoyl chloride (11.4 mL, 1.0 M 
in toluene, 11.4 mmol, 2 eq.), alcohol 135 (2.0 g, 5.7 mmol, 1 eq.), and DMA (15 mL) at -
20 C. The mixture was allowed to stir at -20 C for 1 h, and allowed to warm to 10 C 
over 45 min. The reaction was cooled to -20 C and further sulfamoyl chloride (5.7 mL, 
1.0 M in toluene, 5.7 mmol, 1 eq.) was added. The reaction was allowed to warm to 10 C 
over 45 min, quenched with water, and extracted with EtOAc (50 mL). Saturated aqueous 
NaCl solution was added, and the mixture extracted with CH2Cl2 (3 × 50 mL). The 
organics were combined, dried (MgSO4), and the solvent removed in vacuo. The residue 
was purified by MPLC on SiO2 with a gradient elution from 50% EtOAc/Petrol to 100% 
EtOAc to give a clear glass. (970 mg, 2.24 mmol, 40 %); Rf 0.2 (EtOAc; anisaldehyde); 
max(EtOH)/nm < 220; [α]D
23.2
 +83 (c = 0.51, EtOH); IR  max/cm
-1 
3449, 3384, 3331, 
3235, 2915, 1681 (carbamate I), 1538 (carbamate II), 1370 (SO), 1180 (SO); 
1
H NMR (500 
MHz; CD3OD) H 3.35-3.43 (1H, m, H-4), 3.65-3.69 (2H, m, H-2 and H-3), 3.85 (1H, ddd, 
J = 1.6, 6.0 and 10.2 Hz, H-5), 4.04 (1H, dd, J = 6.0 and 13.1 Hz, OCHaHbCHCH2), 4.22 
(1H, dd, J = 5.0 and 13.1 Hz, OCHaHbCHCH2), 4.29 (1H, dd, J = 6.0 and 10.7 Hz, H-6a), 
4.43 (1H, dd, J = 1.6 and 10.7 Hz, H-6b), 4.89 (1H, d, H-1), 5.11 (1H, d, J = 12.5 Hz, 
CHaHbPh), 5.16 (1H, d, J = 12.5 Hz, CHaHbPh), 5.20 (1H, dd, J = 1.3 and 10.6 Hz, 
CHaHbCHCH2O), 5.27-5.37 (1H, app dq, J = 1.3 and 17.5 Hz, CHaHbCHCH2O), 5.90-6.00 
(1H, m, CH2CHCH3), 7.30-7.43 (5H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 57.1 (C-
2), 67.6 (CH2Ph), 69.5 (CH2CHCH2O), 70.1 (C-6), 71.5 (C-5), 72.1 (C-4), 72.9 (C-3), 98.1 
(C-1), 117.8 (CH2CHCH2O), 128.9 (C-Ar), 129.0 (C-Ar), 129.5 (C-Ar), 135.3 
(CH2CHCH2O), 138.3 (C-Ar), 158.8 (CO); HRMS calcd for C17H23O9N2S1 [M-H]
-
 
431.1130, found 431.1126. 
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((2R,3S,4R,5R,6S)-5-Amino-3,4-dihydroxy-6-propoxytetrahydro-2H-pyran-2-
yl)methyl sulfamate (138) 
 
Prepared according to general procedure A using carbamate 137 (150 mg, 0.35 mmol), 
MeOH (2 mL) and CH2Cl2 (2 mL) for 2 h to give a clear glass (104 mg, 0.35 mmol, 
100%); Rf 0.15 (CH2Cl2:MeOH 70:30; anisaldehyde); max(EtOH)/nm < 220; IR  max/cm
-1 
3348, 3299, 2965, 2932, 1359 (SO), 1176 (SO); 
1
H NMR (500 MHz; CD3OD) H 1.02 
(3H, t, J = 7.4 Hz, CH2CH3), 1.65-1.74 (2H, m, CH2CH3), 2.70 (1H, dd, J = 3.6 and 9.9 
Hz, H-2), 3.32 (1H, dd, J = 9.0 and 9.9 Hz, H-4), 3.44 (1H, J = 6.4 and 9.6 Hz, 
CH3CH2CHaHbO), 3.53 (1H, dd, J = 9.0 and 9.9 Hz, H-3), 3.75 (1H, dt, J =9.6 and 6.7 Hz, 
CH3CH2CHaHbO), 3.85 (1H, ddd, J = 1.9 , 5.9 and 9.9 Hz, H-5), 4.28 (1H, dd, J = 5.9 and 
10.7 Hz, H-6a), 4.42 (1H, dd, J = 1.9 and 10.7 Hz, H-6b), 4.84 (1H, d, J = 3.6 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 11.1 (CH3), 23.8 (CH2CH3), 57.0 (C-2), 70.1 (C-6), 70.8 
(CH2CH2CH3), 71.7 (C-5), 71.8 (C-4), 75.7 (C-3), 99.8 (C-1); HRMS calcd for 
C9H19O7N2S [M-H]
-
 299.0918, found 299.0913. 
Ammonium ((2S,3R,4R,5S,6R)-4,5-dihydroxy-2-propoxy-6-((sulfamoyloxy) 
methyl)tetrahydro-2H-pyran-3-yl)sulfamate (57) 
 
Prepared according to general procedure B, using amine 138 (100 mg, 0.33 mmol, 1 eq.), 
de-ionised water (4 mL) and pyridine-sulfur trioxide complex (79 mg, 0.50 mmol, 2 eq.) 
for 1 h. The crude product was purified by MPLC on SiO2 with a gradient elution from 
70:30:3 to 50:50:5 CH2Cl2/MeOH/NH4OH. Product containing fractions were evaporated, 
the residue dissolved in water (1 mL) and lyophilized to give a white solid (50 mg, 0.13 
mmol, 39%); Rf 0.1 (CH2Cl2:MeOH:NH4OH 70:30:3; anisaldehyhde); mp 50-60 C; 
[α]D
22.2 
+48.0 (c = 0.10, MeOH); max(EtOH)/nm < 220; IR  max/cm
-1 
3224, 3085,
 
2968, 
2937, 1359 (SO), 1171 (SO); 
1
H NMR (500 MHz; CD3OD) H 1.01 (3H, t, J = 7.4 Hz, 
CH2CH3), 1.65-1.74 (2H, m, CH2CH3), 3.27 (1H, dd, J = 3.6 and 10.1 Hz, H-2), 3.40 (1H, 
dd, J = 8.8 and 10.0 Hz, H-4), 3.48 (1H, dt, J = 9.5 and 6.5 Hz, CHaHbCH2CH3), 3.60 (1H, 
dd, J = 8.8 and 10.1 Hz, H-3), 3.71 (1H, dt, J = 9.5 and 6.8 Hz, CHaHbCH2CH3), 3.84 (1H, 
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ddd, J = 1.9, 6.0 and 10.0 Hz, H-5), 4.29 (1H, dd, J = 6.0 and 10.7 Hz, H-6a), 4.43 (1H, 
dd, J = 1.9 and 10.7 Hz, H-6b), 5.10 (1H, d, J = 3.6 Hz, H-1);

CNMR (125 MHz; 
CD3OD)C 11.1 (CH2CH3), 23.8 (CH2CH3), 59.6 (C-2), 70.2 (C-6), 71.0 (CH2CH2CH3), 
71.1 (C-5), 72.0 (C-4), 74.1(C-3), 99.3 (C-1); HRMS calcd for C9H19O10N2S2 [M-H]
-
 
379.0487, found 379.0489. 
((2R,3S,4R,5R,6S)-5-(((Benzyloxy)carbonyl)amino)-3,4-dihydroxy-6-(2-
hydroxyethoxy)tetrahydro-2H-pyran-2-yl)methyl sulfamate (139) 
 
Allyl ether 137 (200 mg, 0.46 mmol) was dissolved in methanol (10 mL), and ozone was 
bubbled through the solution at -78 C for 30 min. The mixture was allowed to stir at -78 
C to r.t. for 2 h and then NaBH4 was added, and stirred for 1 h. The solvent was removed 
in vacuo, and the residue purified by MPLC on SiO2 with a gradient elution from 5-12% 
MeOH/CH2Cl2 to give a white solid (140 mg, 0.32 mmol, 69%); Rf 0.5 (10% 
MeOH/CH2Cl2; anisaldehyde); max(EtOH)/nm < 220; IR  max/cm
-1
 3335, 3094, 2923, 
1693 (carbamate I), 1535.8 (carbamate II), 1365 (SO), 1178 (SO); 
1
H NMR (500 MHz; 
CD3OD) H 3.39 (1H, dd, J = 8.8 and 9.9 Hz, H-4), 3.48-3.55 (1H, m, CHaHbCH2OH), 
3.65-3.71 (2H, m, H-2 and H-3), 3.72-3.76 (2H, m, CHaHbCH2OH and CH2CHaHbOH), 
3.80-3.84 (1H, m, CH2CHaHbOH), 3.88 (1H, ddd, J = 1.9, 6.0, and 9.9 Hz, H-5), 4.29 (1H, 
dd, J = 6.0 and 10.9 Hz, H-6a), 4.44 (1H, dd, J = 1.9 and 10.9 Hz, H-6b), 4.83 (1H, d, J = 
3.3 Hz, H-1), 5.13 (2H, s, CH2Ph), 7.30-7.44 (5H, m, H-Ar); 

CNMR (125 MHz; 
CD3OD)C 57.1 (C-2), 62.1 (CH2CH2OH), 67.7 (CH2Ph), 70.1 (C-6), 70.5 (CH2CH2OH), 
71.5 (C-5), 72.0 (C-4), 73.4 (C-3), 99.5 (C-1), 128.9 (C-Ar), 129.0 (C-Ar), 129.5 (C-Ar), 
138.3 (C-Ar), 159.0 (CO); HRMS calcd for C16H23O10N2S1 [M-H]
-
 436.1079, found 
436.1085. 
((2R,3S,4R,5R,6S)-5-Amino-3,4-dihydroxy-6-(2-hydroxyethoxy) tetrahydro-2H-
pyran-2-yl)methyl sulfamate (140) 
 
Prepared according to general procedure A using alcohol 139 (135 mg, 0.31 mmol), MeOH 
(5 mL) and CH2Cl2 (1 mL) for 3 h to give a clear gum (70 mg, 78%); Rf 0.2 (MeOH; 
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anisaldehyde); max(EtOH)/nm < 220; IR  max/cm
-1
 3360, 3286, 3100, 2939, 2909, 1351 
(SO), 1188 (SO);
1
H NMR (500 MHz; CD3OD) H 2.70 (1H, dd, J = 3.6 and 10.0 Hz, H-
2), 3.32 (1H, dd, J = 9.0 and 10.1 Hz, H-4), 4.87 (1H, d, J = 3.6 Hz, H-1), 3.53-3.59 (2H, 
m, H-3 and CHaCHbCH2OH), 3.76 (2H, m, CH2CH2OH), 3.85 (1H, ddd, J = 3.7, 5.0 and 
10.6 Hz, CHaCHbCH2OH), 3.89 (1H, ddd, J = 1.9, 5.8 and 10.1 Hz, H-5), 4.29 (1H, dd, J 
= 5.8 and 10.7 Hz, H-6a), 4.43 (1H, dd, J =1.9 and 10.7 Hz, H-6b); 

CNMR (125 MHz; 
CD3OD)C 57.1 (C-2), 62.1 (CH2OH), 70.1 (C-6), 70.6 (CH2CH2OH), 71.7 (C-5), 71.8 
(C-4), 75.8 (C-3), 100.4 (C-1); HRMS calcd for C8H17O8N2S1 [M-H]
-
 301.0711, found 
301.0705. 
Sodium ((2S,3R,4R,5S,6R)-4,5-Dihydroxy-2-(2-hydroxyethoxy)-6-
((sulfamoyloxy)methyl) tetrahydro-2H-pyran-3-yl)sulfamate (53) 
 
Prepared according to general procedure B, using amine 140 (65 mg, 0.22 mmol, 1 eq.), 
de-ionised water (1.5 mL) and pyridine-sulfur trioxide complex (40 mg, 0.26 mmol, 1.2 
eq.) for 1 h. The solvent was removed in vacuo and the residue was purified by MPLC on 
C-18 reversed phase SiO2 with a gradient elution from 20-50% MeOH/H2O. Product 
containing fractions were evaporated, dissolved in MeOH (5 mL) and filtered. The solvent 
was removed in vacuo. The residue was dissolved in water (3 mL), frozen and lyophilized 
to give a pale yellow solid (22 mg, 0.058 mmol, 27%); Rf 0.9 (MeOH; anisaldehyde); mp 
184 C dec.; [α]D
20.6
 +50.0 (c = 0.08, MeOH); max(EtOH)/nm < 220; IR  max/cm
-1 
3262 
(br), 1359 (SO), 1175 (SO);
 1
H NMR (500 MHz; CD3OD) H 3.30 (1H, dd, J = 3.6 and 
10.2 Hz, H-2), 3.40 (1H, dd, J = 8.8 and 10.0 Hz, H-4), 3.58-3.63 (1H, m, 1H, 
CHaCHbCH2OH), 3.65 (1H, dd, J = 8.8 and 10.2 Hz, H-3), 3.71-3.85 (3H, m, CH2CH2OH 
and CHaCHbCH2OH), 3.89 (1H, ddd, J = 1.8, 6.0 and 10.0 Hz, H-5), 4.28 (1H, dd, J = 6.0 
and 10.7 Hz, H-6a), 4.44 (1H, dd, J = 1.8 and 10.7 Hz, H-6b), 5.15 (1H, d, J = 3.6 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 59.6 (C-2), 62.1 (CH2CH2OH), 70.2 (C-6), 70.6 
(CH2CH2OH), 71.1 (C-5), 72.0 (C-4), 73.9 (C-3), 99.3 (C-1); HRMS calcd for 
C8H17O11N2S2 [M-H]
-
 381.0279, found 381.0281. 
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(2R,3S,4R,5R,6S)-2-(Acetoxymethyl)-6-(allyloxy)-5-(((benzyloxy) carbonyl) 
amino) tetrahydro-2H-pyran-3,4-diyl diacetate (141) 
 
Alcohol 135 (500 mg, 1.41 mmol, 1 eq.) was dissolved in pyridine (3 mL) and Ac2O (3 
mL) was added. The mixture was stirred at room temperature for 18 h. The solvent was 
removed in vacuo, and the residue purified by MPLC on SiO2 with a gradient elution from 
20-80% EtOAc/petrol to give a white solid (650 mg, 1.35 mmol, 96%); Rf 0.5 (50% 
EtOAc/petrol; anisaldehyde); mp 67-69 C; max(EtOH)/nm < 220; IR  max/cm
-1
 1742, 
1514; 
1
H NMR (500 MHz; CDCl3) H 1.92 (3H, CH3CO), 2.04 (3H, CH3CO), 2.12 (3H, 
CH3CO), 3.97-4.12 (4H, m, H-2, H-4, H-5, H-6a), 4.19 (1H, dd, J = 5.5 and 12.6 Hz, 
OCHaHbCHCH2), 4.27 (1H, dd, J = 4.4 and 12.3 Hz, H-6b), 4.94 (1H, d, J = 3.5 Hz, H-1), 
5.03-5.18 (3H, m, CH2Ph and H-4), 5.22-5.34 (3H, m, OCH2CHCH2 and H-3), 5.85-5.94 
(1H, m, OCH2CHCH2), 7.31-7.41 (5H, m, H-Ar); 

C NMR (125 MHz; CDCl3) C 20.5 
(CH3CO), 20.6 (CH3CO), 20.7 (CH3CO), 53.7 (C-2), 62.0 (C-6), 67.0 (CH2Ph), 67.9 (C-5), 
68.3 (C-4), 68.9 (OCH2CHCH2), 71.3 (C-3), 96.6 (C-1), 118.5 (OCH2CHCH2), 128.1 (C-
Ar), 128.2 (C-Ar), 128.5 (C-Ar), 133.0 (C-Ar), 136.2 (OCH2CHCH2), 169.4 (CH3CO), 
155.8 (COCH2Ph), 170.7 (CH3CO), 171.0 (CH3CO); HRMS calcd for C23H28O10N1 [M-H]
-
 
478.1719, found 478.1721. 
2-(((2S,3R,4R,5S,6R)-4,5-Diacetoxy-6-(acetoxymethyl)-3-(((benzyloxy) 
carbonyl)amino)tetrahydro-2H-pyran-2-yl)oxy)acetic acid (142) 
 
Allyl ether 141 (3.0 g, 6.2 mmol) was dissolved in a mixture of CH2Cl2:MeCN:H2O (10 
mL:10 mL:15 mL). NaIO4 (10.7 g, 50 mmol, 8 eq.) was added, followed by RuCl3 (50 mg, 
0.24 mmol, 0.04 eq.) and the mixture was stirred at room temperature for 30 minutes. The 
reaction was quenched with water, partitioned between CH2Cl2 (5 × 50 mL), and water 
(100 mL). The organic extracts were combined, washed with brine (50 mL), dried over 
MgSO4 and the solvent removed in vacuo. The residue was purified by MPLC on SiO2 
with a gradient elution from 90:10:1 to 75:25:2.5 CH2Cl2/MeOH/NH4OH to give a clear 
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glass (1.85g 3.7 mmol, 60%); Rf 0.15 (25% MeOH/EtOAc; anisaldehyde); mp 82-85 C; 
max(EtOH)/nm < 220; IR  max/cm
-1
 1739, 1586, 1535; 
1
H NMR (500 MHz; CD3OD) H 
1.85 (3H, s, CH3CO), 2.03 (3H, s, CH3CO), 2.09 (3H, s, CH3CO), 4.02 (1H, dd, J = 3.2 
and 10.4 Hz, H-2), 4.12 (1H, d, J = 12.3 Hz, CHaHbCO2H), 4.17 (1H, app. d, J = 10.3 Hz, 
H-5), 4.24-4.32 (3H, m, CH2Ph and CHaHbCO2H), 5.00 (1H, d, J = 3.2 Hz, H-1), 5.02-5.10 
(2H, m, H-4 and H-6a), 5.18 (1H, d, J = 12.4 Hz, H-6b), 5.33 (1H, app. t, J = 10.4 Hz, H-3), 
7.30-7.40 (5H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 20.6 (2 × CH3CO), 20.7 
(CH3CO), 55.0 (C-2), 63.4 (CH2CO2H), 67.5 (C-6), 67.8 (CH2Ph), 69.1 (C-5), 70.2 (C-4), 
73.2 (C-3), 99.1 (C-1), 128.7 (C-Ar), 129.0 (C-Ar), 129.5 (C-Ar), 138.5 (C-Ar), 158.7 
(COCH2Ph), 171.4 (CH3CO), 171.8 (CH3CO), 172.4 (CH3CO), 175.4 (CO2H); HRMS 
calcd for C22H26O12N1 [M-H]
-
 496.1460, found 496.1474. 
(2R,3S,4R,5R,6S)-2-(Acetoxymethyl)-5-(((benzyloxy)carbonyl)amino)-6-(2-
methoxy-2-oxoethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate (143) 
 
Carboxylic acid 142 (1.5 g, 3.0 mmol, 1 eq.) was dissolved in MeCN (30 mL) and 
Cs2CO3(s) (1.97 g, 6.0 mmol, 2 eq.) was added followed by methyl iodide (371 L, 6.0 
mmol, 2 eq.). The mixture was stirred at room temperature for 18 h, filtered, and the 
solvent removed in vacuo. The residue was purified by MPLC on SiO2 with a gradient 
elution from 20-80% EtOAc/Petrol, to give a clear gum, (1.19 g, 2.32 mmol, 77%); Rf 0.4 
(50% EtOAc/Petrol; anisaldehyde); max(EtOH)/nm < 220; IR  max/cm
-1
 1739, 1518; 
1
H 
NMR (500 MHz; CD3OD) H 1.89 (3H, s, CH3CO2R), 2.04 (3H, s, CH3CO2R), 2.09 (3H, s, 
CH3CO2R), 3.79 (3H, s, CO2CH3), 4.02 (1H, dd, J = 3.7 and 10.7 Hz, H-2), 4.13 (1H, dd, J 
= 2.2 and 12.3 Hz, H-6a), 4.19 (1H, ddd, J = 2.2, 4.2, and 10.2 Hz, H-5), 4.29 (1H, dd, J = 
4.2 and 12.3 Hz, H-6b), 4.34 (2H, s, CH2CO2Me), 5.01 (1H, d, J = 3.7 Hz, H-1), 5.07 (1H, 
dd, J = 9.7 and 10.2 Hz, H-4), 5.10 (1H, d, J = 12.6 Hz, CHaHbPh), 5.19 (1H, d, J = 12.6 
Hz, CHaHbPh), 5.31 (1H, dd, J = 9.7 and 10.7 Hz, H-3), 7.30-7.42 (5H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 20.5 (CH3CO), 20.6 (2 × CH3CO), 52.6 (CO2CH3), 55.0 
(C-2), 63.2 (C-6), 66.0 (CH2CO2Me), 67.7 (CH2Ph), 69.5 (C-5), 70.0 (C-4), 72.5 (C-3), 
99.6 (C-1), 128.8 (C-Ar), 129.0 (C-Ar), 129.5 (C-Ar), 138.3 (C-Ar), 158.5 (NCO2CH2Ph), 
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171.3 (CO2R), 172.0 (CO2R), 172.1 (CO2R), 172.4 (CO2Me); MS (ESI-) m/z 510.2 [M-
H]
-
; HRMS calc for C23H33N2O12 [M+NH4OAc]
+
 529.2028, found 529.2039.
 
Methyl 2-(((2S,3R,4R,5S,6R)-3-(((benzyloxy)carbonyl)amino)-4,5-dihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)acetate (144) 
 
NaOMe(s) (8 mg, 0.16 mmol, 0.2 eq.) was added to methyl ester 143 (400 mg, 0.78 mmol, 
1 eq.) in MeOH (5 mL) at room temperature, and the mixture was stirred at room 
temperature for 1 h. The solvent was removed in vacuo, and the residue purified by MPLC 
on SiO2 with a gradient elution from 0-20% MeOH/EtOAc to give a white solid (300 mg, 
0.78 mmol, 100%); Rf 0.5 (5% MeOH/EtOAc; anisaldehyde); mp 150-152 C; 
max(EtOH)/nm < 220; IR  max/cm
-1
 3489, 3327, 3268, 2945, 2890, 1721, 1685, 1530; 
1
H 
NMR (500 MHz; CD3OD)H 3.39 (1H, app t, J = 9.0 Hz, H-4), 3.65 (1H, ddd, J = 2.1, 5.8, 
and 9.8 Hz, H-5), 3.68-3.74 (3H, m, H-2, H-3 and H-6a), 3.77 (3H, s, CO2CH3), 3.85 (1H, 
dd, J = 2.1 and 11.8 Hz, H-6b), 4.25 (1H, d, J = 16.4 Hz, CHaHbCO2Me), 4.31 (1H, d, J = 
16.4 Hz, CHaHbCO2Me), 4.93 (1H, d, J = 3.1 Hz, H-1), 5.11 (1H, d, J = 12.4 Hz, 
CHaHbPh), 5.15 (1H, d, J = 12.4 Hz, CHaHbPh), 7.39-7.43 (5H, m, H-Ar); 

CNMR (125 
MHz; CD3OD)C 52.5 (CO2CH3), 57.0 (C-2), 62.7 (C-6), 65.2 (CH2CO2CH3), 67.6 
(CH2Ph), 72.1 (C-4), 73.0 (C-3), 74.4 (C-5), 99.4 (C-1), 128.9 (C-Ar), 129.0 (C-Ar), 129.5 
(C-Ar), 138.3 (C-Ar), 159.0 (NHCO2Bn), 172.5 (CO2Me); HRMS calcd for C17H22N1O9 
[M-H]
-
 384.1300, found 384.1305. 
Methyl 2-(((2S,3R,4R,5S,6R)-3-(((benzyloxy)carbonyl)amino)-4,5-dihydroxy-6-
((sulfamoyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetate (145) 
 
Prepared according to sulfamoylation method 2 using sulfamoyl chloride (0.78 mL, 1 M in 
MeCN, 0.78 mmol, 1.5 eq.), alcohol 144 (200 mg, 0.52 mmol, 1 eq.) and DMF (4 mL) at   
-40 C. The residue was purified by MPLC on SiO2 with a gradient elution from 50% 
EtOAc/petrol to 100% EtOAc to 7 % MeOH/EtOAc to give a white solid. (162 mg, 0.35 
mmol, 67 %); Rf 0.2 (EtOAc; anisaldehyde); mp 136-137 C; max(EtOH)/nm < 220; IR  
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max/cm
-1 
3432, 3389, 3248, 3242, 1760 (CO ester), 1686 (carbamate I), 1541 (carbamate II), 
1372 (SO), 1180 (SO); 
1
H NMR (500 MHz; CD3OD) H 3.38-3.44 (1H, m, H-4), 3.67-3.74 
(2H, m, H-2 and H-3), 3.77 (3H, s, OMe), 3.93 (1H, ddd, J = 1.7, 5.8 and 9.9 Hz, H-5), 
4.244.33 (3H, m, H-6a and CH2CO2Me), 4.42 (1H, dd, J = 1.7 and 10.9 Hz, H-6b), 4.93 
(1H, d, J = 2.9 Hz, H-1), 5.13 (1H, d, J = 12.6 Hz, CHaHbPh), 5.16 (1H, d, J = 12.6 Hz, 
CHaHbPh), 7.30-7.45 (5H, m, H-Ar); 
1
H NMR (500 MHz; DMSO-d6) H 3.16-3.24 (1H, m, 
H-4), 3.45-3.58 (2H, m, H-2 and H-3), 3.68 (3H, s, OMe), 3.80 (1H, ddd, J = 1.7, 6.0, and 
10.1 Hz, H-5), 4.13 (1H, dd, J = 6.0 and 10.7 Hz, H-6a), 4.19-4.29 (3H, m, CH2CO2Me and 
H-6b), 4.89 (1H, d, J = 3.3 Hz, H-1), 4.97 (1H, d, J = 5.7 Hz, OH-3), 5.08 (2H, s, CH2Ph), 
5.38 (1H, d, J = 6.3 Hz, OH-4), 7.12 (1H, d, J = 8.0 Hz, NHCO2Bn), 7.33-7.37 (1H, m, H-
Ar), 7.38-7.43 (4H, m, H-Ar), 7.50 (2H, br s, SONH2); 

CNMR (125 MHz; CD3OD)C 
52.5 (CO2CH3), 56.9 (C-2), 65.6 (CH2CO2Me), 67.7 (CH2Ph), 70.0 (C-6), 71.8 (C-4), 71.9 
(C-5), 72.9 (C-3), 99.6 (C-1), 128.9 (C-Ar), 129.0 (C-Ar), 129.5 (C-Ar), 138.3 (C-Ar), 
158.9 (NHCO2Bn), 172.4 (CO2Me); HRMS calcd for C17H23O11N2S1 [M-H]
-
 
463.1028, found 463.1031. 
2-(((2S,3R,4R,5S,6R)-3-(((benzyloxy)carbonyl)amino)-4,5-dihydroxy-6-
((sulfamoyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)acetic acid (148) 
 
To methyl ester 145 (100 mg, 0.22 mmol, 1 eq.) in THF (2 mL) at room temperature was 
added NaOH (216 L, 2 M aq., 0.43 mmol, 2 eq.), and the reaction was stirred at room 
temperature for 2 hours. HCl (324 L, 2 M aq., 0.65 mmol, 3 eq.) was added, and the 
mixture extracted with EtOAc (10 mL) and CH2Cl2 (10 mL). The organic extracts were 
combined, dried (MgSO4) and the solvent removed in vacuo to give a clear gum (80 mg, 
0.18 mmol, 82%); Rf 0.15 (20% MeOH/EtOAc; ninhydrin); max(EtOH)/nm < 220; IR  
max/cm
-1 
3400 br, 1693 (str, br), 1531, 1358 (SO), 1178 (SO); 
1
H NMR (500 MHz; CD3OD) 
H 3.38-3.42 (1H, m, H-4), 3.66-3.72 (2H, m, H-2 and H-3), 3.88 (1H, ddd, J = 1.6 , 5.7, 
and 9.9 Hz, H-5), 4.17 (1H, d, J = 16.6 Hz, CHaHbCO2H), 4.24-4.31 (2H, m, H-6a and 
CHaHbCO2H), 4.41 (1H, dd, J = 1.6 and 10.7 Hz, H-6b), 4.90 (1H, d, J = 2.7 Hz, H-1), 5.12 
(2H, s, CH2Ph), 7.28-7.42 (5H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 56.9 (C-2), 
65.4 (CH2CO2H), 67.7 (CH2Ph), 70.0 (C-6), 71.8 (C-5), 71.9 (C-4), 73.1 (C-3), 99.5 (C-1), 
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128.9 (C-Ar), 129.0 (C-Ar), 129.5 (C-Ar), 138.3 (C-Ar), 159.0 (CO2Bn), 173.6 (CO2H); 
HRMS calcd for C16H21O11N2S1 [M-H]
-
 449.0872, found 449.0864. 
2-(((2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-((sulfamoyloxy) methyl) 
tetrahydro-2H-pyran-2-yl)oxy)acetic acid (149) 
 
Carbamate 148 (70 mg, 0.16 mmol) was dissolved in acetic acid (5 mL) and hydrogenated 
on a Thales H-cube on full H2 mode through 5% Pd/C catalyst cartridge at 40 C for 3 h, 
with constant recycling of reaction mixture. The solvent was removed in vacuo to give a 
clear gum. (63 mg, 100%); Rf 0.3 (50:50:5 EtOAc:MeOH:NH4OH; ninhydrin); 
max(EtOH)/nm < 220;IR  max/cm
-1
 3012, 1710, 1365 (SO), 1172 (SO); 
1
H NMR (500 
MHz; CD3OD) H 3.20 (1H, dd, J = 3.6 and 10.6 Hz, H-2), 3.42 (1H, dd, J = 9.3 and 9.8 
Hz, H-4), 3.85-3.92 (2H, m, H-3 and H-5), 4.00 (1H, d, J = 15.6 Hz, CHaHbCO2H), 4.18 
(1H, d, J = 15.6 Hz, CHaHbCO2H), 4.33 (1H, dd, J = 5.4 and 10.9 Hz, H-6a), 4.42 (1H, dd, 
J = 1.8 and 10.9 Hz, H-6b), 5.11 (1H, d, J = 3.6 Hz, H-1); 

CNMR (125 MHz; 
CD3OD)C 20.9 (CH3CO2
-
), 55.6 (C-2), 68.1 (CH2CO2H), 69.3 (C-6), 71.3 (C-4), 71.7 (C-
3), 72.0 (C-5), 97.2 (C-1), 175.4 (CO2H), 176.7 (CH3CO2
-
); MS (ESI-) m/z 315.1 [M-H]
-
, (ESI+) 317.2.3 [M+H]
+
. 
Disodium 2-(((2S,3R,4R,5S,6R)-4,5-dihydroxy-6-((sulfamoyloxy) methyl)-3-
(sulfoamino)tetrahydro-2H-pyran-2-yl)oxy)acetate (55) 
 
Prepared according to general procedure B, using amine 149 (70 mg, 0.18 mmol), de-
ionised water (2 mL) and pyridine-sulfur trioxide complex (59 mg, 0.37 mmol, 3.7 eq.) for 
18 h. The crude product was purified by MPLC on SiO2 with a gradient elution from 50-
80% MeOH/EtOAc. Product containing fractions were evaporated in vacuo. The residue 
was dissolved in water, frozen, and lyophilized to give a white solid (28 mg, 38%); Rf 0.7 
(MeOH; ninhydrin); mp 150 C dec.; max(EtOH)/nm < 220; IR  max/cm
-1 
3224 br, 1587, 
1356 (SO), 1176 (SO); 
1
H NMR (500 MHz; CD3OD) H 3.29 (1H, dd, J = 3.6 and 10.1 Hz, 
H-2), 3.42 (1H, dd, J = 9.0 and 10.1 Hz, H-4), 3.74 (1H, dd, J = 9.0 and 10.1 Hz, H-3), 
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3.90 (1H, ddd, J = 1.7, 5.8, and 10.1 Hz, H-5), 4.05 (1H, d, J = 15.8 Hz, CHaHbCO2H), 
4.21 (1H, d, J = 15.8 Hz CHaHbCO2H), 4.30 (1H, dd, J = 5.8 and 10.8 Hz, H-6a), 4.42 (1H, 
d, J = 1.7 and 10.8 Hz, H-6b), 5.11 (1H, d, J = 3.6 Hz, H-1); 
1
H NMR (500 MHz; D2O) H 
3.19 (1H, dd, J = 3.6 and 10.3 Hz, H-2), 3.47 (1H, dd, J = 9.2 and 10.1 Hz, H-4), 3.67 (1H, 
dd, J = 9.2 and 10.3 Hz, H-3), 3.89-3.95 (2H, m, H-5 and CHaHbCO2H), 4.05 (1H, d, J = 
15.3 Hz, CHaHbCO2H), 4.36 (2H, d, J = 3.3 Hz, H-6), 5.06 (1H, d, J = 3.6 Hz, H-
1);

CNMR (125 MHz; CD3OD)C 59.5 (C-2), 67.5 (CH2CO2H), 70.0 (C-6), 71.4 (C-5), 
71.9 (C-4), 73.9 (C-3), 99.9 (C-1), 175.7 (CO2H); HRMS calcd for C8H15N2O12S2 [M-
H]
-
 395.0072, found 395.0057. 
 (2R,3S,4R,5R,6S)-2-(acetoxymethyl)-5-(((benzyloxy)carbonyl)amino)-6-(3-
hydroxypropoxy)tetrahydro-2H-pyran-3,4-diyl diacetate337 (150) 
 
BH3.THF (1 M in THF, 4.17 mL, 4.17 mmol, 4 eq.) was added to allyl ether 141 (500 mg, 
1.05 mmol, 1 eq.) in THF (50 mL) at 0 C, and stirred at room temperature for 18 h. After 
the addition of phosphate buffer (pH 7.4, 8 mL), hydrogen peroxide (1 mL, 27% in water, 
14 mmol, 13 eq.) was added, and the mixture was stirred at room temperature for 18 h. The 
mixture was extracted with CH2Cl2 (3 × 40 mL), washed with saturated aqueous NaCl, 
dried over MgSO4 and solvent removed in vacuo. The residue was purified by MPLC on 
SiO2 with gradient elution from 20-100% EtOAc/petrol to give a clear oil (180 mg, 35%); 
Rf 0.2 (50% EtOAc/petrol; anisaldehyde); max(EtOH)/nm < 220; IR  max/cm
-1
 1739, 1513; 
1
H NMR (500 MHz; CD3OD) H 1.85-1.92 (5H, m, CH3CO and CH2CH2CH2OH), 2.03 
(3H, s, CH3CO), 2.09 (3H, s, CH3CO), 3.60 (1H, dt, J = 9.9 and 6.1 Hz, 
CHaHbCH2CH2OH), 3.72 (2H, t, J = 6.1 Hz, CH2CH2CH2OH), 3.87 (1H, dt, J = 9.9 and 
6.1 Hz, CHaHbCH2CH2OH), 3.97 (1H, dd, J = 3.3 and 10.9 Hz, H-2), 4.05 (1H, ddd, J = 
2.0 Hz, 4.7, and 9.6 Hz , H-5), 4.14 (1H, dd, J = 2.0 and 12.2 Hz, H-6a), 4.29 (1H, dd, J = 
4.7 and 12.2 Hz, H-6b), 4.90 (1H, d, H-1), 5.00-5.09 (2H, m, H-4 and CHaHbPh), 5.19 (1H, 
d, J = 12.5 Hz, CHaHbPh), 5.26 (1H, app t, J = 9.8 Hz, H-3), 7.30-7.40 (5H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 20.6 (2 × COCH3), 20.7 (COCH3), 33.2 
(CH2CH2CH2OH), 55.1 (C-2), 59.8 (CH2CH2CH2OH), 63.4 (C-6), 66.4 (CH2CH2CH2OH), 
67.7 (CH2Ph), 68.9 (C-5), 70.4 (C-4), 72.8 (C-3), 98.9 (C-1), 128.9 (C-Ar), 129.1 (C-Ar), 
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129.5 (C-Ar), 138.3 (C-Ar), 171.4 (2 × COCH3), 172.4 (COCH3); HRMS calcd for 
C23H31N1O11 [M-H]
-
 496.1824, found 496.1830. 
Benzyl ((2S,3R,4R,5S,6R)-2-(3-(benzyloxy)propoxy)-4,5-dihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-3-yl)carbamate (152) 
 
Compound 102 (1.5g, 4.8 mmol), 3-benzyloxy-1-propanol (5 mL), HCl in dioxane (2 mL, 
4 M) and dioxane (20 mL) were combined and heated to 75 C for 5 h. The mixture was 
allowed to cool to room temperature and the solvent removed in vacuo. The residue was 
purified by MPLC on SiO2 with a gradient elution from 0-5% MeOH/EtOAc. Product 
containing fractions were combined, evaporated, and re-purified by MPLC on SiO2 with a 
gradient elution from 70% EtOAc/Petrol to 100% EtOAc to 8% MeOH/EtOAc to give a 
pale brown solid (685 mg, 1.49 mmol, 31%). Rf 0.5 (5% MeOH/EtOAc; anisaldehyde); mp 
98-101 C; max(EtOH)/nm < 220; IR  max/cm
-1 
3324, 2932, 2881, 1689 (carbamate I), 
1536 (carbamate II); 
1
H NMR (500 MHz; CDCl3) H 1.87 (2H, quint, CH2CH2OBn), 1.98 
(1H, br t, J = 5.7 Hz, C6OH), 2.72 (1H, br s, OH), 2.99 (1H, br s, OH), 3.47-3.72 (6H, m, 
H-3, H-4, H-5, H-6a, CH2O), 3.75-3.86 (4H, m, CH2O, H-2, H-6b), 4.47 (2H, s, 
CH2OCH2Ph), 4.80 (1H, d, J = 3.4 Hz, H-1), 5.11 (2H, s, NCO2CH2Ph), 5.32-5.38 (1H, d, 
J = 8.4 Hz, NH), 7.26-7.36 (10H, m, H-Ar); 

C NMR (125 MHz; CDCl3)C 29.6 
(OCH2CH2CH2O), 55.4 (C-2), 62.4, 65.5 (NHCOCH2Ph), 67.1, 67.5, 71.1, 73.0 
(CH2CH2OCH2Ph), 74.4, 97.5 (C-1), 127.7 (C-Ar), 128.4 (C-Ar), 128.5 (C-Ar), 128.6 (C-
Ar), 138.2 (C-Ar), 157.2 (CO); HRMS calcd for C24H32O8N1 [M+H]
+
 462.2122, 
found 462.2119. 
((2R,3S,4R,5R,6S)-5-(((benzyloxy)carbonyl)amino)-6-(3-(benzyloxy) propoxy)-
3,4-dihydroxytetrahydro-2H-pyran-2-yl)methyl sulfamate (153) 
 
Prepared according to sulfamoylation method 2 using sulfamoyl chloride (2.1 mL, 1 M in 
MeCN, 2.1 mmol, 1.5 eq.), compound 152 (650 mg, 1.4 mmol, 1 eq.), and DMF (8 mL). 
The residue was purified by MPLC on SiO2 with gradient elution from 50% EtOAc/petrol 
255 
 
to 100% EtOAc to give a white solid (435 mg, 57 %); Rf 0.2 (EtOAc; anisaldehyde); mp 
137-139 C; max(EtOH)/nm < 220; IR  max/cm
-1 
3336, 1684 (carbamate I), 1542 
(carbamate II), 1372 (SO), 1182 (SO); 
1
H NMR (500 MHz; CD3OD) H 1.86-1.95 (2H, m, 
OCH2CH2CH2OBn), 3.36-3.42 (1H, m, H-4), 3.52-3.58 (1H, m, OCHaHbCH2CH2OBn), 
3.61-3.68 (4H, m, H-2, H-3, OCH2CH2CH2OBn), 3.81-3.89 (2H, m, H-5 and 
OCHaHbCH2CH2OBn), 4.28 (1H, dd, J = 5.8 and 10.7 Hz, H-6a), 4.41 (1H, dd, J = 1.7 and 
10.7 Hz, H-6b), 4.50 (2H, s, CH2OCH2Ph), 4.83 (1H, d, J = 1.8 Hz, H-1), 5.11 (2H, s, 
NHCO2CH2Ph), 7.27-7.40 (10H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 30.7 
(OCH2CH2CH2OBn), 57.1 (C-2), 66.2 (OCH2CH2CH2OBn), 67.6 (NHCO2CH2Ph), 68.2 
(OCH2CH2CH2OBn), 70.1 (C-6), 71.4 (C-5), 72.0 (C-4), 73.0 (C-3), 74.1 (CH2OCH2Ph), 
99.1 (C-1), 128.7 (C-Ar), 128.9 (C-Ar), 129.0 (C-Ar), 129.1 (C-Ar), 129.4 (C-Ar), 129.5 
(C-Ar), 138.2 (C-Ar), 139.8 (C-Ar), 158.8 (CO); HRMS calcd for C24H33O10N2S1 
[M+Na]
+
 541.1850, found 541.1846. 
(2S,3R,4R,5S,6R)-4,5-dihydroxy-2-(3-hydroxypropoxy)-6-
((sulfamoyloxy)methyl) tetrahydro-2H-pyran-3-aminium acetate (154) 
 
Compound 153 (190 mg, 0.35 mmol) was dissolved in acetic acid (9 mL) and 
hydrogenated on a Thales H-cube at a hydrogen pressure of 20 bar through 5% Pd/C 
catalyst cartridge at 20 C for 1 h, with constant recycling of the reaction mixture at a flow 
rate of 1 mL/minute. The solvent was removed in vacuo to give a clear gum, which was 
triturated with Et2O (4 × 5 mL). The resulting gum was dried in vacuo at 40 C for 18 h to 
give a clear glass (110 mg, 83%); Rf 0.1 (25% MeOH/EtOAc); max(EtOH)/nm < 220; IR  
max/cm
-1 
2939 br, 1707 w, 1539 (CO2
-
), 1361 (SO), 1176 (SO); 
1
H NMR (500 MHz; 
CD3OD) H 1.91 (2H, app. quin, J = 6.2 Hz, CH2CH2CH2OH), 2.00 (3H, s, CH3CO2
-
), 3.12 
(1H, dd, J = 3.1 and 10.4 Hz, H-2), 3.40 (1H, app. t, J = 9.5 Hz, H-4), 3.63 (1H, dt, J = 9.8 
and 6.2 Hz, CHaHbCH2CH2OH), 3.69-3.80 (3H, m, H-3 and CH2OH), 3.87 (1H, ddd, J = 
1.7, 5.7, and 9.5 Hz, H-5), 3.93 (1H, dt, J = 9.8 and 6.2 Hz, CHaHbCH2CH2OH), 4.31 (1H, 
dd, J = 5.7 and 10.9 Hz, H-6a), 4.45 (1H, dd, J = 1.7 and 10.9 Hz, H-6b), 5.01 (1H, d, J = 
3.1 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 22.2 (CH3 acetate), 33.2 
(CH2CH2CH2OH), 55.8 (C-2), 59.7 (CH2CH2CH2OH), 66.4 (CH2CH2CH2OH), 69.6 (C-6), 
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71.5 (C-4), 71.8 (C-5), 72.5 (C-3), 97.5 (C-1), 177.3 (CO); HRMS calcd for 
C9H21N2O8S1 [M+H]
+
 317.1013, found 317.1017. 
Sodium ((2S,3R,4R,5S,6R)-4,5-dihydroxy-2-(3-hydroxypropoxy)-6-
((sulfamoyloxy)methyl)tetrahydro-2H-pyran-3-yl)sulfamate (54) 
 
Prepared according to general procedure B, using compound 154 (100 mg, 0.27 mmol, 1 
eq.), de-ionised water (5 mL) and pyridine-sulfur trioxide complex (126 mg, 0.53 mmol, 3 
eq.) for 18 h. The crude product was purified by MPLC on SiO2 with a gradient elution 
from 20-40% MeOH/EtOAc. Product containing fractions were evaporated in vacuo to 
give a pale glass (43 mg, 41%); Rf 0.3 (30% MeOH/EtOAc; anisaldehyde); mp 105-110 
C; [α]D
18.0 
+85.71c = 0.21, MeOH); max(EtOH)/nm < 220; IR  max/cm
-1 
3287, 2929, 
1361 (SO), 1175 (SO); 
1
H NMR (500 MHz; CD3OD) H 1.82-1.93 (2H, m, 
CH2CH2CH2OH), 3.28 (1H, dd, J = 3.6 and 10.4 Hz, H-2), 3.40 (1H, dd, 9.6 and 10.1 Hz, 
H-4), 3.56-3.63 (2H, m, H-3 and CHaHbCH2CH2OH), 3.67-3.79 (2H, m, CH2CH2CH2OH), 
3.81-3.90 (1H, m, H-5), 4.44 (1H, dd, J = 2.0 and 10.8 Hz, H-6a), CHaHbCH2CH2OH), 
4.28 (1H, dd, J = 6.0 and 10.8 Hz, H-6b), 5.11 (1H, d, J = 3.6 Hz H-1); 

CNMR (125 
MHz; CD3OD)C 33.40 (CH2CH2CH2OH), 59.54 (C-2), 59.94 (CH2CH2CH2OH), 66.2 
(CH2CH2CH2OH), 70.2 (C-6), 71.1 (C-5), 71.9 (C-4), 74.0 (C-3), 99.3 (C-1); HRMS 
calcd for C9H19N2O11S1 395.0436 [M-H]
-
, found 495.0417. 
((2R,3S,4R,5R,6S)-5-amino-6-(3-(benzyloxy)propoxy)-3,4-
dihydroxytetrahydro-2H-pyran-2-yl)methyl sulfamate (155) 
 
Compound 153 (200 mg, 0.37 mmol) was dissolved in EtOH (10 mL) and hydrogenated on 
a Thales H-cube at a hydrogen pressure of 20 bar through 5% Pd/C catalyst cartridge at 20 
C for 1 h, with constant recycling of the reaction mixture at a flow rate of 1 mL/minute. 
The solvent was removed in vacuo to give a clear gum, which was purified by MPLC on 
SiO2 with gradient elution from 15-30% MeOH/EtOAc to give a clear gum (113 mg, 75 
%); Rf 0.1 (15% MeOH/EtOAc; anisaldehyde); max(EtOH)/nm < 220; IR  max/cm
-1 
2931, 
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1363 (SO), 1178 (SO); 
1
H NMR (500 MHz; CD3OD) H 1.96 (2H, m, CH2CH2OBn), 2.63 
(1H, dd, J = 3.6 and 9.9 Hz, H-2), 3.31 (2H, dd, J = 9.0 and 9.9 Hz, H-4), 3.48 (1H, dd, J = 
9.0 and 9.9 Hz, H-3), 3.57 (1H, app. dt, J = 9.8 and 6.2 Hz, CHaHbO), 3.65 (2H, t, J = 6.3 
Hz, CH2OBn), 3.83 (1H, ddd, J = 1.9 , 5.8, and 9.9 Hz, H-5), 3.90 (1H, app dt, J = 9.8 and 
6.2 Hz, CHaHbO), 4.27 (1H, dd, J = 5.8 and 10.7 Hz, H-6a), 4.40 (1H, dd, J = 1.9 and 10.7 
Hz, H-6b), 4.60 (2H, s, CH2Ph), 4.81 (1H, d, J = 3.6 Hz, H-1), 7.29-7.34 (1H, m, H-Ar), 
7.36-7.40 (4H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 30.8 (OCH2CH2CH2OBn), 
57.0 (C-2), 66.1 (OCH2CH2CH2OBn), 68.2 (OCH2CH2CH2OBn), 70.1 (C-6), 71.7 (C-4 
and C-5), 74.0 (CH2Ph), 76.1 (C-3), 100.3 (C-1), 128.7 (C-Ar), 128.9 (C-Ar), 129.4 (C-
Ar), 139.8 (C-Ar); HRMS calcd for C16H25N2O8S1 [M-H]
-
 405.1337, found 405.1339. 
Ammonium ((2S,3R,4R,5S,6R)-2-(3-(benzyloxy)propoxy)-4,5-dihydroxy-6-
((sulfamoyloxy) methyl)tetrahydro-2H-pyran-3-yl)sulfamate (58) 
 
Prepared according to general procedure B, using compound 155 (100 mg, 0.25 mmol), de-
ionised water (3 mL) and pyridine-sulfur trioxide complex (46 mg, 0.30 mmol, 2.2 eq.) for 
18 h. The crude product was purified by MPLC on SiO2 with gradient elution from 
85:15:1.5 to 65:35:3.5 EtOAc:MeOH:NH4OH to give a white solid (74 mg, 62%); Rf 0.2 
(70:30:3 EtOAc/MeOH/NH4OH; anisaldehyde); mp 85-90 C; [α]D
22.7 
+108.6 (c = 0.14, 
MeOH); max(EtOH)/nm < 220; IR  max/cm
-1 
3246, 3064, 2880, 1363 (SO), 1175 (SO); 
1
H 
NMR (500 MHz; CD3OD) H 1.90-2.02 (2H, m, OCH2CH2CH2OBn), 3.28 (1H, dd, J = 3.6 
and 10.2 Hz, H-2), 3.41 (1H, dd, J = 8.9 and 10.0 Hz, H-4), 3.57-3.64 (2H, m, H-3 and 
OCHaHbCH2CH2OBn), 3.64-3.71 (2H, m, OCH2CH2CH2OBn), 3.80-3.91 (2H, m, 
OCHaHbCH2CH2OBn and H-5), 4.27 (1H, dd, J = 6.0 and 10.7 Hz, H-6a), 4.41 (1H, dd, J = 
1.9 and 10.7 Hz, H-6b), 4.56 (2H, s, CH2Ph), 5.10 (1H, d, J = 3.6 Hz, H-1), 7.28-7.32 (1H, 
m, H-Ar), 7.35-7.41 (4H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 30.8 
(OCH2CH2CH2OBn), 59.6 (C-2), 66.4 (OCH2CH2CH2OBn), 68.4 (OCH2CH2CH2OBn), 
70.2 (C-6), 71.1 (C-5), 71.9 (C-4), 74.0 (CH2Ph), 74.1 (C-3), 99.4 (C-1), 128.6 (C-Ar), 
129.0 (C-Ar), 129.4 (C-Ar), 139.9 (C-Ar); HRMS calcd for C16H25N2O11S2 [M-H]
-
 
485.0905, found 485.0914. 
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Benzyl ((2R,4aR,6S,7R,8R,8aS)-8-hydroxy-6-methoxy-2-phenyl 
hexahydropyrano[3,2-d][1,3]dioxin-7-yl)carbamate202 (156) 
 
Compound 103 (200 mg, 0.6 mmol), benzaldehyde dimethyl acetal (230 L, 1.52 mmol, 3 
eq.), and p-toluenesulfonic acid (5 mg, cat.), were combined in DMF (5 mL) and heated to 
75 C for 3 h. The reaction mixture was diluted with EtOAc (20 mL), washed with brine 
(10 mL), dried over MgSO4, and the solvent removed in vacuo. The residue was purified 
by MPLC on SiO2 with gradient elution from 25% EtOAc/petrol to 100% EtOAc to give a 
white solid (197 mg, 78%); Rf 0.4 (40% EtOAc/petrol; anisaldehyde); mp 207-210 C 
(lit.
338
 207-208 C); max(EtOH)/nm < 220; IR  max/cm
-1 
3313, 1685 (carbamate I), 1546 
(carbamate II); 
1
H NMR (500 MHz; CDCl3)H 2.68 (1H, d, J = 1.8 Hz, OH), 3.42 (3H, s, 
OCH3), 3.61 (1H, app t, J = 8.5 Hz, H-4), 3.77-3.87 (2H, m, H-6a and H-5), 3.90-4.02 (2H, 
m, H-2 and H-3), 4.31 (1H, dd, J = 3.5 and 9.0 Hz, H-6b), 4.77 (1H, d, J = 3.6 Hz, H-1), 
5.12-5.21 (3H, m, CH2Ph and NH), 5.59 (1H, s, PhCH(OR)2), 7.33-7.44 (8H, m, H-Ar), 
7.49-7.55 (2H, m, H-Ar); 

C NMR (125 MHz; CDCl3)C 55.1 (OMe), 56.0 (C-2), 62.5 
(C-5), 67.1 (CH2Ph), 68.8 (C-6), 70.8 (C-3), 81.8 (C-4), 99.5 (C-1), 102.3 (PhCH(O)2), 
126.3 (C-Ar), 127.1 (C-Ar), 128.3 (C-Ar), 128.6 (C-Ar), 129.1 (C-Ar), 129.3 (C-Ar), 136.1 
(C-Ar)137.1 (C-Ar), 156.8 (CO); HRMS calcd for C22H26O7N1 [M+H]
+
 416.1704, 
found 416.1705. 
Benzyl ((2R,4aR,6S,7R,8aS)-6-methoxy-2-phenylhexahydropyrano [3,2-d][1,3] 
dioxin-7-yl)carbamate339 (157) 
 
Compound 156 (500 mg, 1.20 mmol, 1 eq.) and 1,1-thiocarbonyl diimidazole (322 mg, 
1.81 mmol, 1.5 eq.) were combined in toluene (12 mL), degassed, and heated at reflux for 
3 h under a nitrogen atmosphere. Tris(trimethylsilyl) silane (743 L, 2.40 mmol, 2 eq.) and 
AIBN (604 L, 0.2 M solution in toluene, 0.12 mmol, 0.1 eq.) were added and the mixture 
heated at reflux for 1 h. A further 0.1 eq. of AIBN solution was added and heating 
continued for a further 30 minutes. The solvent was removed in vacuo, and the residue 
purified by MPLC on SiO2 with a gradient elution from 5-35% EtOAc/petrol to give a 
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white solid (400 mg, 1.00 mmol, 83%); Rf 0.75 (40% EtOAc/Petrol; anisaldehyde); mp 
180-183 C (lit.339 175-176 C); max(EtOH)/nm < 220; IR  max/cm
-1 
3320, 1686 
(carbamate I), 1539 (carbamate II); 
1
H NMR (500 MHz; CD3OD) H 1.91 (app. q, J = 11.5 
Hz, H-3a), 2.10 (1H, app. dt, J = 11.5 and 4.4 Hz, H-3b), 3.46 (3H, s, OMe), 3.66-3.74 (2H, 
m, H-4 and H-5), 3.79 (1H, app. t, J = 10.0 Hz, H-6a), 3.94 (1H, app. dt, J = 12.4 and 3.7 
Hz, H-2), 4.23 (1H, dd, J = 4.4 and 10.0 Hz, H-6b), 4.69 (1H, d, J = 3.7 Hz, H-1), 5.12 
(2H, s, CH2Ph), 5.64 (1H, s, PhCH(O)2), 7.31-7.44 (8H, m, H-Ar), 7.46-7.51 (2H, m, H-
Ar); 
1
H NMR (500 MHz; CDCl3) H 1.83 (1H, app. q, J = 11.4 Hz, H-3a), 2.23 (app. dt, J = 
11.4 and 4.5 Hz, H-3b), 3.40 (3H, s, OMe), 3.60-3.66 (1H, m, H-4), 3.69-3.77 (2H, m, H-5 
and H-6a), 3.98-4.06 (1H, m, H-2), 4.26 (1H, dd, J = 5.5 and 10.2 Hz, H-6b), 4.63 (1H, d, J 
= 3.5 Hz, H-1), 5.05 (1H, d, J = 9.6 Hz, NH), 5.11 (2H, s, CH2Ph), 5.54 (1H, s, 
PhCH(O)2), 7.31-7.39 (8H, m, H-Ar), 7.46-7.49 (2H, m, H-Ar); 

C NMR (125 MHz; 
CDCl3)C 31.2 (C-3), 49.3 (C-2), 55.1 (OMe), 64.0 (C-6), 67.0 (C-5), 69.3 (C-4), 98.0 (C-
1), 101.8 (PhCH(O)2), 126.2 (C-Ar), 128.2 (C-Ar), 128.3 (C-Ar), 128.4 (C-Ar), 128.6 (C-
Ar), 129.1 (C-Ar), 136.2 (C-Ar), 137.4 (C-Ar), 155.5 (CO); HRMS calcd for 
C22H26O6N1 [M-H]
-
 400.1755, found 400.1757. 
Benzyl ((2S,3R,5S,6R)-5-(benzyloxy)-6-(hydroxymethyl)-2-methoxy tetrahydro-
2H-pyran-3-yl)carbamate (159) 
 
BH3.THF (10.2 mL, 1 M in THF, 10.2 mmol, 7 eq.) was added to a solution of compound 
157 in THF (4 mL), followed by the addition of Bu2BOTf (1.45 mL, 1.45 mmol, 1 eq.) at 0 
C, and the mixture was stirred at 0 C for 1 h. Et3N (1.5 mL) was added followed by 
cautious addition of MeOH (2 mL) until the evolution of hydrogen ceased. Further MeOH 
(8 mL) was added, the mixture was evaporated and purified by MPLC on SiO2 with a 
gradient elution from 20-70% EtOAc/petrol to give a white solid (262 mg, 49%); Rf 0.1 
(40% EtOAc/petrol; anisaldehyde); mp 120-122 C; max(EtOH)/nm < 220; IR  max/cm
-1
 
3326, 1681 (carbamate I), 1538 (carbamate II); 
1
H NMR (500 MHz; CDCl3)H 1.65 (1H, 
app q, H-3b), 1.86 (1H, dd, J = 6.0 and 6.9 Hz, C6-OH), 2.36 (1H, dt, J = 11.7 and 4.3 Hz, 
H-3a), 3.37 (3H, s, OMe), 3.48-3.56 (2H, m, H-4 and H-5), 3.58-3.64 (1H, m, H-6a), 3.70-
3.77 (1H, m, H-2), 3.80-3.90 (1H, m, H-6b), 4.45 (1H, d, J = 11.8 Hz, NHCO2CHaCHbPh), 
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4.56-4.66 (2H, m, H-1 and NHCO2CHaCHbPh), 5.01 (1H, d, J = 9.5 Hz, NH), 5.10 (2H, s, 
CH2Ph), 7.27-7.40 (10H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 31.4 (C-3), 50.7 (C-
2), 55.4 (OMe), 62.5 (C-6), 67.6 (CH2Ph), 72.0 (CH2Ph), 73.1 (C-4), 73.5 (C-5), 98.8 (C-
1), 128.8 (C-Ar), 128.9 (C-Ar), 129.0 (C-Ar), 129.1 (C-Ar), 129.4 (C-Ar), 129.5 (C-Ar), 
138.3 (C-Ar), 139.8 (C-Ar), 158.2 (CO); HRMS calcd for C22H28N1O6 [M+H]
+
 
402.1911, found 402.1913. 
((2R,3S,5R,6S)-3-(Benzyloxy)-5-(((benzyloxy)carbonyl)amino)-6-methoxy 
tetrahydro-2H-pyran-2-yl)methyl sulfamate (160) 
 
Prepared according to sulfamoylation method 3 using sulfamoyl chloride (1.54 mL, 1 M in 
MeCN, 1.54 mmol, 2 eq.), compound 159 (310 mg, 0.77 mmol, 1 eq.) in MeCN (5.4 mL) 
containing DMA (600 L) at room temperature. The reaction was stirred at room 
temperature for 15 min, quenched with EtOH (1.5 mL) and partitioned between EtOAc (2 
× 10 mL) and H2O (10 mL). The aqueous layer was extracted with further CH2Cl2 (10 mL), 
the organic extracts were combined, dried over MgSO4 and solvent removed in vacuo. The 
residue was purified by MPLC on SiO2 with gradient elution from 20-60% EtOAc/petrol to 
give a clear gum (270 mg, 73%); Rf 0.4 (50% EtOAc/petrol; anisaldehyde); 
max(EtOH)/nm < 220; IR  max/cm
-1
 3321, 2906, 1699 (carbamate I), 1521 (carbamate II), 
1379 (SO), 1182 (SO); 
1
H NMR (500 MHz; CD3OD) H 1.74 (1H, m, H-3a), 2.29 (1H, m, 
H-3b), 3.44 (3H, s, OMe), 3.54-3.62 (1H, m, H-4), 3.73-3.84 (2H, m, H-2 and H-5), 4.28-
4.33 (1H, dd, J = 5.2 and 10.6 Hz, H-6a), 4.38 (1H, dd, J = 1.9 and 10.6 Hz, H-6b), 4.55 
(1H, d, J = 11.3 Hz, CHOCHaHbPh), 4.63-4.70 (2H, m, H-1 and CHOCHaHbPh), 5.11 (2H, 
s, CO2CH2Ph), 7.27-7.42 (10H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 31.3 (C-3), 
50.5 (C-2), 55.6 (OMe), 67.6 (NHCO2CH2Ph), 70.6 (C-6), 70.9 (C-5), 72.0 (OCH2Ph), 
73.1 (C-4), 98.9 (C-1), 128.8 (C-Ar), 128.9 (C-Ar), 129.0 (C-Ar), 129.0 (C-Ar), 129.2 (C-
Ar), 129.4 (C-Ar), 129.5 (C-Ar), 139.5 (C-Ar), 158.3 (CO); HRMS calcd for C22H27N2O8S 
[M-H]
-
 479.1494, found 479.1495. 
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Benzyl ((2S,3R,5S,6R)-5-hydroxy-6-(hydroxymethyl)-2-methoxytetrahydro-2H-
pyran-3-yl)carbamate (161) 
 
para-Toluenesulfonic acid (10 mg. cat.) was added to a solution of compound 157 (170 
mg, 0.43 mmol) in CH2Cl2 (6 mL) and methanol (6 mL), and the mixture was heated to 80 
C under microwave irradiation for 20 min. The mixture was diluted with CH2Cl2 (50 mL) 
and washed with K2CO3 (2 × 20 mL, 1 M aq.). The organic layer was dried over MgSO4, 
filtered, and evaporated. The residue was purified by MPLC on SiO2 with a gradient 
elution from 80% EtOAc/petrol to 100% EtOAc to give a white solid (95 mg, 72%); Rf 0.2 
(80% EtOAc/petrol; anisaldehyde); mp 109-111 C; max(EtOH)/nm < 220; [α]D
19.2
 +52.3 
(c = 0.11, MeOH); IR  max/cm
-1 
3327, 2921, 1681 (carbamate I), 1538 (carbamate II); 
1
H 
NMR (500 MHz; CD3OD) 1.76 (1H, app. dt, J = 12.5 and 11.7 Hz, H-3a), 2.02 (1H, app. t, 
J = 4.0 and 11.7 Hz, H-3b), 3.40-3.50 (4H, m, H-5 and OMe), 3.57 (1H, app. td, J = 11.0 
and 4.7 Hz, H-4), 3.69 (1H, dd, J = 5.8 and 11.8 Hz, H-6a), 3.78 (1H, app dt, J = 12.8 and 
4.0 Hz, H-2), 3.85 (1H, d, J = 2.2 and 11.8 Hz, H-6b), 4.64 (1H, d, J = 4.0 Hz, H-1), 5.11 
(2H, s, CH2Ph), 7.30-7.42 (5H, m, H-Ar); 

CNMR (125 MHz; CD3OD)C 34.6 (C-3), 
50.9 (C-2), 55.3 (OMe), 62.8 (C-6), 66.2 (C-4), 67.4 (CH2Ph), 74.5 (C-5), 98.7 (C-1), 
128.9 (C-Ar), 129.0 (C-Ar), 129.5 (C-Ar), 140.8 (C-Ar), 160.7 (CO); HRMS calcd for 
C15H22N1O6 [M+H]
+
 312.1447, found 312.1442. 
((2R,3S,5R,6S)-5-(((Benzyloxy)carbonyl)amino)-3-hydroxy-6-methoxy 
tetrahydro-2H-pyran-2-yl)methyl sulfamate (162) 
 
Prepared according to sulfamoylation method 2 using sulfamoyl chloride (1.6 mL, 1 M in 
MeCN, 1.6 mmol, 1.5 eq.), compound 161 (330 mg, 1.06 mmol, 1 eq.), and DMF (7 mL). 
After 18 h further sulfamoyl chloride (320 L, 1 M in MeCN, 0.32 mmol, 0.3 eq.) was 
added and the reaction mixture was stirred at -40 C for 4 h. The mixture was allowed to 
warm to -20 C and stirred at -20 C for 2 h. The reaction was quenched with MeOH, 
allowed to warm to room temperature, diluted with EtOAc (30 mL) and the layers 
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separated. The aqueous layer was further extracted with CH2Cl2 (3 × 30 mL), the organics 
combined, dried over MgSO4, and the solvent removed in vacuo. The residue was purified 
by MPLC on SiO2 with a gradient elution from 65-85% EtOAc/petrol to give a white solid 
(150 mg, 36 %); Rf 0.7 (EtOAc; anisaldehyde); mp 45-48 C; max(EtOH)/nm < 220; 
[α]D
15.9
 +103.3 (c = 0.12, MeOH); IR  max/cm
-1 
3342, 2946, 1692 (carbamate I), 1522 
(carbamate II); 
1
H NMR (500 MHz; CD3OD)H 1.78 (1H, app dt, J = 12.5 and 11.7 Hz, H-
3a), 2.05 (1H, app dt, J = 11.7 and 4.6 Hz, H-3b), 3.42 (3H, s, OCH3), 3.58 (1H, app td, J = 
10.7 and 4.6 Hz, H-3), 3.71 (1H, ddd, J = 1.5, 6.2, and 9.9 Hz, H-5), 3.79 (1H, app dt, J = 
12.5 and 3.6 Hz, H-2), 4.25 (1H, dd, J = 6.2 and 10.6 Hz, H-6a), 4.43 (1H, dd, J = 1.5 and 
10.6 Hz, H-6b), 4.64 (1H, d, J = 3.6 Hz, H-1), 5.11 (2H, s, CH2Ph), 7.30-7.42 (5H, m, H-
Ar); 

CNMR (125 MHz; CD3OD)C 34.7 (C-3), 50.7 (C-2), 55.5 (OCH3), 65.9 (C-4), 
67.6 (CH2Ph), 70.1 (C-6), 72.1 (C-5), 98.8 (C-1), 128.9 (C-Ar), 129.0 (C-Ar), 129.5 (C-
Ar), 138.3 (C-Ar), 158.2 (CO); HRMS calc. for C15H23N2O8S1 [M+H]
+
 391.1170, 
found 391.1174. 
(2S,3R,5S,6R)-5-Hydroxy-2-methoxy-6-((sulfamoyloxy)methyl) tetrahydro-2H-
pyran-3-aminium acetate (163) 
 
Compound 162 (145 mg, 0.37 mmol, 1 eq.), was dissolved in acetic acid (6 mL) and 
hydrogenated on a Thales H-cube on full H2 mode through 10% Pd/C catalyst cartridge at 
40 C for 2 h, with constant recycling of reaction mixture at a flow rate of 1 mL/minute. 
The solvent was removed in vacuo to give a clear gum, which was triturated with toluene 
(4 × 5 mL), dissolved in water, frozen and lyophilised. The residue was dried in vacuo at 
40 C to give a clear gum. (115 mg, 98%); Rf 0.05 (20% MeOH/CH2Cl2; anisaldehyde); 
max(EtOH)/nm < 220; [α]D
18.3
 +94.3 (c = 0.14, MeOH); IR  max/cm
-1
 1342 (SO), 1169 
(SO); 
1
H NMR (500 MHz; CD3OD) H 1.86 (1H, app dt, J = 12.1 and 11.7 Hz, H-3a), 2.20 
(1H, app dt, J = 11.7 and 4.6 Hz, H-3b), 3.26-3.32 (1H, m, H-2), 3.52 (3H, s, OCH3), 3.60-
3.67 (1H, m, H-4), 3.76 (1H, ddd, J = 1.9 , 5.8 and 9.8 Hz, H-5), 4.27 (1H, dd, J = 5.8 and 
10.9 Hz, H-6a), 4.44 (1H, dd, J = 1.9 and 10.9 Hz, H-6b), 4.80 (1H, d, J = 3.5 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 34.1 (C-3), 49.9 (C-2), 55.6 (OMe), 65.1 (C-4), 69.7 (C-
6), 72.3 (C-5), 97.6 (C-1); MS (ESI+) m/z 257.3 [M+H]
+
; (ESI-) m/z 255.3 [M-H]
-
. 
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Sodium-((2S,3R,5S,6R)-5-Hydroxy-2-methoxy-6-((sulfamoyloxy)methyl) 
tetrahydro-2H-pyran-3-yl)sulfamate (63) 
 
Prepared according to general procedure B, using compound 163 (110 mg, 0.35 mmol, 1 
eq.), de-ionised water (5 mL) and pyridine-sulfur trioxide complex (110 mg, 0.70 mmol, 2 
eq.) for 2 h. The crude product was purified by MPLC on SiO2 with a gradient elution from 
10-30% MeOH/EtOAc. Product containing fractions were evaporated in vacuo to give a 
pale glass. The material was re-purified by MPLC on SiO2 with a gradient elution from 10-
25% MeOH/CH2Cl2. Product containing fractions were evaporated, dissolved in water, 
frozen and lyophilized to give a yellow solid (25 mg, 21%); Rf 0.2 (20% MeOH/EtOAc; 
anisaldehyde); mp 130-135 C; max(EtOH)/nm < 220; IR  max/cm
-1
 3283, 1368 (SO), 
1173 (SO); 
1
H NMR (500 MHz; CD3OD) H 1.68 (1H, app dt, J = 12.0 and 12.0 Hz, H-3a), 
2.28 (1H, app dt, J = 11.8 and 4.7 Hz, H-3b), 3.43-3.49 (4H, m, OCH3 and H-2), 3.51-3.59 
(1H, ddd, J = 4.7 Hz, 9.8 and 11.2 Hz, H-4), 3.69 (1H, ddd, J = 1.8 Hz, 6.3 and 9.8 Hz, H-
5), 4.24 (1H, dd, J = 6.3 and 10.7 Hz, H-6a), 4.43 (1H, dd, J = 1.8 and 10.7 Hz, H-6b), 4.87 
(1H, d, J = 3.5 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 35.9 (C-3), 53.1 (C-2), 55.6 
(OCH3), 66.3 (C-4), 70.3 (C-6), 72.1 (C-5), 99.5 (C-1); HRMS calcd for C7H15N2O9S2 
[M-H]
-
 335.0224, found 335.0208. 
((2R,3S,4R,5R,6S)-4-(Benzoyloxy)-5-((benzyloxy)carbonyl) amino)-3-hydroxy-
6-methoxytetrahydro-2H-pyran-2-yl)methyl benzoate (164) 
 
Compound 103 (1.2 g, 3.7 mmol) was dissolved in a mixture of CH2Cl2 (6 mL) and 
pyridine (6 mL) and cooled to -40 C. Benzoyl chloride (767 L, 6.6 mmol, 1.8 eq.) was 
added dropwise over 20 min, and the mixture was allowed to warm to room temperature 
over 90 min. The mixture was cooled to -40 C and benzoyl chloride (170 L, 1.5 mmol, 
0.4 eq.) was added dropwise over 20 min, and the mixture was allowed to warm to room 
temperature over 90 min and stirred at room temperature for 1 h. The reaction was 
quenched with methanol, and the solvent removed in vacuo. The residue was dissolved in 
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CH2Cl2 (30 mL) and washed with HCl (2 × 20 mL, 2 M aq.). The organic layer was dried 
over MgSO4, and the solvent removed in vacuo. The residue was purified by MPLC on 
SiO2 with a gradient elution from 15-65% EtOAc/petrol to give a clear gum (1.05 g, 1.96 
mmol, 54%); Rf 0.4 (40% EtOAc/petrol; anisaldehyde); mp 60-64 C; max(EtOH)/nm 229; 
[α]D
19.3
 +93.3 (c = 0.39, MeOH); IR  max/cm
-1
 3345, 1714 (br) (CO ester and carbamate 
I), 1603, 1518 (carbamate II); 
1
H NMR (500 MHz; CDCl3) H 3.30 (1H, br s, C4-OH), 3.83 
(1H, app. t, J = 9.4 Hz, H-4), 4.00 (1H, ddd, J = 2.1, 4.5 and 9.4 Hz, H-5), 4.21 (1H, app 
td, J = 10.3 and 3.6 Hz, H-2), 4.59 (1H, dd, J = 2.1 and 12.1 Hz, H-6a), 4.74 (1H, dd, J = 
4.5 and 12.1 Hz, H-6b), 4.81 (1H, d, J = 3.6 Hz, H-1), 4.94 (1H, d, J = 12.3 Hz, 
CHaCHbPh), 4.99 (1H, d, J = 12.3 Hz, CHaCHbPh), 5.16 (1H, d, J = 10.3 Hz, NH), 5.33 
(1H, dd, J = 9.4 and 10.3 Hz, H-3), 7.11-7.23 (5H, m, H-Ar), 7.39-7.49 (4H, m, H-Ar), 
7.53-7.62 (2H, m, H-Ar), 8.02-8.10 (4H, m, H-Ar);

C NMR (125 MHz; CDCl3) C 55.4 
(C-2), 60.4 (OMe), 63.4 (C-6), 66.9 (CH2Ph), 69.5 (C-4), 70.4 (C-5), 75.4 (C-3), 98.8 (C-
1), 127.8 (C-Ar), 128.1 (C-Ar), 128.4 (C-Ar), 128.5 (C-Ar), 128.5 (C-Ar), 129.3 (C-Ar), 
129.7 (C-Ar), 129.8 (C-Ar), 130.1 (C-Ar), 133.3 (C-Ar), 133.5 (C-Ar), 136.1 (C-Ar), 156.0 
(CO Cbz), 166.9 (CO Bz), 168.0 (CO Bz); HRMS calcd for C29H30N1O9 [M+H]
+
 
536.1915, found 536.1904. 
((2S,4S,5R,6S)-4-(Benzoyloxy)-5-(((benzyloxy)carbonyl) amino)-6-methoxy 
tetrahydro-2H-pyran-2-yl)methyl benzoate (165) 
 
Compound 164 (150 mg, 0.28 mmol, 1 eq.) was dissolved in toluene (4 mL) and the 
solution degassed. 1,1’-Thiocarbonyldiimidazole (75 mg, 0.42 mmol, 1.5 eq.) was added 
and the mixture heated at reflux for 3 h. Tris(trimethylsilyl)silane (346 L, 1.12 mmol, 4 
eq.) was added to the hot reaction, followed by AIBN (280 L, 0.2 M in toluene, 0.056 
mmol, 0.2 eq.), and the mixture was heated at reflux for 30 min. The reaction was allowed 
to cool and the solvent was evaporated in vacuo. The residue was purified by MPLC on 
SiO2 with a gradient elution from 10-30% EtOAc/petrol to give a white solid (116 mg, 
79%); Rf 0.8 (50% EtOAc/petrol; anisaldehyde); mp 155-158 C; max(EtOH)/nm 229; 
[α]D
19.9
 +125.7 (c = 0.11, MeOH); IR max/cm
-1
 3325, 1718 (CO ester), 1681 (carbamate 
I), 1535 (carbamate II); 
1
H NMR (500 MHz; CD3OD) H 1.82 (1H, app dt, J = 12.4 and 
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11.8 Hz, H-4a), 2.41 (1H, ddd, J = 1.9, 5.0, and 12.4 Hz, H-4b), 3.47 (3H, s, OCH3), 4.09 
(1H, dd, J = 3.6 and 10.8 Hz, H-2), 4.30-4.37 (1H, m, H-5), 4.41-4.49 (2H, m, H-6), 4.89 
(1H, d, J = 3.6 Hz, H-1), 4.99 (1H, d, J = 12.5 Hz, CHaHbPh), 5.12 (1H, d, J = 12.5 Hz, 
CHaHbPh), 5.38 (1H, td, J = 10.8 and 5.0 Hz, H-3), 7.15-7.23 (5H, m, H-Ar), 7.46-7.56 
(4H, m, H-Ar), 7.62-7.68 (2H, m, H-Ar), 8.01-8.04 (2H, m, H-Ar), 8.07-8.11 (2H, m, H-
Ar); 

CNMR (125 MHz; CD3OD)C 34.3 (C-4), 55.7 (C-2 and OCH3), 67.0 (C-5), 67.45 
(CH2Ph), 67.5 (C-6), 71.3 (C-3), 101.0 (C-1), 128.5 (C-Ar), 128.8 (C-Ar), 129.4 (C-Ar), 
129.6 (C-Ar), 129.7 (C-Ar), 130.6 (C-Ar), 130.8 (C-Ar), 131.2 (C-Ar), 131.2 (C-Ar), 134.4 
(C-Ar), 134.4 (C-Ar), 138.2 (C-Ar), 158.8 (NHCO2Bn), 167.6 (PhCO2), 167.7 (PhCO2); 
HRMS calc. for C29H33N2O8 [M+NH4]
+
 537.2231, found 537.2224. 
Benzyl ((2S,3R,4S,6S)-4-hydroxy-6-(hydroxymethyl)-2-methoxy tetrahydro-2H-
pyran-3-yl)carbamate (166) 
 
Compound 165 (340 mg, 0.66 mmol) was dissolved in methanol and sodium methoxide 
(160 L, 1 M in methanol, cat.) was added. The mixture was stirred at room temperature 
for 18 h. The solvent was evaporated in vacuo, the residue was purified by MPLC on SiO2 
with a gradient elution from 80-100% EtOAc/petrol to give a white solid (140 mg, 68%); 
Rf 0.1 (80% EtOAc/petrol; anisaldehyde); mp 112 C dec.; max(EtOH)/nm < 220; [α]D
20.0
 
+92.0 (c = 0.10, MeOH); IR  max/cm
-1
 3334, 2926, 1691; 
1
H NMR (500 MHz; CD3OD) 
H 1.46 (app dt, J = 12.8 and 12.0 Hz, H-4a), 2.01 (1H, J = 2.0, 4.7, and 12.8 Hz, H-4b), 
3.37-3.42 (3H, s, OCH3), 3.52-3.61 (3H, m, H-2 and H-6), 3.80-3.88 (2H, m, H-3 and H-
5), 4.75 (1H, d, J = 3.5 Hz, H-1), 5.13 (2H, s, CH2Ph), 7.30-7.43 (5H, m, H-Ar); 

CNMR 
(125 MHz; CD3OD)C 37.2 (C-4), 55.5 (OCH3), 58.8 (C-2), 65.8 (C-6), 67.2 (C-5), 67.6 
(CH2Ph), 70.0 (C-3), 100.8 (C-1), 128.9 (C-Ar), 129.0 (C-Ar), 129.5 (C-Ar), 138.4 (C-Ar), 
159.0 (CO); HRMS calcd for C15H22N1O6 [M+H]
+
 312.1442, found 312.1447. 
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((2S,4S,5R,6S)-5-(((Benzyloxy)carbonyl)amino)-4-hydroxy-6-methoxy 
tetrahydro-2H-pyran-2-yl)methyl sulfamate (167) 
430-98 
Prepared according to sulfamoylation method 2 using sulfamoyl chloride (0.93 mL, 1 M in 
MeCN, 0.93 mmol, 1.8 eq.), alcohol 166 (160 mg, 0.51 mmol, 1 eq.), and DMF (4 mL). 
After stirring at -40 C for 18 h, further sulfamoyl chloride (200 L, 1 M in MeCN, 0.2 
mmol, 0.4 eq.) was added at -40 C over 30 min, and the reaction mixture was stirred at -
40 C for 18 h. The reaction was quenched with MeOH, allowed to warm to room 
temperature, diluted with water (10 mL) and EtOAc (30 mL) and the layers separated. The 
aqueous layer was further extracted with CH2Cl2 (4 × 15 mL). The organic layers were 
combined, dried over MgSO4, and the solvent removed in vacuo. The residue was purified 
by MPLC on SiO2 with a gradient elution from 50-90% EtOAc/petrol to give a white solid 
(102 mg, 51 %); Rf 0.7 (EtOAc; anisaldehyde); mp 45-48 C; max(EtOH)/nm <220; IR  
max/cm
-1
 3349, 2925, 1693 (carbamate I), 1527 (carbamate II), 1362 (SO), 1177 (SO); 
1
H 
NMR(500 MHz; CD3OD) H 1.52 (1H, app dt, J = 12.0 and 12.0 Hz, H-4a), 2.07 (1H, 
ddd, J = 1.7, 4.5 and 12.0 Hz, H-4b), 3.40 (3H, s, OMe), 3.57 (1H, dd, J = 3.4 and 10.3 Hz, 
H-2), 3.86 (1H, app td, J = 10.9 and 4.7 Hz, H-3), 4.10 (1H, m, H-5), 4.13-4.17 (2H, m, H-
6), 4.76 (1H, d, J = 3.4 Hz, H-1), 5.13 (2H, s, CH2Ph), 7.30-7.44 (5H, m, H-Ar); 

C 
NMR(125 MHz; CD3OD) C 36.9 (C-4), 55.7 (OCH3), 58.6 (C-2), 66.9 (C-3), 67.2 (C-5), 
67.6 (CH2Ph), 72.3 (C-6), 100.8 (C-1), 128.9 (C-Ar), 129.0 (C-Ar), 129.5 (C-Ar), 138.3 
(C-Ar); HRMS calc. for C15H26N3O8S1 [M+NH4]
+
 408.1435, found 408.1436. 
Note: Unable to visualise all carbon signals by 
13
C nmr. 
(2S,3R,4S,6S)-4-Hydroxy-2-methoxy-6-((sulfamoyloxy)methyl) tetrahydro-2H-
pyran-3-aminium acetate (168) 
 
Compound 167 (95 mg, 0.24 mmol) was dissolved in acetic acid (4 mL) and hydrogenated 
on a Thales H-cube on full H2 mode through 10% Pd/C catalyst cartridge at 40 C for 2 h, 
with constant recycling of the reaction mixture at a flow rate of 1 mL/minute. The solvent 
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was removed in vacuo to give a clear gum, which was triturated with toluene (4 × 5 mL). 
The residue was dried in vacuo at 40 C to give a clear gum (54 mg, 70%); Rf 0.05 (20% 
MeOH/CH2Cl2; anisaldehyde); max(EtOH)/nm < 220; IR  max/cm
-1
 3012, 1706, 1547, 
1359 (SO), 1175 (SO); 
1
H NMR(500 MHz; CD3OD) H 1.56 (1H, app dt, J = 12.6 and 
11.5 Hz, H-4a), 2.00 (3H, s, CH3CO2), 2.07-2.14 (1H, m, H-4b), 3.03 (1H, dd, J = 3.5 and 
10.1 Hz, H-2), 3.49 (3H, s, OCH3), 4.00 (app. td, J = 10.9 and 4.9 Hz, H-3), 4.10-4.22 (3H, 
m, H-5 and H-6), 4.96 (1H, d, J = 3.5 Hz, H-1); 

C NMR (125 MHz; CD3OD)C 21.8 
(CH3CO), 36.6 (C-4), 55.8 (C-2), 57.1 (OCH3), 66.0 (C-3), 67.6 (C-6), 71.9 (C-5), 98.8 (C-
1), 176.8 (CO acetate); HRMS calcd for C7H15N2O6S1 [M-H]
-
 255.0656, found 
255.0647. 
Sodium-((2S,3R,4S,6S)-4-hydroxy-2-methoxy-6-((sulfamoyloxy) methyl) 
tetrahydro-2H-pyran-3-yl)sulfamate (62) 
 
Prepared according to general procedure B, using amine 168 (50 mg, 0.16 mmol, 1 eq.), 
de-ionised water (3 mL) and pyridine-sulfur trioxide complex (50 mg, 0.32 mmol, 2 eq.) 
for 2 h. The crude product was purified by MPLC on SiO2 with a gradient elution from 10-
30% MeOH/EtOAc. Product containing fractions were evaporated in vacuo to give a pale 
glass. The material was re-purified by MPLC on SiO2 with a gradient elution from 5-25% 
MeOH/CH2Cl2. Product containing fractions were evaporated, dissolved in water, frozen 
and lyophilized to give a yellow solid (4 mg, 8%); Rf 0.15 (20% MeOH/EtOAc; 
anisaldehyde); m.p. 144-148 C; max(EtOH)/nm < 220; IR  max/cm
-1 
32729, 2936, 1361 
(SO), 1173 (SO); 
1
H NMR (500 MHz; CD3OD) H 1.49 (1H, app dt, J = 12.0 and 11.8 Hz, 
H-4a), 2.05 (1H, ddd, J = 2.2 , 5.0 and 12.8 Hz, H-4b), 3.19 (1H, dd, J = 3.6 and 9.9 Hz, H-
2), 3.49 (3H, s, OCH3), 3.82 (1H, ddd, J = 4.9 Hz, 10.0 and 11.2 Hz, H-3), 4.05-4.19 (3H, 
m, H-5 and H-6), 5.03 (1H, d, J = 3.6 Hz, H-1); 

CNMR (125 MHz; CD3OD)C 36.3 (C-
4), 55.8 (OCH3), 60.8 (C-2), 66.9 (C-5), 68.0 (C-3), 72.4 (C-6), 101.1 (C-1); HRMS calcd 
for C7H15N2O9S2 [M-H]
-
 335.0224, found 335.0210. 
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((2R,3S,4R,5R,6S)-4-(Benzoyloxy)-3-(benzyloxy)-5-(((benzyloxy) carbonyl) 
amino) -6-methoxytetrahydro-2H-pyran-2-yl)methyl benzoate (170) 
 
Benzyl-2,2,2-trichloroacetimidate (78 L, 0.37 mmol, 2 eq.) and trifluoromethanesulfonic 
acid (300 L, 10% v/v in CH2Cl2, 0.02 eq.), were added to a solution of alcohol 164 (100 
mg, 0.19 mmol, 1 eq.) in CH2Cl2 (3 mL) and the mixture stirred at room temperature for 1 
h. Further benzyl-2,2,2-trichloroacetimidate (78 L, 0.37 mmol, 2 eq.) was added and the 
mixture stirred at room temperature for 1 h. Further benzyl-2,2,2-trichloroacetimidate (78 
L, 0.37 mmol, 2 eq.) and trifluoromethanesulfonic acid (300 L, 10% v/v in CH2Cl2, 0.02 
eq.) were added and the mixture was stirred at r.t. for 18 h. The reaction was quenched by 
addition of NaHCO3 (10% w/v aq., 5 mL), diluted with brine (10 mL) and extracted with 
CH2Cl2 (2 × 15 mL). The organic layers were combined, dried over MgSO4, and the 
solvent removed in vacuo. The residue was purified by flash MPLC on SiO2 with gradient 
elution from 5-25% EtOAc/petrol to give a clear gum (88 mg, 75%); Rf 0.3 (20% 
EtOAc/petrol; UV, anisaldehyde); mp. 99-105 C; max(EtOH)/nm 227; [α]D
18.9
 +31.4 (c = 
0.14, EtOH); IR  max/cm
-1 
3364, 33187, 3241, 3186, 1692, 1617; 
1
H NMR (500 MHz; 
CDCl3) H 3.42 (3H, s, OMe), 3.70-3.94 (2H, m, H-4), 4.06 (1H, dt, J = 9.9 and 3.1 Hz, H-
5), 4.18 (1H, td, J = 10.6 and 3.5 Hz, H-2), 4.46-4.62 (4H, m, H-6 and CHOCH2Ph), 4.79 
(1H, d, J = 3.5 Hz, H-1), 4.86-4.96 (2H, m, CO2CH2Ph), 5.12 (1H, d, J = 10.1 Hz, NH), 
5.63 (1H, dd, J = 9.3 and 10.6 Hz, H-3), 7.07-7.21 (10 H, m, H-Ar), 7.42-7.52 (4H, m, H-
Ar), 7.54-7.63 (2H, m, H-Ar), 8.03 - 8.08 (4H, m, H-Ar); 

C NMR (125 MHz; CDCl3)C 
54.2, 55.4, 63.1, 66.8, 69.2, 74.2, 74.8, 75.7, 98.7, 127.7, 127.9, 128.0, 128.3, 128.4, 128.4, 
128.5, 129.7, 129.9, 133.2, 133.3, 136.9, 156.0; HRMS calcd for C36H39N2O9 643.2650 
[M+NH4]
+
, found 643.2645. 
Benzyl ((2S,3R,4R,5S,6R)-5-(benzyloxy)-4-hydroxy-6-(hydroxymethyl)-2-
methoxytetrahydro-2H-pyran-3-yl)carbamate (171) 
 
Lithium aluminium hydride (516 L, 2 M in THF, 1.03 mmol, 3 eq.) was added to 
dibenzoate ester 170 (215 mg, 0.34 mmol, 1 eq.) in THF (5 mL) at 0 C and the mixture 
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was stirred at 0 C for 2 h. Water (60 L) was added, followed by NaOH (15% w/v aq., 
180 L), followed by further water (60 L). The mixture was stirred at room temperature 
for 30 min, filtered through Celite, and the solvent removed in vacuo. The residue was 
purified by MPLC on SiO2 with gradient elution from 20-80% EtOAc/petrol to give a 
white solid (98 mg, 69%); Rf 0.25 (50% EtOAc/petrol; UV, anisaldehyde); mp. 101-104 
C; max(EtOH)/nm 258; [α]D
18.5
 +11.2 (c = 0.08, EtOH); IR  max/cm
-1 
3296, 2918, 1685, 
1540; 
1
H NMR (500 MHz; DMSO-d
6
) H 3.28 (3H, s, OMe), 3.31-3.36 (1H, m, H-4), 3.42 
(1H, m, H-5), 3.47-3.59 (2H, m, H-2 and H-6a), 3.61-3.73 (2H, m, H-3 and H-6b), 4.61 
(1H, d, J = 11.5 Hz, CHaHbPh), 4.64 (1H, d, J = 3.4 Hz, H-1), 4.72 (1H, t, J = 5.8 Hz, OH-
6), 4.91 (1H, d, J = 11.5 Hz, CHaHbPh), 5.02-5.16 (3H, m, CH2Ph and OH-3), 7.19 (1H, d, 
J = 8.2 Hz, NH), 7.28-7.45 (10H, m, H-Ar); 

C NMR (125 MHz; DMSO-d
6
) C 54.4 
(OMe), 56.2 (C-2), 60.4 (C-6), 65.3(CH2Ph), 70.8 (C-3), 71.4(C-5), 73.7 (NHCO2CH2Ph), 
78.6 (C-4), 98.0 (C-1), 127.3 (C-Ar), 127.5 (C-Ar), 127.8 (C-Ar), 128.0 (C-Ar), 128.3 (C-
Ar), 137.1 (C-Ar), 139.0 (C-Ar), 156.2 (CO); HRMS calc. for C22H28N1O7 [M+H]
+
 
418.1860, found 418.1862.
 
((2R,3S,4R,5R,6S)-3-(Benzyloxy)-5-(((benzyloxy)carbonyl)amino)-4-hydroxy-6-
methoxytetrahydro-2H-pyran-2-yl)methyl sulfamate (172) 
 
Prepared according to sulfamoylation method 2 using sulfamoyl chloride (1.15 mL, 1 M in 
MeCN, 1.15 mmol, 2 eq.), alcohol 171 (200 mg, 0.05 mmol, 1 eq.) and DMF (2 mL). 
After stirring at -40 C for 18 h, further sulfamoyl chloride (0.20 mL, 1 M in MeCN, 0.20 
mmol, 0.33 eq.) was added and the mixture was stirred at -40 C for 4 h. The residue was 
purified by MPLC on SiO2 with a gradient elution from EtOAc to 8% EtOAc/petrol to give 
a white solid (150 mg, 52%); Rf 0.3 (50% EtOAc/petrol; anisaldehyde); m.p. 46-48 C; 
max(EtOH)/nm 257; [α]D
19.1
 +74.8 (c = 0.107, EtOH); IR  max/cm
-1 
3332 (br), 2939, 1695 
(carbamate I), 1523 (Carbamate II), 1365 (SO), 1181 (SO);
 1
H NMR (500 MHz; DMSO-
d
6
) H 3.30 (3H, s, OMe), 3.37 (1H, m, H-4), 3.53 (1H, ddd, J = 3.6, 8.5 and 10.6 Hz, H-2), 
3.6 -3.76 (2H, m, H-3 and H-5), 4.20-4.28 (2H, m, H-6), 4.62 (1H, d, J = 10.9 Hz, 
OCHaHbBn), 4.67 (1H, d, J = 3.5 Hz, H-1), 4.94 (1H, d, J = 10.9 Hz, OCHaHbBn), 5.06 
(1H, d, J = 12.6 Hz, CO2OCHaHbBn), 5.10 (1H, d, J = 12.6 Hz, CO2CHaHbBn), 5.23 (1H, 
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d, J = 7.3 Hz, OH
3
), 7.20-7.44 (11H, m, 10 × H-Ar and NH), 7.62 (2H, s, NH2); 

C NMR 
(125 MHz; DMSO-d
6
) C 54.7 (OMe), 56.0 (C-2), 65.4 (CO2CH2Ph), 67.8 (C-6), 68.2 (C-
5), 70.7 (C-3), 73.8 (CH2Ph), 78.1 (C-4), 98.1 (C-1), 127.4 (C-Ar), 127.7 (C-Ar), 127.8 (C-
Ar), 128.1 (C-Ar), 128.3 (C-Ar), 128.6 (C-Ar), 137.0 (C-Ar), 138.6 (C-Ar), 156.2 (CO); 
MS (ES+) m/z 497.5 [M+H]
+
; HRMS calcd for C22H32N3O9S1 [M+NH4]
+
 514.1854, 
found 514.1848. 
((2R,3S,4R,5R,6S)-5-Amino-3-(benzyloxy)-4-hydroxy-6-methoxytetrahydro-2H-
pyran-2-yl)methyl sulfamate (173) 
 
Benzyl ether 172 (220 mg, 0.44 mmol) was dissolved in methanol (5 mL) and 
hydrogenated on a Thales H-cube through 5% Pd/C catalyst cartridge with 10 bar H2 at r.t. 
for 35 min, with constant recycling of reaction mixture at a flow rate of 1 mL/minute. The 
solvent was removed in vacuo to give a clear gum which solidified on standing (160 mg, 
100%). Rf 0.25 (30% MeOH/EtOAc; anisaldehyde); m.p. 50-52 C; max(EtOH)/nm <258; 
[α]D
19.2
 +77.6 (c = 0.107, EtOH); IR  max/cm
-1 
3353.6 (br), 29135, 1362 (SO), 1176 (SO);
 
1
H NMR (500 MHz; DMSO-d
6
) H 1.84 (2H, br, CHNH2), 2.48-2.54 (1H, m, H-2), 3.27 
(1H, dd, J = 8.8 and 9.9 Hz, H-4 ), 3.32 (3H, s, OMe), 3.43-3.49 (1H, m, H-3), 3.70-3.75 
(1H, m, H-5), 4.20-4.27 (2H, m, H-6), 4.62 (2H, m, H-1 and CHaHbPh), 4.93 (1H, d, J = 
11.0 Hz, CHaHbPh), 5.27 (1H, d, J = 5.8 Hz, OH
3
), 7.18-7.43 (5H, m, H-Ar), 7.61 (2H, br 
s, OSO2NH2); 

C NMR (125 MHz; DMSO-d
6
)C 54.68 (OMe), 56.4 (C-2), 68.0 (C-6), 
68.5 (C-5), 73.6 (CH2Ph), 75.0 (C-3), 77.7 (C-4), 100.1 (C-1), 127.4 (C-Ar), 127.7 (C-Ar), 
128.08 (C-Ar), 138.7 (C-Ar); HRMS calc. for C14H23N2O7S1 [M+H]
+
 363.1220, 
found 363.1226. 
((2R,3S,4R,5R,6S)-5-(Benzyloxy)-4-hydroxy-2-methoxy-6-((sulfamoyloxy) 
methyl) tetrahydro-2H-pyran-3-yl)sulfamic acid (61) 
 
Prepared according to general procedure B, using amine 173 (75 mg, 0.2 mmol, 1 eq.), de-
ionised water (6 mL), THF (3 mL) and pyridine-sulfur trioxide complex (132 mg, 0.82 
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mmol, 4 eq.) for 2 h. The crude product was purified by MPLC on SiO2 with a gradient 
elution from 10-30% MeOH/EtOAc. Product containing fractions were evaporated in 
vacuo to give a yellow solid. (23 mg, 25%); Rf 0.3 (30% MeOH/EtOAc; anisaldehyde); 
m.p. 195 C dec.; max(EtOH)/nm 258; [α]D
19.5
 +80 (c = 0.15, EtOH); IR  max/cm
-1 
3291, 
2920, 1363 (SO), 1178 (SO); 
1
H NMR (500 MHz; DMSO-d
6
) H 3.07-3.14 (1H, ddd, J = 
3.5, 8.3 and 10.4 Hz, H-2), 3.28 (3H, s, OMe), 3.31 (1H, dd, J = 8.7 and 10.1 Hz, H-4), 
3.66-3.73 (2H, m, H-3 and H-5), 4.20 (1H, dd, J = 5.0 and 10.5 Hz, H-6a), 4.25 (1H, dd, J 
= 1.7 and 10.5 Hz, H-6b), 4.38 (1H, d, J = 8.3 Hz, CHNH), 4.63 (1H, d, J = 11.0 Hz, 
CHaHbPh), 4.69 (1H, d, J = 3.5 Hz, H-1), 4.96 (1H, d, J = 11.0 Hz, CHaHbPh), 5.75 (1H, d, 
J = 2.2 Hz, OH
3
), 7.26-7.40 (5H, m, H-Ar), 7.60 (2H, br s, NH2); 

C NMR (125 MHz; 
DMSO-d
6
)C 54.8 (OMe), 57.8 (C-2), 67.9 (C-5), 68.0 (C-6), 73.3 (C-3), 73.6 (CH2Ph), 
78.2 (C-4), 99.2 (C-1), 127.3 (C-Ar), 127.6 (C-Ar), 128.1 (C-Ar), 138.8 (C-Ar); HRMS 
calc. for C14H22N2O10S2 [M-H]
-
 441.0643, found 441.0631. 
 
10.3.2 Synthesis of Alkyl Sulfamates 
 
(Tetrahydro-2H-pyran-2-yl) methyl sulfamate (67) 147 
 
Prepared according to sulfamoylation method 4 using tetrahydropyran-2-methnol (283 L, 
2.5 mmol) and sulfamoyl chloride (2.5 mL, 0.3 M in toluene, 7.5 mmol, 3 eq) and DMA (3 
mL). The crude product was purified by MPLC on SiO2 with a gradient elution from 10-
50% EtOAc/petrol to give a clear oil. Re-purification by MPLC on SiO2 with a gradient 
elution from 10-60% EtOAc/petrol gave a clear oil (224 mg, 48%); Rf 0.15 (30% 
EtOAc/petrol; CAM); max(EtOH)/nm 256 weak; IR  max/cm
-1 
3409, 3303, 3117, 1345 
(SO), 1175 (SO); 
R (500 MHz; CDCl3) H 1.34-1.67 (5H, m, H-pyran), 1.89-1.97 
(1H, m, H-pyran), 3.49 (1H, td, J = 11.1 and 3.1 Hz, CH-O pyran), 3.65-3.71 (1H, m, 
CHaHb-O pyran), 4.03-4.07 (1H, m, CHaHb-O pyran), 4.17-4.25 (2H, m, CH2OSO2), 5.14 
(2H, s, NH2); 

CR (125 MHz; DMSO-d
6
) C 22.3 (CCH2C), 25.3 (CCH2C), 27.1 
(CCH2C), 67.2 (CH2O), 71.3 (CH2O), 74.5 ( (CH2)HC(CH2)O); HRMS ASAP calcd for 
C6H14N1O4S1 [M+H]
+ 
196.0638, found 196.0635. 
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4-Nitrophenethyl sulfamate (114)340 
 
Sulfamoyl chloride (1.8 mL, 1.0 M solution in toluene, 1.8 mmol, 3 eq.) was added to 
4-nitrophenethyl alcohol (100 mg, 0.6 mmol, 1 eq.) in anhydrous DMA (1 mL) at room 
temperature and the mixture was allowed to stir overnight. The reaction was quenched with 
water (10 mL), and extracted with CH2Cl2 (3 × 20 mL), dried over MgSO4, and the solvent 
evaporated in vacuo. The residue was purified by MPLC on SiO2 with a gradient elution 
from 20-80% EtOAc:petrol to give a white solid (100 mg, 68%); Rf 0.85 (5% 
MeOH/EtOAc); mp 128-130 C; max(EtOH)/nm 268; max(EtOH)/nm 271; IR  max/cm
-1 
3370, 3286, 1514 (NO2), 1343 (SO), 1190 (SO); 
1
H NMR (500 MHz; CD3OD) H 3.21 
(2H, t, J = 6.4 Hz, CH2Ar), 4.42 (2H, t, J = 6.4 Hz, CH2-O-S), 7.58 (2H, d, J = 8.8 Hz, H-
Ar), 8.23 (2H, d, J = 8.8 Hz, H-Ar); 

CNMR (125 MHz; CD3OD)C 36.0 (CH2Ar), 70.2 
(CH2OSO2NH2), 124.6 (CH-Ar), 131.3 (CH-Ar), 147.0 (C-Ar), 148.4 (C-Ar); HRMS Calc 
for C8H9N2O5S1 [M-H]
- 
245.0238, found 245.0238. 
2,2,2-Trichloroethyl 4-hydroxypiperidine-1-sulfonate (184) 
 
Prepared according to general procedure C using 2,3-dimethyl-1-((2,2,2-
trichloroethoxy)sulfonyl)-1H-imidazol-3-ium tetrafluoroborate (378 mg, 0.99 mmol, 1 
eq.), 4-hydroxypiperidine (100 mg, 0.99 mmol, 1 eq.), and THF (10 mL). The residue was 
purified by MPLC on SiO2 with a gradient elution from 25-50% EtOAc/petrol to yield a 
white solid (290 mg, 94%); Rf 0.3 (50% EtOAc/petrol; KMnO4;); m.p. 80-83 C; 
max(EtOH)/nm < 220; IR  max/cm
-1 
3449, 2952, 2928, 2880, 1362 (SO), 11737 (SO); 
1
H 
NMR (500 MHz; CDCl3) H 1.53 (1H, d, J = 3.9 Hz, OH), 1.67-1.76 (2H, m, 2 × 
CHaxCHO), 1.95-2.02 (2H, m, 2 × CHeqCHO), 3.30 (2H, ddd, J = 3.6 Hz, 8.1 and 12.2 Hz, 
2 × CHaxN), 3.69 (2H, ddd, J = 3.8, 7.6 and 12.0 Hz, 2 × CHeqN), 3.93-4.00 (m, J = 3.8 Hz, 
CHOH), 4.63 (2H, s, CH2CCl3); 

C NMR (125 MHz; CDCl3)C 32.8 (2 × CH2CHOH), 
44.0 (2 × CH2N), 65.6 (CHOH), 77.8 (CH2CCl3), 93.7 (CCl3); MS m/z 312.2 
[M(
35,35,35
Cl)H]
+
, 314.2 [M(
35,35,37
Cl)H]
+
, 316.2 [M(
35,37,37
Cl)H]
+
. 
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1-((2,2,2-Trichloroethoxy)sulfonyl)piperidin-4-yl sulfamate (185) 
 
Sulfamoyl chloride (1.08 mL, 1 M in MeCN, 1.08 mmol, 2 eq.) was added to alcohol 184 
(170 mg, 0.54 mmol, 1 eq.) in DMF (1 mL) containing potassium carbonate (375 mg, 2.7 
mmol, 5 eq.) at -40 C, and the mixture was stirred at -40 C for 18 h. The reaction was 
quenched with methanol, allowed to warm to room temperature, and partitioned between 
EtOAc (3 × 20 mL) and water (15 mL). The aqueous layer was re-extracted with CH2Cl2 
(3 × 20 mL) and EtOAc (2 × 20 mL), the organic layers combined, dried over MgSO4, and 
the solvent removed in vacuo. The residue was purified by MPLC on silica with a gradient 
from 20-50% EtOAc/petrol to give a clear oil. (195 mg, 92%); Rf 0.4 (50% EtOAc/petrol; 
KMnO4); m.p. 74-76 C; max(EtOH)/nm < 220; IR  max/cm
-1 
3378, 3284, 2865, 1358 
(SO), 1175 (SO); 

H NMR (500 MHz; CDCl3) H 2.03-2.17 (4H, m, 2 × CH2CHO), 3.47-
3.55 (2H, m, 2 × CHaxN), 3.56-3.63 (2H, m, 2 × CHeqN), 4.64 (2H, s, CH2CCl3), 4.74-4.88 
(3H, m, CHOSO2NH2 and NH2); 

C NMRC (125 MHz; CDCl3) 30.0 (2 × CH2CHO), 
43.3 (2 × CH2N), 76.8 (CHOSO2NH2), 77.8 (CH2CCl3), 93.6 (CCl3); HRMS calcd for 
C7H17
35
Cl3N3O6S2 [M+NH4]
+
 407.9619, found 407.9624. 
Sodium 4-(sulfamoyloxy)piperidine-1-sulfonate (66) 
 
Zinc powder (238 mg, 3.63 mmol, 15 eq.) was added to sulfamate 185 (95 mg, 0.24 mmol, 
1 eq.) in MeOH (4 mL) and water (4 mL) at r.t., and the mixture was stirred at r.t. for 1 h. 
The mixture was filtered through Celite, the Celite washed with methanol, and the solvent 
removed in vacuo. The residue was dissolved in water and run through a Dowex 50W8X-
200 ion exchange resin which had previously been converted to the sodium form. Product 
containing fractions were frozen and lyophilised to give a white solid, which was dried in 
vacuo with P2O5 to give a white solid (70 mg, 99%). Rf 0.3 (30% MeOH/EtOAc; KMnO4); 
m.p. 220 C dec.; max(EtOH)/nm <220; IR  max/cm
-1 
3222 (br), 2857, 1350 (SO), 1171 
(SO); 
1
H NMR (500 MHz; DMSO-d
6
) H 1.64-1.73 (2H, m, 2 × CHCHOSO2NH2), 1.88-
1.97 (2H, m, 2 × CHCHOSO2NH2), 2.60-2.70 (2H, m, 2 × CHN), 3.10-3.20 (2H, m, 2 × 
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CHN), 4.45 (1H, tt, J = 4.3 Hz, CHOSO2NH2), 7.45 (2H, s, NH2); 

C NMRC (125 MHz; 
CD3OD) 32.1 (2 × CH2CHO), 45.2 (2 × CH2N), 77.9 (CHOSO2NH2); 

C NMR (125 
MHz; DMSO-d
6
)C 30.9 (2 × CH2CHO), 43.9 (2 × CH2N), 76.6 (CHOSO2NH2); HRMS 
calcd for C5H11N2O6S2 [M-H]
-
 259.0064, found 259.0054. 
trans- 2,2,2-Trichloroethyl-(4-hydroxycyclohexyl)sulfamate (181) 
 
Prepared according to general procedure C using 2,3-dimethyl-1-((2,2,2-
trichloroethoxy)sulfonyl)-1H-imidazol-3-ium tetrafluoroborate (331 mg, 0.87 mmol, 1 
eq.), trans-4-aminocyclohexanol (100 mg, 0.87 mmol, 1 eq.), and THF (10 mL). The 
residue was purified by MPLC on SiO2 with a gradient elution from 25-75% EtOAc/petrol 
to yield a white solid (204 mg, 73%); Rf 0.3 (50% EtOAc/petrol; KMnO4); m.p. 120-123 
C; max(EtOH)/nm <220; IR  max/cm
-1
 34958, 3080, 2924, 2828, 1350 (SO), 1174 (SO); 

H NMR (500 MHz; CDCl3) H 1.31-1.45 (4H, m, 2 × CHaxCHOH and 2 × CHaxCHNH), 
1.98-2.05 (2H, m, 2 × CHeqCHOH), 2.15-2.22 (2H, m, 2 × CHeqCHNH), 3.40-3.50 (1H, m, 
CHOH), 3.60-3.68 (1H, m, CHNH), 4.42 (1H, d, J = 7.9 Hz, OH), 4.63 (2H, s, CH2CCl3); 

H NMR (500 MHz; DMSO-d
6
) H 1.17-1.38 (4H, m, 2 × CHaxCHOH and 2 × 
CHaxCHNH), 1.79-1.88 (2H, m, 2 × CHeqCHOH ), 1.91-2.00 (2H, m, 2 × CHeqCHNH), 
3.14-3.22 (1H, m, CHOH), 3.31-3.45 (1H, m, CHNH), 4.59 (1H, d, J = 4.3 Hz, OH), 4.74 
(2H, s, CH2CCl3), 8.31 (1H, br s, NH); 

C NMR (125 MHz; DMSO-d
6
) C 30.6, 33.5, 
52.7, 67.6, 77.1 (CH2CCl3), 94.1 (CCl3); HRMS calcd for C8H18
35
Cl3N2O4S1 
[M+NH4]
+
 343.0047, found 343.0054. 
trans-(2,2,2-Trichloroethyl )(4-(sulfamoyloxy)cyclohexyl)sulfamate (182) 
 
Sulfamoyl chloride (1.04 mL, 1 M in MeCN, 1.04 mmol, 2 eq.) was added to alcohol 181 
(170 mg, 0.52 mmol, 1 eq.) in DMF (1 mL) containing potassium carbonate (359 mg, 2.6 
mmol, 5 eq.) at -40 C, and the mixture stirred at -40 C for 18 h. The reaction was 
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quenched with methanol, allowed to warm to room temperature, and partitioned between 
Et2O (2 × 20 mL) and water (20 mL). The organics layers were combined, dried over 
MgSO4, and the solvent removed in vacuo. The residue was purified by MPLC on silica 
with a gradient from 20-50% EtOAc/petrol to give a clear gum (160 mg, 76%). Rf 0.5 
(30% EtOAc/petrol; KMnO4); m.p. 141-144 C;max(EtOH)/nm <220; IR  max/cm
-1
 3283 
(br), 2954, 1363 (SO), 1176 (SO);

H NMR (500 MHz; DMSO-d
6
) H 1.38-1.49 (2H, m, 2 
× CHaxCHNH), 1.52-1.63 (2H, m, 2 × CHaxCHOSO2NH2), 1.99-2.09 (4H, m, 2 × 
CHeqCHOSO2NH2 and 2 × CHeqCHNH), 3.27-3.38 (1H, m, CHNH), 4.36 (1H, tt, J = 3.8 
and 10.2 Hz, CHCOSO2NH2), 4.76 (2H, s, CH2CCl3), 7.43 (2H, s, NH2), 8.40 (1H, s, NH); 

C NMR (125 MHz; DMSO-d
6
) C 29.7 (2 × CH2CHOSO2NH2), 29.9 (2 × CH2CHNH), 
51.3 (CHNH), 77.2 (CH2CCl3), 77.6 (CHOSO2NH2), 94.1 (CCl3); HRMS calc. for 
C8H19
35
Cl3N3O6S2 [M+NH4]
+
 421.9779, found 421.9775. 
Sodium trans-(4-(sulfamoyloxy)cyclohexyl)sulfamate (64) 
 
Zinc powder (230 mg, 3.5 mmol, 10 eq.) was added to sulfamate 182 (140 mg, 0.35 mmol, 
1 eq.) in MeOH (4 mL) and water (4 mL) at r.t., and the mixture was stirred at r.t. for 1 h. 
Further zinc powder (230 mg, 3.5 mmol, 10 eq.) was added and the mixture stirred at r.t. 
for 1 h. The mixture was filtered through Celite, and the solvent removed in vacuo. The 
residue was dissolved in water and run through a Dowex 50W8X-200 ion exchange resin 
which had previously been converted to the sodium form. Product containing fractions 
were frozen and lyophilised to give a white solid (102 mg, 100%); Rf 0.45 (30% 
EtOAc/petrol; KMnO4); m.p. 205-207 C; max(EtOH)/nm <220; IR  max/cm
-1
 35925, 
3529, 1327 (SO), 1168 (SO);

H NMR (500 MHz; DMSO-d
6
) H 1.14-1.25 (2H, m, 2 × 
CH2CHOSO2NH2), 1.38-1.49 (2H, m, 2 × CHaxCHOSO2NH2), 1.97-2.05 (4H, m, 2 × 
CHeqCHOSO2NH2 and 2 × CHeqCHNH), 2.88-2.97 (1H, m, CHNH), 3.21 (1H, d, J = 5.0 
Hz, NH), 4.32 (1H, tt, J = 3.8 and 9.9 Hz, CHO), 7.30 (2H, s, NH2); 

C NMR (125 MHz; 
DMSO-d
6
) C 30.3 (2 × CH2CHOSO2NH2), 30.4 (2 × CH2CHNH), 50.5 (CHNH), 78.8 
(CHOSO2NH2); HRMS calcd for C6H13N2O6S2 [M-H]
-
 273.0221, found 273.0211. 
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2,2,2-Trichloroethyl 4-(hydroxymethyl)piperidine-1-sulfonate (188) 
 
Prepared according to general procedure C using 2,3-dimethyl-1-((2,2,2-
trichloroethoxy)sulfonyl)-1H-imidazol-3-ium tetrafluoroborate (331 mg, 0.87 mmol, 1 
eq.), 4-piperidine methanol (100 mg, 0.87 mmol, 1 eq.), and THF (10 mL). The residue 
was purified by MPLC on SiO2 with a gradient elution from 25-65% EtOAc/petrol to yield 
a clear oil (265 mg, 94%); Rf 0.2 (45% EtOAc/petrol; KMnO4); max(EtOH)/nm <220; IR  
max/cm
-1
 3352 (br), 1368 (SO), 1175 (SO); 

H NMR (500 MHz; DMSO-d
6
) H 1.25 (2H, 
app qd, J = 4.2 and 12.6 Hz, 2 × CHaxCH2N), 1.52-1.62 (1H, m, CHCH2OH), 1.78 (2H, 
app dd, J = 2.7 and 12.6 Hz, 2 × CHeqCH2N), 3.00 (2H, app td, J = 12.6 and 2.7 Hz, 2 × 
CHaxN), 3.30 (2H, dd, J = 5.4 and 6.1 Hz, CH2OH), 3.75 (2H, m, 2 × CHeqN), 4.60 (1H, t, 
J = 5.4 Hz, OH), 4.91 (2H, s, CH2CCl3); 

C NMR (125 MHz; DMSO-d
6
)C 27.6 (2 × 
CH2CH2N), 37.2 (CHCH2OH), 46.5 (2 × CH2N), 65.2 (CH2OH), 77.7 (CH2CCl3), 94.1 
(CCl3); MS (ES+) m/z 326.3 [M(
35,35,35
Cl)+H]
+
, 328.3 [M(
35,35,37
Cl)+H]
+
, 330.3 
[M(
35,37,37
Cl)+H]
+
. 
(1-((2,2,2-Trichloroethoxy)sulfonyl)piperidin-4-yl)methyl sulfamate (189) 
 
Sulfamoyl chloride (1.5 mL, 1 M in MeCN, 1.5 mmol, 2 eq.) was added to alcohol 188 
(250 mg, 0.75 mmol, 1 eq.) in DMF (2 mL) containing potassium carbonate (528 mg, 3.8 
mmol, 5 eq.) at -40 C, and the mixture stirred at -40 C for 18 h. The reaction was 
quenched with methanol, allowed to warm to room temperature, and partitioned between 
Et2O (2 × 30 mL) and water (20 mL). The organics layers were combined, dried over 
MgSO4, and the solvent removed in vacuo. The residue was purified by MPLC on silica 
with a gradient from 30-60% EtOAc/petrol to give a white crystalline solid (232 mg, 75%); 
Rf 0.3 (45% EtOAc/petrol; KMnO4); m.p. 114-116 C; max(EtOH)/nm <220; IR  max/cm
-1
 
3366, 3263, 1360 (SO), 1178 (SO);

H NMR (500 MHz; DMSO-d
6
) H 1.37 (2H, app qd, J 
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= 12.4 and 4.1 Hz, 2 × CHaxCH2N), 1.81 (2H, app dd, J = 2.4 and 12.4 Hz, 2 × 
CHeqCH2N), 1.87-1.98 (1H, m, CHCH2OH), 3.05 (2H, app td, J = 12.4 and 2.4 Hz, 2 × 
CHaxN), 3.73 - 3.80 (2H, m, 2 × CHeqN), 3.95 (2H, d, J = 6.4 Hz, CH2OSO2NH2), 4.93 
(2H, s, CH2CCl3), 7.50 (2H, s, OSO2NH2); 

C NMR (125 MHz; DMSO-d
6
) C 27.0 (2 × 
CH2CH2N), 33.9 (CHCH2O), 46.0 (2 × CH2N), 72.2 (CH2OSO2NH2), 77.7 (CH2CCl3), 
94.1 (CCl3); MS (ES+) m/z 405.2 [M(
35,35,35
Cl)+H]
+
, 407.2 [M(
35,35,37
Cl)+H]
+
, 409.2 
[M(
35,37,37
Cl)+H]
+
; HRMS calcd for C8H19N3O6
35
Cl3S2 [M+NH4]
+
 421.9775, found 
421.9780. 
Sodium 4-((sulfamoyloxy)methyl)piperidine-1-sulfonate (65) 
 
Activated zinc powder (677 mg, 1.04 mmol, 20 eq.) was added to sulfamate 189 (210 mg, 
0.52 mmol, 1 eq.) in MeOH (6 mL) and water (6 mL) at r.t., and the mixture was stirred at 
r.t. for 1 h. The mixture was filtered through Celite, the Celite washed with methanol, and 
the solvent removed in vacuo. The residue was dissolved in water and run through a 
Dowex 50W8X-200 ion exchange resin which had previously been converted to the 
sodium form. Product containing fractions were frozen and lyophilised to give a white 
solid (138 mg, 90%); Rf 0.5 (30% MeOH/EtOAc; KMnO4); m.p. 245 C 
dec.;max(EtOH)/nm <220; IR  max/cm
-1 
3318, 3219, 31057, 1365 (SO), 1180 (SO);

H 
NMR (500 MHz; DMSO-d
6
) H 1.12-1.23 (2H, m, 2 × CHaxCH2N), 1.57-1.71 (3H, m, 2 × 
CHeqCH2N and CHCH2OH), 2.27 (2H, app td, J = 12.0 and 2.4 Hz, 2 × CHaxN), 3.35-3.41 
(2H, m, 2 × CHeqN), 3.87 (2H, d, J = 6.4 Hz, CH2OSO2NH2), 7.29 (2H, br s, OSO2NH2); 

C NMR (125 MHz; DMSO-d
6
) C 27.9 (2 × CH2CH2N), 35.0 (CHCH2O), 46.1 (2 × 
CH2N), 72.8 (CH2OSO2NH2); HRMS calcd for C6H13N2O6S2 [M-H]
-
 273.0221, found 
273.0214. 
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10.3.3 Synthesis of Phenyl Sulfamates 
 
Phenyl sulfamate (29)341,210 
 
Prepared according to sulfamoylation method 4 using phenol (200 mg, 2.1 mmol, 1 eq.), 
sulfamoyl chloride (6.4 mL, 1 M in toluene, 6.4 mmol, 3 eq.) and DMA (8 mL). The 
resulting crude solid was purified by MPLC on SiO2 with a gradient elution from 10-40% 
EtOAc/petrol to give a white solid (280 mg, 76%). Rf 0.5 (30% EtOAc/petrol); m.p. 82-84 
C (Lit.341 85 C); max(EtOH)/nm 202, 256, 265; IR  max/cm
-1 
3419 (NH), 3303 (NH), 
1361 (SO), 1171 (SO); 
R (500 MHz; DMSO-d
6
) H 7.27-7.36 (3H, m, H-Ar), 7.44-
7.50 (2H, m, H-Ar), 7.98 (2H, s, NH2); 

CR (125 MHz; DMSO-d
6
) C 122.1 (C-Ar), 
126.4 (C-Ar), 129.7 (C-Ar), 150.2 (C-O); MS (ESI-) m/z 172.1 [M-H]
- 
. 
2-Trifluoromethylphenyl sulfamate (68)342 
 
Prepared according to sulfamoylation method 4 using 2-trifluoromethylphenol (195 mg, 
1.2 mmol, 1 eq.), sulfamoyl chloride (1.6 mL, 1.5 M in toluene, 2.4 mmol, 2 eq.) and DMA 
(2 mL). The resulting crude solid was purified by MPLC on SiO2 with a gradient elution 
from 10-40% EtOAc/petrol to give a white solid (90 mg, 31%); Rf 0.1 (20% 
EtOAc/petrol); m.p. 102-104 C; max(EtOH)/nm 212.9, 262.9; IR  max/cm
-1 
3371 (NH), 
3278 (NH), 1383 (SO), 1195 (SO); 
R (500 MHz; CDCl3) H 5.02 (2H, s, NH2), 7.44 
(1H, t, J = 8.0 Hz, H-Ar), 7.65 (1H, td, J = 8.0 and 1.3 Hz, H-Ar), 7.69 (2H, t, J = 8.0 Hz, 
H-Ar); 

CR (125 MHz; CD3OD) C 124.4 (q, J = 272.1 Hz, CF3), 123.2 (CH-Ar), 
127.0 (CH-Ar), 128.2 (q, J = 5.0 Hz, CH-C-CF3), 134.7 (CH-Ar), 150.0 (C-O-S); HRMS 
calcd for C7H7F3N1O3S1 [M+H]
+
 242.0093,
 
found 242.0091. 
3-Trifluoromethylphenyl sulfamate (69) 
 
Prepared according to sulfamoylation method 4 using 3-trifluoromethylphenol (150 L, 
1.2 mmol, 1 eq.), sulfamoyl chloride (0.5 mL, 5 M in CH2Cl2, 2.5 mmol, 2.1 eq.) and 
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DMA (2 mL). The resulting crude solid was purified by MPLC on SiO2 with a gradient 
elution from 10-50% EtOAc/petrol to give the sulfamate as a white solid (269 mg, 93%); 
Rf 0.8 (50% EtOAc/petrol); m.p. 103-106 C (Lit.
343
 100-102 C); max(EtOH)/nm 263; IR 
 max/cm
-1 
3355 (NH), 3281 (NH), 1366 (SO), 1181 (SO); 
R (500 MHz; DMSO-d
6
) 
H 7.60-7.62 (2H, m, H-Ar), 7.73-7.75 (2H, m, H-Ar), 8.20 (2H, s, NH2); 

CR (125 
MHz; CD3OD) C 120.5 (q, CH-C-CF3, J = 3.9 Hz), 125.0 (q, J = 271.6 Hz, CF3,), 124.4 
(q, J = 3.9 Hz, CH-C-CF3), 127.3 (C-Ar), 131.8 (C-Ar), 133.1 (q, J = 32.9 Hz, C-CF3 ), 
152.4 (C-O-S); HRMS calcd for C7H5O3N1F3S1 [M-H]
- 
239.9948, found 239.9953. 
4-Trifluoromethylphenyl sulfamate (70)210 
 
Prepared according to sulfamoylation method 4 using 4-trifluoromethylphenol (195 mg, 
1.2 mmol, 1 eq.), sulfamoyl chloride (1.6 mL, 1.5 M in toluene, 2.4 mmol, 2 eq.) and DMA 
(2 mL). The resulting crude solid was purified by MPLC on SiO2 with a gradient elution 
from 10-40% EtOAc/petrol to give a white solid (200 mg, 93%); Rf 0.05 (10% 
EtOAc/petrol); m.p. 112-113 C (Lit.210 100-102 C); max(EtOH)/nm 219.9, 258.9; IR  
max/cm
-1 
3379 (NH), 3274 (NH), 1350 (SO), 1158 (SO); 
R (500 MHz; CDCl3) H 
5.03 (2H, s, NH2), 7.48 (2H, d, J = 8.4 Hz, H-Ar), 7.73 (2H, d, J = 8.4 Hz, H-Ar); 

CR (125 MHz; CD3OD) C 125.0 (q, J = 271.1 Hz, CF3), 123.9 (2 × C-Ar), 128.1 (q, 
J = 3.8 Hz, 2 × CHCCF3 ), 129.7 (q, J = 32.8 Hz, CCF3), 154.9 (C-O-S); HRMS calcd for 
C12H10O3N1S1 [M+NH4]
+ 
216.0437, found 216.04615. 
2-Cyanophenyl sulfamate (71)344 
 
Prepared according to sulfamoylation method 4 using 2-cyanophenol (143 mg, 1.2 mmol, 1 
eq.), sulfamoyl chloride (1.6 mL, 1.5 M in toluene, 2.4 mmol, 2 eq.) and DMA (3 mL). 
The resulting crude solid was purified by MPLC on SiO2 with a gradient elution from 10-
40% EtOAc/petrol to give a white solid 125 mg (26%); Rf 0.3 (30% EtOAc/petrol); m.p. 
118-120 C;max(EtOH)/nm 230, 273 sh; IR  max/cm
-1 
3358, 3238, 3090, 2246 (CN), 1556 
(NO2), 1384 (SO), 1166 (SO); 
1
H NMR Spectrum: (500 MHz; CDCl3): H 5.30 (2H, s, 
NH2), 7.46 (1H, td, J = 7.7 and 1.0 Hz, H-Ar) 7.63 (1H, dd, J = 8.3 and 0.7 Hz, H-Ar), 
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7.70-7.76 (2H, m, H-Ar); 
13
C-NMR (125 MHz; CD3OD) C 108.7 (C-Ar), 116.3 (CN), 
124.2 (C-Ar), 128.1 (C-Ar), 135.0 (C-Ar), 135.7 (C-Ar), 153.2 (C-O); HRMS calcd for 
C7H10O3N3S1 [M+NH4]
+
 216.0437, found 216.0439. 
3-Cyanophenyl sulfamate (72)343 
 
Prepared according to sulfamoylation method 4 using 3-cyanophenol (143 mg, 1.2 mmol, 1 
eq.), sulfamoyl chloride (3.2 mL, 0.75 M in toluene, 2.4 mmol, 2 eq.) and DMA (3 mL). 
The resulting crude solid was purified by MPLC on SiO2 with a gradient elution from 10-
50% EtOAc/petrol to give a white solid (138 mg, 58%); Rf 0.2 (25% EtOAc/petrol); m.p. 
105-107 C (lit.343 101-104 C); max(EtOH)/nm 280; IR  max/cm
-1 
3342 (NH), 3234 (NH), 
2244, 1383 (SO), 1194 (SO); 
R (500 MHz; CDCl3) H 5.05 (s, 2H, NH2), 7.58 (1H, 
dd, J = 8.2 and 7.9 Hz, H-Ar), 7.62-7.64 (1H, m, H-Ar), 7.65-7.68 (m, 2H, H-Ar); 

CR (125 MHz; DMSO-d
6
)C 114.0 (C-Ar), 117.3 (CN), 125.8 (C-Ar), 127.0 (C-Ar), 
130.96 (C-Ar), 130.99 (C-Ar), 150.1 (C-O); HRMS calcd for C7H10O3N3S1 [M+NH4]
+
 
216.0437,
 
found 216.04615. 
4-Cyanophenyl sulfamate (73)210 
 
Prepared according to sulfamoylation method 4 using 4-cyanophenol (143 mg, 1.2 mmol, 1 
eq.), sulfamoyl chloride (1.6 mL, 1.5 M in toluene, 2.4 mmol, 2 eq.) and DMA (3 mL). 
The resulting crude solid was purified by MPLC on SiO2 with a gradient elution from 10-
50% EtOAc/petrol to give a white solid (50 mg, 21%); Rf 0.2 (20% EtOAc/petrol); m.p. 
147-148 C (Lit.210 152-153 C)max(EtOH)/nm 229.9; IR  max/cm
-1 
3353 (NH), 3251 
(NH), 2240 (CN), 1376 (SO), 1155 (SO); 
R (500 MHz; CDCl3) H 5.04 (2H, s, 
NH2), 7.48 (2H, dt, J = 8.8 and 2.0 Hz, H-Ar), 7.77 (2H, dt, J = 8.8 and 2.0 Hz, H-Ar); 

CR (125 MHz; CD3OD) C 111.4 (C-CN), 119.1 (CN), 124.3 (2 × CH-Ar), 135.2 (2 
× CH-Ar), 155.5 (C-O); HRMS calcd for C7H5N2O3S [M-H]
-
 197.0026, found 197.0027. 
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2-Nitrophenyl sulfamate (74)345 
 
Prepared according to sulfamoylation method 4 using 2-nitrophenol (400 mg, 3.0 mmol, 1 
eq.), sulfamoyl chloride (3 mL, 3 M in toluene, 9 mmol, 3 eq.) and DMA (3 mL). The 
resulting crude solid was purified by MPLC on SiO2 with a gradient elution from 10-50% 
EtOAc/petrol to give a white solid (324 mg, 52%); Rf 0.1 (30% EtOAc/petrol); m.p. 103-
104 C (lit.345 102-104 C); max(EtOH)/nm 249.5 sh; IR  max/cm
-1 
3402 (NH), 3263 (NH), 
1600, 1512, 1355 (SO), 1174 (SO); 
R (500 MHz; DMSO-d
6
) H 7.55-7.61 (2H, m, 
H-Ar), 7.81-7.85 (1H, m, H-Ar) 8.06 (1H, dd, J = 8.1 and 1.6 Hz, H-Ar), 8.40 (2H, s, 
NH2); 

CR (125 MHz; DMSO-d
6
) C 126.1 (C-Ar), 126.6 (C-Ar), 128.3 (C-Ar), 135.2 
(C-Ar), 144.0 (C-Ar), 145.0 (C-O-S); HRMS calcd for C6H5O5N2S1 [M+NH4]
+
 216.9925, 
found: 216.9924. 
3-Nitrophenyl sulfamate (75)346 
 
Prepared according to sulfamoylation method 4 using 3-nitrophenol (208 mg, 1.5 mmol, 1 
eq.), sulfamoyl chloride (1.5 mL, 3 M in toluene, 4.5 mmol, 3 eq.) and DMA (2 mL). The 
resulting crude solid was purified by MPLC on SiO2 with a gradient elution from 10-50% 
EtOAc/petrol to give a white solid (285 mg, 87%); Rf 0.1 (UV, 30% EtOAc/petrol); m.p. 
94-96 C; max(EtOH)/nm 265; IR max/cm
-1 
3368 (NH), 3281 (NH), 1563.3, 1365 (SO), 
1174 (SO); 
R (500 MHz; CDCl3) H 5.08 (2H, s, NH2), 7.66 (1H, t, J = 8.1 Hz, H-
Ar) 7.72 - 7.75 (1H, m, H-Ar), 8.22 - 8.27 (2H, m, H-Ar); 

CR (125 MHz; CD3OD) 
C 118.7 (C-Ar), 122.5 (CN), 129.9 (C-Ar), 131.8 (C-Ar), 150.3 (C-Ar), 152.4 (C-O-S); 
HRMS calcd for C6H5O5N2S1 [M+NH4]
+
 216.9925, found: 216.9926. 
4-Nitrophenyl sulfamate (76)210 
 
Prepared according to sulfamoylation method 4 using 4-nitrophenol (166 mg, 1.2 mmol, 1 
eq.), sulfamoyl chloride (3.2 mL, 0.75 M in toluene, 2.4 mmol, 2 eq.) and DMA (3 mL). . 
The resulting crude solid was purified by MPLC on SiO2 with a gradient elution from 5-
282 
 
40% EtOAc/petrol to give a white solid (64 mg, 24%); Rf 0.25 (20% EtOAc/petrol); m.p. 
105-107 C (Lit.210 100-102 C); max(EtOH)/nm 215.9, 265.9; IR  max/cm
-1 
3419.0 (NH), 
3291 (NH), 1587, 1510, 1351 (SO), 1173 (SO); 
R (500 MHz; CDCl3) H 5.10 (2H, 
s, NH2), 7.53 (2H, dt, J = 9.0 and 2.2 Hz, H-Ar), 8.35 (dt, 2H, J = 9.0 and 2.2 Hz, H-Ar); 

CR (125 MHz; DMSO-d
6
)C 115.8 (C-Ar), 126.2 (C-Ar), 139.6 (C-NO2), 163.9 (C-
O-S); MS (ESI-) m/z: runs as phenol. 
Data were inconsistent with literature
210
 as the 
13
C NMR shifts do not correspond. For 
further structural confirmation, crystallisation was performed using the slow evaporation of 
5mg of the obtained product from MeCN over 2 weeks. X-ray crystallography confirmed 
the product had the desired structure. 
2-Methoxyphenyl sulfamate (77)347 
 
Prepared according to sulfamoylation method 4 using 2-methoxyphenol (248 mg, 2 mmol), 
sulfamoyl chloride (4 mL, 2 M in toluene, 6 mmol, 3 eq.) and DMA (4 mL). The resulting 
crude solid was purified by MPLC on SiO2 with a gradient elution from 10-50% 
EtOAc/petrol to give a white solid (116 mg, 29%); Rf 0.25 (30% EtOAc/petrol); m.p. 84-
86 C, (lit.347 78 C)max(EtOH)/nm 218.9, 270.9 sh; IR  max/cm
-1 
3350 (NH), 3256 (NH), 
1382 (SO), 1108 (SO); 
R (500 MHz; CDCl3) H 3.94 (3H, s, OCH3), 4.99 (2H, s, 
NH2), 7.04 (2H, dd, J = 8.0 and 7.9 Hz, H-Ar), 7.31 (1H, d, J = 8.0 Hz, H-Ar), 7.38 (1H, 
d, J = 8.0 Hz, H-Ar); 

CR (125 MHz; DMSO-d
6
)C 55.8 (OCH3), 113.4 (C-Ar), 
120.4 (C-Ar), 123.2 (C-Ar), 127.3 (C-Ar), 138.9 (C-Ar), 151.8 (C-O-S); HRMS calcd for 
C7H8NO4S [M-H]
-
 202.0180, found 202.0180. 
3-Methoxyphenyl sulfamate (78)343 
 
Prepared according to sulfamoylation method 4 using 3-methoxyphenol (248 mg, 2 mmol), 
sulfamoyl chloride (4 mL, 2 M in toluene, 6 mmol, 3 eq.) and DMA (4 mL). The resulting 
crude solid was purified by MPLC on SiO2 with a gradient elution from 10-50% 
EtOAc/petrol to give an amorphous white solid (225 mg, 56%); Rf 0.25 (30% 
283 
 
EtOAc/petrol); max(EtOH)/nm 219.9, 270.9 sh; IR  max/cm
-1 
3378 (NH), 3279 (NH), 1360 
(SO), 1124 (SO); 
R (500 MHz; CDCl3) H 3.84 (s, 3H, OCH3), 4.97 (s, 2H, NH2), 
6.92 (2H, d, J = 7.6 Hz, H-Ar), 7.29 (1H, s, H-Ar), 7.34 (1H, t, J = 7.6 Hz, H-Ar); 

CR (125 MHz; DMSO-d
6
) C 55.4 (OCH3), 108.1 (C-Ar), 112.1 (C-Ar), 114.1 (C-
Ar), 130.2 (C-Ar), 151.1 (C-O-S), 160.1 (C-O-Me); HRMS calcd for C7H8O4N1S1 [M-H]
-
 
202.0180, Found 202.0175. 
4-Methoxyphenyl sulfamate (79)210 
 
Prepared according to sulfamoylation method 4 using 4-methoxyphenol (149 mg, 1.2 
mmol, 1 eq.), sulfamoyl chloride (1 mL, 2.4 M in CH2Cl2, 2.4 mmol, 2 eq.) and DMA (4 
mL). The resulting crude solid purified by MPLC on SiO2 with a gradient elution from 1-
30% EtOAc/petrol to give a white solid (130 mg, 53%); Rf 0.4 (UV, 30% EtOAc/petrol); 
m.p. 64-67 C (lit.210 62-64 C); max(EtOH)/nm 275; IR  max/cm
-1 
3386 (NH), 3284 (NH), 
1348 (SO), 1166 (SO); 
R (500 MHz; DMSO-d
6
) H 3.77 (s, 3H, OCH3), 7.00 (2H, 
dd, J = 9.2 and 2.3 Hz, H-Ar), 7.20 (2H, dd, J = 9.2 and 2.3 Hz, H-Ar), 7.89 (s, 2H, NH2); 

CR (125 MHz; DMSO-d
6
)C 59.7 (OCH3), 114.6 (C-Ar), 123.3 (C-Ar), 143.5 (C-
Ar), 157.5 (C-Ar); 

CR (125 MHz; CD3OD) C 56.1 (OCH3), 115.6 (CH-Ar), 124.4 
(CH-Ar), 145.5 (C-O-S), 159.6 (C-OMe); HRMS calcd for C7H8O4N1S1 [M-H]
-
202.0180, 
found 202.0185. 
Data were consistent with literature values
210
 except for the 
13
C NMR chemical shift of 
OCH3. The reported literature value is not consistent with expected value for this structure. 
A single crystal was grown for X-ray crystallography studies by dissolving 20mg of 
compound in H2O (1 mL) and allowing to crystallise through slow evaporation for 2 
weeks. X-ray data confirmed that the desired product has been formed.  
2-Phenylphenyl sulfamate (80)348 
 
Prepared according to sulfamoylation method 4 using 2-phenylphenol (204 mg, 1.2 mmol, 
1 eq.), sulfamoyl chloride (1.6 mL, 1.5 M in toluene, 2.4 mmol, 2 eq.) and DMA (2 mL). 
The resulting crude solid was purified by MPLC on SiO2 with a gradient elution from 10-
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40% EtOAc/petrol to give a white solid (200 mg, 67%); Rf 0.5 (20% EtOAc/petrol); m.p. 
89-91 C (Lit.348 87 C); max(EtOH)/nm 213.9, 240.9,; IR  max/cm
-1 
3364, 3268, 3108, 
3065, 1379 (SO), 1105 (SO); 
R (500 MHz; CDCl3) H 4.10 (2H, s, NH2), 7.41-7.60 
(9H, m, H-Ar); 

CR (125 MHz; DMSO-d
6
)C 121.6 (C-Ar), 126.4 (C-Ar), 127.3 (C-
Ar), 128.2 (C-Ar), 128.7 (C-Ar), 129.1 (C-Ar), 131.3 (C-Ar), 134.2 (C-Ar), 137.0 (C-Ar), 
147.4 (C-O); MS (ESI-) m/z 248.1 [M-H]
- 
; HRMS calcd for C12H15O3N2S1 [M+NH4]
+
 
267.0798, found 267.0803. 
3-Phenylphenyl sulfamate (81) 
 
Prepared according to sulfamoylation method 4 using 3-phenylphenol (204 mg, 1.2 mmol, 
1 eq.), sulfamoyl chloride (1.6 mL, 1.5 M in toluene, 2.4 mmol, 2 eq.) and DMA (2 mL). 
The resulting crude solid was purified by MPLC on SiO2 with a gradient elution from 10-
40% EtOAc/petrol to give a white solid (128 mg, 43%); Rf 0.2 (20% EtOAc/petrol); m.p. 
91-93 Cmax(EtOH)/nm 213.9, 248.9; IR  max/cm
-1 
3359 (NH), 3263 (NH), 1353 (SO), 
1147 (SO); 
R (500 MHz; CDCl3) H 4.95 (2H, s, NH2), 7.30-7.70 (9H, m, H-Ar); 

CR (125 MHz; DMSO-d
6
) C 120.4 (C-Ar), 121.2 (C-Ar), 124.9 (C-Ar), 126.8 (C-
Ar), 128.0 (C-Ar), 129.0 (C-Ar), 130.3 (C-Ar), 139.0 (C-Ar), 142.0 (C-Ar), 150.7 (C-O); 
HRMS calcd for C12H10NO3S [M-H]
-
 248.0387, Found 248.0391. 
4-Phenylphenyl sulfamate (82)210 
 
Prepared according to sulfamoylation method 4 using 4-phenylphenol (204 mg, 1.2 mmol, 
1 eq.), sulfamoyl chloride (1 mL, 2.4 M in CH2Cl2, 2.4 mmol, 2 eq.) and DMA (4 mL). 
The resulting crude solid was purified by MPLC on SiO2 with a gradient elution from 10-
40% EtOAc/petrol to give a white solid (201 mg, 67%); Rf 0.4 (25% EtOAc/petrol); m.p. 
165-167 C (Lit.210 160-162 C); max(EtOH)/nm 250; IR  max/cm
-1 
3421 (NH), 3299 
(NH), 3078, 1362 (SO), 1176 (SO); 
R (500 MHz; DMSO-d
6
) H 7.37-7.41 (3H, m, 
H-Ar), 7.49 (2H, tt, J = 8.0 and 1.5 Hz, H-Ar) 7.68 (2H, dq, J = 8.0 and 1.5 Hz, H-Ar), 
7.76 (2H, dt, J = 8.0 and 1.5 Hz, H-Ar), 8.06 (2H, s, NH2); 

CR (125 MHz; DMSO-
d
6
) C 122.7 (C-Ar), 126.7 (C-Ar), 127.6 (C-Ar), 128.0 (C-Ar), 129.0 (C-Ar), 138.6 (C-
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Ar), 139.2 (C-Ar), 149.6 (C-O); HRMS calcd for C12H10N1O3S1 [M-H]
- 
248.0387, found 
248.0390. 
10.3.4 Synthesis of Benzylic Sulfamate Targets 
4-Nitrobenzyl sulfamate (89) 
 
Prepared according to sulfamoylation method 4 using 4-nitrobenzyl alcohol (706 L, 6 
mmol, 1 eq.), sulfamoyl chloride (12 mL, 1.5 M in toluene, 18 mmol, 3 eq.) and DMA (12 
mL). The crude material was purified by MPLC on SiO2 with a gradient elution from 10-
50% EtOAc/petrol to give a white solid (700 mg, 50%); Rf 0.3 (30% EtOAc/petrol); m.p. 
113-104 C; max(EtOH)/nm 213.9, 266.9; IR  max/cm
-1 
3384 (NH), 3287 (NH), 1505.6 
(NO2), 1344 (SO), 1168 (SO); 
R (500 MHz; CDCl3) H 4.82 (2H, s, NH2), 5.33 
(2H, s, CH2), 7.62 (2H, d, J = 8.8 Hz, H-Ar), 8.29 (2H, dt, J = 8.8 and 2.2 Hz, H-Ar); 

CR (125 MHz; DMSO-d
6
)C 68.6 (CH2), 123.6 (2 × CH-Ar), 128.8 (2 × CH-Ar), 
142.5 (C-Ar), 147.3 (C-NO2); HRMS calcd for C7H7O5N2S1 [M-H]
-
 231.0080, found: 
231.0081. 
4-Acetamidobenzyl alcohol (196)83 
 
Acetic anhydride (1 mL, 10.6 mmol, 3.3 eq.) was added to 4-aminobenzyl alcohol (400 
mg, 3.25 mmol, 1 eq.) in methanol (15 mL) at r.t. over 5 minutes and the mixture was 
stirred at r.t. for 3 h. Additional acetic anhydride (0.4 mL) was added and the mixture 
stirred at r.t. for 2 h. Pyridine was added and the mixture stirred at r.t. overnight. The 
solvent was removed in vacuo and the residue purified by MPLC on SiO2 with a gradient 
elution from 1-10% MeOH /CH2Cl2 to give a brown oil. The oil was triturated with Et2O to 
give a beige solid (350 mg, 65%); Rf 0.5 (10% MeOH/CH2Cl2); IR  max/cm
-1 
3415, 3245, 
3186, 1668 (amide I), 1547 (amide II); 
R (500 MHz; CDCl3) H 1.68 (1H, s, OH), 
2.20 (3H, s, CH3), 4.68 (2H, s, CH2), 7.22 (s, 1H, NH), 7.35 (2H, d, J = 8.3 Hz, H-Ar), 
7,51 (2H, d, J = 8.3Hz, H-Ar); 

CR (125 MHz; CD3OD) C 23.8 (CH3), 64.9 (CH2), 
121.1 (2 × C-Ar), 128.6 (2 × C-Ar), 138.5 (C-Ar), 139.1 (C-Ar), 171.6 (COCH3); MS 
(ESI-) m/z 164.1 [M-H]
-
.  
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10.4 ERK5 Project Experimental Procedures 
 
10.4.1 ERK5 Biological Assay Protocols 
 
The ERK5 biological assays were performed by Ms Ai Ching Wong at Cancer Research 
Technology Discovery research Laboratories, London, and in by Lan-Zhen Wang at the 
Paul O’Gorman Building, Newcastle Cancer Centre, Newcastle upon Tyne. 
 
ERK5 IMAP™ Assay Protocol 
 
 Preparation of Assay Buffer (1x) 
The 0.01% Tween®-20 5x stock was supplied as part of IMAP
TM
 FP Progressive Binding 
System Kit (Molecular Devices R7436), which was diluted to 1x using miliQ H2O. 1 μL of 
a 1 M DTT stock was added for every 1 mL of 1x assay buffer to give a final concentration 
of 1 mM DTT. 
Preparation of ERK5 Working Solution 
The final dilution was dependent on activity of the enzyme batches. The initial batch 
(08/08/08) was used at a 1 in 1 in 350 final dilution in assay buffer. A 1:175 dilution of 
ERK5 stock was performed in 1x assay buffer. For 1 plate, 13 μL of ERK5 stock was 
added to 2262 μL of 1x assay buffer. ERK5 was expressed and purified at CRT by Leon 
Pang and Sue Young. Aliquots were stored at -80 C. Batch PO080808 was used at a stock 
concentration of 73.4 ng/μl. 
Preparation of ATP/Substrate Working Solution 
For one plate, ATP disodium salt (90 μL, 20 mM) (Sigma A7699) and FAM-EGFR-
derived peptide (15 μL, 100 μM) (LVEPLTPSGEAPNQ(K-5FAM)-COOH) (Molecular 
Devices RP7129; reconstituted in miliQ H2O to a stock concentration of 100 μL; Stored at 
-20C) was added to 2295 μL of 1x assay buffer. 
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Preparation of IMAP™ binding solution 
For one plate 20.5 μL of IMAP™ binding reagent stock, 1476 μL of 1x binding buffer A 
(60%), and 984 μL of binding buffer B (40%) (IMAP™ FP Progressive screening express 
kit (Molecular Devices R8127) was added to 9819.5 μL of milliQ H2O. 
Assay Procedure 
1 μL of compound (in 60:40 H2O/DMSO) or 60:40 H2O/DMSO (for controls and blanks) 
were dry-spotted into the relevant wells of a 384-well assay plate using the MATRIX 
PlateMate Plus. 5 μL of ERK5 working solution was added to test and control wells, and 
5 μL of 1x assay buffer added to blanks; 4 μL of ATP/substrate working solution was 
added to all wells using a Matrix multichannel pipette. The plate was sealed using DMSO 
resistant 205 clear seal and incubated for 2 h at 37 C. 1 μL of the kinase reaction mixture 
from the first plate was dry spotted into a second 384-well assay plate using the MATRIX 
PlateMate Plus. 9 μL of assay buffer was added, followed by 30 μL of IMAP™ binding 
solution using a multichannel pipette. The plate was incubated at RT in darkness for 2 h. 
The assay plate was then read on an Analyst HT plate reader (Molecular Devices) using 
the settings described below; 
Measurement mode = Fluorescence polarisation; Method ID = ERK5; Integration time = 
100 ms; Excitation filter = Fluorescein 485-20; Emission filter = 530-25; Dichroic mirror = 
505 nm; Plate definition file = Corning 384 black fb; Z-height = 5.715 mm (middle); G-
factor = 1; Attenuator = out; Detector counting = Smartread+; Sensitivity = 2. 
 
p38α LANCE Assay Protocol 
 
Preparation of Assay Buffer (1x) 
1x assay buffer was prepared freshly in house, consisting of the following reagents; 250 
mM tris(hydroxymethyl)aminomethane (Tris) pH 7.5, 25 mM MgCl2, 2.5 mM ethylene 
glycol tetraacetic acid (EGTA), 10 mM dithiothreitol (DTT) and 0.05% Triton X100 in 
milliQ H2O (NB: 1x buffer final assay concentrations were 5x lower than stated above). 
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Preparation of p38α/SAPK2 Working Solution 
The p38α/SAPK2, active N-terminal GST-tagged recombinant full length protein 
(Millipore 14-251) was supplied as a 10 μg/4 μL stock. This was diluted to a 10 μg/40 μL 
(1 μM) concentration by addition of 156 μL of Tris/HCl (pH 7.5, 50 mM), NaCl (150 
mM), EGTA (0.1 mM), Brij-35 surfactant (0.03%), glycerol (50%) and 0.1% 2-
mercaptoethanol (0.1%). The final dilution was dependent on activity of the enzyme 
batches. The p38α concentration used in the assay was 1 nM. A 2x working stock solution 
(2 nM, 500 fold dilution of 1 μM stock) in 1x assay buffer was prepared. For one plate, 9.4 
μL of p38α (1 μM) was added to 1870.6 μL of milliQ H2O. 
Preparation of ATP/Substrate working solution 
For one plate, ATP disodium salt (17.5 μL, 200 mM stock), (Sigma A7699) and Ulight-
MBP Peptide (50 μL, 5 μM stock) (Perkin Elmer TRF0109) was added to 400 μL of 5x 
assay buffer and 1532.5 μL of milliQ H2O. 
Preparation of EDTA/Antibody Detection Reagent  
For one plate, 84 μL of ethylenediaminetetraacetic acid (EDTA) (0.5 M) (Sigma E4378-
100G) and 27 μL of Europium-anti-phospho-MBP antibody (0.625 μM) (Perkin Elmer) 
was added to 420 μL of LANCE detection buffer (1x) and 3669 of milliQ H2O.  
 
Assay Procedure  
1 μL of compound (in 80:20 H2O/DMSO) or 80:20 H2O/DMSO was dry-spotted into the 
relevant wells of a 384-well assay plate using the MATRIX PlateMate Plus. 5 μL of 
p38α working solution was added to test and control wells, and 5 μL of assay buffer added 
to blanks; 4 μL of ATP/substrate working solution was added to all wells using a Thermo 
Multidrop Combi or Matrix multichannel pipette. The plate was sealed using DMSO 
resistant clear seal and incubated for 1 h at 37 C. 10 μL of the EDTA/antibody working 
solution was added to all wells using a Thermo Multidrop Combi or Matrix multichannel 
pipette. The plate was incubated at RT in darkness for 2 h. The assay plate was then read 
on a PheraStar microplate reader using the settings described below;  
Pherastar: Measurement mode = TRF; Method ID = LANCE HTRF ERK5; Optic Module: 
337, 665, 620 nm. Focal Height = 6.0, Positioning delay, 0.1 sec, Number of flashes per 
well = 100, Integration start = 60 
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Hela cell-based densitometry assay protocol 
 
HeLa cells were serum starved overnight followed by treatment with ERK5 inhibitors for 1 
hr. Cells were then stimulated with 100ng/ml EGF for 10 min. The cells were harvested 
and lysed at 4 
o
C for 5-10 min in Laemmli buffer containing Halt protease and phosphate 
inhibitors (Pierce). The lysates were boiled for 10 min at 100 
o
C. A twenty microliter 
sample was run on a 6% tris-glycine gel and transferred to nitrocellulose. Western blotting 
was done with ERK5 antibody (Cell signalling #3372S). The IC50 was calculated from 
densitometry of the top (phosphor-ERK) bands. 
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10.4.2 ERK5 General Synthetic Procedures 
 
A number of compounds were prepared using the general procedures reported below. 
Quantities used and variations are recorded before the analytical data for each compound. 
General procedure D: CDI amide coupling 
Carbonyl diimidazole (CDI, 2 eq.) was added to a solution of the relevant carboxylic acid 
in THF (2 mL/mmol) and the mixture heated to 70 C for 3 h. The relevant amine (2.5 eq.) 
was added and the mixture was heated at 70 C for 2 h. The mixture was partitioned 
between EtOAc (2 × 20 mL) and saturated NaHCO3(aq.). The organic layers were 
combined, washed with brine (20 mL), dried over MgSO4 and solvent removed in vacuo.  
General procedure E: Cyanuric fluoride amide coupling 
Cyanuric fluoride (0.7 eq.) was added to the relevant carboxylic acid (1 eq.) and pyridine 
(1 eq.) in MeCN (2 mL/mmol). The relevant amine (2.5 eq.) was added and the mixture 
was stirred at r.t. for 18 h. The reaction was diluted with EtOAc, washed with water and 
0.5 M aqueous HCl, followed by further washes with saturated aqueous NaHCO3 and 
brine. The organic layer was dried over MgSO4 and the solvent removed in vacuo.  
 General procedure F: PCl3 amide coupling349 
The relevant carboxylic acid (1 eq.), the relevant amine (2.5 eq.) and PCl3 (1 eq.) were 
combined in MeCN (4 mL/mmol) and heated under microwave irradiation to 100 C for 30 
min. The mixture was allowed to cool, 2 M NaOH(aq) (20 mL) was added, the mixture was 
stirred for 10 min, and then extracted with EtOAc (3 × 20 mL). The organic layers were 
combined, washed with brine, dried over MgSO4 and the solvent removed in vacuo.  
General procedure G: Boc deprotection in TFA/CH2Cl2 
TFA (2 mL/mmol) and Et3SiH (2.5 eq.) were added to the relevant carbamate (1 eq.) in 
DCM (2 mL/mmol) and the mixture was stirred at r.t. for 2 h. The solvent was removed in 
vacuo, the residues partitioned between EtOAc (5 × 30 mL) and NaHCO3(aq) (40 mL). The 
organic extracts were combined, dried over MgSO4, and the solvent removed in vacuo. 
General procedure H: Hydrogenation of heteroaromatic nitro group 
The relevant nitro compound (1 eq.) was dissolved in MeOH (5 mL/mmol) and 
hydrogenated on a Thales H-cube over 10% Pd/C on full H2 mode at 40 C for 2 h with 
continuous recycling of the reaction mixture. The solvent was removed in vacuo. 
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 General procedure I: Amine displacement of 4-nitro-2-chloropyrimidine 
 
The relevant amine (1 eq.), 2-chloro-5-nitropyrimidine (1 eq.), and Et3N (1.1 eq.) were 
combined in THF (5 mL/mmol) at 0 C, and the mixture allowed to stir at r.t. for 1 h. The 
solvent was removed in vacuo, and the residue partitioned between EtOAc (2 × 30 mL) 
and water (20 mL). The organic layer washed with brine, dried over MgSO4 and the 
solvent removed in vacuo.  
General procedure J: Mitsunobu alkylation of 4-nitropyrazole 
 
Diethylazodicarboxylate (1.5 eq.) was added dropwise to a mixture of 4-nitropyrazole (1 
eq.), triphenylphosphine (1.73 g, 6.63 mmol, 1.5 eq.) and the substrate alcohol (1 eq.), in 
THF at 0 C. The mixture was stirred at 0 C for 10 min, and then allowed to stir at r.t. for 
18 h. The mixture was partitioned between EtOAc (2 × 30 mL) and water (20 mL), washed 
with brine (20 mL), dried over MgSO4 and the solvent removed in vacuo.  
General procedure K: Eschweiler-Clarke conversion of a Boc protected amine to a 
methylamine  
 
Formaldehyde (37% w/v aqueous, 4 eq.) was added to the substrate carbamate (1 eq.) in 
formic acid (10 mL/mmol), and the mixture was heated to 100 C for 3 h in a sealed tube. 
The mixture was allowed to cool, basified with 10% K2CO3(aq), and extracted with EtOAc 
(2 × 20 mL). The organic extracts were combined, washed with brine, dried over MgSO4, 
and the solvent removed in vacuo.  
General procedure L: Amide coupling with 2-chloro-1-methylpyridinium iodide 
 
Pyrrole acid (1 eq.), Et3N (2.5 eq.), and 2-chloro-1-methylpyridinium iodide (1.1 eq.) were 
combined in DCM (15 mL/mmol) and stirred at r.t. for 10 min, followed by the addition of 
the substrate amine (1.25 eq.) in DCM (2.5 mL/mmol). The reaction was stirred at r.t. for 
18 h, the solvent evaporated, and the mixture partitioned between EtOAc (2 × 15 mL) and 
10% aqueous K2CO3 (15 mL). The organic layers were combined, washed with brine, dried 
over MgSO4 and the solvent removed in vacuo.  
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10.4.3 ERK5 Synthetic Procedures 
 
Methyl 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (334) 
430-199 
To a suspension of AlCl3 (2.23 g, 16.8 mmol, 2.5 eq.) in DCM (17 mL) at 0 C was added 
2-chloro-6-fluorobenzoyl chloride (1.8 mL, 13.3 mmol, 2 eq.). The mixture was stirred at 0 
C for 10 min, and then methyl-1H-pyrrole-2-carboxylate (847 mg, 6.7 mmol, 1 eq.) was 
added. The mixture was stirred at r.t. for 18 h, cooled to 0 C and HCl (1 M aqueous) was 
added until gas evolution ceased. Rochelle’s salt (50 mL, saturated aq.) was added and the 
mixture was stirred at r.t. for 45 min. The mixture was extracted with DCM (3 × 100 mL), 
the organic layers combined, washed with NaHCO3(100 mL, 10% aq.) and brine (100 mL), 
dried over MgSO4, and solvent removed in vacuo. The residue was purified by MPLC on 
SiO2 with a gradient elution from 0-100% EtOAc/petrol to give a white solid (1.74 g, 
92%); Rf 0.5 (5% MeOH/DCM); m.p. 148-150 C; max(EtOH)/nm 280, 233; IR  max/cm
-1
 
3226, 1731, 1638, 1604; 

H NMR (500 MHz; DMSO-d6) H 3.83 (3H, s, OMe), 7.02-7.05 
(1H, m, H-3), 7.42 (1H, app td, J = 8.2 and 0.8 Hz, H-5’), 7.49 (1H, d, J = 8.2 Hz, H-3’), 
7.57 (1H, dd, J = 1.7 and 3.3 Hz, H-5), 7.61 (1H, td, J = 8.2 and 6.3 Hz, H-4’), 12.94 (1H, 
br s, NH); 

F NMR (470 MHz; DMSO-d6) F -114.43; 

C NMR (125 MHz; DMSO-d6) C 
51.7 (OMe), 114.6 (CH-pyrrole), 115.0 (d, JCF = 21.8 Hz, C-5’), 124.5 (C-pyrrole), 125.4 
(C-pyrrole), 125.9 (d, JCF = 3.2 Hz, C-3’), 127.7 (d, JCF = 23.2 Hz, C-1’), 130.1 (C-
pyrrole), 130.3 (d, JCF = 6.4 Hz, C-2’), 131.9 (d, JCF = 9.1 Hz, C-4’), 158.5 (d, JCF = 246.9 
Hz, C-6’), 160.3 (CO-NH), 183.7 (CO); HRMS calcd for C13H10
35
Cl1F1O3N1 [M+H]
+ 
282.0328, found 282.0333. 
4-(2-Chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (336) 
430-203 
A solution of LiOH (2.9 g, 121 mmol, 20 eq.) in H2O (80 mL) was added to ester 334 (1.7 
g, 6.05 mmol, 1 eq.) in THF (48 mL) and heated to 65 C for 18 h. After cooling to r.t., the 
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mixture was acidified to pH 3 with HCl (1 M aq.) and extracted with EtOAc (2 × 150 mL). 
The combined organic layers were washed with water and brine, dried over MgSO4, and 
the solvent removed in vacuo to give a white solid (1.6 g, 99%); Rf 0.15 (10% 
MeOH/DCM); m.p. 220-222 C; max(EtOH)/nm 281, 232; IR  max/cm
-1
 3313, 1637, 1553; 

H NMR (500 MHz; DMSO-d6) H 6.98 (1H, br s, H-pyrrole), 7.42 (td, J = 8.2 and 0.6 Hz, 
H-5’), 7.47-7.51 (2H, m, H-3’ and H-pyrrole), 7.61 (1H, td, J = 8.2 and 6.3 Hz, H-4’), 
12.75 (1H, br s, NH-pyrrole), 12.97 (1H, br s, CO2H); 

F NMR (470 MHz; DMSO-d6) 
F -114.41; 

C NMR (125 MHz; DMSO-d6) C 114.1 (CH-pyrrole), 114.9 (d, JCF = 21.3 
Hz, C-5’), 125.3 (C-pyrrole), 125.8 (d, JCF = 3.2 Hz, C-3’), 125.9 (C-pyrrole), 127.8 (C-
pyrrole), 127.9 (d, JCF = 23.2 Hz, C-1’), 129.7 (C-pyrrole), 130.3 (d, JCF = 6.0 Hz, C-2’), 
131.8 (d, JCF = 9.1 Hz, C-4’), 158.5 (d, JCF = 247 Hz, C-6’), 161.3 (CO-NH), 183.7 (CO); 
HRMS calcd for C12H6
35
Cl1F1N1O3 [M+H]
+
 266.0026, found 266.0018. 
Methyl 4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylate (335) 
451-240 
To a suspension of AlCl3 (11.9 g, 89.6 mmol, 2.5 eq.) in DCM (100 mL) at 0 C was added 
3,6-dichloro-2-fluorobenzoyl chloride (16.3 mL, 71.7 mmol, 2 eq.). The mixture was 
stirred at 0 C for 10 min, and then methyl-1H-pyrrole-2-carboxylate (4.48 g, 35.8 mmol, 1 
eq.) was added. The mixture was stirred at r.t. for 18 h, cooled to 0 C and HCl (1 M aq.) 
added until gas evolution ceased. Rochelle’s salt (sat’d aq., 200 mL) was added and the 
mixture stirred at r.t. for 45 min. The mixture was extracted with DCM (4 × 150 mL), the 
organic layers combined, dried over MgSO4, and solvent removed in vacuo. The residue 
was purified by MPLC on SiO2 with a gradient elution from 0-65% EtOAc/petrol to give a 
white solid (10.12 g, 89%); Rf 0.8 (50/50/0.5 EtOAc/petrol/AcOH); m.p. 136-138 C; 
max(EtOH)/nm 282, 229; IR  max/cm
-1
 3285, 3230, 1689, 1654; H NMR (500 MHz; 
DMSO-d6) H 3.84 (3H, s, CH3), 7.12 (1H, app t, J = 1.5 Hz, H-pyrrole), 7.53 (1H, dd, J = 
0.9 and 8.5 Hz, H-5’), 7.71 (1H, dd, J = 1.5 and 3.2 Hz, H-pyrrole), 7.80 (1H, app t, J = 8.5 
Hz, H-4’), 12.98 (1H, s, NH-pyrrole); F NMR (470 MHz; DMSO-d6) F -116.69; 

C 
NMR (125 MHz; DMSO-d6) C 51.7 (CH3), 114.6 (CH-pyrrole), 119.4 (d, JCF = 18.1 Hz, 
C-3’), 124.8 (C-pyrrole), 124.9 (C-pyrrole), 126.8 (d, JCF = 4.1 Hz, C-5’), 128.9 (d, JCF = 
294 
 
22.7 Hz, C-1’), 129.1 (d, JCF = 5.2 Hz, C-6’), 131.0 (C-pyrrole), 131.9 (C-4’), 153.8 (d, JCF 
= 248.5 Hz, C-2’), 160.3 (CO2Me), 182.5 (CO); MS (ES+) m/z 314.2 [M(
35
Cl)+H]
+
, 316.1 
[M(
37
Cl)+H]
+
. 
4-(3,6-Dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (337) 
451-241 
A solution of LiOH (26.6 g, 632 mmol, 20 eq.) in H2O (140 mL) was added to ester 335 
(10.0 g, 31.6 mmol, 1 eq.) in THF (180 mL) and heated to 65 C for 48 h. After cooling to 
r.t., the mixture was acidified to pH 3 with HCl (1 M aq.) and extracted with EtOAc (2 × 
300 mL). The combined organic layers were washed with water and brine, dried over 
MgSO4, and the solvent removed in vacuo to give a white solid (9.0 g, 95%); Rf 0.25 
(50/50/0.5 EtOAc/petrol/AcOH); m.p. 230-232 C; max(EtOH)/nm 289, 267; IR  max/cm
-1
 
3264br, 1697, 1646; 

H NMR (500 MHz; DMSO-d6) H 7.07 (1H, app t, J = 1.6 Hz, H-
pyrrole), 7.53 (1H, dd, J = 1.1 and 8.6 Hz, H-5’), 7.71 (1H, dd, J = 1.6 and 3.2 Hz, H-
pyrrole), 7.80 (1H, app t, J = 8.6 Hz, H-4’), 12.81 (1H, br s, NH-pyrrole), 13.00 (1H, br s, 
CO2H); 

F NMR (470 MHz; DMSO-d6) F -116.71; 

C NMR (125 MHz; DMSO-d6) C 
114.1 (CH-pyrrole), 119.3 (d, JCF = 18.1 Hz, C-3’), 124.8 (C-pyrrole), 126.1 (C-pyrrole), 
126.8 (d, JCF = 3.6 Hz, C-5’), 129.0 (d, JCF = 23.3 Hz, C-1’), 129.1 (d, JCF = 5.5 Hz, C-6’), 
130.6 (C-pyrrole), 131.9 (C-4’), 153.8 (d, JCF = 248.4 Hz, C-2’), 161.3 (CO2H), 182.5 
(CO); MS (ES+) m/z 302.1 [M(
35
Cl)+H]
+
, 304.1 [M(
37
Cl)+H]
+
.  
4-(2-Chloro-6-fluorobenzoyl)-N-(1-isopropylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide (253) 
430-198 
Prepared according to general procedure D using carboxylic acid 336 (100 mg, 0.37 mmol, 
1 eq.), CDI (121 mg, 0.75 mmol, 2 eq.), Et3N (57 L, 0.41 mmol, 1.1 eq.) and 1-
isopropylpiperidin-4-amine dihydrochloride (200 mg, 0.93 mmol, 2.5 eq.) in THF (2 mL). 
Purification by MPLC on aminopropyl SiO2 with a gradient elution from 0-3% 
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MeOH/DCM to give a white solid (88 mg, 60%); Rf 0.8 (5% MeOH/DCM, NH2 silica); 
m.p. 225 C dec.; max(EtOH)/nm 285, 236; IR  max/cm
-1
 3347, 3122, 2966, 2865, 1617, 
1570; 

H NMR (500 MHz; DMSO-d6) H 0.99 (6H, d, J = 6.5 Hz, 2 × Me), 1.49 (2H, ddd, 
J = 3.6 Hz, 12.1 Hz, and 15.5 Hz, 2 × H-piperidine), 1.75-1.83 (2H, m, 2 × H-piperidine), 
2.14-2.22 (2H, m, 2 × CH-N-piperidine), 2.72 (1H, sept, J = 6.5 Hz, CH(Me)2), 2.77-2.84 
(2H, m, 2 × CH-N-piperidine), 3.64-3.75 (1H, m, CO-NH-CH), 7.23 (1H, br s, H-3), 7.35 
(1H, br s, H-5), 7.39-7.45 (1H, app t, J = 8.2 Hz, H-5’), 7.49 (1H, d, J = 8.2 Hz, H-3’), 
7.60 (1H, td, J = 8.2 and 6.3 Hz, H-4’), 8.13 (1H, d, J = 8.0 Hz, CO-NH), 12.43 (1H, br s, 
NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.42; 

C NMR (125 MHz; DMSO-
d6) C 18.0 (2 × CH3), 32.0 (2 × CH2-piperidine), 47.2 (2 × CH2-piperidine), 53.6 
(CH(Me)2), 109.9 (C-pyrrole), 114.9 (d, JCF = 21.7 Hz, C-5’), 124.9 (C-pyrrole), 125.8 (d, 
JCF = 3.2 Hz, C-3’), 128.2 (d, JCF = 23.4 Hz, C-1’), 128.4 (C-pyrrole), 129.0 (C-pyrrole), 
130.4 (d, JCF = 6.1 Hz, C-2’), 131.7 (d, JCF = 9.1 Hz, C-4’), 158.5 (d, JCF = 248.8 Hz, C-
6’), 159.0 (CO-NH), 183.9 (CO); MS (ES+) m/z 392.4 [M(35Cl)+H]+, 394.4 [M(37Cl)+H]+; 
HRMS calcd for C20H24
35
Cl1F1N3O2 [M+H]
+
 392.1536, found 392.1540. 
4-(2-Chloro-6-fluorobenzoyl)-N-(1-cyclopropylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide (254) 
 
Prepared according to general procedure D using carboxylic acid 336 (95 mg, 0.36 mmol, 
1 eq.), CDI (115 mg, 0.71 mmol, 2 eq.), 1-cyclopropylpiperidin-4-amine (125 mg, 0.81 
mmol, 2.5 eq.) and THF (3 mL). Purification by MPLC on NH2 SiO2 with a gradient 
elution from 0-3% MeOH/CH2Cl2 gave a white solid (72 mg, 52%); Rf 0.25 (NH2 SiO2, 
2% MeOH/CH2Cl2); m.p. 247-249 C; max(EtOH)/nm 284, 238; IR  max/cm
-1
 3343, 3122, 
2944, 1619, 1571; 

H NMR(500 MHz; DMSO-d6) H 0.29-0.33 (2H, 2 × H-cyclopropyl), 
0.41-0.46 (2H, 2 × H-cyclopropyl), 1.40-1.51 (2H, m, 2 × H-piperidine), 1.60-1.65 (1H, m, 
cyclopropyl-CH-N), 1.72-1.80 (2H, m, 2 × H-piperidine), 2.20-2.30 (2H, m, 2 × CH-N-
piperidine), 2.92-3.00 (2H, m, 2 × CH-N-piperidine), 3.68-3.80 (1H, m, CH-NH-
piperidine), 7.23 (1H, s, H-3), 7.34 (1H, s, H-5), 7.38-7.44 (1H, m, H-5’), 7.48 (1H, d, J = 
8.0 Hz, H-3’), 7.60 (1H, td, J = 8.0 and 6.3 Hz, H-4’), 8.10 (1H, d, J = 7.9 Hz, CO-NH), 
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12.42 (1H, s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.42; 

C NMR (125 
MHz; DMSO-d6) C 5.9 (2 × CH2-cPr), 31.5 (2 × CH2-piperidine), 38.0 (CH-cPr), 46.6 
(CH-NH-piperidine), 52.3 (2 × CH2-N-piperidine), 109.9 (CH-pyrrole), 114.9 (d, JCF = 
21.3 Hz, C-5’), 124.9 (C-pyrrole), 125.8 (d, JCF = 3.2 Hz, C-3’), 128.1 (C-pyrrole), 128.2 
(d, JCF = 23.2 Hz, C-1’), 128.9 (CH-pyrrole), 130.4 (d, JCF = 6.1 Hz, C-2’), 131.7 (d, JCF = 
9.1 Hz, C-4’), 158.52 (d, JCF = 247 Hz, C-6’), 159.02 (CO-NH), 183.87 (CO); MS (ES+) 
m/z 390.4 [M(
35
Cl)+H]
+
, 392.4 [M(
37
Cl)+H]
+
; HRMS calcd for C20H22
35
Cl1F1N3O2 
[M+H]
+
 390.1379, found 390.1379. 
tert-Butyl 4-(4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
piperidine-1-carboxylate (258) 
430-200 
Prepared according to general procedure D using carboxylic acid 336 (500 mg, 1.87 mmol, 
1 eq.), CDI (607 mg, 3.75 mmol, 2 eq.), tert-butyl-4-aminopiperidine-1-carboxylate (800 
mg, 4.00 mmol, 2.15 eq.) and THF (10 mL). Purification by MPLC on SiO2 with a gradient 
elution from 30-80% EtOAc/petrol gave a white solid (631 mg, 75%); Rf 0.4 (5% 
MeOH/DCM); m.p. 150-155 C dec.; max(EtOH)/nm 284, 238; IR  max/cm
-1
 3188, 2971, 
2864, 1689, 1619, 1569.6; 

H NMR (500 MHz; DMSO-d6) H 1.30-1.47 (2H, m, 2 × H-
piperidine), 1.44 (9H, s, tBu), 1.79 (2H, dd, J = 3.2 and 12.5 Hz, 2 × H-piperidine), 2.87 
(2H, br s, 2 × CH-N-piperidine), 3.89-4.02 (3H, m, 3 × CH-N-piperidine), 7.22 (1H, br s, 
H-3), 7.36 (1H, br s, H-5), 7.39-7.45 (1H, app t, J = 8.1 Hz, H-5’), 7.49 (1H, d, J = 8.1 Hz, 
H-3’), 7.60 (1H, td, J = 8.1 and 6.3 Hz, H-4’), 8.17 (1H, d, J = 7.9 Hz, CO-NH), 12.47 
(1H, br s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.42; 

C NMR (125 MHz; 
DMSO-d6) C 28.0 (C(CH3)3), 31.4 (2 × CH2-piperidine), 45.9 (2 × CH2-piperidine), 78.6 
(C(CH3)3), 109.9 (CH-pyrrole), 114.9 (d, JCF = 21.8 Hz, C-5’), 125.0 (C-pyrrole), 125.8 (d, 
JCF = 3.1 Hz, C-3’), 128.1 (d, JCF = 23.1 Hz, C-1’), 128.1 (C-pyrrole), 128.8 (CH-pyrrole), 
130.4 (d, JCF = 6.0 Hz, C-2’), 131.7 (d, JCF = 9.0 Hz, C-4’), 153.9 (CO-NH), 158.3 (d, JCF 
= 246 Hz, C-6’), 183.9 (CO); MS (ES-) m/z 448.4 [M(35Cl)-H]-, 450.4 [M(37Cl)-H]-; 
HRMS calcd for C22H24
35
Cl1F1N3O4 [M+H]
+
 448.1445, found 448.1435. 
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4-(2-Chloro-6-fluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide 
(251) 
 
Prepared according to general procedure G using TFA (8 mL), CH2Cl2 (8 mL), Et3SiH 
(533 L, 3.34 mmol, 2.25 eq.) and carbamate 258 (600 mg, 1.33 mmol, 1 eq.) to give a 
white solid (460 mg, 99%); Rf 0.5 (10% MeOH/DCM, NH2 silica); m.p. 160 C dec.; 
max(EtOH)/nm 282, 230; IR  max/cm
-1
 2964 br, 1626, 1568; 

H NMR(500 MHz; DMSO-
d6) H 1.59-1.71 (2H, m, 2 × H-piperidine), 1.91-1.99 (2H, m, 2 × H-piperidine), 2.93-3.04 
(2H, m, 2 × CH-N-piperidine), 3.25-3.34 (2H, m, 2 × CH-N-piperidine), 3.96-4.07 (1H, m, 
CO-NH-CH), 7.28 (1H, br s, H-3), 7.36 (1H, br s, H-5), 7.39-7.45 (1H, app t, J = 8.1 Hz, 
H-5’), 7.49 (1H, d, J = 8.1 Hz, H-3’), 7.60 (1H, td, J = 8.1 and 6.3 Hz, H-4’), 8.00 (1H, br 
s, NH), 8.30 (1H, d, J = 7.6 Hz, CO-NH), 12.47 (1H, br s, NH-pyrrole); 

F NMR (470 
MHz; DMSO-d6) F -114.44; 

C NMR (125 MHz; DMSO-d6) C 29.0 (C-piperidine), 42.7 
(C-piperidine), 44.2 (C-piperidine), 110.0 (CH-pyrrole), 114.9 (d, JCF = 21.6 Hz, C-5’), 
125.0 (C-pyrrole), 125.8 (d, JCF = 2.7 Hz, C-3’), 128.1 (C-1’), 128.4 (C-pyrrole), 128.6 (C-
pyrrole), 130.4 (d, JCF = 6.4 Hz, C-2’), 131.7 (d, JCF = 9.3 Hz, C-4’), 159.2 (d, JCF = 247.5 
Hz, C-6’), 158.9 (CO-NH), 183.85 (CO); MS (ES+) m/z 350.4 [M(35Cl)+H]+, 352.4 
[M(
37
Cl)+H]
+
; HRMS calcd for C17H18
35
Cl1F1O2N3 [M+H]
+
 350.1066, found 350.1072. 
4-(2-Chloro-6-fluorobenzoyl)-N-(1-ethylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide (252) 
451-221 
Amine 251 (120 mg, 0.34 mmol, 1 eq.), acetaladehyde (39 L, 0.69 mmol, 2 eq.), acetic 
acid (39 L, 0.69 mmol, 2 eq.) and MgSO4 (150 mg) were combined in MeOH (3 mL) and 
stirred at r.t. for 1 h. Sodium cyanoborohydride (32 mg, 0.51 mmol, 1.5 eq) was added and 
the mixture was stirred at r.t. for 18 h. The reaction was quenched with water, basified with 
NaHCO3 (10% aq.) and extracted with CH2Cl2 (2 × 15 mL). The organic layers were 
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combined, dried over MgSO4, and the solvent removed in vacuo. The residue was purified 
by MPLC on SiO2 with a gradient elution from 95/5/0/5 to 86/14/1.4 
CH2Cl2/MeOH/NH4OH to give a white solid (21 mg, 16%). Rf 0.15 (90/10/1 
CH2Cl2/MeOH/NH4OH); m.p. 258-260 C dec.; max(EtOH)/nm 287, 237; IR  max/cm
-1
 
3119, 2964, 2815, 1645, 1606, 1571; 

H NMR (500 MHz; DMSO-d6) H 1.02 (3H, t, J = 
7.1 Hz, N-CH2CH3), 1.52 (2H, app qd, J = 11.8 and 3.3Hz, 2 × H-piperidine), 1.74-1.81 
(2H, m, 2 × H-piperidine), 1.90-1.97 (2H, m, 2 × CH-N-piperidine), 2.34 (2H, q, J = 7.1 
Hz, N-CH2CH3), 2.85-2.92 (2H, m, 2 × CH-N-piperidine), 3.67-3.77 (1H, m, CH-NH-
piperidine), 7.23 (br s, H-3), 7.35 (br s, H-5), 7.39-7.44 (1H, app t, J = 8.2 , H-5’), 7.49 
(1H, d, J = 8.2 Hz, H-3’), 7.60 (1H, td, J = 8.2 and 6.3 Hz, H-4’), 8.14 (1H, d, J = 7.7 Hz, 
CO-NH), 12.43 (1H, s, NH pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.42; 

C 
NMR (125 MHz; DMSO-d6) C 12.3 (CH3), 31.6 (2 × CH2 piperidine), 46.6 (CH-NH-
piperidine), 51.6 (2 × CH2-N- piperidine), 51.9 (N-CH2CH3), 109.9 (CH-pyrrole), 114.9 (d, 
JCF = 21.5 Hz, C-5’), 124.9 (C-pyrrole), 125.8 (d, JCF = 2.8 Hz, C-3’), 128.1 (C-1’), 128.2 
(C-pyrrole), 128.9 (CH-pyrrole), 130.4 (JCF = 6.2 Hz, C-2’), 131.7 (JCF = 9.1 Hz, C-4’), 
158.5 (d, JCF = 247 Hz, C-6’), 159.0 (CO-NH), 183.9 (CO); MS (ES+) m/z 378.4 
[M(
35
Cl)+H]
+
, 380.4 [M(
37
Cl)+H]
+
; HRMS calcd for C19H22
35
Cl1F1N3O2 [M+H]
+
 
378.1379, found 378.1388. 
N-(1-Acetylpiperidin-4-yl)-4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-
carboxamide (255) 
 
Acetyl chloride (17 L, 0.24 mmol, 1.1 eq.) was added to amine 251 (75 mg, 0.21 mmol, 1 
eq.) and Et3N (36 L, 0.26 mmol, 1.2 eq.) in DCM (2 mL) at r.t. and the mixture was 
stirred at r.t. for 30 min. Methanol was added and the solvent removed in vacuo. The 
residue was partitioned between EtOAc (2 × 20 mL) and H2O (10 mL), washed with brine 
(10 mL), dried over MgSO4, and the solvent removed in vacuo. The residue was purified 
by MPLC on SiO2 with a gradient elution from 0-5% MeOH/DCM to give a white solid 
(40 mg, 48 %); Rf 0.2 (3% MeOH/EtOAc); m.p. 257-259 C; max(EtOH)/nm 281, 236; IR 
 max/cm
-1
 3503, 3370, 1626, 1565; 

H NMR (500 MHz; DMSO-d6) H 1.29-1.50 (2H, m, 2 
× CH-piperidine), 1.77-1.90 (2H, m, 2 × CH-piperidine), 2.04 (3H, s, CH3), 2.70 (1H, app 
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td, J = 12.5 and 2.5 Hz, CH-N-piperidine), 3.16 (1H, app td, J = 12.5 and 2.5Hz, CH-N-
piperidine), 3.84 (1H, d, J = 13.6 Hz, CH-N-piperidine), 3.96-4.05 (1H, m, CH-NH-
piperidine), 4.35 (1H, d, J = 13.6 Hz, CH-N-piperidine), 7.23 (1H, br s, H-3), 7.37 (1H, br 
s, H-5), 7.39-7.44 (1H, app t, J = 8.2 Hz, H-5’), 7.49 (1H, d, J = 8.2 Hz, H-3’), 7.60 (1H, 
td, J = 8.2 and 6.3 Hz, H-4’), 8.19 (1H, d, J = 8.1 Hz, CO-NH), 12.48 (1H, br s, NH-
pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.42; 

C NMR (125 MHz; DMSO-d6) C 
21.2 (Me), 31.9 (2 × CH2-piperidine), 44.7 (2 × CH2-piperidine), 46.0 (CH-NH-
piperidine), 110.0 (C-pyrrole), 114.9 (d, JCF = 21.8 Hz, C-5’), 125.0 (C-pyrrole), 125.8 (JCF 
= 3.1 Hz, C-3’), 128.1 (d, JCF = 23.2 Hz, C-1’), 128.2 (C-pyrrole) 128.8 (CH-pyrrole), 
130.4 (d, JCF = 5.9 Hz, C-2’), 131.7 (d, JCF = 9.3 Hz, C-4’), 158.5 (d, JCF = 246.9 Hz, C-
6’), 159.0 (CO-NH), 168.0 (CO-N), 183.9 (CO); MS (ES+) m/z 392.4 [M(35Cl)+H]+, 394.4 
[M(
37
Cl)+H]
+
; HRMS calcd for C19H20
35
Cl1F1N3O2 [M+H]
+
 392.1172, found 392.1174. 
4-(2-Chloro-6-fluorobenzoyl)-N-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrrole-
2-carboxamide (256) 
430-222 
Amine 251 (100 mg, 0.29 mmol), methanesulfonyl chloride (24 L, 0.32 mmol, 1.1 eq.) 
and triethylamine (48 L, 0.34 mmol, 1.2 eq.) were combined in CH2Cl2 (1 mL) and 
stirred at r.t. for 1 h. Further methanesulfonyl chloride (20 L, 0.27 mmol, 0.9 eq.) was 
added and the mixture was stirred for a further 30 min, quenched with water (5 mL) and 
extracted with CH2Cl2 (2 × 10 mL). The organic extracts were combined, washed with HCl 
(10 mL, 1 M aq.), dried over MgSO4, and the solvent removed in vacuo. The residue was 
purified by MPLC on SiO2 with a gradient elution from 40-100% EtOAc/petrol to give a 
white solid (33 mg, 27%). Rf 0.25 (EtOAc); m.p. 284-286 C; max(EtOH)/nm 285, 236; IR 
 max/cm
-1
 3240, 3191, 1657, 1622, 1567, 1325 (SO), 1148 (SO); 

H NMR (500 MHz; 
DMSO-d6) H 1.58 (1H, app qd, J = 11.7 and 4.1 Hz, 2 × H-piperidine), 1.87-1.96 (2H, m, 
2 × H-piperidine), 2.84-2.95 (4H, m, 2 × CH-N-piperidine, and CH3), 3.55-3.63 (2H, m, 2 
× CH-N-piperidine), 3.85-3.95 (1H, m, CH-NH-piperidine), 7.23 (1H, br s, H-3), 7.38 (1H, 
br s, H-5), 7.42 (1H app t, J = 8.2 Hz, H-5’), 7.48 (1H, d, J = 8.2 Hz, H-3’), 7.60 (1H, td, J 
= 8.2 and 6.5 Hz, H-4’), 8.25 (1H, d, J = 8.2 Hz, CO-NH), 12.46 (1H, br s, NH-pyrrole); 
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
F NMR (470 MHz; DMSO-d6) F -114.42; 

C NMR (125 MHz; DMSO-d6) C 30.8 (2 × 
CH2-piperidine), 34.2 (CH3), 44.7 (2 × CH2-N- piperidine), 45.4 (CH-NH-piperidine), 
110.0 (CH-pyrrole), 114.9 (d, JCF = 21.8 Hz, C-5’), 125.0 (C-pyrrole), 125.8 (d, JCF = 3.3 
Hz, C-3’), 128.1 (d, JCF = 23.1 Hz, C-1’), 128.2 (C-pyrrole), 128.7 (C-pyrrole), 130.4 (JCF 
= 6.1 Hz, C-2’), 131.7 (d, JCF = 8.9 Hz, C-4’), 158.5 (d, JCF = 246 Hz, C-6’), 159.1 (CO-
NH), 183.9 (CO); MS (ES+) m/z 428.3 [M(
35
Cl)+H]
+
, 430.4 [M(
37
Cl)+H]
+
; HRMS calcd 
for C18H20
35
Cl1F1N3O4S1 [M+H]
+ 
428.0842, found 428.0849. 
4-(2-Chloro-6-fluorobenzoyl)-N-(1-(pyrimidin-2-yl)piperidin-4-yl)-1H-pyrrole-
2-carboxamide (257) 
 
Amine 251 (70 mg, 0.20 mmol, 1 eq.), 2-chloropyrimidine (23 mg, 0.2 mmol, 1 eq.), 
Hunig’s base (42 L, 0.24 mmol, 1.2 eq.), and MeCN (1.5 mL) were combined and heated 
to 150 C for 90 min under microwave irradiation. The mixture was partitioned between 
EtOAc (2 × 20 mL) and citric acid (10 mL, 10% aq.). The organic layers were washed with 
sodium carbonate (10 mL, 10% aq.), dried over MgSO4 and the solvent removed in vacuo. 
The residue was purified by MPLC on SiO2 with a gradient elution from 50-100% 
EtOAc/petrol to give a white solid (20 mg, 23%); Rf 0.5 (10% MeOH/CH2Cl2); m.p. 235-
238 C; max(EtOH)/nm 287, 245; IR  max/cm
-1
 3372, 3191, 3118, 2926, 2853, 1629, 1588, 
1566; 

H NMR (500 MHz; DMSO-d6) H 1.45 (2H, qd, J = 12.1 and 4.1 Hz, 2 × H-
piperidine), 1.84-1.90 (2H, m, 2 × H-piperidine), 3.05 (2H, td, J = 12.1 and 2.4 Hz, 2 × H-
N-piperidine), 4.05-4.15 (1H, m, CH-NH-piperidine), 4.63-4.69 (2H, m, 2 × CH-N-
piperidine), 6.64 (1H, t, J = 4.7 Hz, H-pyrimidine), 7.20 (1H, br s, H-3), 7.35 (1H, br s, H-
5), 7.40 (1H, dd, J = 1.0 and 8.4 Hz, H-Ar), 7.48 (1H, d, J = 8.4 Hz, H-Ar), 7.59 (1H, td, J 
= 8.4 and 6.3 Hz, H-4’), 8.16 (1H, d, J = 7.9 Hz, CONH), 8.40 (2H, d, J = 4.7 Hz, 2 × H-
pyrimidine), 12.47 (1H, br s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.42; 

C NMR (125 MHz; DMSO-d6) C 31.1 (2 × CH-piperidine), 42.6 (2 × CH-N-piperidine), 
46.3 (CH-NH-piperidine), 109.0 (C-pyrimidine), 109.8 (CH-pyrrole), 114.9 (d, JCF = 21.8 
Hz, C-5’), 125.0 (C-pyrrole), 125.8 (d, JCF = 2.8 Hz, C-3’), 128.1 (d, JCF = 23.2 Hz, C-1’), 
128.3 (C-pyrrole), 128.9 (CH-pyrrole), 130.4 (d, JCF = 6.3 Hz, C-2’), 131.7 (d, JCF = 9.1 
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Hz, C-4’), 158.0 (2 × CH-pyrimidine), 158.5 (d, JCF = 246 Hz, C-6’), 159.0 (C-
pyrimidine), 161.7 (CO-NH), 183.9 (CO); MS (ES+) m/z 428.4 [M(
35
Cl)+H]
+
, 430.4 
[M(
37
Cl)+H]
+
; HRMS calcd for C21H20
35
Cl1F1N5O2 [M+H]
+
 428.1284, found 428.1290. 
tert-Butyl 4-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
piperidine-1-carboxylate (263) 
451-18 
Prepared according to general procedure D using carboxylic acid 337 (350 mg, 1.16 mmol, 
1 eq.), CDI (375 mg, 2.31 mmol, 2 eq.), 1-Boc-4-aminopiperidine (578 mg, 2.89 mmol, 2.5 
eq) and THF (6 mL). Purification by MPLC on SiO2 with a gradient elution from 0-5% 
MeOH/CH2Cl2 gave a white solid (440 mg, 79%); Rf 0.4 (2% MeOH/CH2Cl2); m.p. 221-
223 C; max(EtOH)/nm 285, 236; IR  max/cm
-1
 3367, 3179, 1698, 1625, 1569; 

H 
NMR(500 MHz; DMSO-d6) H 1.33-1.47 (11H, m, C(CH3)3 and 2 × H-piperidine), 1.80 
(2H, dd, J = 3.0 and 12.8 Hz, 2 × H-piperidine), 2.87 (2H, br s, 2 × CH-N-piperidine), 
3.89-4.01 (2H, m, 2 × CH-N-piperidine and CH-NH-piperidine), 7.25 (1H, br s, H-
pyrrole), 7.51 (1H, br s, H-pyrrole), 7.54 (1H, dd, J = 1.1 and 8.6 Hz, H-5’), 7.80 (1H, app 
t, J = 8.6 Hz, H-4’), 8.15 (1H, d, J = 8.0 Hz, CO-NH), 12.53 (1H, s, NH-pyrrole); F 
NMR (470 MHz; DMSO-d6) F -116.77; 

C NMR (125 MHz; DMSO-d6) C 28.1 
(C(CH3)3), 31.4 (2 × CH2-piperidine), 45.9 (CH-NH-piperidine), 78.6 (C(CH3)3), 109.8 (C-
3-pyrrole), 119.3 (d, J = 18.1 Hz, C-3’), 124.5 (C-2 pyrrole), 126.8 (d, JCF = 3.8 Hz, C-5’), 
128.7 (C-pyrrole), 129.0 (C-H pyrrole), 129.2 (d, JCF = 3.4 Hz, C-6’), 129.3 (d, JCF = 21.6 
Hz, C-1’), 131.7 (C-4’), 153.8 (d, JCF = 248.4 Hz, C-2’), 153.9 (CO-carbamate), 158.9 
(CO-NH), 182.5 (CO); MS (ES-) m/z 482.2 [M(
35,35
Cl)+H]
+
, 484.2 [M(
35,37
Cl)+H]
+
; 
HRMS calcd for C22H28
35
Cl2F1N4O4 [M+NH4]
+
 501.1466, found 501.1456. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide 
(260) 
 
Prepared according to general procedure G using carbamate 263 (415 mg, 0.86 mmol, 1 
eq.), Et3SiH (342 L, 2.14 mmol, 2.5 eq.) and CH2Cl2 (5 mL). Purification by MPLC on 
NH2 SiO2 with gradient elution from 0-10% MeOH/CH2Cl2 gave a white solid (247 mg, 
75%); Rf 0.3 (5% MeOH:CH2Cl2; NH2 SiO2); m.p. 225-230 C; max(EtOH)/nm 286, 236; 
IR  max/cm
-1
 3279, 2945, 1623, 1563; 

H NMR(500 MHz; DMSO-d6) H 1.39 (2H, dq, J = 
3.8 and 12.0 Hz, 2 × H-piperidine), 1.74 (2H, dd, J = 2.5 and 12.0 Hz, 2 × H-piperidine), 
2.51 (2H, dd, J = 2.5 and 12.0 Hz, 2 × CH-piperidine), 2.94-3.01 (2H, m, 2 × H-
piperidine), 3.75-3.85 (1H, m, CH-NH-CO), 4.13 (1H, br s, NH), 7.27 (1H, br s, H-
pyrrole), 7.49 (1H, br s, H-pyrrole), 7.54 (1H, dd, J = 1.2 and 8.6 Hz, H-5’), 7.80 (1H, app 
t, J = 8.6 Hz, H-4’), 8.12 (1H, d, J = 8.0 Hz, CO-NH); F NMR (470 MHz; DMSO-d6) F 
-116.76; 

C NMR (125 MHz; DMSO-d6) C 33.0 (2 × CH2-piperidine), 45.2 (2 × CH2-N-
piperidine), 46.8 (CH-NH-CO), 109.8 (CH-pyrrole), 119.9 (d, JCF = 17.9 Hz, C-3’), 124.5 
(C-pyrrole), 126.8 (d, JCF = 4.1 Hz, C-5’), 129.0 (CH-pyrrole), 129.2 (d, JCF = 5.7 Hz, C-
6’), 129.3 (d, JCF = 22.9 Hz, C-1’), 129.4 (C-pyrrole), 131.7 (C-4’), 153.8 (d, JCF = 248 Hz, 
C-2’), 158.8 (CO-NH), 182.5 (CO); MS (ES-) m/z 382.1 [M(35,35Cl)+H]+, 383.8 
[M(
35,37
Cl)+H]
+
; HRMS calcd for C17H17
35
Cl2F1N3O2 [M+H]
+
 384.0676, found 384.0681. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-(methylsulfonyl) piperidin-4-yl)-1H-
pyrrole-2-carboxamide (262) 
 
Amine 260 (80 mg, 0.21 mmol, 1 eq.), methanesulfonyl chloride (24 L, 0.31 mmol, 1.5 
eq.) and Et3N (43 L, 0.31 mmol, 1.5 eq) were combined in CH2Cl2 (2 mL) and stirred at 
r.t. for 30 min. Further Et3N (1 eq) and methanesulfonyl chloride (1 eq.) were added and 
the mixture was stirred at r.t. for 1 h, quenched with ethanol, and partitioned between 
CH2Cl2 (3 × 20 mL) and water (10 mL). The organic extracts were combined, washed with 
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brine (10 mL), dried over MgSO4 and the solvent removed in vacuo. The residue was 
purified by MPLC on NH2 SiO2 with a gradient elution from 50-100% EtOAc:petrol to 
give a white solid (34 mg, 35%); Rf 0.25 (NH2 SiO2, 2% MeOH/CH2Cl2); m.p. 298 C 
dec.; max(EtOH)/nm 288, 234; IR  max/cm
-1
 3354, 3223, 1660, 1630, 1562, 1325, 1156; 

H NMR(500 MHz; DMSO-d6) H 1.58 (2H, app qd, J = 3.5 and 12.5 Hz, 2 × H-
piperidine), 1.92 (2H, app dd, J = 2.8 and 12.5 Hz, 2 × H-piperidine), 2.88 (2H, dd, J = 2.2 
and 12.5 Hz, 2 × CH-N-piperidine), 2.92 (3H, s, CH3), 3.56-3.63 (2H, m, 2 × CH-N-
piperidine), 3.86-3.96 (1H, m, CH-NH-piperidine), 7.27 (1H, s, H-pyrrole), 7.52 (1H, s, H-
pyrrole), 7.54 (1H, dd, J = 1.1 and 8.6 Hz, H-5’), 7.81 (1H, app t, J = 8.6 Hz, H-4’), 8.23 
(1H, d, J = 7.7 Hz, CO-NH), 12.55 (1H, s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) 
F -116.76; 

C NMR (125 MHz; DMSO-d6) C 30.9 (2 × CH2-piperidine), 34.3 (CH3), 
44.6 (2 × CH2-N-piperidine), 45.4 (CH-NH-piperidine), 109.9 (CH-pyrrole), 119.3 (d, JCF 
= 18.1 Hz, C-3’), 124.5 (C-pyrrole), 126.8 (d, JCF = 3.7 Hz, C-5’), 129.0 (C-6’), 129.1 
(CH-pyrrole), 129.2 (C-pyrrole), 129.3 (d, JCF = 18.9 Hz, C-1’), 131.8 (C-4’), 153.8 (d, JCF 
= 248.4 Hz, C-2’), 159.1 (CO-NH), 182.6 (CO); MS (ES-) m/z 460.2 [M(35,35Cl)+H]+, 
462.2 [M(
35,37
Cl)+H]
+
; HRMS calcd for C18H19
35
Cl2F1N3O4S [M+H]
+
 462.0452, found 
462.0448. 
N-(1-Acetylpiperidin-4-yl)-4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-
carboxamide (261) 
 
Amine 260 (75 mg, 0.2 mmol, 1 eq), acetyl chloride (15 L, 0.22 mmol, 1.1 eq.) and Et3N 
(33 L, 0.24 mmol, 1.2 eq) were combined in CH2Cl2 (2 mL), and stirred at r.t. for 1 h. 
Further Et3N (0.5 eq) and methanesulfonyl chloride (0.5 eq.) were added and the mixture 
was stirred at r.t. for 1 h, quenched with methanol, and partitioned between CH2Cl2 (20 
mL) and HCl (10 mL, 0.5 M aq.). The organic extract was washed with brine (10 mL), 
dried over MgSO4 and the solvent removed in vacuo. The residue was purified by MPLC 
on NH2 SiO2 with a gradient elution from 1-3% MeOH:CH2Cl2 to give a white solid (43 
mg, 52%); Rf 0.7 (NH2 SiO2, 5% MeOH/CH2Cl2); m.p. 253-255 C; max(EtOH)/nm 281, 
236; IR  max/cm
-1
 3179, 1677, 1624, 1571; 

H NMR(500 MHz; DMSO-d6) H 1.30-1.50 
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(2H, m, 2 × H-piperidine), 1.77-1.90 (2H, m, 2 × H-piperidine), 2.04 (3H, s, CH3), 2.71 
(1H, app td, J = 12.5 and 2.5 Hz, CH-N-piperidine), 3.12-3.20 (1H, m, CH-N-piperidine), 
3.81-3.88 (1H, m, CH-N-piperidine), 3.96-4.06 (1H, m, CH-NH-piperidine), 4.31-4.39 
(1H, m, CH-N-piperidine), 7.26 (1H, s, H-pyrrole), 7.51 (1H, s, H-pyrrole), 7.54 (1H, dd, J 
= 1.2 and 8.6 Hz, H-5’), 7.80 (1H, app t, J = 8.6 Hz, H-4’), 8.17 (1H, d, J = 7.9 Hz, CO-
NH), 12.54 (1H, s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -116.76; 

C NMR 
(125 MHz; DMSO-d6) C 21.2 (CH3), 31.2 (C-piperidine), 32.0 (C-piperidine), 39.8 (C-
piperidine), 44.7 (C-piperidine), 46.0 (C-piperidine), 109.9 (CH-pyrrole), 119.3 (d, JCF = 
18.0 Hz, C-3’), 124.5 (C-pyrrole), 128.8 (d, JCF= 3.6 Hz, C-5’), 129.0 (CH-pyrrole), 129.2 
(C-pyrrole), 129.2 (d, JCF = 5.0 Hz, C-6’), 129.3 (d, JCF = 20.0 Hz, C-1’), 131.7 (C-4’), 
153.8 (d, JCF = 248.4 Hz, C-2’), 159.0 (CO-NH), 168.0 (CO-N), 182.5 (CO); MS (ES-) m/z 
424.3 [M(
35,35
Cl)+H]
+
, 426.2 [M(
35,37
Cl)+H]
+
; HRMS calcd for C19H19
35
Cl2F1N3O3 
[M+H]
+
 426.0782, found 426.0773. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-(2,2,2-trifluoroacetyl) piperidin-4-yl)-
1H-pyrrole-2-carboxamide (269) 
451-132 
Trifluoroacetic anhydride (28 L, 0.3 mmol, 1.5 eq.) was added to a solution of amine 260 
(76 mg, 0.2 mmol, 1 eq.), and Et3N (31 L, 0.24 mol, 1.2 eq.) in CH2Cl2 (2 mL) and 
dioxane (2 mL) at 0 C. The mixture was stirred at r.t. for 2 h, before further trifluoroacetic 
anhydride (54 L, 0.6 mmol, 3 eq) and Et3N (52 L, 0.6 mmol, 2 eq.) were added. After 
stirring for 1 h at r.t. the reaction was partitioned between EtOAc (2 × 20 mL) and water 
(10 mL), the organic layers combined, washed with brine, dried over MgSO4 and the 
solvent removed in vacuo. The residue was purified by MPLC on SiO2 with gradient 
elution from 25-80% EtOAc/petrol to give a white solid (39 mg, 41%); Rf 0.1 (40% 
EtOAc/petrol); m.p. 200 C dec.; max(EtOH)/nm 285, 228; IR  max/cm
-1 
3357, 3165, 1690, 
1626, 1568; 

H NMR(500 MHz; DMSO-d6) H 1.43-1.58 (2H, m, 2 × H-piperidine), 1.92-
2.03 (2H, m, 2 × H-piperidine), 3.08-3.16 (1H, m, H-piperidine), 3.40-3.48 (1H, m, H-
piperidine), 3.86-3.94 (1H, m, H-piperidine), 4.09-4.19 (1H, m, H-piperidine), 4.25-4.33 
(1H, m, H-piperidine), 7.25 (1H, s, H-pyrrole), 7.50-7.57 (2H, m, H-pyrrole and H-5’), 
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7.81 (1H, app t, J = 8.4 Hz, H-4’), 8.21 (1H, d, J = 7.9 Hz, CO-NH), 12.57 (1H, s, NH-
pyrrole); 

F NMR (470 MHz; DMSO-d6) F -68.16, -116.77; 

C NMR (125 MHz; 
DMSO-d6) C 30.9 (C-piperidine), 31.8 (C-piperidine), 42.2 (C-piperidine), 44.2 (C-
piperidine), 45.2 (C-piperidine), 110.0 (CH-pyrrole), 116.4 (q, JCF = 284.4 Hz, CF3), 119.4 
(d, JCF = 18.4 Hz, C-3’), 124.5 (C-pyrrole), 126.8 (d, JCF = 3.7 Hz, C-5’), 128.9 (CH-
pyrrole), 129.1 (C-pyrrole), 129.2 (d, JCF = 5.0 Hz, C-6’), 129.3 (d, JCF = 23.3 Hz, C-1’), 
131.8 (C-4’), 15378 (d, JCF = 248.6 Hz, C-2’), 154.0 (q, JCF = 35.0 Hz, COCF3), 159.0 
(CO-NH), 182.6 (CO); HRMS calcd for C19H19
35
Cl2F4N4O3 [M+NH4]
+
 497.0765, found 
497.0758. 
5-Nitro-2-(pyrrolidin-1-yl)pyrimidine (339)350 
 
Prepared according to general procedure I using pyrrolidine (115 L, 1.38 mmol, 1.1 eq.), 
2-chloro-4-nitropyrimidine (200 mg, 1.25 mmol, 1 eq.), Et3N (192 L, 1.38 mmol, 1.1 eq.) 
and THF (10 mL) with stirring for 18 h to give a yellow solid (195 mg, 80%); Rf 0.65 (5% 
MeOH/DCM); m.p. 203 C dec.; max(EtOH)/nm 346; IR  max/cm
-1
 2982, 2958, 2881, 
1589, 1458, 1315; 

H NMR(500 MHz; DMSO-d6) H 1.98-2.04 (4H, m, 2 × CH2-
pyrrolidine), 3.63-3.68 (4H, m, 2 × CH2-N-pyrrolidine), 9.15 (2H, s, 2 × H-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 24.8 (2 × CH2-pyrrolidine), 47.5 (2 × CH2-N-
pyrrolidine), 133.1 (C-NO2), 154.9 (2 × CH-N-pyrimidine), 159.5 (C-NR2-pyrimidine); 
MS (ES+) m/z 195.3 [M+H]
+
. 
2-(Pyrrolidin-1-yl)pyrimidin-5-amine (340) 350 
 
Prepared according to general procedure H using nitropyrimidine 339 (185 mg, 0.95 
mmol) and MeOH (5 mL) to give a yellow solid (156 mg, 100%); Rf 0.25 (5% 
MeOH/DCM); m.p. 140-144 C; max(EtOH)/nm 255; IR  max/ cm
-1
 3347, 3173, 2967, 
2920, 2857, 1640, 1606; 

H NMR(500 MHz; DMSO-d6)H 1.87-1.96 (4H, m, 2 × CH2-
pyrrolidine), 3.35-3.43 (4H, m, 2 × CH2-N-pyrrolidine), 4.45 (2H br s, NH2), 7.87 (2H, s, 2 
× H-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 25.1 (2 × CH2-pyrrolidine), 46.7 (2 × 
CH2-N-pyrrolidine), 133.0 (C-NH2), 144.6 (2 × CH-pyrimidine), 155.1 (C-N-pyrimidine); 
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MS (ES+) m/z 165.2 [M+H]
+
; HRMS calcd for C8H12N4 [M+H]
+
 165.1135, found 
165.1130.  
4-(2-Chloro-6-fluorobenzoyl)-N-(2-(pyrrolidin-1-yl)pyrimidin-5-yl)-1H-
pyrrole-2-carboxamide (274) 
 
Prepared according to general procedure E using cyanuric fluoride (10 L, 0.11 mmol, 0.7 
eq.), carboxylic acid 336 (46 mg, 0.17 mmol, 1 eq.), amine 340 (70 mg, 0.43 mmol, 2.5 
eq.), pyridine (14 L, 0.17 mmol, 1 eq.), and THF (1 mL). Purification by MPLC on NH2 
silica with a gradient elution from 0-3% MeOH/CH2Cl2 gave a pale yellow solid (30 mg, 
42%); Rf 0.35 (5% MeOH/CH2Cl2); m.p. 243-246 C; max(EtOH)/nm 290, 233; IR  
max/cm
-1
 3199, 2970, 2867, 1632, 1608, 1571; 

H NMR (500 MHz; DMSO-d6) H 2.52-2.56 
(4H, m, 2 × CH2-pyrrolidine), 3.48-3.53 (4H, m, 2 × CH2-N-pyrrolidine), 7.37-7.44 (2H, 
m, CH-pyrrole and H-Ar), 7.47-7.53 (2H, m, CH-pyrrole and H-Ar), 7.58-7.65 (1H, td, J = 
8.2 and 6.3 Hz, H-4’), 8.59 (2H, s, 2 × H-pyrimidine), 10.01 (1H, br s, CO-NH), 12.69 
(1H, br s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.35; 

C NMR (125 MHz; 
DMSO-d6) C 25.0 (2 × CH2-pyrrolidine), 46.5 (2 × CH2-N-pyrrolidine), 111.0 (CH-
pyrrole), 115.0 (d, J = 21.8 Hz, C-5’), 125.2 (C-pyrrole), 125.8 (d, JCF = 2.6 Hz, C-3’), 
128.1 (d, JCF = 23.2 Hz, C-1’), 128.2 (C-pyrrole), 128.8 (CH-pyrrole), 130.4 (d, JCF = 5.9 
Hz, C-2’), 131.8 (d, JCF = 9.5 Hz, C-4’), 151.4 (2 × CH-pyrimidine), 157.4 (C-pyrimidine), 
158.4 (CO-NH), 158.5 (d, JCF = 247 Hz, C-6’), 183.9 (CO); MS (ES+) m/z 414.4 
[M(
35
Cl)+H]
+
, 416.4 [M(
37
Cl)+H]
+
; HRMS calcd for C20H18
35
Cl1F1N5O2 [M+H]
+
 
414.1128, found 414.1132. 
N-Methyl-5-nitropyrimidin-2-amine (341) 
451-61, 63 
Prepared according to general procedure I using 2-chloro-5-nitropyrimidine (300 mg, 1.9 
mmol, 1 eq.), methylamine hydrochloride (141 mg, 2.1 mmol, 1.1 eq.) and Et3N (576 L, 
4.2 mmol, 2.2 eq) in THF (2 mL) to give a yellow solid (160 mg, 55%); Rf 0.3 (NH2 SiO2, 
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30% EtOAc/petrol); m.p. 130 C dec.; max(EtOH)/nm 336, 212; IR  max/cm
-1 
3264, 1558, 
1323; 

H NMR(500 MHz; DMSO-d6)H 2.96 (3H, d, J = 4.9 Hz, CH3), 8.75 (1H, br s, 
NH), 9.06 (1H, d, J = 3.3 Hz, H-pyrimidine), 9.15 (1H, d, J = 3.3 Hz, H-pyrimidine); 

C 
NMR (125 MHz; DMSO-d6) C 28.3 (CH3), 133.6 (C-5), 155.0 (C-4), 155.4 (C-6), 163.1 
(C-2); MS (ES+) m/z 155.2 [M+H]
+
. HRMS - no mass ion 
N2-Methylpyrimidine-2,5-diamine (351) 
451/62 
Prepared according to general procedure H using nitropyrimidine 341 (160 mg, 1.04 
mmol) in MeOH (30 mL) and EtOAc (30 mL) for 3 h to give a yellow gum (128 mg, 
100%); Rf 0.5 (NH2 SiO2, 70% EtOAc/petrol); max(EtOH)/nm 250; IR max/cm
-1 
3271 (br), 
1517; 

H NMR(500 MHz; DMSO-d6) H 2.73 (3H, d, J = 4.7 Hz, CH3), 4.41 (2H, s, NH2), 
6.13 (1H, q, J = 4.7 Hz, NHMe), 7.84 (2H, s, 2 × H-pyrimidine); 

C NMR (125 MHz; 
DMSO-d6) C 28.5 (CH3), 133.4 (C-5), 144.6 (C-4 and C-6), 157.2 (C-2); HRMS calc for 
C5H9N4 [M+H]
+
 125.0822, found 125.0810. 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-(methylamino)pyrimidin-5-yl)-1H-pyrrole-
2-carboxamide (272) 
451-85 
Prepared according to general procedure E using amine 351 (190 mg, 1.4 mmol, 2.5 eq.), 
carboxylic acid 336 (151 mg, 0.57 mmol, 1 eq.), cyanuric fluoride (34 L, 0.40 mmol, 0.7 
eq.), pyridine (46 L, 0.57 mmol, 1 eq.) and MeCN (3 mL). Purification by MPLC on NH2 
SiO2 with a gradient elution from 0-4% MeOH/EtOAc gave a yellow solid (43 mg, 35 %); 
Rf 0.55 (NH2 SiO2, 5% MeOH/EtOAc); m.p. 310-312 C; max(EtOH)/nm 285, 232; IR  
max/cm
-1 
3233, 1651, 1607; 

H NMR(500 MHz; DMSO-d6) H 2.83 (3H, d, J = 4.8 Hz, 
Me), 7.04 (1H, q, J = 4.8 Hz, NHMe), 7.39 (1H, s, H-pyrrole), 7.43 (1H, app t, J = 8.3 Hz, 
H-5’), 7.48 (1H, s, H-pyrrole), 7.50, (1H, d, J = 8.3 Hz, H-3’), 7.62 (1H, qd, J = 6.2 and 
8.3 Hz, H-4’), 8.53 (2H, s, 2 × H-pyrimidine), 9.98 (1H, s, CO-NH), 12.68 (1H, s, NH-
pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.35; 

C NMR (125 MHz; DMSO-d6) C 
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28.1 (CH3), 111.0 (CH-pyrrole), 115.0 (d, JCF = 21.7 Hz, C-5’), 123.2 (C-pyrimidine), 
125.2 (C-pyrrole), 125.8 (d, JCF = 3.1 Hz, C-3’), 128.1 (d, JCF = 23.2 Hz, C-1’), 128.2 (C-
pyrrole), 128.9 (C-pyrrole), 130.4 (d, JCF = 6.4 Hz, C-2’), 131.8 (d, JCF = 9.1 Hz, C-4’), 
151.5 (C-pyrimidine), 158.4 (CONH), 158.6 (d, JCF = 247.0 Hz, C-6’), 160.0 (C-
pyrimidine), 183.9 (CO); LCMS (ES-) m/z 374.3 [M(
35,35
Cl)+H]
+
, 376.3 [M(
35,37
Cl)+H]
+
; 
HRMS calc for C17H13
35
Cl1F1N5O2 [M+H]
+
 374.0815, found 374.0812. 
N,N-Dimethyl-5-nitropyrimidin-2-amine (342)351 
451-54 
Prepared according to general procedure I using 2-chloro-5-nitropyrimidine (300 mg, 1.9 
mmol, 1 eq.), Me2NH (1.4 mL, 2.8 mmol, 1.5 eq., 2.0 M in THF) and Et3N (288 L, 2.1 
mmol, 1.1 eq) in THF (8 mL) to give a yellow solid (275 mg, 87%); Rf 0.75 (NH2 SiO2, 
30% EtOAc/petrol); m.p. 209-212 C (lit.351 222 C); max(EtOH)/nm 341, 219; IR  
max/cm
-1 
1547, 1301; 

H NMR (500 MHz; DMSO-d6) H 3.31 (6H, s, NMe2), 9.15 (2H, s, 2 
× H-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 37.4 (NMe2), 133.4 (C-5-
pyrimidine), 154.8 (2H, s, 2 × CH-pyrimidine), 161.6 (C-2-pyrimidine); HRMS calcd for 
C6H9N4O2 [M+H]
+
 169.0720, found 169.0720.  
N2,N2-Dimethylpyrimidine-2,5-diamine (352)352 
451-56 
Prepared according to general procedure H using nitropyrimidine 342 (263 mg, 1.60 
mmol) in MeOH (60 mL) and EtOAc (60 mL) for 4 h to give a yellow solid (215 mg, 
100%); Rf 0.8 (NH2 SiO2, EtOAc); m.p. 68-72 C (lit.
353
 80-84 C); max(EtOH)/nm 261; 
IR  max/cm
-1 
3206; 

H NMR (500 MHz; DMSO-d6) H 3.12 (6H, s, NMe2), 4.50 (2H, s, 
NH2), 7.01 (2H, s, 2 × CH-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 37.2 (NMe2), 
133.2 (C-5-pyrimidine), 144.3 (2 × CH-pyrimidine), 156.7 (C-2-pyrimidine); HRMS calcd 
for C6H11N4 [M+H]
+
 139.0978, found 139.0978.  
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4-(2-Chloro-6-fluorobenzoyl)-N-(2-(dimethylamino)pyrimidin-5-yl)-1H-
pyrrole-2-carboxamide (273) 
451-60 
Prepared according to general procedure E using amine 352 (100 mg, 0.72 mmol, 2.5 eq.), 
carboxylic acid 336 (77 mg, 0.29 mmol, 1 eq.), cyanuric fluoride (25 L, 0.20 mmol, 0.7 
eq.), pyridine (23 L, 0.29 mmol, 1 eq.) and MeCN (2 mL). Purification by MPLC on NH2 
SiO2 with a gradient elution from 50-100% EtOAc/petrol gave a white solid (38 mg, 34 
%); Rf 0.5 (NH2 SiO2, EtOAc); m.p. 300 C dec.; max(EtOH)/nm 287, 232; IR  max/cm
-1 
2951, 1645, 1622; 

H NMR(500 MHz; DMSO-d6) H 3.15 (6H, s, NMe2), 7.39 (1H, s, H-
pyrrole), 7.44 (1H, app t, J = 8.4 Hz, H-5’), 7.49 (1H, s, H-pyrrole), 7.50 (1H, d, J = 8.4 
Hz, H-3’), 7.62 (1H, td, J = 8.4 and 6.3 Hz, H-4’), 8.61 (2H, s, 2 × H-pyrimidine), 10.02 
(1H, s, CO-NH), 12.70 (1H, s, NH); 

F NMR (470 MHz; DMSO-d6) F -114.35; 

C NMR 
(125 MHz; DMSO-d6) C 36.9 (NMe2), 111.1 (CH-pyrrole), 115.0 (d, JCF = 21.5 Hz, C-5’), 
122.9 (C5-pyrimidine), 125.2 (C-pyrrole), 125.8 (d, JCF = 3.2 Hz, C-3’), 128.1 (d, JCF = 
23.2 Hz, C-1’), 128.2 (C-pyrrole), 128.9 (CH-pyrrole), 130.4 (d, JCF = 5.9 Hz, C-2’), 131.8 
(d, J = 9.1 Hz, C-4’), 151.2 (2 × CH-pyrimidine), 158.4 (C-2-pyrimidine), 158.6 (d, JCF = 
247.0 Hz, C-6’), 159.1 (CO-NH), 183.9 (CO); LCMS (ES-) m/z 388.4 [M(35Cl)+H]+, 390.3 
[M(
37
Cl)+H]
+
; HRMS calcd for C18H16
35
Cl1F1N5O2 [M+H]
+
 388.0971, found 388.0977. 
2-(4-Methylpiperazin-1-yl)-5-nitropyrimidine (343)354 
 
Prepared according to general procedure I using 1-methylpiperazine (382 L, 3.45 mmol, 
1.1 eq.), 2-chloro-5-nitropyrimidine (500 mg, 3.14 mmol, 1 eq.), Et3N (480 L, 3.45 
mmol, 1.1 eq.) and THF (15 mL). The residue was purified by MPLC on SiO2 with a 
gradient elution from 0-13% MeOH/EtOAc to give a yellow solid. (573 mg, 82%); Rf 0.6 
(NH2 SiO2, Ethyl acetate); m.p. 149-152 C; max(EtOH)/nm 346, 332, 219; IR  max/cm
-1
 
1567, 1474; 

H NMR (500 MHz; DMSO-d6) H 2.26 (3H, s, Me), 2.41-2.46 (4H, m, H-
piperazine), 3.92-3.99 (4H, m, H-piperazine), 9.15 (2H, s, H-pyrimidine); 

C NMR (125 
MHz; DMSO-d6) C 44.0 (2 × C-piperazine), 45.5 (NMe), 54.1 (2 × C-piperazine), 133.2 
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(C-NO2), 155.1 (2 × CH-pyrimidine), 160.8 (C-pyrimidine); MS (ES+) m/z 224.3 [M+H]
+
; 
HRMS calcd for C9H14N5O2 [M+H]
+ 
224.1142, found 224.1136. 
2-(4-Methylpiperazin-1-yl)pyrimidin-5-amine(353)355  
 
Prepared according to general procedure H using nitropyrimidine 343 (195 mg, 0.87 
mmol) and MeOH (5 mL) to give a pale yellow solid (168 mg, 99%). Rf 0.5 (NH2 SiO2, 5% 
MeOH/CH2Cl2); m.p. 139-142 C; max(EtOH)/nm 353, 255; IR  max/cm
-1
 3347, 3173, 
2967, 2920, 1640, 1606; 

H NMR(500 MHz; DMSO-d6) H 2.22 (3H, s, NMe), 2.31-2.40 
(4H, m, H-piperazine), 3.48-3.58 (4H, m, H-piperazine), 4.64 (2H, s, NH2), 7.92 (2H, s, H-
pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 44.3 (2 × C-piperazine), 45.9 (NMe), 
54.4 (2 × C-piperazine), 134.3 (C-NH2), 144.0 (2 × CH-pyrimidine), 156.0 (C-pyrimidine); 
MS (ES+) m/z 194.3 [M+H]
+
; HRMS calcd for C9H16N5 [M+H]
+
 194.1400, found 
194.1399. 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-
1H-pyrrole-2-carboxamide (275) 
  
Prepared according to general procedure E using carboxylic acid 336 (150 mg, 0.78 mmol, 
2.5 eq.), amine 353 (83 mg, 0.31 mmol, 1 eq.), cyanuric fluoride (19 L, 0.22 mmol, 0.7 
eq.) pyridine (25 L, 0.31 mmol, 1 eq.) and MeCN (2 mL). Purification by MPLC on NH2 
SiO2 with a gradient elution from 0-4% MeOH/CH2Cl2 gave a white solid (68 mg, 50%); 
Rf 0.3 (NH2 SiO2, 5% MeOH/CH2Cl2); m.p. 246 C dec.; max(EtOH)/nm 289, 231; IR  
max/cm
-1
 3186, 1661, 1641, 1606, 1582; 

H NMR(500 MHz; DMSO-d6) H 2.24 (3H, s, 
NMe), 2.35-2.42 (4H, m, H-piperazine), 3.68-3.76 (4H, m, H-piperazine), 7.40 (1H, s, H-
pyrrole), 7.44 (1H, app t, J = 8.2 Hz, H-5’), 7.48-7.54 (2H, m, H-pyrrole and H-3’), 7.62 
(1H, td, J = 8.2 and 6.3 Hz, H-4’), 8.61 (2H, s, 2 × H-pyrimidine), 10.05 (1H, s, CO-NH), 
12.69 (1H, s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.36; 

C NMR (125 
MHz; DMSO-d6) C 43.6 (2 × CH2 piperazine), 45.8 (NMe), 54.3 (2 × CH2 piperazine), 
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111.1 (CH-pyrrole), 115.0 (d, JCF = 21.5 Hz, C-5’), 125.2 (C-pyrrole), 125.8 (d, JCF = 3.2 
Hz, C-3’), 127.9 (C-pyrimidine), 128.0 (d, JCF = 22.7 Hz, C-1’), 128.1 (C-pyrrole), 129.0 
(CH-pyrrole), 130.4 (d, JCF = 6.2 Hz, C-2’), 131.8 (d, JCF = 9.1 Hz, C-4’), 151.0 (2 × CH-
pyrimidine), 158.4 (CO-NH), 158.4 (C-pyrimidine), 158.5 (d, JCF = 247 Hz, C-6’), 183.9 
(CO); MS (ES+) m/z 443.5 [M(
35
Cl)+H]
+
, 445.4 [M(
37
Cl)+H]
+
; HRMS calcd for 
C21H21
35
Cl1F1N6O2 [M+H]
+
 443.193, found 443.193. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-(4-methylpiperazin-1-yl)pyrimidin-5-
yl)-1H-pyrrole-2-carboxamide (276) 
 
Prepared according to general procedure E using amine 353 (160 mg, 0.83 mmol, 2.5 eq.), 
carboxylic acid 337 (100 mg, 0.33 mmol, 1 eq.), cyanuric fluoride (20 L, 0.23 mmol, 0.7 
eq.), pyridine (27 L, 0.33 mmol, 1 eq.) and MeCN (2 mL). Purification by MPLC on NH2 
SiO2 with a gradient elution from 0-4% MeOH/CH2Cl2 gave a white solid (65 mg, 41%); 
Rf 0.65 (NH2 SiO2, 5% MeOH/EtOAc); m.p. 226-228 C; max(EtOH)/nm 287, 227; IR  
max/cm
-1
 3174, 1663, 1639, 1592; 

H NMR(500 MHz; DMSO-d6) H 2.25 (3H, s, CH3), 
2.37-2.41 (4H, m, 2 × CH2-piperazine), 3.70-3.76 (4H, m, 2 × CH2-piperazine), 7.44 (1H, 
s, H-pyrrole), 7.56 (1H, dd, J = 1.1 and 8.6 Hz, H-5’), 7.64 (1H, s, H-pyrrole), 7.82 (1H, 
app t, J = 8.6 Hz, H-4’), 8.64 (2H, s, 2 × H-pyrimidine), 10.07 (1H, s, CO-NH), 12.78 (1H, 
s, NH); 

F NMR (470 MHz; DMSO-d6) F -116.68; 

C NMR (125 MHz; DMSO-d6) C 
43.6 (2 × CH2-piperazine), 45.8 (CH3), 54.3 (2 × CH2-piperazine), 111.0 (CH-pyrrole), 
119.3 (d, JCF = 18.3 Hz, C-3’), 123.7 (C-pyrimidine), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.8 
Hz, C-5’), 128.4 (C-pyrrole), 129.1 (d, JCF = 22.3 Hz, C-1’), 129.2 (d, JCF = 5.6 Hz, C-6’), 
129.9 (CH-pyrrole), 131.8 (C-4’), 151.1 (2 × CH-pyrimidine), 153.8 (d, JCF = 248.4 Hz, C-
2’), 158.4 (C-pyrimidine), 158.4 (CO-NH), 182.6 (NH-pyrrole); MS (ES+) m/z 477.3 
[M(
35,35
Cl)+H]
+
, 479.3 [M(
35,37
Cl)+H]
+
; HRMS calcd for C21H20
35
Cl2F1N6O2 [M+H]
+
 
477.1003, found 477.1008. 
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2-(4-Cyclopropylpiperazin-1-yl)-5-nitropyrimidine (344) 
451-106 
Prepared according to general procedure I using 1-cyclopropylpiperazine (250 mg, 1.98 
mmol, 1 eq.), 2-chloro-5-nitropyrimidine (316 mg, 1.98 mmol, 1 eq.), Et3N (304 L, 2.18 
mmol, 1.1 eq.) and THF (4 mL) with stirring for 18 h to give a yellow solid (222 mg, 
95%); Rf 0.9 (EtOAc, NH2 SiO2); m.p. 184 C dec.; max(EtOH)/nm 339; IR max/cm
-1 
1552, 1303; 
1
H NMR(500 MHz; DMSO-d6) H 0.38-0.43(2H, m, 2 × H-cyclopropyl), 
0.46-0.52 (2H, m, 2 × H-cyclopropyl), 1.68-1.74 (1H, m, N-CH-cPr), 2.63-2.69 (4H, m, 2 
× CH2-piperazine), 3.90-3.95 (4H, m, 2 × CH2-piperazine), 9.15 (2H, s, 2 × H-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 5.8 (2 × CH2-cyclopropyl), 37.8 (CHN-cyclopropyl), 
44.1 (2 × CH2-piperazine), 52.3 (2 × CH2-piperazine), 133.1 (C-5-pyrimidine), 155.1 (C-4 
and C-6-pyrimidine), 160.8 (C-2-pyrimidine); HRMS calc for C11H16N5O2 [M+H]
+
 
250.1299, found 250.1294. 
2-(4-Cyclopropylpiperazin-1-yl)pyrimidin-5-amine (354) 
451-108 
Prepared according to general procedure H using nitropyrimidine 344 (420 mg, 1.7 mmol) 
in MeOH (30 mL) and EtOAc (30 mL) for 3 h to give an orange solid (360 mg, 98%); Rf 
0.2 (CH2Cl2, NH2 SiO2); m.p. 79-84 C; max(EtOH)/nm 256; IR max/cm
-1 
3205, 2818; 

H 
NMR(500 MHz; DMSO-d6) H 0.34-0.39 (2H, m, 2 × H-cyclopropyl), 0.43-0.49 (2H, m, 
2 × H-cyclopropyl), 1.61-1.68 (1H, m, N-CH-cPr), 2.56-2.63 (4H, m, 2 × CH2-piperazine), 
3.46-3.54 (4H, m, 2 × CH2-piperazine), 4.62 (2H, s, NH2), 7.92 (2H, s, 2 × H-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 5.6 (2 × CH2-cyclopropyl), 38.2 (CH-N-cyclopropyl), 
44.4 (2 × CH2-piperazine), 52.6 (2 × CH2-piperazine), 134.3 (C-5-pyrimidine), 144.0 (C-4 
and C-6-pyrimidine), 155.9 (C-2-pyrimidine); HRMS calc for C11H18N5 [M+H]
+
 220.1557, 
found 220.1554. 
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N-(2-(4-cyclopropylpiperazin-1-yl)pyrimidin-5-yl)-4-(3,6-dichloro-2-
fluorobenzoyl)-1H-pyrrole-2-carboxamide (287) 
451-109 
Prepared according to general procedure E using amine 354 (94 mg, 0.78 mmol, 2.5 eq.), 
carboxylic acid 337 (94 mg, 0.31 mmol, 1 eq.), cyanuric fluoride (8 L, 0.09 mmol, 0.3 
eq.), pyridine (25 L, 0.31 mmol, 1 eq.) and MeCN (2 mL) with stirring at r.t. for 72 h. 
Purification by MPLC on SiO2 with a gradient elution from 50-100% EtOAc/petrol gave a 
white solid. This solid was repurified by MPLC on NH2 SiO2 with gradient elution from 0-
2% MeOH/CH2Cl2 to give a white solid (28 mg, 18%); Rf 0.3 (2% MeOH/CH2Cl2 , NH2 
SiO2); m.p. 224 C dec.; max(EtOH)/nm 290, 236; IR max/cm
-1 
3180, 2937, 2843, 1657, 
1637; 

H NMR(500 MHz; DMSO-d6) H 0.37-0.41 (2H, m, 2 × H-cyclopropyl), 0.45-0.50 
(2H, m, 2 × H-cyclopropyl), 1.65-1.71 (1H, m, N-CH-cPr), 2.60-2.64 (4H, m, 2 × CH2-
piperazine), 3.68-3.72 (4H, m, 2 × CH2-piperazine), 7.43 (1H, s, H-pyrrole), 7.56 (1H, dd, 
J = 1.1 and 8.5 Hz, H-5’), 7.64 (1H, s, H-pyrrole), 7.82 (1H, app t, J = 8.5 Hz, H-4’), 8.64 
(2H, s, 2 × H-pyrimidine), 10.07 (CO-NH), 12.78 (NH-pyrrole); 

F NMR (470 MHz; 
DMSO-d6) F -116.68; 

C NMR (125 MHz; DMSO-d6) C 5.7 (2 × CH2-cyclopropyl), 
38.1 (CHN-cyclopropyl), 43.7 (2 × CH2-piperazine), 52.6 (2 × CH2-piperazine), 111.0 
(CH-pyrrole), 119.3 (d, JCF = 18.0 Hz, C-3’), 123.6 (C-pyrimidine), 124.7 (C-pyrrole), 
126.9 (d, JCF = 3.6 Hz, C-5’), 128.3 (C-pyrrole), 129.2 (d, JCF = 22.9 Hz, C-1’), 129.2 (d, 
JCF = 5.4 Hz, C-6’), 129.8 (CH-pyrrole), 131.8 (C-2’), 151.1 (C-pyrimidine), 153.5 (d, JCF 
= 248.5 Hz, C-2’), 157.4 (C-pyrimidine), 158.4 (CO-NH), 182.6 (CO); MS (ES+) m/z 
462.4, 464.4 [M+H]
+
; HRMS calc for C23H22
35
Cl2F1N6O2 [M+H]
+
 503.1160, found 
503.1143. 
tert-Butyl 4-(5-nitropyrimidin-2-yl)piperazine-1-carboxylate (345)356 
 
Prepared according to general procedure I using 2-chloro-5-nitropyrimidine (350 mg, 2.2 
mmol, 1 eq.), 1-Boc-piperazine (450 mg, 2.4 mmol, 1.1 eq.), Et3N (336 L, 2.4 mmol, 1.1 
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eq) and THF (12 mL). The residue was purified by MPLC on SiO2 with a gradient elution 
from 15-100% EtOAc/petrol to give a yellow solid (460 mg, 68%); Rf 0.4 (SiO2, 20% 
EtOAc/petrol); m.p. 196-199 C; max(EtOH)/nm 339, 221; IR  max/cm
-1
 1676, 1539, 
1325; 

H NMR(500 MHz; DMSO-d6) H 1.47 (9H, s, C(CH3)3), 3.47-4.57 (4H, m, 2 × 
CH2-piperazine), 3.92-3.99 (4H, m, 2 × CH2-piperazine), 9.17 (2H, s, 2 × H-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 28.0 (C(CH3)3), 42.5 (2 × CH2-piperazine), 43.9 (2 × 
CH2-piperazine), 79.3 (C(CH3)3), 133.4 (C-5-pyrimidine), 153.8 (CO), 155.1 (C-4 and C-
6-pyrimidine), 161.0 (C-2-pyrimidine); HRMS calcd for C13H20N5O4 [M+H]
+
 310.1510, 
found 310.1510. 
tert-Butyl 4-(5-aminopyrimidin-2-yl)piperazine-1-carboxylate (355)357 (No 
data) 
 
Prepared according to general procedure H using nitropyimidine 345 (440 mg, 1.42 mmol) 
in MeOH (75 mL) and EtOAc (75 mL) to give a yellow solid (395 mg, 99%); Rf 0.15 (NH2 
SiO2, 70% EtOAc/petrol); m.p. 131-133 C; max(EtOH)/nm 252; IR  max/cm
-1
 3336, 
1676; 

H NMR(500 MHz; DMSO-d6) H 1.45 (9H, s, C(CH3)3), 3.38-3.42 (4H, m, 2 × 
CH2-piperazine), 3.50-3.55 (4H, m, 2 × CH2-piperazine), 4.68 (2H, s, NH2), 7.94 (2H, s, 2 
× H-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 28.1 (C(CH3)3), 44.2 (2 × CH2-
piperazine), 44.7 (2 × CH2-piperazine), 78.9 (C(CH3)3), 134.7 (C-5-pyrimidine), 144.0 (C-
4 and C-6-pyrimidine), 154.0 (CO), 155.6 (C-2-pyrimidine); HRMS calcd for C13H20N5O2 
[M-H]
-
 278.1622 , found 278.1609. 
tert-Butyl 4-(5-(4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyrimidin-2-yl)piperazine-1-carboxylate (361) 
451-42 
Prepared according to general procedure E using amine 355 (200 mg, 0.72 mmol, 2.5 eq.), 
carboxylic acid 336 (76 mg, 0.29 mmol, 1 eq.), cyanuric fluoride (24 L, 0.20 mmol, 0.7 
eq.), pyridine (23 L, 0.29 mmol, 1 eq.) and MeCN (2 mL). Purification by MPLC on NH2 
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SiO2 with a gradient elution from 50-100% EtOAc/petrol gave a white solid (74 mg, 49%); 
Rf 0.15 (NH2 SiO2, 70% EtOAc/petrol); m.p. 219-221 C; max(EtOH)/nm 310; IR  
max/cm
-1
 3300, 1637 (br); 

H NMR(500 MHz; DMSO-d6) H 1.46 (9H, s, C(CH3)3), 3.41-
3.48 (4H, m, 2 × CH2-piperazine), 3.68-3.76 (4H, m, 2 × CH2-piperazine), 7.40 (1H, s, H-
pyrrole), 7.44 (1H, app t, J = 8.4 Hz, H-5’), 7.47-7.53 (2H, m, H-pyrrole and H-3’), 7.62 
(1H, app dt, J = 8.4 and 6.1 Hz, H-4’), 8.67 (2H, s, 2 × H-pyrimidine), 10.10 (1H, s, CO-
NH), 12.71 (1H, s, NH); 

F NMR (470 MHz; DMSO-d6) F -114.35; 

C NMR (125 MHz; 
DMSO-d6) C 28.1 (C(CH3)3), 43.5 (4 × CH2-piperazine), 79.0 (C(CH3)3), 111.2 (CH-
pyrrole), 115.0 (d, JCF = 21.7 Hz, C-5’), 124.0 (C-pyrimidine), 125.2 (C-pyrrole), 125.9 (d, 
JCF = 2.5 Hz, C-3’), 128.1 (C-1’), 128.1 (C-pyrrole), 129.0 (CH-pyrrole), 130.4 (d, JCF = 
6.8 Hz (C-2’), 131.8 (d, JCF = 9.5 Hz, C-4’), 151.0 (2 × CH-pyrimidine), 152.4 (d, JCF = 
248.9, C-6’), 153.9 (CO-carbamate), 158.2 (C-pyrimidine), 158.5 (CO-NH), 184.1 (CO); 
HRMS calcd for C25H25
35
Cl1F1N6O3 [M-H]
-
 527.1615, found 527.1615. 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-(piperazin-1-yl)pyrimidin-5-yl)-1H-pyrrole-
2-carboxamide (285) 
451-50 
Prepared according to general procedure G using Et3SiH (48 L, 0.30 mmol, 2.5 eq.), TFA 
(0.6 mL), CH2Cl2 (0.6 mL) and carbamate 361 (64 mg, 0.12 mmol, 1 eq.) to give a white 
solid (27 mg, 52%); Rf 0.1 (NH2 SiO2, EtOAc); m.p. 311 C dec.; max(EtOH)/nm 291, 
233; IR  max/cm
-1 
3266, 1634, 1607, 1572; 

H NMR(500 MHz; DMSO-d6) H 2.75-2.79 
(4H, m, 2 × CH2-piperazine), 3.64-3.68 (4H, m, 2 × CH2-piperazine), 7.39 (1H, s, H-
pyrrole), 7.43 (1H, app t, J = 8.4 Hz, H-5’), 7.49 (1H, s, H-pyrrole), 7.50 (1H, d, J = 8.4 
Hz, H-3’), 7.62 (1H, app dt, J = 6.3 and 8.4 Hz, H-4’), 8.62 (2H, s, 2 × H-pyrimidine), 
10.06 (1H, s, CO-NH); 

F NMR (470 MHz; DMSO-d6) F -114.35; 

C NMR (125 MHz; 
DMSO-d6) C 44.9 (2 × C-piperazine), , 45.4 (2 × C-piperazine), 111.1 (CH-pyrrole), 
115.0 (d, JCF = 21.6 Hz, C-5’), 123.4 (C-pyrimidine), 125.2 (C-pyrrole), 125.8 (d, JCF = 3.2 
Hz, C-3’), 129.0 (d, JCF = 23.0 Hz, C-1’), 128.2 (C-pyrrole), 129.0 (CH-pyrrole), 130.4 (d, 
JCF = 6.2 Hz, C-2’), 131.8 (d, JCF = 9.1 Hz, C-4’), 151.1 (C-pyrimidine), 158.5 (CO-N), 
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158.5 (C-pyrimidine), 158.6 (d, JCF = 247.0 Hz, C-6’), 183.9 (CO); HRMS calcd for 
C20H19
35
Cl1F1N6O2 [M+H]
+
 429.1237, found 429.1232. 
tert-Butyl 4-(5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyrimidin-2-yl)piperazine-1-carboxylate (362) 
451-64 
Prepared according to general procedure E using amine 355 (190 mg, 0.68 mmol, 2.5 eq.), 
carboxylic acid 337 (82 mg, 0.27 mmol, 1 eq.), cyanuric fluoride (16 L, 0.19 mmol, 0.7 
eq.), pyridine (22 L, 0.27 mmol, 1 eq.) and MeCN (4 mL). Purification by MPLC on NH2 
SiO2 with a gradient elution from 40-100% EtOAc/petrol gave a white solid (105 mg, 
69%); Rf 0.25 (NH2 SiO2, 70% EtOAc/petrol); m.p. 211-213 C; max(EtOH)/nm 283, 223; 
IR  max/cm
-1 
3199, 1637, 1573; 

H NMR(500 MHz; DMSO-d6) H 1.46 (9H, s, C(CH3)3, 
3.40-3.47 (4H, m, 2 × CH2-piperazine), 3.70-3.76 (4H, m, 2 × CH2-piperazine), 7.44 (1H, 
s, H-pyrrole), 7.56 (1H, d, J = 8.6 Hz, H-5’), 7.82 (1H, app t, J = 8.6 Hz, H-4’), 8.67 (2H, 
s, 2 × H-pyrimidine), 10.10 (1H, s, CO-NH), 12.79 (1H, s, NH); 

F NMR (470 MHz; 
DMSO-d6) F -116.69; 

C NMR (125 MHz; DMSO-d6) C 28.1 (C(CH3)3), 43.5 (4 × CH2-
piperazine), 79.0 (C(CH3)3), 111.1 (CH-pyrrole), 119.3 (d, JCF = 18.0 Hz, C-3’), 124.0 (C-
pyrimidine), 124.7 (C-pyrrole), 126.9(d, JCF = 3.5 Hz, C-5’), 128.3 (C-1’), 128.3 (C-
pyrrole), 129.2 (d, JCF = 5.5 Hz, C-6’), 129.2 (CH-pyrrole), 131.8 (C-4’), 151.1 (2 × CH-
pyrimidine), 153.8 (d, JCF = 248.4 Hz, C-2’), 153.9, 158.2 (C-pyrimidine), 158.4 (CO-NH), 
182.6 (C-O); HRMS calcd for C25H24
35
Cl2F1N6O4 [M+H]
+
 563.1197, found 563.121. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-(piperazin-1-yl)pyrimidin-5-yl)-1H-
pyrrole-2-carboxamide (286) 
451-69 
Prepared according to general procedure G using Et3SiH (64 L, 0.40 mmol, 2.5 eq.), TFA 
(1 mL), CH2Cl2 (1 mL) and carbamate 362 (90 mg, 0.16 mmol, 1 eq.) to give a white solid 
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(35 mg, 47%); Rf 0.2 (NH2 SiO2, 5% MeOH/EtOAc); m.p. 230 C dec.; max(EtOH)/nm 
303, 225; IR  max/cm
-1 
3275 (br), 2922, 2847, 1635; 

H NMR (500 MHz; DMSO-d6) H 
2.75-2.79 (4H, m, 2 × CH2-piperazine), 3.64-3.69 (4H, m, 2 × CH2-piperazine), 7.42 (1H, 
s, H-pyrrole), 7.55 (1H, d, J = 8.6 Hz, H-5’), 7.63 (1H, s, H-pyrrole), 7.82 (1H, app t, J = 
8.6 Hz, H-4’), 8.62 (2H, s, 2 × H-pyrimidine), 10.05 (1H, br s, CO-NH); C NMR (125 
MHz; DMSO-d6) C 44.9 (2 × C-piperazine), 45.4 (2 × C-piperazine), 111.0 (CH-pyrrole), 
119.3 (d, JCF = 18.1 Hz, C-3’), 123.4 (C-pyrimidine), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.6 
Hz), 128.4 (C-pyrrole), 129.2 (d, JCF = 23.2 Hz, C-1’), 129.2, (d, JCF = 5.3 Hz, C-6’), 129.9 
(CH-pyrrole), 131.8 (C-4’), 151.1 (2 × CH-pyrimidine), 153.8 (d, JCF = 248.7 Hz, C-2’), 
158.4 (C-pyrimidine), 158.6 (CO-NH), 182.6 (CO); HRMS calcd for C20H18
35
Cl2F1N6O2 
[M+H]
+
 463.0847, found 463.0853. 
4-(5-Nitropyrimidin-2-yl)morpholine (346) 
 
Prepared according to general procedure I using 2-chloro-5-nitropyrimidine (300 mg, 1.88 
mmol, 1 eq.) morpholine (181 L, 2.07 mmol, 1.1 eq.), Et3N (288 L, 2.07 mmol, 1.1 eq) 
and THF (12 mL). The residue was purified by MPLC on SiO2 with a gradient elution 
from 20-100% EtOAc/petrol to give a yellow solid (290 mg, 73%); Rf 0.35 (SiO2, 30% 
EtOAc/petrol); m.p. 161-164 C (lit.358 165-168 C); max(EtOH)/nm 339, 221; IR  
max/cm
-1
 1545 (NO2), 1326 (NO2); 

H NMR(500 MHz; DMSO-d6) H 3.71-3.75 (4H, m, 2 
× CH2-morpholine), 3.94-3.97 (4H, m, 2 × CH2-morpholine), 2.14 (2H, s, 2 × H-
pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 44.5 (2 × CH2-morpholine), 65.8 (2 × 
CH2-morpholine), 133.4 (C-5-pyrimidine), 155.1 (C-4 and C-6-pyrimidine), 161.0 (C-2-
pyrimidine); HRMS calcd for C8H11N4O3 [M+H]
+
 211.0826, found 211.0828. 
2-Morpholinopyrimidin-5-amine (356) 
 
Prepared according to general procedure H using nitropyrimidine 346 (278 mg, 1.54 
mmol) in MeOH (35 mL) and EtOAc (15 mL) to give a yellow solid (239 mg, 100%); Rf 
0.3 (NH2 SiO2, 70% EtOAc/petrol); m.p. 110-113 C (lit.
358
 99 C); max(EtOH)/nm 255; 
IR  max/cm
-1
 3301, 3203 (NH2); 

H NMR(500 MHz; DMSO-d6) H 3.46-3.50 (4H, m, 2 × 
CH2-morpholine), 3.63-3.70 (4H, m, 2 × CH2-morpholine), 4.68 (2H, s, NH2), 7.94 (2H, s, 
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2 × H-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 45.0 (2 × CH2-morpholine), 66.0 
(2 × CH2-morpholine), 134.8 (C-5-pyrimidine), 143.9 (C-4 and C-6-pyrimidine), 155.9 (C-
2-pyrimidine); HRMS calcd for C8H13N4O1 [M+H]
+
 181.1084, found 181.1084. 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-morpholinopyrimidin-5-yl)-1H-pyrrole-2-
carboxamide (279) 
 
Prepared according to general procedure E using amine 356 (110 mg, 0.61 mmol, 2.5 eq.), 
carboxylic acid 336 (65 mg, 0.24 mmol, 1 eq.), cyanuric fluoride (15 L, 0.17 mmol, 0.7 
eq.), pyridine (20 L, 0.24 mmol, 1 eq.) and MeCN (2 mL). Purification by MPLC on NH2 
SiO2 with a gradient elution from 50-100% EtOAc/petrol gave a white solid (52 mg, 50%); 
Rf 0.4 (NH2 SiO2, EtOAc); m.p. 286-287 C; max(EtOH)/nm 292, 232; IR  max/cm
-1
 3211, 
1656, 1634; 

H NMR(500 MHz; DMSO-d6) H 3.70 (8H, s, 4 × CH2-morpholine), 7.41 
(1H, m, H-pyrrole), 7.44 (1H, app. t, J = 8.3 Hz, H-5’), 7.48-7.52 (2H, m, H-pyrrole and 
H-3’), 7.62 (1H, td, J = 8.3 and 6.3 Hz, H-4’), 8.68 (2H, s, 2 × H-pyrimidine), 10.10 (CO-
NH), 12.72 (NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.35; 

C NMR (125 
MHz; DMSO-d6) C 44.2 (2 × CH2-morpholine), 65.9 (2 × CH2-morpholine), 111.2 (CH-
pyrrole), 115.0 (d, JCF = 21.5 Hz, C-5’), 124.1 (C-pyrimidine), 125.2 (C-pyrrole), 125.8 
(JCF = 2.7 Hz, C-3’), 128.7 (d, JCF = 22.7 Hz, C-1’), 128.1 (C-pyrrole), 129.0 (CH-pyrrole), 
130.4 (d, JCF = 6.4 Hz, C-2’), 131.8 (d, JCF = 8.6 Hz, C-4’), 151.0 (2 × CH-pyrimidine), 
158.4 (CO-NH and C-pyrimidine), 158.6 (d, J = 247.0 Hz, C-6’), 183.9 (CO); HRMS 
calcd for C20H18
35
Cl1F1N5O3 [M+H]
+
 430.1077, found 430.1083. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-morpholinopyrimidin-5-yl)-1H-pyrrole-
2-carboxamide(280) 
451-51 
Prepared according to general procedure E using amine 356 (110 mg, 0.57 mmol, 2.5 eq.), 
carboxylic acid 337 (74 mg, 0.24 mmol, 1 eq.), cyanuric fluoride (15 L, 0.17 mmol, 0.7 
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eq.), pyridine (20 L, 0.24 mmol, 1 eq.) and MeCN (2 mL). Purification by MPLC on NH2 
SiO2 with a gradient elution from 50-100% EtOAc/petrol gave a beige solid (45 mg, 40%); 
Rf 0.1 (NH2 SiO2, 70% EtOAc/petrol); m.p. 165-170 C; max(EtOH)/nm 285, 226; IR  
max/cm
-1 
2922, 1635; 

H NMR(500 MHz; DMSO-d6) H 3.70 (8H, s, 4 × CH2-
morpholine), 7.44 (1H, s, H-pyrrole), 7.56 (1H, d, J = 8.4 Hz, H-5’), 7.65 (1H, s, H-
pyrrole), 7.82 (app t, J = 8.4 H, H-4’), 8.68 (2H, s, 2 × H-pyrimidine), 10.10 (1H, s, CO-
NH), 12.79 (1H, s, NH); 

F NMR (470 MHz; DMSO-d6) F -116.68; 

C NMR (125 MHz; 
DMSO-d6) C 44.2 (2 × C-morpholine), 65.9 (2 × C-morpholine), 111.1 (CH-pyrrole), 
119.3 (d, JCF = 17.8 Hz, C-3’), 124.1 (C-pyrimidine), 124.7 (C-pyrrole), 126.9 (d, JCF = 4.1 
Hz, C-5’), 128.3 (C-pyrrole), 129.1 (d, JCF = 23.0 Hz, C-1’), 129.2 (d, JCF = 5.4 Hz, C-6’), 
129.9 (CH-pyrrole), 131.8 (C-4’), 151.0 (C-pyrimidine), 153.8 (d, JCF = 248.5 Hz, C-2’), 
158.4 (C-pyrimidine), 158.5 (CO-NH), 182.6 (CO); HRMS calcd for C20H17
35
Cl2F1N5O3 
[M+H]
+
 464.0687, found 464.0692. 
1-(5-Nitropyrimidin-2-yl)piperidin-4-ol (347) 
451-53 
Prepared according to general procedure I using 2-chloro-5-nitropyrimidine (300 mg, 1.9 
mmol, 1 eq.), 4-hydroxypiperidine (209 mg, 2.1 mmol, 1.1 eq.), Et3N (288 L, 2.1 mmol, 
1.1 eq) and THF (10 mL) to give a yellow solid (397 mg, 94%); Rf 0.25 (NH2 SiO2, 60% 
EtOAc/petrol); m.p. 178-180 C; max(EtOH)/nm 348, 222; IR  max/cm
-1
 1548.5, 1326.1; 

H NMR(500 MHz; DMSO-d6) H 1.41-1.49 (2H, m, 2 × H-piperidine), 1.82-1.90 (2H, m, 
2 × H-piperidine), 3.60-3.68 (2H, m, 2 × H-piperidine), 3.82-3.90 (1H, m, CH-OH), 4.28-
4.36 (2H, m, 2 × H-piperidine), 4.89 (1H, d, J = 4.1 Hz, OH), 9.13 (2H, s, 2 × H-
pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 33.8 (2 × CH2-piperidine), 41.7 (2 × CH2-
N-piperidine), 65.0 (CH-OH), 132.9 (C-5-pyrimidine), 155.1 (2 × CH-pyrimidine), 160.7 
(C-2-pyrimidine); HRMS calcd for C9H13N4O3 [M+H]
+
 225.0982, found 225.0985. 
1-(5-Aminopyrimidin-2-yl)piperidin-4-ol (357) 
 
Prepared according to general procedure H using nitropyrimidine 347 (382 mg, 1.70 
mmol), MeOH (40 mL) and EtOAc (40 mL) for 4 h to give a yellow gum (237 mg, 72%); 
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Rf 0.3 (NH2 SiO2, EtOAc); IR  max/cm
-1 
3329, 3223, 2852;

H NMR (500 MHz; DMSO-d6) 
H 1.26 - 1.36 (2H, m, 2 × H-piperidine), 1.71 - 1.79 (2H, m, 2 × H-piperidine), 2.99 - 3.08 
(2H, m, 2 × H-piperidine), 3.63 - 3.72 (1H, m, CH-OH), 4.10 - 4.18 (2H, m, 2 × H-
piperidine), 4.57 (2H, s, NH2), 4.66 (1H, d, J = 4.3 Hz, OH), 7.90 (2H, s, 2 × H-
pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 33.8 (2 × CH2-piperidine), 42.3 (2 × CH2-
N-piperidine), 66.6 (CH-OH), 133.8 (C-5-pyrimidine), 144.2 (2 × CH-pyrimidine), 155.9 
(C-2-pyrimidine); MS (ES+) m/z 195.3 [M+H]
+
. 
1-(5-Nitropyrimidin-2-yl)piperidin-4-yl acetate (348) 
451-79 
TFA (10 mL) was added to tert-butyl 4-acetoxypiperidine-1-carboxylate
359
 (500 mg, 2.06 
mmol) in DCM (10 mL) and the mixture was stirred at r.t. for 90 min. The solvent was 
removed in vacuo to give a clear oil. This oil was added to a solution of 2-chloro-5-
nitropyrimidine (263 mg, 1.65 mmol, 1 eq.) and triethylamine (2.3 mL, 16.5 mmol, 10 eq.) 
in THF (5 mL) and the mixture was stirred at r.t. for 30 min. The mixture was partitioned 
between EtOAc (30 mL) and HCl (2 × 20 mL, 0.5 M aq.), washed with brine, dried over 
MgSO4 and the solvent removed in vacuo to give a clear oil (1.1 g, 91%); Rf 0.2 (20% 
EtOAc/petrol); m.p. 177-179 C; max(EtOH)/nm 339; IR  max/cm
-1 
1740, 1548, 1329; 

H 
NMR(500 MHz; DMSO-d6) H 1.60-1.71 (2H, m, 2 × H-piperidine), 1.93-2.02 71 (2H, m, 
2 × H-piperidine), 2.07 (3H, s, COCH3), 3.81 (2H, ddd, J = 3.6 Hz, 8.7 and 13.6 Hz, 2 × H-
piperidine), 4.24-4.32 (2H, m, 2 × H-piperidine), 4.98-5.05 (1H, m, CHOAc), 9.12 (2H, s, 
2 × H-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 21.0 (CH3), 30.1 (2 × CH2-
piperidine), 41.4 (2 × CH2-piperidine), 68.9 (CHOAc), 133.2 (C-2-pyrimidine), 155.1 (2 × 
CH-pyrimidine), 160.8 (C-5-pyrimidine), 169.8 (CO-CH3); HRMS calcd for C11H15N4O4 
[M+H]
+
 267.1088, found 267.1089. 
1-(5-Aminopyrimidin-2-yl)piperidin-4-yl acetate (358) 
451-80 and 81 
Prepared according to general procedure H using nitropyrimidine 348 (370 mg, 1.70 
mmol) in EtOAc (40 mL) for 3 h to give a yellow solid (328 mg, 100%); Rf 0.15 (70% 
EtOAc/petrol); m.p. 119-121 C; max(EtOH)/nm 256, 350; IR  max/cm
-1 
3404, 1719; 

H 
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NMR(500 MHz; DMSO-d6) H 1.46-1.57 (2H, m, 2 × H-piperidine), 1.82-1.90 (2H, m, 2 
× H-piperidine), 2.04 (3H, s, COCH3), 3.26 (2H, ddd, J = 3.3 Hz, 9.6 and 13.4 Hz, 2 × H-
piperidine), 4.01-4.10 (2H, m, 2 × H-piperidine), 4.62 (2H, s, NH2), 4.85-4.93 (1H, m, 
CHOAc), 7.92 (2H, s, 2 × H-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 21.0 
(COCH3), 29.84 (2 × CH2-piperidine), 41.9 (2 × CH2N-piperidine), 70.3 (CH-OAc), 134.1 
(C-5-pyrimidine), 144.1 (C-4 and -6-pyrimidine), 155.7 (C-2-pyrimidine), 169.8 (COCH3); 
HRMS calc for C11H17N4O2 [M+H]
+
 237.1346, found 237.1343. 
1-(5-(4-(2-Chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxamido)pyrimidin-2-
yl)piperidin-4-yl acetate (283) 
451/82 
Prepared according to general procedure E using amine 358 (190 mg, 0.81 mmol, 2.5 eq.), 
carboxylic acid 336 (86 mg, 0.32 mmol, 1 eq.), cyanuric fluoride (19 L, 0.23 mmol, 0.7 
eq.), pyridine (26 L, 0.32 mmol, 1 eq.) and MeCN (2 mL). Purification by MPLC on NH2 
SiO2 with a gradient elution from 20-70% EtOAc/petrol gave a pale yellow solid (74 mg, 
47%); Rf 0.55 (70% EtOAc/petrol); m.p. 279-281 C; max(EtOH)/nm 288, 233; IR  
max/cm
-1 
3224, 1710, 1639, 1572; 

H NMR(500 MHz; DMSO-d6) H 1.51-1.61 (2H, m, 2 × 
H-piperidine), 1.88-1.95 (2H, m, 2 × H-piperidine), 2.06 (3H, s, COCH3), 3.45-3.53 (2H, 
m, 2 × H-piperidine), 4.15-4.22 (2H, m, 2 × H-piperidine), 4.92-4.99 (1H, m, CHOAc), 
7.40 (1H, s, H-pyrrole), 7.44 (1H, app t, J = 8.5 Hz, H-5’), 7.48-7.53 (2H, m, H-pyrrole 
and H-3’), 7.62 (1H, td, J = 8.5 and 6.1 Hz, H-4’), 8.64 (2H, s, 2 × H-pyrimidine), 10.07 
(1H, s, CO-NH), 12.71 (1H, s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.35; 

C NMR (125 MHz; DMSO-d6) C 21.0 (CH3), 30.0 (2 × CH2-piperidine), 41.1 (2 × 
CH2N-piperidine), 69.9 (CHOAc), 111.1 (CH-pyrrole), 115.0 (d, JCF = 21.7 Hz, C-5’), 
123.6 (C-pyrimidine), 125.2 (C-pyrrole), 125.9 (C-pyrrole), 128.0 (d, JCF = 18.6 Hz, C-1’), 
128.1 (d, JCF = 3.6 Hz, C-3’), 129.0 (CH-pyrrole), 130.4 (d, JCF = 6.1 Hz, C-2’), 131.8 (d, 
JCF = 9.1 Hz, C-4’), 151.1 (2 × CH-pyrimidine), 158.2 (C-pyrimidine), 158.4 (CO-NH), 
158.6 (d, JCF = 247.2 Hz, C-6’), 169.8 (CO-Me), 183.9 (CO); HRMS calc for 
C23H22
35
Cl1F1N4O4 [M+H]
+
 486.1339, found 486.1329. 
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4-(2-Chloro-6-fluorobenzoyl)-N-(2-(4-hydroxypiperidin-1-yl)pyrimidin-5-yl)-
1H-pyrrole-2-carboxamide (281) 
451-86 
K2CO3 (37 mg, 0.27 mmol, 2 eq.) was added to a solution of acetate ester 283 (65 mg, 0.13 
mmol, 1 eq.) in a mixture of THF (2 mL), MeOH (2 mL) and H2O (2 mL). The mixture 
was stirred at r.t for 18 h, partitioned between EtOAc (2 × 25 mL) and H2O (20 mL), 
washed with brine, dried over MgSO4 and the solvent removed in vacuo to give a pale 
yellow solid (55 mg, 93%); Rf 0.3 (NH2 SiO2, 5% MeOH/EtOAc); m.p. 164-166 C; 
max(EtOH)/nm 293, 233; IR  max/cm
-1 
3246, 2970, 1639, 1513; 

H NMR (500 MHz; 
DMSO-d6) H 1.31-1.42 (2H, m, 2 × H-piperidine), 1.76-1.84 (2H, m, 2 × H-piperidine), 
3.23-3.33 (2H, m, 2 × H-piperidine), 3.72-3.80 (1H, m, CHOH), 4.23-4.30 (2H, m, 2 × H-
piperidine), 4.75 (1H, d, J = 4.2 Hz, OH), 7.40 (1H, s, H-pyrrole), 7.44 (1H, app t, J = 8.5 
Hz, H-5’), 7.49 (1H, s, H-pyrrole), 8.23 (1H, d, J = 8.5 Hz, H-3’), 7.62 (1H, td, J = 8.5 and 
6.1 Hz, H-4’), 8.61 (2H, s, 2 × H-pyrimidine), 10.05 (1H, s, CO-NH), 12.70 (1H, s, NH-
pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.35; 

C NMR (125 MHz; DMSO-d6) C 
33.9 (C-piperidine), 48.6 (C-piperidine), 66.2 (C-piperidine), 111.1 (CH-pyrrole), 115.0 (d, 
JCF = 21.5 Hz, C-5’), 123.2 (C-pyrimidine), 125.2 (C-pyrrole), 125.8 (d, JCF = 3.6 Hz, C-
3’), 128.1 (d, JCF = 22.7 Hz, C-1’), 128.1 (C-pyrrole), 128.9 (CH-pyrrole), 130.4 (d, JCF = 
5.4 Hz, C-2’), 131.8 (d, JCF = 8.6 Hz, C-4’), 151.2 (2 × CH-pyrimidine), 158.4 (C-
pyrimidine), 158.4 (CO-NH), 158.6 (d, JCF = 246.8 Hz, C-2’), 183.9 (CO); HRMS calc for 
C21H20
35
Cl1F1N5O3 [M+H]
+
 444.1233, found 444.1225. 
1-(5-(4-(3,6-Dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido)pyrimidin-
2-yl)piperidin-4-yl acetate (284) 
451-87 
Prepared according to general procedure E using amine 358 (190 mg, 0.81 mmol, 2.5 eq.), 
carboxylic acid 337 (98 mg, 0.32 mmol, 1 eq.), cyanuric fluoride (19 L, 0.23 mmol, 0.7 
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eq.), pyridine (26 L, 0.32 mmol, 1 eq.) and MeCN (2 mL). Purification by MPLC on NH2 
SiO2 with a gradient elution from 20-55% EtOAc/petrol gave a pale yellow solid (90 mg, 
54%); Rf 0.3 (NH2 SiO2, 50% EtOAc/petrol); m.p. 252-254 C; max(EtOH)/nm 290, 226; 
IR  max/cm
-1 
3238, 1711, 1650, 1577; 

H NMR (500 MHz; DMSO-d6) H 1.50-1.61 (2H, 
m, 2 × H-piperidine), 1.87-1.96 (2H, m, 2 × H-piperidine), 2.06 (3H, s, COCH3), 3.46-3.53 
(2H, m, 2 × H-piperidine), 4.16-4.23 (2H, m, 2 × H-piperidine), 4.92-4.99 (1H, m, 
CHOAc), 7.44 (1H, s, H-pyrrole), 7.56 (1H, dd, J = 1.2 and 8.7 Hz, H-5’), 7.64 (1H, s, H-
pyrrole), 7.82 (1H, app t, J = 8.7 Hz, H-4’), 8.65 (2H, s, 2 × H-pyrimidine), 10.07 (1H, s, 
CO-NH), 12.78 (1H, s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -116.68; 

C 
NMR (125 MHz; DMSO-d6) C 21.0 (CH3), 30.0 (2 × CH2-piperidine), 41.1 (2 × CH2N-
piperidine), 69.9 (CH-NH-piperidine), 111.0 (CH-pyrrole), 119.3 (d, JCF = 18.1 Hz, C-3’), 
123.6 (C-pyrimidine), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.6 Hz, C-5’), 128.3 (C-pyrrole), 
129.2 (d, JCF = 19.4 Hz, C-1’), 129.2 (C-6’), 129.9 (CH-pyrrole), 131.8 (C-4’), 151.2 (2 × 
CH-pyrimidine), 153.8 (d, JCF = 248.3 Hz, C-2’), 158.2 (CO-NH), 158.4 (C-pyrimidine), 
169.8 (CO-acetate), 182.6 (CO); HRMS calc for C23H21
35
Cl2F1N5O4 [M+H]
+
 520.0949, 
found 520.0939. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-(4-hydroxypiperidin-1-yl)pyrimidin-5-
yl)-1H-pyrrole-2-carboxamide (282) 
451-88 
K2CO3(s) (42 mg, 0.31 mmol, 2 eq.) was added to a solution of 284 (80 mg, 0.15 mmol, 1 
eq.) in a mixture of THF (2 mL), MeOH (2 mL) and H2O (2 mL). The mixture was stirred 
at r.t for 18 h, partitioned between EtOAc (2 × 25 mL) and H2O (20 mL), washed with 
brine, dried over MgSO4 and the solvent removed in vacuo to give a pale yellow solid (40 
mg, 54%); Rf 0.5 (EtOAc); m.p. 200-202 C; max(EtOH)/nm 289, 227; IR  max/cm
-1 
3251, 
2934, 1638, 1585; 

H NMR(500 MHz; DMSO-d6) H 1.31-1.41 (2H, m, 2 × H-
piperidine), 1.76-1.86 (2H, m, 2 × H-piperidine), 3.28 (2H, ddd, J = 3.2 Hz, 10.0 and 13.3 
Hz, 2 × CH-N piperidine), 3.72-3.80 (1H, m, CH-OH), 4.22-4.32 (2H, m, 2 × CH-N 
piperidine), 4.75 (1H, d, J = 4.3 Hz, OH), 7.43 (1H, s, H-pyrrole), 7.56 (1H, dd, J = 1.3 
and 8.6 Hz, H-5’), 7.64 (1H, s, CH-pyrrole), 7.83 (1H, app t, J = 8.6 Hz, H-4’), 8.62 (2H, s, 
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2 × H-pyrimidine), 10.05 (1H, s, CO-NH), 12.77 (1H, s, NH-pyrrole); 

F NMR (470 
MHz; DMSO-d6) F -116.68; 

C NMR (125 MHz; DMSO-d6) C 33.9 (2 × CH2-
piperidine), 41.5 (2 × CH2-piperidine), 66.2 (CHOH), 111.0 (CH-pyrrole), 119.3 (d, JCF = 
18.1 Hz, C-3’), 123.2 (C-pyrimidine), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.6 Hz, C-5’), 
128.4 (C-pyrrole), 129.2 (d, JCF = 17.5 Hz, C-1’), 129.3 (C-6’), 129.9 (CH-pyrrole), 131.8 
(C-4’), 151.2 (2 × CH-pyrimidine), 153.8 (d, JCF = 248.4 Hz, C-2’), 158.4 (CO-NH), 158.4 
(C-pyrimidine), 182.6 (CO); HRMS calc for C21H19
35
Cl2F1N5O3 [M+H]
+
 478.0843, found 
478.0834. 
N-(1-Methylpiperidin-4-yl)-5-nitropyrimidin-2-amine (349)360 
451-72  
Prepared according to general procedure I using 2-chloro-5-nitropyrimidine (300 mg, 1.9 
mmol, 1 eq.), 4-amino-1-methylpiperidine (259 L, 2.1 mmol, 1.1 eq.), Et3N (288 L, 2.1 
mmol, 1.1 eq) and THF (10 mL) to give a yellow solid (370 mg, 83%); Rf 0.5 (NH2 SiO2, 
EtOAc); m.p. 154-157 C; max(EtOH)/nm 340, 213; IR  max/cm
-1 
3242, 1587, 1329; 

H 
NMR(500 MHz; DMSO-d6) H 1.61 (2H, qd, J = 3.5 and 11.9 Hz, 2 × H-piperidine), 1.80-
1.89 (2H, m, 2 × H-piperidine), 1.93-2.03 (2H, m, 2 × H-piperidine), 2.20 (3H, s, CH3), 
2.77-2.84 (2H, m, 2 × H-piperidine), 3.80-3.90 (1H, m, CH-NH), 8.83 (1H, d, J = 8.4 Hz, 
NH), 9.07 (1H, d, J = 3.4 Hz, H-pyrimidine), 9.13 (1H, d, J = 3.4 Hz, H-pyrimidine); 

C 
NMR (125 MHz; DMSO-d6) C 30.9 (2 × CH2-piperidine), 45.9 (N-CH3), 48.4 (CH-NH), 
54.1 (2 × CH2-N-piperidine), 133.5 (C-5-pyrimidine), 155.2 (CH-pyrimidine), 155.4 (CH-
pyrimidine), 162.1 (C-2-pyrimidine); HRMS calcd for C10H16N5O2 [M+H]
+
 238.1299, 
found 238.1301. 
N2-(1-Methylpiperidin-4-yl)pyrimidine-2,5-diamine (359)360 
451/66 
Prepared according to general procedure H using nitropyrimidine 349 (360 mg, 1.52 
mmol) and MeOH (30 mL) for 2 h to give a pale yellow solid (290 mg, 92%); Rf 0.5 (NH2 
SiO2, 5% MeOH/EtOAc); m.p. 158-161 C; max(EtOH)/nm 248; IR  max/cm
-1 
3257, 2967, 
2789; 

H NMR(500 MHz; DMSO-d6) H 1.45 (2H, qd, J = 3.6 and 11.7 Hz, 2 × H-
piperidine), 1.78-1.86 (2H, m, 2 × H-piperidine), 1.90-1.99 (2H, m, 2 × H-piperidine), 2.17 
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(3H, s, CH3), 2.70-2.77 (2H, m, 2 × H-piperidine), 3.46-3.56 (1H, m, CH-NH), 4.41 (2H, s, 
NH2), 6.02 (1H, d, J = 8.0 Hz, NH), 7.82 (2H, s, 2 × H-pyrimidine); 

C NMR (125 MHz; 
DMSO-d6) C 31.8 (2 × CH2-piperidine), 46.1 (N-CH3), 47.5 (CH-NH), 54.6 (2 × CH2N-
piperidine), 133.5 (C-5 pyrimidine), 144.6 (2 × CH-pyrimidine), 156.0 (C-2 pyrimidine); 
HRMS calcd for C10H18N5 [M+H]
+
 208.1557, found 208.1559. 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-((1-methylpiperidin-4-yl)amino)pyrimidin-
5-yl)-1H-pyrrole-2-carboxamide (288) 
 
Prepared according to general procedure E using amine 359 (140 mg, 0.68 mmol, 2.5 eq.), 
carboxylic acid 336 (72 mg, 0.27 mmol, 1 eq.), cyanuric fluoride (16 L, 0.19 mmol, 0.7 
eq.), pyridine (22 L, 0.27 mmol, 1 eq.) and MeCN (2 mL). Purification by MPLC on NH2 
SiO2 with a gradient elution from 1-8% MeOH/EtOAc gave a white solid (43 mg, 35 %); 
Rf 0.25 (NH2 SiO2, 10% MeOH/EtOAc); m.p. 287 C dec.; max(EtOH)/nm 284, 233; IR  
max/cm
-1 
3278, 1637, 1607; 

H NMR(500 MHz; DMSO-d6) H 1.53 (2H, qd, J = 3.1 and 
11.4 Hz, 2 × H-piperidine), 1.80-1.89 (2H, m, 2 × H-piperidine), 1.98 (2H, app t, J = 11.4 
Hz, 2 × H-piperidine), 2.19 (3H, s, CH3), 2.73-2.82 (2H, m, 2 × H-piperidine), 3.60-3.71 
(1H, m, CH-NH), 7.03 (1H, d, J = 7.9 Hz, NH-piperidine), 7.39 (1H, s, H-pyrrole), 7.43 
(1H, app t, J = 8.4 Hz, H-5’), 7.48 (1H, s, H-pyrrole), 7.50 (1H, d, J = 8.4 Hz, H-3’), 7.62 
(1H, td, J = 8.4 and 6.3 Hz Hz, H-4’), 8.51 (2H, s, 2 × H-pyrimidine), 9.98 (1H, s, CO-
NH), 12.68 (1H, s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.36; 

C NMR 
(125 MHz; DMSO-d6) C 31.5 (2 × CH2-piperidine), 46.0 (CH3), 48.6 (CHNH-piperidine), 
54.5 (2 × CH2N-piperidine), 111.0 (CH-pyrrole), 115.0 (d, JCF = 21.7 Hz, C-5’), 123.2 (C-
pyrimidine), 125.2 (C-pyrrole), 125.8 (d, JCF = 3.2 Hz, C-3’), 128.1 (d, JCF = 22.98 Hz, C-
1’), 128.2 (C-pyrrole), 128.9 (CH-pyrrole), 130.4 (d, JCF = 6.4 Hz, C-2’), 131.8 (d, JCF = 
9.1 Hz, C-4’), 151.6 (2 × CH-pyrimidine), 158.4 (CO-NH), 158.5 (d, JCF = 247.0 Hz, C-6), 
158.9 (C-pyrimidine), 183.9 (CO); HRMS calcd for C22H23
35
Cl1F1N6O3 [M+H]
+
 457.1550, 
found 457.1531. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-((1-methylpiperidin-4-yl)amino) 
pyrimidin -5-yl)-1H-pyrrole-2-carboxamide (289) 
451-74 
Prepared according to general procedure E using amine 359 (150 mg, 0.72 mmol, 2.5 eq.), 
carboxylic acid 337 (88 mg, 0.29 mmol, 1 eq.), cyanuric fluoride (21 L, 0.24 mmol, 0.7 
eq.), pyridine (23 L, 0.29 mmol, 1 eq.) and MeCN (2 mL). Purification by MPLC on NH2 
SiO2 with a gradient elution from 1-7% MeOH/EtOAc gave a white solid (50 mg, 35 %); 
Rf 0.20 (5% MeOH/EtOAc, NH2 SiO2); m.p. 275 C dec.; max(EtOH)/nm 283, 226; IR  
max/cm
-1 
3163, 1642, 1593; 

H NMR(500 MHz; DMSO-d6) H 1.54 (2H, qd, J = 3.1 and 
11.5 Hz, 2 × H-piperidine), 1.81-1.89 (2H, m, 2 × H-piperidine), 1.92-2.02 (2H, m, 2 × H-
piperidine), 2.19 (3H, s, CH3), 2.73-2.81 (2H, m, 2 × H-piperidine), 3.61-3.72 (1H, m, CH-
NH-piperidine), 7.02 (1H, d, J = 7.8 Hz, NH-piperidine), 7.42 (1H, s, H-pyrrole), 7.56 (1H, 
d, J = 8.6 Hz, H-5’), 7.63 (1H, s, H-pyrrole), 7.82 (1H, app t, J = 8.6 Hz, H-4’), 8.51 (2H, 
s, 2 × H-pyrimidine), 9.98 (1H, s, CO-NH), 12.74 (1H, br s, NH-pyrrole); 

F NMR (470 
MHz; DMSO-d6) F -116.67; 

C NMR (125 MHz; DMSO-d6) C 31.5 (2 × CH2-
piperidine), 46.0 (CH3), 48.6 (CH-NH-piperidine), 54.5 (2 × CH2N-piperidine), 110.9 (CH-
pyrrole), 119.3 (d, JCF = 18.0 Hz, C-3’), 123.2 (C-pyrimidine), 124.7 (C-pyrrole), 126.9 (d, 
JCF = 3.6 Hz, C-5’), 128.5 (C-pyrrole), 128.8 (CH-pyrrole), 129.2 (d, JCF = 22.3 Hz, C-1’), 
129.2 (d. JCF = 5.1 Hz, C-6’), 131.8 (C-4’), 151.6 (2 × CH-pyrimidine), 153.8 (d, JCF = 
248.9 Hz, C-2’), 158.4 (CO-NH), 158.9 (C-pyrimidine), 182.6 (CO); HRMS calcd for 
C22H21
35
Cl2F1N6O2 [M+H]
+
 491.1160, found 491.1150. 
N-(1-Cyclopropylpiperidin-4-yl)-5-nitropyrimidin-2-amine (350) 
451-99 
Prepared according to general procedure I using 1-cyclopropylpiperidin-4-amine (125 mg, 
0.89 mmol, 1 eq.), 2-chloro-4-nitropyrimidine (142 mg, 0.89 mmol, 1 eq.), Et3N (136 L, 
0.98 mmol, 1.1 eq.) and THF (2 mL) with stirring for 3 h to give a yellow solid (222 mg, 
95%); Rf 0.8 (EtOAc, NH2 SiO2); m.p. 141-143 C; max(EtOH)/nm 348, 216; IR max/cm
-1 
1576, 1545, 1328; 

H NMR(500 MHz; DMSO-d6) H 0.29-0.34 (2H, m, 2 × H-cPr), 0.42-
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0.47 (2H, m, 2 × H-cPr), 1.52 (2H, qd, J = 3.6 and 12.0 Hz, 2 × H-piperidine), 1.60-1.66 
(1H, m, N-CH cPr), 1.80-1.88 (2H, m, 2 × H-piperidine), 2.21-2.30 (2H, m, 2 × H-
piperidine), 2.93-3.00 (2H, m, 2 × H-piperidine), 3.84-3.94 (1H, m, CH-NH piperidine), 
8.83 (1H, d, J = 7.9 Hz, NH), 9.07 (1H, d, J = 3.3 Hz, H-pyrimidine), 9.14 (1H, d, J = 3.3 
Hz, H-pyrimidine); 

C NMR (125 MHz; DMSO-d6) C 6.0 (2 × CH2-cPr), 31.0 (2 × CH2-
piperdine), 38.0 (CHN-cPr), 49.0 (CHN-piperidine), 52.0 (2 × CH2-piperdine), 133.5 (C-
pyrimidine), 155.2 (CH-pyrimidine), 155.4 (CH-pyrimidine), 162.1 (C-pyrimidine); 
HRMS calcd for C12H18N5O2 [M+H]
+
 264.1455, found 264.1455. 
N2-(1-cyclopropylpiperidin-4-yl)pyrimidine-2,5-diamine (360) 
451-100 
Prepared according to general procedure H using nitropyrimidine 350 (207 mg, 0.79 
mmol), MeOH (20 mL) and EtOAc (20 mL) for 2 h to give an orange gum (279 mg, 
100%); Rf 0.3 (EtOAc, NH2 SiO2); m.p. 120-122 C; max(EtOH)/nm 250, 228; IR max/cm
-
1 
3285, 3204, 2932, 2789; 

H NMR(500 MHz; DMSO-d6) H 0.27-0.32 (2H, m, 2 × H-
cPr), 0.41-0.45 (2H, m, 2 × H-cPr), 1.37 (2H, qd, J = 3.2 and 11.3 Hz, 2 × H-piperidine), 
1.57-1.63 (1H, m, N-CH cPr), 1.78-1.85 (2H, m, 2 × H-piperidine), 2.19-2.27 (2H, m, 2 × 
H-piperidine), 2.88-2.95 (2H, m, 2 × H-piperidine), 3.50-3.61 (1H, m, CH-NH piperidine), 
4.40 (2H, s, NH2), 6.01 (1H, d, J = 8.1 Hz, NH), 7.82 (2H, s, 2 × H-pyrimidine); 

C NMR 
(125 MHz; DMSO-d6) C 5.9 (2 × CH2-cyclopropyl), 31.8 (2 × CH2-piperidine), 38.1 
(CHN-cyclopropyl), 48.1 (CHN-piperidine), 52.4 (2 × CH2-piperidine), 133.5 (C-5-
pyrimidine), 144.6 (C-4 and C-6-pyrimidine), 155.9 (C-2-pyrimidine); HRMS calc for 
C23H21
35
Cl2F1N5O4 [M+H]
+
 234.1713, found 234.1710. 
N-(2-((1-Cyclopropylpiperidin-4-yl)amino)pyrimidin-5-yl)-4-(3,6-dichloro-2-
fluorobenzoyl)-1H-pyrrole-2-carboxamide (290) 
451-103 
Prepared according to general procedure E using amine 360 (170 mg, 0.73 mmol, 2.5 eq.), 
carboxylic acid 337 (88 mg, 0.29 mmol, 1 eq.), cyanuric fluoride (7 L, 0.09 mmol, 0.3 
328 
 
eq.), pyridine (23 L, 0.29 mmol, 1 eq.) and MeCN (2 mL), with stirring for 24 h at room 
temperature followed by 24 h at 40 C. Purification by MPLC on SiO2 with a gradient 
elution from 4-15% MeOH/EtOAc gave a yellow solid (23 mg, 15%); Rf 0.25 (EtOAc, 
NH2 SiO2); m.p. 170 C dec.; max(EtOH)/nm 294, 216; IR max/cm
-1 
3311 (br), 1640, 
1609; 

H NMR(500 MHz; DMSO-d6) H 0.29-0.34 (2H, m, 2 × H-cyclopropyl), 0.41-0.46 
(2H, m, 2 × H-cyclopropyl), 1.45 (2H, app qd, J = 3.6 and 11.8 Hz, 2 × H-piperidine), 
1.59-1.65 (1H, m, N-CH-cyclopropyl), 1.81-1.88 (2H, m, 2 × H-piperidine), 2.25 (2H, app 
td, J = 11.8 and 2.0 Hz, 2 × H-piperidine), 2.90-3.00 (2H, m, 2 × H-piperidine), 3.65-3.75 
(1H, m, NH-CH--piperidine), 7.03 (1H, d, J = 7.9 Hz, NH), 7.42 (1H, s, H-pyrrole), 7.56 
(1H, dd, J = 1.1 and 8.5 Hz, H-4‘), 7.63 (1H, s, H-pyrrole), 7.82 (1H, app t, J = 8.5 Hz, H-
5’), 8.51 (2H, s, 2 × H-pyrimidine); F NMR (470 MHz; DMSO-d6) F -116.68; 

C NMR 
(125 MHz; DMSO-d6) C 6.0 (2 × CH2-cPr), 31.500 (2 × CH2-piperidine), 38.1 (CHN-
cPr), 48.1 (CHN-piperidine), 52.3 (2 × CH2N-piperidine), 110.9 (CH-pyrrole), 119.3 (d, 
JCF = 18.2 Hz, C-3’), 123.1 (C-pyrimidine), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.6 Hz, C-
5’), 128.4 (C-pyrrole), 129.2 (d, JCF = 22.71 Hz, C-1’), 129.2 (d, JCF = 5.2 Hz, C-6’), 129.8 
(CH-pyrrole), 131.8 (C-4’), 151.6 (C-pyrimidine), 153.8 (d, JCF = 248.5 Hz, C-2’), 158.4 
(CO-NH), 158.9 (C-pyrimidine), 182.6 (CO); HRMS calcd for C24H24
35
Cl2F1N6O2 [M+H]
+
 
517.1319, found 517.1304. 
2-Methoxy-5-nitropyrimidine (363)361,362 
 
Sodium (35 mg, 1.5 mmol, 1.2 eq.) was added to methanol (5 mL) and the mixture stirred 
under nitrogen until the sodium had dissolved. 5-Nitro-2-chloropyrimidine (200 mg, 1.25 
mmol, 1 eq.) was added and the mixture heated at reflux for 1 h. The solvent was removed 
in vacuo and the residue purified by MPLC on SiO2 with a gradient elution from 10-20% 
EtOAc/petrol to give a yellow solid (115 mg, 59%); Rf 0.4 (20% EtOAc/petrol); m.p. 65-
67 C (Lit.361 69-70 C); max(EtOH)/nm 270 nm; IR  max/cm
-1
 1567, 1474, 1404, 1315; 

H 
NMR (500 MHz; DMSO-d6) H 4.08 (3H, s, OMe), 9.42 (2H, s, H-pyrimidine); 

C NMR 
(125 MHz; DMSO-d6) C 56.4 (Me), 138.8 (C-NO2), 156.4 (2 × CH-pyrimidine), 166.7 (C-
O-Me); MS m/z (ES+) 156.2 [M+H]
+
. 
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2-Methoxypyrimidin-5-amine (364)363 
 
Prepared according to general procedure H using nitropyrimidine 363 (140 mg, 0.9 mmol) 
in MeOH (5 mL) for 90 min. The solvent was removed in vacuo to give a white solid (109 
mg, 97%); Rf 0.1 (5% MeOH/DCM, NH2 SiO2); m.p. 113-116 C (lit.
363
 119-120 C) ; 
max(EtOH)/nm 327, 237; IR  max/cm
-1
 3304, 3180, 1648(w), 1565; 

H NMR (500 MHz; 
DMSO-d6) H 3.78 (3H, s, OMe), 5.01 (2H, s, NH2), 7.99 (s, 2H, H-pyrimidine); 

C NMR 
(125 MHz; DMSO-d6) C 53.9 (OMe), 137.9, (C-NH2), 144.3 (2 × CH-pyrimidine), 157.8 
(C-O-Me); MS m/z (ES+) 126.2 [M+H]
+
. 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-methoxypyrimidin-5-yl)-1H-pyrrole-2-
carboxamide (271) 
 
Prepared according to general procedure E using carboxylic acid 336 (86 mg, 0.32 mmol, 1 
eq.), amine 364 (100 mg, 0.8 mmol, 2.5 eq.), pyridine (26 L, 0.32 mmol, 1 eq.) and 
cyanuric fluoride (19 L, 0.22 mmol, 0.7 eq.). Purification by MPLC on SiO2 with a 
gradient elution from 0-3% MeOH/CH2Cl2 gave a white solid (52 mg, 43 %); Rf ; 0.15 
(50% EtOAc/petrol); m.p. 258 C dec.; max(EtOH)/nm 267; IR  max/cm
-1
 3337, 2961, 
1649, 1616, 1583; 

H NMR (500 MHz; DMSO-d6) H 3.94 (3H, s, OMe), 7.41-7.48 (2H, 
m, H-pyrrole and H-5’), 7.51 (1H, d, J = 8.3 Hz, H-3’), 7.54 (1H, br s, H-pyrrole), 7.62 
(1H, td, J = 8.3 and 6.3 Hz, H-4’), 8.90 (2H, s, 2 × CH-pyrimidine), 10.34 (1H, s, NH), 
12.78 (1H, br s, NH); 

F NMR (470 MHz; DMSO-d6) F -114.34; 

C NMR (125 MHz; 
DMSO-d6) C 54.7 (OMe), 111.6 (CH-pyrrole), 115.0 (d, JCF = 21.3 Hz, C-5’), 125.3 (C-
pyrrole), 125.9 (d, JCF = 3.0 Hz, C-3’), 127.8 (C-pyrimidine), 128.0 (d, JCF = 23.2 Hz, C-
1’), 128.6 (C-pyrrole), 129.3 (CH-pyrrole), 130.4 (d, JCF = 5.9 Hz, C-2’), 131.9 (d, JCF = 
9.1 Hz, C-4’), 151.4 (C-pyrimidine), 156.6 (d, JCF = 248 Hz, C-6’), 158.55 (C-pyrimidine), 
161.3 (CO-NH), 183.9 (CO); MS (ES+) m/z 375.3 (75.8%) [M(
35
Cl)+H]
+
, 377.3 (24.2%) 
[M(
37
Cl)+H]
+
; HRMS calcd for C17H12
35
Cl1F1N4O3 [M+H]
+
 375.0655, found 375.0648. 
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tert-Butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate (366)365 
451-98 
N
1
-Boc-piperazine (2.35 g, 12.7 mmol, 2 eq.), 2-chloro-5-nitropyridine (1.00 g, 6.3 mmol, 
1 eq.) and K2CO3 (1.75 g, 12.7 mmol, 2 eq.) were combined in THF (10 mL) and stirred at 
r.t. for 72 h. The mixture was partitioned between EtOAc (2 × 70 mL) and HCl (2 × 30 
mL, 0.5 M aq.) washed with brine, dried over MgSO4 and the solvent removed in vacuo to 
give an orange oil (1.85 g, 97 %); Rf 0.5 (50% EtOAc/Petrol); m.p.168-170 C (Lit.
364
 169 
C); max(EtOH)/nm 358, 228; IR max/cm
-1 
1688, 1594, 1338; 

H NMR(500 MHz; 
DMSO-d6) H 1.46 (9H, s, C(CH3)3), 3.46-3.52 (4H, m, 4 × H-piperazine), 3.78-3.83 (4H, 
m, 4 × H-piperazine), 6.97 (1H, d, J = 9.6 Hz, H-3-pyridine), 8.29 (1H, dd, J = 2.8 and 9.6 
Hz, H-4-pyridine), 9.01 (1H, d, J = 2.8 Hz, H-6-pyridine); 

C NMR (125 MHz; DMSO-
d6) C 28.0 (C(CH3)3), 44.1 (C-piperazine), 79.2 (C(CH3)3), 105.7 (C-3-pyridine), 132.9 
(C-4-pyridine), 134.4 (C-5-pyridine), 146.0 (C-6-pyridine), 153.8 (C-2-pyridine), 160.1 
(CO); HRMS calc for C14H21N4O4 [M+H]
+
 309.1557, found 309.1558.  
tert-Butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate (368)366 
451-102 
Prepared according to general procedure H using nitropyridine 366 (1.83 g, 5.9 mmol), 
MeOH (60 mL) and EtOAc (60 mL) for 24 h to give a beige solid (1.65 g, 100%); Rf 0.65 
(EtOAc, NH2 SiO2); m.p. 109 C dec.; max(EtOH)/nm 255; IR max/cm
-1 
3382, 3321, 
2975.8, 2820, 1685; 

H NMR(500 MHz; DMSO-d6) H 1.45 (9H, s, C(CH3)3), 3.19-3.25 
(4H, m, 4 × H-piperazine), 3.40-3.47 (4H, m, 4 × H-piperazine), 4.64 (2H, br s, NH2), 6.68 
(1H, d, J = 8.7 Hz, H-3-pyridine), 6.96 (1H, dd, J = 2.9 and 8.7 Hz, H-4-pyridine), 7.64 
(1H, d, J = 2.9 Hz, H-6-pyridine); 

C NMR (125 MHz; DMSO-d6) C 28.1 (C(CH3)3), 
43.4 (C-piperazine), 46.3 (C-piperazine), 78.8 (C(CH3)3), 108.8 (C-3-pyridine), 124.4 (C-
4-pyridine), 133.3 (C-5-pyridine), 137.6 (C-6-pyridine), 152.0 (C-2-pyridine), 153.9 (CO-
carbamate); HRMS calc for C14H21N4O2 [M-H]
-
 277.1670, found 277.1666.  
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tert-Butyl 4-(5-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido) 
pyridin-2-yl)piperazine-1-carboxylate (370) 
451-105 
Prepared according to general procedure E using amine 368 (436 mg, 1.57 mmol, 2.5 eq.), 
carboxylic acid 337 (190 mg, 0.63 mmol, 1 eq.), cyanuric fluoride (16 L, 0.19 mmol, 0.3 
eq.), pyridine (51 L, 0.63 mmol, 1 eq.) and MeCN (4 mL) with stirring at 40 C for 18 h. 
Purification by MPLC on SiO2 with a gradient elution from 20-60% EtOAc/petrol gave a 
grey solid (160 mg, 45%); Rf 0.5 (EtOAc, NH2 SiO2); m.p. 159-160 C; max(EtOH)/nm 
293, 213; IR max/cm
-1 
1663, 1647; 

H NMR(500 MHz; DMSO-d6) H 1.46 (9H, s, 
C(CH3)3), 3.34-3.38 (4H, br s, 8 × H-piperazine), 6.91 (1H, d, J = 9.0 Hz, H-3-pyridine), 
7.46 (1H, br s, H-pyrrole), 7.55 (1H, dd, J = 1.3 and 8.8 Hz, H-3’), 7.61 (1H, br s, H-
pyrrole), 7.82 (1H, app t, J = 8.8 Hz, H-4’), 7.90 (1H, dd, J = 2.5 and 9.0 Hz, H-4-
pyridine’), 8.46 (1H, d, J = 2.5 Hz, H-6-pyridine), 10.01 (1H, s, CO-NH), 12.72 (1H, s, 
NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -116.67; 

C NMR (125 MHz; DMSO-d6, 
110 C) C 28.7 (C(CH3)3), 43.6 (2 × CH2-piperazine)), 45.6 (2 × CH2-piperazine), 79.5 
(C(CH3)3), 107.4 (C-3-pyridine), 111.4 (CH-pyrrole), 119.4 (d, JCF = 18.1 Hz), 124.7 (C-
pyrrole), 126.4 (C-pyridine), 126.9 (d, JCF = 3.6 Hz, C-5’), 128.8 (C-pyrrole), 129.2 (d, JCF 
= 23.2 Hz, C-1’), 129.2 (d, JCF = 5.0 Hz, C-6’), 129.8 (CH-pyrrole), 131.0 (C-pyridine), 
131.8 (C-4’), 140.0 (C-pyridine), 153.8 (d, JCF = 248.4 Hz, C-2’), 153.9 (CO-carbamate), 
155.6 (C-pyridine), 158.2 (CO-NH), 182.6 (CO); HRMS calc for C26H27
35
Cl2F1N5O4 
[M+H]
+
 562.1419, found 562.1415. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-(piperazin-1-yl)pyridin-3-yl)-1H-
pyrrole-2-carboxamide (292) 
451-107 
Prepared according to general procedure G using carbamate 370 (145 mg, 0.26 mmol, 1 
eq.), Et3SiH (102 L, 0.64 mmol, 2.5 eq.), TFA (1.5 mL) and CH2Cl2 (1.5 mL). The 
reaction was purified by MPLC on NH2 SiO2 with a gradient elution from 0-4% 
MeOH/EtOAc gave a yellow solid 55 mg (46%); Rf 0.4 (5% MeOH/EtOAc, NH2 SiO2); 
m.p. 195 C dec.; max(EtOH)/nm 293, 213; IR max/cm
-1 
1633; 

H NMR(500 MHz; 
DMSO-d6) H 2.78-2.84 (4H, m, 4 × H-piperazine), 3.36-3.41 (4H, m, 4 × H-piperazine), 
6.85 (1H, d, J = 9.1 Hz, H-3-pyridine), 7.45 (1H, s, H-pyrrole), 7.55 (1H, dd, J = 1.2 and 
8.6 Hz, H-3’), 7.61 (1H, s, H-pyrrole), 7.82 (1H, app t, J = 8.6 Hz, H-4’), 7.86 (1H, dd, J = 
2.6 and 9.1 Hz, H-4-pyridine), 8.43 (1H, d, J = 2.6 Hz, H-6-pyridine), 9.98 (1H, s, CO-
NH); 

F NMR (470 MHz; DMSO-d6) F -116.66; 

C NMR (125 MHz; DMSO-d6) C 45.4 
(2 × CH2-piperazine), 46.2 (2 × CH2-piperazine), 106.6 (C-3-pyridine), 110.7 (CH-
pyrrole), 119.3 (d, JCF = 18.1 Hz, C-3’), 124.7 (C-pyrrole), 125.9 (C-pyridine), 126.9 (d, 
JCF = 3.7 Hz, C-5’), 128.9 (C-pyrrole), 129.2 (d, JCF = 5.1 Hz, C-6’), 129.2 (d, JCF = 23.2 
Hz, C-1’), 129.8 (CH-pyrrole), 130.9 (C-2-pyridine), 131.8 (C-4-pyridine), 140.1 (C-6-
pyridine), 153.8 (d, JCF = 248.4 Hz, C-2’), 156.3 (C-5-pyridine), 158.2 (CO-NH), 182.6 
(CO); HRMS calc for C21H19
35
Cl2F1N5O2 [M+H]
+
 462.0894, found 462.0884. 
tert-Butyl 4-(5-(4-(6-chloro-2-fluoro-3-methoxybenzoyl)-1H-pyrrole-2-
carboxamido)pyridin-2-yl)piperazine-1-carboxylate (422) 
451-151 
Prepared according to general procedure E using amine 368 (350 mg, 1.26 mmol, 2.5 eq.), 
carboxylic acid 421 (150 mg, 0.50 mmol, 1 eq.), cyanuric fluoride (30 L, 0.35 mmol, 0.7 
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eq.), pyridine (41 L, 0.50 mmol, 1 eq.) and MeCN (3 mL) with stirring at r.t. for 18 h. 
Purification by MPLC on SiO2 with a gradient elution from 40-60% EtOAc/petrol gave a 
white solid (141 mg, 50%);. Rf 0.1 (40% EtOAc/petrol, SiO2); m.p. 144 C dec.; IR 
max/cm
-1 
3269 br, 2975.9, 1644.8; 

H NMR(500 MHz; DMSO-d6) H 1.46 (9H, s, 
C(CH3)3), 3.36 (8H, br s, 8 × CH-piperazine), 3.94 (3H, s OCH3), 6.91 (1H, d, J = 9.1 Hz, 
H-3-pyridine), 7.36 (1H, app t, J = 9.0 Hz, H-4’), 7.40-7.45 (2H, m, H-pyrrole and H-3’), 
7.47 (H-pyrrole), 7.90 (1H, dd, J = 2.6 and 9.1 Hz, H-4-pyridine’), 8.46 (1H, d, J = 2.6 Hz, 
H-6-pyridine), 10.01 (1H, s, CO-NH), 12.64 (1H, s, NH-pyrrole); 

F NMR (470 MHz; 
DMSO-d6) F -136.15; 

C NMR (125 MHz; DMSO-d6) C 28.1 (C(CH3)3), 44.9 (4 × CH2-
piperazine), 56.4 (OCH3), 79.0 (C(CH3)3), 107.1 (C-3-pyridine), 110.9 (CH-pyrrole), 115.1 
(C-4’), 120.2 (d, JCF = 4.8 Hz, C-1’), 125.1 (C-pyrrole), 125.5 (d, JCF = 3.6 Hz, C-5’), 
126.4 (C-pyridine), 128.4 (C-6’), 128.5 (C-pyrrole), 129.0 (CH-pyrrole), 130.9 (C-4-
pyridine), 140.0 (C-6-pyridine), 146.4 (d, JCF = 10.7 Hz, C-3’), 147.9 (d, JCF = 247.0 Hz, 
C-2’), 153.9 (CO-carbamate), 155.6 (C-5-pyridine), 158.2 (CO-NH), 183.6 (CO); HRMS 
calcd for C27H30
35
Cl1F1N5O5 [M+H]
+
 558.1925, found 558.1911. 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(6-(piperazin-1-yl)pyridin-3-yl)-
1H-pyrrole-2-carboxamide (321) 
451-155 
Prepared according to general procedure G using carbamate 422 (120 mg, 0.22 mmol, 1 
eq.) and Et3SiH (86 L, 0.54 mmol, 2.5 eq.), TFA (1 mL) and CH2Cl2 (1 mL). Purification 
by MPLC on NH2 SiO2 with a gradient elution from 2-8% MeOH/CH2Cl2 gave a white 
solid (71 mg, 72%); Rf 0.3 (10% MeOH/CH2Cl2, NH2 SiO2); m.p. 184C dec.; 
max(EtOH)/nm 298, 230; IR max/cm
-1 
3133.5 br, 2839.5, 1635.0; 

H NMR(500 MHz; 
DMSO-d6) H 2.78-2.84 (4H, m, 4 × CH-piperazine), 3.34-3.41 (4H, m, 4 × CH-
piperazine), 3.94 (3H, s OCH3), 6.84 (1H, d, J = 9.1 Hz, H-3-pyridine), 7.36 (1H, app t, J = 
8.9 Hz, H-4’), 7.39-7.44 (2H, m, H-pyrrole and H-3’), 7.47 (H-pyrrole), 7.85 (1H, dd, J = 
2.6 and 9.1 Hz, H-4-pyridine’), 8.42 (1H, d, J = 2.6 Hz, H-6-pyridine), 9.98 (1H, s, CO-
NH); 

F NMR (470 MHz; DMSO-d6) F -136.15; 

C NMR (125 MHz; DMSO-d6) C 45.4 
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(2 × CH2-piperazine), 46.2 (2 × CH2-piperazine), 56.4 (OCH3), 106.6 (C-3-pyridine), 110.8 
(CH-pyrrole), 115.1 (C-4’), 120.2 (d, JCF = 4.5 Hz, C-1’), 125.1 (C-pyrrole), 125.5 (d, JCF 
= 3.6 Hz, C-5’), 125.9 (C-pyrrole), 130.9 (C-4-pyridine), 140.1 (C-6-pyridine), 146.4 (d, 
JCF = 10.4 Hz, C-3’), 147.9 (d, JCF = 247.5 Hz, C-2’), 156.3 (C-5-pyridine), 158.2 (CO-
NH), 183.6 (CO); HRMS calcd for C22H22
35
Cl1F1N6O3 [M+H]
+
 458.1390, found 458.1382. 
N-(1-Methylpiperidin-4-yl)-5-nitropyridin-2-amine (367) 
451-125 
1-Methyl-4-aminopiperidine (794 L, 6.32 mmol, 2 eq.), 2-chloro-5-nitropyridine (500 
mg, 3.15 mmol, 1 eq.) and K2CO3 (304 L, 2.18 mmol, 1.1 eq.) were combined in THF 
(10 mL) and heated to 80 C for 3 h. The mixture was allowed to cool to r.t., partitioned 
between EtOAc (2 × 50 mL) and water (30 mL), washed with brine, dried over MgSO4 and 
solvent removed in vacuo. The residue was purified by MPLC on SiO2 with gradient 
elution from 50-100% EtOAc/petrol to give a yellow solid (417 mg, 56 %); Rf 0.75 (5% 
MeOH/CH2Cl2, NH2 SiO2); m.p. 142-145 C; max(EtOH)/nm 224, 362; IR  max/cm
-1 
3357, 
1600, 1278; 

H NMR(500 MHz; DMSO-d6) H 1.46-1.58 (2H, m, 2 × H-piperidine), 1.85-
1.93 (2H, m, 2 × H-piperidine), 1.97-2.06 (2H, m, 2 × H-piperidine), 2.20 (3H, s, CH3), 
2.73-2.81 (2H, m, 2 × H-piperidine), 3.85-3.97 (1H, m, CH-piperidine), 6.58 (1H, d, J = 
9.4 Hz, H-3-pyridine), 8.09 (2H, m, NH and H-4-pyridine), 8.94 (1H, d, J = 2.8 Hz, H-6-
pyridine); 

C NMR (125 MHz; DMSO-d6) C 14.1 (2 × C-piperidine), 45.9 (CH3), 48.2 
(CH-piperidine), 54.0 (2 × C-piperidine), 108.5 (C-pyridine), 131.6 (C-pyridine), 134.1 (C-
pyridine), 146.9 (C-pyridine), 160.7 (C-pyridine); HRMS calc for C11H17N4O2 [M+H]
+
 
237.1346, found 237.1340. 
N2-(1-Methylpiperidin-4-yl)pyridine-2,5-diamine (369) 
451-127 
Prepared according to general procedure H using nitropyridine 367 (400 mg, 1.69 mmol) 
and MeOH (35 mL) for 18 h to give a pale pink solid (330 mg, 95 %); Rf 0.3 (5% 
MeOH/EtOAc, NH2 SiO2); m.p. 125-130 C; max(EtOH)/nm 250; IR max/cm
-1 
3286, 
3136, 2981, 2780; 

H NMR(500 MHz; DMSO-d6) H 1.37 (2H, qd, J = 11.3 and 3.5 Hz, 2 
× CH-piperidine), 1.82-1.90 (2H, m, 2 × CH-piperidine), 1.93-2.01 (2H, m, 2 × CH-
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piperidine), 2.18 (CH3), 2.69-2.76 (2H, m, 2 × CH-piperidine), 3.42-3.52 (1H, m, CH-
piperidine), 4.26 (2H, s, NH2), 5.39 (1H, d, J = 5.9 Hz, NH), 6.31 (1H, d, J = 8.7 Hz, H-3-
pyridine), 6.83 (1H, dd, J = 2.7 and 8.7 Hz, H-4-pyridine), 7.46 (1H, d, J = 2.7 Hz, H-6-
pyridine); 

C NMR (125 MHz; DMSO-d6) C 32.1 (2 × CH-piperidine), 46.1 (CH3), 47.4 
(CHNH-piperidine), 54.5 (2 × CH-piperidine), 108.7 (C-Ar), 125.4 (C-Ar), 133.1 (C-Ar), 
135.0 (C-Ar), 151.2 (C-Ar); HRMS calc for C11H19N4 [M+H]
+
 207.1604, found 207.1601. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(6-((1-methylpiperidin-4-yl)amino) 
pyridin-3-yl)-1H-pyrrole-2-carboxamide (293) 
451-130 
Amine 369 (150 mg, 0.73 mmol, 1.5 eq) was added to carboxylic acid 337 (147 mg, 0.48 
mmol, 1 eq.), pyridine (39 L, 0.48 mmol, 1 eq) and PyBrOP (339 mg, 0.73 mmol, 1.5 eq) 
in MeCN (2 mL), and the mixture was stirred at r.t. for 1 h and then partitioned between 
EtOAc (2 × 30 mL) and H2O (20 mL). The organic layers were combined, washed with 
brine, dried (MgSO4) and the solvent removed in vacuo. The residue was purified by 
MPLC on NH2 SiO2 with gradient elution from 3-15% MeOH/CH2Cl2 to give a beige 
solid, which was re-purified by MPLC on SiO2 with gradient elution from 93/3/0.3 to 
88/12/1.2 EtOAc/MeOH/NH4OH to give a white solid (45 mg, 19%); Rf 0.15 (90/10/1 
EtOAc/MeOH/NH4OH); m.p. 195-200 C; max(EtOH)/nm 280, 228; IR max/cm
-1 
2944, 
1639, 1593; 

H NMR(500 MHz; DMSO-d6) H 1.45 (2H, qd, J = 11.0 and 3.8 Hz, 2 × CH-
piperidine), 1.86-1.93 (2H, m, 2 × CH-piperidine), 1.96-2.05 (2H, m, 2 × CH-piperidine), 
2.19 (3H, s, CH3), 2.72-2.79 (2H, m, 2 × CH-piperidine), 3.59-3.69 (1H, m, CH-NH-
piperidine), 6.33 (1H, d, J = 7.8 Hz, NH-piperidine), 6.50 (1H, d, J = 8.9 Hz, H-3-
pyridine), 7.42 (1H, s, H-pyrazole), 7.55 (1H, dd, J = 1.0 and 8.6 Hz, H-5’), 7.58 (1H, s, H-
pyrazole), 7.63 (1H, dd, J = 2.6 and 9.0 Hz, H-4-pyridine), 7.81 (1H, app t, J = 8.6 Hz, H-
4’), 8.23 (1H, d, J = 2.6 Hz, H-6-pyridine), 9.85 (1H, s, CO-NH), 12.59 (1H, br s, NH-
pyrrole); 

F NMR (470 MHz; DMSO-d6) F -116.68; 

C NMR (125 MHz; DMSO-d6) C 
31.8 (2 × C-piperidine), 46.1 (CH3), 47.0 (CH-piperidine), 54.4 (2 × C-piperidine), 107.9 
(C-3-pyridine), 110.5 (CH-pyrrole), 119.3 (d, JCF = 18.3 Hz, C-3’), 124.2 (C-pyrrole), 
124.7 (C-pyridine), 126.8 (d, JCF = 3.6 Hz, C-5’), 129.0 (C-pyrrole), 129.2 (d, JCF = 9.4 
Hz, C-6’), 129.3 (d, JCF = 18.7 Hz, C-1’), 129.6 (CH-pyrrole), 131.2 (C-2-pyridine), 131.8 
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(C-4’), 140.5 (C-6-pyridine), 153.8 (d, JCF = 248.4 Hz, C-2’), 155.3 (C-5-pyridine), 158.2 
(CO-NH), 182.5 (CO); HRMS calcd for C23H23
35
Cl2F1N5O2 [M+H]
+
 490.1207, found 
490.1193. 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(6-((1-methylpiperidin-4-
yl)amino)pyridin-3-yl)-1H-pyrrole-2-carboxamide (322) 
451-154 
Prepared according to general procedure E using amine 369 (135 mg, 0.66 mmol, 2.5 eq.), 
carboxylic acid 421 (78 mg, 0.26 mmol, 1 eq.), cyanuric fluoride (16 L, 0.18 mmol, 0.7 
eq.), pyridine (21 L, 0.26 mmol, 1 eq.) and MeCN (2 mL) with stirring at r.t. for 18 h. 
Purification by MPLC on NH2 SiO2 with a gradient elution from 0-7% MeOH/CH2Cl2 
gave a red solid. Re-purification by MPLC on SiO2 with a gradient elution from 10-40% 
MeOH/CH2Cl2 gave a pale pink solid (45 mg, 35%); Rf 0.3 (5% MeOH/EtOAc, NH2 
SiO2); m.p. 255-259 C; max(EtOH)/nm 304, 228; IR max/cm
-1 
3215.1 br, 2942.4, 1622.0 
1557.8; 

H NMR(500 MHz; DMSO-d6) H 1.38-1.50 (2H, m, 2 × CH-piperidine), 1.84-
1.94 (2H, m, 2 × CH-piperidine), 1.96-2.05 (2H, m, 2 × CH-piperidine), 2.19 (3H, s, 
NCH3), 2.71-2.80 (2H, m, 2 × CH-piperidine), 3.58-3.69 (1H, m, CH-NH-piperidine), 3.94 
(OCH3), 6.32 (1H, d, J = 7.7 Hz, NH-piperidine), 6.49 (1H, d, J = 9.0 Hz, H-3-pyridine), 
7.32-7.47 (4H, m, 2 × H-pyrazole, H-4’ and H-5’), 7.64 (1H, dd, J = 2.1 & 8.9 Hz, H-4-
pyridine), 8.23 (1H, d, J = 2.1 Hz, H-6-pyridine), 9.84 (1H, s, CO-NH), 12.60 (1H, br s, 
NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -136.15; 

C NMR (125 MHz; DMSO-
d6) C 31.9 (2 × C-piperidine), 46.1 (NCH3), 47.0 (CH-piperidine), 54.4 (2 × C-piperidine), 
56.4 (OCH3), 107.9 (C-3-pyridine), 110.6 (CH-pyrrole), 115.1 (C-4’), 120.2 (d, JCF = 4.5 
Hz, C-1’), 124.2 (C-pyrrole), 125.1 (C-pyrrole), 125.5 (d, JCF = 4.5 Hz, C-5’), 128.8 (C-
6’), 128.8 (CH-pyrrole), 131.2 (C-2-pyridine), 140.5 (C-6-pyridine), 146.4 (d, JCF = 10.6 
Hz, C-3’), 147.9 (d, JCF = 246.9 Hz, C-2’), 155.2 (C-5-pyridine), 158.2 (CO-NH), 183.6 
(CO); HRMS calcd for C24H26
35
Cl1F1N5O3 [M+H]
+
 486.1703, found 486.1689. 
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4-Nitro-2-(pyrrolidin-1-yl)pyridine 1-oxide (372)314  
 
2-Chloro-4-nitropyrimidine-N-oxide (200 mg, 1.15 mmol, 1 eq.), pyrrolidine (96 L, 1.15 
mmol, 1 eq.) and NaHCO3(s) (106 mg, 1.27 mmol, 1.1 eq.) were combined in 2-propanol (5 
mL) and heated at reflux for 2 h. The solvent was removed in vacuo and the residue 
partitioned between EtOAc (3 × 30 mL) and saturated aqueous NaHCO3 (10 mL). The 
organic extracts were combined, dried over MgSO4 and the solvent removed in vacuo. The 
residue was purified by MPLC on SiO2 with a gradient from 0-10% MeOH/EtOAc to give 
a red solid (210 mg, 88%). Rf 0.4 (10% MeOH/EtOAc); m.p. 149-151 C (lit.
367
 148.5-
149.5 C); max(EtOH)/nm 400, 283, 214; IR  max/cm
-1
 1613, 1519, 1497, 1442, 1336; 

H 
NMR (500 MHz; DMSO-d6) H 1.87-1.95 (4H, m, H-pyrrolidine), 3.62-3.67 (4H, m, CH-
N-pyrrolidine), 7.49 (1H, d, J = 3.1 Hz, H-3), 7.57 (1H, dd, J = 3.1 and 7.2 Hz, H-5), 8.26 
(1H, d, J = 7.2 Hz, H-6); 

C NMR (125 MHz; DMSO-d6) C 24.7 (2 × CH2-pyrrolidine), 
49.8 (2 × CH2-N-pyrrolidine), 105.1 (C-3), 108.6 (C-5), 140.4 (C-6), 142.9 (C-4), 151.8 
(C-2); HRMS calcd for C9H12N3O3 [M+H]
+
 210.0873, found 210.0869. 
2-(Pyrrolidin-1-yl)pyridin-4-amine (373) 
 
Pyridine N-oxide 372 was dissolved in methanol (5 mL) and hydrogenated on a Thales H-
cube over 20% Pd(OH)2/C at 50 bar H2/t 50 C for 3 h with continuous recycling of the 
reaction mixture. The solvent was removed in vacuo to give a white solid (230 mg, 89%). 
Rf 0.55 (NH2 SiO2, 10% MeOH/CH2Cl2); m.p. 171-175 C (lit.
367
 178-179.5 C); 
max(EtOH)/nm 292, 233; IR  max/cm
-1
 3453, 3406, 3116, 2846, 1597; 

H NMR(500 
MHz; DMSO-d6) H 1.86-1.95 (4H, m, 2 × CH2-pyrrolidine), 3.26-3.31 (4H, m, 2 × CH2-
N-pyrrolidine), 5.52 (1H, d, J = 1.8 Hz, H-3), 5.57 (2H, br s, NH2), 5.84 (1H, dd, J = 1.8 
and 5.6 Hz, H-4), 7.58 (1H, d, J = 5.6 Hz, H-5); 

C NMR (125 MHz; DMSO-d6) C 25.0 
(2 × CH2-pyrrolidine), 46.2 (2 × CH2-N-pyrrolidine), 88.9 (C-3), 100.2 (C-5), 147.7 (C-6), 
155.0 (C-4), 158.2 (C-2); HRMS calcd for C9H14N3 [M+H]
+
 164.1182, found 164.1178. 
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4-(2-Chloro-6-fluorobenzoyl)-N-(2-chloropyridin-4-yl)-1H-pyrrole-2-
carboxamide (294) 
 
Prepared according to general procedure F using carboxylic acid 336 (360 mg, 1.35 mmol, 
1 eq.), 4-amino-2-chloropyridine (434 mg, 3.4 mmol, 2.5 eq.), PCl3 (117 L, 1.35 mmol) 
and MeCN (5 mL). Purification by MPLC on NH2 SiO2 with a gradient elution from 60-
100% EtOAc:petrol gave a white solid (227 mg, 45%); Rf 0.3 (NH2 SiO2, EtOAc); m.p. 
268-270 C; max(EtOH)/nm 295; IR  max/cm
-1
 3346, 2965, 2852, 1685, 1629; 

H 
NMR(500 MHz; DMSO-d6) H 7.44 (1H, app t, J = 8.4 Hz, H-5’), 7.51 (1H, d, J = 8.4 Hz, 
C-3’), 7.57 (1H, s, H-pyrrole), 7.58 (1H, s, H-pyrrole), 7.63 (1H, td, J = 8.4 and 6.3 Hz, H-
4’), 7.73 (1H, dd, J = 1.7 and 5.7 Hz, C-5-pyridine), 7.92 (1H, d, J = 1.7 Hz, C-3-pyridine), 
8.33 (1H, d, J = 5.7 Hz, C-6-pyridine), 10.55 (1H, s, CO-NH), 12.85 (1H, s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.31; 

C NMR (125 MHz; DMSO-d6) C 112.6 
(CH-pyrrole), 112.9 (C-3-pyridine), 113.1 (C-5-pyridine), 115.0 (d, JCF = 21.5 Hz, C-5’), 
125.4 (C-pyrrole), 125.9 (d, JCF = 3.3 Hz, C-3’), 127.6 (C-pyrrole), 127.9 (d, JCF = 21.5 
Hz, C-1’), 130.1 (CH-pyrrole), 130.4 (d, JCF = 5.9 Hz, C-2’), 131.9 (d, JCF = 9.1 Hz, C-4’), 
148.3 (C-2-pyridine), 150.3 (C-6-pyridine), 150.8 (C-4-pyridine), 158.6 (d, JCF = 246.5 Hz, 
C-6’), 159.1 (CO-NH), 183.9 (CO); HRMS calcd for C17H11
35
Cl2F1N3O2 [M+H]
+
 
378.0207, found 378.0210. 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-(pyrrolidin-1-yl)pyridin-4-yl)-1H-pyrrole-2-
carboxamide (297) 
 
Procedure 1: Prepared according to general procedure L, using carboxylic acid 336 (61 
mg, 0.23 mmol, 1 eq.), amine 373 (74 mg, 0.45 mmol, 2 eq.), 2-chloro-1-methylpyridinium 
iodide (64 mg, 0.25 mmol, 1.1 eq.) and triethylamine (79 L, 0.57 mmol, 2.5 eq.) in 
CH2Cl2 (4 mL). The mixture was heated in a sealed tube at 50 C for 2 h. The solvent was 
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removed in vacuo, and the residue was purified by MPLC on NH2 SiO2 with gradient 
elution from 0-5% MeOH/CH2Cl2. Product containing fractions were combined and the 
solvent removed in vacuo. The residue was re-purified by MPLC on SiO2 with a gradient 
elution from 50:50:0.5:0.05 to 50:50:4:0.4 EtOAc/petrol/EtOH/NH4OH to give a white 
solid (20 mg, 21%); Procedure 2: Chloropyridine 294 (60 mg, 0.15 mmol, 1 eq.) and 
pyrrolidine (20 L, 0.30 mmol, 2 eq.) were combined in NMP (1 mL) and heated under 
microwave irradiation at 250 C for 3 h. The solvent was removed in vacuo and the residue 
was purified by MPLC on NH2 SiO2 with gradient elution from 0-3% MeOH/CH2Cl2 to 
give a pale brown solid (27 mg, 42%); Rf 0.5 (NH2 SiO2, 5% MeOH/CH2Cl2); m.p. 198-
201 C; max(EtOH)/nm 293, 252; IR  max/cm
-1
 3352, 2958, 2854, 1634, 1571; 

H 
NMR500 MHz; DMSO-d6) H 1.95-2.01 (4H, m, 2 × CH2 pyrrolidine), 3.36-3.42 (4H, m, 
2 × CH2-N-pyrrolidine), 6.89 (d, 1H, J = 1.5 Hz, H-3-pyridine), 7.02 (1H, dd, J = 1.5 and 
5.7 Hz, H-5-pyridine), 7.44 (1H, app t, J = 8.4 Hz, H-5’), 7.48-7.56 (3H, m, H-3-pyrrole, 
H-5-pyrrole and H-3’), 7.62 (1H, td, J = 8.4 and 6.2 Hz, H-4’), 7.98 (1H, d, J = 5.7 Hz, H-
6-pyridine), 10.09 (1H, s, CO-NH), 12.70 (1H, br s, NH-pyrrole); 

F NMR (470 MHz; 
DMSO-d6) F -114.31; 

C NMR (125 MHz; DMSO-d6) C 25.0. (2 × CH2-pyrrolidine), 
46.3 (2 × CH2-N-pyrrolidine), 95.2 (C-3-pyridine), 103.0 (C-5-pyridine), 111.6 (CH-
pyrrole), 115.0 (d, JCF = 21.4 Hz, C-5’), 125.3 (C-pyrrole), 125.9 (d, JCF = 2.7 Hz, C-3’), 
128.3 (C-pyrrole), 129.5 (CH-pyrrole), 130.4 (d, JCF = 6.0 Hz, C-2’), 131.9 (d, JCF = 9.0 
Hz, C-4’), 146.4 (C-2-pyridine), 148.4 (C-6-pyridine), 157.9 (C-4-pyridine), 158.6 (d, JCF 
= 246.7 Hz, C-6’), 158.8 (CO-NH), 183.9 (CO); HRMS calcd for C21H19
35
Cl1F1N4O2 
[M+H]
+
 413.1175, found 413.1167. 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-
pyrrole-2-carboxamide (298) 
451-119 
Chloropyridine 294 (60 mg, 0.16 mmol), 1-methylpiperazine (36 L, 0.32 mmol, 2 eq.) 
and NMP (1 mL) were combined and heated to 250 C under microwave irradiation for 3 
h. The solvent was removed in vacuo and the residue was purified by MPLC on SiO2 with 
a gradient elution from 99:1:0.1 to 95:5:0.5 EtOAc/MeOH/NH4OH. Product containing 
fractions were combined, evaporated and the residue re-was purified by MPLC on NH2 
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SiO2 with gradient elution from 0-5% MeOH/CH2Cl2 to give a pale brown solid (10 mg, 
14%); Rf 0.25 (NH2 SiO2, 5% MeOH/EtOAc); m.p. 275 C dec.; max(EtOH)/nm 292, 250; 
IR  max/cm
-1
 3245, 1655, 1621, 1573; 

H NMR(500 MHz; DMSO-d6) H 2.25 (3H, s, 
CH3), 2.41-2.46 (4H, m, 2 × CH2-piperazine), 3.43-3.49 (4H, m, 2 × CH2-piperazine), 7.15 
(1H, dd, J = 1.3 and 5.5 Hz, H-5-pyridine), 7.19 (1H, s, H-pyrrole), 7.44 (1H, app t, J = 8.5 
Hz, H-5’), 7.48-7.58 (3H, m, H-pyrrole, H-3’ and H-3-pyridine), 7.62 (1H, dt, J = 6.1 and 
8.5 Hz, H-4’), 8.05 (1H, d, J = 5.5 Hz, H-6-pyridine), 10.11 (1H, s, CO-NH), 12.70 (1H, br 
s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -114.31; 

C NMR (125 MHz; DMSO-
d6) C 44.7 (2 × CH2-piperazine), 45.8 (CH3), 54.3 (2 × CH2-piperazine), 96.1 (C-3-
pyridine), 104.7 (C-5-pyridine), 111.7 (CH-pyrrole), 115.0 (d, JCF = 21.5 Hz, C-5’), 125.3 
(C-pyrrole), 125.9 (d, JCF = 3.1 Hz, C-3’), 128.0 (d, JCF = 23.2 Hz, C-1’), 128.2 (C-pyrrole) 
130.0 (CH-pyrrole), 130.4 (d, JCF = 5.9 Hz, C-2’), 131.9 (d, JCF = 9.1 Hz, C-4’), 147.1 (C-
2-pyridine), 148.3 (C-6-pyridine), 158.6 (d, JCF = 247.0 Hz, C-6’), 158.9 (CO-NH), 160.0 
(C-4-pyridine), 184.0 (CO); HRMS calc for C22H22
35
Cl1F1N5O2 [M+H]
+
 442.1441, found 
442.1430. 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrrole-
2-carboxamide (295) 
 
Prepared according to general procedure F using carboxylic acid 336 (112 mg, 0.42 mmol, 
1 eq.), 4-amino-2-trifluoromethyl pyridine (170 mg, 1.05 mmol, 2.5 eq.), PCl3 (37 L, 0.42 
mmol, 1 eq) and MeCN 2 mL). Purification by MPLC on NH2 SiO2 with a gradient elution 
from 50-100% EtOAc:petrol gave a white solid (63 mg, 45%); Rf 0.3 (NH2 SiO2, EtOAc); 
m.p. 311-313 C; max(EtOH)/nm 291, 272; IR  max/cm
-1
 3238, 1623, 1592, 1555; 

H 
NMR (500 MHz; DMSO-d6) H 7.42 (1H, app t, J = 8.2 Hz, H-5’), 7.49 (1H, d, J = 8.2 Hz, 
H-3’), 7.56 (1H, s, H-pyrrole), 7.57 (1H, s, H-pyrrole), 7.60 (1H, td, J = 8.2 and 6.0 Hz, H-
4’), 8.03 (1H, dd, J = 1.9 and 5.6 Hz, H-5-pyridine), 8.23 (1H, d, J = 1.9 Hz, H-3-
pyridine), 8.65 (1H, d, J = 5.6 Hz, H-6-pyridine), 10.67 (CO-NH), 12.85 (NH -pyrrole); 

F 
NMR (470 MHz; DMSO-d6) F -85.76, -114.31; 

C NMR (125 MHz; DMSO-d6) C 109.8 
(q, 3.0 Hz, C-2 pyridine), 112.7 (CH-pyrrole), 115.0 (d, JCF = 21.3 Hz, C-5’), 116.1 (C-4 
pyridine), 121.6 (q, JCF = 274.0 Hz, CF3), 125.5 (C-pyrrole), 125.9 (d, JCF = 2.7 Hz, C-3’), 
341 
 
127.6 (C-pyrrole), 127.9 (d, JCF = 22.7 Hz, C-1’), 130.2 (CH-pyrrole), 130.4 (d, JCF = 5.9 
Hz, C-2’), 132.0 (d, JCF = 9.2 Hz, C-4’), 147.2 (q, JCF = 24.9 Hz, C-2 pyridine), 147.4 (C-
pyridine), 151.1 (C-pyridine), 158.6 (d, JCF = 247.0 Hz, C-6’), 159.2 (CO-NH), 184.0 
(CO); HRMS calcd for C18H11
35
Cl1F4N3O2 [M+H]
+
 412.0470, found 412.0478. 
4-(2-Chloro-6-fluorobenzoyl)-N-(2-methoxypyridin-4-yl)-1H-pyrrole-2-
carboxamide (296) 
 
Prepared according to general procedure E using 2-methoxy-4-aminopyridine (105 mg, 
0.84 mmol, 2.5 eq.), carboxylic acid 336 (90 mg, 0.34 mmol, 1 eq.), cyanuric fluoride (20 
L, 0.24 mmol, 0.7 eq.), pyridine (27 L, 0.34 mmol, 1 eq.) and MeCN (2 mL). 
Purification by MPLC on SiO2 with a gradient elution from 20-100% EtOAc/petrol gave a 
red oil which was re-purified by MPLC on NH2 SiO2 with gradient elution from 1-7% 
MeOH/CH2Cl2 to give a white solid (42 mg, 33%); Rf 0.15 (50% EtOAc/petrol); m.p. 232 
C dec.; max(EtOH)/nm 289, 267; IR  max/cm
-1
 3225, 1631, 1587; 

H NMR(500 MHz; 
DMSO-d6)H 3.86 (3H, s, CH3), 7.31 (1H, s, H-pyrrole), 7.32 (1H, d, J = 1.6 Hz, H-3-
pyridine), 7.44 (1H, app t, J = 8.5 Hz, H-5’), 7.49-7.57 (3H, m, H-pyrrole, H-3’ and H-5-
pyridine), 7.62 (1H, app dt, J = 6.3 and 8.5 Hz, H-4’), 8.09 (1H, d, J = 5.7 Hz, H-6-
pyridine), 10.33 (CO-NH), 12.97 (NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -
114.31; 

C NMR (125 MHz; DMSO-d6) C 53.1 (CH3), 98.9 (C-pyridine), 108.5 (C-
pyridine), 112.0 (CH-pyrrole), 115.0 (d, JCF = 21.8 Hz, C-5’), 125.3 (C-pyrrole), 125.9 (d, 
JCF = 3.2 Hz, C-3’), 128.0 (C-1’), 128.0 (C-pyrrole), 129.8 (C-pyrrole), 130.4 (d, JCF = 6.8 
Hz, C-2’), 131.9 (d, JCF = 9.5 Hz, C-4’), 147.2 (C-pyridine), 148.0 (C-pyridine), 158.6 (d, 
JCF = 247.0 Hz, C-6’), 159.0 (CO-NH), 164.5 (C-2’), 183.9 (CO); HRMS calcd for 
C18H12
35
Cl1F1N3O3 [M-H]
-
 372.0557, found 372.0549. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide 
(377) 
451-158 
Prepared according to general procedure F using carboxylic acid 337 (500 mg, 1.65 mmol, 
1 eq.), 4-aminopyridine (388 mg, 4.13 mmol, 2.5 eq), PCl3 (144 L, 1.65 mmol, 1 eq.) and 
MeCN (5 mL). Purification by MPLC on SiO2 with a gradient elution from 2-10% 
MeOH/CH2Cl2 gave a white solid (360 mg, 58%); Rf 0.35 (70% EtOAc/Petrol); m.p. 267 
C dec.; max(EtOH)/nm 292, 271, 211; IR max/cm
-1 
3242, 1641; 

H NMR(500 MHz; 
DMSO-d6) H 7.56 (1H, dd, J = 1.3 and 8.6 Hz, H-5’), 7.61 (1H, s, H-pyrrole), 7.68-7.71 
(1H, m, H-pyrrole), 7.77 (1H, dd, J = 1.5 and 4.8 Hz, 2 × H-pyridine), 7.83 (1H, app t, J = 
8.6 Hz, H-4’), 8.50 (2H, dd, J = 1.5 and 4.8 Hz,, 2 × H-pyridine), 10.39 (1H, s, CO-NH), 
12.87 (1H, s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -116.64; 

C NMR (125 
MHz; DMSO-d6) C 112.0 (C-3 and C-5 pyridine), 113.7 (CH-pyrrole), 119.4 (d, JCF = 
17.9 Hz, C-3’), 124.8 (C-pyrrole), 126.9 (d, JCF = 3.6 Hz, C-5’), 128.2 (C-pyrrole), 128.9 
(C-pyrrole), 129.1 (d, JCF = 22.7 Hz, C-1’), 129.2 (d, JCF = 7.8 Hz, C-6’), 130.7 (C-4’), 
145.6 (C-2 and C-6 pyridine), 150.3 (C-4 pyridine), 153.8 (d, JCF = 248.3 Hz, C-2’), 159.0 
(CO-NH), 182.6 (CO); HRMS calcd for C17H11
35
Cl1F1N3O2 [M+H]
+
 378.0207, found 
378.0210. 
4-(4-(3,6-Dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido)pyridine-1-
oxide (378) 
451-161 
mCPBA (339 mg, 1.96 mmol, 1.5 eq.) was added to a suspension of pyridyl amide 377 
(340 mg, 0.9 mmol, 1 eq.) in MeCN (8 mL), and the mixture was stirred at r.t. for 18 h. 
Two drops of water were added, the solvent removed in vacuo, and the residue was 
purified by MPLC on SiO2 with a gradient elution from 4-15% MeOH/EtOAc to give a 
white solid (340 mg, 72%); Rf 0.5 (10% MeOH/CH2Cl2, NH2 SiO2); m.p. 211 C dec.; 
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max(EtOH)/nm 308, 299, 214; IR  max/cm
-1 
3082 br, 1646, 1207 (N-oxide); 

H NMR(500 
MHz; DMSO-d6) H 7.54-7.58 (2H, m, H-pyrrole and H-5’), 7.69 (1H, dd, J = 1.3 and 3.3 
Hz, H-pyrrole), 7.78-7.85 (3H, m, 2 × H-pyridine and H-4’), 8.17-8.21 (2H, m, 2 × H-
pyridine), 10.51 (1H, s, CO-NH), 12.87 (1H, s, NH-pyrrole); 

F NMR (470 MHz; DMSO-
d6) F -116.64; 

C NMR (125 MHz; DMSO-d6) C 111.8 (CH-pyrrole), 116.4 (C-3- and C-
5-pyridine), 119.4 (d, JCF = 18.1 Hz, C-3’), 124.8 (C-pyrrole), 126.9 (d, JCF = 3.7 Hz, C-
5’), 128.1 (C-pyrrole), 129.0 (d, JCF = 23.0 Hz, C-1’), 129.2 (d, JCF = 5.4 Hz, C-6’), 130.7 
(C-pyrrole), 131.9 (C-4’), 136.2 (C-4-pyridine), 138.8 (C-2- and C-6-pyridine), 153.8 (d, 
JCF = 248.8 Hz, C-2’), 158.4 (CO-NH), 182.6 (CO); HRMS calcd for C17H11
35
Cl2F1N3O3 
[M+H]
+
 394.0156, found 394.0154. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-
1H-pyrrole-2-carboxamide (299) 
451-166 
PyBrOP (154 mg, 0.33 mmol, 1.3 eq.) was added to a suspension of pyridine N-oxide 378 
(100 mg, 0.25 mmol, 1 eq.), 1-methylpiperazine (36 L, 0.32 mmol, 1.25 eq.) and Hunig’s 
base (165 L, 0.95 mmol, 3.75 eq.) in DCM (1.6 mL) and the reaction was stirred at r.t for 
18 h. The mixture was partitioned between EtOAc (2 × 30 mL) and H2O (20 mL), washed 
with brine, dried over MgSO4, and the solvent removed in vacuo. The residue was purified 
by MPLC on SiO2 with gradient elution from 3-8% MeOH/DCM to give impure product 
(52 mg). This was further purified by semi-preparative HPLC (mobile phase gradient from 
95:5 to 0:100 water + 0.1% v/v formic acid:MeCN on an ACE 5 C18-AR 150 x 21.2 mm 
i.d. (S/No. A110809) column). Product containing fractions were evaporated, partitioned 
between EtOAc (2 × 30 mL) and K2CO3 (20 mL, 10% aq.), washed with brine, dried over 
MgSO4, and the solvent removed in vacuo to give a white solid (20 mg, 17%); Rf 0.5 (5% 
MeOH/EtOAc, NH2 SiO2); m.p. 185 C dec.; max(EtOH)/nm 250, 222; IR  max/cm
-1 
3112, 
2932, 1641; 

H NMR(500 MHz; DMSO-d6) H 2.25 (CH3), 2.41-2.46 (4H, m, H-
piperazine), 3.44-3.50 (4H, m, H-piperazine), 7.16 (1H, dd, J = 1.6 and 5.5 Hz, H-5-
pyridine), 7.19 (H-3-pyridine), 7.53-7.58 (2H, m, H-pyrrole and H-5’), 7.68 (1H, s, H-
pyrrole), 7.83 (1H, app t, J = 8.4 Hz, H-4’), 8.05 (1H, d, J = 5.7 Hz, H-6-pyridine), 10.13 
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(1H, s, CO-NH), 12.80 (1H, br s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -
116.66; 

C NMR (125 MHz; DMSO-d6) C 44.6 (2 × CH2-piperazine), 45.8 (CH3), 54.3 (2 
× CH2-piperazine), 96.1 (C-3-pyridine), 104.7 (C-5-pyridine), 111.6 (CH-pyrrole), 119.3 
(d, JCF = 18.3 Hz, C-3’), 124.8 (C-pyrrole), 126.9 (d, JCF = 3.6 Hz, C-5’), 128.5 (C-
pyrrole), 129.1 (d, JCF = 22.7 Hz, C-1’), 129.2 (d, JCF = 5.2 Hz, ), 130.5 (C-pyrrole), 131.9 
(C-4’), 147.1 (C-pyridine), 148.3 (C-6-pyridine), 153.8 (d, JCF = 248.5 Hz, C-2’), 158.8 
(CO-NH), 160.0 (C-pyridine), 182.6 (CO); HRMS calcd for C22H21
35
Cl2F1N5O2 [M+H]
+
 
476.1051, found 476.1044. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(2-morpholinopyridin-4-yl)-1H-pyrrole-2-
carboxamide (300) 
451-181 
PyBrOP (154 mg, 0.33 mmol, 1.3 eq.) was added to a suspension of pyridine N-oxide 378 
(100 mg, 0.25 mmol, 1 eq.), morpholine (28 L, 0.37 mmol, 1.25 eq.) and Hunig’s base 
(165 L, 0.95 mmol, 3.75 eq.) in CH2Cl2 (1.6 mL) and the reaction was stirred at r.t for 18 
h. The mixture was partitioned between CH2Cl2 (2 × 20 mL) and K2CO3 (20 mL, 10% aq.), 
washed with brine, dried over MgSO4, and the solvent removed in vacuo. The residue was 
purified by MPLC on C18 reversed phase SiO2 with gradient elution from 60:40:0.4 
MeOH/H2O/HCO2H to 99.9:0.1 MeOH/HCO2H. Product containing fractions were re-
purified by MPLC on NH2 SiO2 with gradient elution from 0-4% MeOH/CH2Cl2 to give a 
white solid (16 mg, 14%); Rf 0.3 (5% MeOH/CH2Cl2); m.p. 136-140 C; max(EtOH)/nm 
251, 294; IR  max/cm
-1 
3182, 2962, 2922, 2853, 1639, 1595; 

H NMR (500 MHz; DMSO-
d6) H 3.41-3.45 (4H, m, H-morpholine), 3.72-3.77 (4H, m, H-morpholine), 7.18-7.22 (2H, 
m, H-3 pyridine and H-5-pyridine), 7.54-7.59 (2H, m, H-pyrrole and H-5’), 7.68 (1H, br s, 
H-pyrrole), 7.83 (1H, app t, J = 8.4 Hz, H-4’), 8.06-8.09 (1H, m, H-6-pyridine), 10.16 (1H, 
s, CO-NH), 12.79 (1H, br s, NH-pyrrole); 

F NMR(470 MHz; DMSO-d6) F -116.65; 

C 
NMR (125 MHz; DMSO-d6) C 45.2, 65.9, 96.0 (C-3-pyridine), 105.1 (C-5-pyridine), 
111.6 (C-pyrrole), 119.3 (d, JCF = 18.0 Hz, C-3’), 124.8 (C-pyrrole), 126.9 (d, JCF = 3.6 
Hz, C-5’), 128.4 (C-pyrrole), 129.1 (d, JCF = 22.7 Hz, C-1’), 129.2 (d, JCF = 5.0 Hz, ), 
130.5 (C-pyrrole), 131.9 (C-4’), 147.1 (C-pyridine), 148.3 (C-6-pyridine), 153.8 (d, JCF = 
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248.4 Hz, C-2’), 158.9 (CO-NH), 160.2 (C-pyridine), 182.6 (CO); HRMS calcd for 
C21H18
35
Cl2F1N4O3 [M+H]
+
 463.0735, found 463.0725. 
tert-Butyl 4-(4-nitro-1H-pyrazol-1-yl)piperidine-1-carboxylate (380)328,368  
451-90 
Prepared according to general procedure J using Boc-4-piperidinol (889 mg, 4.4 mmol), 
PPh3 (1.73 g, 6.6 mmol, 1.5 eq.), 4-nitropyrazole (500 mg, 4.4 mmol, 1 eq.) and DEAD 
(1.04 mL, 5.3 mmol, 1.5 eq.) in THF (10 mL). The residue was purified by MPLC on SiO2 
with a gradient elution from 20-40% EtOAc/petrol to give a white solid (880 mg, 67%); Rf 
0.5 (20% EtOAc/petrol); m.p. 116-118 C; max(EtOH)/nm 274; IR max/cm
-1 
3099, 2971, 
2875, 1671, 1301; 

H NMR(500 MHz; DMSO-d6) H 1.45 (9H, s, C(CH3)3), 1.85 (2H, qd, 
J = 4.2 and 11.6 Hz, 2 × H-piperidine), 2.04-2.11 (2H, m, 2 × H-piperidine), 2.80-3.07 
(2H, m, 2 × H-piperidine), 3.99-4.19 (2H, m, 2 × H-piperidine), 4.50 (1H, tt, J = 4.2 and 
11.6 Hz, CH2CHCCH2-piperidine), 8.32 (1H, s, H-pyrazole), 9.00 (1H, s, H-pyrazole); 

C 
NMR (125 MHz; DMSO-d6) C 28.0 (C(CH3)3), 31.3 (2 × CH2-piperidine), 42.4 (2 × CH2-
piperidine), 59.5 (CH-N-piperidine), 78.9 (C(CH3)3), 128.9 (C-pyrazole), 134.8 (C-
pyrazole), 135.3 (C-pyrazole), 153.7 (CO); HRMS calc for C13H19N4O4 [M-H]
-
 295.1412, 
found 295.1408. 
tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate (393)328,368 
451-92 + 94 
Prepared according to general procedure H using nitropyrazole 380 (310 mg, 1.05 mmol) 
in MeOH (15 mL) and EtOAc (15 mL) for 3 h to give a white solid (279 mg, 100%); Rf 0.4 
(EtOAc, NH2 SiO2); m.p. 86-89 C dec.; max(EtOH)/nm 248; IR max/cm
-1 
3238, 2972, 
2930, 2865, 1697, 1669; 

H NMR(500 MHz; DMSO-d6) H 1.45 (9H, s, C(CH3)3), 1.71 
(2H, qd, J = 4.2 and 11.7 Hz, 2 × H-piperidine), 1.90-1.97 (2H, m, 2 × H-piperidine), 2.75-
3.04 (2H, m, 2 × H-piperidine), 3.80 (2H, br s, NH2), 3.96-4.09 (2H, m, 2 × H-piperidine), 
4.16 (1H, tt, J = 4.2 and 11.7 Hz, CH2CHCCH2-piperidine), 6.94 (1H, s, H-pyrazole), 7.10 
(1H, s, H-pyrazole); 

C NMR (125 MHz; DMSO-d6) C 28.0 (C(CH3)3), 31.9 (2 × CH2-
piperidine), 43.2 (2 × CH2-piperidine), 57.6 (CHN-piperidine), 78.7 (C(CH3)3), 114.4 (CH-
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pyrazole), 128.9 (CH-pyrazole), 131.1 (C-pyrazole), 153.8 (CO); HRMS calc for 
C13H23N4O2 [M+H]
+
 267.1816, found 267.1815.   
tert-Butyl 4-(4-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido)-
1H-pyrazol-1-yl)piperidine-1-carboxylate (414) 
451-136 
Prepared according to general procedure E using amine 393 (200 mg, 0.75 mmol, 2.5 eq.), 
carboxylic acid 337 (91 mg, 0.30 mmol, 1 eq.), cyanuric fluoride (18 L, 0.21 mmol, 0.7 
eq.), pyridine (24 L, 0.30 mmol, 1 eq.) and MeCN (2 mL). Purification by MPLC on SiO2 
with a gradient elution from 40-70% EtOAc/petrol gave a yellow oil (125 mg, 76%); Rf 
0.35 (70% EtOAc/petrol); m.p. 144 C dec.; IR  max/cm
-1 
3123 br, 2975, 1637; 

H 
NMR(500 MHz; DMSO-d6) H 1.46 (9H, s, C(CH3)3), 1.80 (2H, app qd, J = 4.1 and 11.6 
Hz, 2 × H-piperidine), 1.97-2.04 (2H, m, 2 × H-piperidine), 2.82-3.02 (2H, m, , 2 × H-
piperidine), 4.01-4.12 (2H, m, 2 × H-piperidine), 4.38 (1H, tt, J = 3.9 and 11.5 Hz, 
CH2CHCCH2-piperidine), 7.36 (1H, s, CH-pyrrole), 7.55 (1H, dd, J = 1.1 and 8.6 Hz, H-
5’), 7.58-7.62 (2H, m, H-pyrrole and H-pyrazole), 7.82 (1H, app t, J = 8.6 Hz, H-4’), 8.02 
(1H, s, H-pyrazole), 10.30 (1H, s, CO-NH), 12.67 (1H, s, NH-pyrazole); 

F NMR (470 
MHz; DMSO-d6) F -116.66; 

C NMR (125 MHz; DMSO-d6) C 28.0 (C(CH3)3), 31.9 (2 
× CH2-piperidine), 42.8 (2 × CH2-piperidine), 58.0 (CHN-piperidine), 78.8 (C(CH3)3), 
110.2 (CH-pyrrole), 118.9 (CH-pyrazole), 119.3 (d, JCF = 18.1 Hz, C-3’), 120.9 (C-
pyrazole), 124.7 (C-pyrrole), 126.9 (d, JCF = 4.1 Hz, C-5’), 128.7 (C-pyrrole), 129.2 (JCF = 
23.1 Hz, C-1’), 129.2 (JCF = 5.1 Hz, C-6’), 129.6 (C-pyrrole), 130.0 (CH-pyrazole), 131.8 
(C-4’), 153.8 (JCF = 248.4 Hz, C-2’), 153.8 (CO-carbamate), 156.8 (CO-NH), 182.6 (CO); 
HRMS calcd for C25H27
35
Cl2F1N5O4 [M+H]
+
 550.1419, found 550.1414. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-1H-
pyrrole-2-carboxamide (302) 
451-140 
Prepared according to general procedure G using carbamate 414 (110 mg, 0.20 mmol, 1 
eq.), Et3SiH (80 L, 0.50 mmol, 2.5 eq.), TFA (1 mL) and CH2Cl2 (1 mL). The residue was 
purified by MPLC on NH2 SiO2 with a gradient elution from 1-4% MeOH/CH2Cl2 to give 
a white solid (62 mg, 69%); Rf 0.3 (10% MeOH/CH2Cl2, NH2 SiO2); m.p. 199 C dec.; 
max(EtOH)/nm 255, 223; IR  max/cm
-1 
3122 br, 2949, 1633, 1592; 

H NMR(500 MHz; 
DMSO-d6) H 1.78 (2H, app qd, J = 3.9 and 11.8 Hz, 2 × H-piperidine), 1.91-1.98 (2H, m, 
2 × H-piperidine), 2.57-2.66 (2H, m, 2 × H-piperidine), 3.01-3.11 (2H, m, 2 × H-
piperidine), 4.21 (1H, tt, J = 4.1 and 11.7 Hz, N-CH-piperidine), 7.35 (1H, s, H-pyrrole), 
7.56 (1H, d, J = 8.6 Hz, H-5’), 7.57-7.61 (2H, m, H-pyrrole and H-pyrazole), 7.82 (1H, app 
t, J = 8.6 Hz, H-4’), 7.98 (1H, s, H-pyrazole), 10.27 (1H, s, CO-NH); F NMR (470 MHz; 
DMSO-d6) F -116.66; 

C NMR (125 MHz; DMSO-d6) C 33.5 (2 × CH2-piperidine), 45.1 
(2 × CH2-piperidine), 59.0 (CHN-piperidine), 110.2 (CH-pyrrole), 118.4 (CH-pyrazole), 
119.3 (d, JCF = 18.0 Hz, C-3’), 120.8 (C-pyrazole), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.6 
Hz, C-5’), 128.8 (CH-pyrrole), 129.2 (JCF = 22.9 Hz, C-1’), 129.2 (JCF = 4.8 Hz, C-6’), 
129.7 (C-pyrrole), 130.0 (CH-pyrazole), 131.8 (C-4’), 153.8 (JCF = 248.5 Hz, C-2’), 156.9 
(CO-NH), 182.5 (CO); HRMS calcd for C20H19
35
Cl2F1N5O2 [M+H]
+
 450.0894, found 
450.0888. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-
yl)-1H-pyrrole-2-carboxamide (303) 
451-160 
Prepared according to general procedure K using carbamate 414 (75 mg, 0.137 mmol), 
formic acid (1.5 mL), and formaldehyde (44 L, 0.55 mmol, 4 eq.). The residue was 
purified by MPLC on NH2 SiO2 with a gradient elution from 2-6 % MeOH/EtOAc to give 
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a white solid (63 mg, 100%); Rf 0.25 (5% MeOH/EtOAc); m.p. 220-222 C; 
max(EtOH)/nm 252; IR  max/cm
-1 
3121, 2938, 2788, 1631; 
1
H NMR(500 MHz; DMSO-
d6) H 1.93-2.03 (4H, m, 4 × H-piperidine), 2.09-2.21 (2H, m, 2 × H-piperidine), 2.28 (3H, 
s, NCH3), 2.88-2.98 (2H, m, 2 × H-piperidine), 4.10-4.211 (1H, m, N-CH-piperidine), 7.36 
(1H, s, H-pyrrole), 7.56 (1H, dd, J = 1.3 and 8.6 Hz, H-5’), 7.58-7.61 (2H, m, H-pyrrole 
and H-pyrazole), 7.82 (1H, app t, J = 8.6 Hz, H-4’), 8.01 (1H, s, H-pyrazole), 10.29 (1H, s, 
CO-NH), 12.67 (1H, s, NH-pyrazole); 

F NMR (470 MHz; DMSO-d6) F -116.66; 

C 
NMR (125 MHz; DMSO-d6) C 31.8 (2 × CH2-piperidine), 45.5 (N-CH3), 54.0 (2 × CH2-
piperidine), , 57.8 (CHN-piperidine), 110.1 (CH-pyrrole), 118.8 (CH-pyrazole), 119.3 (d, 
JCF = 18.2 Hz, C-3’), 120.8 (C-pyrazole), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.7 Hz, C-5’), 
128.7 (CH-pyrrole), 129.2 (d, JCF = 23.1 Hz, C-1’), 129.2 (d, JCF = 4.8 Hz, C-6’), 129.5 (C-
pyrrole), 129.9 (CH-pyrazole), 131.8 (C-4’), 154.8 (d, JCF = 248.5 Hz, C-2’), 156.8 (CO-
NH), 182.6 (CO); HRMS calcd for C21H21
35
Cl2F1N5O2 [M+H]
+
 464.1051, found 464.1043. 
tert-Butyl 3-(4-nitro-1H-pyrazol-1-yl)azetidine-1-carboxylate (381)328 
451-137 
Prepared according to general procedure J using 1-Boc-3-hydroxyazetidine (766 mg, 4.42 
mmol, 1 eq.), PPh3 (1.74 g, 6.6 mmol, 1.5 eq.), 4-nitropyrazole (500 mg, 4.4 mmol, 1 eq.) 
and DEAD (1.04 mL, 6.6 mmol, 1.5 eq.) in THF (10 mL) with stirring at r.t. for 72 h. The 
residue was purified by MPLC on SiO2 with a gradient elution from 10-40% EtOAc/petrol 
to give a white solid (765 mg, 63%); Rf 0.5 (40% EtOAc/petrol); m.p. 113-117 C; 
max(EtOH)/nm 276; IR max/cm
-1 
3117, 2973, 1675; 

H NMR(500 MHz; DMSO-d6) H 
1.44 (9H, s, (9H, s, C(CH3)3), 4.14-4.24 (2H, m, 2 × CH-azetidine), 4.29-4.39 (2H, m, 2 × 
CH-azetidine), 5.31 (1H, tt, J = 5.0 and 7.9 Hz, CH2-CH-CH2-azetidine), 8.43 (1H, s, H-
pyrazole), 9.09 (1H, s, H-pyrazole); 

C NMR (125 MHz; DMSO-d6) C 28.0 (C(CH3)3), 
50.5 (C-azetidine), 79.1 (C(CH3)3), 130.8 (C-pyrazole), 135.0 (C-pyrazole), 136.3 (C-
pyrazole), 155.4 (CO); HRMS calcd for C11H20N5O4 [M+NH4]
+
 286.1510, found 
286.1511. 
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tert-Butyl 3-(4-amino-1H-pyrazol-1-yl)azetidine-1-carboxylate (394)328 
451-139 
Prepared according to general procedure H using nitropyrazole 381 (250 mg, 0.93 mmol) 
in MeOH (20 mL) for 3 h to give a clear oil (220 mg, 99 %); Rf 0.1 (EtOAc); 
max(EtOH)/nm 249; IR max/cm
-1 
3335 br, 2974, 1678; 

H NMR(500 MHz; DMSO-d6) H 
1.43 (9H, s, C(CH3)3), 3.93 (2H, br s, NH2), 4.02-4.12 (2H, m, 2 × CH-azetidine), 4.20-
4.28 (2H, m, 2 × CH-azetidine), 4.98-5.05 (1H, m, CH2-CH-CH2-azetidine), 7.07 (1H, s, 
H-pyrazole), 7.17 (1H, s, H-pyrazole); 

C NMR (125 MHz; DMSO-d6) C 28.0 (C(CH3)3), 
48.8 (C-azetidine), 55.8 (2 × C-azetidine), 78.8 (C(CH3)3), 115.7 (C-pyrazole), 130.5 (C-
pyrazole), 131.4 (C-pyrazole), 155.5 (CO); HRMS calcd for C11H18N4O2 [M+H]
+
 
239.1513, found 239.1503. 
tert-Butyl 3-(4-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido)-
1H-pyrazol-1-yl)azetidine-1-carboxylate (415) 
451-142 
Prepared according to General procedure E using amine 394 (200 mg, 0.84 mmol, 2.5 eq.), 
carboxylic acid 337 (100 mg, 0.34 mmol, 1 eq.), cyanuric fluoride (20 L, 0.24 mmol, 0.7 
eq.), pyridine (27 L, 0.34 mmol, 1 eq.) and MeCN (2 mL) with stirring at r.t. for 18 h. 
Purification by MPLC on SiO2 with a gradient elution from 40-80% EtOAc/petrol gave a 
yellow solid (124 mg, 70%); Rf 0.3 (70% EtOAc/petrol); m.p. 164 C dec.; max(EtOH)/nm 
285, 253, 223; IR max/cm
-1 
1627; 

H NMR(500 MHz; DMSO-d6) H 1.45 (9H, s, 
C(CH3)3), 4.10-4.20 (2H, m, 2 × H-azetidine), 4.25-4.36 (2H, m, 2 × H-azetidine), 5.26 
(1H, tt, J = 5.3 and 7.9 Hz, CH2-CH-CH2-azetidine), 7.37 (1H, s, H-pyrrole), 7.56 (1H, dd, 
J = 1.0 and 8.6 Hz, H-5’), 7.60 (1H, s, H-pyrrole), 7.71 (1H, s, H-pyrazole), 7.82 (1H, app 
t, J = 8.6 Hz, H-4’), 8.13 (1H, s, H-pyrazole), 10.35 (1H, s, CO-NH), 12.70 (1H, s, NH-
pyrrole);

F NMR (470 MHz; DMSO-d6) F -116.66; 

C NMR (125 MHz; DMSO-d6) C 
28.0 (C(CH3)3), 49.1 (C-azetidine), 55.8 (2 × C-azetidine), 78.9 (C(CH3)3), 110.3 (CH-
pyrrole), 119.3 (d, JCF = 18.1 Hz, C-3’), 120.7 (C-pyrazole), 121.4 (C-pyrazole), 124.7 (C-
pyrrole), 126.9 (d, JCF = 4.0 Hz, C-5’), 128.6 (C-pyrrole), 129.2 (d, JCF = 23.0 Hz, C-1’), 
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129.2 (d, JCF = 5.0 Hz, C-6’), 129.6 (C-pyrrole), 131.4 (C-pyrazole), 131.8 (C-4’), 153.8 
(d, JCF = 248.5 Hz, C-2’), 155.6 (CO-carbamate), 156.9 (CO-NH), 182.6 (CO); HRMS 
calcd for C23H23
35
Cl2F1N5O4 [M+H]
+
 522.1106, found 522.1103. 
N-(1-(Azetidin-3-yl)-1H-pyrazol-4-yl)-4-(3,6-dichloro-2-fluorobenzoyl)-1H-
pyrrole-2-carboxamide (304) 
451-145 
Prepared according to general procedure G using carbamate 415 (100 mg, 0.19 mmol, 1 
eq.), Et3SiH (76 L, 0.48 mmol, 2.5 eq.), TFA (1 mL) and CH2Cl2 (1 mL). Purification by 
MPLC on NH2 SiO2 with a gradient elution from 2-8% MeOH/CH2Cl2 gave a white solid 
(69 mg, 85%); Rf 0.15 (5% MeOH/CH2Cl2, NH2 SiO2); m.p. 306-309 C; max(EtOH)/nm 
254, 223; IR max/cm
-1 
3123.7 br, 2961.7, 1634.0, 1592.8, 1563.2; 

H NMR(500 MHz; 
DMSO-d6) H 3.76 (2H, app t, J = 7.7 Hz, 2 × H-azetidine), 3.89-3.95 (2H, m, 2 ×H-
azetidine), 5.21 (1H, quin, J = 7.7 Hz, CH-N-azetidine), 7.36 (1H, s, H-pyrrole), 7.56 (1H, 
dd, J = 1.0 and 8.5 Hz, H-5’), 7.60 (1H, s, H-pyrrole), 7.64 (1H, s, H-pyrazole), 7.83 (1H, 
app t, J = 8.5 Hz, H-4’), 8.13 (1H, s, H-pyrazole), 10.32 (1H, s, CO-NH); F NMR (470 
MHz; DMSO-d6) F -116.66; 

C NMR (125 MHz; DMSO-d6) C 53.4 (2 × C-azetidine), 
54.4(C-azetidine), 110.3 (CH-pyrrole), 119.3 (d, JCF = 18.0 Hz, C-3’), 119.7 (C-pyrazole), 
121.3 (C-pyrazole), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.5 Hz, C-5’), 128.7 (C-pyrrole), 
129.2 (d, JCF = 22.9 Hz, C-1’), 129.2 (d, JCF = 5.3 Hz, C-6’), 129.7 (C-pyrrole), 130.5 (C-
pyrazole), 131.8 (C-4’), 153.8 (d, JCF = 248.6 Hz, C-2’), 156.9 (CO-NH), 182.5 (CO); 
HRMS calcd for C18H15
35
Cl2F1N5O2 [M+H]
+
 422.0581, found 422.0578. 
tert-Butyl 4-((4-nitro-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate (382) 
451-113 
Prepared according to general procedure J using Boc-4-piperidinemethanol (951 mg, 4.4 
mmol, 1 eq.), PPh3 (1.74 g, 6.6 mmol, 1.5 eq.), 4-nitropyrazole (500 mg, 4.4 mmol, 1 eq.) 
and DEAD (1.04 mL, 6.6 mmol, 1.5 eq.) in THF (10 mL). The residue was purified by 
MPLC on SiO2 with a gradient elution from 10-60% EtOAc/petrol to give a white solid 
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(1.135 g, 82%); Rf 0.35 (40% EtOAc/petrol); m.p. 158-160 C; max(EtOH)/nm 271; IR 
max/cm
-1 
1665, 1506, 1312.; 

H NMR(500 MHz; DMSO-d6) H 1.10 (2H, qd, J = 4.1 and 
12.6 Hz, 2 × H-piperidine), 1.42 (9H, s, C(CH3)3), 1.45-1.53 (2H, m, 2 × H-piperidine), 
2.02-2.12 (1H, m, H-piperidine), 2.61-2.82 (m, 2 × CH-N-piperidine), 3.88-4.01 (2H, m, 2 
× CH-N-piperidine), 4.13 (2H, d, J = 7.2 Hz, N-CH2-CH), 8.31 (H-pyrazole), 8.92 (H-
pyrazole); 

C NMR (125 MHz; DMSO-d6) C 28.0 (C(CH3)3), 28.7 (C-piperidine), 35.9 (2 
× C-piperidine), 42.8 (2 × C-piperidine), 57.2 (N-CH2-CH), 78.5 (C(CH3)3), 130.8 (CH-
pyrazole), 134.7 (C-4-pyrazole), 135.6 (CH-pyrazole), 153.8 (CO); HRMS calc for 
C14H21O4N4 [M-H]
-
 309.1568, found 309.1565. 
tert-Butyl 4-((4-amino-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate (395) 
451-115 
Prepared according to General procedure H using nitropyrazole 382 (1.1 g, 3.5 mmol) in 
MeOH (40 mL) and EtOAc (40 mL) for 5 h to give an orange solid (945 mg, 95%); Rf 0.35 
(EtOAc, NH2 SiO2); m.p. 104-107 C; max(EtOH)/nm 247; IR max/cm
-1 
2966, 2929,
 
1672; 

H NMR(500 MHz; DMSO-d6) H 1.04 (2H, qd, J = 4.3 and 12.3 Hz, 2 × H-piperidine), 
1.42 (9H, s, C(CH3)3), 1.42-1.49 (2H, m, 2 × H-piperidine), 1.85-1.97 (1H, m, H-
piperidine), 2.58-2.82 (m, 2 × CH-N-piperidine), 3.79-3.87 (4H, m, N-CH2-CH and NH2), 
3.88-3.99 (2H, m, 2 × H-N-piperidine), 6.92 (H-pyrazole), 7.03 (H-pyrazole); 

C NMR 
(125 MHz; DMSO-d6) C 28.1 (C(CH3)3), 29.0 (C-piperidine), 36.7 (2 × C-piperidine), 
42.5 (2 × C-piperidine), 56.2 (N-CH2-CH), 78.4 (C(CH3)3), 117.0 (C-2-pyrazole), 129.2 
(C-4-pyrazole), 130.5 (C-3-pyrazole), 153.8 (CO); HRMS calc for C14H25N4O4 [M+H]
+
 
281.1972, found 281.1972. 
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tert-Butyl 4-((4-(4-(3,6-dichloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido)-
1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate (416) 
451-117 
Prepared according to general procedure E using amine 395 (450 mg, 1.6 mmol, 2.5 eq.), 
carboxylic acid 337 (195 mg, 0.64 mmol, 1 eq.), cyanuric fluoride (18 L, 0.21 mmol, 0.3 
eq.) and pyridine (52 L, 0.64 mmol, 1 eq.) in MeCN (2 mL) with stirring at r.t. for 18 h. 
Purification by MPLC on SiO2 with a gradient elution from 50-100% EtOAc/petrol gave a 
yellow solid (214 mg, 59%); Rf 0.1 (EtOAc, NH2 SiO2); m.p. 211 C dec.; max(EtOH)/nm 
254; IR max/cm
-1
 3126, 2977, 2932, 2860, 1645, 1592; 

H NMR(500 MHz; DMSO-d6) H 
1.09 (2H, qd, J = 3.6 and 12.3 Hz, 2 × CH-piperidine), 1.42 (9H, s, C(CH3)3), 1.44-1.52 
(2H, m, 2 × H-piperidine), 1.94-2.07 (1H, m, H-piperidine), 2.60-2.80 (m, 2 × CH-N-
piperidine), 3.87-4.01 (2H, m, 2 × CH-N-piperidine), 4.02 (2H, d, J = 7.1 Hz, N-CH2-CH), 
7.36 (1H, s, H-pyrrole), 7.56 (1H, dd, J = 1.3 and 8.6 Hz, H-4’), 7.58 (s, H-pyrazole), 7.60 
(1H, s, H-pyrrole), 7.82 (1H, app t, J = 8.6 Hz, H-3’), 7.99 (1H, s, H-pyrazole), 10.29 (1H, 
s, CO-NH), 12.66 (1H, s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -116.65; 

C 
NMR (125 MHz; DMSO-d6) C 28.1 (C(CH3)3), 30.0 (C-piperidine), 36.6 (2 × C-
piperidine), 42.8 (2 × C-piperidine), 56.3 (N-CH2-CH), 78.5 (C(CH3)3), 110.1 (CH-
pyrrole), 119.3 (d, JCF = 18.0 Hz, C-3’), 120.9 (C-pyrazole), 121.2 (C-pyrazole), 124.7 (C-
pyrrole), 126.9 (d, JCF = 3.8 Hz, C-5’), 128.7 (C-pyrrole), 129.2 (d, JCF = 23.0 Hz, C-1’), 
129.2 (d, JCF = 5.1 Hz, C-6’), 129.5 (C-pyrrole), 130.2 (C-3-pyrazole), 131.8 (C-4’), 153.8 
(CO-carbamate), 153.8 (d, JCF = 248.5 Hz, C-2’), 156.8 (CO-NH), 182.6 (CO); HRMS calc 
for C26H29
35
Cl2F1N5O4 [M+H]
+
 564.1575, found 564.1566. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-(piperidin-4-ylmethyl)-1H-pyrazol-4-
yl)-1H-pyrrole-2-carboxamide (305) 
415-120 
Prepared according to general procedure G using carbamate 416 (200 mg, 0.35 mmol, 1 
eq.), Et3SiH (283 L, 1.77 mmol, 5 eq.), TFA (1.5 mL) and CH2Cl2 (1.5 mL). Purification 
by MPLC on NH2 SiO2 with a gradient elution from 3-15% MeOH/EtOAc gave a white 
solid (106 mg, 64%); Rf 0.05 (5% MeOH/EtOAc); m.p. 147 C dec.; max(EtOH)/nm 254; 
IR max/cm
-1 
2926, 1633, 1592; 

H NMR(500 MHz; DMSO-d6) H 1.09 (2H, qd, J = 3.6 
and 12.0 Hz, 2 × H-piperidine), 1.39-1.47 (2H, m, 2 × H-piperidine), 1.82-1.94 (1H, m, H-
piperidine), 2.43 (td, J = 12.0 and 2.2 Hz, 2 × CH-N-piperidine), 2.90-2.97 (2H, m, 2 × 
CH-N-piperidine), 3.97 (2H, d, J = 7.1 Hz, pyrazole-CH2-piperidine), 7.33 (1H, s, H-
pyrrole), 7.55 (1H, dd, J = 1.3 and 8.7 Hz, H-4’), 7.57 (1H, s, H-pyrazole), 7.58 (1H, s, H-
pyrrole), 7.82 (1H, app t, J = 8.7 Hz, H-3’), 7.97 (1H, s, H-pyrazole), 10.26 (1H, s, CO-
NH); 

F NMR (470 MHz; DMSO-d6) F -116.64; 

C NMR (125 MHz; DMSO-d6) C 30.2 
(C-piperidine), 37.3 (2 × C-piperidine), 45.5 (2 × C-piperidine), 57.2 (pyrazole-CH2-
piperidine), 110.2 (CH-pyrrole), 119.3 (d, JCF = 18.2 Hz, C-3’), 120.9 (C-pyrazole), 121.1 
(C-pyrazole), 124.7 (C-pyrrole), 126.8 (d, JCF = 3.8 Hz, C-5’), 129.1 (C-pyrrole), 129.2 (d, 
JCF = 11.6 Hz, C-6’), 129.2 (CH-pyrrole), 129.3 (d, JCF = 20.5 Hz, C-1’), 130.0 (C-
pyrazole), 131.7 (C-4’), 153.8 (d, JCF = 248.86 Hz, C-2’), 157.0 (CO-NH), 182.4 (CO); 
HRMS calc for C21H21
35
Cl2F1N5O2 [M+H]
+
 464.1051, found 464.1038. 
1-Methyl-4-((4-nitro-1H-pyrazol-1-yl)methyl)piperidine (383) 
451-122 
Procedure 1: Prepared according to general procedure J using 1-methyl-4-
piperidinemethanol (349 L, 2.7 mmol), PPh3 (1.04 g, 4.0 mmol, 1.5 eq.), 4-nitropyrazole 
(300 mg, 2.7 mmol, 1 eq.) and DEAD (626 L, 4.0 mmol, 1.5 eq.) in THF (6 mL). 
Purification by MPLC on NH2 SiO2 with a gradient elution from 30-80% CH2Cl2/petrol 
gave a white solid, containing product, reduced DEAD and Ph3PO. This mixture was 
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dissolved in 5% MeOH/CH2Cl2 and passed through an SCX ion exchange column, eluting 
with 5% MeOH/CH2Cl2 followed by 80/20/2 CH2Cl2/MeOH/NH4OH to give a beige solid 
(200 mg, 34%). Procedure 2: Prepared according to general procedure K to give a clear 
oil (304 mg, 84%); Rf 0.3 (CH2Cl2, NH2 SiO2); m.p. 70-73 C; max(EtOH)/nm 274; IR 
max/cm
-1 
3067, 2943, 2903, 2797, 1511, 1312; 

H NMR(500 MHz; DMSO-d6) H 1.24 
(2H, qd, J = 3.6 and 12.5 Hz, 2 × H-piperidine), 1.42-1.50 (2H, m, 2 × H-piperidine), 1.77-
1.89 (3H, m, 3 × H-piperidine), 2.16 (3H, s, CH3), 2.72-2.80 (2H, m, 2 × H-piperidine), 
4.11 (2H, d, J = 7.3 Hz, pyrazole-CH2-piperidine), 8.30 (1H, s, H-pyrazole), 8.93(1H, s, H-
pyrazole); 

C NMR (125 MHz; DMSO-d6) C 28.9 (2 × CH2-piperidine), 35.5 (CH-
piperidine), 46.0 (CH3), 54.6 (2 × CH2-piperidine), 57.5 (N-CH2-CH), 130.8 (CH-
pyrazole), 134.7 (C-pyrazole), 135.6 (CH-pyrazole); HRMS calc for C10H17N4O2 [M+H]
+
 
225.1346, found 225.1341. 
1-((1-Methylpiperidin-4-yl)methyl)-1H-pyrazol-4-amine (396) 
451-126, 451-146 
Prepared according to general procedure H using nitropyrazole 383 (190 mg, 0.85 mmol) 
and MeOH (20 mL) for 2 h to give a pale brown oil (150 mg, 91%); Rf 0.4 (7% 
MeOH/CH2Cl2, NH2 SiO2); m.p. 50-55 C; max(EtOH)/nm 246; IR max/cm
-1 
3304, 3127, 
2919, 2794; 

H NMR(500 MHz; DMSO-d6) H 1.18 (2H, qd, J = 12.5 and 3.7 Hz, 2 × H-
piperidine), 1.39-1.47 (2H, m, 2 × H-piperidine), 1.61-1.72 (1H, m, H-piperidine), 1.74-
1.84 (2H, m, 2 × H-piperidine), 2.15 (3H, s, CH3), 2.70-2.78 (2H, m, 2 × H-piperidine), 
3.80 (2H, d, J = 7.3 Hz, N-CH2-CH), 6.91 (1H, s, H-pyrazole), 7.02 (1H, s, H-pyrazole); 

C NMR (125 MHz; DMSO-d6) C 29.3 (2 × CH2-piperidine), 36.3 (2 × CH2-piperidine), 
46.1 (CH3), 54.9 (2 × CH2-piperidine), 56.5 (N-CH2-CH), 116.9 (CH-pyrazole), 129.0 
(CH-pyrazole), 130.5 (C-pyrazole); HRMS calc for C10H18N4 [M+H]
+
 195.1604, found 
195.1600. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-((1-methylpiperidin-4-yl)methyl)-1H-
pyrazol-4-yl)-1H-pyrrole-2-carboxamide (306) 
451-129 
Amine 396 (140 mg, 0.43 mmol, 1.5 eq) was added to carboxylic acid 337 (87 mg, 0.29 
mmol, 1 eq.), pyridine (23 L, 0.29 mmol, 1 eq) and PyBrOP (200 mg, 0.43 mmol, 1.5 eq) 
in MeCN (2 mL). The mixture was stirred at r.t. for 1 h and then partitioned between 
EtOAc (2 × 30 mL) and H2O (20 mL). The organic layers were combined, washed with 
brine, dried (MgSO4) and the solvent removed in vacuo. Purification by MPLC on NH2 
SiO2 with gradient elution from 1-4% MeOH/CH2Cl2 gave a beige solid (53 mg, 39%); Rf 
0.4 (7% MeOH/CH2Cl2, NH2 SiO2); m.p. 124-128 C; max(EtOH)/nm 252; IR max/cm
-1 
2935, 1639, 1592; 

H NMR(500 MHz; DMSO-d6) H 1.23 (2H, qd, J = 3.0 and 12.5 Hz, 2 
× H-piperidine), 1.41-1.51 (2H, m, 2 × H-piperidine), 1.70-1.85 (3H, m, 3 × H-piperidine), 
2.15 (CH3), 2.72-2.80 (2H, m, 2 × H-piperidine), 4.00 (2H, d, J = 7.3 Hz, N-CH2-CH), 
7.35 (1H, s, H-pyrrole), 7.53-7.61 (3H, m, H-4’, H-pyrrole and H-pyrazole), 7.82 (1H, app 
t, J = 8.4 Hz, H-3’), 7.97 (1H, s, H-pyrazole), 10.28 (1H, s, CO-NH), 12.52 (1H, br s, NH-
pyrrole); 

F NMR (470 MHz; DMSO-d6) F -116.65; 

C NMR (125 MHz; DMSO-d6) C 
29.2 (2 × C-piperidine), 36.2 (C-piperidine), 46.1 (CH3), 54.8 (2 × C-piperidine), 56.7 (N-
CH2-CH), 110.5 (CH-pyrrole), 121.0 (d, JCF = 29.7 Hz, C-3’), 121.3 (CH-pyrazole), 124.7 
(C-pyrrole), 126.9 (d, JCF = 4.1 Hz, C-5’), 128.2 (C-pyrrole), 128.7 (CH-pyrrole), 129.2 (d, 
JCF = 21.8 Hz, C-1’), 129.2 (d, JCF = 5.4 Hz, C-6’), 130.1 (C-1’), 130.5 (C-pyrazole), 131.8 
(C-4’), 153.8 (d, JCF = 248.2 Hz, C-2’), 156.8 (CO-NH), 182.6 (CO); HRMS calc for 
C22H23
35
Cl2F1N5O2 [M+H]
+
 478.1207, found 478.1195. 
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4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(1-((1-methylpiperidin-4-
yl)methyl)-1H-pyrazol-4-yl)-1H-pyrrole-2-carboxamide (325) 
451-153 
Prepared according to general procedure E using amine 396 (250 mg, 1.11 mmol, 2.5 eq.), 
carboxylic acid 421 (133 mg, 0.45 mmol, 1 eq.), cyanuric fluoride (27 L, 0.31 mmol, 0.7 
eq.), pyridine (36 L, 0.45 mmol, 1 eq.) and MeCN (3 mL) with stirring at r.t. for 18 h. 
Purification by MPLC on NH2 SiO2 with a gradient elution from 0-7% MeOH/CH2Cl2 gave 
a white solid (91 mg, 43%); Rf 0.4 (5% MeOH/CH2Cl2, NH2 SiO2); m.p. 204 C dec.; 
max(EtOH)/nm 252, 227; IR max/cm
-1 
3124.1 br, 2951.7, 1641.1, 1602.0, 1575.4; 

H 
NMR(500 MHz; DMSO-d6) H 1.23 (2H, qd, J = 12.0 and 3.1 Hz, 2 × CH-piperidine), 
1.41-1.51 (2H, m, 2 × CH-piperidine), 1.69-1.86 (3H, m, 3 × CH-piperidine), 2.15 (3H, s, 
NCH3), 2.72-2.79 (2H, m, 2 × CH-piperidine), 3.94 (3H, s, OCH3), 3.99 (2H, d, J = 7.1 Hz, 
N-CH2-CH), 7.32 (1H, s, H-pyrrole), 7.37 (1H, app t, J = 9.0 Hz, H-4’), 7.42 (1H, dd, J = 
0.8 and 9.0 Hz, H-5’), 7.46 (H-pyrrole), 7.56 (H-pyrazole), 7.97 (H-pyrazole), 10.28 (CO-
NH), 12.58 (1H, br s, NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -136.14; 

C NMR 
(125 MHz; DMSO-d6) C 29.2 (2 × C-piperidine), 36.2 (C-piperidine), 46.1 (NCH3), 54.8 
(2 × C-piperidine), 56.4 (OCH3), 56.7 (N-CH2-CH), 110.3 (CH-pyrrole), 115.1 (C-4’), 
120.2 (d, JCF = 4.7 Hz, C-1’), 120.8 (C-pyrazole), 121.0 (CH-pyrazole), 125.1 (C-pyrrole), 
125.5 (d, JCF = 3.6 Hz, C-5’), 128.5 (C-6’), 128.6 (C-pyrrole) 128.8 (CH-pyrrole), 130.0 
(CH-pyrazole), 146.4 (d, JCF = 10.6 Hz, C-3’), 147.9 (d, JCF = 247.0 Hz, C-2’), 156.8 (CO-
NH), 183.6 (CO); HRMS calcd for C23H26
35
Cl1F1N5O3 [M+H]
+
 474.1703, found 474.1691. 
2,2,2-Trifluoro-1-(4-hydroxypiperidin-1-yl)ethanone (408)369 
451-182 
Trifluoroacetic anhydride (1.51 mL, 10.9 mmol, 1.1 eq.) was added to a mixture of 4-
hydroxypiperidine (1 g, 9.9 mmol, 1 eq.) and pyridine (1.6 mL, 19.8 mmol, 2 eq.) in 
CH2Cl2 (25 mL) at 0 C, and the reaction was stirred at r.t. for 18 h. The mixture was 
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washed with KHSO4 (2 × 25 mL, 15% aq), followed by NaHCO3 (10% aq, 20 mL). The 
organic layer was dried over MgSO4, and the solvent removed in vacuo. The residue was 
suspended in MeOH (20 mL) and NaHCO3 (10% aq, 20 mL), stirred at r.t. for 20 min and 
extracted with EtOAc (2 × 50 mL). The organic extracts were washed with water (20 mL) 
and brine (20 mL), dried over MgSO4, and the solvent removed in vacuo to give a clear oil 
(910 mg, 47%); Rf 0.4 (5% MeOH/CH2Cl2; KMnO4); max(EtOH)/nm 208; IR  max/cm
-1 
3383 br, 1673; 

H NMR(500 MHz; DMSO-d6) H 1.38-1.50 (2H, m, H-piperidine), 1.78-
1.88 (2H, m, H-piperidine), 3.33-3.45 (2H, m, H-piperidine), 3.69-3.77 (1H, m, H-
piperidine), 3.78-3.91 (2H, m, H-piperidine), 4.92 (1H, d, J = 4.0 Hz, OH); 

F NMR(470 
MHz; DMSO-d6) F -68.11; 

C NMR (125 MHz; DMSO-d6) C 33.3 (C-piperidine), 34.2 
(C-piperidine), 40.6 (C-piperidine), 42.6 (q, JCF = 3.4 Hz, C-piperidine), 64.3 (C-OH), 
116.4 (q, JCF = 288.5 Hz, CF3), 153.9 (q, JCF = 35.6 Hz, CO); MS (ES+) m/z 198.2 
[M+H]
+
. 
1-(2,2,2-Trifluoroethyl)piperidin-4-ol (409)370 
451-183 451-184 
Borane.THF complex (1 M in THF, 5.25 mL, 5.25 mmol, 2.5 eq.) was added to a solution 
of trifluoroacetamide 408 (690 mg, 3.5 mmol, 1 eq.) in THF (10 mL) and heated at reflux 
for 3 h. The reaction was allowed to cool to r.t., and HCl (1 M aq.) was added until gas 
evolution ceased. The mixture was heated to 70 C for 20 min, allowed to cool to r.t., and 
basified with NaOH (2 M aq, 10 mL). The mixture was extracted with EtOAc (2 × 30 mL), 
dried over MgSO4, and the solvent removed in vacuo to give a clear oil (458 mg, 71%); Rf 
0.35 (5% MeOH/CH2Cl2; KMnO4); max(EtOH)/nm 273 weak; IR  max/cm
-1 
3337 br; 

H 
NMR500 MHz; DMSO-d6) H 1.36-1.45 (2H, m, H-piperidine), 1.68-1.75 (2H, m, H-
piperidine), 2.36-2.44 (2H, m, H-piperidine), 2.80-2.87 (2H, m, H-piperidine), 3.14 (2H, q, 
JHF = 10.3 Hz, CH2CF3), 3.45-3.52 (1H, m, CHOH), 4.60 (1H, d, J = 4.1 Hz, OH); 

F 
NMR(470 MHz; DMSO-d6) F -67.99; 

C NMR (125 MHz; DMSO-d6) C 34.2 (C-
piperidine), 51.3 (C-piperidine), 56.8 (q, JCF = 28.9 Hz, CH2CF3), 65.4 (C-piperidine), 
126.1 (q, JCF = 280.4 Hz, CF3); MS: No mass ion detected. 
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4-(4-Nitro-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)piperidine (384) 
451-187 
Prepared according to general procedure J using alcohol 409 (486 mg, 2.7 mmol, 1 eq.), 
PPh3 (1.04 g, 4.0 mmol, 1.5 eq.), 4-nitropyrazole (300 mg, 2.7 mmol, 1 eq.) and DEAD 
(626 L, 4.0 mmol, 1.5 eq.) in THF (5 mL) with stirring at r.t. for 18 h. The residue was 
purified by MPLC on SiO2 with a gradient elution from 5-40% EtOAc/petrol to give a 
white solid (395 mg, 54%); Rf 0.25 (30% EtOAc/petrol); m.p. 94-95 C; max(EtOH)/nm 
251; IR  max/cm
-1 
1494, 1304; 

H NMR(500 MHz; DMSO-d6) H 1.97-2.07 (4H, m, H-
piperidine), 2.53-2.61 (2H, m, H-piperidine), 3.01-3.09 (2H, m, H-piperidine), 3.28 (2H, q, 
JHF = 10.2 Hz, CH2CF3), 4.28-4.36 (1H, m, H-piperidine), 8.32 (H-pyrazole), 8.98 (H-
pyrazole); 

F NMR(470 MHz; DMSO-d6) F -68.05; 

C NMR (125 MHz; DMSO-d6) C 
31.2 (C-piperidine), 51.9 (C-piperidine), 56.2 (q, JCF = 29.4 Hz, CH2CF3), 59.3 (C-
piperidine), 126.1 (q, JCF = 280.5 Hz, CF3), 128.8 (C-pyrazole), 134.8 (C-NO2), 135.2 (C-
pyrazole); HRMS calcd for C10H14F3N4O2 [M+H]
+
 279.1063, found 279.1062. 
1-(1-(2,2,2-Trifluoroethyl)piperidin-4-yl)-1H-pyrazol-4-amine (397) 
451-189 
Palladium on carbon (10%, 40 mg) was added to nitropyrazole 384 (370 mg, 1.3 mmol) in 
MeOH (30 mL), and the mixture was stirred at r.t. under an atmosphere of hydrogen for 18 
h. The reaction was filtered through Celite, and the solvent removed in vacuo to give a 
deep red solid (321 mg, 97%); Rf (5% MeOH/EtOAc); m.p. 80-83 C; max(EtOH)/nm 274; 
IR  max/cm
-1 
3355, 3212, 2838; 

H NMR(500 MHz; DMSO-d6) H 1.82-1.96 (4H, m, H-
piperidine), 2.46-2.58 (2H, m, H-piperidine), 2.95-3.04 (2H, m, H-piperidine), 3.24 (2H, q, 
JHF = 10.3 Hz, CH2CF3), 3.79 (2H, s, NH2), 3.93-4.01 (1H, m, H-piperidine), 6.93 (1H, d, J 
= 0.8 Hz, H-pyrazole), 7.10 (1H, d, J = 0.8 Hz, H-pyrazole); 

F NMR(470 MHz; DMSO-
d6) F -68.00; 

C NMR (125 MHz; DMSO-d6) C 31.9 (C-piperidine), 52.4 (C-piperidine), 
56.5 (q, JCF = 29.4 Hz, CH2CF3), 57.4 (C-piperidine), 114.3 (C-pyrazole), 126.1 (q, JCF = 
280.5 Hz, CF3), 128.8 (C-pyrazole), 130.5 (C-pyrazole); MS (ES+) m/z 249.3 [M+H]
+
;
 
HRMS calcd for C10H16F3N4 [M+H]
+
 249.1322, found 249.1319. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-(1-(2,2,2-trifluoroethyl) piperidin-4-yl)-
1H-pyrazol-4-yl)-1H-pyrrole-2-carboxamide (308) 
451-193 
Prepared according to general procedure L using carboxylic acid 337 (100 mg, 0.33 mmol, 
1 eq.), Et3N (115 L, 0.83 mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (93 mg, 
0.36 mmol, 1.1 eq.) in DCM (4 mL) followed by the addition of amine 397 (102 mg, 0.41 
mmol, 1.25 eq.) with stirring at r.t. for 18 h. The residue was purified by MPLC on SiO2 
with gradient elution from 20-45% EtOAc/petrol to give a white solid (60 mg, 34%); Rf 0.1 
(30% EtOAc/petrol); m.p. 253-255 C; max(EtOH)/nm 253sh; IR  max/cm
-1 
3349, 3178, 
1627, 1605; 

H NMR(500 MHz; DMSO-d6) H 1.90-2.03 (4H, m, H-piperidine), 2.53-2.61 
(2H, m, H-piperidine), 3.01-3.08 (2H, m, H-piperidine), 3.27 (2H, q, JHF = 10.2 Hz, 
CH2CF3), 4.15-4.24 (1H, m, H-piperidine), 7.36 (1H, s, H-pyrrole), 7.56 (1H, dd, J = 1.1 
and 8.6 Hz, H-5’), 7.58-7.62 (2H, m, H-pyrrole and H-pyrazole), 7.82 (1H, app t, J = 8.6 
Hz, H-4’), 8.02 (1H, s, H-pyrazole), 10.29 (1H, s, CO-NH), 12.67 (1H, br s, NH-pyrrole); 

F NMR(470 MHz; DMSO-d6) -67.98, -116.65; 

C NMR (125 MHz; DMSO-d6) C 31.9 
(C-piperidine), 52.3 (C-piperidine), 56.4 (q, JCF = 29.4 Hz, CH2CF3), 57.8 (C-piperidine), 
110.1 (CH-pyrrole), 118.7 (C-pyrazole), 119.3 (d, JCF = 18.2 Hz, C-3’), 120.8 (CH-
pyrazole), 121.7 (C-pyrazole), 124.7 (C-pyrrole), 125.0, 126.4 (q, J = 271.0 Hz, CF3), 
126.9 (d, JCF = 4.1 Hz, C-5’), 128.7 (C-pyrrole), 129.2 (d, JCF = 23.2 Hz, C-1’), 129.2 (d, 
JCF = 5.1 Hz, C-6’), 129.5 (C-pyrrole), 129.9 (CH-pyrazole), 131.8 (C-4’), 153.8 (d, JCF = 
248.4 Hz, C-2’), 156.8 (CO-NH), 182.6 (CO); HRMS calcd for C22H20
35
Cl2F4N5O2 
[M+H]
+
 532.0925, found 532.0911. 
1H-Pyrazol-4-amine (410)371 
451-141 
Prepared according to general procedure H using 4-nitropyrazole (500 mg, 4.40 mmol) and 
MeOH (30 mL) to give a red gum (360 mg, 98 %); max(EtOH)/nm 238; IR max/cm
-1 
3374, 
3114, 2955, 2891, 2842, 1585; 

H NMRH (500 MHz; DMSO-d6)H 7.03 (2H, s, 2 × H-
pyrazole); 

C NMR (125 MHz; DMSO-d6) C 122.5, 130.0; MS: No mass ion detected. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1H-pyrazol-4-yl)-1H-pyrrole-2-
carboxamide (313) 
451-144 
Prepared according to general procedure E using amine 410 (69 mg, 0.83 mmol, 2.5 eq.), 
carboxylic acid 337 (100 mg, 0.33 mmol, 1 eq.), cyanuric fluoride (20 L, 0.24 mmol, 0.7 
eq.), pyridine (27 L, 0.34 mmol, 1 eq.) and MeCN (2 mL) with stirring at r.t. for 18 h. 
Purification by MPLC on SiO2 with a gradient elution from 2-8% MeOH/EtOAc gave a 
yellow solid (78 mg, 64%); Rf 0.35 (5% MeOH/EtOAc, NH2 SiO2); m.p. 300-304 C; 
max(EtOH)/nm 255, 223; IR max/cm
-1 
3361.0, 3241.5 br, 2971.9, 1636.3, 1586.2; 

H 
NMR(500 MHz; DMSO-d6) H 7.36 (1H, s, H-pyrrole), 7.56 (1H, dd, J = 1.1 & 8.5 Hz, H-
5’), 7.60 (1H, s, H-pyrrole), 7.57 (1H, s, H-pyrazole), 7.82 (1H, app t, J = 8.5 Hz, H-4’), 
7.97 (1H, s, H-pyrazole), 10.29 (1H, s, CO-NH), 12.60-12.73 (2H, m, NH-pyrrole and NH-
pyrazole); 

F NMR (470 MHz; DMSO-d6) F -116.66; 

C NMR (125 MHz; DMSO-d6) C 
110.1 (CH-pyrrole), 119.3 (d, JCF = 18.1 Hz, C-3’), 120.8 (CH-pyrazole), 124.7 (C-
pyrrole), 126.9 (d, JCF = 4.1 Hz, C-5’), 128.8 (C-pyrrole), 129.2 (d, JCF = 5.2 Hz, C-6’), 
129.2 (d, JCF = 22.7 Hz, C-1’), 129.5 (C-pyrrole), 131.0 (CH-pyrazole), 131.8 (C-4’), 
153.8 (d, JCF = 248.8 Hz, C-2’), 156.9 (CO-NH), 182.6 (CO); HRMS calcd for 
C15H10
35
Cl2F1N4O2 [M+H]
+
 367.0159, found 367.0158. 
1-Methyl-4-nitro-1H-pyrazole (385)372 
451-163 
Prepared according to general procedure J using methanol (11 L, 2.65 mmol, 1 eq.), PPh3 
(1.04 g, 4.0 mmol, 1.5 eq.), 4-nitropyrazole (300 mg, 2.7 mmol, 1 eq.) and DEAD (626 L, 
4.0 mmol, 1.5 eq.) in THF (5 mL) with stirring at r.t. for 18 h. The residue was purified by 
MPLC on SiO2 with a gradient elution from 20-50% EtOAc/petrol to give impure product 
which was re-purified by MPLC on SiO2 with a gradient elution from 10-40% 
EtOAc/petrol to give a white solid (227 mg, 67%); Rf 0.8 (EtOAc); m.p. 90-94 C (Lit.
372
 
91-92 C) ; max(EtOH)/nm 266; IR max/cm
-1 
1504, 1310; 

H NMR(500 MHz; DMSO-d6) 
H 3.92 (3H, s, CH3), 8.25 (1H, s, H-pyrazole), 8.86 (1H, s, H-pyrazole); 

C NMR (125 
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MHz; DMSO-d6) C 39.6 (CH3), 131.0 (CH-pyrazole), 134.8 (CH-pyrazole), 135.5 (C-
NO2). MS (ES+) 128.1 [M+H]
+
. 
1-Methyl-1H-pyrazol-4-amine (398) 
451-168 
Prepared according to general procedure H using nitropyrazole 385 (200 mg, 1.57 mmol) 
and MeOH (10 mL) for 2 h to give an orange oil (150 mg, 98 %); Rf 0.1 (EtOAc); 
max(EtOH)/nm 244; IR max/cm
-1 
3322, 3111; 

H NMR(500 MHz; DMSO-d6) H 3.68 
(3H, s, CH3), 3.82 (2H, br s, NH2), 6.90 (1H, d, J = 0.6 Hz, H-pyrazole), 7.01 (1H, d, J = 
0.6 Hz, H-pyrazole); 

C NMR (125 MHz; DMSO-d6) C 38.3 (CH3), 117.2 (CH-pyrazole), 
128.9 (CH-pyrazole), 131.0 (C-pyrazole); MS: No mass ion detected. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrole-2-
carboxamide (314) 
451-169 
Prepared according to general procedure E using amine 398 (130 mg, 1.3 mmol, 2.5 eq.) 
and carboxylic acid 337 (162 mg, 0.54 mmol, 1 eq.), cyanuric fluoride (32 L, 0.37 mmol, 
0.7 eq.), pyridine (43 L, 0.50 mmol, 1 eq.) and MeCN (2 mL) with stirring at r.t. for 18 h. 
Purification by MPLC on SiO2 with a gradient elution from 30-60% EtOAc/petrol gave a 
yellow solid (120 mg, 59%); Rf 0.1 (50% EtOAc/petrol); m.p. 216-219 C; max(EtOH)/nm 
252, 225; IR  max/cm
-1 
3195, 3121, 2938, 1630; 

H NMR(500 MHz; DMSO-d6) H 3.85 
(3H, s, CH3), 7.36 (1H, s, H-pyrrole), 7.54 (1H, s, H-pyrazole), 7.56 (1H, dd, J = 1.2 & 8.5 
Hz, H-5’), 7.59 (1H, s, H-pyrrole), 7.82 (1H, app t, J = 8.5 Hz, H-4’), 7.98 (1H, s, H-
pyrazole), 10.28 (1H, s, CO-NH), 12.68 (NH-pyrrole); 

F NMR(470 MHz; DMSO-d6) F 
-116.66; 

C NMR (125 MHz; DMSO-d6) C 38.7 (CH3), 110.2 (CH-pyrrole), 119.3 (d, JCF 
= 18.2 Hz, C-3’), 121.2 (CH-pyrazole), 121.4 (C-pyrazole), 124.7 (C-pyrrole), 126.9 (d, 
JCF = 3.7 Hz, C-5’), 128.7 (C-pyrrole), 129.2 (d, JCF = 23.2 Hz, C-1’), 129.2 (d, JCF = 5.2 
Hz, C-6’), 129.5 (C-pyrrole), 129.9 (CH-pyrazole), 131.8 (C-4’), 153.8 (d, JCF = 248.4 Hz, 
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C-2’), 156.8 (CO-NH), 182.6 (CO); HRMS calcd for C16H12
35
Cl2F1N4O2 [M+H]
+
 
381.0319, found 381.0318. 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-
pyrrole-2-carboxamide (323) 
451-215 
Prepared according to general procedure L using carboxylic acid 421 (150 mg, 0.51 mmol, 
1 eq.), Et3N (172 L, 1.24 mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (139 mg, 
0.54 mmol, 1.1 eq.) in DCM (5 mL) followed by the addition of amine 398 (60 mg, 0.62 
mmol, 1.25 eq.) with stirring at r.t. for 18 h. The residue was purified by MPLC on SiO2 
with gradient elution from 50-80% EtOAc/petrol to give a white solid (114 mg, 60%); Rf 
0.15 (75% EtOAc/petrol); m.p. 261-263 C; max(EtOH)/nm 227, 250sh; IR  max/cm
-1 
3322, 3202, 1649, 1622; 

H NMR (500 MHz; DMSO-d6) H 3.85 (3H, s, N-CH3), 3.94 (3H, 
s, O-CH3), 7.31 (1H, s, H-pyrrole), 7.36 (1H, app t, J = 9.0 Hz, H-4’), 7.42 (1H, dd, J = 1.0 
and 9.0 Hz, H-5’), 7.45 (1H, s, H-pyrrole), 7.53 (1H, s, H-pyrazole), 7.98 (1H, s, H-
pyrazole), 10.27 (1H, s, CO-NH), 12.60 (1H, s, NH-pyrrole); 

F NMR(470 MHz; DMSO-
d6) F -136.15; 

C NMR (125 MHz; DMSO-d6) C 38.7 (N-CH3), 56.4 (O-CH3), 110.3 
(CH-pyrrole), 115.1 (C-4’), 120.2 (d, J = 4.9 Hz, C-1’), 121.2 (CH-pyrazole), 121.4 (C-
pyrazole), 125.1 (C-pyrrole), 125.5 (d, J = 3.6 Hz, C-5’), 128.4 (C-pyrrole), 128.5 (C-6’), 
128.6 (C-pyrrole), 128.8 (C-pyrrole), 129.9 (CH-pyrazole), 146.4 (d, J = 10.6 Hz, C-3’), 
147.9 (d, JCF = 247.0 Hz, C-2’), 156.8 (CO-NH), 183.6 (CO); HRMS calcd for 
C17H15
35
Cl1F1N4O3 [M+H]
+
 377.0811, found 377.0808. 
1-Ethyl-4-nitro-1H-pyrazole (386) 
451-198 
Prepared according to general procedure J using ethanol (129 L, 2.2 mmol, 1 eq.), PPh3 
(869 mg, 3.3 mmol, 1.5 eq.), 4-nitropyrazole (250 mg, 2.2 mmol, 1 eq.) and DEAD (522 
L, 3.3 mmol, 1.5 eq.) in THF (3 mL) with stirring at r.t. for 18 h. The residue was purified 
by MPLC on SiO2 with a gradient elution from 10 to 35% EtOAc/petrol to give a clear oil 
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(170 mg, 54%); Rf 0.3 (25% EtOAc/petrol); m.p. 62-64 C (lit.
373
 63-64 C); 
max(EtOH)/nm 272sh; IR  max/cm
-1 
1505, 1302; 

H NMR (500 MHz; DMSO-d6) H 1.44 
(3H, t, J = 7.3 Hz, CH3), 4.24 (2H, q, J = 7.3 Hz, CH2), 8.29 (1H, s, H-pyrazole), 8.94 (1H, 
s, H-pyrazole); 

C NMR (125 MHz; DMSO-d6) C 14.8 (CH3), 47.6 (CH2), 129.8 (CH-
pyrazole), 134.7 (C-NO2), 135.4 (CH-pyrazole); MS (ES+) m/z 142.1 [M+H]
+
. 
1-Ethyl-1H-pyrazol-4-amine (399)60 
451-200 
Palladium on carbon (10%, 30 mg) was added to nitropyrazole 386 (160 mg, 1.13 mmol) 
in MeOH (15 mL), and the mixture was stirred at r.t. under an atmosphere of hydrogen for 
18 h. The reaction was filtered through Celite, and the solvent removed in vacuo to give a 
brown oil (125 mg, 100%); Rf 0.25 (10% MeOH/EtOAc); max(EtOH)/nm 245; IR  max/cm
-
1 
3331 br, 2980; 

H NMR (500 MHz; DMSO-d6) H 1.31 (3H, t, J = 7.3 Hz, CH3), 3.79 
(2H, br s, NH2), 3.96 (2H, q, J = 7.3 Hz, CH2), 6.91 (1H, s, H-pyrazole), 7.05 (1H, s, H-
pyrazole); MS (ES+) m/z 112.2 [M+H]
+
. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-ethyl-1H-pyrazol-4-yl)-1H-pyrrole-2-
carboxamide (315) 
451-207 
Prepared according to general procedure L using carboxylic acid 337 (100 mg, 0.33 mmol, 
1 eq.), Et3N (115 L, 0.86 mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (93 mg, 
0.36 mmol, 1.25 eq.) in DCM (4 mL) followed by the addition of amine 399 (46 mg, 0.41 
mmol, 1.25 eq.) with stirring at r.t. for 18 h. The residue was purified by MPLC on SiO2 
with gradient elution from 40-70 % EtOAc/petrol to give a white solid (34 mg, 26%); Rf 
0.5 (80% EtOAc/petrol); m.p. 197-201 C; max(EtOH)/nm 239sh; IR  max/cm
-1 
3358, 
3211, 3124, 1628, 1601; 

H NMR (500 MHz; DMSO-d6) H 1.39 (3H, t, J = 7.3 Hz, CH3), 
4.15 (2H, q, J = 7.3 Hz, CH2), 7.35 (1H, s, H-pyrrole), 7.53-7.58 (2H, m, H-5’ and H-
pyrazole), 7.59 (1H, s, H-pyrrole), 7.82 (1H, app t, J = 8.4 Hz, H-4’), 8.00 (1H, s, H-
pyrazole), 10.27 (1H, s, CO-NH), 12.66 (1H, s, NH-pyrrole); 

F NMR(470 MHz; DMSO-
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d6) F -116.66; 

C NMR (125 MHz; DMSO-d6) C 15.5 (CH3), 46.3 (CH2), 110.1 (CH-
pyrrole), 119.3 (d, JCF = 18.1 Hz, C-3’), 120.0 (CH-pyrazole), 121.0 (C-pyrazole), 124.7 
(C-pyrrole), 126.9 (d, JCF = 3.7 Hz, C-5’), 128.7 (C-pyrrole), 129.2 (d, JCF = 23.2 Hz, C-
1’), 129.2 (d, JCF = 5.3 Hz, C-6’), 129.5 (C-pyrrole), 129.9 (CH-pyrazole), 131.8 (C-4’), 
153.8 (d, JCF = 248.8 Hz, C-2’), 156.8 (CO-NH), 182.6 (CO); HRMS calcd for 
C17H14
35
Cl2F1N4O2 [M+H]
+
 395.0472, found 395.0470. 
N,N-Diethyl-2-(4-nitro-1H-pyrazol-1-yl)ethanamine (387)374 
451-164 
Prepared according to general procedure J using 2-(diethylamino)ethan-1-ol (47 L, 3.54 
mmol, 1 eq.), PPh3 (1.39 g, 5.3 mmol, 1.5 eq.), 4-nitropyrazole (400 mg, 3.5 mmol, 1 eq.) 
and DEAD (836 L, 5.3 mmol, 1.5 eq.) in THF (7 mL) with stirring at r.t. for 18 h. The 
residue was purified on an SCX cartridge eluting with MeOH followed by 10% 
NH4OH/MeOH to give an orange oil which was further purified by MPLC on SiO2 with a 
gradient elution from 10-50% EtOAc/petrol to give the product as a yellow gum (20 mg, 
3%). Impure fractions were also obtained (300 mg, 40%) which were taken forward 
without further purification. Rf 0.25 (EtOAc); max(EtOH)/nm 272; IR max/cm
-1 
1506, 
1307; 

H NMR(500 MHz; DMSO-d6) H 0.90 (6H, t, J = 7.1 Hz, N-CH2-CH3), 2.49 (4H, 
q, J = 7.1 Hz, N-CH2-CH3), 2.72 (2H, t, J = 6.9 Hz, CH2-NEt2), 3.78 (2H, br s, NH2), 3.97 
(2H, t, J = 6.9 Hz, CH2-CH2-NEt2), 6.91 (1H, d, J = 0.9 Hz,, H-pyrazole), 7.07 (1H, d, J = 
0.9 Hz,, H-pyrazole); 

C NMR (125 MHz; DMSO-d6) C 11.8 (CH3), 46.4 (CH2CH3), 51.1 
(CH2CH2NEt2), 51.5 (CH2-NEt2), 130.9 (CH-pyrazole), 135.4 (CH-pyrazole), 135.9 (C-
NO2); MS: No mass ion detected. 
1-(2-(Diethylamino)ethyl)-1H-pyrazol-4-amine (400)374 
451-167 
Prepared according to general procedure H using nitropyrazole 387 (300 mg, 4.40 mmol) 
and MeOH (15 mL) to give a brown oil (72 mg, 28 %); Rf 0.3 (90:10:1 
EtOAc/MeOH/NH4OH); max(EtOH)/nm 246; IR max/cm
-1 
3320, 2967; 

H NMR(500 
MHz; DMSO-d6) H 0.95 (6H, t, J = 7.1 Hz, N-CH2-CH3), 2.49 (4H, q, J = 7.1 Hz, N-CH2-
CH3), 2.72 (2H, t, J = 6.9 Hz, CH2-NEt2), 3.78 (2H, br s, NH2), 3.97 (2H, t, J = 6.9 Hz, 
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CH2-CH2-NEt2), 6.91 (1H, d, J = 0.9 Hz,, H-pyrazole), 7.07 (1H, d, J = 0.9 Hz,, H-
pyrazole); 

C NMR (125 MHz; DMSO-d6) C 11.8 (2 × CH3), 46.7 (2 × CH2CH3), 50.0 
(CH2-CH2-NEt2), 52.8 (CH2-NEt2), 116.9 (CH-pyrazole), 129.1 (CH-pyrazole), 130.5 (C-
NH2); MS (ES+) m/z 182.3 [M]
+
. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-(2-(diethylamino)ethyl)-1H-pyrazol-4-
yl)-1H-pyrrole-2-carboxamide (307) 
451-170 
Prepared according to general procedure L using carboxylic acid 337 (80 mg, 0.26 mmol, 1 
eq.), amine 400 (60 mg, 0.33 mmol, 1.25 eq.), Et3N (92 L, 0.66 mmol, 2.5 eq.), and 2-
chloromethylpyridinium iodide (74 mg, 0.29 mmol, 1.1 eq.) in DCM (3 mL) with stirring 
at r.t. for 18 h. The residue was purified by MPLC on SiO2 with gradient elution from 0-
3% MeOH/DCM to give a white solid (53 mg, 43%); Rf 0.2 (2% MeOH/CH2Cl2, NH2 
SiO2); m.p. 140-142 C; max(EtOH)/nm 254, 222; IR  max/cm
-1 
3122, 2967, 1630; 

H 
NMR(500 MHz; DMSO-d6) H 0.95 (6H, t, J = 7.1 Hz, N-CH2-CH3), 2.51 (4H, q, J = 7.1 
Hz, N-CH2-CH3), 2.78 (2H, t, J = 6.5 Hz, CH2-NEt2), 4.14 (2H, t, J = 6.5 Hz, CH2-CH2-
NEt2), 7.35 (1H, s, H-pyrrole), 7.54-7.57 (2H, m, H-pyrazole and H-5’), 7.59 (1H, s, H-
pyrrole), 7.82 (1H, app t, J = 8.4 Hz, H-4’), 8.03 (1H, s, H-pyrazole), 10.26 (1H, s, CO-
NH), 12.66 (NH-pyrrole); 

F NMR (470 MHz; DMSO-d6) F -166.65; 

C NMR (125 
MHz; DMSO-d6) C 11.9 (2 × CH3), 46.5 (2 × CH2CH3), 50.1 (CH2-CH2-NEt2), 52.5 
(CH2-CH2-NEt2), 110.1 (CH-pyrrole), 119.3 (d, JCF = 18.2 Hz, C-3’), 120.7 (CH-pyrazole), 
121.2 (C-pyrazole), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.7 Hz, C-5’), 128.8 (C-pyrrole), 
129.2 (d, JCF = 22.7 Hz, C-1’), 129.2 (d, JCF = 5.1 Hz, C-6’), 129.5 (C-pyrrole), 129.9 (CH-
pyrazole), 131.8 (C-4’), 153.8 (d, JCF = 248.4 Hz, C-2’), 156.8 (CO-NH), 182.5 (CO); 
HRMS calcd for C21H23
35
Cl2F1N5O2 [M+H]
+
 466.1207, found 466.1201. 
 
 
 
366 
 
2-((4-Nitro-1H-pyrazol-1-yl)methyl)pyridine (388) 
451-171 
Prepared according to general procedure J using 2-pyridylmethanol (342 L, 3.5 mmol, 1 
eq.), PPh3 (1.39 g, 5.3 mmol, 1.5 eq.), 4-nitropyrazole (400 mg, 3.5 mmol, 1 eq.) and 
DEAD (836 L, 5.3 mmol, 1.5 eq.) in THF (7 mL) with stirring at r.t. for 18 h. The residue 
was purified by MPLC on NH2 SiO2 with a gradient elution from 10-30% EtOAc/petrol to 
give a white solid (599 mg, 83%); Rf 0.2 (20% EtOAc/petrol, NH2 SiO2); m.p. 95-101 C; 
max(EtOH)/nm 267; IR  max/cm
-1 
1504, 1304; 

H NMR(500 MHz; DMSO-d6) H 5.57 
(2H, s, CH2), 7.34 (1H, d, J = 7.4 Hz, H-pyridine), 7.39 (1H, dd, J = 5.0 and 7.4 Hz, H-
pyridine), 7.83 (1H, td, J = 7.7 and 1.7 Hz, H-pyridine), 8.33 (1H, s, H-pyrrole), 8.57 (1H, 
d, J = 5.0 Hz, H-pyridine), 9.09 (1H, s, H-pyrrole); 

C NMR (125 MHz; DMSO-d6) C 
57.2 (CH2), 122.2 (CH-pyridine), 123.2 (CH-pyridine), 131.5 (CH-pyrazole), 135.0 (C-
NO2), 136.0 (CH-pyrazole), 137.3 (CH-pyridine), 149.4 (CH-pyridine), 154.8 (C-2 
pyridine); HRMS calcd for C9H9N4O2 [M+H]
+
 205.0720, found 205.0718. 
1-(Pyridin-2-ylmethyl)-1H-pyrazol-4-amine (401) 
451-173 
Prepared according to general procedure H using nitropyrazole 388 (580 mg, 2.84 mmol) 
and MeOH (20 mL), to give an orange oil (474 mg, 96 %); Rf 0.6 (EtOAc); max(EtOH)/nm 
260; IR  max/cm
-1 
3314; 

H NMR(500 MHz; DMSO-d6) H 3.90 (2H, br s, NH2), 5.26 
(2H, s, CH2), 6.93 (1H, d, J = 7.8 Hz, H-pyridine), 7.01 (1H, d, J = 0.6 Hz, H-pyrazole), 
7.17 (1H, d, J = 0.6 Hz, H-pyrazole), 7.32 (1H, ddd, J = 0.8, 4.9 and 7.4 Hz, H-pyridine), 
7.77 (1H, td, J = 7.8 and 1.7 Hz, H-pyridine), 8.53-8.57 (1H, m, H-pyridine); 

C NMR 
(125 MHz; DMSO-d6) C 56.6 (CH2), 117.1 (C-pyrazole), 121.2 (C-pyridine), 122.5 (C-
pyridine), 130.0 (C-pyrazole), 131.4 (C-NH2), 137.0 (C-pyridine), 148.9 (C-pyridine), 
157.6 (C-2-pyridine); HRMS calcd for C9H11N4 [M+H]
+
 175.0978, found 175.0976. 
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl)-
1H-pyrrole-2-carboxamide (309) 
451-174 
Prepared according to general procedure L using carboxylic acid 337 (100 mg, 0.33 mmol, 
1 eq.), Et3N (115 L, 0.83 mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (93 mg, 
0.36 mmol, 1.1 eq.) in DCM (5 mL) followed by the addition of amine 401 (72 mg, 0.41 
mmol, 1.25 eq.) in DCM (1 mL) with stirring at r.t. for 18 h. The residue was purified by 
MPLC on SiO2 with gradient elution from 60-100% EtOAc/petrol to give a white solid (83 
mg, 55%); Rf 0.25 (EtOAc); m.p. 224-226 C; max(EtOH)/nm 256; IR  max/cm
-1 
3123, 
1631; 

H NMR(500 MHz; DMSO-d6) H 5.45 (2H, s, CH2), 7.07 (1H, d, J = 7.9 Hz, H-
pyridine), 7.32-7.39 (2H, m, H-pyrrole and H-4’), 7.56 (1H, dd, J = 0.9 and 8.7 Hz, H-5’), 
7.60 (1H, s, H-pyrrole), 7.64 (1H, s, H-pyrazole), 7.78-7.85 (2H, m, 2 × H-pyridine), 8.15 
(1H, s, H-pyrazole), 8.55-8.60 (1H, m, H-pyridine), 10.35 (CO-NH), 12.68 (NH-pyrrole); 

F NMR(470 MHz; DMSO-d6) F -116.64; 
13
C 

C NMR (125 MHz; DMSO-d6) C 56.7 
(CH2), 110.2 (CH-pyrrole), 119.3 (d, JCF = 18.1 Hz, C-3’), 121.5 (C-pyrazole), 121.6 (C-
pyrazole), 122.7 (C-pyridine), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.6 Hz, C-5’), 128.7 (C-
pyrrole), 129.2 (d, JCF = 23.2 Hz, C-1’), 129.2 (d, JCF = 5.1 Hz, C-6’), 129.6 (C-pyrrole), 
130.8 (C-pyrazole), 131.8 (C-4’), 137.1 (C-4-pyridine), 149.1 (C-pyridine), 153.8 (d, JCF = 
248.4 Hz, C-2’), 156.8 (CO-NH), 156.9 (C-2-pyridine), 182.6 (CO); HRMS calcd for 
C21H15
35
Cl2F1N5O2 [M+H]
+
 458.0581, found 458.0579. 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(1-(pyridin-2-ylmethyl)-1H-
pyrazol-4-yl)-1H-pyrrole-2-carboxamide (327) 
451-177 
Prepared according to general procedure L using carboxylic acid 421 (100 mg, 0.34 mmol, 
1 eq.), Et3N (117 L, 0.84 mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (94 mg, 
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0.37 mmol, 1.1 eq.) in DCM (5 mL) followed by the addition of amine 401 (73 mg, 0.42 
mmol, 1.25 eq.) in DCM (1 mL) with stirring at r.t. for 18 h. The residue was purified by 
MPLC on SiO2 with gradient elution from 70-100% EtOAc/petrol to give a white solid (69 
mg, 45%); Rf 0.2 (EtOAc); m.p. 160 C dec.; max(EtOH)/nm 255, 227; IR  max/cm
-1 
3122, 
1631; 

H NMR(500 MHz; DMSO-d6) H 3.94 (CH3), 5.45 (2H, s, CH2), 7.07 (1H, d, J = 
7.9 Hz, H-pyridine), 7.30-7.40 (3H, m, H-pyrrole, H-4’ and H-pyridine), 7.42 (1H, dd, J = 
1.1 and 9.0 Hz, H-5’), 7.46 (1H, s, H-pyrrole), 7.63 (1H, s, H-pyrazole), 7.80 (1H, td, J = 
7.7 and 1.9 Hz, H-pyridine), 8.15 (1H, s, H-pyrazole), 8.55-8.60 (1H, m, H-pyridine), 
10.34 (1H, s, CO-NH), 12.61 (1H, s, NH-pyrrole); 

F NMR(470 MHz; DMSO-d6) F -
136.13; 

C NMR (125 MHz; DMSO-d6) C 56.4 (OCH3), 56.7 (CH2), 110.3 (CH-pyrrole), 
115.1 (C-4’), 120.2 (d, JCF = 4.6 Hz, C-1’), 121.5 (C-pyrazole), 121.6 (C-pyrazole), 122.7 
(C-pyridine), 125.1 (C-pyrrole), 125.5 (d, JCF = 3.6 Hz, C-5’), 128.4 (C-pyrrole), 128.5 (d, 
JCF = 20.0 Hz, C-6’), 128.8 (CH-pyrrole), 130.8 (CH-pyrazole), 137.1 (C-4-pyridine), 
146.4 (d, JCF = 10.7 Hz, C-3’), 147.9 (d, JCF = 247.0 Hz, C-2’), 149.1 (C-6-pyridine), 156.8 
(CO-NH), 156.9 (C-2-pyridine), 183.6 (CO); HRMS calcd for C22H18
35
Cl1F1N5O3 [M+H]
+
 
454.1077, found 454.1072. 
3-((4-Nitro-1H-pyrazol-1-yl)methyl)pyridine (389) 
451-172 
Prepared according to general procedure J using 3-pyridylmethanol (343 L, 3.5 mmol, 1 
eq.), PPh3 (1.39 g, 5.3 mmol, 1.5 eq.), 4-nitropyrazole (400 mg, 3.5 mmol, 1 eq.) and 
DEAD (836 L, 5.3 mmol, 1.5 eq.) in THF (7 mL) with stirring at r.t. for 18 h. The residue 
was purified by MPLC on NH2 SiO2 with a gradient elution from 10-30% EtOAc/petrol to 
give a clear oil, which was re-purified by MPLC on SiO2 with a gradient elution from 30-
60% EtOAc/petrol to give a clear oil (290 mg, 40%); Rf 0.3 (EtOAc); max(EtOH)/nm 267; 
IR  max/cm
-1 
1498, 1318; 

H NMR(500 MHz; DMSO-d6) H 5.47 (2H, s, CH2), 7.44 (1H, 
dd, J = 4.7 and 7.7 Hz, H-5-pyridine), 7.79 (1H, ddd, J = 1.7, 2.0 and 7.7 Hz, H-4-
pyridine), 8.33 (1H, d, J = 0.6 Hz, H-pyrrole), 8.58 (1H, dd, J = 1.7 and 4.7 Hz, H-6-
pyridine), 8.64 (1H, d, J = 2.0 Hz, H-2-pyridine), 9.11 (1H, s, H-pyrrole); 

C NMR (125 
MHz; DMSO-d6) C 53.3 (CH2), 123.7 (CH-pyridine), 130.8 (CH-pyridine), 131.4 (CH-
pyrazole), 135.1 (C-NO2), 135.9 (CH-pyrazole), 136.2 (CH-pyridine), 149.3 (CH-
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pyridine), 149.4 (C-3-pyridine); HRMS calcd for C9H9N4O2 [M+H]
+
 205.0720, found 
205.0718. 
1-(Pyridin-3-ylmethyl)-1H-pyrazol-4-amine (402)375 
451-175 
Prepared according to general procedure H using nitropyrazole 389 (270 mg, 1.32 mmol) 
and MeOH (15 mL), to give a brown oil (210 mg, 91%); Rf 0.2 (NH2 SiO2, EtOAc); 
max(EtOH)/nm 255; IR  max/cm
-1 
3321; 

H NMR(500 MHz; DMSO-d6) H 3.89 (2H, s, 
NH2), 5.21 (2H, s, CH2), 6.99 (1H, d, J = 0.8 Hz, H-pyrazole), 7.17 (1H, d, J = 0.8 Hz, H-
pyrazole), 7.39 (1H, ddd, J = 0.6, 4.7 and 7.7 Hz, H-5-pyridine), 7.57-7.62 (1H, m, H-6-
pyridine), 8.47 (1H, d, J = 1.7 Hz, H-2-pyridine), 8.51 (1H, dd, J = 1.7 and 4.7 Hz, H-4-
pyridine); 

C NMR (125 MHz; DMSO-d6) C 52.2 (CH2), 116.5 (C-pyrazole), 123.5 (CH-
pyridine), 130.0 (CH-pyrazole), 131.5 (C-NH2), 133.7 (C-3-pyridine), 135.1 (C-6-
pyridine), 148.6 (C-2-pyridine), 148.7 (C-4-pyridine); HRMS calcd for C9H11N4 [M+H]
+
 
175.0978, found 175.0977. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl)-
1H-pyrrole-2-carboxamide (310) 
451-178

Prepared according to general procedure L using carboxylic acid 337 (125 mg, 0.41 mmol, 
1 eq.), Et3N (144 L, 1.03 mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (105 mg, 
0.41 mmol, 1.1 eq.) in DCM (5 mL) followed by the addition of amine 402 (90 mg, 0.52 
mmol, 1.25 eq.) in DCM (1 mL) with stirring at r.t. for 18 h. The residue was purified by 
MPLC on SiO2 with gradient elution from EtOAc to 5% MeOH/EtOAc give a white solid 
which was purified by MPLC on NH2 SiO2 with gradient elution from 0-10% 
MeOH/CH2Cl2 to give a white solid. This material was re-purified by MPLC on SiO2 with 
gradient elution from 0-5% MeOH/EtOAc give a white solid (29 mg, 16%); Rf 0.7 (NH2 
SiO2, 5% MeOH/CH2Cl2); mp 130-135 C; max(EtOH)/nm 256, 222; IR  max/cm
-1 
3123, 
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1634; 

H NMR(500 MHz; DMSO-d6) H 5.41 (2H, s, CH2), 7.35 (1H, s, H-pyrrole), 7.41 
(1H, ddd, J = 0.8, 4.9 and 7.9 Hz, H-5-pyridine), 7.55 (1H, dd, J = 1.3 and 8.6 Hz, H-5’), 
7.60 (1H, s, H-pyrrole), 7.62 (1H, d, J = 0.6 Hz, H-pyrazole), 7.66-7.69 (1H, m, H-4-
pyridine), 7.82 (1H, app t, J = 8.6 Hz, H-4’), 8.17 (1H, s, H-pyrazole), 8.52-8.56 (2H, m, 
H-2-pyridine and H-6-pyridine), 10.34 (1H, s, CO-NH), 12.66 (1H, br s, NH-pyrrole); 

F 
NMR(470 MHz; DMSO-d6) F -116.65; 

C NMR (125 MHz; DMSO-d6) C 52.3 (CH2), 
110.2 (CH-pyrrole), 119.3 (d, JCF = 18.1 Hz, C-3’), 121.0 (CH-pyrazole), 121.6 (C-
pyrazole), 123.6 (C-pyridine), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.6 Hz, C-5’), 128.6 (C-
pyrrole), 129.9 (d, JCF = 22.9 Hz, C-1’), 129.2 (d, JCF = 5.1Hz, C-6’), 129.6 (C-pyrrole), 
130.8 (C-pyrazole), 131.8 (C-4’), 133.2 (C-pyridine), 135.4 (C-pyridine), 148.9 (C-
pyridine), 153.8 (d, JCF = 248.4 Hz, C-2’), 156.8 (CO-NH), 182.6 (CO); HRMS calcd for 
C21H15
35
Cl2F1N5O2 [M+H]
+
 458.0581, found 458.0579. 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(1-(pyridin-3-ylmethyl)-1H-
pyrazol-4-yl)-1H-pyrrole-2-carboxamide (328) 
451-179 
Prepared according to general procedure L using carboxylic acid 421 (123 mg, 0.41 mmol, 
1 eq.), Et3N (144 L, 1.03 mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (105 mg, 
0.41 mmol, 1.1 eq.) in DCM (5 mL) followed by the addition of amine 402 (90 mg, 0.52 
mmol, 1.25 eq.) in DCM (1 mL) with stirring at r.t. for 18 h. The residue was purified by 
MPLC on SiO2 with gradient elution from 0-5% MeOH/EtOAc give a white solid. This 
was dissolved in MeOH and passed through a SCX column eluting with MeOH (100 mL) 
followed by 10% NH4OH/MeOH (100 mL). Product containing fraction were evaporated 
and purified by MPLC on NH2 SiO2 with gradient elution from 0-10% MeOH/CH2Cl2 to 
give a white solid (56 mg, 30%); Rf 0.6 (NH2 SiO2, 5% MeOH/CH2Cl2); mp 170 C dec.; 
max(EtOH)/nm 254, 227; IR  max/cm
-1 
3122, 2935, 1634; 

H NMR(500 MHz; DMSO-d6) 
H 3.94 (3H, s, CH3), 5.40 (2H, s, CH2), 7.31 (1H, s, H-pyrrole), 7.36 (1H, app t, J = 9.1 
Hz, H-4’), 7.39-7.44 (2H, m, H-5-pyridine and H-5’), 7.46 (1H, s, H-pyrrole), 7.61 (1H, s, 
H-pyrazole), 7.65-7.69 (1H, m, H-4-pyridine), 8.17 (1H, s, H-pyrazole), 8.52-8.56 (2H, m, 
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H-2-pyridine and H-6-pyridine), 10.33 (1H, s, CO-NH), 12.60 (1H, br s, NH-pyrrole); 

F 
NMR(470 MHz; DMSO-d6) F -136.15; 

C NMR (125 MHz; DMSO-d6) C 52.3 (CH2), 
56.4 (OCH3), 110.4 (CH-pyrrole), 115.1 (C-4’), 120.2 (d, JCF = 5.0 Hz, C-1’), 120.9 (CH-
pyrazole), 121.6 (C-pyrazole), 123.6 (C-pyridine), 125.1 (C-pyrrole), 125.5 (d, JCF = 3.2 
Hz, C-5’), 128.4 (C-pyrrole), 128.5 (C-6’), 128.8 (CH-pyrrole), 130.9 (CH-pyrazole), 
133.2 (C-pyridine), 146.4 (d, JCF = 10.4 Hz, C-3’), 147.9 (d, JCF = 245.4 Hz, C-2’), 148.9 
(C-pyridine), 156.8 (CO-NH), 183.6 (CO); HRMS calcd for C22H18
35
Cl1F1N5O3 [M+H]
+
 
454.1077, found 454.1072. 
4-((4-Nitro-1H-pyrazol-1-yl)methyl)pyridine (390)376 
451-180 
Prepared according to general procedure J using 4-pyridylmethanol (478 mg, 4.4 mmol, 1 
eq.), PPh3 (1.74 g, 6.6 mmol, 1.5 eq.), 4-nitropyrazole (500 mg, 4.4 mmol, 1 eq.) and 
DEAD (1.04 mL, 6.6 mmol, 1.5 eq.) in THF (8 mL) with stirring at r.t. for 72 h. The 
residue was dissolved in MeOH and passed through a 5 g SCX cartridge eluting with 
MeOH (100 mL) followed by 10% NH4OH/MeOH (50 mL), and product containing 
fractions were evaporated. The residue was purified by MPLC on SiO2 with a gradient 
elution from 25-60% EtOAc/petrol to give a white solid (495 mg, 55%); Rf 0.4 (5% 
MeOH/CH2Cl2); m.p. 87-90 C; max(EtOH)/nm 264; IR  max/cm
-1 
1499, 1318; 

H 
NMR(500 MHz; DMSO-d6) H 5.50 (2H, s, CH2), 7.25-7.29 (2H, m, H-pyridine), 8.37 
(1H, s, H-pyrazole), 8.58-8.61 (2H, m, H-pyridine), 9.12 (1H, s, H-pyrazole); 

C NMR 
(125 MHz; DMSO-d6) C 54.5 (CH2), 122.4 (C-3 and C-5-pyridine), 131.4 (CH-pyrazole), 
135.2 (C-NO2), 136.3 (CH-pyrazole), 144.6 (C-4-pyridine), 150.0 (C-2 and C-6-pyridine); 
MS (ES+) m/z 205.3 [M+H]
+
;
 
HRMS calcd for C9H9N4O2 [M+H]
+
 205.0720, found 
205.0717. 
1-(Pyridin-4-ylmethyl)-1H-pyrazol-4-amine (403)376 
451-190 
Palladium on carbon (10%, 40 mg) was added to nitropyrazole 390 (470 mg, 2.3 mmol) in 
MeOH (30 mL), and the mixture was stirred at r.t. under an atmosphere of hydrogen for 18 
h. The reaction was filtered through Celite, and the solvent removed in vacuo to give a 
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beige solid (398 mg, 98%); Rf 0.1 (5% MeOH/EtOAc); m.p. 80-85 C; max(EtOH)/nm 
247; IR  max/cm
-1 
3398, 3309, 3198, 2936; 

H NMR(500 MHz; DMSO-d6) H 3.93 (2H, s, 
NH2), 5.23 (2H, s, CH2), 7.03 (1H, d, J = 0.8 Hz, H-pyrazole), 7.02-7.11 (2H, m, H-
pyridine), 7.17 (1H, d, J = 0.8 Hz, H-pyrazole), 8.51-8.55 (2H, m, H-pyridine); 

C NMR 
(125 MHz; DMSO-d6) C 53.4 (CH2), 117.0 (CH-pyrazole), 121.9 (C-3 and C-5-pyridine), 
130.2 (CH-pyrazole), 131.5 (C-3-pyrazole), 147.3 (C-4-pyridine), 149.7 (C-2 and C-6-
pyridine); HRMS calcd for C9H11N4 [M+H]
+
 175.0978, found 175.0974. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-(pyridin-4-ylmethyl)-1H-pyrazol-4-yl)-
1H-pyrrole-2-carboxamide (311) 
451-194 
Prepared according to general procedure L using carboxylic acid 337 (100 mg, 0.33 mmol, 
1 eq.), Et3N (115 L, 0.83 mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (93 mg, 
0.36 mmol, 1.1 eq.) in DCM (4 mL) followed by the addition of amine 403 (72 mg, 0.41 
mmol, 1.25 eq.) in DCM (1 mL) with stirring at r.t. for 18 h. The residue was purified by 
MPLC on SiO2 with gradient elution from 80% EtOAc/petrol to 100% EtOAc give a white 
solid. This was further purified by MPLC on NH2 SiO2 with gradient elution from CH2Cl2 
to 4% MeOH/CH2Cl2 to give a white solid (37 mg, 25%); Rf 0.2 (EtOAc); m.p. 165-169 
C; max(EtOH)/nm 254sh; IR  max/cm
-1 
3122, 2924, 1634, 1590; 

H NMR(500 MHz; 
DMSO-d6) H 5.44 (2H, s, CH2), 7.14-7.17 (2H, m, H-pyridine), 7.37 (1H, br s, H-pyrrole), 
7.56 (1H, dd, J = 1.4 and 8.6 Hz, H-5’), 7.60 (1H, br s, H-pyrrole), 7.66 (1H, d, J = 0.5 Hz, 
H-pyrazole), 7.82 (1H, app t, J = 8.6 Hz, H-4’), 8.19 (1H, d, J = 0.5 Hz, H-pyrazole), 8.54-
8.58 (2H, m, H-pyridine), 10.37 (1H, s, CO-NH), 12.69 (1H, br s, NH-pyrrole); 

F 
NMR(470 MHz; DMSO-d6) F -116.64; 

C NMR (125 MHz; DMSO-d6) C 53.6 (CH2), 
110.3 (CH-pyrrole), 119.3 (d, JCF = 18.2 Hz, C-3’), 121.4 (CH-pyrazole), 121.6 (C-
pyridine), 122.0 (C-pyrazole), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.6 Hz, C-5’), 128.6 (C-
pyrrole), 129.2 (d, JCF = 22.7 Hz, C-1’), 129.2 (d, JCF = 5.0 Hz, C-6’), 129.6 (C-pyrrole), 
131.1 (C-pyrazole), 131.8 (C-4’), 146.7 (C-pyridine), 149.8 (C-pyridine), 153.8 (d, JCF = 
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248.4 Hz, C-2’), 156.9 (CO-NH), 182.6 (CO); HRMS calcd for C21H15
35
Cl2F1N5O2 
[M+H]
+
 458.0581, found 458.0575. 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(1-(pyridin-4-ylmethyl)-1H-
pyrazol-4-yl)-1H-pyrrole-2-carboxamide (329) 
451-197 
Prepared according to general procedure L using carboxylic acid 421 (800 mg, 0.27 mmol, 
1 eq.), Et3N (93 L, 0.67 mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (76 mg, 
0.30 mmol, 1.1 eq.) in DCM (4 mL) followed by the addition of amine 403 (58 mg, 0.34 
mmol, 1.25 eq.) in DCM (1 mL) with stirring at r.t. for 18 h. The residue was purified by 
MPLC on SiO2 with gradient elution from 0-5% MeOH/EtOAc give a white solid. This 
was further purified by MPLC on NH2 SiO2 with gradient elution from 0-4% 
MeOH/CH2Cl2 to give a white solid (32 mg, 26%); Rf 0.2 (5% MeOH/EtOAc); m.p. 190-
192 C; max(EtOH)/nm 253sh, 227; IR max/cm
-1 
3332, 1626; 

H NMR(500 MHz; 
DMSO-d6) H 3.94 (3H, s, CH3), 5.43 (2H, s, CH2), 7.13-7.18 (2H, m, H-pyridine), 7.33 
(1H, br s, H-pyrrole), 7.36 (1H, app t, J = 9.0 Hz, H-4’), 7.42 (1H, dd, J = 1.3 and 9.0 Hz, 
H-5’), 7.47 (1H, br s, H-pyrrole), 7.65 (1H, d, J = 0.5 Hz, H-pyrazole), 8.18 (1H, d, J = 0.5 
Hz, H-pyrazole), 8.53-8.58 (2H, m, H-pyridine), 10.36 (1H, s, CO-NH), 12.61 (1H, br s, 
NH-pyrrole); 

F NMR(470 MHz; DMSO-d6) F ; -136.14; 

C NMR (125 MHz; DMSO-
d6) C 53.6 (CH2), 56.4 (OCH3), 110.4 (CH-pyrrole), 115.1 (C-4’), 120.2 (d, JCF = 4.8 Hz, 
C-1’), 121.4 (CH-pyrazole), 121.7 (C-pyrazole), 122.0 (C-pyridine), 125.1 (C-pyrrole), 
125.5 (d, JCF = 3.6 Hz, C-5’), 128.4 (C-pyrrole), 128.5 (C-6’), 128.9 (C-pyrrole), 131.0 (C-
pyrazole), 146.4 (d, JCF = 10.4 Hz, C-3’), 146.7 (C-pyridine), 147.9 (d, JCF = 247.5 Hz, C-
2’), 149.8 (C-pyridine), 156.9 (CO-NH), 183.6 (CO); HRMS calcd for C22H18
35
Cl1F1N5O3 
[M+H]
+
 454.1077, found 454.1067. 
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4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(1-(1-(2,2,2-trifluoroethyl) 
piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrrole-2-carboxamide (326) 
451-196 
Prepared according to general procedure L using carboxylic acid 421 (80 mg, 0.27 mmol, 1 
eq.), Et3N (93 L, 0.67 mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (76 mg, 0.30 
mmol, 1.1 eq.) in DCM (4 mL) followed by the addition of amine 397 (83 mg, 0.34 mmol, 
1.25 eq.) with stirring at r.t. for 18 h. The residue was purified by MPLC on SiO2 with 
gradient elution from 40-80% EtOAc/petrol to give a white solid (70 mg, 49%); Rf 0.1 
(60% EtOAc/petrol); m.p. 236-239 C; max(EtOH)/nm 252 sh, 227; IR  max/cm
-1 
3353, 
3204, 3123, 2951, 1630, 1602; 

H NMR(500 MHz; DMSO-d6) H 1.93-2.01 (4H, m, H-
piperidine), 2.53-2.60 (2H, m, H-piperidine), 3.00-3.07 (2H, m, H-piperidine), 3.27 (2H, q, 
JHF = 10.3 Hz, CH2CF3), 3.94 (3H, s, OCH3), 4.14-4.23 (1H, m, H-piperidine), 7.32 (1H, s, 
H-pyrrole), 7.36 (1H, app t, J = 9.0 Hz, H-4’), 7.42 (1H, dd, J = 1.3 and 9.0 Hz, H-5’), 7.46 
(1H, s, H-pyrrole), 7.59 (1H, s, H-pyrazole), 8.01 (1H, s, H-pyrazole), 10.28 (1H, s, CO-
NH), 12.59 (1H, br s, NH-pyrrole); 

F NMR(470 MHz; DMSO-d6) -67.98, -136.15; 

C 
NMR (125 MHz; DMSO-d6) C 31.9 (C-piperidine), 52.3 (C-piperidine), 56.4 (q, JCF = 
29.1 Hz, CH2CF3), 56.4 (OMe), 57.8 (C-piperidine), 110.3 (CH-pyrrole), 115.1 (C-4’), 
118.7 (CH-pyrazole), 120.2 (d, JCF = 5.0 Hz, C-1’), 120.9 (C-pyrazole), 125.1 (C-pyrrole), 
125.5 (d, JCF = 3.6 Hz, C-5’), 125.6 (q, J = 294.0 Hz, CF3), 127.2, 128.4 (C-pyrazole), 
128.5 (C-6’), 128.6 (C-pyrrole), 128.8 (CH-pyrrole), 129.9 (CH-pyrazole), 146.4 (d, JCF = 
10.9 Hz, C-3’), 147.9 (d, JCF = 247.3 Hz, C-2’), 156.9 (CO-NH), 183.6 (CO); HRMS calcd 
for C23H23
35
Cl1F4N5O3 [M+H]
+
 528.1420, found 528.1406. 
1-(2-Methoxyethyl)-4-nitro-1H-pyrazole (391)377 
451-186 
Prepared according to general procedure J using 2-methoxyethanol (244 L, 3.1 mmol, 1 
eq.), PPh3 (1.22 g, 4.6 mmol, 1.5 eq.), 4-nitropyrazole (350 mg, 3.1 mmol, 1 eq.) and 
DEAD (731 L, 4.6 mmol, 1.5 eq.) in THF (6 mL) with stirring at r.t. for 18 h. The residue 
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was purified by MPLC on SiO2 with a gradient elution from 20-60% EtOAc/petrol to give 
a clear oil (450 mg, 85%); Rf 0.75( EtOAc); max(EtOH)/nm 272; IR  max/cm
-1 
1506, 1297; 

H NMR(500 MHz; DMSO-d6) H 3.27 (3H, s, OMe), 3.76 (2H, d, J = 5.2 Hz, 
CH2CH2OMe), 4.38 (2H, d, J = 5.2 Hz, CH2CH2OMe), 8.31 (1H, s, H-pyrazole), 8.89 (1H, 
s, H-pyrazole); 

C NMR (125 MHz; DMSO-d6) C 52.1 (CH2), 57.9 (Me), 69.4 (CH2), 
130.9 (C-pyrazole), 134.8 (C-NO2), 135.6 (C-pyrazole); MS (ES+) m/z 172.2 [M+H]
+
. 
1-(2-Methoxyethyl)-1H-pyrazol-4-amine (404)377 
451-188 
Palladium on carbon (10%, 40 mg) was added to nitropyrazole 391 (440 mg, 2.6 mmol) in 
MeOH (30 mL), and the mixture was stirred at r.t. under an atmosphere of hydrogen for 18 
h. The reaction was filtered through Celite, and the solvent removed in vacuo to give a 
brown oil (330 mg, 91%); Rf 0.1 (5% MeOH/EtOAc); max(EtOH)/nm 246; IR  max/cm
-1 
3332, 2933; 

H NMR(500 MHz; DMSO-d6) H 3.25 (3H, s, OMe), 3.62 (2H, d, J = 5.5 
Hz, CH2CH2OMe), 3.80 (2H, s, NH2), 4.08 (2H, d, J = 5.5 Hz, CH2CH2OMe), 6.93 (1H, s, 
H-pyrazole), 7.05 (1H, s, H-pyrazole); 

C NMR (125 MHz; DMSO-d6) C 50.9 (CH2), 
57.9 (Me), 70.9 (CH2), 116.9 (C-pyrazole), 129.2 (C-pyrazole), 130.7 (C-NH2); MS (ES+) 
m/z 142.2 [M+H]
+ 
. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-1H-
pyrrole-2-carboxamide (316) 
451-191 
Prepared according to general procedure L using carboxylic acid 337 (150 mg, 0.50 mmol, 
1 eq.), Et3N (173 L, 1.24mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (139 mg, 
0.54 mmol, 1.1 eq.) in DCM (5 mL) followed by the addition of amine 404 (87 mg, 0.62 
mmol, 1.25 eq.) with stirring at r.t. for 18 h. The residue was purified by MPLC on SiO2 
with gradient elution from 40% EtOAc/petrol to 100% EtOAc give a white solid. (102 mg, 
49%); Rf 0.3 (EtOAc); m.p.155-160 C; max(EtOH)/nm 253sh, 224; IR  max/cm
-1 
3194, 
3124, 2929, 1628, 1591; 

H NMR(500 MHz; DMSO-d6) H 3.27 (3H, s, CH3), 3.70 (2H, t, 
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J = 5.3 Hz, CH2-N), 4.27 (2H, t, J = 5.3 Hz, CH2-O), 7.35 (1H, s, H-pyrrole), 7.56 70 (1H, 
dd, J = 1.2 and 8.5 Hz, H-5’), 7.58 (1H, s, H-pyrazole), 7.60 (1H, s, H-pyrrole), 7.82 (1H, 
app t, J = 8.5 Hz, H-4’), 8.00 (1H, s, H-pyrazole), 10.28 (1H, s, CO-NH), 12.67 (1H, s, 
NH-pyrrole); 

F NMR(470 MHz; DMSO-d6) F -116.65; 

C NMR (125 MHz; DMSO-
d6) C 51.2 (CH2-O), 57.9 (CH3), 70.6 (CH2-N), 110.1 (CH-pyrrole), 119.3 (d, JCF = 18.1 
Hz, C-3’), 121.0 (CH-pyrazole), 121.2 (C-pyrazole), 124.7 (C-pyrrole), 126.9 (d, JCF = 3.6 
Hz, C-5’), 128.7 (C-pyrrole), 129.2 (d, JCF = 22.7 Hz, C-1’), 129.2 (d, JCF = 5.1 Hz, C-6’), 
129.6 (C-pyrrole), 130.2 (CH-pyrazole), 131.8 (C-4’), 153.8 (d, JCF = 248.4 Hz, C-2’), 
156.8 (CO-NH), 182.6, (CO); HRMS calcd for C18H16
35
Cl2F1N4O3 [M+H]
+
 425.0578, 
found 425.0573. 
4-(6-Chloro-2-fluoro-3-methoxybenzoyl)-N-(1-(2-methoxyethyl)-1H-pyrazol-4-
yl)-1H-pyrrole-2-carboxamide (324) 
451-192 
Prepared according to general procedure L using carboxylic acid 421 (125 mg, 0.42 mmol, 
1 eq.), Et3N (146 L, 1.05mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (118 mg, 
0.46 mmol, 1.1 eq.) in DCM (4 mL) followed by the addition of amine 404 (74 mg, 0.52 
mmol, 1.25 eq.) with stirring at r.t. for 18 h. The residue was purified by MPLC on SiO2 
with gradient elution from 40% EtOAc/petrol to 100% EtOAc give a white solid. (80 mg, 
45%); Rf 0.25 (EtOAc); m.p. 217-221 C; max(EtOH)/nm 252 sh, 224; IR  max/cm
-1 
3354, 
3208, 3115, 1636, 1615, 1592; 

H NMR(500 MHz; DMSO-d6) H 3.27 (3H, s, CH2-O-
CH3), 3.70 (2H, t, J = 5.3 Hz, CH2-N), 3.94 (1H, s, Ar-O-CH3), 4.27 (2H, t, J = 5.3 Hz, 
CH2-O), 7.32 (1H, s, H-pyrrole), 7.36 (1H, app t, J = 8.9 Hz, H-4’), 7.42 (1H, dd, J = 1.0 
Hz and 8.9 Hz, H-5’), 7.46 (1H, s, H-pyrrole), 7.57 (1H, s, H-pyrazole), 8.00 (1H, s, H-
pyrazole), 10.28 (1H, s, CO-NH), 12.60 (1H, s, NH-pyrrole); 

F NMR(470 MHz; DMSO-
d6) F -136.15; 

C NMR (125 MHz; DMSO-d6) C 51.2 (CH2-O), 56.4 (Ar-O-CH3)57.9 
(CH2-O-CH3), 70.6 (CH2-N), 110.3 (CH-pyrrole), 115.1 (d, JCF = 18.1 Hz, C-4’), 120.2 (d, 
JCF = 4.8 Hz, C-1’), 121.0 (CH-pyrazole), 121.1 (C-pyrazole), 125.0 (C-pyrrole), 125.5 (d, 
JCF = 3.6 Hz, C-5’), 128.4 (C-pyrrole), 128.5 (C-6’), 128.6 (CH-pyrrole and C-pyrrole), 
146.4 (d, J = 10.6 Hz, C-3’), 147.9 (d, JCF = 246.9 Hz, C-2’), 156.8 (CO-NH), 183.6 (CO); 
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MS (ES+) m/z 421.4 [M
35,35
Cl+H]
+
,
 
423.4 [M
35,37
Cl+H]
+ 
; HRMS calcd for 
C19H19
35
Cl1F1N4O4 [M+H]
+
 421.1073, found 421.1067. 
1-((1-Methyl-1H-imidazol-2-yl)methyl)-4-nitro-1H-pyrazole (392) 
451-199-c 
Prepared according to general procedure J using 1-methyl-2-hydroxymethylimidazole (298 
mg, 2.65 mmol, 1 eq.), PPh3 (1.04 g, 4.0 mmol, 1.5 eq.), 4-nitropyrazole (300 mg, 2.65 
mmol, 1 eq.) and DEAD (1.04 mL, 4.0 mmol, 1.5 eq.) in THF (4 mL) with stirring at r.t. 
for 18 h. The residue was dissolved in MeOH and run through a 20 g SCX cartridge eluting 
with MeOH (100 mL) followed by 20% NH4OH/MeOH (50 mL). Product containing 
fractions were evaporated and purified by MPLC on SiO2 with a gradient elution from 80-
100% EtOAc/petrol to give a clear oil (98 mg, 18%); Rf 0.2 (5% MeOH/EtOAc); m.p. 128-
132 C; max(EtOH)/nm 271; IR  max/cm
-1 
1509, 1312; 

H NMR (500 MHz; DMSO-d6) H 
3.73 (3H, s, CH3), 5.55 (1H, s, CH2), 6.89 (1H, d, J = 1.2 Hz, H-imidazole), 7.20 (1H, d, J 
= 1.2 Hz, H-imidazole), 8.31 (1H, d, J = 0.5 Hz, H-pyrazole), 8.97 (1H, d, J = 0.5 Hz, H-
pyrazole); 

C NMR (125 MHz; DMSO-d6) 32.7 (CH3), 47.8 (CH2), 122.8 (CH-imidazole), 
127.2 (CH-imidazole), 130.6 (CH-pyrazole), 135.0 (C-NO2), 135.9 (CH-pyrazole), 141.3 
(C-2-imidazole); HRMS calcd for C8H10N5O2 [M+H]
+
 208.0829, found 208.0825. 
1,1'-1,2-Dimethyl-4,5-dihydro-1H-imidazole-4,5-diyl)bis(4-nitro-1H-pyrazole) 
(411) 
 
Compound 411 was obtained as a by-product from the above synthesis of 392, and isolated 
as a white solid (154 mg, 18%); Rf 0.5 (EtOAc); m.p. 187-191 C; max(EtOH)/nm ; IR  
max/cm
-1 
1599, 1497, 1407, 1293; 

H NMR (500 MHz; DMSO-d6) H 2.12 (3H, d, J = 0.9 
Hz, Me), 2.84 (3H, s, N-Me), 6.24 (1H, d, J = 3.3 Hz, CH-dihydroimidazole), 6.32 (1H, d, 
J = 0.9 and 3.3 Hz, CH-dihydroimidazole) , 8.42 (1H, s, H-pyrazole), 8.51 (1H, s, H-
pyrazole), 9.00 (1H, d, J = 0.6 Hz, H-pyrazole), 9.5 (1H, d,, J = 0.6 Hz, H-pyrazole); 

C 
NMR (125 MHz; DMSO-d6) 14.0 (Me), 29.7 (N-Me), 82.3 (CH-dihydroimidazole), 85.4 
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(CH-dihydroimidazole), 129.8 (C-pyrazole), 131.0 (C-pyrazole), 135.1 (C-pyrazole), 135.2 
(C-pyrazole), 136.5 (C-pyrazole), 137.4 (C-pyrazole), 167.7 (C-2 dihydroimidazole); MS 
(ES+) m/z 208.3 [M-C3N3O2H]
+
.
 
 
1-((1-Methyl-1H-imidazol-2-yl)methyl)-1H-pyrazol-4-amine (405) 
451-208 
Palladium on carbon (10%, 30 mg) was added to nitropyrazole 392 (90 mg, 0.43 mmol) in 
MeOH (10 mL), and the mixture was stirred at r.t. under an atmosphere of hydrogen for 18 
h. The reaction was filtered through Celite, and the solvent removed in vacuo to give a 
brown oil (74 mg, 96%); Rf 0.35 (5% MeOH/EtOAc; NH2 SiO2); max(EtOH)/nm 245; IR  
max/cm
-1 
3325 br, 3112, 1613; 

H NMR (500 MHz; DMSO-d6) H 3.61 (3H, s, CH3), 3.87 
(2H, br s, NH2), 5.22 (1H, s, CH2), 6.84 (1H, d, J = 1.2 Hz, H-imidazole), 6.94 (1H, d, J = 
0.8 Hz, H-pyrazole), 6.98 (1H, d, J = 0.8 Hz, H-pyrazole), 7.12 (1H, d, J = 1.2 Hz, H-
imidazole); 

C NMR (125 MHz; DMSO-d6) 32.5 (CH3), 47.1 (CH2), 116.0 (CH-pyrazole), 
122.4 (CH-imidazole), 126.7 (CH-imidazole), 129.5 (CH-pyrazole), 131.4 (C-NH2), 143.1 
(C-2-imidazole); HRMS calcd for C8H12N5 [M+H]
+
 178.1087, found 178.1083.
 
 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-((1-methyl-1H-imidazol-2-yl)methyl)-
1H-pyrazol-4-yl)-1H-pyrrole-2-carboxamide (312) 
451-212 
Prepared according to general procedure L using carboxylic acid 337 (82 mg, 0.27 mmol, 1 
eq.), Et3N (94 L, 0.68 mmol, 2.5 eq.), and 2-chloromethylpyridinium iodide (76 mg, 0.30 
mmol, 1.25 eq.) in DCM (4 mL) followed by the addition of amine 405 (60 mg, 0.34 
mmol, 1.25 eq.) with stirring at r.t. for 18 h. The residue was purified by MPLC on NH2 
SiO2 with gradient elution from 0-4% MeOH/EtOAc to give a yellow solid (54 mg, 43%); 
Rf 0.5 (5% MeOH/EtOAc; NH2 SiO2); m.p. 285 C dec.; max(EtOH)/nm 254sh; IR  
max/cm
-1 
3159, 1657, 1634, 1592; 

H NMR (500 MHz; DMSO-d6) H 3.67 (3H, s, CH3), 
5.42 (2H, s, CH2), 6.87 (1H, s, H-imidazole), 7.16 (1H, s, H-imidazole), 7.34 (1H, s, H-
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pyrrole), 7.55 (1H, d, J = 8.5 Hz, H-4’), 7.57-7.64 (2H, m, H-pyrazole and H-pyrrole), 7.81 
(1H, app t, J = 8.5 Hz, H-4’), 8.00 (1H, s, H-pyrazole), 10.32 (1H, s, CO-NH), 12.68 (1H, 
br s, NH-pyrrole); 

F NMR(470 MHz; DMSO-d6) F -116.65; 

C NMR (125 MHz; 
DMSO-d6) C 32.6 (CH3), 47.2 (CH2), 110.2 (CH-pyrrole), 119.3 (d, JCF = 18.0 Hz, C-3’), 
120.5 (CH-pyrazole), 121.5 (CH-imidazole), 122.5 (CH-imidazole), 124.7 (C-pyrrole), 
126.8 (d, JCF = 4.1 Hz, C-5’), 128.6 (C-pyrrole), 129.2 (d, JCF = 23.2 Hz, C-1’), 129.2 (d, 
JCF = 5.3 Hz, C-6’), 129.6 (CH-pyrrole), 130.4 (CH-pyrazole), 131.8 (C-4’), 142.7 (C-2-
imidazole), 153.8 (d, JCF = 248.9 Hz, C-2’), 156.8 (CO-NH), 182.5 (CO); HRMS calcd for 
C20H16
35
Cl2F1N6O2 [M+H]
+
 461.0690, found 461.0683.
  
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(3-methylisoxazol-5-yl)-1H-pyrrole-2-
carboxamide (317) 
451-204 
Prepared according to general procedure F using carboxylic acid 337 (75 mg, 0.25 mmol, 1 
eq.), 5-amino-3-methylisoxazole (85 mg, 0.87 mmol, 3.5 eq.), PCl3 (22 L, 0.25 mmol, 1 
eq.) and MeCN (1 mL). Purification by MPLC on SiO2 with a gradient elution from 10-
40% EtOAc:petrol gave a white solid (32 mg, 34%); Rf 0.6 (40% EtOAc/petrol); m.p. 228 
C dec.; max(EtOH)/nm 294, 240; IR  max/cm
-1 
3253, 3126, 3055, 1680, 1640; 

H NMR 
(500 MHz; DMSO-d6) H 2.25 (3H, s, CH3), 6.29 (1H, s, H-isoxazole), 7.57 (1H, dd, J = 
1.3 and 8.4 Hz, H-3’), 7.62 (1H, br s, H-pyrrole), 7.74 (1H, s, H-pyrrole), 7.83 (1H, app t, J 
= 8.6 Hz, H-4’), 11.80 (1H, s, CO-NH), 12.94 (1H, s, NH-pyrrole); F NMR(470 MHz; 
DMSO-d6) F -116.62; 

C NMR (125 MHz; DMSO-d6) C 11.3 (CH3), 89.2 (CH-
isoxazole), 113.0 (CH-pyrrole), 119.3 (d, JCF = 18.0 Hz, C-3’), 124.9 (C-pyrrole), 126.9 (d, 
JCF = 3.8 Hz, C-5’), 127.1 (C-pyrrole), 129.0 (d, JCF = 23.0 Hz, C-1’), 129.2 (d, JCF = 5.1 
Hz, C-6’), 130.7 (C-pyrrole), 131.9 (C-4’), 153.8 (d, JCF = 248.4 Hz, C-2’), 156.3 (CO-
NH), 160.7 (C-isoxazole), 161.1 (C-isoxazole), 182.6, (CO); HRMS calcd for 
C16H11
35
Cl2F1N3O3 [M+H]
+
 382.0156, found 382.0153.
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4-(3,6-Dichloro-2-fluorobenzoyl)-N-(5-methylisoxazol-3-yl)-1H-pyrrole-2-
carboxamide (318) 
451-205 
Prepared according to general procedure F using carboxylic acid 337 (100 mg, 0.33 mmol, 
1 eq.), 3-amino-5-methylisoxazole (113 mg, 1.16 mmol, 3.5 eq.), PCl3 (29 L, 0.33 mmol, 
1 eq.) and MeCN (1.5 mL). Purification by MPLC on SiO2 with a gradient elution from 
10-35% EtOAc:petrol gave a white solid (50 mg, 40%); Rf 0.6 (40% EtOAc/petrol); m.p. 
255 C dec.; max(EtOH)/nm 288, 240; IR  max/cm
-1 
3423, 3129, 3081, 1654, 1619; 

H 
NMR (500 MHz; DMSO-d6) H 2.44 (3H, d, J = 0.7 Hz, CH3), 6.76 (1H, d, J = 0.7 Hz, H-
isoxazole), 7.56 (1H, dd, J = 1.4 and 8.4 Hz, H-3’), 7.64 (1H, br s, H-pyrrole), 7.69 (1H, s, 
H-pyrrole), 7.82 (1H, app t, J = 8.6 Hz, H-4’), 11.20 (1H, s, CO-NH), 12.83 (1H, s, NH-
pyrrole); 

F NMR(470 MHz; DMSO-d6) F -116.64; 

C NMR (125 MHz; DMSO-d6) C 
12.1 (CH3), 96.7 (CH-isoxazole), 112.9 (CH-pyrrole), 119.2 (d, JCF = 18.0 Hz, C-3’), 124.8 
(C-pyrrole), 126.9 (d, JCF = 4.1 Hz, C-5’), 127.5 (C-pyrrole), 129.1 (d, JCF = 23.0 Hz, C-
1’), 129.2 (d, JCF = 5.1 Hz, C-6’), 130.3 (C-pyrrole), 131.8 (C-4’), 153.8 (d, JCF = 248.5 
Hz, C-2’), 158.0 (CO-NH), 158.1 (C-isoxazole), 169.4 (C-isoxazole), 182.6, (CO); MS 
(ES+) m/z 382.3 [M
35,35
Cl+H]
+
,
 
384.3 [M
35,37
Cl+H]
+ 
; HRMS calcd for C16H11
35
Cl2F1N3O3 
[M+H]
+
 382.0156, found 382.0155. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-methyl-1H-pyrazol-3-yl)-1H-pyrrole-2-
carboxamide (319) 
451-206 
Prepared according to general procedure F using carboxylic acid 337 (100 mg, 0.33 mmol, 
1 eq.), 3-amino-5-methylpyrazole (113 mg, 1.16 mmol, 3.5 eq.), PCl3 (29 L, 0.33 mmol, 
1 eq.) and MeCN (1.5 mL). Purification by MPLC on SiO2 with a gradient elution from 
50-80% EtOAc:petrol gave a white solid which was re-purified by MPLC on NH2 SiO2 
with a gradient elution from 50-80% EtOAc/petrol to give a white solid (85 mg, 67%); Rf 
381 
 
0.3 (75% EtOAc/petrol); m.p. 240-242 C; max(EtOH)/nm 254sh; IR  max/cm
-1 
3200, 
3131, 1636, 1574; 

H NMR (500 MHz; DMSO-d6) H 3.81 (3H, s, CH3), 6.57 (1H, d, J = 
2.2 Hz, H-pyrazole), 7.55 (1H, dd, J = 1.4 and 8.6 Hz, H-5’), 7.56 (1H, br s, H-pyrrole), 
7.60 (1H, br s, H-pyrrole), 7.62 (1H, d, J = 2.2 Hz, H-pyrazole), 7.81 (1H, app t, J = 8.6 
Hz, H-4’), 10.75 (1H, s, CO-NH), 12.64 (1H, br s, NH-pyrrole); F NMR(470 MHz; 
DMSO-d6) F -116.63; 

C NMR (125 MHz; DMSO-d6) C 38.3 (CH3), 97.2 (C-4-
pyrazole), 111.5 (CH-pyrrole), 119.2 (d, JCF = 18.2 Hz, C-3’), 124.7 (C-pyrrole), 126.8 (d, 
JCF = 3.6 Hz, C-5’), 128.5 (CH-pyrrole), 129.2 (d, JCF = 5.1 Hz, C-6’), 129.3 (d, JCF = 23.2 
Hz, C-1’), 129.6 (C-pyrrole), 130.9 (C-5-pyrazole), 131.7 (C-4’), 146.6 (C-3-pyrazole), 
153.8 (d, JCF = 248.4 Hz, C-2’), 157.4 (CO-NH), 170.3, 182.5 (CO); HRMS calcd for 
C16H12
35
Cl2F1N4O2 [M+H]
+
 381.0316, found 381.0313. 
1-Methyl-4-nitro-1H-imidazole (418) 
451-217 
Dimethyl oxalate (522 mg, 4.42 mmol, 1 eq.) was added to 4-nitroimidazole (500 mg, 4.42 
mmol, 1 eq.) and KO
t
Bu (496 mg, 4.42 mmol, 1 eq.) in DMF (13 mL) and the mixture was 
heated at 140 C for 2 h. Further dimethyl oxalate (261 mg, 2.21 mmol, 0.5 eq.) and 
KO
t
Bu (248 mg, 2.21 mmol, 0.5 eq.) were added and the mixture heated at 140 C for a 
further 2 h. The solvent was removed in vacuo, the residue partitioned between EtOAc (2 × 
30 mL) and K2CO3 (20 mL, 10% aq.). The organic layers were combined, dried over 
MgSO4, and the solvent removed in vacuo. The crude mixture was purified by MPLC on 
NH2 SiO2 with a gradient elution from 30-70% EtOAc/petrol to give a white solid (275 
mg, 49%); Rf 0.5 (50% EtOAc/petrol, NH2 SiO2); m.p. 132-135 C (lit.
378
 134 C); 
max(EtOH)/nm 285; IR  max/cm
-1 
1523, 1316; 

H NMR (500 MHz; CDCl3) H 3.81 (3H, s, 
CH3), 7.41 (1H, s, H-imidazole), 7.74 (1H, s, H-imidazole); 

C NMR (125 MHz; DMSO-
d6) C 34.6 (CH3), 120.1 (C-5-imidazole), 136.6 (C-2-imidazole), 148.2 (C-NO2); MS 
(ES+) m/z 128.1 [M+H]
+
. 
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1-Methyl-1H-imidazol-4-amine (420) 
451-219 
Prepared according to general procedure H using nitroimidazole 418 (250 mg, 1.97 mmol) 
in MeOH (10 mL) and EtOAc (10 mL) to give a brown oil (190 mg, 99%); Rf 0.1 (15% 
MeOH/EtOAc); max(EtOH)/nm 232, 283; IR  max/cm
-1 
3298 br; 

H NMR (500 MHz; 
CDCl3) H 3.56 (3H, CH3), 6.18 (1H, s, H-imidazole), 7.04 (1H, s, H-imidazole); 

C NMR 
not obtained due to chemical instability; MS: no mass ion detected. 
4-(3,6-Dichloro-2-fluorobenzoyl)-N-(1-methyl-1H-imidazol-4-yl)-1H-pyrrole-2-
carboxamide (320) 
451-220 
Prepared according to general procedure F using carboxylic acid 337 (125 mg, 0.33 mmol, 
1 eq.), amine 420 (100 mg, 1.03 mmol, 3 eq.), PCl3 (29 L, 0.33 mmol, 1 eq.) and MeCN 
(1.5 mL). Purification by MPLC on NH2 SiO2 with a gradient elution from 0-4% 
MeOH/EtOAc gave a white solid (30 mg, 24%); Rf 0.7 (5% MeOH/EtOAc); m.p. 258-260 
C; max(EtOH)/nm 227, 250 sh; IR  max/cm
-1 
3262, 3122, 1657, 1637; 

H NMR (500 
MHz; DMSO-d6) H 3.68 (3H, CH3), 7.33 (1H, s, H-imidazole), 7.47 (1H, s, H-imidazole), 
7.52-7.60 (3H, m, H-5’ and 2 × H-pyrrole), 7.81 (1H, app t, J = 8.3 Hz, H-4’), 10.67 (1H, 
s, CO-NH), 12.61 (1H, s, NH-pyrrole); 

F NMR(470 MHz; DMSO-d6) F -116.15; 

C 
NMR (125 MHz; DMSO-d6) C 33.1 (CH3), 108.2 (CH-imidazole), 111.2 (CH-pyrrole), 
119.2 (d, JCF = 18.3 Hz, C-3’), 124.7 (C-pyrrole), 126.8 (d, JCF = 3.6 Hz, C-5’), 128.5 (CH-
pyrrole), 129.2 (d, JCF = 5.4 Hz, C-6’), 129.3 (d, JCF = 22.7 Hz, C-1’), 131.7 (C-4’), 133.9 
(CH-imidazole), 137.6 (C-imidazole), 153.8 (d, JCF = 248.4 Hz, C-2’), 156.6 (CO-NH), 
182.6 (CO); HRMS calcd for C16H12
35
Cl2F1N4O2 [M+H]
+
 381.0316, found 381.0315. 
383 
 
References 
 
1. Stratton, M. R.; Campbell, P. J.; Futreal, P. A., The cancer genome. Nature 2009, 
458, 719-724. 
2. Futreal, P. A.; Coin, L.; Marshall, M.; Down, T.; Hubbard, T.; Wooster, R.; 
Rahman, N.; Stratton, M. R., A census of human cancer genes. Nat. Rev. Cancer 
2004, 4, 177-183. 
3. Haber, D. A.; Settleman, J., Cancer: Drivers and passengers. Nature 2007, 446, 
145-146. 
4. Hanahan, D.; Weinberg, R. A., The Hallmarks of Cancer. Cell 2000, 100, 57-70. 
5. Hanahan, D.; Weinberg, Robert A., Hallmarks of Cancer: The Next Generation. 
Cell 2011, 144, 646-674. 
6. Loeb, L. A., Human cancers express mutator phenotypes: origin, consequences and 
targeting. Nat. Rev. Cancer 2011, 11, 450-457. 
7. Talbot, S. J.; Crawford, D. H., Viruses and tumours – an update. Eur. J. Cancer 
2004, 40, 1998-2005. 
8. De Palma, M.; Hanahan, D., The biology of personalized cancer medicine: Facing 
individual complexities underlying hallmark capabilities. Mol. Oncol. 2012, 6, 111-
127. 
9. Horne, S. D.; Stevens, J. B.; Abdallah, B. Y.; Liu, G.; Bremer, S. W.; Ye, C. J.; 
Heng, H. H. Q., Why imatinib remains an exception of cancer research. J. Cell. 
Physiol. 2013, 228, 665-670. 
10. Visvader, Jane E.; Lindeman, Geoffrey J., Cancer Stem Cells: Current Status and 
Evolving Complexities. Cell Stem Cell 2012, 10, 717-728. 
11. DeVita, V. T.; Chu, E., A History of Cancer Chemotherapy. Cancer Res. 2008, 68, 
8643-8653. 
12. Colvin, O. M., An overview of cyclophosphamide development and clinical 
applications. Curr. Pharm. Des. 1999, 5, 555-560. 
13. Heidelberger, C.; Chaudhuri, N. K.; Danneberg, P.; Mooren, D.; Griesbach, L.; 
Duschinsky, R.; Schnitzer, R. J.; Pleven, E.; Scheiner, J., Fluorinated Pyrimidines, 
A New Class of Tumour-Inhibitory Compounds. Nature 1957, 179, 663-666. 
384 
 
14. Jolivet, J.; Cowan, K. H.; Curt, G. A.; Clendeninn, N. J.; Chabner, B. A., The 
Pharmacology and Clinical Use of Methotrexate. New Engl. J. Med. 1983, 309, 
1094-1104. 
15. Huennekens, F. M., The methotrexate story: A paradigm for development of cancer 
chemotherapeutic agents. Adv. Enzyme Regul. 1994, 34, 397-419. 
16. Wright, D. E. Pyrazole derivatives. US3102890, 1963. 
17. Rosenberg, B.; Van Camp, L.; Krigas, T., Inhibition of Cell Division in Escherichia 
coli by Electrolysis Products from a Platinum Electrode. Nature 1965, 205, 698-
699. 
18. Chabner, B. A.; Roberts, T. G., Chemotherapy and the war on cancer. Nat. Rev. 
Cancer 2005, 5, 65-72. 
19. Himes, R. H.; Kersey, R. N.; Heller-Bettinger, I.; Samson, F. E., Action of the 
Vinca Alkaloids Vincristine, Vinblastine, and Desacetyl Vinblastine Amide on 
Microtubules in Vitro. Cancer Res. 1976, 36, 3798-3802. 
20. Wagstaff, A.; Ward, A.; Benfield, P.; Heel, R., Carboplatin. Drugs 1989, 37, 162-
190. 
21. Chari, R. V. J., Targeted Cancer Therapy: Conferring Specificity to Cytotoxic 
Drugs. Acc. Chem. Res. 2007, 41, 98-107. 
22. Marks, A. M.; Packer, R. J., A Review of Secondary Central Nervous System 
Tumors After Treatment of a Primary Pediatric Malignancy. Seminars in Pediatric 
Neurology 2012, 19, 43-48. 
23. Masui, K.; Gini, B.; Wykosky, J.; Zanca, C.; Mischel, P. S.; Furnari, F.; Cavenee, 
W., A Tale of Two Approaches: Complementary Mechanisms of Cytotoxic and 
Targeted Therapy Resistance May Inform Next Generation Cancer Treatments. 
Carcinogenesis 2013. 
24. Jordan, V. C., Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug 
Discov. 2003, 2, 205-213. 
25. Barrett-Connor, E., Raloxifene: Risks and Benefits. Ann. N. Y. Acad. Sci. 2001, 
949, 295-303. 
26. Cui, Q.; Ma, Y.; Jaramillo, M.; Bari, H.; Awan, A.; Yang, S.; Zhang, S.; Liu, L.; 
Lu, M.; O'Connor-McCourt, M.; Purisima, E. O.; Wang, E., A map of human 
cancer signaling. Mol. Syst. Biol. 2007, 3. 
27. Brognard, J.; Hunter, T., Protein kinase signaling networks in cancer. Curr. Opin. 
Genet. Dev. 2011, 21, 4-11. 
385 
 
28. Guardavaccaro, D.; Clevers, H., Wnt/-Catenin and MAPK Signaling: Allies and 
Enemies in Different Battlefields. Sci. Signal. 2012, 5, pe15-. 
29. Natarajan, M.; Lin, K.-M.; Hsueh, R. C.; Sternweis, P. C.; Ranganathan, R., A 
global analysis of cross-talk in a mammalian cellular signalling network. Nat. Cell. 
Biol. 2006, 8, 571-580. 
30. Moser, C.; Lang, S. A.; Stoeltzing, O., Heat-shock Protein 90 (Hsp90) as a 
Molecular Target for Therapy of Gastrointestinal Cancer. Anticancer Res. 2009, 29, 
2031-2042. 
31. Wakeling, A. E., Epidermal growth factor receptor tyrosine kinase inhibitors. Curr. 
Opin. Pharmacol. 2002, 2, 382-387. 
32. Force, T.; Krause, D. S.; Van Etten, R. A., Molecular mechanisms of cardiotoxicity 
of tyrosine kinase inhibition. Nat. Rev. Cancer 2007, 7, 332-344. 
33. Garber, K., Drugging the Wnt Pathway: Problems And Progress. J. Natl. Cancer 
Inst. 2009, 101, 548-550. 
34. Villanueva, J.; Vultur, A.; Lee, J. T.; Somasundaram, R.; Fukunaga-Kalabis, M.; 
Cipolla, A. K.; Wubbenhorst, B.; Xu, X.; Gimotty, P. A.; Kee, D.; Santiago-
Walker, A. E.; Letrero, R.; D'Andrea, K.; Pushparajan, A.; Hayden, J. E.; Brown, 
K. D.; Laquerre, S.; McArthur, G. A.; Sosman, J. A.; Nathanson, K. L.; Herlyn, M., 
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in 
Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. Cancer Cell 
2010, 18, 683-695. 
35. Kim, E. K.; Choi, E.-J., Pathological roles of MAPK signaling pathways in human 
diseases. Biochim. Biophys. Acta 2010, 1802, 396-405. 
36. Nithianandarajah-Jones, G. N.; Wilm, B.; Goldring, C. E. P.; Müller, J.; Cross, M. 
J., ERK5: Structure, regulation and function. Cell. Signal. 2012, 24, 2187-2196. 
37. Cargnello, M.; Roux, P. P., Activation and Function of the MAPKs and Their 
Substrates, the MAPK-Activated Protein Kinases. Microbiol. Mol. Biol. Rev. 2011, 
75, 50-83. 
38. Aronov, A. M.; Tang, Q.; Martinez-Botella, G.; Bemis, G. W.; Cao, J.; Chen, G.; 
Ewing, N. P.; Ford, P. J.; Germann, U. A.; Green, J.; Hale, M. R.; Jacobs, M.; 
Janetka, J. W.; Maltais, F.; Markland, W.; Namchuk, M. N.; Nanthakumar, S.; 
Poondru, S.; Straub, J.; ter Haar, E.; Xie, X., Structure-Guided Design of Potent 
386 
 
and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase 
(ERK) Using Conformational Control. J. Med. Chem. 2009, 52, 6362-6368. 
39. Pratilas, C. A.; Solit, D. B., Targeting the Mitogen-Activated Protein Kinase 
Pathway: Physiological Feedback and Drug Response. Clin. Cancer. Res. 2010, 16, 
3329-3334. 
40. Huang, P.; Han, J.; Hui, L., MAPK signaling in inflammation-associated cancer 
development. Protein Cell 2010, 1, 218-226. 
41. De Luca, A.; Maiello, M. R.; D'Alessio, A.; Pergameno, M.; Normanno, N., The 
RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer 
pathogenesis and implications for therapeutic approaches. Expert Opin. Ther. 
Targets 2012, 16, S17-S27. 
42. Wan, P. T. C.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. 
M.; Project, C. G.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; 
Marais, R., Mechanism of Activation of the RAF-ERK Signaling Pathway by 
Oncogenic Mutations of B-RAF. Cell 2004, 116, 855-867. 
43. Kudchadkar, R. R.; Smalley, K. S. M.; Glass, L. F.; Trimble, J. S.; Sondak, V. K., 
Targeted therapy in melanoma. Clinics in Dermatology 2013, 31, 200-208. 
44. Wilhelm, S. M.; Adnane, L.; Newell, P.; Villanueva, A.; Llovet, J. M.; Lynch, M., 
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and 
VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008, 7, 
3129-3140. 
45. Brown, A.; Carlson, T. G.; Loi, C.-M.; Graziano, M., Pharmacodynamic and 
toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat 
following oral and intravenous administration. Cancer Chemother. Pharmacol. 
2007, 59, 671-679. 
46. Boasberg, P.; Redfern, C.; Daniels, G.; Bodkin, D.; Garrett, C.; Ricart, A., Pilot 
study of PD-0325901 in previously treated patients with advanced melanoma, 
breast cancer, and colon cancer. Cancer Chemother. Pharmacol. 2011, 68, 547-
552. 
47. Patel, S. P.; Kim, K. B., Selumetinib (AZD6244; ARRY-142886) in the treatment 
of metastatic melanoma. Expert Opin. Invest. Drugs 2012, 21, 531-539. 
48. Roskoski Jr, R., ERK1/2 MAP kinases: Structure, function, and regulation. Pharm. 
Res. 2012, 66, 105-143. 
387 
 
49. Ohori, M.; Kinoshita, T.; Yoshimura, S.; Warizaya, M.; Nakajima, H.; Miyake, H., 
Role of a cysteine residue in the active site of ERK and the MAPKK family. 
Biochem. Biophys. Res. Commun. 2007, 353, 633-637. 
50. Sawyers, C., Targeted cancer therapy. Nature 2004, 432, 294-297. 
51. Galmarini, D.; Galmarini, C. M.; Galmarini, F. C., Cancer chemotherapy: A critical 
analysis of its 60 years of history. Crit. Rev. Oncol./Hematol. 2012, 84, 181-199. 
52. O'Hare, T.; Deininger, M. W. N.; Eide, C. A.; Clackson, T.; Druker, B. J., 
Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia 
Chromosome-Positive Leukemia. Clin. Cancer. Res. 2011, 17, 212-221. 
53. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A., Glivec (STI571, 
imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 
2002, 1, 493-502. 
54. Dagher, R.; Cohen, M.; Williams, G.; Rothmann, M.; Gobburu, J.; Robbie, G.; 
Rahman, A.; Chen, G.; Staten, A.; Griebel, D.; Pazdur, R., Approval Summary: 
Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant 
Gastrointestinal Stromal Tumors. Clin. Cancer. Res. 2002, 8, 3034-3038. 
55. Price, K. E.; Saleem, N.; Lee, G.; Steinberg, M., Potential of ponatinib to treat 
chronic myeloid leukemia and acute lymphoblastic leukemia. OncoTargets and 
Therapy 2013, 6, 1111-1118. 
56. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; 
Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I.; Fujita, Y.; Okinaga, S.; 
Hirano, H.; Yoshimori, K.; Harada, T.; Ogura, T.; Ando, M.; Miyazawa, H.; 
Tanaka, T.; Saijo, Y.; Hagiwara, K.; Morita, S.; Nukiwa, T., Gefitinib or 
Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. New Engl. J. 
Med. 2010, 362, 2380-2388. 
57. Shepard, H. M.; Jin, P.; Slamon, D. J.; Pirot, Z.; Maneval, D. C., Herceptin. In 
Therapeutic Antibodies, Chernajovsky, Y.; Nissim, A., Eds. Springer Berlin 
Heidelberg2008; Vol. 181, pp 183-219. 
58. Adams, J.; Kauffman, M., Development of the Proteasome Inhibitor Velcade™ 
(Bortezomib). Cancer Invest. 2004, 22, 304-311. 
59. Tsukamoto, S.; Yokosawa, H., Targeting the proteasome pathway. Expert Opin. 
Ther. Targets 2009, 13, 605-621. 
60. Jung, F. H.; Ple, P. Quinoline Derivatives. WO2007099326, 2007. 
388 
 
61. Federico, M.; Bagella, L., Histone Deacetylase Inhibitors in the Treatment of 
Hematological Malignancies and Solid Tumors. J. Biomed. Biotechnol. 2011, 2011. 
62. Ho, C., New Drugs Approved by US FDA in 2006. Trends In Bio/Pharmaceutical 
Industry 2007, 13. 
63. Kaminskas, E.; Farrell, A. T.; Wang, Y.-C.; Sridhara, R.; Pazdur, R., FDA Drug 
Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable 
Suspension. The Oncologist 2005, 10, 176-182. 
64. Blum, W.; Klisovic, R. B.; Hackanson, B.; Liu, Z.; Liu, S.; Devine, H.; 
Vukosavljevic, T.; Huynh, L.; Lozanski, G.; Kefauver, C.; Plass, C.; Devine, S. M.; 
Heerema, N. A.; Murgo, A.; Chan, K. K.; Grever, M. R.; Byrd, J. C.; Marcucci, G., 
Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute 
Myeloid Leukemia. J. Clin. Oncology 2007, 25, 3884-3891. 
65. Fenaux, P.; Mufti, G. J.; Hellstrom-Lindberg, E.; Santini, V.; Finelli, C.; 
Giagounidis, A.; Schoch, R.; Gattermann, N.; Sanz, G.; List, A.; Gore, S. D.; 
Seymour, J. F.; Bennett, J. M.; Byrd, J.; Backstrom, J.; Zimmerman, L.; McKenzie, 
D.; Beach, C. L.; Silverman, L. R., Efficacy of azacitidine compared with that of 
conventional care regimens in the treatment of higher-risk myelodysplastic 
syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009, 10, 
223-232. 
66. Poulikakos, P. I.; Persaud, Y.; Janakiraman, M.; Kong, X.; Ng, C.; Moriceau, G.; 
Shi, H.; Atefi, M.; Titz, B.; Gabay, M. T.; Salton, M.; Dahlman, K. B.; Tadi, M.; 
Wargo, J. A.; Flaherty, K. T.; Kelley, M. C.; Misteli, T.; Chapman, P. B.; Sosman, 
J. A.; Graeber, T. G.; Ribas, A.; Lo, R. S.; Rosen, N.; Solit, D. B., RAF inhibitor 
resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 
2011, 480, 387-390. 
67. Basanta, D.; Gatenby, R.; Anderson, A., Exploiting evolution to treat drug 
resistance: Combination therapy and the double bind. In Nature precedings2011. 
68. Hamburg, M. A.; Collins, F. S., The Path to Personalized Medicine. New Engl. J. 
Med. 2010, 363, 301-304. 
69. Marsh, S.; McLeod, H. L., Pharmacogenomics: from bedside to clinical practice. 
Hum. Mol. Genet. 2006, 15, R89-R93. 
70. Ong, F. S.; Das, K.; Wang, J.; Vakil, H.; Kuo, J. Z.; Blackwell, W.-L. B.; Lim, S. 
W.; Goodarzi, M. O.; Bernstein, K. E.; Rotter, J. I.; Grody, W. W., Personalized 
389 
 
medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. 
Expert Rev. Mol. Diagn. 2012, 12, 593-602. 
71. Manallack, D. T.; Prankerd, R. J.; Yuriev, E.; Oprea, T. I.; Chalmers, D. K., The 
significance of acid/base properties in drug discovery. Chem. Soc. Rev. 2013, 42, 
485-496. 
72. Whittaker, P. A., The role of bioinformatics in target validation. Drug Discov. 
Today: Technologies 2004, 1, 125-133. 
73. Hann, M. M., Molecular obesity, potency and other addictions in drug discovery. 
MedChemComm 2011, 2, 349-355. 
74. Fotouhi, N.; Gillespie, P.; Goodnow, J. R., Lead generation: reality check on 
commonly held views. Expert Opin. Drug Discovery 2008, 3, 733-744. 
75. Orita, M.; Ohno, K.; Warizaya, M.; Amano, Y.; Niimi, T., Chapter fifteen - Lead 
Generation and Examples: Opinion Regarding How to Follow Up Hits. In Methods 
Enzymol., Lawrence, C. K., Ed. Academic Press2011; Vol. Volume 493, pp 383-
419. 
76. Frye, S. V., The art of the chemical probe. Nat. Chem. Biol. 2010, 6, 159-161. 
77. Bleicher, K. H.; Bohm, H.-J.; Muller, K.; Alanine, A. I., Hit and lead generation: 
beyond high-throughput screening. Nat. Rev. Drug Discov. 2003, 2, 369-378. 
78. Blagg, J.; Abraham, D. J., Structural Alerts for Toxicity. In Burger's Medicinal 
Chemistry and Drug Discovery, John Wiley & Sons, Inc.2003. 
79. Korfmacher, W. A., Advances in the integration of drug metabolism into the lead 
optimization paradigm. Mini-Rev. Med. Chem. 2009, 9, 703-716. 
80. Bray, F.; Jemal, A.; Grey, N.; Ferlay, J.; Forman, D., Global cancer transitions 
according to the Human Development Index (2008–2030): a population-based 
study. Lancet Oncol. 2012, 13, 790-801. 
81. Lai, J.-P.; Thompson, J. R.; Sandhu, D. S.; Roberts, L. R., Heparin Degrading 
Sulfatases in Hepatocellular Cancer: roles in pathogenesis and therapy targets. 
Future Oncol. 2008, 4, 803-814. 
82. Hanson, S. R.; Best, M. D.; Wong, C.-H., Sulfatases: Structure, Mechanism, 
Biological Activity, Inhibition, and Synthetic Utility. Angew. Chem., Int. Ed. 2004, 
43, 5736-5763. 
83. Diez-Roux, G.; Ballabio, A., Sulfatases and human disease. Ann. Rev. Genomics 
Hum. Genet. 2005, 6, 355-379. 
390 
 
84. Morimoto-Tomita, M.; Uchimura, K.; Werb, Z.; Hemmerich, S.; Rosen, S. D., 
Cloning and Characterization of Two Extracellular Heparin-degrading 
Endosulfatases in Mice and Humans. J. Biol. Chem. 2002, 277, 49175-49185. 
85. Hur, K.; Han, T.-S.; Jung, E.-J.; Yu, J.; Lee, H.-J.; Kim, W. H.; Goel, A.; Yang, H.-
K., Up-regulated expression of sulfatases (SULF1 and SULF2) as prognostic and 
metastasis predictive markers in human gastric cancer. J. Pathol. 2012, 228, 88-98. 
86. Iozzo, R. V., Heparan sulfate proteoglycans: intricate molecules with intriguing 
functions. J. Clin. Invest. 2001, 108, 165-167. 
87. Varki, A.; Cummings, R.; Esko, J.; Freeze, H.; Hart, G.; Marth, J., Essentials of 
Glycobiology. Cold Spring Harbor Laboratory Press 1999. 
88. Saad, O. M.; Ebel, H.; Uchimura, K.; Rosen, S. D.; Bertozzi, C. R.; Leary, J. A., 
Compositional profiling of heparin/heparan sulfate using mass spectrometry: assay 
for specificity of a novel extracellular human endosulfatase. Glycobiology 2005, 
15, 818-826. 
89. Lindahl, U.; Kusche-Gullberg, M.; Kjellén, L., Regulated Diversity of Heparan 
Sulfate. J. Biol. Chem. 1998, 273, 24979-24982. 
90. Rosen, S. D.; Lemjabbar-Alaoui, H., Sulf-2: an extracellular modulator of cell 
signaling and a cancer target candidate. Expert Opin. Ther. Targets 2010, 14, 935-
949. 
91. Lamanna, W. C.; Frese, M.-A.; Balleininger, M.; Dierks, T., Sulf Loss Influences 
N-, 2-O-, and 6-O-Sulfation of Multiple Heparan Sulfate Proteoglycans and 
Modulates Fibroblast Growth Factor Signaling. J. Biol. Chem. 2008, 283, 27724-
27735. 
92. Grigoriadis, A.; Mackay, A.; Reis-Filho, J.; Steele, D.; Iseli, C.; Stevenson, B.; 
Jongeneel, C. V.; Valgeirsson, H.; Fenwick, K.; Iravani, M.; Leao, M.; Simpson, 
A.; Strausberg, R.; Jat, P.; Ashworth, A.; Neville, A. M.; O'Hare, M., Establishment 
of the epithelial-specific transcriptome of normal and malignant human breast cells 
based on MPSS and array expression data. Breast Cancer Res. 2006, 8, R56. 
93. Morimoto-Tomita, M.; Uchimura, K.; Bistrup, A.; Lum, D. H.; Egeblad, M.; 
Boudreau, N.; Werb, Z.; Rosen, S. D., Sulf-2, a Proangiogenic Heparan Sulfate 
Endosulfatase, Is Upregulated in Breast Cancer. Neoplasia 2005, 7, 1001-1010. 
94. Lee, J.; Chu, I. S.; Heo, J.; Calvisi, D. F.; Sun, Z.; Roskams, T.; Durnez, A.; 
Demetris, A. J.; Thorgeirsson, S. S., Classification and prediction of survival in 
391 
 
hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40, 667-
676. 
95. Lemjabbar-Alaoui, H.; van Zante, A.; Singer, M. S.; Xue, Q.; Wang, Y.-Q.; Tsay, 
D.; He, B.; Jablons, D. M.; Rosen, S. D., Sulf-2, a heparan sulfate endosulfatase, 
promotes human lung carcinogenesis. Oncogene 2010, 29, 635-646. 
96. Phillips, J. J.; Huillard, E.; Robinson, A. E.; Ward, A.; Lum, D. H.; Polley, M.-Y.; 
Rosen, S. D.; Rowitch, D. H.; Werb, Z., Heparan sulfate sulfatase SULF2 regulates 
PDGFRα signaling and growth in human and mouse malignant glioma. J. Clin. 
Invest. 2012, 122, 911-922. 
97. Lui, N. S.; van Zante, A.; Rosen, S. D.; Jablons, D. M.; Lemjabbar-Alaoui, H., 
SULF2 expression by immunohistochemistry and overall survival in oesophageal 
cancer: a cohort study. BMJ Open 2012, 2. 
98. Nawroth, R.; van Zante, A.; Cervantes, S.; McManus, M.; Hebrok, M.; Rosen, S. 
D., Extracellular sulfatases, elements of the Wnt signaling pathway, positively 
regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One 
2007, 2, e392. 
99. Dai, Y.; Yang, Y.; MacLeod, V.; Yue, X.; Rapraeger, A. C.; Shriver, Z.; 
Venkataraman, G.; Sasisekharan, R.; Sanderson, R. D., HSulf-1 and HSulf-2 are 
potent inhibitors of myeloma tumor growth in vivo. J. Biol. Chem. 2005, 280, 
40066-40073. 
100. Lai, J.; Chien, J.; Staub, J.; Avula, R.; Greene, E. L.; Matthews, T. A.; Smith, D. I.; 
Kaufmann, S. H.; Roberts, L. R.; Shridhar, V., Loss of HSulf-1 Up-regulates 
Heparin-binding Growth Factor Signaling in Cancer. J. Biol. Chem. 2003, 278, 
23107-23117. 
101. Gill, R. B. S.; Day, A.; Barstow, A.; Liu, H.; Zaman, G.; Dhoot, G. K., Sulf2 gene 
is alternatively spliced in mammalian developing and tumour tissues with 
functional implications. Biochem. Biophys. Res. Commun. 2011, 414, 468-473. 
102. Mohammadi, M.; Olsen, S. K.; Ibrahimi, O. A., Structural basis for fibroblast 
growth factor receptor activation. Cytokine Growth Factor Rev. 2005, 16, 107-137. 
103. Turner, N.; Grose, R., Fibroblast growth factor signalling: from development to 
cancer. Nat. Rev. Cancer 2010, 10, 116-129. 
104. Nu Nguyen, T. K.; Raman, K.; Tran, V. M.; Kuberan, B., Investigating the 
mechanism of the assembly of FGF1-binding heparan sulfate motifs. FEBS Lett. 
2011, 585, 2698-2702. 
392 
 
105. Staples, G. O.; Shi, X.; Zaia, J., Glycomics Analysis of Mammalian Heparan 
Sulfates Modified by the Human Extracellular Sulfatase HSulf2. PLoS One 2011, 
6, e16689. 
106. Eisenmann, D. M., Wnt signaling: The C. elegans Research Community, 
WormBook, doi/10.1895/wormbook.1.7.1, http://www.wormbook.org.; Greenwald, 
I., Ed.2005. 
107. Moon, R. T.; Kohn, A. D.; Ferrari, G. V. D.; Kaykas, A., WNT and -catenin 
signalling: diseases and therapies. Nat. Rev. Genet. 2004, 5, 691-701. 
108. Klaus, A.; Birchmeier, W., Wnt signalling and its impact on development and 
cancer. Nat. Rev. Cancer 2008, 8, 387-398. 
109. Yao, H.; Ashihara, E.; Maekawa, T., Targeting the Wnt/β-catenin signaling 
pathway in human cancers. Expert Opin. Ther. Targets 2011, 15, 873-887. 
110. Nishisho, I.; Nakamura, Y.; Miyoshi, Y.; Miki, Y.; Ando, H.; Horii, A.; Koyama, 
K.; Utsunomiya, J.; Baba, S.; Hedge, P., Mutations of chromosome 5q21 genes in 
FAP and colorectal cancer patients. Science 1991, 253, 665-669. 
111. Wei, W.; Chua, M.-S.; Grepper, S.; So, S., Blockade of Wnt-1 signaling leads to 
anti-tumor effects in hepatocellular carcinoma cells. Mol. Cancer 2009, 8, 76. 
112. Mikami, I.; You, L.; He, B.; Xu, Z.; Batra, S.; Lee, A.; Mazieres, J.; Reguart, N.; 
Uematsu, K.; Koizumi, K.; Jablons, D., Efficacy of Wnt-1 monoclonal antibody in 
sarcoma cells. BMC Cancer 2005, 5, 53. 
113. Kar, S.; Deb, M.; Sengupta, D.; Shilpi, A.; Bhutia, S. K.; Patra, S. K., Intricacies of 
hedgehog signaling pathways: A perspective in tumorigenesis. Exp. Cell Res. 2012, 
318, 1959-1972. 
114. Zhang, F.; McLellan, J. S.; Ayala, A. M.; Leahy, D. J.; Linhardt, R. J., Kinetic and 
Structural Studies on Interactions between Heparin or Heparan Sulfate and Proteins 
of the Hedgehog Signaling Pathway. Biochemistry 2007, 46, 3933-3941. 
115. Cirrone, F.; Harris, C. S., Vismodegib and the Hedgehog Pathway: A New 
Treatment for Basal Cell Carcinoma. Clin. Ther. 2012, 34, 2039-2050. 
116. Ji, W.; Yang, J.; Wang, D.; Cao, L.; Tan, W.; Qian, H.; Sun, B.; Qian, Q.; Yin, Z.; 
Wu, M.; Su, C., hSulf-1 Gene Exhibits Anticancer Efficacy through Negatively 
Regulating VEGFR-2 Signaling in Human Cancers. PLoS One. 2011, 6, e23274. 
117. Yang, J. D.; Sun, Z.; Hu, C.; Lai, J.; Dove, R.; Nakamura, I.; Lee, J.-S.; 
Thorgeirsson, S. S.; Kang, K. J.; Chu, I.-S.; Roberts, L. R., Sulfatase 1 and 
393 
 
sulfatase 2 in hepatocellular carcinoma: Associated signaling pathways, tumor 
phenotypes, and survival. Genes, Chromosomes Cancer 2011, 50, 122-135. 
118. Forner, A.; Llovet, J. M.; Bruix, J., Hepatocellular carcinoma. Lancet. 
119. Taura, K.; Ikai, I.; Hatano, E.; Yasuchika, K.; Nakajima, A.; Tada, M.; Seo, S.; 
Machimoto, T.; Uemoto, S., Influence of coexisting cirrhosis on outcomes after 
partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: 
an analysis of 293 patients. Surgery 2007, 142, 685-694. 
120. Avila, M. A.; Berasain, C.; Sangro, B.; Prieto, J., New Therapies for Hepatocellular 
Carcinoma. Oncogene 2006, 25, 3866-3884. 
121. Lang, L., FDA approves sorafenib for patients with inoperable liver cancer. 
Gastroenterology 2008, 134, 379. 
122. Llovet, J.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, 
A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; 
Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Häussinger, D.; 
Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J., Sorafenib in 
advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378-390. 
123. Frese, M.-A.; Milz, F.; Dick, M.; Lamanna, W. C.; Dierks, T., Characterization of 
the Human Sulfatase Sulf1 and Its High Affinity Heparin/Heparan Sulfate 
Interaction Domain. J. Biol. Chem. 2009, 284, 28033-28044. 
124. Ghosh, D., Human sulfatases: A structural perspective to catalysis. Cell. Mol. Life 
Sci 2007, 64, 2013-2022. 
125. Uhlhorn-Dierks, G.; Kolter, T.; Sandhoff, K., How Does Nature Cleave Sulfuric 
Acid Esters? A Novel Posttranslational Modification of Sulfatases. Angew. Chem., 
Int. Ed. 1998, 37, 2453-2455. 
126. Boltes, I.; Czapinska, H.; Kahnert, A.; von Bülow, R.; Dierks, T.; Schmidt, B.; von 
Figura, K.; Kertesz, M. A.; Usón, I., 1.3 Å Structure of Arylsulfatase from 
Pseudomonas aeruginosa Establishes the Catalytic Mechanism of Sulfate Ester 
Cleavage in the Sulfatase Family. Structure 2001, 9, 483-491. 
127. Buono, M.; P, C. M., Sulfatase activities towards the regulation of cell metabolism 
and signaling in mammals. Cell. Mol. Life Sci. 2010, 67, 769-780. 
128. Sardiello, M.; Annunziata, I.; Roma, G.; Ballabio, A., Sulfatases and sulfatase 
modifying factors: an exclusive and promiscuous relationship. Hum. Mol. Genet. 
2005, 14, 3203-3217. 
394 
 
129. Ghosh, D., Three-dimensional structures of sulfatases. Methods Enzymol. 2005, 
400, 273-293. 
130. Ai, X.; Do, A.-T.; Kusche-Gullberg, M.; Lindahl, U.; Lu, K.; Emerson, C. P., 
Substrate Specificity and Domain Functions of Extracellular Heparan Sulfate 6-O-
Endosulfatases, QSulf1 and QSulf2. J. Biol. Chem. 2006, 281, 4969-4976. 
131. Myette, J. R.; Soundararajan, V.; Shriver, Z.; Raman, R.; Sasisekharan, R., 
Heparin/Heparan Sulfate 6-O-Sulfatase from Flavobacterium heparinum. J. Biol. 
Chem. 2009, 284, 35177-35188. 
132. Schelwies, M.; Brinson, D.; Otsuki, S.; Hong, Y.-H.; Lotz, M. K.; Wong, C.-H.; 
Hanson, S. R., Glucosamine-6-sulfamate Analogues of Heparan Sulfate as 
Inhibitors of Endosulfatases. ChemBioChem 2010, 11, 2393-2397. 
133. Zheng, X.; Gai, X.; Han, S.; Moser, C. D.; Hu, C.; Shire, A. M.; Floyd, R. A.; 
Roberts, L. R., The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-
butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma 
mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes 
Chromosomes Cancer 2012, 225-236. 
134. Floyd, R. A.; Kopke, R. D.; Choi, C.-H.; Foster, S. B.; Doblas, S.; Towner, R. A., 
Nitrones as therapeutics. Free Radical Biol. Med. 2008, 45, 1361-1374. 
135. Howarth, N. M.; Purohit, A.; Reed, M. J.; Potter, B. V. L., Estrone sulfamates: 
potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 
1994, 37, 219-221. 
136. Woo, L. W. L.; Purohit, A.; Reed, M. J.; Potter, B. V. L., Oestrone 3-O-(N-
acetyl)sulphamate, a potential molecular probe of the active site of oestrone 
sulphatase. Bioorg. Med. Chem. Lett. 1997, 7, 3075-3080. 
137. Howarth, N. M.; Purohit, A.; Reed, M. J.; Potter, B. V. L., Estrone sulfonates as 
inhibitors of estrone sulfatase. Steroids 1997, 62, 346-350. 
138. Poirier, D.; Ciobanu, L. C.; Maltais, R., Steroid sulfatase inhibitors. Expert Opin. 
Ther. Pat. 1999, 9, 1083-1099. 
139. Woo, L. W. L.; Lightowler, M.; Purohit, A.; Reed, M. J.; Potter, B. V. L., 
Heteroatom-substituted analogues of the active-site directed inhibitor estra-
1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different 
mechanism. J. Steroid Biochem. Mol. Biol. 1996, 57, 79-88. 
140. Schreiner, E. P.; Billich, A., Estrone formate: a novel type of irreversible inhibitor 
of human steroid sulfatase. Bioorg. Med. Chem. Lett. 2004, 14, 4999-5002. 
395 
 
141. Reed, J. E.; Lawrence Woo, L. W.; Robinson, J. J.; Leblond, B.; Leese, M. P.; 
Purohit, A.; Reed, M. J.; Potter, B. V. L., 2-Difluoromethyloestrone 3-O-
sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. 
Comm. 2004, 317, 169-175. 
142. Woo, L. W. L.; Purohit, A.; Malini, B.; Reed, M. J.; Potter, B. V. L., Potent active 
site-directed inhibition of steroid sulphatase by tricyclic coumarin-based 
sulphamates. Chem. Biol. 2000, 7, 773-791. 
143. Stanway, S. J.; Purohit, A.; Woo, L. W. L.; Sufi, S.; Vigushin, D.; Ward, R.; 
Wilson, R. H.; Stanczyk, F. Z.; Dobbs, N.; Kulinskaya, E.; Elliott, M.; Potter, B. V. 
L.; Reed, M. J.; Coombes, R. C., Phase I Study of STX 64 (667 Coumate) in Breast 
Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor. Clin. Cancer Res. 
2006, 12, 1585-1592. 
144. Huang, Z.; Fasco, M. J.; Kaminsky, L. S., Inhibition of estrone sulfatase in human 
liver microsomes by quercetin and other flavonoids. J. Steroid Biochem. Mol. Biol. 
1997, 63, 9-15. 
145. Nussbaumer, P.; Geyl, D.; Horvath, A.; Lehr, P.; Wolff, B.; Billich, A., 
Nortropinyl-Arylsulfonylureas as novel, reversible inhibitors of human steroid 
sulfatase. Bioorg. Med. Chem. Lett. 2003, 13, 3673-3677. 
146. Lopez, M.; Trajkovic, J.; Bornaghi, L. F.; Innocenti, A.; Vullo, D.; Supuran, C. T.; 
Poulsen, S.-A., Design, Synthesis, and Biological Evaluation of Novel 
Carbohydrate-Based Sulfamates as Carbonic Anhydrase Inhibitors. J. Med. Chem. 
2011, 54, 1481-1489. 
147. Maryanoff, B. E.; Nortey, S. O.; Gardocki, J. F.; Shank, R. P.; Dodgson, S. P., 
Anticonvulsant O-Alkyl Sulfamates J. Med. Chem. 1987, 30, 880-887. 
148. Maryanoff, B. E.; Costanzo, M. J.; Nortey, S. O.; Greco, M. N.; Shank, R. P.; 
Schupsky, J. J.; Ortegon, M. P.; Vaught, J. L., Structure−Activity Studies on 
Anticonvulsant Sugar Sulfamates Related to Topiramate. Enhanced Potency with 
Cyclic Sulfate Derivatives. J. Med. Chem. 1998, 41, 1315-1343. 
149. Hossain, M. M.; Hosono-Fukao, T.; Tang, R.; Sugaya, N.; van Kuppevelt, T. H.; 
Jenniskens, G. J.; Kimata, K.; Rosen, S. D.; Uchimura, K., Direct detection of 
HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition 
by PI-88. Glycobiology 2010, 20, 175-186. 
150. Kaur, I. P.; Smitha, R.; Aggarwal, D.; Kapil, M., Acetazolamide: future perspective 
in topical glaucoma therapeutics. Int. J. Pharm. 2002, 248, 1-14. 
396 
 
151. Kossoff, Eric H.; Pyzik, Paula L.; Furth, Susan L.; Hladky, Heather D.; Freeman, 
John M.; Vining, Eileen P. G., Kidney Stones, Carbonic Anhydrase Inhibitors, and 
the Ketogenic Diet. Epilepsia 2002, 43, 1168-1171. 
152. Hinderling, P. H., Red Blood Cells: A Neglected Compartment in 
Pharmacokinetics and Pharmacodynamics. Pharmacol. Rev. 1997, 49, 279-295. 
153. Kodadek, T., Rethinking screening. Nat. Chem. Biol. 2010, 6, 162-165. 
154. Lindsay, M. A., Target discovery. Nat. Rev. Drug Discov. 2003, 2, 831-838. 
155. Prinz, F.; Schlange, T.; Asadullah, K., Believe it or not: how much can we rely on 
published data on potential drug targets? Nat. Rev. Drug Discov. 2011, 10, 712-
712. 
156. Hopkins, A. L.; Groom, C. R., The druggable genome. Nat. Rev. Drug Discov. 
2002, 1, 727-730. 
157. Bunnage, M. E.; Chekler, E. L. P.; Jones, L. H., Target validation using chemical 
probes. Nat. Chem. Biol. 2013, 9, 195-199. 
158. Workman, P.; Collins, I., Probing the Probes: Fitness Factors For Small Molecule 
Tools. Chem. Biol. 2010, 17, 561-577. 
159. Hanson, S. R.; Whalen, L. J.; Wong, C.-H., Synthesis and evaluation of general 
mechanism-based inhibitors of sulfatases based on (difluoro)methyl phenyl sulfate 
and cyclic phenyl sulfamate motifs. Bioorg. Med. Chem. 2006, 14, 8386-8395. 
160. Rudd, T. R.; Yates, E. A.; Hricovini, M., Spectroscopic and Theoretical 
Approaches for the Determination of Heparin Saccharide Structure and the Study 
of Protein-Glycosaminoglycan Complexes in Solution. Curr. Med. Chem. 2009, 16, 
4750-4766. 
161. Mulloy, B.; Forster, M. J., Conformation and dynamics of heparin and heparan 
sulfate. Glycobiology 2000, 10, 1147-1156. 
162. Mulloy, B.; Forster, M. J.; Jones, C.; Davies, D. B., N.m.r. and molecular-
modelling studies of the solution conformation of heparin. Biochem. J. 1993, 293, 
849-858. 
163. Sears, P.; Wong, C.-H., Carbohydrate Mimetics: A New Strategy for Tackling the 
Problem of Carbohydrate-Mediated Biological Recognition. Angew. Chem., Int. Ed. 
1999, 38, 2300-2324. 
164. Quiocho, F. A.; Spurlino, J. C.; Rodseth, L. E., Extensive features of tight 
oligosaccharide binding revealed in high-resolution structures of the maltodextrin 
397 
 
transport/chemosensory receptor. Structure (London, England : 1993) 1997, 5, 997-
1015. 
165. Cardin, A.; Weintraub, H., Molecular modeling of protein-glycosaminoglycan 
interactions. Arterioscler. Thromb. Vasc. Biol. 1989, 9, 21-32. 
166. Capila, I.; Linhardt, R. J., Heparin–Protein Interactions. Angew. Chem., Int. Ed. 
2002, 41, 390-412. 
167. Mulloy, B.; Linhardt, R. J., Order out of complexity - protein structures that 
interact with heparin. Curr. Opin. Struct. Biol. 2001, 11, 623-628. 
168. Moon, A. F.; Edavettal, S. C.; Krahn, J. M.; Munoz, E. M.; Negishi, M.; Linhardt, 
R. J.; Liu, J.; Pedersen, L. C., Structural Analysis of the Sulfotransferase (3-O-
Sulfotransferase Isoform 3) Involved in the Biosynthesis of an Entry Receptor for 
Herpes Simplex Virus 1. J. Biol. Chem. 2004, 279, 45185-45193. 
169. pKa values were calculated using ACD labs pKa prediction software. 
170. Patel, C. K.; Galisson, K. J.; James, K.; Owen, C. P.; Ahmed, S., Structure-activity 
relationship determination within a group of substituted phenyl sulfamate based 
compounds against the enzyme oestrone sulfatase. J. Pharm. Pharm. 2003, 55, 
211-218. 
171. Manetti, F.; Cappello, V.; Botta, M.; Corelli, F.; Mongelli, N.; Biasoli, G.; 
Lombardi Borgia, A.; Ciomei, M., Synthesis and binding mode of heterocyclic 
analogues of suramin inhibiting the human basic fibroblast growth factor. Bioorg. 
Med. Chem. 1998, 6, 947-958. 
172. Raiber, E.-A.; Wilkinson, J. A.; Manetti, F.; Botta, M.; Deakin, J.; Gallagher, J.; 
Lyon, M.; Ducki, S. W., Novel heparin/heparan sulfate mimics as inhibitors of 
HGF/SF-induced MET activation. Bioorg. Med. Chem. Lett. 2007, 17, 6321-6325. 
173. Yoffe, A. D., Thermal Decomposition and Explosion of Azides. Proc. Royal Soc. 
London. Ser. A, Math. Phys. Sci. 1951, 208, 188-199. 
174. Hassner, A.; Stern, M.; Gottlieb, H. E.; Frolow, F., Synthetic methods. 33. Utility 
of a polymeric azide reagent in the formation of di- and triazidomethane. Their 
NMR spectra and the x-ray structure of derived triazoles. J. Org. Chem. 1990, 55, 
2304-2306. 
175. Lukkarila, J. L.; da Silva, S. R.; Ali, M.; Shahani, V. M.; Xu, G. W.; Berman, J.; 
Roughton, A.; Dhe-Paganon, S.; Schimmer, A. D.; Gunning, P. T., Identification of 
NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the 
398 
 
Structural Determinants of NAE Specificity. ACS Med. Chem. Lett. 2011, 2, 577-
582. 
176. Gao, F.; Yan, X.; Shakya, T.; Baettig, O. M.; Ait-Mohand-Brunet, S.; Berghuis, A. 
M.; Wright, G. D.; Auclair, K., Synthesis and Structure−Activity Relationships of 
Truncated Bisubstrate Inhibitors of Aminoglycoside 6‘-N-Acetyltransferases. J. 
Med. Chem. 2006, 49, 5273-5281. 
177. Karplus, M., Vicinal Proton Coupling in Nuclear Magnetic Resonance. J. Am. 
Chem. Soc. 1963, 85, 2870-2871. 
178. Neuberger, A.; Wilson, B. M., The separation of glycosides on a strongly basic ion-
exchange resin: An interpretation in terms of acidity. Carbohydr. Res. 1971, 17, 89-
95. 
179. Appel, R.; Berger, G., Hydrazinsulfonsäure-amide, I. Über das Hydrazodisulfamid. 
Chem. Ber. 1958, 91, 1339-1341. 
180. Fry, A., A Tracer Study of the Reaction of Isocyanates with Carboxylic Acids1,2. 
J. Am. Chem. Soc. 1953, 75, 2686-2688. 
181. Modesti, M.; Baldoin, N.; Simioni, F., Formic acid as a co-blowing agent in rigid 
polyurethane foams. European Polym. J. 1998, 34, 1233-1241. 
182. Schuemacher, A. C.; Hoffmann, R. W., Condensation between isocyanates and 
carobxylic acids in the presence of DMAP, a mild and efficient synthesis of 
amides. Synthesis 2001, 243-246. 
183. Okada, M.; Iwashita, S.; Koizumi, N., Efficient general method for sulfamoylation 
of a hydroxyl group. Tetrahedron Lett. 2000, 41, 7047-7051. 
184. Schwarz, S.; Thieme, I.; Richter, M.; Undeutsch, B.; Henkel, H.; Elger, W., 
Synthesis of estrogen sulfamates: Compounds with a novel endocrinological 
profile. Steroids 1996, 61, 710-717. 
185. Hasuoka, A.; Nishikimi, Y.; Nakayama, Y.; Kamiyama, K.; Nakao, M.; Miyagawa, 
K. I.; Nishimura, O.; Fujino, M., Total synthesis of novel antibiotics pyloricidin A, 
B and C and their application in the study of pyloricidin derivatives. J. Antibiot. 
2002, 55, 191-203. 
186. Warner, D. T.; Coleman, L. L., Selective Sulfonation of Amino Groups in Amino 
Alcohols. J. Org. Chem. 1958, 23, 1133-1135. 
187. Pearson, A. G.; Kiefel, M. J.; Ferro, V.; von Itzstein, M., Synthesis of simple 
heparanase substrates. Org. Biomol. Chem. 2011, 9, 4614-4625. 
399 
 
188. Baumgarten, P., Über N-Pyridinium-sulfonsäure. (II. Mitteilung über den Abbau 
des Pyridins zu Glutaconsäure-dialdehyd). Ber. Dtsch. Chem. Ges. 1926, 59, 1166-
1171. 
189. Atkins, G. M.; Burgess, E. M., The reactions of an N-sulfonylamine inner salt. J. 
Am. Chem. Soc. 1968, 90, 4744-4745. 
190. Armitage, I.; Berne, A. M.; Elliott, E. E.; Fu, M.; Hicks, F.; McCubbin, Q.; Zhu, L., 
N-(tert-Butoxycarbonyl)-N-[(triethylenediammonium)sulfonyl]azanide: A 
Convenient Sulfamoylation Reagent for Alcohols. Org. Lett. 2012, 14, 2626-2629. 
191. Williams, J. M.; Richardson, A. C., Selective acylation of pyranoside-I.: 
Benzoylation of methyl α-D-glycopyranosides of mannose, glucose and galactose. 
Tetrahedron 1967, 23, 1369-1378. 
192. Bamford, M. J.; Pichel, J. C.; Husman, W.; Patel, B.; Storer, R.; Weir, N. G., 
Synthesis of 6-, 7- and 8-carbon sugar analogues of potent anti-influenza 2,3-
didehydro-2,3-dideoxy-N-acetylneuraminic acid derivatives. J. Chem. Soc. Perkin 
Trans. 1 1995, 1181-1187. 
193. Harrowven, D. C.; Curran, D. P.; Kostiuk, S. L.; Wallis-Guy, I. L.; Whiting, S.; 
Stenning, K. J.; Tang, B.; Packard, E.; Nanson, L., Potassium carbonate-silica: a 
highly effective stationary phase for the chromatographic removal of organotin 
impurities. Chem. Commun. 2010, 46, 6335-6337. 
194. Chatgilialoglu, C., Organosilanes as radical-based reducing agents in synthesis. 
Accounts of Chemical Research 1992, 25, 188-194. 
195. Zemplen, G., Saponification of acetylated carbohydrates. Matematikai es 
Termeszettudomanyi Ertesito 1937, 55, 432-439. 
196. Marshall, J. A.; Garofalo, A. W., Oxidative cleavage of mono-, di-, and 
trisubstituted olefins to methyl esters through ozonolysis in methanolic sodium 
hydroxide. J. Org. Chem. 1993, 58, 3675-3680. 
197. Griffith, W. P.; Shoair, A. G.; Suriaatmaja, M., Ruthenium-Catalysed Cleavage of 
Alkenes and Alkynes to Carboxylic Acids. Synth. Commun. 2000, 30, 3091-3095. 
198. Brown, H. C.; Knights, E. F.; Scouten, C. G., Hydroboration. XXXVI. Direct route 
to 9-borabicyclo[3.3.1]nonane via the cyclic hydroboration of 1,5-cyclooctadiene. 
9-Borabicyclo[3.3.1]nonane as a uniquely selective reagent for the hydroboration 
of olefins. J. Am. Chem. Soc. 1974, 96, 7765-7770. 
400 
 
199. Foley, D.; Pieri, M.; Pettecrew, R.; Price, R.; Miles, S.; Lam, H. K.; Bailey, P.; 
Meredith, D., The in vitro transport of model thiodipeptide prodrugs designed to 
target the intestinal oligopeptide transporter, PepT1. Org. Biomol. Chem. 2009, 7. 
200. Sajiki, H.; Hirota, K., A novel type of PdMC-catalyzed hydrogenation using a 
catalyst poison: Chemoselective inhibition of the hydrogenolysis for O-benzyl 
protective group by the addition of a nitrogen-containing base. Tetrahedron 1998, 
54, 13981-13996. 
201. L nse, C. E.; Schmidt, M. S.; Wittmann, V.; Mayer, G. n., Carba-sugars Activate 
the glmS-Riboswitch of Staphylococcus aureus. ACS Chemical Biology 2011, 6, 
675-678. 
202. Barton, D. H. R.; Augy-Dorey, S.; Camara, J.; Dalko, P.; Delaumény, J. M.; Géro, 
S. D.; Quiclet-Sire, B.; Stütz, P., Synthetic methods for the preparation of basic D- 
and L-pseudo-sugars. Synthesis of carbocyclic analogues of N-acetyl-muramyl-L-
alanyl-D-isoglutamine (MDP). Tetrahedron 1990, 46, 215-230. 
203. Barton, D. H. R.; McCombie, S. W., A new method for the deoxygenation of 
secondary alcohols. J. Chem. Soc. Perkin Trans. 1 1975, 1574-1585. 
204. Barton, D. H. R.; Crich, D.; Löbberding, A.; Zard, S. Z., On the mechanism of the 
deoxygenation of secondary alcohols by the reduction of their methyl xanthates by 
tin hydrides. Tetrahedron 1986, 42, 2329-2338. 
205. Daragics, K.; Fügedi, P., Regio- and chemoselective reductive cleavage of 4,6-O-
benzylidene-type acetals of hexopyranosides using BH3·THF–TMSOTf. 
Tetrahedron Lett. 2009, 50, 2914-2916. 
206. Jiang, L.; Chan, T.-H., Borane Bu2BOTf: A mild reagent for the regioselective 
reductive ring opening of benzylidene acetals in carbohydrates. Tetrahedron Lett. 
1998, 39, 355-358. 
207. Karst, N.; Jacquinet, J.-C., Chemical synthesis of -D-GlcpA(2SO4)-(1-3)-D-
GalpNAc(6SO4), the disaccharide repeating unit of shark cartilage chondroitin 
sulfate D, and of its methyl -D-glycoside derivative. J. Chem. Soc. Perkin Trans. 
1 2000, 2709-2717. 
208. Iversen, T.; Bundle, D. R., Benzyl trichloroacetimidate, a versatile reagent for acid-
catalysed benzylation of hydroxy-groups. J. Chem. Soc., Chem. Commun. 1981, 
1240-1241. 
401 
 
209. Sanders, W. J.; Manning, D. D.; Koeller, K. M.; Kiessling, L. L., Synthesis of 
sulfated trisaccharide ligands for the selectins. Tetrahedron 1997, 53, 16391-16422. 
210. Winum, J.-Y.; Vullo, D.; Casini, A.; Montero, J.-L.; Scozzafava, A.; Supuran, C. 
T., Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and 
Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including 
EMATE Also Acting as Steroid Sulfatase Inhibitors. J. Med. Chem. 2003, 46, 
2197-2204. 
211. Endicott, J. A.; Noble, M. E. M.; Johnson, L. N., The Structural Basis for Control 
of Eukaryotic Protein Kinases. Annu. Rev. Biochem. 2012, 81, 587-613. 
212. Blume-Jensen, P.; Hunter, T., Oncogenic kinase signalling. Nature 2001, 411, 355-
365. 
213. Barouch-Bentov, R.; Sauer, K., Mechanisms of drug resistance in kinases. Expert 
Opin. Invest. Drugs 2011, 20, 153-208. 
214. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S., The Protein 
Kinase Complement of the Human Genome. Science 2002, 298, 1912-1934. 
215. Ang, A.; Lang, Y. Protein Kinases. http://chem3513-
2007.pbworks.com/w/page/15648440/Protein%20Kinases (Aug 2013).  
216. Schwartz, P. A.; Murray, B. W., Protein kinase biochemistry and drug discovery. 
Bioorg. Chem. 2011, 39, 192-210. 
217. Norman, R. A.; Toader, D.; Ferguson, A. D., Structural approaches to obtain kinase 
selectivity. Trends Pharmacol. Sci. 2012, 33, 273-278. 
218. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. 
T.; Clarkson, B.; Kuriyan, J., Crystal Structures of the Kinase Domain of c-Abl in 
Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571). 
Cancer Res. 2002, 62, 4236-4243. 
219. Zhang, J.; Yang, P. L.; Gray, N. S., Targeting cancer with small molecule kinase 
inhibitors. Nat. Rev. Cancer 2009, 9, 28-39. 
220. Gavrin, L. K.; Saiah, E., Approaches to discover non-ATP site kinase inhibitors. 
MedChemComm 2013, 4, 41-51. 
221. Hui, L.; Zatloukal, K.; Scheuch, H.; Stepniak, E.; Wagner, E. F., Proliferation of 
human HCC cells and chemically induced mouse liver cancers requires JNK1-
dependent p21 downregulation. J. Clin. Invest. 2008, 118, 3943-3953. 
222. Hui, L.; Bakiri, L.; Mairhorfer, A.; Schweifer, N.; Haslinger, C.; Kenner, L.; 
Komnenovic, V.; Scheuch, H.; Beug, H.; Wagner, E. F., p38suppresses normal 
402 
 
and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat. Genet. 
2007, 39, 741-749. 
223. Zhou, G.; Bao, Z. Q.; Dixon, J. E., Components of a New Human Protein Kinase 
Signal Transduction Pathway. J. Biol. Chem. 1995, 270, 12665-12669. 
224. Nakamura, K.; Uhlik, M. T.; Johnson, N. L.; Hahn, K. M.; Johnson, G. L., PB1 
Domain-Dependent Signaling Complex Is Required for Extracellular Signal-
Regulated Kinase 5 Activation. Mol. Cell. Biol. 2006, 26, 2065-2079. 
225. Yan, L.; Carr, J.; Ashby, P.; Murry-Tait, V.; Thompson, C.; Arthur, J. S., Knockout 
of ERK5 causes multiple defects in placental and embryonic development. BMC 
Dev. Biol. 2003, 3, 11. 
226. Montero, J. C.; Ocaña, A.; Abad, M.; Ortiz-Ruiz, M. J.; Pandiella, A.; Esparís-
Ogando, A., Expression of Erk5 in Early Stage Breast Cancer and Association with 
Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target. 
PLoS One 2009, 4, e5565. 
227. Mehta, P. B.; Jenkins, B. L.; McCarthy, L.; Thilak, L.; Robson, C. N.; Neal, D. E.; 
Leung, H. Y., MEK5 overexpression is associated with metastatic prostate cancer, 
and stimulates proliferation, MMP-9 expression and invasion. Oncogene 2003, 22, 
1381-1389. 
228. Zen, K.; Yasui, K.; Nakajima, T.; Zen, Y.; Zen, K.; Gen, Y.; Mitsuyoshi, H.; 
Minami, M.; Mitsufuji, S.; Tanaka, S.; Itoh, Y.; Nakanuma, Y.; Taniwaki, M.; Arii, 
S.; Okanoue, T.; Yoshikawa, T., ERK5 is a target for gene amplification at 17p11 
and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry. 
Genes, Chromosomes Cancer 2009, 48, 109-120. 
229. McCracken, S. R. C.; Ramsay, A.; Heer, R.; Mathers, M. E.; Jenkins, B. L.; 
Edwards, J.; Robson, C. N.; Marquez, R.; Cohen, P.; Leung, H. Y., Aberrant 
expression of extracellular signal-regulated kinase 5 in human prostate cancer. 
Oncogene 2007, 27, 2978-2988. 
230. Kato, Y.; Tapping, R. I.; Huang, S.; Watson, M. H.; Ulevitch, R. J.; Lee, J.-D., 
Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. 
Nature 1998, 395, 713-716. 
231. Perez-Madrigal, D.; Finegan, K. G.; Paramo, B.; Tournier, C., The extracellular-
regulated protein kinase 5 (ERK5) promotes cell proliferation through the down-
regulation of inhibitors of cyclin dependent protein kinases (CDKs). Cell. Signal. 
2012, 24, 2360-2368. 
403 
 
232. Lochhead, P. A.; Gilley, R.; Cook, S. J., ERK5 and its role in tumour development. 
Biochem. Soc. Trans. 2012, 40, 251-256. 
233. Ramsay, A. K.; McCracken, S. R. C.; Soofi, M.; Fleming, J.; Yu, A. X.; Ahmad, I.; 
Morland, R.; Machesky, L.; Nixon, C.; Edwards, D. R.; Nuttall, R. K.; Seywright, 
M.; Marquez, R.; Keller, E.; Leung, H. Y., ERK5 signalling in prostate cancer 
promotes an invasive phenotype. Br. J. Cancer 2011, 104, 664-672. 
234. Castro, N.; Lange, C., Breast tumor kinase and extracellular signal-regulated kinase 
5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast 
Cancer Res. 2010, 12, R60. 
235. Carvajal-Vergara, X.; Tabera, S.; Montero, J. C.; Esparís-Ogando, A.; López-Pérez, 
R.; Mateo, G.; Gutiérrez, N.; Parmo-Cabañas, M.; Teixidó, J.; San Miguel, J. F.; 
Pandiella, A., Multifunctional role of Erk5 in multiple myeloma. Blood 2005, 105, 
4492-4499. 
236. Wang, X.; Merritt, A. J.; Seyfried, J.; Guo, C.; Papadakis, E. S.; Finegan, K. G.; 
Kayahara, M.; Dixon, J.; Boot-Handford, R. P.; Cartwright, E. J.; Mayer, U.; 
Tournier, C., Targeted Deletion of mek5 Causes Early Embryonic Death and 
Defects in the Extracellular Signal-Regulated Kinase 5/Myocyte Enhancer Factor 2 
Cell Survival Pathway. Mol. Cell. Biol. 2005, 25, 336-345. 
237. Roberts, O. L.; Holmes, K.; Müller, J.; Cross, D. A. E.; Cross, M. J., ERK5 is 
required for VEGF-mediated survival and tubular morphogenesis of primary 
human microvascular endothelial cells. J. Cell Sci. 2010, 123, 3189-3200. 
238. Song, H.; Jin, X.; Lin, J., Stat3 upregulates MEK5 expression in human breast 
cancer cells. Oncogene 2004, 23, 8301-8309. 
239. Lee, J. D.; Ulevitch, R. J.; Han, J. H., Primary Structure of BMK1: A New 
Mammalian MAP Kinase. Biochem. Biophys. Res. Commun. 1995, 213, 715-724. 
240. Nishimoto, S.; Nishida, E., MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 
2006, 7, 782-786. 
241. Sturla, L.-M.; Cowan, C. W.; Guenther, L.; Castellino, R. C.; Kim, J. Y. H.; 
Pomeroy, S. L., A Novel Role for Extracellular Signal-Regulated Kinase 5 and 
Myocyte Enhancer Factor 2 in Medulloblastoma Cell Death. Cancer Res. 2005, 65, 
5683-5689. 
242. Sohn, S. J.; Li, D.; Lee, L. K.; Winoto, A., Transcriptional Regulation of Tissue-
Specific Genes by the ERK5 Mitogen-Activated Protein Kinase. Mol. Cell. Biol. 
2005, 25, 8553-8566. 
404 
 
243. Morimoto, H.; Kondoh, K.; Nishimoto, S.; Terasawa, K.; Nishida, E., Activation of 
a C-terminal Transcriptional Activation Domain of ERK5 by Autophosphorylation. 
J. Biol. Chem. 2007, 282, 35449-35456. 
244. Lu, C.; Shen, Q.; DuPre, E.; Kim, H.; Hilsenbeck, S.; Brown, P. H., cFos is critical 
for MCF-7 breast cancer cell growth. Oncogene 2005, 24, 6516-6524. 
245. Deng, X.; Yang, Q.; Kwiatkowski, N.; Sim, T.; McDermott, U.; Settleman, J. E.; 
Lee, J.-D.; Gray, N. S., Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-
6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1. ACS Med. 
Chem. Lett. 2011, 2, 195-200. 
246. Tatake, R. J.; O’Neill, M. M.; Kennedy, C. A.; Wayne, A. L.; Jakes, S.; Wu, D.; 
Kugler Jr, S. Z.; Kashem, M. A.; Kaplita, P.; Snow, R. J., Identification of 
pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem. Biophys. Res. 
Commun. 2008, 377, 120-125. 
247. Elkins, J. M.; Wang, J.; Deng, X.; Pattison, M. J.; Arthur, J. S. C.; Erazo, T.; 
Gomez, N.; Lizcano, J. M.; Gray, N. S.; Knapp, S., X-ray Crystal Structure of 
ERK5 (MAPK7) in Complex with a Specific Inhibitor. J. Med. Chem. 2013. 
248. Yang, Q.; Deng, X.; Lu, B.; Cameron, M.; Fearns, C.; Patricelli, M. P.; Yates Iii, J. 
R.; Gray, N. S.; Lee, J.-D., Pharmacological Inhibition of BMK1 Suppresses 
Tumor Growth through Promyelocytic Leukemia Protein. Cancer Cell 2010, 18, 
258-267. 
249. Molecular Devices http://www.moleculardevices.com/products/assay-
kits/enzymes/imap-assays.html (10-08-2013).  
250. de Groot, M. J.; Wakenhut, F.; Whitlock, G.; Hyland, R., Understanding CYP2D6 
interactions. Drug Discov. Today 2009, 14, 964-972. 
251. Lewis, D. F. V.; Dickins, M., Substrate SARs in human P450s. Drug Discov. Today 
2002, 7, 918-925. 
252. Bawn, R. Development of Small Molecule Inhibitors of ERK5 for the Treatment of 
Cancer. Newcastle University, Newcastle upon Tyne, 2011. 
253. Myers, S. M. The Discovery and Optimization of ERK5 Inhibitors. Newcastle 
University, Newcastle upon Tyne, 2012. 
254. Lave, T.; Dupin, S.; Schmitt, C.; Chou, R. C.; Jaeck, D.; Coassolo, P., Integration 
of in vitro data into allometric scaling to predict hepatic metabolic clearance in 
man: Application to 10 extensively metabolized drugs. J. Pharm. Sci. 1997, 86, 
584-590. 
405 
 
255. Riley, R. J.; Parker, A. J.; Trigg, S.; Manners, C. N., Development of a 
Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in 
Early Drug Discovery. Pharm. Res. 2001, 18, 652-655. 
256. Jones, G.; Willett, P.; Glen, R. C., Molecular recognition of receptor sites using a 
genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53. 
257. O'Hare, T.; Walters, D. K.; Stoffregen, E. P.; Jia, T.; Manley, P. W.; Mestan, J.; 
Cowan-Jacob, S. W.; Lee, F. Y.; Heinrich, M. C.; Deininger, M. W. N.; Druker, B. 
J., In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against 
Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Res. 
2005, 65, 4500-4505. 
258. Khoury, H. J.; Cortes, J. E.; Kantarjian, H. M.; Gambacorti-Passerini, C. B.; 
Baccarani, M.; Kim, D.-W.; Zaritskey, A.; Countouriotis, A.; Besson, N.; Leip, E.; 
Kelly, V.; Brummendorf, T. H., Bosutinib is active in chronic phase chronic 
myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. 
Blood 2012. 
259. European Medicines Agency Tasigna EPAR product information: 
EMEA/H/C/000798 -II/0058. 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/
000798/human_med_001079.jsp&mid=WC0b01ac058001d124 (July 2013).  
260. Zhou, T.; Commodore, L.; Huang, W.-S.; Wang, Y.; Thomas, M.; Keats, J.; Xu, Q.; 
Rivera, V. M.; Shakespeare, W. C.; Clackson, T.; Dalgarno, D. C.; Zhu, X., 
Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): 
Lessons for Overcoming Kinase Inhibitor Resistance. Chem. Biol. Drug Des. 2011, 
77, 1-11. 
261. Sebastian, S.; Settleman, J.; Reshkin, S. J.; Azzariti, A.; Bellizzi, A.; Paradiso, A., 
The complexity of targeting EGFR signalling in cancer: From expression to 
turnover. Biochim. Biophys. Acta - Reviews on Cancer 2006, 1766, 120-139. 
262. Kosaka, T.; Yatabe, Y.; Endoh, H.; Yoshida, K.; Hida, T.; Tsuboi, M.; Tada, H.; 
Kuwano, H.; Mitsudomi, T., Analysis of Epidermal Growth Factor Receptor Gene 
Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to 
Gefitinib. Clin. Cancer. Res. 2006, 12, 5764-5769. 
263. Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. 
P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; 
Richards, L., Studies leading to the identification of ZD1839 (iressa™): an orally 
406 
 
active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted 
to the treatment of cancer. Bioorg. Med. Chem. Lett. 2001, 11, 1911-1914. 
264. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, 
L. R., Epidermal growth factor receptor tyrosine kinase: Investigation of catalytic 
mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. 
Pharmacol. 1994, 48, 659-666. 
265. MacFarlane, R. J.; Gelmon, K. A., Lapatinib for breast cancer: a review of the 
current literature. Expert Opin. Drug Saf. 2011, 10, 109-121. 
266. Hoelder, S.; Clarke, P. A.; Workman, P., Discovery of small molecule cancer 
drugs: Successes, challenges and opportunities. Mol. Oncol. 2012, 6, 155-176. 
267. Duda, D. G.; Batchelor, T. T.; Willett, C. G.; Jain, R. K., VEGF-targeted cancer 
therapy strategies: current progress, hurdles and future prospects. Trends Mol. Med. 
2007, 13, 223-230. 
268. Amir, E.; Mandoky, L.; Blackhall, F.; Thatcher, N.; Klepetko, W.; Ankersmit, H. 
J.; Reza Hoda, M. A.; Ostoros, G.; Dank, M.; Dome, B., Antivascular agents for 
non-small-cell lung cancer: current status and future directions. Expert Opin. 
Invest. Drugs 2009, 18, 1667-1686. 
269. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R. A.; 
Schwartz, B.; Simantov, R.; Kelley, S., Discovery and development of sorafenib: a 
multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006, 5, 835-844. 
270. Strumberg, D.; Schultheis, B., Regorafenib for cancer. Expert Opin. Invest. Drugs 
2012, 21, 879-889. 
271. Patson, B.; B Cohen, R.; Olszanski, A. J., Pharmacokinetic evaluation of axitinib. 
Expert Opin. Drug Metab. Toxicol. 2012, 8, 259-270. 
272. Traynor, K., Cabozantinib approved for advanced medullary thyroid cancer. Am. J. 
Health-Syst. Pharm. 2013, 70, 88. 
273. Yakes, F. M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; 
Bentzien, F.; Cancilla, B.; Orf, J.; You, A.; Laird, A. D.; Engst, S.; Lee, L.; Lesch, 
J.; Chou, Y.-C.; Joly, A. H., Cabozantinib (XL184), a Novel MET and VEGFR2 
Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor 
Growth. Mol. Cancer Ther. 2011, 10, 2298-2308. 
274. Flaherty, K. T.; Yasothan, U.; Kirkpatrick, P., Vemurafenib. Nat. Rev. Drug 
Discov. 2011, 10, 811-812. 
407 
 
275. Forde, P. M.; Rudin, C. M., Crizotinib in the treatment of non-small-cell lung 
cancer. Expert Opin. Pharmacother. 2012, 13, 1195-1201. 
276. Cui, J. J.; Tran-Dub , M.; Shen, H.; Nambu, M.; Kung, P.-P.; Pairish, M.; Jia, L.; 
Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; 
Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; 
Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P., Structure Based Drug 
Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of 
Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic 
Lymphoma Kinase (ALK). J. Med. Chem. 2011, 54, 6342-6363. 
277. Deisseroth, A.; Kaminskas, E.; Grillo, J.; Chen, W.; Saber, H.; Lu, H. L.; 
Rothmann, M. D.; Brar, S.; Wang, J.; Garnett, C.; Bullock, J.; Burke, L. B.; 
Rahman, A.; Sridhara, R.; Farrell, A.; Pazdur, R., U.S. Food and Drug 
Administration Approval: Ruxolitinib for the Treatment of Patients with 
Intermediate and High-Risk Myelofibrosis. Clin. Cancer. Res. 2012, 18, 3212-
3217. 
278. Ni, H.; Moe, S.; Myint, K. T.; Htet, A., Oral Janus Kinase Inhibitor for the 
Treatment of Rheumatoid Arthritis: Tofacitinib. ISRN Rheumatology 2013, 2013, 9. 
279. Leeson, P. D.; Springthorpe, B., The influence of drug-like concepts on decision-
making in medicinal chemistry. Nat. Rev. Drug Discov. 2007, 6, 881-890. 
280. Ryckmans, T.; Edwards, M. P.; Horne, V. A.; Correia, A. M.; Owen, D. R.; 
Thompson, L. R.; Tran, I.; Tutt, M. F.; Young, T., Rapid assessment of a novel 
series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic 
Efficiency (LipE) analysis. Bioorg. Med. Chem. Lett. 2009, 19, 4406-4409. 
281. NDA 21-588 Review - Imatinib, Clinical Pharmacology and Biopharmaceutics 
Review. FDA2002. 
282. NDA 21-986 Review - Dasatinib, Clinical Pharmacology Pharmacometrics 
Review. FDA2006. 
283. NDA 22-068 - Nilotinib, Summary Review. FDA2007. 
284. NDA 203-341 Review – Bosutinib, 203341Clinical Pharmacology Review. FDA, 
Ed.2012. 
285. NDA203469Orig1s000 - Ponatinib, Pharmacology Review. FDA2012. 
286. NDA21-399 - Geftinib, Pharmacology Review. FDA2003. 
287. NDA 24-713 Erlotinib, Pharmacology Review. FDA2004. 
408 
 
288. NDA 22-059 Lapatinib, Clinical Pharmacology and Biopharmaceutic Review.  
FDA2007. 
289. NDA-21 938 Sunitinib, clinical Pharmacology and Biopharmaceutic Review.  
FDA2005. 
290. NDA 21 923 - Sorafenib, Clinical Pharmacology and Bipharmaceutic Review.  
FDA2005. 
291. NDA 203085Orig1s000 - Regorafenib, Clinical Pharmacology and 
Biopharmaceutic Review. FDA2012. 
292. NDA 202324Orig1s000 - Axitinib, Clinical Pharmacology and Biopharmaceutics 
Review. FDA2012. 
293. NDA 22-465 - Pazopanib, Clinical Pharmacology and Biopharmaceutics Review.  
FDA2008. 
294. NDA 022405Orig1s000 - Vandetanib, Clinical Pharmacology and 
Biopharmaceutics Review. FDA2010. 
295. NDA 202429Orig1s000 - Vemurafenib, Clinical Pharmacology and 
Biopharmaceutics Review. FDA2011. 
296. NDA 202570Orig1s000 - Crizotinib, Clinical Pharmacology and Biopharmaceutics 
Review. FDA2011. 
297. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Experimental and 
computational approaches to estimate solubility and permeability in drug discovery 
and development settings. Adv. Drug Del. Rev. 1997, 23, 3-25. 
298. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D., A 
Comparison of Physiochemical Property Profiles of Development and Marketed 
Oral Drugs. J. Med. Chem. 2003, 46, 1250-1256. 
299. Ertl, P.; Rohde, B.; Selzer, P., Fast Calculation of Molecular Polar Surface Area as 
a Sum of Fragment-Based Contributions and Its Application to the Prediction of 
Drug Transport Properties. J. Med. Chem. 2000, 43, 3714-3717. 
300. Hou, T.; Wang, J.; Zhang, W.; Xu, X., ADME Evaluation in Drug Discovery. 6. 
Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular 
Property-Based Rules? J. Chem. Inf. Model. 2007, 47, 460-463. 
301. Peng, B.; Lloyd, P.; Schran, H., Clinical Pharmacokinetics of Imatinib. Clin. 
Pharmacokinet. 2005, 44, 879-894. 
302. European Medicines Agency Iclusig EPAR product information: 
EMEA/H/C/002695. 
409 
 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/
002695/human_med_001656.jsp&mid=WC0b01ac058001d124 (July 2013).  
303. Chouhan, J. D.; Zamarripa, D. E.; Lai, P. H.; Oramasionwu, C. U.; Grabinski, J. L., 
Sunitinib (Sutent®): A novel agent for the treatment of metastatic renal cell 
carcinoma. J. Oncol. Pharm. Pract. 2007, 13, 5-15. 
304. Rose, J.; Castagnoli, N., The metabolism of tertiary amines. Med. Res. Rev. 1983, 
3, 73-88. 
305. Maubon, N.; Le Vee, M.; Fossati, L.; Audry, M.; Le Ferrec, E.; Bolze, S.; Fardel, 
O., Analysis of drug transporter expression in human intestinal Caco-2 cells by 
real-time PCR. Fund. Clin. Pharmacol. 2007, 21, 659-663. 
306. Seelig, A., A general pattern for substrate recognition by P-glycoprotein. Eur. J. 
Biochem. 1998, 251, 252-261. 
307. Hitchcock, S. A., Structural Modifications that Alter the P-Glycoprotein Efflux 
Properties of Compounds. J. Med. Chem. 2012, 55, 4877-4895. 
308. Alex, A.; Millan, D. S.; Perez, M.; Wakenhut, F.; Whitlock, G. A., Intramolecular 
hydrogen bonding to improve membrane permeability and absorption in beyond 
rule of five chemical space. MedChemComm 2011, 2, 669-674. 
309. Palm, K.; Stenberg, P.; Luthman, K.; Artursson, P., Polar Molecular Surface 
Properties Predict the Intestinal Absorption of Drugs in Humans. Pharm. Res. 
1997, 14, 568-571. 
310. Kuduk, S. D.; Di Marco, C. N.; Chang, R. K.; Wood, M. R.; Schirripa, K. M.; Kim, 
J. J.; Wai, J. M. C.; DiPardo, R. M.; Murphy, K. L.; Ransom, R. W.; Harrell, C. M.; 
Reiss, D. R.; Holahan, M. A.; Cook, J.; Hess, J. F.; Sain, N.; Urban, M. O.; Tang, 
C.; Prueksaritanont, T.; Pettibone, D. J.; Bock, M. G., Development of Orally 
Bioavailable and CNS Penetrant Biphenylaminocyclopropane Carboxamide 
Bradykinin B1 Receptor Antagonists. J. Med. Chem. 2006, 50, 272-282. 
311. Miller, D. C.; Klute, W.; Calabrese, A.; Brown, A. D., Optimising metabolic 
stability in lipophilic chemical space: The identification of a metabolically stable 
pyrazolopyrimidine CRF-1 receptor antagonist. Bioorg. Med. Chem. Lett. 2009, 19, 
6144-6147. 
312. Cerny, M. A.; Hanzlik, R. P., Cyclopropylamine inactivation of cytochromes P450: 
Role of metabolic intermediate complexes. Arch. Biochem. Biophys. 2005, 436, 
265-275. 
410 
 
313. Hagmann, W. K., The Many Roles for Fluorine in Medicinal Chemistry. J. Med. 
Chem. 2008, 51, 4359-4369. 
314. Owen, D. R.; Rodriguez-Lens, M.; Corless, M. D.; Gaulier, S. M.; Horne, V. A.; 
Kinloch, R. A.; Maw, G. N.; Pearce, D. W.; Rees, H.; Ringer, T. J.; Ryckmans, T.; 
Stammen, B. L. C., 2,4-Diaminopyridine δ-opioid receptor agonists and their 
associated hERG pharmacology. Bioorg. Med. Chem. Lett. 2009, 19, 1702-1706. 
315. Blizzard, T. A.; Chen, H.; Gude, C.; Hermes, J. D.; Imbriglio, J. E.; Kim, S.; Wu, J. 
Y.; Ha, S.; Mortko, C. J.; Mangion, I.; Rivera, N.; Ruck, R. T.; Shelvin, M. Beta-
lactamase inhibitors. WO2009091856, 2009. 
316. Huang, H.; Iwasawa, N.; Mukaiyama, T., A convenient method for the construction 
of beta-lactam compounds from beta-aminoacids using 2-chloro-1-
methylpyridinium iodide as condensing reagent. Chem. Lett. 1984, 13, 1465-1466. 
317. Beletskaya, I. P.; Cheprakov, A. V., The Complementary Competitors: Palladium 
and Copper in C–N Cross-Coupling Reactions. Organometallics 2012, 31, 7753-
7808. 
318. Wolfe, J. P.; Tomori, H.; Sadighi, J. P.; Yin, J.; Buchwald, S. L., Simple, Efficient 
Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, 
Bromides, and Triflates. J. Org. Chem. 2000, 65, 1158-1174. 
319. Maiti, D.; Fors, B. P.; Henderson, J. L.; Nakamura, Y.; Buchwald, S. L., Palladium-
catalyzed coupling of functionalized primary and secondary amines with aryl and 
heteroaryl halides: two ligands suffice in most cases. Chem. Sci. 2011, 2, 57-68. 
320. Surry, D. S.; Buchwald, S. L., Dialkylbiaryl phosphines in Pd-catalyzed amination: 
a user's guide. Chem. Sci. 2011, 2, 27-50. 
321. Yaunner, R. S.; Barros, J. C.; da Silva, J. F. M., Microwave-promoted 
piperidination of halopyridines: a comparison between Ullmann, Buchwald–
Hartwig and uncatalysed SNAr reactions. Appl. Organomet. Chem. 2012, 26, 273-
276. 
322. Keegstra, M. A.; Peters, T. H. A.; Brandsma, L., Copper(I) halide catalysed 
synthesis of alkyl aryl and alkyl heteroaryl ethers. Tetrahedron 1992, 48, 3633-
3652. 
323. Corcoran, R. C.; Bang, S. H., Iodopyridines from bromo- and chloropyridines. 
Tetrahedron Lett. 1990, 31, 6757-6758. 
411 
 
324. Yin, J.; Xiang, B.; Huffman, M. A.; Raab, C. E.; Davies, I. W., A General and 
Efficient 2-Amination of Pyridines and Quinolines. J. Org. Chem. 2007, 72, 4554-
4557. 
325. Londregan, A. T.; Jennings, S.; Wei, L., Mild Addition of Nucleophiles to 
Pyridine-N-Oxides. Org. Lett. 2011, 13, 1840-1843. 
326. Londregan, A. T.; Jennings, S.; Wei, L., General and Mild Preparation of 2-
Aminopyridines. Org. Lett. 2010, 12, 5254-5257. 
327. Austin, M. W.; Blackborow, J. R.; Ridd, J. H.; Smith, B. V., The kinetics and 
mechanism of heteroaromatic nitration. Part II. Pyrazole and imidazole. J. Chem. 
Soc. 1965, 1051-1057. 
328. Zabierek, A. A.; Konrad, K. M.; Haidle, A. M., A practical, two-step synthesis of 
1-alkyl-4-aminopyrazoles. Tetrahedron Lett. 2008, 49, 2996-2998. 
329. Eschweiler, W., Ersatz von an Stickstoff gebundenen Wasserstoffatomen durch die 
Methylgruppe mit Hülfe von Formaldehyd. Ber. Dtsch. Chem. Ges. 1905, 38, 880-
882. 
330. Clarke, H. T.; Gillespie, H. B.; Weisshaus, S. Z., The Action of Formaldehyde on 
Amines and Amino Acids 1. J. Am. Chem. Soc. 1933, 55, 4571-4587. 
331. Kawasaki, I.; Osaki, T.; Tsunoda, K.; Watanabe, E.; Matsuyama, M.; Sanai, A.; 
Khadeer, A.; Yamashita, M.; Ohta, S., Double nucleophilic reaction of amines to 
the imidazole nucleus and selective synthesis of 5-aminoimidazoles. Tetrahedron 
2004, 60, 6639-6648. 
332. Ridd, J. H.; Smith, B. V., The mechanisms of N-substitution in glyoxaline 
derivatives. Part III. Factors determining the orientation of N-methylation in 
substituted glyoxalines and benzimidazoles. J. Chem. Soc. (Resumed) 1960, 1363-
1369. 
333. Bergman, J.; Sand, P., A new simple procedure for alkylation of nitrogen 
heterocycles using dialkyl oxalates and alkoxides. Tetrahedron Lett. 1984, 25, 
1957-1960. 
334. Grimison, A.; Ridd, J. H.; Smith, B. V., The mechanisms of N-substitution in 
glyoxaline derivatives. Part I. Introduction, and study of prototropic equilibria 
involving 4(5)-nitroglyoxaline. J. Chem. Soc. (Resumed) 1960, 1352-1356. 
335. Grimison, A.; Ridd, J. H.; Smith, B. V., The mechanisms of N-substitution in 
glyoxaline derivatives. Part II. The methylation of 4(5)-nitroglyoxaline by methyl 
sulphate. J. Chem. Soc. (Resumed) 1960, 1357-1362. 
412 
 
336. Kamst, E.; Zegelaar-Jaarsveld, K.; van der Marel, G. A.; van Boom, J. H.; 
Lugtenberg, B. J. J.; Spaink, H. P., Chemical synthesis of N-acetylglucosamine 
derivatives and their use as glycosyl acceptors by the Mesorhizobium loti chitin 
oligosaccharide synthase NodC. Carbohydrate Res. 1999, 321, 176-189. 
337. Sixta, G.; Hofinger, A.; Kosma, P., Synthesis of spacer-containing chlamydial 
disaccharides as analogues of the α-Kdop-(2-8)-α-Kdop-(2-4)-α-Kdop trisaccharide 
epitope. Carbohydrate Res. 2007, 342, 576-585. 
338. Saito, K.; Nishimura, Y.; Kondo, S.; Takeuchi, T., Synthesis of Carbocyclic Lignan 
Variants Related to Podophyllotoxin. Chem. Lett. 1988, 17, 1235-1238. 
339. Vatèle, J.-M.; Hanessian, S., Design and reactivity of organic functional groups - 
preparation and nucleophilic displacement reactions of imidazole-1-sulfonates 
(imidazylates). Tetrahedron 1996, 52, 10557-10568. 
340. Zhang, J.; Hong Chan, P. W.; Che, C.-M., Enantioselective intramolecular 
amidation of sulfamate esters catalyzed by chiral manganese(III) Schiff-base 
complexes. Tetrahedron Lett. 2005, 46, 5403-5408. 
341. Hedayatullah, M.; Guy, A., A Convenient Synthesis of Aryl Sulfamates. Synthesis 
1978, 1978, 357-357. 
342. Ban, H.; Asano, S. Preparation of heterocycle- and benzene-containing sulfonamide 
derivatives as LDL receptor agonists. EP1736467, 2005. 
343. Lo, Y. S.; Nolan, J. C.; Walsh, D. A.; Welstead, W. J. J. Preparation of sulfamate 
esters for use against arthritis and osteoporosis. US5194446, 1993. 
344. Kamal, A.; Rao, M. V.; Rao, A. B., Heterocycles 1990, 31, 577. 
345. Woo, L. W. L.; Howarth, N. M.; Purohit, A.; Hejaz, A. M.; Reed, M. J.; Potter, B. 
V. L., Steroidal and Nonsteroidal Sulfamates as Potent Inhibitors of Steroid 
Sulfatase. J. Med. Chem. 1998, 41, 1068. 
346. Denehy, E.; White, J. M.; Williams, S. J., Ground state structures of sulfate 
monoesters and sulfamates reveal similar reaction coordinates for sulfuryl and 
sulfamyl transfer. Chem. Commun. 2006, 3, 314-316. 
347. Otto, E.; Muschaweck, R. Sulfamic acid esters DE2418217, 1975. 
348. Hetayatullah, M.; Guy, A., A convenient synthesis of aryl sulfamates. Synthesis 
1978, 357. 
349. Colombo, M.; Bossolo, S.; Aramini, A., Phosphorus Trichloride-Mediated and 
Microwave-Assisted Synthesis of a Small Collection of Amides Bearing Strong 
413 
 
Electron-Withdrawing Group Substituted Anilines. J. Comb. Chem. 2009, 11, 335-
337. 
350. Baindur, N.; Gaul, M. D.; Kreutter, K. D.; Baumann, C. A.; Kim, A. J.; Xu, G.; 
Tuman, R. W.; Johnson, D. L. Alkylquinoline and alkylquinazoline kinase 
modulators. US2006281772, 2006. 
351. Rahamin, Y.; Sharvit, J.; Mandelbaum, A.; Sprecher, M., Electron impact-induced 
methyl migration in dimethylaminoheteroaromatic systems. J. Org. Chem. 1967, 
32, 3856-3859. 
352. Nara, S. J.; Jha, M.; Brinkhorst, J.; Zemanek, T. J.; Pratt, D. A., A Simple Cu-
Catalyzed Coupling Approach to Substituted 3-Pyridinol and 5-Pyrimidinol 
Antioxidants. J. Org. Chem. 2008, 73, 9326-9333. 
353. Krchňák, V.; Arnold, Z., Novel pyrimidine derivatives, reactions and ultraviolet 
spectra. Collect. Czech. Chem. Commun. 1975, 40, 1396-1402. 
354. Axten, J. M.; Betancourt, T. J. R. M.; Johnson, N. W.; Semone, M. 
Anthranilamides. WO2008147831, 2008. 
355. Tsou, H.-R.; Otteng, M.; Tran, T.; Floyd, M. B.; Reich, M.; Birnberg, G.; Kutterer, 
K.; Ayral-Kaloustian, S.; Ravi, M.; Nilakantan, R.; Grillo, M.; McGinnis, J. P.; 
Rabindran, S. K., 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as 
Potent and Selective Inhibitors of the Cyclin-Dependent Kinase 4 (CDK4). J. Med. 
Chem. 2008, 51, 3507-3525. 
356. Bolin, D. R.; Cheung, A. W.-H.; FIirooznia, F.; Hamilton, M. M.; McDermott, L. 
A.; Qian, Y.; Tan, J.; Yun, W. Diacylglycerol Acyltransferase Inhibitors. 2008. 
357. Qian, Y.; Wertheimer, S. J.; Ahmad, M.; Cheung, A. W.-H.; Firooznia, F.; 
Hamilton, M. M.; Hayden, S.; Li, S.; Marcopulos, N.; McDermott, L.; Tan, J.; Yun, 
W.; Guo, L.; Pamidimukkala, A.; Chen, Y.; Huang, K.-S.; Ramsey, G. B.; 
Whittard, T.; Conde-Knape, K.; Taub, R.; Rondinone, C. M.; Tilley, J.; Bolin, D., 
Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-
trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 
Inhibitors for the Potential Treatment of Obesity and Diabetes. J. Med. Chem. 
2011, 54, 2433-2446. 
358. Hurst, D. T.; Christophides, J., The Synthesis of Some 2-Substituted 5-
Nitropyrimidines. Heterocycles 1977, 6, 1999-2004. 
359. Ammala, C.; Briscoe, C. Gpr119 agonists for the treatment of diabetes and related 
disorders WO2008008895, 2008. 
414 
 
360. DiMauro, E. F.; Newcomb, J.; Nunes, J. J.; Bemis, J. E.; Boucher, C.; Chai, L.; 
Chaffee, S. C.; Deak, H. L.; Epstein, L. F.; Faust, T.; Gallant, P.; Gore, A.; Gu, Y.; 
Henkle, B.; Hsieh, F.; Huang, X.; Kim, J. L.; Lee, J. H.; Martin, M. W.; McGowan, 
D. C.; Metz, D.; Mohn, D.; Morgenstern, K. A.; Oliveira-dos-Santos, A.; Patel, V. 
F.; Powers, D.; Rose, P. E.; Schneider, S.; Tomlinson, S. A.; Tudor, Y.-Y.; Turci, 
S. M.; Welcher, A. A.; Zhao, H.; Zhu, L.; Zhu, X., Structure-Guided Design of 
Aminopyrimidine Amides as Potent, Selective Inhibitors of Lymphocyte Specific 
Kinase: Synthesis, Structure–Activity Relationships, and Inhibition of in Vivo T 
Cell Activation. J. Med. Chem. 2008, 51, 1681-1694. 
361. Brown, D. J.; Sugimoto, T., Aza-analogues of pteridine. Part II. The novel use of 
silver oxide in transetherification of alkoxy-1,2,4,6,8-penta-azanaphthalenes, 
alkoxynitropyrimidines, and related systems. J. Chem. Soc. C 1970, 0, 2661-2666. 
362. Cherkasov, V. M.; Remennikov, G. Y.; Kisilenko, A. A.; Romanenko, E. A., Sigma 
complexes in the pyrimidine series. 2. σ Complexes of 5-nitropyrimidine and 
methoxy-substituted 5-nitropyrimidines with the acetone anion. Chem. Heterocycl. 
Compd. 1980, 16, 179-182. 
363. Krchňák, V.; Arnold, Z., Novel pyrimidine derivatives, reactions and ultraviolet 
spectra. Collect. Czech. Chem. Commun 1975, 40, 1396-1402. 
364. Dodic, N. Bioisosteric benzamide derivatives and their use as apob-100 secretion 
inhibitors US2004009988, 2004. 
365. Adjabeng, G.; Bifulco, N.; Davis-Ward, R. G.; Dickerson, S. H.; Donaldson, K. H.; 
Harris, P. A.; Hornberger, K.; Petrov, K.; Rheaul, T. R.; Schaaf, G.; Stellwagen, J.; 
Uehling, D. E.; Waterson, A. G. Thiazole and oxazole kinase inhibitors. 
WO2009032667, 2009. 
366. Spencer, J.; Patel, H.; Callear, S. K.; Coles, S. J.; Deadman, J. J., Synthesis and 
solid state study of pyridine- and pyrimidine-based fragment libraries. Tetrahedron 
Lett. 2011, 52, 5905-5909. 
367. Sazonov, N. V.; Safonova, T. S.; Minakova, S. M.; Chernov, V. A., 
Diethylenimides of 3-pyridyl- and 4-pyridylamidophosphoric acids. Pharm. Chem. 
J. 1972, 6, 146-149. 
368. Barlamm, B. C.; Foote, K. M.; Ple, P. Pyridine Compounds. WO2009153589, 
2009. 
369. Wessig, P.; M llnitz, K., Nanoscale Molecular Rods with a New Building Block 
for Solubility Enhancement. J. Org. Chem. 2008, 73, 4452-4457. 
415 
 
370. Bailey, J. M.; Booth, H.; Al-Shirayda, H. A. R. Y.; Trimble, M. L., Ring inversion 
equilibria in 4-chloro-, 4-bromo-, and 4-methoxy-1-alkylpiperidines in a non-polar 
solvent. J. Chem. Soc. Perkin Trans. 2 1984, 0, 737-743. 
371. Park, S.; Lee, I. S.; Park, J., A magnetically separable gold catalyst for 
chemoselective reduction of nitro compounds. Org. Biomol. Chem. 2013, 11, 395-
399. 
372. Ravi, P.; Gore, G. M.; Sikder, A. K.; Tewari, S. P., Silica-Sulfuric Acid Catalyzed 
Nitrodeiodination of Iodopyrazoles. Synth. Commun. 2012, 42, 3463-3471. 
373. Chang, K.; Grimmett, M. R.; Ward, D. D.; Weavers, R. T., The Nitration of 
Brominated Pyrazoles in Aqueous Sulfuric Acid. Aust. J. Chem. 1979, 32, 1727-
1734. 
374. Ramsden, N.; Harrison, R. J.; Oxenford, S.; Bell, K.; Piton, N.; Dagostin, C.; 
Boussard, C.; Ratcliffe, A. Heterocyclyl pyrazolopyrimidine analogues as JAK 
inhibitors WO2011/48082, 2011. 
375. Castro Pichel, J.; Fernandez Menendez, R.; Fernandez Velando, E. P.; Gonzalez del 
Valle, S.; Mallo-Rubio, A. WO2012/49161. 2012. 
376. Boyer, S. J.; Gao, D. A.; Guo, X.; Kirrane, T. M. J.; Sarko, C. R.; Snow, R. J.; 
Soleymanzadeh, F.; Zhang, Y. Heteroccyclic compounds containing an indole core 
WO2011/71716 2011. 
377. Jung, F. H.; Ple, P. Quinoline Derivatives. WO2007099326, 2007. 
378. Matthews, H. R.; Rapoport, H., Differentiation of 1,4- and 1,5-disubstituted 
imidazoles. J. Am. Chem. Soc. 1973, 95, 2297-2303. 
  
416 
 
Appendices 
 
Crystal Data for 4-Nitrophenyl Sulfamate 76 
 
Chemical formula (moiety) C6H6N2O5S 
Chemical formula (total) C6H6N2O5S 
Formula weight  218.19 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, P121/n1 
Unit cell parameters a = 9.9376(4) Å  = 90° 
 b = 6.9353(2) Å  = 98.447(4)° 
 c = 12.2078(5) Å  = 90° 
Cell volume 832.24(5) Å
3
 
Z 4 
Calculated density  1.741 g/cm
3
 
Absorption coefficient  0.388 mm1 
F(000) 448 
Crystal colour and size colourless, 0.30  0.10  0.10 mm3 
Reflections for cell refinement 3865 ( range 2.9 to 28.0°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.9 to 28.0° 
Index ranges h 13 to 9, k 9 to 8, l 13 to 16 
Completeness to  = 26.0° 99.9 %  
Reflections collected 5672 
Independent reflections 1860 (Rint = 0.0258) 
Reflections with F
2
>2 1678 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.8926 and 0.9623 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0297, 0.4072 
Data / restraints / parameters 1860 / 0 / 136 
Final R indices [F
2
>2] R1 = 0.0284, wR2 = 0.0702 
R indices (all data) R1 = 0.0328, wR2 = 0.0731 
Goodness-of-fit on F
2
 1.087 
Extinction coefficient 0.0047(13) 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.27 and 0.38 e Å3 
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Crystal Data for 4-Methoxyphenyl Sulfamate 79 
 
Chemical formula (moiety) C7H9NO4S 
Chemical formula (total) C7H9NO4S 
Formula weight  203.21 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  orthorhombic, P212121 
Unit cell parameters a = 4.9653(2) Å  = 90° 
 b = 7.0222(4) Å  = 90° 
 c = 25.0707(12) Å  = 90° 
Cell volume 874.15(7) Å
3
 
Z 4 
Calculated density  1.544 g/cm
3
 
Absorption coefficient  0.351 mm1 
F(000) 424 
Crystal colour and size colourless, 0.50  0.10  0.10 mm3 
Reflections for cell refinement 1742 ( range 2.9 to 27.9°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
    thick-slice  scans 
 range for data collection 3.0 to 28.0° 
Index ranges h 1 to 6, k 6 to 9, l 31 to 24 
Completeness to  = 26.0° 99.9 %  
Reflections collected 2200 
Independent reflections 1651 (Rint = 0.0171) 
Reflections with F
2
>2 1579 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.8439 and 0.9657 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0408, 0.1032 
Data / restraints / parameters 1651 / 0 / 128 
Final R indices [F
2
>2] R1 = 0.0270, wR2 = 0.0707 
R indices (all data) R1 = 0.0288, wR2 = 0.0723 
Goodness-of-fit on F
2
 1.066 
Absolute structure parameter  0.14(8) 
Extinction coefficient 0.007(2) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.21 and 0.30 e Å3 
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Crystal data and structure refinement for Monosaccharide 48. 
 
Identification code  rjg60 
Chemical formula (moiety) C8H18N2O9S2 
Chemical formula (total) C8H18N2O9S2 
Formula weight  350.36 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  orthorhombic, P212121 
Unit cell parameters a = 7.9595(3) Å  = 90° 
 b = 9.8112(3) Å  = 90° 
 c = 17.7254(6) Å  = 90° 
Cell volume 1384.22(8) Å
3
 
Z 4 
Calculated density  1.681 g/cm
3
 
Absorption coefficient  0.433 mm1 
F(000) 736 
Crystal colour and size colourless, 0.40  0.30  0.30 mm3 
Reflections for cell refinement 4135 ( range 3.3 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.3 to 28.5° 
Index ranges h 8 to 10, k 11 to 13, l 22 to 14 
Completeness to  = 25.0° 99.6 %  
Reflections collected 6200 
Independent reflections 2944 (Rint = 0.0194) 
Reflections with F
2
>2 2850 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.8458 and 0.8810 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0372, 0.2774 
Data / restraints / parameters 2944 / 0 / 213 
Final R indices [F
2
>2] R1 = 0.0259, wR2 = 0.0647 
R indices (all data) R1 = 0.0275, wR2 = 0.0666 
Goodness-of-fit on F
2
 1.049 
Absolute structure parameter 0.03(6) 
Extinction coefficient 0.0022(9) 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.24 and 0.29 e Å3 
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Crystal data and structure refinement for 411 
  
Empirical formula C11H12N8O4 
Formula weight 320.29 
Temperature/K 100.0 
Crystal system monoclinic 
Space group P21/n 
a/Å 8.3770(9) 
b/Å 10.2686(11) 
c/Å 17.1922(18) 
α/° 90 
β/° 100.9530(19) 
γ/° 90 
Volume/Å
3
 1451.9(3) 
Z 4 
ρcalcmg/mm
3
 1.465 
m/mm
-1
 0.991 
F(000) 664.0 
Crystal size/mm
3
 0.2 × 0.08 × 0.05 
Radiation Cu Kα (λ = 1.54178) 
2Θ range for data collection 10.082 to 132.6° 
Index ranges -8 ≤ h ≤ 9, -11 ≤ k ≤ 12, -20 ≤ l ≤ 20 
Reflections collected 14908 
Independent reflections 2406[R(int) = 0.0350] 
Data/restraints/parameters 2406/0/210 
Goodness-of-fit on F
2
 1.070 
Final R indexes [I>=2σ (I)] R1 = 0.0355, wR2 = 0.0901 
Final R indexes [all data] R1 = 0.0364, wR2 = 0.0915 
Largest diff. peak/hole / e Å
-3
 0.24/-0.23 
 
